<SEC-DOCUMENT>0001590750-24-000023.txt : 20241112
<SEC-HEADER>0001590750-24-000023.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112071536
ACCESSION NUMBER:		0001590750-24-000023
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viridian Therapeutics, Inc.\DE
		CENTRAL INDEX KEY:			0001590750
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				471187261
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36483
		FILM NUMBER:		241443252

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		SUITE 103A
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		617.272.4600

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT STREET
		STREET 2:		SUITE 103A
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MIRAGEN THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20170213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MIRAGEN THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20170213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SIGNAL GENETICS, INC.
		DATE OF NAME CHANGE:	20140710
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vrdn-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:bdb425b1-8ce6-48d2-af7c-3659fd6d6265,g:f76e6810-2604-4ff8-8a2b-997429168b4a,d:2e52e163a2594578be1a28935e1f5f13-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:vrdn="http://www.viridiantherapeutics.com/20240930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrdn-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0001590750</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-25">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-29">Viridian Therapeutics, Inc./DE</ix:nonNumeric><ix:nonNumeric contextRef="c-117" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-485">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-605">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-606">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-739">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-741">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrdn-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>vrdn:segment</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>vrdn:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="renewal_term"><xbrli:measure>vrdn:renewal_term</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>vrdn:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrdn:DebtCovenantPeriodAxis">vrdn:DebtCovenantPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrdn:DebtCovenantPeriodAxis">vrdn:DebtCovenantPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:EnableInjectionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:EnableInjectionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesAPreferredStockConversionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesAPreferredStockConversionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesBPreferredStockConversionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesBPreferredStockConversionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2008PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2008PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-06</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vrdn:FormerExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vrdn:FormerExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vrdn:FormerExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2e52e163a2594578be1a28935e1f5f13_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September&#160;30, 2024</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36483</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-6">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-7">47-1187261</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">221 Crescent Street, Suite 103A,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">MA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02453</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address, including zip code, of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">272-4600</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.522%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-14">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-15">VRDN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-16">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-17">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746; &#160;&#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> o</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-18">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746; &#160;&#160; No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> o</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-19">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#9746;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November&#160;7, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-23">79,212,747</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_7"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I. FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_13">7</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_67">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_67">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_76">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_76">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_79">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_79">50</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II. OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_88">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_88">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_91">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_91">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_94">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_94">98</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_97">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_97">98</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_100">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_100">98</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_103">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_103">98</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_106">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_106">98</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward looking statements contained in this Quarterly Report include, but are not limited to, statements about: </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other results;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential utility, efficacy, potency, safety, clinical benefits, half-life, clinical response, convenience  and number of indications of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and focus of our ongoing and future preclinical studies and clinical trials and the timing of reporting data from those studies and trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supply chain disruptions, enrollment in clinical trials involving our product candidates or other delays in such trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our plans relating to commercializing our product candidates, including our plans to commercialize products candidates as combination products, if approved, including the geographic areas of focus and sales strategy;</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expectations regarding the initiation of clinical trials and interactions and alignment with regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approvals, including our expectation to seek an accelerated approval pathway and special designations, such as orphan drug designation, for our product candidates for various diseases;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development of our product candidates, including additional indications we may pursue;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to obtain or protect intellectual property rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates and for the manufacture of our product candidates for preclinical studies, clinical trials and commercialization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans regarding any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and our ability to obtain additional financing to fund our operations and complete further development and commercialization of our product candidates; and</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise mentioned or unless the context requires otherwise, all references in this Quarterly Report, to &#8220;Viridian,&#8221; &#8220;Viridian Therapeutics,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; or similar references refer to Viridian Therapeutics, Inc. and our consolidated subsidiaries.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Item 1A. Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report and our other filings with the SEC, before making an investment decision regarding our common stock.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to raise additional capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory approval processes are lengthy, time consuming and inherently unpredictable. Failure to obtain regulatory approval for our product candidates would have a material adverse effect upon our business and business prospects.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of approved labeling, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily dependent on the success of our product candidates, which are in clinical development. Some of our product candidates have produced results only in non-clinical settings, or for other indications than those for which we contemplate conducting development and seeking U.S. Food and Drug Administration or other regulatory approval, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may find it difficult to enroll and maintain patients or subjects in our clinical trials, in part due to the limited number of patients or subjects who have the diseases for which our product candidates are being studied or the availability of competing therapies and clinical trials. We cannot predict if we will have difficulty enrolling and maintaining patients or subjects in our future clinical trials. Difficulty in enrolling and maintaining patients or subjects could delay or prevent clinical trials of our product candidates.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our preclinical development activities and clinical trials, manufacture our product candidates, and perform other services. If these third parties do not successfully perform and/or comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval, or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on patent rights, trade secret protections, and confidentiality agreements to protect intellectual property, including intellectual property related to our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell our product candidates, we may be unable to generate any revenue.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition and our competitors may discover, develop, or commercialize products faster or more successfully than us.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends in part on our ability to attract, retain, and motivate qualified personnel. If we lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop our product candidates will be impaired and our business may be harmed.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_13"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_19"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-30">200,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-31">102,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-32">552,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">374,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">14,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">9,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unbilled revenue - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="f-36">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="f-37">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">767,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">486,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-41">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-43">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-44">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-45">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">771,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-47">490,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">6,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">2,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities and other (including related party of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">3,725</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-51">374</ix:nonFraction> as of September&#160;30, 2024 and December&#160;31, 2023, respectively)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">34,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">24,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of deferred revenue - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-54">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-55">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">41,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">26,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">20,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">20,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue  - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="f-60">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="f-61">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-63">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 47.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">64,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">48,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, series A non-voting convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-68"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-69">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-71">435,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-72"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-73">134,864</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-75">172,435</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="f-76">61,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="f-77">78,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, series B non-voting convertible preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-78"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-79">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-81">500,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-83">145,160</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-85">143,522</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="f-86">127,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:num-dot-decimal" scale="3" id="f-87">128,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-88"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-89">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-91">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-93">79,181,445</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95">53,986,112</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-96">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-97">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-98">1,433,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-99">960,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-100">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-101">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-102">916,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-103">725,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 47.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-104">707,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-105">442,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-106">771,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-107">490,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these condensed consolidated financial statements.</span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.833%"><tr><td style="width:1.0%"/><td style="width:48.148%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.093%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-108">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-109">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-110">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="f-111">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (including related party expenses of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-112">7,725</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-113">10,937</ix:nonFraction> during the  three and nine months ended September 30, 2024, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-114">1,099</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-115">6,521</ix:nonFraction> during the three and nine months ended September 30, 2023, respectively.)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-116">69,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-117">30,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-118">166,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-119">121,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">14,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">20,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">45,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">62,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-124">83,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-125">51,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-126">211,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-127">183,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">83,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">51,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">211,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">182,972</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-132">7,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-133">4,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-134">23,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-135">13,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-136">1,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-137">600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-138">2,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-139">931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">6,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">3,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-142">21,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-143">12,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">76,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">47,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">190,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-147">170,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-148"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-149">1.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-150"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-151">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-152"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153">2.98</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-154"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-155">3.97</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-156"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157">66,420,063</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-158"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-159">43,654,577</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-160"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-161">63,800,798</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-162"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-163">43,057,658</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">76,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">47,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">190,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">170,874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-168">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-169">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-170">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-171">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive gain</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-172">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-173">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-174">594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-175">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-176">75,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-177">47,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-178">189,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-179">170,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these condensed consolidated financial statements.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_25"></div><hr style="page-break-after:always"/><div style="min-height:64.8pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.760%"><tr><td style="width:1.0%"/><td style="width:27.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:4.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.181%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.073%"/><td style="width:0.1%"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-180">172,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">78,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-182">143,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">128,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-184">53,986,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-185">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">960,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-187">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">725,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">442,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-190">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-191">6,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-192">1,000,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-193">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-194">6,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="f-195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, January 2024 Public Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-196">9,304</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-197">7,142,858</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-198">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-199">140,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-200">140,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, September 2022 ATM, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-201">1,088</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-202">1,561,570</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-203">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-204">35,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-205">35,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-206">66,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-207">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-208">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-209">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-210">22,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-211">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-212">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-213">19,115</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-214">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-215">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">12,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-218">12,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-219">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-220">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-221">48,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-222">48,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-223">157,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">71,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-225">143,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">128,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-227">63,798,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-228">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">1,156,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-230">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">774,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">582,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-233">81,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-234">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-235">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-236">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-237">11,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-238">11,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-239">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-240">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-241">64,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-242">64,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-243">157,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">71,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-245">143,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">128,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-247">63,879,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-248">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">1,168,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-250">543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">839,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-252">529,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-253">22,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-254">10,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-255">18,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-256">24,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-257">2,729,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-258">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-259">34,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Series B preferred stock and common stock, September 2024 Public Offering , net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-261">15,524</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-262">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-263">23,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-264">12,466,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-265">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-266">219,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-267">243,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-268">84,676</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-269">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-270">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-271">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-272">21,494</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-273">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-274">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-275">8,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-276">8,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-277">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-278">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-279">76,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-280">76,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-281">134,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-282">61,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-283">145,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-284">127,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-285">79,181,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-286">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">1,433,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-288">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">916,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-290">707,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.329%"><tr><td style="width:1.0%"/><td style="width:27.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:4.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.300%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.928%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.103%"/><td style="width:0.1%"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-291">188,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">85,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-293">51,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">56,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-295">41,305,947</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-296">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-297">741,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-298">390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-299">488,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-300">395,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon the conversion of convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-301">15,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-302">7,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-303">1,063,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-304">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-305">7,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercises of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares" format="ixt:num-dot-decimal" scale="0" id="f-307">57,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="f-308">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="f-309">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="f-310">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-311">612,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-312">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-313">6,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-314">6,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-315">15,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-316">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-317">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-318">15,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-319">15,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-320">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-321">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-322">68,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">68,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-324">172,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-325">78,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-326">51,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-327">56,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-328">43,055,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-329">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-330">771,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-331">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-332">556,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-333">350,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-334">204,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-335">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-336">4,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="f-337">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercises of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares" format="ixt:num-dot-decimal" scale="0" id="f-338">56,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="f-339">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="f-340">934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue" scale="3" id="f-341">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-342">245,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-343">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-344">2,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-345">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-346">12,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-347">12,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-348">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-349">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-350">55,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-351">55,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-352">172,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-353">78,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-354">51,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-355">56,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-356">43,562,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-357">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-358">792,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-359">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-360">611,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-361">315,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-362">39,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-363">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="f-364">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-365">84,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-366">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-367">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-368">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-369">15,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-370">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-371">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-372">13,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-373">13,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-374">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-375">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-376">47,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-377">47,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-378">172,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-379">78,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-380">51,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-381">56,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-382">43,700,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-383">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-384">807,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-385">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-386">659,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-387">283,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these condensed consolidated financial statements.</span></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_28"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.753%"><tr><td style="width:1.0%"/><td style="width:71.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.309%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-388">190,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-389">170,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-390">33,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-391">41,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under license agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:fixed-zero" scale="3" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="f-393">5,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense and amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-394">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-395">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-396">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-397">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion and amortization of premiums and discounts on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-398">12,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-399">8,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrdn:NonCashLeaseExpense" scale="3" id="f-400">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="vrdn:NonCashLeaseExpense" scale="3" id="f-401">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-403">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fees paid directly to creditor related to extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vrdn:DebtExtinguishmentExpense" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="vrdn:DebtExtinguishmentExpense" scale="3" id="f-405">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-406">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-409">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-410">5,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-411">4,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unbilled revenue - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="f-412">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-414">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-415">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-416">3,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-417">10,524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-418">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-419">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-420">158,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-421">146,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-422">513,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-423">135,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-424">347,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-425">211,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-426">397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-427">850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:48pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-428">165,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-429">75,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock, pursuant to January 2024 Public Offering, September 2024 Public Offering and September 2022 ATM Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-430">420,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of issuance costs associated with the sale of common stock </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-432">24,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of Series B preferred stock, pursuant to September 2024 Public Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="f-434">25,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of issuance costs associated with the sale of preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-436">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-439">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of debt extinguishment costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" id="f-441">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock upon the exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-443">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock upon the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-444">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-445">9,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock for cash under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-446">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-447">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-448">422,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-449">26,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.753%"><tr><td style="width:1.0%"/><td style="width:71.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.309%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:60pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-450">97,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-451">43,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-452">102,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-453">155,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-454">200,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-455">111,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-456">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-457">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Conversion of preferred stock to common stock </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="f-458">41,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="f-459">7,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Unpaid common stock issuance costs included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="f-460">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Purchase of property and equipment in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-462">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-463">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Extinguishment of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NotesReduction" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NotesReduction" format="ixt:num-dot-decimal" scale="3" id="f-465">4,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Issuance of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:num-dot-decimal" scale="3" id="f-467">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these condensed consolidated financial statements.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_31"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_34"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-468" continuedAt="f-468-1" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-468-1" continuedAt="f-468-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viridian Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Viridian&#8221;), is a biopharmaceutical company advancing new treatments for patients suffering from serious diseases that are underserved by today&#8217;s therapies. The Company&#8217;s most advanced program, veligrotug (formerly known as VRDN-001), is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (&#8220;IGF-1R&#8221;), a clinically and commercially validated target for the treatment of thyroid eye disease (&#8220;TED&#8221;). The Company&#8217;s second product candidate, VRDN-003, is an extended half-life monoclonal antibody with the same binding domains as veligrotug designed for administration as convenient, low-volume, subcutaneous pen injections. TED is a serious and debilitating rare autoimmune disease that causes inflammation within the orbit of the eye that can cause bulging of the eyes, redness and swelling, double vision, pain, and potential blindness.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to developing therapies for TED, the Company is also developing a portfolio of engineered anti-neonatal Fc receptor (&#8220;FcRn&#8221;) inhibitors, including VRDN-006 and VRDN-008. FcRn inhibitors have the potential to treat a broad array of autoimmune diseases, representing a significant commercial market opportunity. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on a basis that assumes the Company is a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to its ability to continue as a going concern. The Company has funded its operations to date principally through proceeds received from the sale of the Company&#8217;s common stock, its Series A Preferred Stock, Series B Preferred Stock, and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. Since its inception and through September&#160;30, 2024, the Company has generated an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-469">916.1</ix:nonFraction> million. The Company expects to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no products approved for commercial sale, has not generated any revenue from product sales, and cannot guarantee when or if it will generate any revenue from product sales. Substantially all of the Company&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to incur significant expenses and operating losses for at least the next several years as it continues the development of, and seeks regulatory approval for, its product candidates. It is expected that operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of development programs and efforts to achieve regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-470">753.2</ix:nonFraction> million in cash, cash equivalents, and short-term investments. In addition, the Company also has access to additional undrawn funds under the Hercules Loan and Security Agreement Amended Term Loan, as further described in Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of the issuance date of these condensed consolidated financial statements, the Company expects that its current resources will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require additional capital in order to continue to finance its operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of the Company&#8217;s clinical development efforts, timing of market research and other professional and consulting </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-468-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities to prepare for commercial activities, equity financings, entering into license and collaboration agreements, and issuing debt or other financing vehicles. The Company&#8217;s ability to secure additional capital is dependent upon a number of factors, some of which are outside of the Company&#8217;s control, including success in developing its product candidates, operational performance, and market conditions, including those resulting from the current inflationary and broader macroeconomic environment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated.</span></div></ix:continuation><div id="i2e52e163a2594578be1a28935e1f5f13_37"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-471" continuedAt="f-471-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-471-1" continuedAt="f-471-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-472" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Updates (&#8220;ASU&#8221;), or the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company&#8217;s subsidiaries have no employees or operations. All intercompany balances and transactions have been eliminated in consolidation. Management has determined that the Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-473">one</ix:nonFraction> segment, which is the business of developing and commercializing novel therapeutics. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#8217;s consolidated financial statements and the accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 27, 2024. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these unaudited condensed consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties &#8211; Global Economic Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan, the conflict in Israel and surrounding area and other political tensions. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, high interest rates, foreign exchange volatility and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.</span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-471-2" continuedAt="f-471-3"><ix:nonNumeric contextRef="c-1" name="vrdn:GoingConcernPolicyPolicyTextBlock" id="f-474" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s evaluation entails, among other things, analyzing the results of the Company&#8217;s clinical development efforts, license and collaboration agreements as well as the entity&#8217;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#8217;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents, and short-term investments balance.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-475" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs, including manufacturing activities, and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-476" continuedAt="f-476-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#8217;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div></ix:nonNumeric></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-476-1" continuedAt="f-476-2"><ix:continuation id="f-471-3" continuedAt="f-471-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s agreements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div></ix:continuation></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-471-4" continuedAt="f-471-5"><ix:continuation id="f-476-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-477" continuedAt="f-477-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges including severance costs, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to have clinical trial materials manufactured on the Company&#8217;s behalf, purchases of laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-477-1">The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or when other significant risk factors are abated. Such up-front and milestone payments are reflected as cash used in operating activities within the condensed consolidated statement of cash flows.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="vrdn:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" id="f-478" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-479" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards to employees and non-employees in the form of stock options and restricted stock units (&#8220;RSUs&#8221;). The Company measures and recognizes share-based compensation expense for its stock-based awards granted to employees and non-employees based on the estimated grant date fair value in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Compensation - Stock Compensation&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and determines the fair value of RSUs based on the fair value of its common stock. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.</span></div></ix:nonNumeric></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-471-5" continuedAt="f-471-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-480" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-481" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are reported as a component of stockholders&#8217; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-482" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-483" continuedAt="f-483-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-483-1">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</ix:continuation> </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-471-6" continuedAt="f-471-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-484" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-485">three</span> to <ix:nonNumeric contextRef="c-118" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-486">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-487" continuedAt="f-487-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Right-of-Use Assets and Liabilities</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="f-487-1" continuedAt="f-487-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in ASU No. 2016-02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Leases (Topic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">842), </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-487-2">and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#8220;ASC 842&#8221;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#8217;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#8217;s operating lease assets in the Company&#8217;s condensed consolidated balance sheets. The Company&#8217;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#8217;s condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</ix:continuation> Refer to Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies - Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information related to the Company&#8217;s operating leases.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-488" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Debt Issuance Costs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#8217;s Term Loan (as defined in Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-489" continuedAt="f-489-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-489-1">The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-490" continuedAt="f-490-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-490-1">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-491"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-492">No</ix:nonFraction></ix:nonFraction> impairment charges were recorded during the nine months ended September 30, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-493" continuedAt="f-493-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the </span></div></ix:nonNumeric></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-471-7" continuedAt="f-471-8"><ix:continuation id="f-493-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-494" continuedAt="f-494-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-494-1">Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the condensed consolidated statements of changes in stockholders&#8217; equity.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-495" continuedAt="f-495-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-495-1">The Company has <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-496">no</ix:nonFraction> unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations and comprehensive loss as general and administrative expenses.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-497"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-498">No</ix:nonFraction></ix:nonFraction> such expenses have been recognized during the nine months ended September 30, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="vrdn:WarrantsPolicyPolicyTextBlock" id="f-499" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-500" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in&#160;<ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-501">one</ix:nonFraction>&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</span></div></ix:nonNumeric></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-502" continuedAt="f-502-1" escape="true"><ix:continuation id="f-471-8" continuedAt="f-471-9"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements &#8211; To Be Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Report Segment Disclosures (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires enhanced disclosures about significant segment expenses, enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. ASU 2023-07 is effective for the Company&#8217;s annual reporting period beginning after December 15, 2023, and subsequent interim periods, with early adoption permitted. ASU 2023-07 requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 requires a company's annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#8217;s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-502-1"><ix:continuation id="f-471-9">In November 2024, the FASB issued ASU-2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). ASU 2024-03 requires additional disclosures of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. ASU 2024-03 is effective for the Company's annual reporting periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_40"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-503" continuedAt="f-503-1" escape="true">INVESTMENTS AND FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-503-1" continuedAt="f-503-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-504" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following as of September 30, 2024 and December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"><tr><td style="width:1.0%"/><td style="width:39.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.736%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-505">183,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-508">183,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-509">231,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-510">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-511">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-512">231,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-513">311,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-514">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-515">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-516">311,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-517">9,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-518">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-520">9,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-521">735,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-522">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-523">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-524">736,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-525">77,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-526">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-528">77,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-529">148,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-530">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-531">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-532">148,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-533">227,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-534">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-535">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-536">227,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-537">9,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-538">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-540">9,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-541">462,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-542">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-543">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-544">463,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The money market funds above are included in cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company considers the unrealized losses in its investment portfolio to be temporary in nature and not due to credit losses. The Company has the intent and ability to hold such investments until their recovery at fair value. The Company did <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-545"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-546"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-547"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-548">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> have any realized gains or losses in its available for sale securities during the three and nine months ended September 30, 2024 and 2023. The Company did <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="f-549"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="f-550"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="f-551"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="f-552">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> have any sales of short-term investments during the three and nine months ended September 30, 2024 and 2023. The contractual maturity dates of all of the Company&#8217;s investments are less than <ix:nonNumeric contextRef="c-3" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durmonth" id="f-553">24</ix:nonNumeric> months.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-554" continuedAt="f-554-1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div></ix:nonNumeric></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-554-1"><ix:continuation id="f-503-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"><tr><td style="width:1.0%"/><td style="width:39.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.736%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-555">183,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-558">183,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-560">231,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-562">231,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-564">311,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-566">311,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-568">9,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-570">9,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-571">183,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-572">552,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-574">736,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-575">77,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-578">77,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-580">10,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-582">10,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-584">148,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-586">148,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-588">216,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-590">216,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-592">9,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-594">9,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-595">77,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-596">385,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-598">463,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_43"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-599" continuedAt="f-599-1" escape="true">ACCRUED LIABILITIES AND OTHER</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-600" escape="true"><ix:continuation id="f-599-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued outsourced clinical trials and preclinical studies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrdn:AccruedOutsourcingClinicalandPreclinicalStudies" format="ixt:num-dot-decimal" scale="3" id="f-601">21,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrdn:AccruedOutsourcingClinicalandPreclinicalStudies" format="ixt:num-dot-decimal" scale="3" id="f-602">10,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee compensation and related taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-603">10,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-604">10,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-605"><span style="-sec-ix-hidden:f-606">Operating lease liability, short-term</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-607">589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-608">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal fees and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrdn:AccruedLegalFeesCurrent" scale="3" id="f-609">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrdn:AccruedLegalFeesCurrent" scale="3" id="f-610">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other professional service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-611">762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-612">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of liability-classified stock purchase warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vrdn:AccruedLiabilityofWarrantsonTemporaryEquity" scale="3" id="f-613">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vrdn:AccruedLiabilityofWarrantsonTemporaryEquity" scale="3" id="f-614">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-615">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-616">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-617">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-618">902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-619">34,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-620">24,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div id="i2e52e163a2594578be1a28935e1f5f13_46"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-621" continuedAt="f-621-1" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="f-621-1" continuedAt="f-621-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan and Security Agreement with Hercules Capital, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into a loan and security agreement (the &#8220;Hercules Loan and Security Agreement&#8221;) among the Company, certain of its subsidiaries from time to time party thereto (together with the Company, collectively, the &#8220;Borrower&#8221;), Hercules Capital, Inc. (&#8220;Hercules&#8221;) and certain other lenders named therein (the &#8220;Lenders&#8221;). Under the Hercules Loan and Security Agreement, the Lenders provided the Company with access to a term loan with an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-622">75.0</ix:nonFraction>&#160;million, in <ix:nonFraction unitRef="tranche" contextRef="c-167" decimals="INF" name="vrdn:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-623">four</ix:nonFraction> tranches (collectively the &#8220;Term Loan&#8221;), including an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="INF" name="vrdn:DebtInstrumentFaceAmountFirstTranche" format="ixt:num-dot-decimal" scale="6" id="f-624">25.0</ix:nonFraction>&#160;million, available to the Company through June 15, 2023. Upon signing the Hercules Loan and Security Agreement, the Company drew an initial principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-625">5.0</ix:nonFraction>&#160;million (the &#8220;initial draw&#8221;). The Company incurred debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-626">0.2</ix:nonFraction>&#160;million in connection with the Term Loan and paid to the Lenders a facility fee of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="vrdn:DebtInstrumentFacilityFee" format="ixt:num-dot-decimal" scale="6" id="f-627">0.1</ix:nonFraction>&#160;million, as well as $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="vrdn:DebtInstrumentOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="f-628">0.1</ix:nonFraction>&#160;million of other expenses incurred by the Lenders and reimbursed by the Company (&#8220;Lender Expenses&#8221;) in connection with the initial draw. The debt issuance costs and the Lender Expenses were being amortized as additional interest expense over the term of the loan. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was originally obligated to make interest-only payments through April 1, 2024, which was extended to October 1, 2024 upon achievement of a development milestone in August 2022. In addition, the Borrower was required to pay an end-of-term fee equal to <ix:nonFraction unitRef="number" contextRef="c-167" decimals="2" name="vrdn:DebtInstrumentPrincipalAmountTermFee" scale="-2" id="f-629">6</ix:nonFraction>% of the principal amount of funded Term Loan advances at maturity, which were being accreted as additional interest expense over the term of the loan. The obligations of the Borrower under the Hercules Loan and Security Agreement were secured by substantially all of the assets of the Borrower, excluding the Borrower&#8217;s intellectual property. The Term Loan had a maturity date of October 1, 2026. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company executed an amendment to the Hercules Loan and Security Agreement (the &#8220;Hercules Amendment&#8221;) to modify certain terms of the agreement and increase the aggregate principal amount to up to $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-630">150.0</ix:nonFraction>&#160;million. Upon execution of the Hercules Amendment in August 2023, the Company drew a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-631">15.0</ix:nonFraction>&#160;million. The Hercules Amendment was determined to substantially alter the Hercules Loan and Security Agreement and therefore was accounted for as a debt extinguishment. The Company </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-621-2" continuedAt="f-621-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-632">0.2</ix:nonFraction>&#160;million in August 2023 related to unamortized debt discount and debt issuance costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hercules Amendment, the Lenders provided the Company access to an increased term loan with an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-633">150.0</ix:nonFraction>&#160;million, in <ix:nonFraction unitRef="tranche" contextRef="c-169" decimals="INF" name="vrdn:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-634">four</ix:nonFraction> tranches (collectively the &#8220;Amended Term Loan&#8221;), consisting of (1) an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="vrdn:DebtInstrumentFaceAmountFirstTranche" format="ixt:num-dot-decimal" scale="6" id="f-635">50.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-636">5.0</ix:nonFraction>&#160;million of which was drawn at closing of the Hercules Loan and Security Agreement in April 2022, $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-637">15.0</ix:nonFraction>&#160;million of which was drawn at closing of the Hercules Amendment in August 2023, $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="INF" name="vrdn:DebtInstrumentFaceAmountFirstTranche" format="ixt:num-dot-decimal" scale="6" id="f-638">5.0</ix:nonFraction>&#160;million of which was available through December 15, 2023, and $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="INF" name="vrdn:DebtInstrumentFaceAmountFirstTranche" format="ixt:num-dot-decimal" scale="6" id="f-639">25.0</ix:nonFraction>&#160;million of which is available from July 1, 2024 through December 15, 2024; (2) a second tranche of $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="vrdn:DebtInstrumentFaceAmountSecondTranche" format="ixt:num-dot-decimal" scale="6" id="f-640">20.0</ix:nonFraction>&#160;million, subject to achievement of certain regulatory milestones, available through February 15, 2025; (3) a third tranche of $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="vrdn:DebtInstrumentFaceAmountThirdTranche" format="ixt:num-dot-decimal" scale="6" id="f-641">20.0</ix:nonFraction>&#160;million, subject to achievement of certain regulatory milestones, available through March 31, 2025; and (4) a fourth tranche of $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="vrdn:DebtInstrumentFaceAmountFourthTranche" format="ixt:num-dot-decimal" scale="6" id="f-642">60.0</ix:nonFraction>&#160;million subject to approval by the Lenders&#8217; investment committee(s), available through June 15, 2025. The milestones for the second and third tranches have not yet been achieved. The obligations of the Borrower under the Hercules Amendment agreement are secured by substantially all of the assets of the Borrower, excluding the Borrower&#8217;s intellectual property. The Amended Term Loan has a maturity date of October 1, 2026.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Term Loan bears interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="c-169" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-643">7.45</ix:nonFraction>% and (ii) <ix:nonFraction unitRef="number" contextRef="c-170" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-644">4.2</ix:nonFraction>% above the Prime Rate (as defined therein), provided that the Term Loan interest rate shall not exceed a per annum rate of <ix:nonFraction unitRef="number" contextRef="c-169" decimals="INF" name="vrdn:DebtInstrumentInterestRateMaximum" scale="-2" id="f-645">8.95</ix:nonFraction>%. Interest is payable monthly in arrears on the first day of each month. The interest rate as of September&#160;30, 2024 was <ix:nonFraction unitRef="number" contextRef="c-173" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-646">8.95</ix:nonFraction>%. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the Hercules Amendment, the Company was originally obligated to make interest-only payments through April 1, 2025. Upon achievement of certain development milestones related to topline results for the Company&#8217;s phase 3 THRIVE trial in September 2024, the interest-only period was extended to October 1, 2025. If additional development milestones are met, the interest-only period will be further extended to April 1, 2026. The Borrower is required to repay the Amended Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, the Borrower is required to pay an end-of-term fee equal to <ix:nonFraction unitRef="number" contextRef="c-169" decimals="INF" name="vrdn:DebtInstrumentPrincipalAmountTermFee" scale="-2" id="f-647">6</ix:nonFraction>% of the principal amount of funded Amended Term Loan advances at maturity, which are being accreted as additional interest expense over the term of the loan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of all items (cash interest, the amortization/accretion of the debt issuance costs and the end-of-term fee) is being recognized as interest expense using an effective interest rate of approximately <ix:nonFraction unitRef="number" contextRef="c-169" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-648">9.3</ix:nonFraction>%. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-649">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-650">1.7</ix:nonFraction> million during the three and nine months ended September 30, 2024, and $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="6" id="f-651">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="6" id="f-652">0.8</ix:nonFraction>&#160;million during the three and nine months ended September 30, 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-653" continuedAt="f-653-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of the Term Loan, on the Company&#8217;s condensed consolidated balance sheet at September&#160;30, 2024:</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><ix:continuation id="f-653-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"><tr><td style="width:1.0%"/><td style="width:74.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross term loan proceeds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-654">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued end-of-term fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="f-655">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-656">20,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-658">20,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-621-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Term Loan approximates its fair value. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-659" continuedAt="f-659-1" escape="true">Future principal payments, which exclude the end of term fee, in connection with the Hercules Loan and Security Agreement as of September&#160;30, 2024 are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-659-1"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"><tr><td style="width:1.0%"/><td style="width:74.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:fixed-zero" scale="3" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-661">4,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-662">15,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-663">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i2e52e163a2594578be1a28935e1f5f13_49"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-664" continuedAt="f-664-1" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-664-1" continuedAt="f-664-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Zenas BioPharma</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company became party to a license agreement with Zenas BioPharma (Cayman) Limited (&#8220;Zenas BioPharma&#8221;) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma. Since February 2021, the Company has entered into several letter agreements with Zenas BioPharma pursuant to which the Company agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing. In May 2022, the Company entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma to manufacture and supply, or to have manufactured and supplied, clinical drug product for developmental purposes. The license agreement and subsequent letter agreements and supply agreement (collectively, the &#8220;Zenas Agreements&#8221;) were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. Under the terms of the Zenas Agreements, the Company granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the Zenas Agreements, the transaction price included upfront non-cash consideration and variable consideration in the form of payment for the Company&#8217;s goods and services and milestone payments due upon the achievement of specified events. Under the Zenas Agreements, the Company can receive non-refundable milestone payments upon achieving specific milestone events during the contract term. Additionally, the Company may receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to the Company for the royalty term in the Zenas Agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zenas Agreements would qualify as a collaborative arrangement under the scope of Accounting Standards Codification, Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 808&#8221;). While this arrangement is in the scope of ASC 808, the Company applied ASC 606 to account for certain aspects of this arrangement. The Company applied ASC 606 for certain activities within the arrangement associated with the Company&#8217;s transfer of a good or service (i.e., a unit of account) that is part of the Company&#8217;s ongoing major or central operations. The Company allocated the transaction price based on the relative estimated standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. Research and development activities are priced generally at cost. The Company&#8217;s license of goods and services to Zenas BioPharma during the contract term was determined to be a single performance obligation satisfied over time. The Company will recognize the transaction price from the license agreement over the Company&#8217;s estimated period to complete its activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the arrangement, the Company evaluated whether the milestones were considered probable of being reached and estimated the amount to be included in the transaction price using the most likely amount </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-664-2" continuedAt="f-664-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method. As it was not probable that a significant revenue reversal would not occur, none of the associated milestone payments were included in the transaction price at contract inception. For the sales-based royalties included in the arrangement, the license was deemed to be the predominant item to which the royalties relate. The Company will recognize royalty revenues at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). During the three and nine months ended September 30, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-665">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-666">0.2</ix:nonFraction> million, respectively, of collaboration revenue related to the Zenas Agreements. During the three and nine months ended September 30, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-667">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-668">0.2</ix:nonFraction> million, respectively, of collaboration revenue related to the Zenas Agreements. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company entered into a letter agreement with Zenas BioPharma (the &#8220;Zenas Letter Agreement&#8221;) pursuant to which Zenas BioPharma agreed to support the Company&#8217;s THRIVE-2 and STRIVE trials by initiating and managing the studies in China. Under the Zenas Letter Agreement, the Company agreed to reimburse costs incurred by Zenas BioPharma, including a full-time equivalent rate for services rendered. In connection with the execution of the Zenas Letter Agreement, the Company made an initial payment of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="vrdn:CollaborationArrangementInitialPayment" format="ixt:num-dot-decimal" scale="6" id="f-669">1.5</ix:nonFraction>&#160;million, which was recorded as research and development expense during the nine months ended September 30, 2024 as services were performed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zenas Agreements are considered related party transactions because Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-670">5</ix:nonFraction>% of the Company&#8217;s common stock and is also a <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-671">5</ix:nonFraction>% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharma&#8217;s board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody and Discovery Option Agreement with Paragon Therapeutics, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company and Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) entered into an antibody and discovery option agreement (the &#8220;Paragon Research Agreement&#8221;) under which the Company and Paragon will cooperate to develop one or more proteins or antibodies. Under the terms of the Paragon Research Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and the Company will pay Paragon agreed upon development fees in exchange for Paragon&#8217;s commitment of the necessary personnel and resources to perform these activities. The Paragon Research Agreement stipulates a final deliverable to the Company comprising of a report summarizing the experiments and processes performed under the research plan (the &#8220;Final Deliverable&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Paragon agreed to grant the Company an option for an exclusive license to all of Paragon&#8217;s right, title and interest in and to certain antibody technology and the Final Deliverable, and a non-exclusive license to certain background intellectual property owned by Paragon solely to research, develop, make, use, sell, offer for sale and import of the licensed intellectual property and resulting products worldwide (each, an &#8220;Option&#8221; and together, the &#8220;Options&#8221;). Paragon also granted to the Company a limited, exclusive, royalty-free license, without the right to sublicense, to certain antibody technology and the Final Deliverable, and a non-exclusive, royalty-free license without the right to sublicense, under certain background intellectual property owned by Paragon, solely to evaluate the antibody technology and Option and for the purpose of allowing the Company to determine whether to exercise the Option with respect to certain programs. The Company may, at its sole discretion, exercise the Option with respect to specified programs (&#8220;Programs&#8221;) at any time until the date that is 90 days after the Company&#8217;s receipt of the Final Deliverable the applicable program, or such longer period as agreed upon by the parties (&#8220;Option Period&#8221;) by delivering written notice of such exercise to Paragon. If the Company fails to exercise an Option prior to expiration of the applicable Option Period, such Option for such Programs will terminate. In consideration for Paragon&#8217;s grant of the Options to the Company, the Company paid to Paragon a non-refundable, non-creditable one-time fee of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="vrdn:CollaborativeArrangementUpfrontFeePayment" format="ixt:num-dot-decimal" scale="6" id="f-672">2.5</ix:nonFraction>&#160;million, which was recorded as research and development expense during the three months ended March 31, 2022. In December 2022, the Company and Paragon entered into a first amendment to the Paragon Research Agreement, under which the Company obtained an additional limited license for the purpose of conducting certain activities. In consideration for the rights and licenses obtained under the first amendment, Viridian paid Paragon a non-refundable fee of </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-664-3" continuedAt="f-664-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="vrdn:CollaborativeArrangementRightsAndLicensesFee" format="ixt:num-dot-decimal" scale="6" id="f-673">2.3</ix:nonFraction>&#160;million (the &#8220;First Amendment Payment&#8221;), which was recorded as research and development expense during the three months ended December 31, 2022. The non-refundable upfront fee and the First Amendment Payment are separate from any development costs or cost advance paid or owing with respect to the specified program.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company entered into a License Agreement with Paragon (the &#8220;Paragon License Agreement&#8221;) as a result of exercising its Option under the Paragon Research Agreement to obtain exclusive licenses to develop, manufacture and commercialize certain antibodies, proteins and associated products. In connection with the execution of the Paragon License Agreement, the Company made an initial payment of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="vrdn:CollaborationArrangementInitialPayment" format="ixt:num-dot-decimal" scale="6" id="f-674">5.3</ix:nonFraction>&#160;million, which was recorded as research and development expense during the three months ended December 31, 2023. As further described below, the Paragon License Agreement was amended and restated by the Amended and Restated License Agreement with Paragon in September 2024. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company entered into a letter agreement with Paragon pursuant to which Paragon agreed to continue to perform development activities under the existing Paragon Research Agreement and Paragon License Agreement, which the Company renewed in July 2024. In consideration for the development activities to be conducted by Paragon, the Company will reimburse Paragon for actual development costs incurred and agreed upon development fees in exchange for Paragon&#8217;s commitment of the necessary personnel and resources to perform these activities. In September 2024, the Company entered into a second amendment to the Paragon Research Agreement to include additional development activities to be performed by Paragon. Under the amended Paragon Research Agreement, the Company will be obligated to make a one-time non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="vrdn:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-675">3.5</ix:nonFraction>&#160;million to Paragon following the achievement of certain research and development objectives.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into the Amended and Restated License Agreement with Paragon (the &#8220;Amended Paragon License Agreement&#8221;) which amended and restated the Paragon License Agreement. In connection with the execution of the Amended Paragon License Agreement, the Company paid Paragon a non-refundable fee of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="vrdn:CollaborativeArrangementUpfrontFeePayment" format="ixt:num-dot-decimal" scale="6" id="f-676">4.0</ix:nonFraction>&#160;million in September 2024, which was recorded as research and development expense during the three months ended September 30, 2024. In consideration for rights granted by Paragon, the Company is obligated to make certain future milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="vrdn:CollaborationArrangementFutureDevelopmentsMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-677">16.0</ix:nonFraction>&#160;million on a program-by-program bases upon the achievement of specified clinical or regulatory milestones, with total milestone payments under all programs not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="vrdn:CollaborationArrangementMaximumMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-678">40.0</ix:nonFraction>&#160;million. Additionally, if the Company develops a product utilizing certain intellectual property rights granted to it under the Amended Paragon License Agreement, the Company is obligated to pay Paragon potential additional future development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="vrdn:CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" format="ixt:num-dot-decimal" scale="6" id="f-679">3.1</ix:nonFraction>&#160;million and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="vrdn:CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" format="ixt:num-dot-decimal" scale="6" id="f-680">17.0</ix:nonFraction>&#160;million with respect to such product. If the Company successfully commercializes any product candidate subject to the Amended Paragon License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of such product&#8217;s net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-681">7.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-682">10.9</ix:nonFraction> million, respectively, in research and development costs related to the Paragon Research Agreement and Amended Paragon License Agreement (collectively, the &#8220;Paragon Agreements&#8221;). During the three and nine months ended September 30, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-683">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-684">6.5</ix:nonFraction> million, respectively, in research and development costs related to the Paragon Agreements. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-664-4">The Paragon Agreements are considered related party transactions because Fairmount beneficially owns more than <ix:nonFraction unitRef="number" contextRef="c-192" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-685">5</ix:nonFraction>% of the Company&#8217;s capital stock and has two seats on the Company&#8217;s board of directors, and beneficially owns more than <ix:nonFraction unitRef="number" contextRef="c-192" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-686">5</ix:nonFraction>% of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers.</ix:continuation> </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_52"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-687" continuedAt="f-687-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-687-1" continuedAt="f-687-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with ImmunoGen, Inc. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company became party to a license agreement (the &#8220;ImmunoGen License Agreement&#8221;) with Immunogen, Inc. (&#8220;ImmunoGen&#8221;), under which the Company obtained an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to develop, manufacture, and commercialize certain products for non-oncology and non-radiopharmaceutical indications. In consideration for rights granted by ImmunoGen, the Company is obligated to make certain future development milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="INF" name="vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum" format="ixt:num-dot-decimal" scale="6" id="f-688">48.0</ix:nonFraction>&#160;million upon the achievement of specified clinical and regulatory milestones. In December 2021, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="vrdn:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-689">2.5</ix:nonFraction>&#160;million milestone payment to ImmunoGen upon the submission of an investigational new drug (&#8220;IND&#8221;) application for veligrotug with the FDA. In May 2022, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="vrdn:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-690">3.0</ix:nonFraction>&#160;million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug. In December 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="vrdn:CollaborativeArrangementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-691">10.0</ix:nonFraction>&#160;million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, amount which was paid in January 2023. Additionally, if the Company successfully commercializes any product candidate subject to the ImmunoGen License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="INF" name="vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="f-692">95.0</ix:nonFraction>&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of a specified product in each country until the later of (i) the expiration of the last patent claim subject to the ImmunoGen License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained for each product in such country, or (iii) the 12th anniversary of the date of the first commercial sale of such product in such country. On February 12, 2024, AbbVie Inc. acquired ImmunoGen.&#160;The terms of the ImmunoGen License Agreement did not change as a result of this acquisition. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and License Agreement with Enable Injections</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company entered into a Development and License Agreement (the &#8220;Enable License Agreement&#8221;) with Enable Injections, Inc. (&#8220;Enable&#8221;), under which Enable granted the Company an exclusive, royalty-bearing, sublicensable, non-transferrable license to (i) develop, commercialize, seek marketing approval for and otherwise use and exploit certain products, and (ii) make and have made such product solely for such permitted uses. Pursuant to the terms of the Enable License Agreement, the Company granted Enable a non-exclusive, royalty-free, non-sublicensable, non-transferable license. In consideration for the rights granted by Enable, the Company paid Enable an initial, non-creditable, non-refundable license fee of $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="vrdn:CollaborativeArrangementRightsAndLicensesFee" format="ixt:num-dot-decimal" scale="6" id="f-693">15.0</ix:nonFraction>&#160;million in January 2023. This amount is included in research and development expense during the nine months ended September 30, 2023 in the accompanying condensed consolidated statement of operations and comprehensive loss. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make certain future milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="INF" name="vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum" format="ixt:num-dot-decimal" scale="6" id="f-694">45.0</ix:nonFraction>&#160;million upon the achievement of specified development, clinical and regulatory milestones. Additionally, if the Company is successful in commercializing any product candidate subject to the Enable License Agreement, the Company is obligated to make certain commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="INF" name="vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="f-695">150.0</ix:nonFraction>&#160;million and royalty payments equal to a percentage in the mid-single digits. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights Agreement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the merger agreement with miRagen Therapeutics, Inc. (&#8220;miRagen&#8221;), on November 4, 2020, the Company entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), pursuant to which each holder of the Company&#8217;s common stock as of November 6, 2020, other than former stockholders of the private entity Viridian Therapeutics, Inc. (which merged with miRagen), received one contingent value right (a &#8220;CVR&#8221;) for each share of Company common stock held by such holder on that date. Under the CVR Agreement, holders </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-687-2" continuedAt="f-687-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of CVRs would have been entitled to receive a portion of the net proceeds for any dispositions of certain legacy miRagen assets consummated through December 31, 2021. As of December 31, 2021, the disposition period had expired. There were no dispositions of any such legacy assets prior to that time and, accordingly, there will be no payments made under the CVR Agreement. The CVR Agreement expires on November 4, 2025. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company and a third-party collaborator entered into an Exclusive License and Collaboration Agreement to collaborate and conduct certain IND-enabling activities with respect to the licensed compound and licensed product. Under the terms of the agreement, the Company was granted an exclusive, royalty-bearing, worldwide license to develop, manufacture, and commercialize certain licensed compounds and licensed products in the field (the &#8220;License&#8221;). In consideration for the rights granted by the License, the Company initially issued <ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="vrdn:CollaborativeArrangementSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="0" id="f-696">204,843</ix:nonFraction> shares of its common stock to certain stockholders of the third-party. The shares were valued at $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="6" id="f-697">5.0</ix:nonFraction>&#160;million and recorded as research and development expense during the three months ended June 30, 2023. On July 24, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="vrdn:CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="0" id="f-698">39,059</ix:nonFraction> additional shares of its common stock to certain stockholders of the third-party and recorded the related $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="6" id="f-699">0.7</ix:nonFraction>&#160;million expense as research and development expenses during three months ended September 30, 2023. Additionally, upon the date when the Company decides to pursue certain studies for the licensed compound under the agreement, the Company shall issue the third-party collaborator the equivalent of $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="vrdn:CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" format="ixt:num-dot-decimal" scale="6" id="f-700">10.0</ix:nonFraction>&#160;million in shares of its common stock. The Company is also obligated to make certain future milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="INF" name="vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum" scale="6" id="f-701">45.0</ix:nonFraction> million upon the achievement of certain development milestones. Remaining development milestone payments shall be payable in cash. If the Company is successful in commercializing products related to the licensed compound, the Company is also obligated to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="INF" name="vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="f-702">60.0</ix:nonFraction>&#160;million upon the achievement of certain sales milestones as well as royalty payments equal to a percentage in the mid-single to double digits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Colorado-based Office and Lab Space</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Colorado-based office and lab space (the &#8220;Colorado Lease&#8221;). The Colorado Lease includes rent escalation clauses through the lease term and a Company option to extend the lease term for up to <ix:nonFraction unitRef="renewal_term" contextRef="c-204" decimals="INF" name="vrdn:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="f-703">three</ix:nonFraction> terms of <ix:nonNumeric contextRef="c-205" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-704">three years</ix:nonNumeric> each. Minimum base lease payments under the Colorado Lease, including the impact of tenant improvement allowances, are recognized on a straight-line basis over the full term of the lease. The lease term was amended in March 2021 to extend the lease maturity date to December 31, 2024. Upon adoption of ASC 842 and upon subsequent modification of the lease in 2020 and in March 2021, the Company recognized a right-of-use asset and corresponding lease liability for the Colorado Lease of approximately $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-705"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-706">1.6</ix:nonFraction></ix:nonFraction>&#160;million by calculating the present value of lease payments, discounted at <ix:nonFraction unitRef="number" contextRef="c-206" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-707">6</ix:nonFraction>%, the Company&#8217;s estimated incremental borrowing rate, over the <ix:nonNumeric contextRef="c-206" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth" id="f-708">12</ix:nonNumeric> months expected remaining term.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into a new, multi-year lease agreement for its Colorado-based office and lab space (the &#8220;New Colorado Lease&#8221;). Under ASC 842, the New Colorado Lease was treated as a lease modification representing an extension of the lease term for a reduced portion of the space currently in use under the existing Colorado Lease. As of the effective date, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-709"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-710">0.3</ix:nonFraction></ix:nonFraction>&#160;million increase in the right-of-use asset and corresponding lease liability for the extension of the lease term. The remaining space under the Colorado Lease will terminate at the original maturity date of December 31, 2024. The New Colorado Lease provides for annual base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="vrdn:OperatingLeaseAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-711">0.1</ix:nonFraction>&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes, and operating expenses. The New Colorado Lease is set to expire in December 2026. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Massachusetts-based Office Space</span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-687-3" continuedAt="f-687-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Massachusetts-based office space (as subsequently amended in July 2021, April 2022, July 2022 and April 2024, the &#8220;Massachusetts Lease&#8221;). The Massachusetts Lease includes rent escalation clauses throughout the lease term. Minimum base lease payments under the Massachusetts Lease are recognized on a straight-line basis over the full term of the Massachusetts Lease. Upon initial assumption of the Massachusetts Lease in October 2020, the Company recognized a right-of-use asset and corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-712"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-713">0.1</ix:nonFraction></ix:nonFraction>&#160;million by calculating the present value of lease payments, discounted at <ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-714">6</ix:nonFraction>%, the Company&#8217;s estimated incremental borrowing rate, over the expected remaining term. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a Fourth Amendment of the Massachusetts Lease (the &#8220;Fourth Amendment&#8221;). The Fourth Amendment makes certain modifications to the Massachusetts Lease, including (i) securing <ix:nonFraction unitRef="sqft" contextRef="c-209" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-715">10,427</ix:nonFraction> square feet of office space in a new building suite (the &#8220;New Premises&#8221;), (ii) the termination of the <ix:nonFraction unitRef="sqft" contextRef="c-210" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-716">10,956</ix:nonFraction> square feet of leased space under the existing Massachusetts Lease (the &#8220;Original Premises&#8221;), and (iii) the extension of the expiration date of the leased space to <ix:nonNumeric contextRef="c-209" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-717">five years</ix:nonNumeric> from the delivery of the New Premises. The Massachusetts Lease provides for annual base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="vrdn:OperatingLeaseAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-718">0.5</ix:nonFraction>&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses. Under the Fourth Amendment, the Massachusetts Lease will expire in July 2029. The Company has the option to extend the lease term for an additional period of <ix:nonNumeric contextRef="c-209" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-719">three years</ix:nonNumeric> upon notice to the landlord.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a new right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-720">1.6</ix:nonFraction>&#160;million and corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-721">1.9</ix:nonFraction>&#160;million for the New Premises and simultaneously derecognized the right-of-use asset of  $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="vrdn:OperatingLeaseRightOfUseAssetDerecognized" format="ixt:num-dot-decimal" scale="6" id="f-722">1.1</ix:nonFraction> million and corresponding lease liability of  $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="vrdn:OperatingLeaseLiabilityCurrentDerecognized" format="ixt:num-dot-decimal" scale="6" id="f-723">1.2</ix:nonFraction> million for the Original Premises on the lease commencement date in April 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into a Fifth Amendment of the Massachusetts Lease (the &#8220;Fifth Amendment&#8221;) to lease an additional <ix:nonFraction unitRef="sqft" contextRef="c-212" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="f-724">2,788</ix:nonFraction> square feet of office space in the same building. The Fifth Amendment provides for additional annual base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="vrdn:OperatingLeaseAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-725">0.1</ix:nonFraction>&#160;million for the additional office space and includes annual base rent escalation clauses during the lease term. The Fifth Amendment was treated as a lease modification accounted for as a separate contract and the Company recorded a new right-of-use asset and corresponding lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-726"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-727">0.5</ix:nonFraction></ix:nonFraction>&#160;million related to the Fifth Amendment on the lease commencement date. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-728" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under noncancellable leases as of September&#160;30, 2024 are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.666%"><tr><td style="width:1.0%"/><td style="width:69.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-729">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-730">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-731">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-732">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-733">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-734">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-735">3,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-736">603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-737">2,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company&#8217;s operating lease obligations were reflected as short-term operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-738">0.6</ix:nonFraction>&#160;million within <span style="-sec-ix-hidden:f-739">accrued liabilities</span> and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-740">2.2</ix:nonFraction> million of long-term lease obligations as <span style="-sec-ix-hidden:f-741">other liabilities</span> in the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-742">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-743">0.8</ix:nonFraction> million for the three and nine months ended September 30, </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-687-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024, respectively, which was included in operating expense in the condensed consolidated statements of operations and comprehensive loss. Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="f-744">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="6" id="f-745">0.6</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2023. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to pay for certain costs, taxes, and operating expenses related to both the Colorado Lease and Massachusetts Lease, which were $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="vrdn:OperatingLeasesOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-746"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="vrdn:OperatingLeasesOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-747">0.1</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="vrdn:OperatingLeasesOperatingExpense" scale="6" id="f-748"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="vrdn:OperatingLeasesOperatingExpense" scale="6" id="f-749">0.3</ix:nonFraction></ix:nonFraction> million for the three and nine months ended September 30, 2024 and 2023, respectively. The operating expenses are incurred separately and were not included in the present value of lease payments.</span></div></ix:continuation><div id="i2e52e163a2594578be1a28935e1f5f13_55"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-750" continuedAt="f-750-1" escape="true">CAPITAL STOCK</ix:nonNumeric></span></div><ix:continuation id="f-750-1" continuedAt="f-750-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="vrdn:CapitalStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-751">205,000,000</ix:nonFraction> shares of its stock, of which <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-752">200,000,000</ix:nonFraction> shares have been designated as common stock and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-753">5,000,000</ix:nonFraction> shares have been designated as preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-754"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-755">0.01</ix:nonFraction></ix:nonFraction> per&#160;share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="c-3" decimals="INF" name="vrdn:CommonStockVotePerShare" format="ixt-sec:numwordsen" scale="0" id="f-756">one</ix:nonFraction> vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Sales Agreements - Jefferies LLC</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="INF" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-757">175.0</ix:nonFraction>&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of <ix:nonFraction unitRef="number" contextRef="c-214" decimals="INF" name="vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds" scale="-2" id="f-758">3.0</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-759"><ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-760">No</ix:nonFraction></ix:nonFraction> shares were sold under the September 2022 ATM Agreement during the three months ended September 30, 2024 and 2023. During the nine months ended September 30, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-761">1,561,570</ix:nonFraction> shares under the September 2022 ATM Agreement with Jefferies at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-217" decimals="2" name="vrdn:SaleOfStockWeightedAverageSharePrice" scale="0" id="f-762">23.22</ix:nonFraction> per share, for aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-763">35.2</ix:nonFraction>&#160;million, including commissions to Jefferies as a sales agent. <ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-764">No</ix:nonFraction> shares were sold under the September 2022 ATM Agreement during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company issued and sold in private placement transactions an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-219" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-765">8,869,797</ix:nonFraction> shares of the Company&#8217;s common stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-766">12.38</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-221" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-767">92,312</ix:nonFraction> shares of the Company&#8217;s Series B Preferred Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-222" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-768">825.3746</ix:nonFraction>, pursuant to securities purchase agreements with certain institutional and accredited investors. The Company received aggregate gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-769">186.0</ix:nonFraction>&#160;million, before deducting offering expenses payable by the Company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company entered into an underwriting agreement with Jefferies and Leerink Partners LLC  relating to the offer and sale (the &#8220;January 2024 Public Offering&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-224" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-770">7,142,858</ix:nonFraction> shares of the Company&#8217;s common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-225" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-771">21.00</ix:nonFraction> per share. The aggregate gross proceeds to the Company from the January 2024 Public Offering were approximately $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-772">150.0</ix:nonFraction>&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-750-2" continuedAt="f-750-3"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into an underwriting agreement with Jefferies, Goldman Sachs &amp; Co. LLC and Stifel, Nicolaus &amp; Company, Incorporated related to the offer and sale (the &#8220;September 2024 Public Offering&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-227" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-773">12,466,600</ix:nonFraction> shares of the Company&#8217;s common stock, which included <ix:nonFraction unitRef="shares" contextRef="c-228" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-774">1,800,000</ix:nonFraction> shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-229" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-775">18.75</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="c-230" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-776">20,000</ix:nonFraction> shares of the Company&#8217;s Series B Preferred Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="4" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="f-777">1,250.0625</ix:nonFraction> per share. The aggregate gross proceeds to the Company from the September 2024 Public Offering, including the exercise of the option, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-778">258.8</ix:nonFraction>&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company&#8217;s board of directors has the authority to designate and issue up to <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-779">5,000,000</ix:nonFraction> shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#8217;s stockholders. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least <ix:nonFraction unitRef="number" contextRef="c-233" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="f-780">30</ix:nonFraction>% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into <ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="f-781">66.67</ix:nonFraction> shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between <ix:nonFraction unitRef="number" contextRef="c-234" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="f-782">4.99</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-235" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="f-783">19.99</ix:nonFraction>%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December 31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-784">134,864</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-785">172,435</ix:nonFraction> shares of Series A Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-236" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-786">37,571</ix:nonFraction> shares of Series A Preferred Stock were converted into <ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-787">2,504,855</ix:nonFraction> shares of common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="f-788">66.67</ix:nonFraction> shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between <ix:nonFraction unitRef="number" contextRef="c-238" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="f-789">4.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-239" decimals="INF" name="vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership" scale="-2" id="f-790">19.9</ix:nonFraction>%) of the total number of shares of common stock issued and outstanding immediately after </span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-750-3" continuedAt="f-750-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in September 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December 31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-791">145,160</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-792">143,522</ix:nonFraction> shares of Series B Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-240" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-793">18,362</ix:nonFraction> of Series B Preferred Stock were converted into <ix:nonFraction unitRef="shares" contextRef="c-241" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-794">1,224,193</ix:nonFraction> shares of common stock.</span></div></ix:continuation><div id="i2e52e163a2594578be1a28935e1f5f13_58"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:continuation id="f-750-4" continuedAt="f-750-5">WARRANTS</ix:continuation></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-795" continuedAt="f-795-1" escape="true"><ix:continuation id="f-750-5" continuedAt="f-750-6"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at September&#160;30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at September&#160;30, 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(No. Years)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" scale="0" id="f-796">781</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" scale="0" id="f-797">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-242" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-798">127.95</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-244" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="f-799">0.58</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-800">29,446</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-801">29,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-245" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-802">0.02</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-247" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="f-803">5.98</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-804">218,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-249" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-805">218,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-248" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-806">14.44</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-250" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="f-807">0.37</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-808">1,606</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-252" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-809">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-251" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-810">0.69</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-253" name="vrdn:ClassofWarrantorRightRemainingTerm" format="ixt-sec:duryear" id="f-811">0.12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-812">249,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-813">249,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-254" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-814">15.15</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-815">249,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" format="ixt:num-dot-decimal" scale="0" id="f-816">249,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-817">15.51</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div></ix:continuation></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-795-1"><ix:continuation id="f-750-6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the nine months ended September 30, 2024 is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-818">249,883</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-819">15.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="vrdn:ClassOfWarrantOrRightExercisedInPeriod" format="ixt:fixed-zero" scale="0" id="f-820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="vrdn:ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-822">249,883</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-823">15.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;margin-top:5pt"><span><br/></span></div><div id="i2e52e163a2594578be1a28935e1f5f13_61"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-824" continuedAt="f-824-1" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-824-1" continuedAt="f-824-2"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under its 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;), its amended and restated 2016 Equity Incentive Plan ( the &#8220;2016 Plan&#8221;), and the Viridian 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221; and collectively with the 2008 Plan and the 2016 Plan, the &#8220;Equity Incentive Plans&#8221;). Additionally, beginning in July 2021, the Company granted stock options and RSUs outside of its Equity Incentive Plans to certain employees to induce them to accept employment with the Company (the &#8220;Inducement Awards&#8221;). The terms and conditions of the Inducement Awards are substantially similar to those awards granted under the Company&#8217;s Equity Incentive Plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company&#8217;s stockholders approved the amendment and restatement of the 2016 Plan to, among other things, transfer the then remaining number of shares available for issuance under the 2020 Plan into the 2016 Plan so that the Company operates from a single equity plan going forward. In June 2023, the Company&#8217;s stockholders approved a further amendment and restatement of the 2016 Plan to, among other things, increase the number of shares reserved for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-825">2,000,000</ix:nonFraction> shares. In June 2024, the Company&#8217;s stockholders approved a further amendment and restatement of the 2016 Plan to, among other things, increase the number of shares reserved for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-826">2,000,000</ix:nonFraction> shares. The 2016 Plan will terminate on April 19, 2034.  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-827" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company had the following balances by plan: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Available for Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-829">5,663,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-260" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-832">125,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="f-833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-834">514,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-835">5,563,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-836">4,639,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-838">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="f-839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-840">514,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-841">11,352,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-842">4,639,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted under the Equity Incentive Plans and the Inducement Awards generally vest annually over a <ix:nonNumeric contextRef="c-267" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-843">4-year</ix:nonNumeric> period and are settled in shares of the Company&#8217;s common stock. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-844" continuedAt="f-844-1" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity is as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-824-2" continuedAt="f-824-3"><ix:continuation id="f-844-1"><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.666%"><tr><td style="width:1.0%"/><td style="width:65.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-845">804,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-268" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-846">15.82</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-847">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-848">18.85</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-849">19,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-850">35.40</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-851">276,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-852">16.33</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-853">514,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-266" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-854">14.85</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the Equity Incentive Plans and the Inducement Awards have an exercise price equal to the market value of the common stock at the date of grant and expire <ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-855">10</ix:nonNumeric> years from the date of grant. Options generally vest <ix:nonFraction unitRef="number" contextRef="c-270" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-856">25</ix:nonFraction>% on the first anniversary of the vesting commencement date and <ix:nonFraction unitRef="number" contextRef="c-271" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-857">75</ix:nonFraction>% ratably in equal monthly installments over the remaining <ix:nonNumeric contextRef="c-271" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-858">36</ix:nonNumeric> months or in equal monthly or quarterly amounts over periods of up to <ix:nonNumeric contextRef="c-269" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-859">48</ix:nonNumeric> months.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-860" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-861">11,533,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-272" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-862">19.68</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-273" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-863">8.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-864">54,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-865">2,996,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-866">15.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-867">232,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-868">9.31</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-869">2,945,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-870">22.58</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-871">11,352,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-872">17.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-873">8.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-874">68,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-875">11,352,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-876">17.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-877">8.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-878">68,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-879">3,324,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-880">21.66</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-881">5.39</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-882">9,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-883">3,324,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-884">21.66</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-885">5.39</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-886">9,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Assumptions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under its equity compensation plans. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected terms of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on a blend of historical data from public companies that are similar to the Company in size and nature of operations, as well as the Company&#8217;s own volatility. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company accounts for forfeitures as they occur. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted, and actual and expected option-exercise behaviors. The fair value of the underlying common stock is based on the closing price of the common stock on The Nasdaq Capital Market at the date of grant.</span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><ix:continuation id="f-824-3" continuedAt="f-824-4"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-887">10.83</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-275" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-888">23.19</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-889" continuedAt="f-889-1" escape="true">The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-889-1"><div style="margin-bottom:12pt;padding-right:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-890">5.11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-275" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-891">5.57</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-892">88.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-275" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-893">90.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-894">4.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-275" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-895">3.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-896">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-275" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-897">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-274" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-898">15.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-276" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-899">31.07</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) allows qualified employees to purchase shares of common stock at a price equal to&#160;<ix:nonFraction unitRef="number" contextRef="c-277" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-900">85</ix:nonFraction>%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. As of&#160;September&#160;30, 2024, the Company had&#160;<ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-901">1,187,109</ix:nonFraction>&#160;shares available for issuance, and <ix:nonFraction unitRef="shares" contextRef="c-279" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-902">102,426</ix:nonFraction> cumulative shares had been issued under the ESPP.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-903" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans, the Inducement Awards, and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the condensed consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.236%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-904">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-905">4,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-906">17,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-907">11,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-908">4,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-909">9,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-910">16,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-911">29,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total share-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-912">8,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-913">13,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-914">33,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-915">41,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-916">4.6</ix:nonFraction>&#160;million in share-based compensation related to the acceleration of vesting for former executive officers, an amount which includes $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-917">0.3</ix:nonFraction>&#160;million related to the modification of the terms of options outstanding at the time of termination for one executive which would have otherwise forfeited. The Company also recorded $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-918">2.0</ix:nonFraction>&#160;million in share-based compensation related to the accounting for a modification of the equity awards to extend the post-termination exercise period of certain vested stock options for a former executive.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-919">9.1</ix:nonFraction>&#160;million in share-based compensation related to the acceleration of vesting for former executive officers, an amount which includes $<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-920">1.6</ix:nonFraction>&#160;million related to the modification of the terms of options outstanding at the time of termination for one executive which would have otherwise forfeited.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-921">87.1</ix:nonFraction> million of total unrecognized share-based compensation costs related to stock options, which the Company expects to recognize over a weighted-average remaining period of <ix:nonNumeric contextRef="c-269" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-922">2.95</ix:nonNumeric> years. As of September&#160;30, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-923">5.9</ix:nonFraction> million of total unrecognized share-</span></div></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-824-4">based compensation costs related to unvested RSUs, which the Company expects to recognize over a weighted-average remaining period of <ix:nonNumeric contextRef="c-267" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-924">3.03</ix:nonNumeric> years.</ix:continuation> </span></div><div id="i2e52e163a2594578be1a28935e1f5f13_64"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-925" continuedAt="f-925-1" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-925-1"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of common stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Diluted net loss per share is the same as basic net loss per share of common stock, as the effects of potentially dilutive securities are antidilutive.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-926" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities include the following:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.000%"><tr><td style="width:1.0%"/><td style="width:68.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock (as converted to shares of common stock)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-927">8,991,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-928">11,496,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock (as converted to shares of common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-293" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-929">9,677,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-930">3,414,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-931">11,352,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-296" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-932">8,261,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-933">249,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-934">249,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-299" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-935">514,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-300" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-936">338,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-937">30,785,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-938">23,760,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_67"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read together with our condensed consolidated financial statements and the related notes thereto included in Part I, Item 1 of this Quarterly Report and our consolidated financial statements and related notes thereto for the year ended December 31, 2023 included in our Annual Report on Form 10-K filed with the SEC on February 27, 2024 (&#8220;2023 Annual Report on Form 10-K&#8221;). This discussion and other parts of this report contain forward-looking statements reflecting our current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, intentions, and beliefs. See &#8220;Forward-Looking Statements&#8221; for a discussion of the uncertainties, risks, and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk Factors&#8221; included elsewhere in this Quarterly Report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Recent Developments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases. We target disease areas where marketed therapies often leave room for improvements in efficacy, safety, and/or dosing convenience. We believe that first-generation medicines rarely represent optimal solutions, especially in rare disease areas, and that there is potential to develop differentiated, best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, expanded market access, and augmented market competition. Our business model is designed to identify and evaluate product opportunities in disease areas where trial data establishes proof-of-concept for a drug target in the clinic, but the competitive evolution of the product life cycle management and number of entrants appears incomplete. We intend to prioritize indications where a fast-follower and a potentially differentiated drug candidate, or overall product profile, could create significant medical benefit for patients. We are engineering product candidates to address unmet medical needs for patients and further advance drug innovation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to identify and evaluate product concepts leveraging clinically validated molecular targets using established therapeutic modalities. We prioritize product concepts that are aligned with clinical and commercial hypotheses, which we expect will provide an attractive balance of risk and opportunity, thereby representing a compelling allocation of our resources. We focus on advancing therapeutic proteins, including antibodies, that we either in-license or discover internally, incorporating proprietary therapeutic protein and antibody discovery and optimization platforms to advance clinical candidates with unique characteristics. We have built relevant expertise in protein and antibody discovery and engineering, biologics manufacturing, nonclinical and clinical development for TED, development of anti-neonatal Fc receptor therapies, and nonclinical and clinical development for indications in rare and autoimmune diseases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to rapidly discovering and developing novel therapeutics relies on our scientific expertise in evaluating pre-existing clinical proof-of-concept data for the drug targets we are pursuing, and opportunities to improve upon existing investigational and/or approved therapies. This approach informs how we design, select, and develop our product candidates, including in critical areas such as pharmacokinetics, pharmacodynamics, clinical trial design, trial endpoints, and the selection and recruitment of patients. We believe this strategy reduces the risks associated with discovering and developing novel therapeutics.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have first prioritized the development of therapies for the treatment of TED, a serious and debilitating rare autoimmune disease that causes inflammation within the orbit of the eye that can cause bulging of the eyes, redness and swelling, double vision, pain, and potential blindness. TED significantly impacts quality of life, imposing a high burden on activities of daily living and mental health for patients suffering from the disease. TED is a progressive disease consisting of an initial active phase, followed by a transition to a secondary </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chronic phase. The only medicine approved by the FDA for TED is Tepezza&#174; (teprotumumab), which is an intravenously administered monoclonal antibody that targets IGF-1R. Tepezza&#174; is marketed in the United States by Horizon Therapeutics plc (&#8220;Horizon&#8221;), which was acquired by Amgen Inc. (&#8220;Amgen&#8221;) in October 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results from clinical trials of teprotumumab conducted by Horizon provide strong clinical validation linking the targeting of IGF-1R to clinical benefit in patients with TED. However, clinical trials evaluating teprotumumab in patients with TED reported to date used a single dosing regimen, providing little guidance as to the optimal dosing required for clinical activity in TED. We believe that there are multiple opportunities to develop fast-follower therapeutics that improve on teprotumumab&#8217;s features, including dosing schedule, route of administration, and safety profile.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing two product candidates, veligrotug (formerly known as VRDN-001) for intravenous and VRDN-003 for subcutaneous administration, to treat patients who suffer from TED. Our most advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In previously presented </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical data, we showed that veligrotug is a potentially differentiated full antagonist of IGF-1R, compared to teprotumumab&#8217;s incomplete antagonism of IGF-1R. We also conducted phase 1/2 clinical trials of veligrotug in patients with active or chronic TED. In the active TED portion of the phase 1/2 clinical trials, data reported from all three dose cohorts of veligrotug (n=21) showed significant and rapid improvement in both the signs and symptoms of TED after two infusions of veligrotug compared to placebo. Across all veligrotug treated patients in the active TED trial, 71% were proptosis responders, 67% were overall responders, 62% achieved a CAS of 0 or 1, and 54% had complete resolution of their diplopia. In the chronic TED portion of the phase 1/2 clinical trials, data reported from both dose cohorts of veligrotug (n=12) showed significant and rapid improvement in the signs and symptoms of TED after two infusions of veligrotug compared to placebo. Across all veligrotug treated patients in the chronic TED trial, 42% were proptosis responders, 40% achieved a CAS of 0 or 1, and no patients had complete resolution of their diplopia. In the phase 1/2 clinical trials of both active and chronic TED, veligrotug had a favorable safety profile and was well-tolerated by all patients treated in all dose cohorts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a global pivotal program for veligrotug, including evaluating its efficacy and safety in two global well-controlled phase 3 clinical trials, THRIVE and THRIVE-2, for the treatment of active and chronic TED, respectively. On September 10, 2024, we announced topline data from the THRIVE study, which enrolled 113 patients, randomized to veligrotug (n=75) and placebo (n=38). THRIVE achieved all primary and secondary endpoints with a high level of statistical significance (p &lt; 0.0001) and was generally well-tolerated, with no treatment-related SAEs. Veligrotug additionally showed a rapid onset of action, with the majority (53%) of veligrotug-treated patients achieving a proptosis response after just one infusion, or three weeks after start of therapy. We completed enrollment of THRIVE-2 in July 2024, and expect to announce topline data for this study by the end of 2024. THRIVE and THRIVE-2 are each designed to compare a five-dose IV treatment arm of veligrotug at 10 mg/kg, dosed three weeks apart, to placebo. This five-dose veligrotug regimen features fewer infusions and a shorter time per infusion compared to teprotumumab, the currently marketed IGF-1R inhibitor. In addition, to meet the 300 patient standard safety database requirements for the veligrotug biologics license application (&#8220;BLA&#8221;), we are actively enrolling patients into our STRIVE clinical trial. STRIVE is a global study of veligrotug in TED patients that utilizes broad inclusion criteria (e.g., any severity or duration of disease) and is randomized 3:1 (10 mg/kg IV with an active control of 3 mg/kg IV). We are also enrolling patients in the open label extension study for non-responding patients in THRIVE and THRIVE-2. We anticipate filing a BLA for veligrotug in the second half of 2025.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our veligrotug IV program, in December 2023 we selected VRDN-003 as our subcutaneous product candidate for pivotal development in TED following positive data in a phase 1 clinical trial in healthy volunteers. We believe VRDN-003 has the potential to be the best-in-class subcutaneous anti-IGF-1R product candidate by preserving the efficacy of anti-IGF-1Rs in TED, improving safety, and maximizing convenience for patients. VRDN-003 has the same binding domain as veligrotug, and was engineered to have a longer half-</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">life. VRDN-003 is designed to be a low-volume, self-administered, infrequently dosed subcutaneous IGF-1R for TED, which we plan to launch commercially with an auto-injector.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VRDN-003 phase 1 clinical study showed VRDN-003 to have a prolonged half-life of 40 to 50 days, which is four to five times that of veligrotug. Because of the healthy volunteer data and the similarities between the veligrotug and VRDN-003 antibodies, we expect VRDN-003 to have similar clinical responses at the exposure levels of veligrotug that led to robust clinical activity in its clinical trials to date in TED. Further, pharmacokinetic modeling of VRDN-003 based on the healthy volunteer data predicted that exposure levels of VRDN-003 could be achieved that are equivalent to exposure levels of veligrotug that produced clinically meaningful results with multiple dosing regimens of VRDN-003, i.e., subcutaneous injection every two, four, or eight weeks. We are advancing our VRDN-003 program, including the initiation of two global phase 3 clinical trials for VRDN-003 in August 2024: REVEAL-1 and REVEAL-2 in active and chronic TED, respectively. Both studies will evaluate subcutaneous VRDN-003 administered every four weeks or every eight weeks and will assess outcomes versus placebo. We also anticipate that the program will include a safety study to complete a 300 patient standard safety database (to include patients from the REVEAL-1 and REVEAL-2 trials), and we expect that it will also include the required development to have an auto-injector device available at the time of commercial launch, if approved. We anticipate topline data for REVEAL-1 and REVEAL-2 in the first half of 2026, and we anticipate submitting a BLA for VRDN-003 for the treatment of TED by the end of 2026.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to developing therapies for TED, we have also prioritized developing a portfolio of engineered anti-FcRn inhibitors, including VRDN-006 and VRDN-008. FcRn inhibitors have the potential to treat a broad array of autoimmune diseases, representing a possible significant commercial market opportunity. Our multi-pronged engineering approach has resulted in a portfolio of FcRn-targeting molecules that leverage the clinically and commercially validated mechanism of FcRn inhibition while potentially addressing the limitations of current agents such as incomplete immunoglobulin G (&#8220;IgG&#8221;) suppression, safety, and inconvenience of dosing.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VRDN-006 is a FcRn-targeting Fc fragment, and in non-human primate studies, demonstrated specificity for blocking FcRn-IgG interactions while not showing decreases in albumin or increases in LDL levels, which are known potential side effects associated with certain full-length anti-FcRn monoclonal antibodies. In our head-to-head non-human primate studies, VRDN-006 demonstrated comparable potency and IgG reductions to efgartigimod, which is the current standard of care in FcRn inhibition, as well as a similar safety profile. We plan to file an IND for VRDN-006 by the end of 2024 and expect healthy volunteer data for VRDN-006 in the second half of 2025. VRDN-008 is a novel, potential first-in-class FcRn inhibitor that aims to pair IgG suppression with extended half-life technology, potentially enabling deeper and more durable suppression of IgG than existing anti-FcRn therapies. Both molecules are designed to be convenient, self-administered, subcutaneous products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Global Economic Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan, the conflict in Israel and surrounding area and other political tensions. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, high interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue has historically consisted primarily of up-front payments for licenses, milestone payments, and payments for other research and development services earned under license and collaboration agreements as well as for amounts earned under certain grants we have been awarded.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we became party to a license agreement with Zenas BioPharma (Cayman) Limited (&#8220;Zenas BioPharma&#8221;). Since February 2021, we have entered into several letter agreements with Zenas BioPharma in which we agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing (collectively with the license agreement, the &#8220;Zenas Agreements&#8221;). Under the terms of the Zenas Agreements, we granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China in exchange for upfront non-cash consideration and non-refundable milestone payments upon achieving specific milestone events during the contract term. Zenas BioPharma announced that it had obtained IND approval in China in July 2022. Under the license agreement, we received a $1.0 million milestone payment from Zenas BioPharma. Additionally, we are eligible to receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to us for the royalty term in the Zenas Agreements. In May 2022, we entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma to manufacture and supply, or have manufactured and supplied, clinical drug product for development purposes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect to continue to generate revenue from a combination of license fees and other up-front payments, payments for research and development services, milestone payments, product sales, and royalties in connection with strategic alliances. We expect that any revenue we generate could fluctuate from quarter to quarter as a result of the timing of our achievement of development and commercial milestones, the timing and amount of payments relating to such milestones, and the extent to which any of our product candidates are approved and successfully commercialized by us or our strategic alliance collaborators, if any. If we or our strategic alliance collaborators, if any, fail to develop product candidates in a timely manner or to obtain regulatory approval for them, then our ability to generate future revenue, and our results of operations and financial position would be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred for the research and development of our therapeutic programs and product candidates, which include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, severance, retention, benefits, insurance, and share-based compensation expense;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with clinical research organizations (&#8220;CROs&#8221;), investigative sites that conduct our clinical trials, and other clinical trial-related vendors, and consultants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of acquiring, developing, and manufacturing and testing clinical and preclinical materials, including costs incurred under agreements with contract manufacturing organizations (&#8220;CMOs&#8221;);</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with non-clinical activities and regulatory operations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees and milestone payments related to the acquisition and retention of certain licensed technology and intellectual property rights; and</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation, market research, and other expenses, which include allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make non-refundable advance payments for goods and services that will be used in future research and development activities. These payments are recorded as expense in the period in which we receive or take ownership of the goods or when the services are performed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record up-front and milestone payments to acquire and retain contractual rights to in-licensed technology and intellectual property rights as research and development expenses when incurred if there is uncertainty in our receiving future economic benefit from the acquired contractual rights. We consider future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the FDA or other regulatory authorities, or when other significant risk factors are abated.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will increase as we expand our clinical development programs and initiate new clinical trials. The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We, or our strategic alliance collaborators, if any, may never succeed in achieving marketing approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including clinical data, preclinical data, competition, manufacturability, and commercial viability of our product candidates. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of future product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new strategic alliances with respect to each program or potential product candidate, the scientific and clinical success of each future product candidate, and ongoing assessments as to each future product candidate&#8217;s commercial potential. We will need to raise additional capital and may seek additional strategic alliances in the future in order to advance the various clinical trials that are part of our clinical development program described above.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation, and severance and retention benefits related to our finance, accounting, human resources, legal, business development, and other support functions, professional fees for auditing, tax, and legal services, market research and other professional and consulting fees to prepare for commercial activities, as well as insurance, board of director compensation, consulting, and other administrative expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income, net of fees, and various income items of a non-recurring nature. Interest expense consists of cash and non-cash interest expense on our long-term debt. We earn interest income from interest-bearing accounts, money market funds, and short-term investments. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our critical accounting policies as disclosed in our 2023 Annual Report on Form 10-K during the nine months ended September 30, 2024. Our significant accounting policies are disclosed in Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_70"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2024 and 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.401%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for both the three months ended September 30, 2024 and 2023 was attributable to our collaboration agreement with Zenas BioPharma. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $69.2 million during the three months ended September 30, 2024, compared to $30.4 million during the three months ended September 30, 2023. The $38.8 million increase in research and development expenses is primarily attributable to the following:  </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$17.4 million increase in clinical trial costs mainly due to expenses associated with our ongoing THRIVE and THRIVE-2 clinical trials; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$10.6 million increase in chemistry, manufacturing and controls costs to support our ongoing and planned clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.3 million increase in milestone, license and option fees due to the $4.0 million upfront payment to Paragon for an exclusive license agreement during the three months ended September 30, 2024;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.3 million increase in preclinical research costs to advance our FcRn inhibitor portfolio; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.9 million increase in personnel related costs, due primarily to increased headcount to support our ongoing research and development efforts, including share-based compensation and other employee compensation and recruiting costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase as we continue to advance our clinical and preclinical programs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $14.4 million during the three months ended September 30, 2024, compared to $20.9 million during the three months ended September 30, 2023. The $6.5 million decrease in general and administrative expenses is primarily attributable to a $7.1 million decrease in personnel-related costs, primarily due to a decrease in headcount and a decrease in share-based compensation and other employee compensation and recruiting costs. This decrease is partially offset by a $0.7 million increase in market research and other professional services fees. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $6.8 million during the three months ended September 30, 2024 compared to $3.6 million during the three months ended September 30, 2023. Other income, net for the three months ended September 30, 2024 is comprised of $7.5 million of interest income earned on short-term investments, $0.2 million gain on investment as well as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of sub-lease income, offset by $0.5 million in interest expense related to our Hercules Loan and Security Agreement and $0.4 million loss on disposal of equipment. Other income, net for the three months ended September 30, 2023 is comprised of $4.1 million of interest income earned on short-term investments as well as $0.1 million of sub-lease income, partially offset by $0.4 million in interest expense related to our Hercules Loan and Security Agreement and a $0.2 million loss on debt extinguishment related to the Hercules Amendment. The increase in interest income, as compared to prior year, is primarily attributable to higher average short-term investment balances during the three months ended September 30, 2024 as compared to the three months ended September 30, 2023. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2024 and 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.401%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for both the nine months ended September 30, 2024 and 2023 was attributable to our collaboration agreement with Zenas BioPharma. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $166.3 million during the nine months ended September 30, 2024, compared to $121.2 million during the nine months ended September 30, 2023. The $45.1 million increase in research and development expenses is primarily attributable to the following:  </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$37.6 million increase in clinical trial costs mainly due to expenses associated with our ongoing THRIVE and THRIVE-2 clinical trials; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$8.5 million increase in chemistry, manufacturing and controls costs to support our ongoing and planned clinical trials;</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$4.2 million increase in severance costs primarily related to separation agreements with former executive officers, including a $3.2 million increase in share-based compensation related to the acceleration of stock option vesting during the nine months ended September 30, 2024; </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$8.1 million increase in personnel related costs, due primarily to increase in headcount to support our ongoing research and development efforts, including increased share-based compensation and other employee compensation and recruiting costs;</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.4 million increase in professional service fees for consultants and contractors to support ongoing programs; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.9 million increase in preclinical research costs to advance our FcRn inhibitor portfolio.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases are partially offset by a $16.7 million decrease in milestone, license and option fees as a result of the $15.0 million upfront payment for development of subcutaneous delivery systems and the $5.7 million upfront payment for an exclusive license and collaboration agreement incurred during the nine months ended September 30, 2023, offset by the $4.0 million upfront payment to Paragon for an exclusive license agreement during the nine months ended September 30, 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase as we continue to advance our clinical and preclinical programs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $45.5 million during the nine months ended September 30, 2024, compared to $62.0 million during the nine months ended September 30, 2023. The $16.5 million decrease in general and administrative expenses is primarily attributable to the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$8.2 million decrease in severance costs primarily related to separation agreements with former executive officers, including a $5.7 million decrease in share-based compensation related to the modification and acceleration of stock option vesting for former executives. Share-based compensation costs for the nine months ended September 30, 2024 included $3.4&#160;million in costs related to the modification and acceleration of vesting for former executive officers as compared to $9.1 million for the nine months ended September 30, 2023; and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$8.8 million decrease in personnel-related costs, primarily due to a decrease in headcount and a decrease in share-based compensation and other employee compensation and recruiting costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by a $0.9 million increase in consulting and other professional services fees. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net was $21.3 million during the nine months ended September 30, 2024 compared to $12.1 million during the nine months ended September 30, 2023. Other income, net for the nine months ended September 30, 2024 is comprised of $23.1 million of interest income earned on cash equivalents and short-term investments, $0.2 million gain on investment as well as $0.3 million of sub-lease income, offset by $1.7 million in interest expense related to our Hercules Loan and Security Agreement and $0.4 million loss on disposal of equipment. Other income, net for the nine months ended September 30, 2023 is comprised of $12.8 million of interest income earned on cash equivalents and short-term investments as well as $0.2 million of sub-lease income, partially offset by $0.8 million in interest expense related to our Hercules Loan and Security Agreement and a $0.2 million loss on debt extinguishment related to the Hercules Amendment. The increase in </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest income, as compared to prior year, is primarily attributable to higher average cash equivalent and short-term investment balances during the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023. </span></div><div id="i2e52e163a2594578be1a28935e1f5f13_73"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations to date principally through proceeds received from the sale of our common stock, our Series A Preferred Stock, our Series B Preferred Stock and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. As of September&#160;30, 2024, we had $753.2 million in cash, cash equivalents, and short-term investments. We expect that our current cash, cash equivalents and short-term investments will be sufficient to fund our operations, including our clinical development plan described above, into the second half of 2027. In addition, as of September&#160;30, 2024, the Company has access to additional undrawn funds under the Hercules Amended Term Loan, as described below.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. Since our inception and through September&#160;30, 2024, we have generated an accumulated deficit of $916.1 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to require substantial additional capital to continue the development of our product candidates, and potential commercialization activities, and to fund our ongoing operations, including our clinical development plan described above. The amount and timing of future funding requirements will depend on many factors, including the pace and results of our clinical development efforts, equity financings, securing additional license and collaboration agreements, and issuing debt or other financing vehicles. Our ability to secure capital is dependent upon a number of factors, including success in developing our technology and product candidates. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Changing circumstances, such as changes in the scope and timing of our clinical studies, may cause us to consume capital significantly faster or slower than we currently anticipate. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to complete future milestones. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings or entering into strategic collaborations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments primarily consist of obligations under our collaboration, development, and license agreements. Under these agreements, we are required to make milestone payments upon successful completion of certain regulatory and sales milestones. The payment obligations under the license agreements are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As of September 30, 2024, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional information regarding our agreements, see Note 6 and Note 7 to our condensed consolidated financial statements included elsewhere in this report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease obligations primarily consist of lease payments on our lab and office facilities in Boulder, Colorado and our office space in Waltham, Massachusetts. For additional information regarding our lease obligations, see Note 7 to our condensed consolidated financial statements included elsewhere in this report.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have entered into agreements with third-party contract manufacturers for the manufacture and processing of certain of our product candidates for clinical testing purposes, and we have entered and will enter into other contracts in the normal course of business with contract research organizations for clinical trials and </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation with appropriate notice, other than for costs already incurred. We expect to enter into additional clinical development, contract research, clinical and commercial manufacturing, supplier and collaborative research agreements in the future, which may require upfront payments and long-term commitments of capital resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through the issuance of debt, the obligations related to such debt could be senior to rights of holders of our capital stock and could contain covenants that may restrict our operations. Should additional capital not be available to us in the near term, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business, which may, among other alternatives, cause us to further delay, substantially reduce, or discontinue operational activities to conserve our cash resources.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan and Security Agreement with Hercules Capital, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we entered into a loan and security agreement (the &#8220;Hercules Loan and Security Agreement&#8221;) among the Company, certain of our subsidiaries from time to time party thereto (together with the Company, collectively, the &#8220;Borrower&#8221;), Hercules Capital, Inc. (&#8220;Hercules&#8221;) and certain other lenders party thereto (the &#8220;Lenders&#8221;). Under the Hercules Loan and Security Agreement, the Lenders provided us with access to a term loan with an aggregate principal amount of up to $75.0 million, in four tranches (collectively the &#8220;Term Loan&#8221;), including an initial tranche of $25.0 million, which was available through June 15, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the Hercules Loan and Security Agreement, we were originally obligated to make interest-only payments through April 1, 2024, which was extended to October 1, 2024 upon the achievement of a development milestone in August 2022. We were required to repay the Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, we were required to pay an end-of-term fee equal to 6% of the principal amount of funded Term Loan Advances (as defined in the Hercules Loan and Security Agreement) at maturity, which were being accreted as additional interest expense over the term of the loan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we executed an amendment to the Hercules Loan and Security Agreement (the &#8220;Hercules Amendment&#8221;).The Hercules Amendment was determined to substantially alter the Hercules Loan and Security Agreement and therefore was accounted for as a debt extinguishment. We recognized a loss on debt extinguishment of $0.2 million in August 2023 related to unamortized debt discount and debt issuance costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hercules Amendment, the Lenders provided the Company access to an increased term loan with an aggregate principal amount of up to $150 million, in four tranches (collectively the &#8220;Amended Term Loan&#8221;), consisting of (1) an initial tranche of $50.0 million, $5.0 million of which was drawn at closing of the Hercules Loan and Security Agreement in April 2022, $15.0 million of which was drawn at closing of the Hercules Amendment in August 2023, $5.0 million of which was available through December 15, 2023, and $25.0 million available from July 1, 2024 through December 15, 2024; (2) a second tranche of $20.0 million, subject to achievement of certain regulatory milestones, available through February 15, 2025; (3) a third tranche of $20.0 million, subject to achievement of certain regulatory milestones, available through March 31, 2025; and (4) a fourth tranche of $60.0 million subject to approval by the Lenders&#8217; investment committee(s), available through June 15, 2025. The milestones for the second and third tranches have not yet been achieved. The obligations of the Borrower under the Hercules Amendment agreement are secured by substantially all of the assets of the Borrower, excluding the Borrower&#8217;s intellectual property. The Amended Term Loan has a maturity date of October 1, 2026.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Term Loan bears interest at a floating per annum rate equal to the greater of (i) 7.45% and (ii) 4.2% above the Prime Rate (as defined therein), provided that the Term Loan interest rate shall not exceed a per </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annum rate of 8.95%. Interest is payable monthly in arrears on the first day of each month. The interest rate as of September 30, 2024 was 8.95%.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the Hercules Amendment, we were originally obligated to make interest-only payments through April 1, 2025. Upon achievement of certain development milestones related to our topline results for our phase 3 THRIVE trial in September 2024, the interest-only period was extended to October 1, 2025. If additional development milestones are met, the interest-only period will be further extended to April 1, 2026. The Borrower is required to repay the Amended Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, the Borrower is required to pay an end-of-term fee equal to 6% of the principal amount of funded Amended Term Loan advances at maturity, which are being accreted as additional interest expense over the term of the loan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we entered into an underwriting agreement with Jefferies LLC (&#8220;Jefferies&#8221;) and Leerink Partners LLC relating to the offer and sale (the &#8220;January 2024 Public Offering&#8221;) of 7,142,858 shares of our common stock at a public offering price of $21.00 per share. The aggregate gross proceeds to us from the January 2024 Public Offering were approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, we entered into an underwriting agreement with Jefferies, Goldman Sachs &amp; Co. LLC and Stifel, Nicolaus &amp; Company, Incorporated related to the offer and sale (the &#8220;September 2024 Public Offering&#8221;) of 12,466,600 shares of our common stock, which includes 1,800,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $18.75 per share, and 20,000 shares of our Series B Preferred Stock at a price per share of $1,250.0625 per share. The aggregate gross proceeds to us from the September 2024 Public Offering, including the exercise of the option, were approximately $258.8 million, before deducting underwriting discounts and commissions and other offering expenses payable by us. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we issued and sold in private placement transactions an aggregate of 8,869,797 shares of our common stock at a price per share of $12.38 and 92,312 shares of our Series B Preferred Stock at a price per share of $825.3746, pursuant to securities purchase agreements with certain institutional and accredited investors. We received aggregate gross proceeds of approximately $186.0 million, before deducting offering expenses payable by us. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Agreement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $175.0 million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as the sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. During the year ended December 31, 2023, the Company sold 684,298 shares under the September 2022 ATM Agreement with Jefferies at a weighted average price of $22.30 per share, for aggregate net proceeds of approximately $14.8 million, including commissions to Jefferies as a sales agent. During the nine months ended September 30, 2024, we sold 1,561,570 shares under the September 2022 ATM Agreement with Jefferies at a weighted average price of $23.22 per share, for aggregate net proceeds of approximately $35.2 million, including commissions to Jefferies as a sales agent. During the three months ended September 30, 2024, there were no sales under the September 2022 ATM Agreement.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized cash flows for the nine months ended September 30, 2024 and 2023 are as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.401%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,982)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $159.0 million for the nine months ended September 30, 2024, and primarily consisted of our net loss of $190.2 million, adjusted for non-cash items of $22.1 million (primarily share-based compensation of $33.2 million, offset by the accretion and amortization of premiums and discounts on available-for-sale securities of $12.4 million), and changes in working capital of $9.1 million. The change in working capital was primarily related to a net increase of $14.6 million in accounts payable and accrued and other liabilities, partially offset by an increase of $5.3 million in prepaid expenses and other current assets due to the timing of payments to vendors for ongoing clinical trial and manufacturing activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $146.2 million for the nine months ended September 30, 2023, and primarily consisted of a net loss of $170.9 million, adjusted for non-cash items of $39.7 million (primarily share-based compensation of $41.1 million) and changes in working capital of $15.0 million. The change in working capital was primarily related to a net decrease of $10.3 million in accounts payable and accrued and other liabilities and an increase of $4.5 million in prepaid expenses and other current assets due to the timing of payments to vendors for ongoing clinical trial and manufacturing activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $165.7 million during the nine months ended September 30, 2024, and consisted primarily of $165.3 million in net purchases of short-term investments and $0.4 million in purchases of property and equipment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $75.5 million during the nine months ended September 30, 2023, and consisted primarily of $76.3 million in net maturities of short-term investments, offset by $0.9 million in purchases of property and equipment.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2e52e163a2594578be1a28935e1f5f13_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $422.2 million during the nine months ended September 30, 2024, and consisted of primarily of net proceeds of $419.4 million from the January 2024 Public Offering, September 2024 Public Offering and the September 2022 ATM Agreement, as well as $2.2 million in proceeds from the exercise of stock options and $0.7 million in proceeds from the issuance of common stock under our employee stock purchase plan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $26.7 million during the nine months ended September 30, 2023, and consisted primarily of $14.5 million in net proceeds from the Hercules Amendment, as well as $9.8&#160;million in proceeds from the exercise of stock options, $1.9&#160;million in proceeds from the exercise of warrants and $0.6&#160;million in proceeds from the issuance of common stock under our employee stock purchase plan.</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_76"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes to our market risks in the nine months ended September 30, 2024, when compared to the disclosures in Item 7A of our 2023 Annual Report on Form 10-K.</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_79"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, an evaluation was carried out under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) as of the end of the quarter covered by this Quarterly Report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable level of assurance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div id="i2e52e163a2594578be1a28935e1f5f13_82"></div><div style="text-align:center"><span><br/></span></div><div id="i2e52e163a2594578be1a28935e1f5f13_85"></div><div style="text-align:center"><span><br/></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i2e52e163a2594578be1a28935e1f5f13_88"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings in the ordinary course of business. We are currently not a party to any legal proceedings that we believe would have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i2e52e163a2594578be1a28935e1f5f13_91"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown, including but not limited to those described below. Any one or more of such factors could directly or indirectly cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, results of operations, and stock price. The following information should be read in conjunction with the other information contained in this Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the unaudited condensed consolidated financial statements and related notes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Capital Requirements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred losses, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a limited operating history. We have historically incurred net losses. During the nine months ended September 30, 2024 and 2023, our net loss was $190.2 million and $170.9 million, respectively. As of September&#160;30, 2024, we had an accumulated deficit of $916.1 million and cash, cash equivalents, and short-term investments of $753.2 million.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current cash, cash equivalents and short-term investments will be sufficient to fund our operations, including our clinical development plan, and enable us to fund our operating expenses and capital expenditure requirements into the second half of 2027. We will need to raise substantial additional capital to continue to fund our operations in the future. The amount and timing of our future funding requirements will depend on many factors, including the pace, results and costs of our clinical development efforts and macroeconomic conditions affecting our business and industry. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to complete future milestones. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings or entering into strategic collaborations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including conducting clinical trials and providing general and administrative support for our operations. To date, we have financed our operations primarily through the sale of equity securities, convertible promissory notes and the Hercules Loan and Security Agreement. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates continue advancing through clinical development and as new product candidates enter clinical trials and then advance through clinical development. It may be several years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to establish and maintain a commercial supply chain in each market, achieve sufficient market acceptance, pricing, coverage, and adequate reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Additionally, patients and physicians may not use our products as intended, if approved, which could impact the pricing and reimbursement of our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue efforts to discover and develop new product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the manufacturing of our product candidates or increase volumes manufactured by third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to advance our programs into large, expensive clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional preclinical studies or clinical trials for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory and marketing approvals and reimbursement for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing, and supply chain and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, assess, acquire, and/or develop other product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone, royalty, or other payments under third-party license agreements or enter into additional third-party license agreements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to attract and retain skilled personnel; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer follow-up for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, we had $753.2 million of cash, cash equivalents, and short-term investments. We believe that our current cash, cash equivalents and short-term investments, will be sufficient to fund our operations, including our clinical development plan, into the second half of 2027. We will need to raise additional capital to continue to fund our operations and service our obligations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developing our product candidates requires a substantial amount of capital. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We will need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. For example, even if our clinical trials generate data that we view favorably, investors may not share our interpretation of these data, and we may be unable to raise additional funds. There can be no assurance that sufficient funds will be available to us when required or on acceptable terms, if at all.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly delay, scale back, or discontinue the development or commercialization of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek strategic alliances, or amend existing alliances, for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue the sale of our company to a third party at a price that may result in a loss on investment for our stockholders; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">file for bankruptcy or cease operations altogether.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, operating results, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated any revenue from product sales and may never be profitable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, obtain the regulatory and marketing approvals, and build and maintain a commercial supply chain necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing research and development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory and marketing approvals for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining a commercial supply chain for our product candidates in the countries or regions in which we obtain regulatory approval for them, including receipt and maintenance of necessary licenses, permits, or similar permissions, either directly or with a collaborator or distributor;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing, launching, and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gaining market acceptance of our product candidates as treatment options;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing, protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining coverage and adequate reimbursement from third-party payors and maintaining pricing for our product candidates that supports profitability; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Portions of our current pipeline of product candidates have been in-licensed from third parties, which make the commercial sale of such in-licensed products potentially subject to additional royalty and milestone payments to such third parties. We will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of our product candidates. For instance, if the costs of manufacturing our drug product are not commercially feasible, we will need to develop or procure our drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from the sale of our product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings, and license and development agreements. To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity, including pursuant to any sales under our September 2022 ATM Agreement with Jefferies, convertible debt, or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Any additional sales of our capital stock by us will dilute the ownership interest of our stockholders and may cause the price per share of our common stock to decrease. In addition, any exercise of outstanding warrants will dilute the ownership interest of our stockholders and may cause the price per share of our common stock to decrease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing, including under our Hercules Loan and Security Agreement, may include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot be assured that we will be able to obtain additional funding, if and when necessary, to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially harm our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our third-party research institution collaborators, CROs, CMOs, and other contractors and consultants, could be subject to acts of war, earthquakes, power shortages, information technology and telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, governmental actions, medical pandemics or epidemics, such as the novel coronavirus, and other natural or man-made disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development is expensive, time consuming, and involves significant risk. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to:</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to generate satisfactory preclinical, toxicology, or other in vivo or in vitro data or diagnostics to support the initiation or continuation of clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs, clinical trial sites, and in countries or regions where our trials are conducted;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in obtaining required approvals from institutional review boards or independent ethics committees at each clinical trial site;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to permit the conduct of a clinical trial by regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or inability to recruit a sufficient number of eligible patients and/or subjects in our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by clinical sites, CROs, or other third parties to adhere to clinical trial requirements or to perform their obligations related to the clinical development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of CMOs, shipping logistics providers or other third parties to deliver necessary clinical material;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by our clinical sites, CROs, or other third parties to perform in accordance with current good clinical practice (&#8220;GCP&#8221;), current good laboratory practice (&#8220;GLP&#8221;), current good manufacturing practice (&#8220;cGMP&#8221;) or other applicable requirements of the FDA or applicable foreign regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients and/or subjects dropping out of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse events or tolerability or animal toxicology issues significant enough in our studies, in studies of third parties, or as reported for marketed products for the FDA or other regulatory agencies to put any or all clinical trials on hold, require us to change how we conduct our IND-enabling studies or our ongoing or future trials, including amending or submitting new clinical protocols or additional safety monitoring or measurements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of adverse events associated with our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical unrest and adverse regulatory or other actions taken against us, or third parties on whom we rely, by foreign governments or entities, including in Israel and China, where we have current or planned clinical trial operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs of clinical trials of our product candidates, including manufacturing activities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials or the trials of third parties with related or similar product candidates, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development programs in other ongoing or planned indications for a product candidate, or change how we conduct our IND-enabling studies or our ongoing or future trials, including amending or submitting new clinical protocols or additional safety monitoring or measurements; and</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with third-party manufacturers and the time to manufacture sufficient quantities of our product candidates acceptable for use in clinical trials. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expecting that that the THRIVE and THRIVE-2 phase 3 clinical trials, together with a safety database comprising 300 treated patients, will support global health authority registration for veligrotug for marketing approval in both active and chronic TED, respectively. However, the FDA or other regulatory authorities may require additional patients in this safety database or may require us to take other additional steps. In August 2024, we initiated a pivotal program for VRDN-003. We may be required to take other additional steps in the course of development and regulatory interaction regarding our product candidates, including veligrotug and VRDN-003. Such additional steps may include, without limitation, initiating new trials, starting at an earlier phase of clinical trial, conducting bridging studies, enrolling more patients, amending trial protocols, or requiring us to assess additional parameters related to safety or efficacy. For example, we may make adjustments to the VRDN-003 clinical trial designs as a result of the veligrotug data. These additional requirements or steps could increase the cost of development of our product candidates, negatively affect our anticipated timelines, delay our time to market with our product candidates, if approved, and could harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory authorities may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or non-compliance with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions, for example, under a Risk Evaluation Mitigation Strategy (&#8220;REMS&#8221;) program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market, or product recalls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters, or holds on post-approval clinical studies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA or other regulatory authorities to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal of the FDA or other regulatory authorities to permit the import or export of products; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete clinical development and obtain regulatory approval for our product candidates could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional clinical or nonclinical studies and the results obtained from studying such new formulation may not be consistent with previous results obtained. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory approval processes are lengthy, time consuming and inherently unpredictable. Failure to obtain regulatory approval for our product candidates would have a material adverse effect upon our business and business prospects.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the advancement of our clinical programs and before we can commercialize any of our current or future product candidates, we must obtain marketing approval from regulatory authorities. We may not be able to receive approval to market any of our current or future product candidates from regulatory authorities in our desired indications in any jurisdiction, and it is possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. We may need to rely on third party CROs and regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish a product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the biologic manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authorities, who may deny approval based on the results of such submissions and inspections. Our current or future product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. The FDA and other regulatory authorities have substantial discretion in the approval process, including determining when or whether regulatory approval will be obtained for a product candidate. Even if we believe the data collected from clinical trials are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority or such authorities may request additional information that may be difficult to generate or provide. Further, following approval, the FDA or other regulatory authorities may conduct additional inspections and, based on the results of such inspections, deem the inspected manufacturing facilities to be deficient, suspending our ability to manufacture our product candidates until we can secure satisfactory alternative manufacturing facilities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the United States, we may seek regulatory approval to commercialize our product candidates in other jurisdictions. While the scope of regulatory approval is similar in many countries, to obtain separate regulatory approval in multiple countries will require us to comply with numerous and varying regulatory requirements of each such country or jurisdiction regarding safety, efficacy and quality, and governing, among other things, clinical trials, commercial sales, pricing and distribution, and we cannot predict success in any such jurisdictions, even if we were to receive approval in the United States.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals, both in the United States and in other countries, is time consuming, expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted BLA, or equivalent application types, may cause delays in the approval or rejection of an application.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies or clinical or other trials for our current or future product candidates. Our current and future product candidates could be delayed in receiving, or fail to receive, regulatory approval or we may fail or cease to advance their development for many reasons, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may disagree with the number, design or implementation of our clinical trials to support further development or approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of regulatory authorities that a product candidate is safe and effective for its proposed indication or that its clinical and other benefits outweigh its safety risks;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities could require us to collect additional data or conduct additional clinical trials, which could include a requirement to compare our products or product candidates to other therapies for the treatment of the same indication;</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities, following the discovery of adverse safety signals or side effects from approved therapeutics or therapeutics in development in the same or related class as our products or product candidates, could require us to collect additional data or conduct additional clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may produce negative, inconclusive or uncompetitive results, which may result in us deciding, or regulatory authorities requiring us, to conduct additional clinical trials or to modify or cease development programs for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the primary or secondary endpoints of the applicable trial or the level of statistical significance required by regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA, supplementary BLA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of participants required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or we may fail to recruit suitable participants for a trial;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with data quality and regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may believe that we have not sufficiently demonstrated our ability to manufacture our candidates to the requisite level of quality standards, including that such material is sufficiently comparable to material used in previous clinical trials, or they may fail to approve our manufacturing processes or facilities, or the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may conclude that on-site inspections and data audits have not sufficiently demonstrated the quality and integrity of the clinical trial conduct and of data submitted to regulatory authorities in support of our new product approvals and marketing applications;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects, toxicities or other unexpected characteristics, causing us or our investigators, regulatory authorities, institutional review boards or ethics committees to reject, suspend or terminate the clinical trials; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of regulatory authorities may significantly change in a manner rendering our clinical data, biologic manufacturing process and other supporting information insufficient for approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval for one or more of our current or future product candidates, regulatory authorities may approve such product candidates for fewer indications or more limited patient populations than we request. Furthermore, regulatory authorities or payers may not approve the price we intend to charge, may grant approval contingent on the performance of costly post-marketing clinical trials, may impose certain post-marketing requirements that impose limits on our marketing and distribution activities, or may approve a product candidate with labeling that does not include the claims necessary or desirable for the </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our current or future product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain regulatory approval for our product candidates would have a material adverse effect upon our business and business prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of approved labeling, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are or may develop our product candidates in areas with existing investigational and/or approved products where such products may have known risk profiles. Undesirable side effects caused by our product candidates, or other product candidates, including in the TED space, could cause us or regulatory authorities to interrupt, delay, or terminate clinical trials. Such side effects additionally may result in a delay or denial of regulatory approval by the FDA, EMA, or comparable foreign authorities, or, even in the instance that an affected product candidate is approved, may result in restrictive drug labeling. For example, hearing impairment observed in Tepezza&#174;, or other negative side effects of other IGF-1R antagonists in development, may negatively affect clinical trials for our product candidates, delay regulatory approval or result in restrictive drug labeling, if approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the drug labeling;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a REMS, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients or subjects; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional time may be required to obtain marketing authorizations for certain of our product candidates because they are, or are anticipated to be, combination products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our product candidates, including VRDN-003, VRDN-006 and VRDN-008, are or are anticipated to be combination products that will require coordination within the FDA and similar foreign regulatory agencies for review of their device and drug components. Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products, such as drugs that utilize delivery systems like auto-injectors or prefilled syringes, we may experience delays in the development and commercialization of our product candidates due to complexities arising from them being combination products and associated regulatory timing constraints and uncertainties in the product development and approval process. Of note, prior clearance or approval of one component of a combination product does not increase the likelihood that the FDA will approve a later product combining the previously cleared product or approved </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">active ingredient with a novel active ingredient. See &#8220;Business&#8212;Government Regulation&#8212;Regulation of Combination Products&#8221; in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product development program may not uncover all possible adverse events that patients or subjects who take our product candidates may experience. The number of patients or subjects exposed to our product candidates and the average exposure time in the clinical development program may be inadequate to detect rare adverse events that may only be detected once the product is administered to more patients or subjects and for greater periods of time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials by their nature utilize a sample of the potential patient population. But, with a limited number of subjects and limited duration of exposure, we cannot be fully assured that rare and severe side effects of our product candidates will be uncovered. Such rare and severe side effects may only be uncovered with a significantly larger number of patients or subjects exposed to the drug. If such safety problems occur or are identified after our product candidates reach the market, the FDA or other regulatory authorities may require that we amend the labeling of the product, implement a REMS, recall the product, conduct a post-approval study or studies, implement surveillance measures, or may even withdraw approval for the product. Later discovered undesirable side effects could further result in reduced market acceptance and utilization of our product or potential product liability claims. Any of these occurrences may materially harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the success of our product candidates, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested substantially all of our effort and financial resources to identify, acquire, and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize one or more product candidates. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a product candidate. We continue to evaluate and pursue additional opportunities to expand our product pipeline, either by discovering novel antibodies or proteins internally, or by acquiring rights to existing antibodies or antibody sequences or proteins and protein sequences. Our goal is to build a sustainable portfolio of protein and antibody therapies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a limited number of product candidates. There can be no assurance that the data that we may or may not develop for our product candidates in our planned indications will be sufficiently supportive to obtain regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not permitted to market or promote any of our product candidates before they receive regulatory approval from the FDA, EMA, or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. In addition, from time to time, we may publicly disclose interim, topline, or preliminary data from our preclinical studies and clinical trials, which is based on a </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as more patient data become available. The interim, topline, or preliminary results that we report may differ from final results upon study completion, or different conclusions or considerations may qualify such results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will have to conduct well-controlled trials in our proposed indications to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Larger scale clinical trials for our product candidates may generate additional data that raise issues regarding the safety and efficacy of our product candidates that were not observed in smaller clinical trials. Certain approaches that we take in our clinical trials with respect to measurement of safety and efficacy outcomes may differ in important respects as compared to the trials of our competitors, which may lead to negative regulatory and/or commercial outcomes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, both preclinical and clinical data are often susceptible to varying interpretations and analyses. Third parties upon whom we rely may analyze data differently than others, or differently than we do. As a result, they or we may reach different conclusions regarding the results of our studies, including our clinical studies. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate safety and efficacy of our product candidates, with respect to the proposed indication for use, sufficient to receive regulatory approval to market our drug candidates. Failure to demonstrate safety and efficacy of our product candidates, and failure to obtain regulatory approval, would have a material adverse effect upon our business and business prospects. Additionally, differences in our clinical trial designs as compared to those of our competitors could render our product candidates less attractive than those of our competitors. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary data from our clinical trials that we announce or publish are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary data from our clinical trials. On December 18, 2023, we reported clinical data from our phase 1 clinical study in healthy volunteers and announced the selection of VRDN-003 as our lead subcutaneous product candidate for TED. Based on the comparable pharmacology of VRDN-003 to veligrotug, we believe VRDN-003 has the potential to maintain the clinical response of veligrotug while significantly increasing patient convenience. However, we have just initiated clinical trials of VRDN-003 in patients with TED in August of 2024, and results of any clinical trials conducted in TED patients with VRDN-003 may not demonstrate safety or efficacy comparable to veligrotug or at all. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2024, we announced topline data from the phase 3 THRIVE trial of veligrotug in patients with active TED. While THRIVE met all primary and secondary endpoints at 15 weeks, this data may not be fully reflective of the final results for the THRIVE trial. These THRIVE topline results may also not be reflective of our phase 3 THRIVE-2 trial, for which topline results are expected by year end 2024. If clinical data from the THRIVE-2 trial are not positive or favorable, it could negatively impact or alter the development of veligrotug and could materially harm our business prospects. If clinical data from the veligrotug trials are not positive or favorable, it could negatively impact or alter the development of VRDN-003 and could materially harm our business prospects. Similarly, negative or unfavorable clinical data from our VRDN-003 product candidate could negatively impact veligrotug and could materially harm our business prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topline or preliminary data from our clinical trials that we announce or publish from time to time, including the data from our phase 1 study in healthy volunteers, the data for veligrotug from our ongoing trials, and topline data may change as more patient data become available and we become subject to audit and verification procedures that could result in material changes in the final data. This creates a risk that the final results could be materially different from the preliminary results reported, including those reported to date. Additionally, differences in patient populations across our clinical trials may lead to inconsistent or unrepresentative data. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant adverse differences between preliminary data and final, audited and verified data could negatively affect the prospect of regulatory approval for our product candidates and could materially harm our reputation and business prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and human resources, we may forgo or delay the pursuit of opportunities with some programs or product candidates or for other indications, that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or more profitable market opportunities. Our spending on current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. We may also enter into additional strategic collaboration agreements to develop and commercialize some of our programs and potential product candidates in indications with potentially large commercial markets. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaborations, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. We may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll and maintain patients or subjects in our clinical trials, in part due to the limited number of patients or subjects who have the diseases for which our product candidates are being studied or the availability of competing therapies and clinical trials. We cannot predict if we will have difficulty enrolling and maintaining patients or subjects in our future clinical trials. Difficulty in enrolling and maintaining patients or subjects could delay or prevent clinical trials of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and enrolling patients or subjects to participate in clinical trials of our product candidates is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit patients or subjects to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment. Our current or future clinical trials may face increased competition for and difficulty recruiting eligible patients for enrollment, for example, as a result of additional therapies for TED being tested in clinical trials or the availability of approved therapies. In addition, our enrollment has been, and may in the future be, delayed due to supply chain delays and difficulties in site activation. Delays in enrollment may delay the generation of clinical data and the completion of our clinical trials. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The eligibility criteria of our clinical trials may further limit the available eligible trial participants, as we expect to require that patients or subjects have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical trials. We may not be able to identify, recruit, enroll and maintain a sufficient number of patients or subjects to complete our clinical trials in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, the option for patients to choose alternate existing approved therapies and the willingness of physicians to participate in our planned clinical trials. Additional factors outside our control, such as pandemics or other public health crises, may also impact our ability to enroll patients in our planned clinical trials. If patients or subjects are unwilling or unable to participate in our clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of our product candidates may be delayed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trials of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials would likely increase our overall costs, impair product candidate development, and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face liability for our products, if approved, and for our product candidates, and if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our approved products, if any, or product candidates harm patients or subjects, or is perceived to harm patients or subjects even when such harm is unrelated to our approved products, if any, or product candidates, our regulatory approvals, if any, could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims. If we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage, a material liability claim could adversely affect our financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use or misuse of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval exposes us to the risk of potential product liability claims. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. Patients with the diseases targeted by our product candidates may already be in severe and advanced stages of disease and have both known and unknown significant preexisting and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact, or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which an adverse event is unrelated to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may delay our regulatory approval process or impact and limit the type of regulatory approvals our product candidates receive or maintain.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have product liability insurance, which covers our historical clinical trials in the United States, for up to $10.0 million per occurrence, up to an aggregate limit of $10.0 million, our insurance may be insufficient to reimburse us for any expenses or losses we may suffer. We will also likely be required to increase our product liability insurance coverage for any future clinical trials that we may initiate. If we obtain marketing approval for any of our product candidates, we will need to expand our insurance coverage to include the sale of commercial products. There is no way to know if we will be able to continue to obtain product liability coverage and obtain expanded coverage, if we require it, in sufficient amounts to protect us against losses due to liability, on acceptable terms, or at all. We may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage. Where we have provided indemnities in favor of third parties under our agreements with them, there is also a risk that these third parties could incur liability and bring a claim under such indemnities. An individual may bring a product liability claim against us alleging that one of our product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. Any product liability claim brought against us, with or without merit, could result in:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to recruit clinical trial volunteers, investigators, patients or subjects, or trial sites;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial volunteers, investigators, patients or subjects, or trial sites, or limitations on approved indications;</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in the development of product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize, or if commercialized, decreased demand for, our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if commercialized, product recalls, labeling, marketing or promotional restrictions, or the need for product modification;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial costs of litigation, including monetary awards to patients or other claimants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention from our business; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our reputation and the reputation of our products and our technology.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our preclinical development activities and clinical trials, manufacture our product candidates, and perform other services. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval, or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third-party CROs to conduct, monitor, and manage preclinical and clinical programs. Adding or changing CROs for our clinical programs carries implementation risk and may delay advancement of our clinical programs. We rely on these parties for execution of clinical trials, and we manage and control only some aspects of their activities. We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with all applicable laws, regulations, and guidelines, including those required by the FDA, EMA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our CROs or vendors fail to comply with applicable and evolving laws, regulations, and guidelines, the results generated in our clinical trials may be deemed insufficient or unreliable, and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. For example, we are aware of certain instances of non-compliance with GCP regulations. While we believe that we have made significant progress in remediating these deficiencies, we cannot be assured that our CROs, clinical sites, and other vendors will fully remediate any deficiencies and will meet these requirements on an ongoing basis, or that upon inspection by any regulatory authority, such regulatory authority will determine that efforts, including any of our clinical trials, comply with applicable requirements. Any non-compliance with these laws, regulations and guidelines may negatively impact the integrity of the data collected in our clinical trials and may prevent approval or require us </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to repeat clinical trials or add patients to ongoing clinical trials, which would be costly and delay the regulatory submission and/or approval process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical trials relative to those of other customers, and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical trials. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical trials may be delayed or terminated, and we may not be able to meet our current plans with respect to our product candidates. Additionally, regional disruptions, including natural disasters or health emergencies (such as novel viruses or pandemics), could significantly disrupt the timing of clinical trials. CROs may also involve higher costs than anticipated, which could negatively affect our financial condition and operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortages and governmental restrictions resulting from pandemics or other public health crises may disrupt the ability of or increase the cost for our clinical trial sites and other CROs to procure items that are essential for our research and development activities, including animals that are used for preclinical studies. For example, the COVID-19 pandemic and resulting disruptions to the global supply chain caused shortages of various animals used in research studies, such as several types of monkeys, which are typically sourced from China.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we currently plan to establish, the capability to manufacture product candidates for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale without the use of third-party manufacturers. We rely, and plan to continue to rely, on third-party manufacturers whose responsibilities include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical trials and regulatory approval. There are expected to be a limited number of suppliers for the active ingredients and other materials, including devices and device components, that we expect to use to manufacture and deliver our product candidates, including those of our product candidates that are anticipated to be combination products. We may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture of our product candidates for our clinical trials, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the trial, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate, could delay completion of our clinical trials and potential timing for regulatory approval of our product candidates, which would harm our business and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing processes are complex, and we may encounter difficulties in production, which would delay or prevent our ability to provide a sufficient supply of our product candidates for clinical trials or commercialization, if approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our biologic product candidates is complex, highly regulated, variable, and subject to numerous risks. Our manufacturing process is susceptible to product loss or failure, or product variation that may negatively impact patient outcomes, due to logistical issues associated with preparing the product for administration, administering the product to patients, manufacturing issues, or different product characteristics resulting from changing a manufacturer, changing a manufacturing location, the inherent differences in starting materials, variations between reagent lots, interruptions in the manufacturing process, contamination, equipment or reagent failure, improper installation or operation of equipment and/or programs, vendor or operator error, loss of product during shipment or storage and variability in product characteristics. Some of our product candidates, including VRDN-003, VRDN-006 and VRDN-008, are or are anticipated to be combination products. In particular, we anticipate using an autoinjector device in connection with our product candidate VRDN-003. Combination products are complex to manufacture, and this manufacturing complexity could lead to delays in manufacturing and product candidate availability for our clinical trials. In addition, </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination products typically have a longer and more complex supply chain that increases the risk of supply interruptions and could negatively impact product candidate availability. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even minor variations in starting reagents and materials, deviations from normal manufacturing processes, changing a manufacturer, or changing a manufacturing location could result in reduced production yields, product shortages, product defects, manufacturing failure, changes in product characteristics and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in any of the manufacturing facilities in which products or other materials are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any failure in the foregoing processes could render a batch of product unusable, could affect the regulatory approval of such product candidate, could cause us to incur fines or penalties, or could harm our reputation and that of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may make changes to our manufacturing process for various reasons, such as to control costs, increase yield or dose, achieve scale, decrease processing time, increase manufacturing success rate, availability of raw materials, or for other reasons. Changes to our process made during the course of clinical development could require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. Other changes to our manufacturing process made before or after commercialization could require us to show the comparability of the resulting product to the product candidate used in the clinical trials using earlier processes. Such showings could require us to collect additional nonclinical or clinical data from any modified process prior to obtaining marketing approval for the product candidate produced with such modified process. If such data are not ultimately comparable to that seen in the earlier trials or earlier in the same trial in terms of safety or efficacy, we may be required to make further changes to our process and/or undertake additional clinical testing, either of which could significantly delay the clinical development or commercialization of the associated product candidate, which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, including Chinese manufacturers WuXi Biologics and WuXi AppTec, for drug substance and drug product, and other third parties for devices and device components. If we are unable to source these supplies on a timely basis, at sufficient quantities, or at acceptable quality or prices, establish longer-term contracts with our suppliers, or if our third party manufacturers fail to comply with applicable regulatory requirements, the development and, if approved, commercialization of our product candidates could be stopped, delayed, or made less profitable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we currently plan to develop, the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates, devices, or device components on a clinical or commercial scale. We currently rely on outside vendors to manufacture our clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates, devices, or device components on a commercial scale, if approved. In particular, we rely upon single-sourced manufacturing with one CMO for manufacturing our product candidates, including drug substance and drug product. We also rely on single-sourced manufacturing for various elements of our combination products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates and our current cost to manufacture our drug products may not be commercially feasible. Additionally, the actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party manufacturers exposes us to the following additional risks:</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to identify additional manufacturers of our product candidates, including combination product candidates, on acceptable terms or at all.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contract manufacturers may not be able to execute our manufacturing process or procedures appropriately.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future third-party manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our commercial products, if approved.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on single-sourced manufacturing with one CMO increases the risk that any problems or delays with that CMO could materially, negatively affect the development of our product candidates, or their commercialization, if approved.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, applicable foreign regulatory authorities and some state agencies to ensure strict compliance with current good manufacturing practice and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers&#8217; performance, available capacity and ability to manufacture clinical or commercial products may be impacted by mergers and or acquisitions. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience labor disputes or shortages, raw material shortages or manufacturing capacity shortages, including from the effects of health emergencies (such as novel viruses or pandemics) and natural disasters.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our third-party manufacturers may be impacted by global conflicts, including any potential conflict involving China and Taiwan, and any resulting trade sanctions or regulatory actions. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily reliant on third-party manufacturing operations in China, and any regional or geopolitical disruption could negatively impact our clinical trials and development or commercialization of our product candidates, which would harm our business.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign third-party manufacturers may be subject to U.S. legislation, regulatory actions, or investigations, including the proposed BIOSECURE Act, trade restrictions and other U.S. or foreign regulatory requirements, which could increase the cost or reduce the supply of material available to us, delay or prevent the procurement or supply of such material, delay clinical trials, delay commercial launch, affect the ability to transfer to different manufacturers or have an adverse effect on our ability to secure commitments from governments to purchase our potential therapies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay our clinical trials, as well as the approval, if any, of our product candidates by the FDA or other regulatory authorities, or the commercialization of our product candidates, or could result in higher costs, or could deprive us of potential product revenue. </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not appropriately conducted and test data are not reliable, patients could be put at risk of serious harm, and this could result in product liability suits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we currently rely upon single suppliers for the development and manufacture of our product candidates, we are taking steps to build redundancy into our supply chain. In connection with those efforts, we are currently evaluating options and taking steps to establish the development and/or manufacture of our product candidates at new manufacturers. If we encounter any material problems in connection with that process, we may be delayed in the development or commercialization of our product candidates, including veligrotug, and our business could be harmed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of drug products, including combination products that comprise a biological drug product and a device, is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques, process controls and product testing methods. Manufacturers of medical products often encounter difficulties in production, particularly in scaling up and validating initial production and absence of contamination. These problems include difficulties with raw material supply, production costs and yields, quality control, stability of the product, quality assurance testing, operator error, shortages of qualified personnel, logistical problems or delays encountered when using multiple sites for manufacturing and testing, as well as compliance with strictly enforced federal, state, and foreign regulations. These problems may be more likely, or worse, in cases where the products candidates being manufactured are combination products, like certain of our product candidates, due to the increased complexity in their manufacture and associated supply chain. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot be assured that any stability issue or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes, shortages, including from the effects of heath emergencies (such as novel viruses or pandemics) and natural disasters, or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our product candidates to patients or subjects in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the initiation or completion of clinical trials, increase the costs associated with initiating or maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on the Chinese contract research, development and manufacturing organizations (&#8220;CDMOs&#8221;) WuXi AppTec (Hong Kong) Limited and WuXi Biologics (Hong Kong) Limited (together, &#8220;WuXi&#8221;) and other foreign CDMOs, to develop and manufacture our product candidates, and will likely continue to rely on them in the future. There has been increased governmental focus in the United States on the role of Chinese companies in the life sciences industry. This focus has included U.S. legislative proposals, such as the proposed BIOSECURE Act, which has been passed by the U.S. House of Representatives and is pending before the U.S. Senate.   If enacted, the BIOSECURE Act would, among other things, prohibit U.S. federal agencies from entering into or renewing any contract with any entity that uses biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221; to perform that contract with the government. Although the proposed Act has not been enacted and thus is subject to change through the legislative process, a version of the Act passed by the U.S. House of Representatives defines a &#8220;biotechnology company of concern&#8221; to include WuXi Biologics and WuXi AppTec. If adopted, the BIOSECURE Act could cause us to seek to exit some or all of our arrangements with WuXi (or any other China-based service provider determined to be &#8220;biotechnology companies of concern&#8221;) and accelerate the transition of these services to alternative companies or continue to engage redundant suppliers for the U.S. market.  Additionally, the legislation could adversely impact WuXi&#8217;s operations or financial position which, in turn, could impact their ability to perform under our agreements with it. Our reliance on Chinese-based contract research organizations, such as WuXi, may also cause us to face </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional risks due to geopolitical tensions between the U.S. and China and related legal and regulatory restrictions and requirements, including measures directly affecting WuXi.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these entities may be subject to other U.S. legislation, sanctions, investigations, regulations, trade restrictions, regulatory actions, or ex-U.S. legislation, regulatory actions or requirements that could increase the cost or reduce the supply of material available to us, delay or prevent the procurement or supply of such material, delay or impact the availability of our product candidates, delay or impact clinical trials, availability of commercial supply, or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. Any of the foregoing outcomes could adversely affect our financial condition and business prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in February 2024, the chair and ranking member of the House Select Committee on the Chinese Communist Party, along with certain Senators, sent a letter to the Biden administration requesting that certain WuXi related entities be added to the Department of Defense&#8217;s Chinese Military Companies List (pursuant to Section 1260H of the National Defense Authorization Act for Fiscal Year 2021), the Department of Commerce&#8217;s Bureau of Industry and Security Entity List, and the Department of Treasury&#8217;s Non-SDN Chinese Military-Industrial Complex Companies List. While the Biden administration has yet to take action on this letter, adding either or both previously mentioned WuXi entities on any or all of the aforementioned lists could materially impact our agreements with WuXi and could delay the initiation or completion of clinical trials, increase the costs associated with starting or maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely or adversely impact our financial condition and business prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the biopharmaceutical industry in China is strictly regulated by the Chinese government, including Chinese collaborators and service providers such as CROs and CDMOs. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may adversely impact or have a material adverse effect on us or on our collaborators or in China. Such changes may also adversely impact the management of data generated in China, the availability of data generated with Chinese collaborators or in studies in China and the availability of data or records generated by service providers, which could have an adverse effect on our business, the development of our product candidates, our financial condition, results of operations and business prospects. In addition, it may be difficult or impossible to obtain certain source documentation from Chinese entities, which may adversely affect our business where such source documentation is required. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolving changes in China&#8217;s economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the U.S. and the U.K., could also negatively impact our ability to use Chinese companies to manufacture our product candidates for our clinical trials or have an adverse effect on our ability to secure commitments from governments to purchase our potential therapies, which could cause us to delay our clinical development programs or adversely affect our financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it becomes necessary to shift our operations away from reliance upon WuXi or other non-US based CROs and CMOs, we will need to find suitable replacements for their services. We may encounter significant difficulty in finding suitable replacement partners and vendors, difficulties in transferring our programs or processes from one CRO or CMO to another, and such parties may have limited capacity due to the influx of demand from other companies, including other biotechnology and biopharmaceutical companies in a position similar to ours. Inability to find suitable replacements for these necessary services could increase the cost or reduce or eliminate the supply of material available to us, delay or prevent the procurement or supply of such material, delay or impact the availability of our product candidates, delay or impact clinical trials, availability of commercial supply, or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. Any of the foregoing outcomes could adversely affect our financial condition and business prospects.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to realize the potential benefits of any collaboration.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in entering into additional future collaborations with respect to the development and/or commercialization of one or more product candidates, there is no guarantee that the collaboration will be successful. Collaborations may pose a number of risks, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators often have significant discretion in determining the efforts and resources that they will apply to the collaboration and may not commit sufficient resources to the development, marketing, or commercialization of the product or products that are subject to the collaboration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any such collaboration may significantly limit our share of potential future profits from the associated program and may require us to relinquish potentially valuable rights to our current product candidates, potential products, proprietary technologies, or grant licenses on terms that are not favorable to us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may cease to devote resources to the development or commercialization of our product candidates if the collaborators view our product candidates as competitive with their own products or product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, or the course of development, might cause delays or termination of the development or commercialization of product candidates, and might result in legal proceedings, which would be time consuming, distracting, and expensive;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from the collaboration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability, which would be time consuming, distracting, and expensive;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the collaborations may not result in us achieving revenue to justify such transactions; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for us to raise additional capital to pursue further development or commercialization of the applicable product candidate.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, a collaboration may not result in the successful development or commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, we could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into commercial, service, licensing, consulting, and other agreements that contain indemnification provisions. With respect to our research agreements, we typically indemnify the party and related parties from losses arising from claims relating to the products, processes, or services made, used, sold, or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#8217; exercise of rights under the agreement. With respect to future collaboration agreements, we may indemnify our collaborators from any third-party product liability claims that could result from the production, use, or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we indemnify them from claims arising from the good faith performance of their services.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage, our business, financial condition, and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patent rights, trade secret protections and confidentiality agreements to protect the intellectual property related to our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our ability to obtain regulatory exclusivity and our and our licensors&#8217; ability to maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technologies and product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sought to protect our proprietary position by filing and licensing the rights to patent applications in the United States and abroad related to our technologies and product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles continue to evolve and may remain unresolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable, unpatentable, or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, independently or together with our licensors, have filed patent applications covering various aspects of our product candidates, including compositions of matter and their methods of use. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether any issued patents will be found invalid and unenforceable or unpatentable following a challenge by third parties. Any successful post-grant review proceeding or litigation with respect to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection or data exclusivity, for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have sufficient patent term protections for our product candidates to effectively protect our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Additional patent terms may be available through a patent term adjustment process, resulting from the United States Patent and Trademark Office (&#8220;USPTO&#8221;) delays during prosecution. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term extensions (&#8220;PTEs&#8221;) under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity terms of our product candidates. We will likely rely on PTEs, and we cannot provide any assurances that any such PTEs will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our product candidates for an extended period after regulatory approval, if any, which would negatively impact our business, financial condition, results of operations, and prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products, and recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming, and inherently uncertain. In addition, in 2011 the U.S. enacted the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) and is still currently implementing wide-ranging patent reform legislation. Recent rulings from the U.S. Supreme Court and the Court of Appeals for the Federal Circuit have narrowed the scope of patent protection available in specified circumstances and weakened the rights of patent owners in specified situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO has issued subject matter eligibility guidance instructing USPTO examiners on the ramifications of the Supreme Court rulings in Mayo Collaborative Services v. Prometheus Laboratories, Inc. and Association for Molecular Pathology v. Myriad Genetics, Inc., and applied the Myriad ruling to natural products and principles including all naturally occurring molecules. In addition, the USPTO continues to provide updates to its guidance continues to be a developing area. The USPTO guidance may make it impossible for us to obtain similar patent claims in future patent applications. Currently, our patent portfolio contains claims of various types and scope, including methods of medical treatment. The presence of varying types of claims in our patent portfolio significantly reduces, but may not eliminate, our exposure to potential validity challenges.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our U.S. patent applications, which contain claims entitled to priority after March 16, 2013, there is a greater level of uncertainty due to the Leahy-Smith Act mentioned above. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO has promulgated regulations and developed procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, did not come into effect until March 16, 2013. The Leahy-Smith Act and its implementation could increase the </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important change introduced by the Leahy-Smith Act is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either: (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications until these filings are no longer confidential.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among some of the other changes introduced by the Leahy-Smith Act are changes that limit where a patentee may file a patent infringement suit and new post-grant review procedures providing opportunities for third parties to challenge any issued patent in the USPTO. Included in these new procedures is a process known as Inter Partes Review, which has been generally used by many third parties since the enactment of the Leahy-Smith Act to render patents unpatentable. These post-grant review procedures are and continue to be an evolving and developing area of law.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical actions in the U.S. and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the U.S. and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, operations and prospects may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) came into force on June 1, 2023. The UPC will be a common patent court to hear patent infringement and revocation proceedings effective for member states of the European Union. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. A revocation of any European patents and applications that we may own now or license or obtain in the future could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time and may adversely affect our ability to enforce or defend the validity of any European patents obtained. We may decide to opt out from the UPC for any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, even if we are able to or decide to opt out of the UPC.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, such as processes for which patents are difficult to enforce, other elements of our product candidate discovery and/or development processes that involve proprietary know-how, information, or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, the agreements or security measures may be breached, and we may not have adequate remedies for such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, or that our trade secrets and other confidential proprietary information will not be disclosed, or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business, financial condition, or results of operations. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market, and sell our product candidates and use our proprietary technology without infringing the patent rights of third parties. Numerous third-party U.S. and non-U.S. issued patents and pending applications exist in the area of our product candidates. From time to time, we may also monitor these patents and patent applications. We may in the future pursue available proceedings in the U.S. and foreign patent offices to challenge these patents and patent applications. In addition, or alternatively, we may consider whether to seek to negotiate a license of rights to technology covered by one or more of such third-party patents and patent applications. If any patents or patent applications cover our product candidates or technologies, we may not be free to manufacture or market our product candidates as planned, absent such a license, which may not be available to us on commercially reasonable terms, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 remain confidential until patents issue, and applications filed after that date that will not be filed outside the United States can elect to remain confidential until patents issue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale, or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable, unpatentable, or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to specified limitations, be later amended in a manner that could cover our technologies, our product candidates, or the use of our product candidates.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits in federal courts, and interferences, oppositions, inter partes reviews, post-grant reviews, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign-issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, cease development or commercialization, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on intellectual property licensed from third parties. We may not be successful in meeting our obligations under our existing license agreements necessary to maintain our product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to certain intellectual property, through licenses from third parties and under technology and patents that we do not own, to develop and commercialize our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain in effect these proprietary rights. Mergers and acquisitions involving the third parties from whom we license intellectual property may negatively impact our rights. Any termination of license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license their patent rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development or commercialization of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when the prosecution and maintenance of patent applications and patents relating to our product candidates are controlled by our licensors. In these instances, we normally seek a right to participate in such prosecution or maintenance, which is not always granted. If any of our licensors fail to appropriately follow our </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instructions or consider our comments with regard to the prosecution and maintenance of patent protection for patents covering any of our product candidates, it may result in patent rights that do not or do not sufficiently cover products. If this happens, our ability to develop and commercialize those product candidates may be adversely affected, and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications, we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business, which would harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to intellectual property licenses and supply agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing agreements impose, and we expect that future license agreements will impose, various diligence, milestone payments, royalties, purchasing, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, our agreements may be subject to termination by the licensor, in which event we would not be able to develop, manufacture, or market products covered by the license or subject to supply commitments. Further, these agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. If material disputes with respect to these agreements prevent or impair our ability to maintain our current arrangements on acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property or supply our needs, we may be unable to successfully develop and commercialize the affected product candidates. Any material disputes with our licensors or suppliers or any termination of the agreements on which we depend could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits or post-grant review proceedings to defend, protect, or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. If we, or one of our licensing partners, were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable or file a post-grant review proceeding to challenge the patentability of the patent. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability and post-grant review proceeding to challenge the patentability of the patent are commonplace. Grounds for these challenges could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, clarity, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity, unenforceability, and patentability is unpredictable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or offer us a license at all. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation or post-grant review proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants, and independent contractors do not use the proprietary information or intellectual property rights of others in their work for us, we may in the future be subject to any claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly some developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and therapeutic products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biologics, and they may be subject to competition from biosimilar and interchangeable biological products.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA was enacted as part of the ACA to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the current 12-year period of exclusivity provided law. However, there is a risk that this exclusivity could be shortened in the future due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. The approval of a biologic product biosimilar to one of our product candidates could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug designation for our product candidates, but we might not receive such designation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are no longer pursuing orphan drug designation for veligrotug for thyroid eye disease in the U.S., but we may seek orphan drug designation for veligrotug in other indications and/or territories and for our other product candidates in various indications and/or territories. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug designation for any of our current and potential future product candidates, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Exclusive marketing rights in the United States also may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for an existing or future product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties still can be approved for the same condition even with an orphan drug designation. Additionally, even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory agency responsible for the granting of orphan drug exclusivity may change their interpretation of the scope of orphan drug exclusivity. For example, the FDA&#8217;s longstanding interpretation of the Orphan Drug Act is that exclusivity is specific to the orphan indication for which the drug was actually </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved. As a result, the scope of exclusivity has been narrow and protected only against competition from the same &#8220;use or indication&#8221; rather than the broader &#8220;disease or condition.&#8221; See &#8220;Business&#8212;Government Regulation&#8212;Orphan Drug Designation&#8221; in our 2023 Annual Report on Form 10-K. Our ability to obtain and maintain orphan drug designation and the benefits thereof, including orphan drug exclusivity, may materially impact our financial performance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek Breakthrough Therapy designation for one or more of our product candidates from the FDA, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a breakthrough therapy designation from the FDA for some of our product candidates. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one of our product candidates is designated as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the conditions for designation and the designation may be rescinded. See &#8220;Business&#8212;Government Regulation&#8212;Expedited Development and Review Programs&#8221; in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek Fast Track designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a product candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval in any particular timeframe or at all. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. See &#8220;Business&#8212;Government Regulation&#8212;Expedited Development and Review Programs&#8221; in our 2023 Annual Report on Form 10-K. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to obtain accelerated approval of our product candidates. If we are unable to obtain accelerated approval, we may be required to conduct clinical trials beyond those that we contemplate, or the size and duration of our pivotal clinical trials could be greater than currently planned, which could increase the expense of obtaining, reduce the likelihood of obtaining, and/or delay the timing of obtaining necessary marketing approvals. Even if we receive accelerated approval from the FDA, the FDA may require that we conduct confirmatory trials to verify clinical benefit. If our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-approval requirements, the FDA may seek to withdraw accelerated approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek accelerated approval for our product candidates. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease. If granted, accelerated approval may be contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s predicted effect on irreversible morbidity or mortality or </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such confirmatory studies be underway prior to approval for a product granted accelerated approval.  If such post-approval studies fail to confirm the drug&#8217;s clinical benefits relative to its risks, the FDA may withdraw its approval of the drug. If we choose to pursue accelerated approval, there can be no assurance that the FDA will agree that our proposed primary endpoint is an appropriate surrogate endpoint. Similarly, there can be no assurance that after subsequent FDA feedback that we will continue to pursue accelerated approval or any other form of expedited development, review, or approval, even if we initially decide to do so. Furthermore, if we submit an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting approval of any type. We might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-approval requirements, including submission to the FDA of all promotional materials prior to their dissemination. The FDA may require us to conduct a confirmatory study to verify the predicted clinical benefit. The FDA could withdraw accelerated approval for multiple reasons, including our failure to conduct any required post-approval study with due diligence, or the inability of such study to confirm the predicted clinical benefit. A failure to obtain accelerated approval or any other form of expedited review or approval for a product candidate could result in a longer time period prior to commercializing such product candidate, increase the cost of development of such product candidate, and harm our competitive position in the marketplace.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved, we will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing clinical trials, and submission of safety, efficacy, and other post-approval information, including both federal and state requirements in the United States, and requirements of the EMA and comparable foreign regulatory authorities. See &#8220;Business&#8212;Government Regulation&#8212;Expedited Development and Review Programs&#8221; and &#8220;Business&#8212;Government Regulation&#8212;Regulation in the European Union&#8221; in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the marketed product. We will be required to report adverse reactions and production problems, if any, to the FDA, EMA, and comparable foreign regulatory authorities. Any new legislation could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was granted accelerated approval by the FDA, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit of our products. Other regulatory authorities outside of the United States may have similar requirements. An unsuccessful post-marketing clinical trial or failure to complete such a trial could result in the withdrawal of marketing approval. We and any of our suppliers or collaborators, including our CDMOs, would be subject to periodic inspections by the FDA, EMA, and, as applicable, comparable foreign regulatory authorities to monitor compliance with cGMPs and other FDA, EMA, and, as applicable, any comparable foreign regulatory requirements. Application holders must further notify the FDA, and any comparable foreign regulatory authorities, as applicable, and depending on the nature of the change, obtain FDA pre-approval or pre-approval from other comparable foreign regulatory authorities, as applicable, for product and manufacturing changes.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with requirements concerning advertising and promotion for any product candidates for which we seek or obtain marketing approval. Promotional communications with respect to drugs and biologics are </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to a variety of legal and regulatory restrictions by the FDA and comparable foreign regulatory authorities. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. If we are not able to obtain FDA or comparable foreign regulatory authority approval for desired uses or indications for our product candidates, we may not market or promote them for those indications and uses, and our business, financial condition, results of operations, prospects and reputation may be materially harmed. We also must sufficiently substantiate any claims that we make for our products, including claims comparing our products to other companies&#8217; products, and must abide by the FDA or comparable foreign regulatory authority&#8217;s strict requirements regarding the content of promotion and advertising. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation or enforcement action concerning alleged violations of law, including with respect to promotional requirements, would be expected to require us to expend significant time and resources in response and could result in significant liability, including civil and administrative remedies as well as criminal sanctions and fines. Even if it is later determined that we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters. Any non-compliance with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products, and the value of the company and our operating results would be adversely affected. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business, financial condition, or results of operations, and current and future legislation may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continues to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which was intended to substantially change the way healthcare is financed by both governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. More recently, on August 16, 2022, President Biden signed into law the IRA, which, among other provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. See &#8220;Business&#8212;Health Reform&#8221; in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our product candidates or additional pricing pressures. We cannot be sure whether additional legislation or rulemaking related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to foreign, federal, and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, sanctions, or other liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations may be subject to various foreign, federal, and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and Physician Payments Sunshine Act, the European General Data Protection Regulation 2016/679, and other regulations. These laws may impact, among other things, our relationships with healthcare professionals and our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government and the states in which we conduct our business. See &#8220;Business&#8212;Other Regulations&#8221; in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including significant civil, criminal, and administrative penalties, disgorgement, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts, and business operations, and cause environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of specified materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-compliance with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or non-compliance with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation of personal data or personal information processing is evolving, as federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of such data. We, our collaborators, and our service providers may be subject to current, new, or modified federal, state, and foreign data protection laws and regulations (e.g., laws and regulations that address data privacy and data security, including, without limitation, health data). These new or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. These and other requirements could require us or our collaborators to incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our collaborators&#8217; ability to process or use data in order to support the provision </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our products or services, affect our or our collaborators&#8217; ability to offer our products and services or operate in certain locations, cause regulators to reject, limit, or disrupt our clinical trial activities, result in increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of or commitments to customers or collaborators. See &#8220;Business&#8212;Other Regulations&#8221; in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance with U.S. and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties, fines, or sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients or subjects about whom we or our collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Any failure by our third-party collaborators, service providers, contractors, or consultants to comply with applicable law, regulations, or contractual obligations related to data privacy or security could result in proceedings against us by governmental entities or others.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publish privacy policies and other documentation regarding our collection, processing, use, and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to potential foreign, local, state, and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Any of these matters could materially adversely affect our business, financial condition, or operational results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish commercial manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell our product candidates, we may be unable to generate any revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although some of our employees may have been employed at companies that have launched pharmaceutical products in the past, we have no experience establishing commercial manufacturing relationships for or selling and marketing our product candidates and we currently have no commercial manufacturing relationships or marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to find one or more collaborators to commercialize our products or invest in and develop these capabilities, either on our own or with others, which would be expensive, difficult, and time consuming. Any failure or delay in entering into agreements with third parties to market or sell our product candidates or in the timely development of our internal commercialization capabilities could adversely impact the potential for the launch and success of our products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If commercialization collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, particularly in the markets our </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may attempt to form strategic collaborations, create joint ventures, or enter into licensing arrangements with third parties with respect to our programs that we believe will complement or augment our existing business. We may face significant competition in seeking appropriate strategic collaborators, and the negotiation process to secure appropriate terms is time consuming and complex. We may not be successful in our efforts to establish such a strategic collaboration for any product candidates and programs on terms that are acceptable to us, or at all. This may be because our product candidates and programs may be deemed to be at too early of a stage of development for collaborative effort, our research and development pipeline may be viewed as insufficient, the competitive or intellectual property landscape may be viewed as too intense or risky, and/or third parties may not view our product candidates and programs as having sufficient potential for commercialization, including the likelihood of an adequate safety and efficacy profile. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully enter into a collaboration regarding the development or commercialization of our product candidates, we cannot guarantee that such a collaboration will be successful. Any delays in identifying suitable collaborators and entering into agreements to develop and/or commercialize our product candidates could delay the development or commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. Absent a strategic collaborator, we would need to undertake development and/or commercialization activities at our own expense. If we elect to fund and undertake development and/or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to do so, we may not be able to develop our product candidates or bring them to market and our business may be materially and adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, and our competitors may discover, develop, or commercialize products faster or more successfully than us.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive, particularly in the treatment of TED. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities, and other research institutions worldwide with respect to our product candidates. We are aware that the following companies, among others, have therapeutics marketed or in development for TED: Amgen, argenx SE (&#8220;Argenx&#8221;), Immunovant, Inc., Roche Holdings AG, Acelyrin, Inc., Tourmaline Bio, Inc., Lassen Therapeutics and Sling Therapeutics, Inc. Other companies such as Kriya Therapeutics, Inc., Septerna and Crinetics Pharmaceuticals, Inc. among others, have earlier stage products in development which, if successfully developed, may impact the value of our product candidates over their lifecycle. If approved, veligrotug and VRDN-003 will also compete against generic medications, such as corticosteroids, and surgical procedures that are prescribed for the treatment of TED. We are also aware that the following companies, among others, may have anti-FcRn therapeutics marketed or in development: Argenx, UCB S.A., Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Immunovant, Inc. and AstraZeneca/Alexion Pharmaceuticals, Inc. Moreover, there are more than 20 indications announced or in development across the FcRn class. Depending on the indications in which we choose to develop VRDN-006 and VRDN-008, there may be further competition from marketed and in-development therapeutics targeting other mechanisms such as complement inhibition, T-cell inhibitors, anti-1L-6 and other mechanisms of action.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may demonstrate inferior efficacy and safety profiles as compared to currently approved drugs, or product candidates currently in development by our competitors. Our competitors may succeed in developing, acquiring, or licensing technologies and drug products that are more effective or less costly than our product candidates that we are currently developing or that we may develop, which could render our product </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates obsolete and noncompetitive. Our competitors may also adopt a similar licensing and development strategy as ours with regard to the development of an existing anti-IGF-1R monoclonal antibody for the treatment of TED. If any competitor was able to effect this strategy in a more efficient manner, there may be less demand for our product candidates if any are approved.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Third-party payors, including governmental and private insurers, may also encourage the use of generic products. For example, if veligrotug is approved, it may be priced at a significant premium over other competitive products. This may make it difficult for veligrotug or any other future products to compete with these products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our competitors obtain marketing approval from the FDA, EMA, or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research, and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. For example, in October 2023, Amgen completed its acquisition of Horizon, which could have a significant impact on the competitive landscape for clinical trials and therapeutics for TED. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors. If our product candidates fail to compete effectively against established treatment options or future products currently in development, this would harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with the approvals from the FDA, EMA, and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the healthcare providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, and third-party payors. The degree of market acceptance of any of our products will depend on a number of factors, including but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy or safety of the product as demonstrated in clinical trials and potential advantages over competing treatments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of the disease and any side effects;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which approval is granted, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the patients and physicians to accept these therapies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived ratio of risk and benefit of these therapies by physicians and the willingness of physicians to recommend these therapies to patients based on such risks and benefits;</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the marketing, sales, and distribution support for the product;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the publicity concerning our products or competing products and treatments; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and availability of third-party payor coverage and adequate reimbursement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product remains uncertain. We may be unable to penetrate the existing TED market and successfully commercialize our product candidates, if approved. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other healthcare providers, we will not be able to generate sufficient revenue to become or remain profitable.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the market for TED therapies may fail to continue its growth, or may shrink, which could affect the commercial viability of our product candidates and could negatively impact revenues from any approved products. For example, sales of Tepezza&#174; may fall, and this could cause our business to be negatively impacted. Our estimates of the market size and market opportunity for our product candidates may prove inaccurate, which could negatively impact their commercial viability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in any efforts to identify, license, discover, develop, or commercialize additional product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our effort will focus on clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not succeed in preclinical or clinical testing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business, financial condition, or results of operations and could potentially cause us to cease operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain or maintain adequate reimbursement or insurance coverage for our products, if any, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, as well as the coverage, and reimbursement of our approved products, if any, must be sufficient to support our commercial efforts and other development programs, and the availability of coverage and adequacy of reimbursement by third-party payors, including government healthcare programs, health maintenance organizations, private insurers, and other healthcare management organizations, are essential for most patients to be able to afford expensive treatments. Sales of our approved products, if any, will depend substantially, both domestically and abroad, on the extent to which the costs of our approved products, if any, will be paid for or reimbursed by third-party payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free, or we may not be able to successfully commercialize our products. See &#8220;Business&#8212;Coverage and Reimbursement&#8221; in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products, if any. Accordingly, in markets outside the U.S., the potential revenue may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has increased and is expected to continue to increase in the future. As a result, profitability of our products, if any, may be more difficult to achieve even if they receive regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends in part on our ability to attract, retain, and motivate qualified personnel. If we lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop our product candidates will be impaired and our business may be harmed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends greatly upon our ability to attract and retain highly qualified managerial, scientific and medical personnel with particular subject matter expertise. We are highly dependent on our management team. The loss of the services of key personnel, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we are able to replace departed employees effectively, we may require current employees to fill additional roles, and this could overextend their responsibilities. As a result, we may experience increased turnover due to employees being overworked. Employees also may be unable to perform these multiple roles effectively due to time and resource constraints. Additionally, if we are unable to retain key personnel, we may </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be required to cover the roles previously performed by such employees with consultants. These consultants may lack the same skills and performance of departed employees and, as a result, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily conduct our business in Massachusetts. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we may grant equity awards that vest over time or vest upon the achievement of certain pre-established milestones. The value to employees of equity awards has been, and may continue to be, significantly affected by movements in our stock price that are beyond our control, and these equity awards may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, they may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize shares under our Amended and Restated 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) to issue equity awards, in order to induce new employees to join our Company and to retain existing employees. We historically seek stockholder approval to increase the number of shares issuable under the 2016 Plan. If stockholders do not approve future increases to the number of shares issuable under the 2016 Plan, however, our ability to attract and retain employee talent, and our ability to compete for talent, may be adversely affected, which could negatively affect our ability to attract and retain talent and negatively affect our business and business prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our development and commercialization plans and strategies develop and our geographical footprint expands, we expect to need additional managerial, operational, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of our attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions, inflation, increases in interest rates, natural disasters, public health crises such as the COVID-19 pandemic, political crises, geopolitical events, such as the crisis in Ukraine, or other macroeconomic conditions, may have serious adverse consequences on our business and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, have experienced extreme volatility and disruptions at various points over the last few decades, including, among other things, diminished liquidity and </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine, the rising tensions between China and Taiwan, the conflict in Israel and surrounding area and domestic tensions within the U.S. have created, or may create, significant volatility in the capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our clinical trials, our business and the third parties on whom we rely. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and share price and could require us to delay or abandon development or commercialization plans. In addition, there is a risk that one or more of our service providers, manufacturers or other partners would not survive or be able to meet their commitments to us under such circumstances, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hercules Loan and Security Agreement contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hercules Loan and Security Agreement, we have pledged substantially all of our assets, other than our intellectual property rights. Additionally, the Hercules Loan and Security Agreement contains certain affirmative and negative covenants that could prevent us from taking certain actions without the consent of our lenders. These covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our stockholders. The Hercules Loan and Security Agreement also contains customary affirmative and negative covenants that, among other things, limit our ability, subject to certain exceptions, to incur indebtedness, grant liens, enter into a merger or consolidation, enter into transactions with affiliates, or sell all or a portion of our property, business or assets. The Hercules Loan and Security Agreement contains customary events of default. Upon the occurrence and continuation of an event of default, all amounts due under the Hercules Loan and Security Agreement become (in the case of an insolvency or bankruptcy event), or may become (in the case of all other events of default and at the option of Hercules), immediately due and payable. If an event of default under the Hercules Loan and Security Agreement should occur, we could be required to immediately repay any outstanding indebtedness. If we are unable to repay such debt, the lenders would be able to foreclose on the secured collateral, including our cash accounts, and take other remedies permitted under the Hercules Loan and Security Agreement. Even if we are able to repay any indebtedness on an event of default, the repayment of these sums may significantly reduce our working capital and impair our ability to operate as planned.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure in our information technology and storage systems, or those of third parties upon whom we rely, could significantly disrupt the operation of our business and adversely impact our financial condition.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute our business plan and maintain operations depends on the continued and uninterrupted performance of our information technology (&#8220;IT&#8221;) systems or those of third parties upon whom we rely. IT systems are vulnerable to risks and damages from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters (such as a tornado, an earthquake, or a fire). Moreover, despite network security and back-up measures, some of our and our vendors&#8217; servers are potentially vulnerable to physical or electronic break-ins, including cyber-attacks, computer viruses, and similar disruptive problems. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently, and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If the IT systems are compromised, we could be subject to fines, damages, litigation, and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. Despite precautionary measures designed to prevent unanticipated problems that could affect the IT systems, sustained or repeated system failures that interrupt our ability to generate and maintain data could adversely affect our ability to operate our business. In addition, the failure of our systems, maintenance problems, upgrading or transitioning to new platforms, or a breach in security could result in delays and reduce efficiency in our operations. Remediation of such problems could result in significant, unplanned capital investments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, parties in our supply chain may be operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A data breach, security incident, or other unauthorized network intrusion or access may allow unauthorized access to our network or data, which could result in a material disruption of our clinical trials, harm our reputation, harm our business, create additional liability and adversely impact our financial results or operational results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity threats to our information networks and systems, and those of our service providers or collaborators have generally increased in sophistication, scale, and frequency in recent years. In addition to threats from natural disasters, telecommunications and electrical failures, traditional computer hackers, malicious code (such as malware, viruses, worms, and ransomware), employee error, theft or misuse, password spraying, phishing, and distributed denial-of-service attacks, we now also face threats from sophisticated nation-state and nation-state supported actors who engage in attacks (including advanced persistent threat intrusions) that add to the risks to our internal networks and systems, our third-party service providers, our collaborators and the information that they store and process. Despite having implemented technical and organizational security measures and made other significant efforts to safeguard against such threats, it is virtually impossible for us to entirely mitigate these risks. The security measures we have integrated into our internal networks and systems, which are designed to detect unauthorized activity and prevent or minimize security incidents or breaches, may not function as expected or may not be sufficient to protect our internal networks and platform against certain threats. In addition, techniques used to obtain unauthorized access to networks in which data is stored or through which data is transmitted change frequently and generally are not recognized until launched against a target. As a result, we may be unable to anticipate these techniques or implement adequate preventative measures to prevent such an event.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, security incidents or breaches affecting us or our current or future collaborators or third-party service providers could result in the unauthorized access to, or disclosure or loss of information, including information that we process. This, in turn, could require notification under applicable data privacy regulations or contracts, and could lead to financial losses, litigation, governmental audits, investigations, fines, penalties, and other possible liability, damage our relationships with our collaborators, trigger indemnification and other contractual obligations, cause us to incur investigation, mitigation and remediation expenses, have a negative impact on our ability to conduct clinical trials, and cause reputational damage. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have adequate insurance coverage for security incidents or breaches or information system failures. The successful assertion of one or more large claims against us that exceeds our available insurance coverage or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that any existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third-party service providers to comply with our data privacy, security, protection, or confidentiality, or to respond to any data security incidents, breaches or other unauthorized access, acquisition, or disclosure of sensitive information (including, without limitation personal information), may result in financial losses, additional cost and/or liability to us, including costs from governmental investigations, enforcement actions, regulatory fines, litigation, costs of doing business or damage to our reputation. Any of these events could cause harm to our reputation, business, financial condition or operational results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss (&#8220;NOL&#8221;) carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax years beginning after December 31, 2017 is limited. It is uncertain if and to what extent various states will conform to the Tax Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. Our most recent analysis of possible ownership changes was completed for certain tax periods ending through December 31, 2023. It is possible that we have in the past undergone and may in the future undergo, additional ownership changes that could result in additional limitations on our NOL and tax credit carryforwards. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use, or other tax laws, statutes, rules, regulations, or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in numerous U.S. states and territories and non-U.S. jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors including the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes, and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law and the terms of some of our contracts could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Certificate of Incorporation and Bylaws may delay or prevent an acquisition or a change in management. These provisions include a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us, unless certain conditions are met. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Certificate of Designation of our Series A Preferred Stock and the provisions of our warrants issued in 2020 may delay or prevent a change in control of our company. At any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, we may not consummate a Fundamental Transaction (as defined in the Certificate of Designation of the Series A Preferred Stock) or any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of the capital stock of the Company immediately after such transaction, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock. As of December 31, 2023, a majority of the then outstanding shares of Series A Preferred Stock was held by entities affiliated with one stockholder. This provision of the Certificate of Designation may make it more difficult for us to enter into any of the aforementioned transactions. In addition, pursuant to such warrants, under certain circumstances each warrant holder has the right to demand that we redeem the warrant for a cash amount equal to the Black-Scholes value of a portion of the warrant upon the occurrence of specified events, including a merger, an asset sale or certain other change of control transactions. A takeover of us may trigger the requirement that we redeem the warrants, which could make it more costly for a potential acquirer to engage in a business combination transaction with us.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the Delaware General Corporation Law, our certificate of incorporation or our Bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. Our Bylaws further provide that, unless we consent in writing to an alternative forum, federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While these choice of forum provisions do not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction, the choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against our and our directors, officers, and other employees. If a court were to find the choice of forum provision contained in the bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause our stock price to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of equity and debt could result in additional dilution to our stockholders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will need significant additional capital to fund our current and future operations, including to complete potential clinical trials for our product candidates. To raise capital, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. As a result, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to our equity incentive plans, we may grant equity awards and issue additional shares of our common stock to our employees, directors, and consultants, and the number of shares of our common stock reserved for future issuance under certain of these plans will be subject to automatic annual increases in accordance with the terms of the plans. To the extent that new options are granted and exercised, or we issue additional shares of common stock in the future, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors, officers, 5% stockholders, and their affiliates currently beneficially own a substantial portion of our outstanding voting stock. Therefore, these stockholders have the ability and may continue to have the ability to influence us through this ownership position. These stockholders may be able to determine some or all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has historically been volatile, and the market price of our common stock may drop in the future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been, and may continue to be, subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. In addition to the factors described elsewhere in this &#8220;Risk Factors,&#8221; some of the factors that may cause the market price of our common stock to fluctuate greatly, and to decline significantly, include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections we may provide to the public and the investment community;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of investors to view the clinical trial data that we generate favorably, even if we view the data favorably;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative outcomes, or perceived negative outcomes, from our interactions with regulatory authorities in connection with the development of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of the pharmaceutical and biotechnology industries by the public, legislatures, regulators, and the investment community;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the possible market size, or perceived market size, for our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of technological innovations or new therapies that compete with our potential products;</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the capital markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including volatility resulting from general global macroeconomic conditions. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our business and reputation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to risks related to litigation and other legal proceedings that may materially adversely affect our business, operating results or financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time in the ordinary course of its business, we and our directors and officers may become involved in various legal proceedings, including commercial, employment and other litigation and claims, as well as governmental and other regulatory investigations and proceedings. Such matters can be time-consuming, divert management&#8217;s attention and resources and cause us to incur significant expenses. Litigation is inherently unpredictable, the results of any such actions may have a material adverse effect on our business, operating results or financial condition. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting, and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), as well as rules implemented by the SEC and The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). These rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules and regulations may also make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> may be negatively affected.</span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our annual report filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. This requires that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner for each period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, it could result in a material misstatement of our financial statements that would not be prevented or detected on a timely basis, which could require a restatement, cause us to be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, cause investors to lose confidence in our financial information, or cause our stock price to decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting, insurance, and other expenses, and our management and other personnel have and will need to continue to devote a substantial amount of time to compliance initiatives resulting from operating as a public company. We also anticipate that these costs and compliance initiatives will continue to increase as a result of ceasing to be a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our transition to being a large accelerated filer and compliance with Section 404 of the Sarbanes-Oxley Act of 2002 has been and will continue to be time consuming and costly. Our inability to maintain effective internal control over financial reporting in the future could result in investors losing confidence in the accuracy and completeness of our financial reports and negatively affect the market price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. We became a large accelerated filer effective December 31, 2023, and Section 404 of the Sarbanes-Oxley Act requires our independent registered public accounting firm to attest to the effectiveness of our internal control over financial reporting. Our transition to becoming subject to additional requirements of Section 404 of the Sarbanes-Oxley Act has been and will continue to be time-consuming, and there is a risk of noncompliance. Further, the costs associated with the compliance with and implementation of procedures under these and future laws and related rules could have a material impact on our results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, if we are unable to assert that our internal controls over financial reporting is effective or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our common stock could be </span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negatively affected. In addition, we could become subject to investigations by any stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources, which could have an adverse impact on our business.</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_94"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i2e52e163a2594578be1a28935e1f5f13_97"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_100"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_103"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 Trading Arrangements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024, none of our Company&#8217;s directors or officers <ix:nonNumeric contextRef="c-11" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-939"><ix:nonNumeric contextRef="c-11" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-940">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-11" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-941"><ix:nonNumeric contextRef="c-11" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-942">terminated</ix:nonNumeric></ix:nonNumeric> any &#8220;Rule 10b5-1 trading arrangement&#8221; or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></div><div id="i2e52e163a2594578be1a28935e1f5f13_106"></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBIT INDEX</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed in the Exhibit Index are required by Item 601 of Regulation S-K. The SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q, and 8-K is 001-36483.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.733%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No. </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/ex31_vrdnxsecondrestatedce.htm">Second Restated Certificate of Incorporation of the Registrant, effective as of March 9, 2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/11/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312523297131/d668915dex31.htm">Fourth Amended and Restated Bylaws of the Registrant, effective as of December 15, 2023.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312520279263/d49501dex31.htm">Certificate of Designation of Series A Non-Voting Convertible Preferred Stock.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/28/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312521280729/d208955dex31.htm">Certificate of Designation of Series B Non-Voting Convertible Preferred Stock.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/23/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000114420414016510/v369400_ex4-1.htm">Specimen Common Stock Certificate.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1590750/000119312520027538/d879847dex41.htm">Form of Warrant to Purchase Common Stock.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/7/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_bi-watchfactory.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_bi-watchfactory.htm">ifth</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_bi-watchfactory.htm"> Amendment to Lease by and between Registrant and Watch City Ventures MT, LLC dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_bi-watchfactory.htm">September 19</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_bi-watchfactory.htm">, 2024.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="viridian-paragonamendedand.htm">Amended and Restated License Agreement by and between Registrant and Paragon Therapeutics, Inc. dated as of September 20, 2024.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311_2024-09.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.733%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.302%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312_2024-09.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321_2024-09.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicates management contract or compensatory plan</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed/furnished herewith.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i2e52e163a2594578be1a28935e1f5f13_109"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:26.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.833%"><tr><td style="width:1.0%"/><td style="width:35.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.693%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIRIDIAN THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Stephen Mahoney</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen Mahoney</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Seth Harmon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seth Harmon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President of Finance and Accounting</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer; Principal Accounting Officer)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:81pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101_bi-watchfactory.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0c98cc963dd44b67949eec52eee9c489_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">FIFTH AMENDMENT TO LEASE</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIFTH AMENDMENT TO LEASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (this &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;) is made as of the 19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of September, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WATCH CITY VENTURES MT LL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">C, a Massachusetts limited liability company, having an address at c&#47;o Berkeley Investments, Inc., 125 High Street, Suite 531, Boston, Massachusetts 02110 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation, having an address at 221 Crescent Street, Suite 401, Waltham,  Massachusetts 02453 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as successor in interest to Viridian, LLC, a Massachusetts limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Viridian LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REFERENCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is made to a certain Lease, dated January 13, 2020 by and between Landlord and Viridian LLC as Tenant&#8217;s predecessor in interest, pursuant to that certain Assignment and Consent Agreement entered into between the Landlord, Tenant and Viridian, LLC, dated September 27, 2020, as amended by that certain First Amendment to Lease dated July 6, 2021, as further amended by that certain Second Amendment to Lease dated April 13, 2022, as further amended by that certain Third Amendment to Lease dated July 29, 2022, and as further amended by that certain Fourth Amendment to Lease dated April 8, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Amendment&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for certain premises consisting of approximately 10,427 rentable square feet on the first (1st) floor of Buildings #18 and #19, as shown as Suite 103A on the plan attached to the Lease as Exhibit A-1.4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite 103A Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Original Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Tenant desires to exercise its right of first refusal to lease an additional approximately 2,788 rentable square feet on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) floor of Building #20, as shown as Suite 103B on the plan attached</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suite 103B Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord and Tenant acknowledge that nothing contained in this Amendment shall be deemed to modify any of the terms and conditions of the Fourth Amendment with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Tenant&#8217;s lease and occupancy of the Suite 103A Premises, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the New Premises Rent Commencement Date (as that term is defined in the Fourth Amendment) with respect to the Suite 103A Premises, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the payment of Suite 103A Premises Base Rent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Landlord&#8217;s payment of the Suite 103A Tenant Improvement Allowance, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Tenant&#8217;s surrender of the Original Premises (as defined in the Fourth Amendment collectively as the Suite 102 Premises, the Suite 401 Premises, the Suite 406 Premises, the Suite 110 Premises, and the Suite 111 Premises) on the Original Premises Surrender Date (as defined in the Fourth Amendment), it being the intent of Landlord and Tenant that Tenant is simply exercising its right of first refusal with respect to the Suite 103B Premises as set forth in the Fourth Amendment&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the rent commencement date for the Suite 103B Premises shall be the later to occur of (a) delivery of the Suite 103B Premises to Tenant, and (b) September 1, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Premises Rent Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant has agreed to accept the Suite 103B Premises in its current &#8220;as is&#8221; condition, and Landlord shall not be obligated to construct any improvements on behalf of Tenant or to alter, remodel, improve, renovate, repair or decorate the Suite 103B Premises, the Building, or any part thereof, or to provide any allowance for such purposes&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Tenant has requested and Landlord has agreed to grant to Tenant a one-time right of first refusal solely with respect to space, consisting of (a) approximately 2,737 rentable square feet located on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) floor of Building #4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite 110 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (b) approximately 2,503 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rentable square feet located on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) floor of Building #4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite 111 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), all as shown on the plan attached</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ROFR Expansion Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in accordance with the terms of this Amendment&#59; and </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord and Tenant desire to amend the Lease to (i) add the New Premises to the Premises, (ii) adjust the Base Rent, (iii) adjust the number of parking spaces available to Tenant, (iv) adjust Tenant&#8217;s Proportionate Share, and (v) provide Tenant with an ongoing right of first refusal with respect to the ROFR Expansion Premises, all in accordance with the terms and provisions as hereinafter set forth.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of Tenant's agreement to pay additional Base Rent as hereinafter set forth, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and for the mutual promises hereinafter set forth, Landlord and Tenant agree to amend the Lease, effective as of the Effective Date, as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;Capitalized terms used herein and not otherwise defined shall have the meaning ascribed thereto in the Lease. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The following definitions shall be added to Article 1 (Definitions) of the Lease&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Suite 103B Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  approximately 2,788 rentable square feet on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) floor of Building #20, as shown as Suite 103B on the plan attached</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Suite 103B Premises Commencement Date (&#8220;S103BPCD&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Suite 103B Premises Delivery Date.  See Section 2.1.5 below.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Suite 103B Premises Rent Commencement Date (&#8220;S103BPRCD&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The later to occur of (a) the Suite 103B Premises Delivery Date, or (b) September 1, 2024.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Suite 103B Premises Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:65.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.141%"><tr><td style="width:1.0%"></td><td style="width:25.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RSF Paying Rent On</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Base Rent</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Yearly Base</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;Rent</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Monthly Base</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;Rent</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">S103BPRCD &#8211; End of Lease Year 1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,788</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$44.00&#47;RSF</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$122,672.00</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$10,222.67</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lease Year 2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,788</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$45.00&#47;RSF</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$125,460.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10.455.00</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lease Year 3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,788</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$46.00&#47;RSF</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$128,248.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,687.33</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lease Year 4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,788</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$47.00&#47;RSF</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$131,036.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,919.67</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lease Year 5</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(through S103ATD)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,788</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$48.00&#47;RSF</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$133,824.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$11,152.00</font></td></tr></table></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Suite 103A Termination Date (&#8220;S103ATD&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  The last day of the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) consecutive full calendar month following the Suite 103A Premises Rent Commencement Date.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Suite 103B Premises Term&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The period commencing on the Suite 103B Premises Commencement Date and ending at 11&#58;59 P.M. on the Suite 103A Termination Date, unless sooner terminated or extended as provided in this Lease.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;The first sentence of the definition of &#8220;Additional Rent&#8221; appearing in Article 1 (Definitions) of the Lease is hereby deleted and replaced with the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 102 Premises, Tenant&#8217;s Proportionate Share (as defined below) of the cost of any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> reasonable and customary operating expenses for the Buildings, the Common Areas and the Property (as defined below) as reasonably determined by Landlord (including, without limitation, gas, heat, air conditioning, electricity, water, sewer, cleaning, trash collection, snow removal and sanding, and insurance, as applicable) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in excess of the Operating Expenses for Calendar Year 2020&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> real estate taxes for the Property (as defined below) and the Buildings in excess of the real estate taxes imposed against the Property and the Buildings for Fiscal Year 2020 (July 1, 2019 &#8211; June 30, 2020)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 401 Premises, Tenant&#8217;s Proportionate Share (as defined below) of the cost of any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Operating Expenses in excess of the Operating Expenses for Calendar Year 2021&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> real estate taxes for the Property (as defined below) and the Buildings in excess of the real estate taxes imposed against the Property and the Buildings for Fiscal Year 2022 (July 1, 2021 &#8211; June 30, 2022)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 110&#47;111 Premises and the Suite 406 Premises, Tenant&#8217;s Proportionate Share (as defined below) of the cost of any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Operating Expenses in excess of the Operating Expenses for Calendar Year 2022&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> real estate taxes for the Property (as defined below) and the Buildings in excess of the real estate taxes imposed against the Property and the Buildings for Fiscal Year 2023 (July 1, 2022 &#8211; June 30, 2023)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 103A Premises and the Suite 103B Premises, Tenant&#8217;s Proportionate Share (as defined below) of the cost of any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Operating Expenses in excess of the Operating Expenses for Calendar Year 2024&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> real estate taxes for the Property (as defined below) and the Buildings in excess of the real estate taxes imposed against the Property and the Buildings for Fiscal Year 2024 (July 1, 2023 &#8211; June 30, 2024).&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The following definitions set forth in Article 1 (Definitions) of the Lease shall be deleted in their entirety and replaced as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Lease Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  With respect to the Suite 102 Premises, the first &#8220;Lease Year&#8221; shall be the period commencing on the Commencement Date and ending on the last day of the calendar month in which the first anniversary of the Rent Commencement Date occurs if the Rent Commencement Date is other than the first day of a calendar month.  If the Rent Commencement Date is the first day of a calendar month, then the first &#8220;Lease Year&#8221; with respect to the Suite 102 Premises shall be the period commencing on the Commencement Date and ending on the day (last of the calendar month) immediately prior to the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Rent Commencement Date.  With respect to the Suite 401 Premises, the first &#8220;Lease Year&#8221; shall be the period commencing on the Suite 401 Premises Commencement Date and ending on the last day of the calendar month in which the first anniversary of the Suite 401 Premises Rent Commencement Date occurs if the Suite 401 Premises Rent Commencement Date is other than the first day of a calendar month.  If the Suite 401 Premises Rent Commencement Date is the first day of a calendar month, then the first &#8220;Lease Year&#8221; with respect to the Suite 401 Premises shall be the period commencing on the Suite 401 Premises Commencement Date and ending on the day (last of the calendar month) immediately prior to the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Suite 401 Premises Rent Commencement Date.  With respect to the Suite 406 Premises, the first &#8220;Lease </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Year&#8221; shall be the period commencing on the Suite 406 Premises Commencement Date and ending on the last day of the calendar month in which the first anniversary of the Suite 406 Premises Rent Commencement Date occurs if the Suite 406 Premises Rent Commencement Date is other than the first day of a calendar month.  If the Suite 406 Premises Rent Commencement Date is the first day of a calendar month, then the first &#8220;Lease Year&#8221; with respect to the Suite 406 Premises shall be the period commencing on the Suite 406 Premises Commencement Date and ending on the day (last of the calendar month) immediately prior to the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Suite 406 Premises Rent Commencement Date.  With respect to the Suite 110&#47;111 Premises, the first &#8220;Lease Year&#8221; shall be the period commencing on the Suite 110&#47;111 Premises Commencement Date and ending on the last day of the calendar month in which the first anniversary of the Suite 110&#47;111 Premises Rent Commencement Date occurs if the Suite 110&#47;111 Premises Rent Commencement Date is other than the first day of a calendar month.  If the Suite 110&#47;111 Premises Rent Commencement Date is the first day of a calendar month, then the first &#8220;Lease Year&#8221; with respect to the Suite 110&#47;111 Premises shall be the period commencing on the Suite 110&#47;111 Premises Commencement Date and ending on the day (last of the calendar month) immediately prior to the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Suite 110&#47;111 Premises Rent Commencement Date.  With respect to the Suite 103A Premises, the first &#8220;Lease Year&#8221; shall be the period commencing on the Suite 103A Premises Commencement Date and ending on the last day of the calendar month in which the first anniversary of the Suite 103A Premises Rent Commencement Date occurs if the Suite 103A Premises Rent Commencement Date is other than the first day of a calendar month.  If the Suite 103A Premises Rent Commencement Date is the first day of a calendar month, then the first &#8220;Lease Year&#8221; with respect to the Suite 103A Premises shall be the period commencing on the Suite 103A Premises Commencement Date and ending on the day (last of the calendar month) immediately prior to the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Suite 103A Premises Rent Commencement Date.  With respect to the Suite 103B Premises, the first &#8220;Lease Year&#8221; shall be the period commencing on the Suite 103B Premises Commencement Date and ending on the last day of the calendar month in which the first anniversary of the Suite 103A Premises Rent Commencement Date occurs if the Suite 103A Premises Rent Commencement Date is other than the first day of a calendar month.  If the Suite 103A Premises Rent Commencement Date is the first day of a calendar month, then the first &#8220;Lease Year&#8221; with respect to the Suite 103B Premises shall be the period commencing on the Suite 103B Premises Commencement Date and ending on the day (last of the calendar month) immediately prior to the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) anniversary of the Suite 103A Premises Rent Commencement Date, it being the intention of the parties that the first &#8220;Lease Year&#8221; with respect to both the Suite 103A Premises and the Suite 103B Premises, be co-terminus. In either case of the Suite 102 Premises, the Suite 110&#47;111 Premises, the Suite 401 Premises, the Suite 406 Premises, the Suite 103A Premises or the Suite 103B Premises, each succeeding twelve (12) month period thereafter, as the case may be, shall be a Lease Year, with the final Lease Year of each of the Suite 102 Premises, the Suite 110&#47;111Premises, the Suite 401 Premises, and the Suite 406 Premises, all ending on the Original Premises Surrender Date (as defined in the Fourth Amendment), and with the final Lease Year of the Suite 103A Premises and the Suite 103B Premises ending on the Suite 103A Termination Date.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; From and after the date hereof, Tenant shall have the non-exclusive right, in common with Landlord and others, to use and occupy during the remainder of the Term up to thirty-six (36) parking spaces in the parking lots serving the Buildings as shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, attached hereto, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parking Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and from and after the Original Premises Surrender Date, Tenant shall have the non-exclusive right, in common with Landlord and others, to use and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">occupy during the remainder of the Term, up to forty-four (44) parking spaces in the Parking Facilities, all at no additional fee or cost, but subject to the reasonable rules and regulations established by Landlord from time to time of uniform application to all users, and of which Tenant has received prior notice.  Landlord reserves the right in its sole discretion, from time to time, to modify, reconfigure, or relocate the Parking Facilities within reasonable proximity to the Parking Facilities as shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Tenant&#8217;s Proportionate Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 102 Premises during the Suite 102 Premises Term, Sixty-Seven One Hundredths percent (0.67%), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 110&#47;111 Premises during the Suite 110&#47;111 Premises Term, Three and Twenty-Four One Hundredths percent (3.24%), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 401 Premises during the Suite 401 Premises Term, Two and Three One Hundredths percent (2.03%), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 406 Premises during the Suite 406 Premises Term, One and Fifty One Hundredths percent (1.50%), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 103A Premises during the Suite 103A Premises Term, Six and Forty-Four One Hundredths percent (6.44%), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 103B Premises during the Suite 103B Premises Term, One and Seventy-Two One Hundredths percent (1.72%),which percentages have been determined by dividing the total number of rentable square feet in the Suite 102 Premises, Suite 110&#47;111 Premises, the Suite 401 Premises, the Suite 406 Premises, and the Suite 103A Premises respectively, by the Total Building Rentable Square Footage (161,790) and multiplying the resulting quotient by one hundred (100).  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 102 Premises, the period commencing on the Commencement Date and ending at 11&#58;59 p.m. on the Original Premises Surrender Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 110&#47;111 Premises, the period commencing on the Suite 110&#47;111 Premises Commencement Date and ending at 11&#58;59 p.m. on the Original Premises Surrender Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 401 Premises, the period commencing on the Suite 401 Premises Commencement Date and ending at 11&#58;59 p.m. on the Original Premises Surrender Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 406 Premises, the period commencing on the Suite 406 Premises Commencement Date and ending at 11&#58;59 p.m. on the Original Premises Surrender Date, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 103A Premises, the period commencing on the Suite 103A Premises Commencement Date and ending at 11&#58;59 p.m. on the Suite 103A Termination Date, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the Suite 103B Premises, the period commencing on the Suite 103B Premises Commencement Date and ending at 11&#58;59 p.m. on the Suite 103A Termination Date, it being the intention of the parties that the Term with respect to the Suite 103 A Premises and the Suite 103B Premises be co-terminus.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The following shall be added as new Section 2.1.5&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Suite 103B Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Landlord hereby leases to Tenant the Suite 103B Premises for the Suite 103B Premises Term, subject to the terms and conditions set forth herein. For the purposes of this Lease, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite 103B Premises Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred on the later to occur of (a) the full execution and delivery of this Amendment, and (b) the date Landlord has made the Suite 103B Premises available to Tenant. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;The following shall be added as new Section 2.2.5&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Acceptance of Suite 103B Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Tenant acknowledges and agrees that Tenant is accepting the Suite 103B Premises in its &#8220;as is&#8221; condition and Landlord shall not be obligated to construct any improvements on behalf of Tenant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord shall deliver the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Suite 103B Premises to Tenant free of other occupants and personal property and in broom clean condition.  Landlord has no obligation and has made no promises to alter, remodel, improve, renovate, repair or decorate the Suite 103B Premises, the Building, or any part thereof, or to provide any allowance for such purposes, and that no representations respecting the condition of the Suite 103B Premises or the Building have been made by Landlord to Tenant (except as otherwise specifically set forth herein).  In no event shall Tenant be permitted to any portion of the Suite 103A Tenant Improvement Allowance (as defined in the Fourth Amendment) toward any Suite 103B Alterations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;Section 2.7 shall be deleted in its entirety and replaced with the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.7.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Expansion&#59; Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Tenant shall have a one-time right (which shall be a one-time right held by Tenant, with respect to each respective suite comprising the ROFR Expansion Premises, only with respect to the first time each respective suite comprising the ROFR Expansion Premises becomes available during the Term, strictly in accordance with this Section 2.7, and subject to the rights of any of Landlord&#8217;s other existing tenants in the Buildings, to lease (a) (a) approximately 2,737 rentable square feet located on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) floor of Building #4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite 110 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (b) approximately 2,503 rentable square feet located on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) floor of Building #4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite 111 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and as shown on the plan attached</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(each suite individually and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ROFR Expansion Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) on the following terms and conditions&#58;  (i) Landlord shall notify Tenant in writing that Landlord has received a signed offer to lease the ROFR Expansion Premises which Landlord is prepared to accept and the basic terms and conditions of such offer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord&#8217;s ROFR Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; (ii) Tenant shall be entitled to lease the ROFR Expansion Premises upon the same terms and conditions as contained in Landlord&#8217;s ROFR Notice&#59; (iii) there shall remain not less than twenty-four (24) months remaining in the unexpired initial Term of this Lease, or if there shall remain less than twenty-four (24) months remaining in the initial Term of this Lease, Landlord&#8217;s ROFR Notice shall include Landlord&#8217;s determination of Prevailing Market Rate (for the then existing Premises) in accordance with Section 2.6 above and Tenant&#8217;s election to lease the ROFR Expansion Premises shall be conditioned upon Tenant exercising its option to extend the Term of this Lease for the Extended Term, pursuant to Section 2.6 hereof&#59; (iv) Tenant shall have ten (10) business days from receipt of Landlord's ROFR Notice, time being of the essence, to notify Landlord in writing that Tenant elects to lease the ROFR Expansion Premises on such terms and conditions as are set forth in Landlord&#8217;s ROFR Notice, and otherwise as set forth herein, or that Tenant disputes Landlord&#8217;s calculation of Prevailing Market Rate, in which case Landlord and Tenant shall proceed with the appraisal procedure set forth in Section 2.6 above, and Tenant's failure to so timely notify Landlord shall be deemed a waiver of the right to lease the ROFR Expansion Premises in accordance with this Section 2.7 and Landlord shall be entitled to lease the ROFR Expansion Premises (or such applicable portion of the ROFR Expansion Premises included in Landlord&#8217;s ROFR Notice) free and clear of any rights of Tenant&#59; provided however, if Landlord subsequently reduces the economic terms set forth in Landlord&#8217;s ROFR Notice by 10% or more, Landlord shall again offer the ROFR Expansion Premises to Tenant pursuant to the terms of this Section 2.7&#59; (v) the ROFR Expansion Premises shall be leased in its then &#34;as is&#34; condition except as set forth in Landlord&#8217;s ROFR Notice&#59;  and (vi) within ten (10) business days of Tenant&#8217;s receipt from Landlord of an amendment to this Lease solely reflecting Tenant's exercise of its option for the ROFR Expansion Premises and reflecting the modification of only the applicable terms of the Lease which relate to Tenant&#8217;s exercise of its option for the ROFR Expansion Premises including, without limitation, the Base Rent and Additional Rent, time being of the essence, Tenant shall execute such amendment and return same to Landlord.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant&#8217;s failure to timely comply with any of the above conditions, time being of the essence, shall be deemed Tenant&#8217;s waiver of the rights contained in this Section 2.7 to lease such portion of the ROFR Expansion Premises included in Landlord&#8217;s ROFR Notice), and thereafter Tenant shall have no further rights with respect to such portion of the ROFR Expansion Premises included in Landlord&#8217;s ROFR Notice. At Landlord's option, Tenant's exercise of its option for the ROFR Expansion Premises shall be effective only if, at the time of Tenant's notice and through the date on which Landlord is to deliver the ROFR Expansion Premises to Tenant, there is no default under this Lease, or condition which would be a default with the passage of time and&#47;or the giving of notice. Notwithstanding anything contained in this Section 2.7 to the contrary, (i) Tenant&#8217;s right to lease the ROFR Expansion Premises, or any portion thereof, shall expire on the date which is nine (9) months prior to the expiration of the initial Term, unless Tenant has exercised its right to extend the Term of this Lease for the Extended Term in accordance with Section 2.6 hereof, (ii) in the event Tenant has exercised its right to extend the Term of this Lease for the Extended Term in accordance with Section 2.6 hereof, Tenant&#8217;s right to lease the ROFR Expansion Premises, or any portion thereof, shall expire on the date which is twenty four (24) months prior to the expiration of the Extended Term.   Upon Tenant&#8217;s waiver or deemed waiver of its rights to lease any portion of the ROFR Expansion Premises, such portion shall be deemed removed from the ROFR Expansion Premises and Tenant shall have no further rights under this Section 2.7 with respect to such portion of ROFR Expansion Premises so removed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;Section 3.1 of the Lease is hereby deleted in its entirety and shall be replaced by the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.1.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Base Rent and Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  From and after (i) the Rent Commencement Date with respect to the Suite 102 Premises, (ii) the date which is two (2) months after the Suite 401 Premises Commencement Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite 401 Premises Rent Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with respect to the Suite 401 Premises, (iii) the Suite 406 Premises Rent Commencement Date with respect to the Suite 406 Premises, (iv) the Suite 110&#47;111 Premises Rent Commencement Date with respect to the Suite 110&#47;111 Premises, (v) the Suite 103A Premises Rent Commencement Date with respect to the Suite 103A Premises, and (vi) the Suite 103B Premises Rent Commencement Date with respect to the Suite 103B Premises, Tenant agrees to pay the Base Rent, with respect to the Suite 102 Premises, the Suite 401 Premises Base Rent, with respect to the Suite 401 Premises, the Suite 406 Premises Base Rent, with respect to the Suite 406 Premises, the Suite 110&#47;111 Premises Base Rent, with respect to the Suite 110&#47;111 Premises, the Suite 103A Base Rent, with respect to the Suite 103A Premises, the Suite 103B Base Rent, with respect to the Suite 103B Premises, and the Additional Rent in lawful money of the United States in advance on the first day of each and every calendar month during the Term of this Lease, at the Payment Address or at such other place as Landlord may from time to time designate by notice.  Tenant&#8217;s payment of any increased Security Deposit shall be due and payable within thirty (30) days from full execution and delivery of this Amendment.  Landlord may, from time to time, (but not more frequently than once for each calendar year) provide Tenant with an estimate of the Additional Rent for the coming year and such estimated Additional Rent shall be payable by Tenant to Landlord in accordance with the provisions of the preceding sentence in 12 equal monthly installments. The Base Rent, Suite 401 Premises Base Rent, the Suite 406 Premises Base Rent, the Suite 110&#47;111 Premises Base Rent, the Suite 103A Premises Base Rent, the Suite 103B Premises Base Rent, and Additional Rent for any partial month shall be prorated on the basis of a 30 day month. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto showing the Suite 103B Premises shall be added as new </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto showing the ROFR Expansion Premises shall be added as new </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A-1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;Tenant and Landlord each represent and warrant to the other that it has not directly or indirectly dealt, with respect to the leasing of office space in the Building, including without limitation, the Suite 103B Premises, with any broker or had its attention called to the Premises, Suite 103B Premises or other space to let in the Building by anyone other than Newmark.  Landlord assumes sole responsibility for compensating such brokers.  Notwithstanding the foregoing, if Tenant fails to take occupancy of the Suite 103B Premises, due to Tenant&#8217;s fault, Tenant shall reimburse Landlord for any amounts that Landlord has or will pay to any brokers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;From and after the S103BPCD, all references appearing in the Lease to the Premises shall be amended and read hereafter to be references to the Original Premises (as defined in the Fourth Amendment), the Suite 103A Premises, and the Suite 103B Premises, unless specifically set forth in this Amendment to the contrary.  From and after the Original Premises Surrender Date (as defined in the Fourth Amendment), all references appearing in the Lease to the Premises shall be amended and read thereafter to be references only to the Suite 103A Premises and the Suite 103B Premises.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;From and after the S103BPCD, all references appearing in the Lease to the Rent shall be amended and read hereafter to include, without limitation, the Suite 103B Premises Base Rent.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;The Lease is hereby ratified and confirmed and, as modified by this Amendment, shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;All references appearing in the Lease and in any related instruments shall be amended and read hereafter to be references to the Lease as amended by this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;This Amendment shall have the effect of an agreement under seal and shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, executors, administrators, successors and assigns.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;Except as otherwise specifically provided herein, all of the terms and conditions of the Lease shall remain in full force and effect for the extended Lease term and this Amendment is effective as of the date first set forth above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, and all of which shall constitute one and the same agreement.  This Amendment (and any further amendments to the Lease and any other instruments relating to the transactions contemplated hereby, other than any instruments to be recorded, witnessed and&#47;or notarized) may be electronically signed by the parties by the use of DocuSign, which will be treated as an original copy as though ink-signed by officers or other duly authorized representatives of such party.  Ink-signed or electronically signed executed copies hereof may be delivered by telecopier or email and upon receipt will be deemed originals and binding upon the parties hereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Blank.  Signatures on the Following Page.&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXECUTED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> under seal as of the date first set forth above.</font></div><div><font><br></font></div><div style="padding-right:-45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LANDLORD&#58;&#160;&#160;&#160;&#160;WATCH CITY VENTURES MT LLC,</font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Massachusetts limited liability company</font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;  Berkeley Watch MM LLC, its Managing Member</font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font><br></font></div><div style="padding-left:130.5pt;padding-right:-45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Young Park&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:130.5pt;padding-right:-45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Young Park&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:130.5pt;padding-right:-45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Its&#58;  Authorized signatory&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:130.5pt;padding-right:-45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(hereunto duly authorized)</font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:-45pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TENANT&#58;&#160;&#160;&#160;&#160;VIRIDIAN THERAPEUTICS, INC.,</font></div><div style="padding-left:216pt;text-indent:-216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Tom Beetham&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Tom Beetham</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;  COO</font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="padding-left:216pt;text-indent:-216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-9-</font></div></div></div><div id="i0c98cc963dd44b67949eec52eee9c489_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A-1.5</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">PLAN SHOWING SUITE 103B PREMISES </font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:328px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A-1.6</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">PLAN SHOWING ROFR EXPANSION PREMISES</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image_1.jpg" src="image_1.jpg" style="height:710px;margin-bottom:5pt;vertical-align:text-bottom;width:548px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_2.jpg" src="image_2.jpg" style="height:744px;margin-bottom:5pt;vertical-align:text-bottom;width:575px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-3-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>viridian-paragonamendedand.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i35760df1a6f24f949f724e3753244cc0_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:22pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div style="margin-bottom:11pt;text-align:center;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93; &#61; Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED LICENSE AGREEMENT</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">his </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">mended and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">estated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">icense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">greement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into and effective as of September 20, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A&#38;R Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between Paragon Therapeutics, Inc., a company organized under the laws of the State of Delaware, having its principal place of business at 221 Crescent Street, Suite 105, Waltham, MA 02453 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Viridian Therapeutics, Inc., a company organized under the laws of the State of Delaware, having its principal place of business at 221 Crescent Street, Suite 103A, Waltham, MA 02453 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Viridian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Paragon and Viridian are referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.34pt">Pursuant to that certain Antibody Discovery and Option Agreement entered into by and between the Parties, dated January 19, 2022, as amended by that certain First Amendment to Antibody Discovery and Option Agreement, dated December 12, 2022, and that certain Second Amendment to Antibody Discovery and Option Agreement, dated as of the A&#38;R Effective Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Viridian engaged Paragon to leverage its proprietary platform technology for therapeutic antibody discovery to identify, evaluate and develop one or more therapeutic antibody-based candidates directed to the human FcRn.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24pt">Under the Research Agreement, Paragon granted Viridian exclusive options with respect to each of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Program and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Program thereunder to obtain exclusive licenses to develop, manufacture and commercialize resulting antibodies, antibody-based proteins and associated products.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24pt">Viridian exercised both such options with respect to the Licensed Target under the Research Agreement, and the Parties entered into that certain License Agreement, dated October 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), under which Paragon granted to Viridian the License with respect to such Licensed Target (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.34pt">Pursuant to the Research Agreement and that certain Letter Agreement entered into by and between the Parties, dated January 26, 2024, as renewed by that certain First Renewal of Letter Agreement, dated July 16, 2024 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Letter Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Viridian has continued to engage Paragon to identify, evaluate, and develop therapeutic antibody candidates under the Research Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.67pt">The Parties desire to amend and restate the Original License Agreement to ensure that Viridian obtains all necessary rights to Develop, Manufacture and Commercialize the Licensed Antibodies, Derived Antibodies and Products resulting from any and all past, present or future activities conducted by the Parties under the Research Agreement, and to reflect other terms and conditions not covered in the Original License Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ow </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">herefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are hereby acknowledged, the Parties, intending to be legally bound, agree to amend and restate the Original License Agreement in its entirety as follows&#58;</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following initially capitalized terms have the following meanings (and derivative forms of them shall be interpreted accordingly)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means U.S. generally accepted accounting principles (GAAP), or International Financial Reporting Standards (IFRS), in each case consistently applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party&#8217;s Affiliates, other than the applicable Party in the definition of Change of Control and such Party&#8217;s Affiliates, determined as of immediately prior to the closing of such Change of Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any entity controlled by, controlling, or under common control with a Party. For the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control&#8221;) means the direct or indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding the foregoing, (a) with respect to either Party, Affiliates of such Party do not include </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or its Affiliates other than such Party and its subsidiaries, (b) Paragon and its subsidiaries, on the one hand, and Viridian and its subsidiaries, on the other hand, shall not be deemed to be Affiliates of each other, and (c) Affiliates of Paragon do not include new entities formed by or on behalf of Paragon for the sole </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> purpose of further developing, manufacturing, commercializing or otherwise exploiting antibodies and antibody products (excluding any Licensed Antibodies, Derived Antibodies or Products) using, among other sources, funds from Third Party investors (such new entities, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). However, if any Licensed Antibody Technology Controlled by Excluded Entities were used in the performance of Development Activities by or on behalf of Paragon, such Excluded Entities will be deemed Affiliates of Paragon under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;, a Delaware limited liability company, and any permitted assignee of &#91;***&#93; under the terms of the &#91;***&#93; License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the &#91;***&#93; Licensed Patents and the &#91;***&#93; Licensed Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain License Agreement dated &#91;***&#93;, between Paragon and &#91;***&#93;, as amended by that certain First Amendment to License Agreement dated &#91;***&#93;, as such agreement may be amended or restated from time to time, subject to the terms of this Agreement. A copy of the &#91;***&#93; License Agreement as of the A&#38;R Effective Date is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> which shall be updated by Paragon from time to time in the event of any amendment to or restatement of the &#91;***&#93; License Agreement becoming effective or executed after the A&#38;R Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Licensed Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Know-How (as defined in the &#91;***&#93; License Agreement) that (a) is licensed by &#91;***&#93; to Paragon under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">License Agreement, and (b)(i) actually used by Paragon in the course of performing any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Development Activities under any Research Program or (ii) is reasonably necessary or useful for the research, use, Development, Manufacturing, sale, import, Commercialization, or other exploitation of Licensed Antibodies, Derived Antibodies and Products in the Field in the Territory.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patent Rights (as defined in the &#91;***&#93; License Agreement) that are (a) licensed by &#91;***&#93; to Paragon under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement, and (b)(i) actually used by Paragon in the course of performing any Development Activities under any Research Program or (ii) reasonably necessary or useful for the research, use, Development, Manufacturing, sale, import, Commercialization, or other exploitation of Licensed Antibodies, Derived Antibodies and Products in the Field in the Territory.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any molecule, including &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any national, supra-national, federal, state or local laws, rules, guidances and regulations, in each case, as applicable to the subject matter and the Party at issue.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Patents and Know-How Controlled by a Party (a) as of December 12, 2022 (the effective date of the Research Agreement), or (b) that otherwise arise outside of and independently of the Research Agreement and this Agreement. Paragon&#8217;s Background IP includes the Paragon Platform Technology.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.5 </a>(Insolvency)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankruptcy Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.5 </a>(Insolvency)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biologics License Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Biologics License Application for Regulatory Approval of a Product that is filed with the United States Food and Drug Administration, or any successor entity thereof performing substantially the same functions.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the development program that has been or to be conducted by or on behalf of Paragon under the Research Agreement to discover, identify, generate, and characterize &#91;***&#93; Antibodies &#91;***&#93;, as such program is further described in the Research Plan attached to the Research Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day other than Saturday, Sunday or other national holiday in the United States.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than 50% of the combined voting power of the surviving </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of more than 50% of the combined voting power of the outstanding voting securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party&#8217;s business or assets to which the subject matter of this Agreement relates. For clarity, a Change of Control does not include (i) an internal consolidation, merger, share exchange or other reorganization of a Party between or among such Party and one or more of its Affiliates, or (ii) a sale of assets, merger, or other transaction effected exclusively for the purpose of changing domicile of a Party.</font></div><div style="margin-bottom:11pt;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.3 </a>(Indemnification Procedures)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize an Antibody, including any Licensed Antibody or Derived Antibody, or Product, as applicable. When used as a noun, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all activities involved in Commercializing.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the level of efforts, expertise, and resources commonly applied by Viridian to carry out a particular task or obligation consistent with the general practice followed by Viridian relating to other pharmaceutical compounds, products or therapies owned by it, or to which it has exclusive rights, which are of similar market potential at a similar stage in their development or product life, taking into account issues of safety and efficacy, product profile, the competitiveness of other products in development and in the marketplace, supply chain management considerations, the regulatory structure involved, the profitability of the applicable compound, product or therapy (including pricing and reimbursement status achieved), and other relevant technical, legal, scientific or medical factors.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.1(b) </a>(Non-Compete)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Party means any and all non-public scientific, business, regulatory or technical information that is disclosed or made available by or on behalf of one Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in connection with this Agreement, whether in writing, orally, visually or otherwise. As between the Parties, the &#91;***&#93; IP constitute the Confidential Information of Paragon.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.25</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (including any variations such as &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Controlled</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Controlling</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) means, with respect to any Know-How or other Intellectual Property Rights, possession by a Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under such Know-How or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party.</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything in this Agreement to the contrary, a Party or its Affiliate will not be deemed to Control Know-How or other Intellectual Property Rights that are owned or inlicensed by an Acquirer, unless (1) such Know-How or other Intellectual Property Rights owned or in-licensed by the Acquirer were generated from participation by employees or consultants of such Acquirer in the performance of Development Activities under a Research Program after such Change of Control, (2) such Know-How or other Intellectual Property Rights owned or in-licensed </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by such Acquirer are used by such acquired Party or any of its Affiliates in the performance of Development Activities under a Research Program, or (3) if, prior to the consummation of such Change of Control, such acquired Party or any of its Affiliates also Controlled such Know-How or other Intellectual Property Rights, in each of which cases ((1)-(3)), such Know-How or other Intellectual Property Rights owned or in-licensed by such Acquirer will be deemed Controlled by the acquired Party for purposes of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular product, any Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CREATE Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.3(d) </a>(CREATE Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means collectively all deliverables, samples, Sequence Information and such other data, results, summaries, information, or reports as Paragon may be required to deliver under the Research Agreement. For the avoidance of doubt, any &#8220;Deliverables&#8221; (as such term is defined under the Research Agreement) provided by Paragon under the Research Agreement, shall be Deliverables under this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Derived Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Antibody (including any chimeric, humanized, human, non-human, single chain, monovalent, divalent, polyvalent, monospecific, bispecific or other Antibody, fragment thereof, or polynucleotide encoding any of the foregoing) that &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means to discover, evaluate, test, research or otherwise develop an Antibody, including a Licensed Antibody or Derived Antibody, or Product. When used as a noun, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all activities involved in Developing.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the development activities that have been performed or are to be performed by or on behalf of Paragon for the Research Programs, as further described in the Research Plan attached to the Research Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Directed To</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with regard to an Antibody or Product, that such Antibody or Product is developed or designed to &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 1.24 </a>(The Definition of &#8220;Confidential Information&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10.7 </a>(Dispute Resolution)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a U.S. dollar, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be interpreted accordingly.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the first sale of a Product by Viridian, or one of its Affiliates or its or their Sublicensees, to a Third Party after receipt of all Regulatory Approvals required to market and sell the Product have been obtained in the country in which such Product is sold. &#8220;First Commercial Sale&#8221; shall not include (i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the portion of the &#91;***&#93; Program that is described &#91;***&#93; in the Research Plan attached to the Research Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.3 </a>(Indemnification Procedures)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.3 </a>(Indemnification Procedures)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all proprietary rights provided under (a) patent law, including any Patents&#59; (b) copyright law&#59; or (c) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in Know-How, or the expression or use thereof.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.42</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets, data, specifications,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions, processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding the foregoing, Know-How excludes Patent claims.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.1(a) </a>(License)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Antibodies that are discovered, generated, identified or characterized by or on behalf of Paragon in the course of performing the Development Activities under a Research Program under the Research Agreement that &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.45</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Antibody Invention</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) any Know-How Controlled by Paragon or its Affiliates, whether or not patentable, that is discovered, made or created in the course of, or that results from performance of, any activity(ies) by or on behalf of either Party, under the Research Agreement, including any invention or discovery that constitutes the composition of matter of, or any method of making or using, any Licensed Antibody, any Derived Antibody, any fragment of the foregoing, any polynucleotide encoding any of the foregoing, or any Product&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">all Intellectual Property Rights in each of the foregoing. For the avoidance of doubt, Licensed Antibody Inventions include all Project Antibody Inventions (as such term is defined under the Research Agreement) generated under the Research Agreement, including &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Antibody Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Patents Controlled by Paragon or any of its Affiliates as of the Original Effective Date or during the Term, that Cover any Licensed Antibody Invention, Licensed Antibody, Derived Antibody, or Product in the Territory. The Licensed Antibody Patents existing as of the A&#38;R Effective Date are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto. Upon the request of Viridian from time to time during the Term, Paragon shall update </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to include the then-existing Licensed Antibody Patents. Notwithstanding anything to the contrary herein, Licensed Antibody Patents exclude &#91;***&#93;.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.47</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Antibody Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) all Licensed Antibody Inventions&#59; (b) all Licensed Antibody Patents&#59; (c) all Deliverables, including all Sequence Information and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Results&#59; and (d) all Intellectual Property Rights therein. For the avoidance of doubt, Licensed Antibody Technology includes &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Background IP that is Controlled by Paragon (including any Paragon Platform Technology) during the term of any Research Program and that is &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means human FcRn.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.1 </a>(By Viridian)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable regulations promulgated thereunder by the FDA&#59; (b) a Biologics License Application in the United States&#59; or (c) any application filed with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Market Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store an Antibody, including any a Licensed Antibody or Derived Antibody, or Product or any component thereof. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing an Antibody, including any a Licensed Antibody or Derived Antibody, or Product or any component thereof.</font></div><div style="margin-bottom:11pt;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4.2 </a>(Milestones Payment)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4.2 </a>(Milestones Payment)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the development program that has been or to be conducted by or on behalf of Paragon under the Research Agreement to discover, identify, generate, and characterize &#91;***&#93; Antibodies &#91;***&#93; as such program is further described in the Research Plan attached to the Research Agreement. &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.57</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the gross amounts received for Products by Viridian, its Affiliates and Sublicensees for sales, transfers or other commercial disposition of Products, less the following reasonable and customary deductions, in each case related specifically to the Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and actually incurred, paid or accrued by Viridian, its Affiliates or Sublicensees and not otherwise recovered by or reimbursed to Viridian, its Affiliates, or Sublicensees&#58;</font></div><div style="margin-bottom:11pt;padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">&#91;***&#93;&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.03pt">&#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net Sales will include &#91;***&#93;. Net Sales will be calculated only once for the first </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> arm&#8217;s length sale of the Product by Viridian, its Affiliates or its Sublicensees to a Third Party, and will not include sales of Products between or among &#91;***&#93; where the purchaser will resell such Product. Net Sales shall not include &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net Sales shall be determined from the books and records of Viridian, Affiliates of Viridian or any Sublicensee maintained in accordance with Accounting Standards, in each case as consistently applied throughout such entity&#8217;s organization.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Product is sold as a Combination Product (as defined below), the Net Sales of such Combination Product shall be determined as follows&#58; &#91;***&#93;. If any Other Component in the Combination Product is not sold separately, Net Sales shall be calculated by &#91;***&#93;. If both the Licensed Component and any of the Other Components are not sold separately, the adjustment to Net Sales shall be determined by the Parties &#91;***&#93; to reasonably reflect &#91;***&#93; of such Combination Product.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this definition, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product that contains two (2) or more active ingredients, including both (A) a Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (B) one (1) or more active pharmaceutical or biological ingredients that are not a Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Components</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#8221;), either as a &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notice of Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.7 (Dispute Resolution)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 1.57 </a>(Definition of Net </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sales).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the recitals.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.1 </a>(By Viridian)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How in the Licensed Antibody Technology.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon Platform Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Paragon Platform Know-How, Paragon Platform Know-How Improvements and Paragon Platform Patents. For the avoidance of doubt, Paragon Platform Technology does not include &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:73pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this definition, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon Platform Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Know-How Controlled by Paragon or its Affiliates prior to or during the Term relating generally to Antibody discovery, (b) all methods, materials, and other Know-How Controlled and used by Paragon or its Affiliates generally in connection with Antibody discovery, and (c) physical platforms embodying components, component steps or other portions of any of the foregoing in</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">and (b) that are Controlled by Paragon or its Affiliates. &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon Platform Know-How Improvement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Know-How, other than Licensed Antibody Invention, that is developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or discovered through or as a result of the Development Activities by or on behalf of Paragon </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under the Research Agreement and that is Controlled by Paragon &#91;***&#93;. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon Platform Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Patents that Paragon or its Affiliates Control prior to or during the Term that Cover Paragon Platform Know-How or Paragon Platform Know-How Improvements.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.4(a) </a>(Notice of Patent Infringement and Patent Challenge)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.4(a) </a>(Notice of Patent Infringement and Patent Challenge)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) unexpired patents and patent applications, (b) any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c) any and all foreign equivalents of the foregoing.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase I Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase III Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167; 312.21(c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) any product that constitutes, incorporates, comprises or contains any Licensed Antibody or Derived Antibody, (ii) any Licensed Antibody or (iii) any Derived Antibody&#59; in each case ((i)-(iii)), alone or in combination with one or more Other Components or as part of a combination therapy with one or more other products concurrently or sequentially administered, in any form, mode of administration, dosage form, formulation or strength.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.3(a)</a> (Prosecution Generally)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 1.24 </a>(Definition of Confidential Information)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all clearances, approvals (including approval of an MAA as well as any applicable pricing and&#47;or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical product in a country or territory under this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture, marketing or sale of a Product in a country or region, including the FDA in the United States and the EMA in Europe.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Party means such Party&#8217;s officers, directors, employees, contractors, subcontractors, agents and consultants.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the research plan attached to the Research Agreement as Exhibit A, which may be updated from time-to-time in accordance with the terms of the Research Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any past, present or future research program conducted by the Parties pursuant to the Research Agreement and the Letter Agreement with respect to the Licensed Target, including the &#91;***&#93; Program and the &#91;***&#93; Program.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all data, results, analysis, conclusions, outcomes, information, documentation and reports (in each case, excluding Licensed Antibody Inventions, Licensed Antibody Patents, and the Sequence Information) that are generated by or on behalf of Paragon in performance of a Research Program, excluding Licensed Antibodies.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.6 </a>(Effect of Termination of this Agreement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4.3 </a>(Royalties)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, on a Product-by-Product and country-by-country basis, the period commencing on First Commercial Sale of the applicable Product in the applicable country and ending, with respect to the particular Product and country at issue on the latest of the following dates&#58; (a) the twelfth (12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of the date of First Commercial Sale of such Product in such country&#59; and (b) the expiration of the last-to-expire Valid Claim of a Licensed Antibody Patent Covering the manufacture, use or sale of such Product in such country.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sequence Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means electronic files containing all Licensed Antibody sequences generated under a Research Program.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Third Party with respect to Viridian, to whom Viridian grants a sublicense of, or other authorization or permission granted under, the rights granted to Viridian in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.1 </a>(License Grant from Paragon)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a protein molecule that (a) is chemically distinct from other molecules, and (b) wherein a binding entity derives recognized therapeutic value from binding to such molecule.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.1 </a>(Term)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means worldwide.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any person or entity other than Paragon or Viridian or an Affiliate of either Paragon or Viridian.</font></div><div style="margin-bottom:11pt;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.1 </a>(By Viridian)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">US</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America and its possessions and territories, including Puerto Rico.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular country, a claim (including a process, use, or composition of matter claim) of an issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a) irretrievably lapsed or been </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">abandoned, permanently revoked, dedicated to the public or disclaimed, or (b) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal.</font></div><div style="margin-bottom:12pt;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Viridian Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.2 </a>(By Paragon)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Viridian Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.3</a> (Termination by Paragon)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE II</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LICENSES&#59; TECHNOLOGY TRANSFER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">License Grant from Paragon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the terms of this Agreement (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4 (Reservation of Rights))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Paragon hereby grants to Viridian (i) a worldwide, royalty-bearing, exclusive (even as to Paragon and its Affiliates) right and license, including the right to sublicense through multiple tiers, under Paragon&#8217;s interest in and to the Licensed Antibody Technology&#59; (ii) a worldwide, royalty-bearing, non-exclusive right and license, including the right to sublicense through multiple tiers, under Paragon&#8217;s interest in and to the Licensed Background IP&#59; and (iii) a worldwide sublicense, including the right to further sublicense through multiple tiers, under Paragon&#8217;s interest in and to &#91;***&#93; IP, in each case ((i), (ii) and (iii)), to research, use, make, have made, sell, offer for sale, have sold, import, export and otherwise exploit Licensed Antibodies, Derived Antibodies and Products in the Field in the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that notwithstanding the foregoing or any other provision herein to the contrary, (a) Viridian&#8217;s non-exclusive license under the foregoing clause (ii) shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> include the right to use or practice Licensed Background IP to research, use, make, have made, sell, offer for sale, have sold, import, export or otherwise exploit Derived Antibodies except to the extent such Licensed Background IP was incorporated by Paragon into any Licensed Antibody under any Research Program or to use Deliverables, in the form in which such Deliverables were provided to Viridian, in its research, use, making, having made, selling, offering for sale, having sold, importing, exporting or otherwise exploiting Derived Antibodies, even if those Deliverables contain or are based on Licensed Background IP, and (b) as between the Parties, the sublicense Viridian receives under the foregoing clause (iii) is exclusive, even with respect to Paragon (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt;text-decoration:underline">Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Paragon (itself and on behalf of its Affiliates) shall not</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">research, Develop, Manufacture or Commercialize (including seek Regulatory Approval for),</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">authorize or otherwise assist any Third Party in researching, Developing, Manufacturing or Commercializing or (3) supply to any Third Party&#58; (x) any Licensed Antibody or Derived Antibody, or any other Antibody that binds to the Licensed Target and inhibits the binding of the Licensed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Target to &#91;***&#93; or (y) any product that constitutes, incorporates, comprises or contains any of the foregoing Antibodies, in each case ((x)-(y)) in the Field in the Territory, whether alone or in combination with one or more Other Components or as part of a combination therapy with one or more other products concurrently or sequentially administered, in any form, mode of administration, dosage form, formulation or strength&#59; for a period of &#91;***&#93; years from the Original Effective Date. For clarity, the foregoing restrictions shall not apply to &#91;***&#93;. </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.1(b) </a>(Non-Compete),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if a Third Party becomes an Affiliate of Paragon during the Term through a Change of Control of Paragon and such new Affiliate, as of the effective date of such Change of Control, is engaged in Development, Manufacturing, Commercialization, or other exploitation activities that, if conducted by Paragon, would cause Paragon to violate the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.1(b) </a>(Non-Compete)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the program of conduct of such activities, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then the new Affiliate will not be in violation of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.1(b) </a>(Non-Compete)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as long as (A) no Licensed Antibody Technology, Licensed Background IP or other Confidential Information of Viridian is used by or on behalf of Paragon or its Affiliates in connection with any activities relating to the Competing Program, and (B) Paragon and its Affiliates institute commercially reasonable technical and administrative safeguards to comply with foregoing clause (A), including a customary &#8220;firewall&#8221; segregating personnel working on the research, Development, Manufacture, or Commercialization of the Competing Program from personnel working on Licensed Antibodies, Derived Antibodies, or Products.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragon IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(b),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Viridian shall have the right to grant sublicenses (or further rights of reference), through multiple tiers of sublicensees, under the License to Sublicensees, provided that any such sublicense shall be consistent with the terms and conditions of this Agreement. No sublicense shall relieve or waive any obligations of Viridian hereunder. Viridian shall remain responsible for the performance by its Affiliates and Sublicensees of the rights and obligations hereunder. In respect of such sublicenses (or sub-sublicenses) and Affiliates and without limiting the foregoing&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.69pt">Viridian will remain responsible for the payment to Paragon of all Royalty Payments payable under this Agreement with respect to Net Sales made by Viridian&#8217;s Affiliates and Sublicensees&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.36pt">Viridian shall be responsible for failure by its Affiliates and Sublicensees to comply with the terms and conditions of this Agreement&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.03pt">Viridian shall, within &#91;***&#93; days of a grant of a sublicense, notify Paragon of each sublicense granted to any Third Party, including the identity of such Third Party and the scope of the license granted, and deliver a copy of such sublicense (and any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> amendments thereto), which may be reasonably redacted to remove sensitive financial data&#59; provided, that for the avoidance of doubt the foregoing obligations shall not apply with respect to Third Party service providers or distributors&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.69pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.8 </a>(Survival of Sublicenses),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> all sublicenses shall automatically terminate upon termination (for whatever reason) of this Agreement, but not expiration of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt;text-decoration:underline">&#91;***&#93; IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any sublicense granted by Viridian under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2 (Sublicenses)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes a further sublicense by Viridian of the sublicense granted to Viridian in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> under &#91;***&#93; IP, then the following terms and conditions shall also apply&#58;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.69pt">each sublicense of &#91;***&#93; IP shall be subject and subordinate to the &#91;***&#93; License Agreement, and shall contain provisions consistent with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.5 (&#91;***&#93; License Agreement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> applicable to the sublicense of &#91;***&#93; IP&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.36pt">except as to sublicenses of &#91;***&#93; IP to Affiliates, subcontractors and service providers, Viridian shall as soon as reasonably practicable provide Paragon with (or, at the request of Paragon, provide directly to &#91;***&#93;) a copy of any executed sublicense agreement (which copy may be redacted to remove financial and other provisions that are not necessary to monitor compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2(b)(&#91;***&#93; IP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4 (Sublicenses to &#91;***&#93; Programs)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement)&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.03pt">each such sublicense agreement shall contain a requirement that the sublicensee comply with the confidentiality and non-use restrictions at least as stringent as those set forth in the &#91;***&#93; License Agreement with respect to &#91;***&#93; Confidential Information (as defined under the &#91;***&#93; License Agreement), provided that Paragon clearly marks such Confidential Information owned by &#91;***&#93; and provided to Viridian as such.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Initial Information Transfer to Viridian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Within &#91;***&#93; days after the A&#38;R Effective Date, at Paragon&#8217;s sole cost and expense, Paragon shall transfer to Viridian copies of all Paragon Know-How, Sequence Information, and Results in existence as of the A&#38;R Effective Date that has not already been provided to Viridian. Except as otherwise reasonably requested by Viridian, any such transfer will be conducted via a secure data room selected by Viridian.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Reservation of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the License and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI (Protection of Confidential Information)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.1(b) </a>(Non-Compete),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Paragon reserves the right to use and practice the Licensed Antibody Technology solely to perform any Research Program pursuant to the Research Agreement for the benefit of Viridian.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">&#91;***&#93; License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicability of the &#91;***&#93; License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties acknowledge and agree that&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.69pt">the &#91;***&#93; IP has been or will be licensed by &#91;***&#93; to Paragon under the &#91;***&#93; License Agreement and sublicensed by Paragon to Viridian under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.36pt">Viridian agrees to be bound by the following articles and sections of the &#91;***&#93; License Agreement to the extent applicable to the sublicense of &#91;***&#93; IP granted by Paragon to Viridian hereunder&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 4 (Fees and Payments)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (to the extent set for in Section 4.2 of this Agreement), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8 (Compliance with Law)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9 (Confidentiality)&#59; Section 3.4 (Sublicenses to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Programs)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1 (Tax Matters), Section 5.2 (Records&#59; Audits), Section 5.3 (Reports), Section 10.6 (Effect of Termination or Expiration&#59; Surviving Obligations), Section 11.4 (Insurance)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.03pt">in the event of any conflict between the terms of this Agreement and the terms of the &#91;***&#93; License Agreement that are applicable to Viridian with respect to the sublicense granted to Viridian under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(iii),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the terms of the &#91;***&#93; License Agreement </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall control to the extent necessary for Paragon to maintain compliance with the terms of the &#91;***&#93; License Agreement.</font></div><div style="text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.02pt">Required Disclosures under the &#91;***&#93; License Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything else herein to the contrary, Viridian hereby consents to Paragon&#58;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">providing an executed copy of this Agreement to &#91;***&#93; (which copy shall be redacted to remove financial and other provisions that are not necessary for &#91;***&#93; to monitor compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4 (Sublicenses to &#91;***&#93; Programs)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement)&#59; and (ii) disclosing to &#91;***&#93; any Confidential Information of Viridian that is expressly and specifically required to be disclosed by Paragon to &#91;***&#93; under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4 (Sublicenses to Partnered Antibody Programs)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.3 (Reports)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement. Paragon shall prominently mark such copy of this Agreement and copies of Viridian&#8217;s Confidential Information as &#8220;Confidential Information of Viridian Therapeutics, Inc.&#8221; and require &#91;***&#93; to acknowledge in writing that it is bound by its obligations of confidentiality and non-use set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9 (Confidentiality)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement with respect thereto.</font></div><div style="margin-bottom:11pt;padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt;text-decoration:underline">Covenants by Viridian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian hereby covenants and agrees that&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.69pt">On or before &#91;***&#93; of each year during the Term, Viridian shall deliver to Paragon a written report for its activities under this Agreement meeting the reporting requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.3 (Reports)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.36pt">Viridian shall cure any breach of the &#91;***&#93; License Agreement caused by Viridian, its Affiliates or Sublicensees within &#91;***&#93; days of written notice thereof, and shall provide Paragon with written notice of such cure upon completion thereof&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.03pt">Except as expressly required under this Agreement solely with respect to the &#91;***&#93; License Agreement, Viridian shall not communicate directly with &#91;***&#93; with respect to matters under this Agreement without Paragon&#8217;s prior written consent, which consent may be withheld in Paragon&#8217;s sole discretion, unless required by Applicable Law or administrative order.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEVELOPMENT, MANUFACTURING &#38; COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Development, Manufacturing and Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, Viridian shall be solely responsible for and have sole authority over and control of all aspects of the Development, Manufacturing, and Commercialization of Licensed Antibodies, Derived Antibodies and Products in the Territory in the Field. As between the Parties, Viridian shall be solely responsible for selection, registration and maintenance of all trademarks associated with the Products in the Field in the Territory. As between the Parties, Viridian shall solely own such trademarks in the Territory and pay all relevant costs thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, Viridian shall have the sole authority over and control of the regulatory strategy, regulatory filings, regulatory activities (including clinical trials for Products) and communication with each Regulatory Authority for the Products in the Field in the Territory and shall own all corresponding Regulatory Approvals.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Diligence&#59; Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall, itself or through its Affiliates, Sublicensees, or contractors&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least one Product in the Field in each of (i) the United States and (ii) at least one other Major Market Country&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">upon receipt of Regulatory Approval for a given Product in a given country, use Commercially Reasonable Efforts to Commercialize such Product in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On or before &#91;***&#93; of each Calendar Year prior to the First Commercial Sale of a Product in the Territory, Viridian shall deliver to Paragon a report summarizing its material development efforts with respect to any Licensed Antibodies, Derived Antibodies and Products, including preclinical and clinical activities, and achievement of any Milestones, during the preceding &#91;***&#93;. Such report shall be the Confidential Information of Viridian.</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IV</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL TERMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Payments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In partial consideration of the rights granted under this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">Viridian shall pay to Paragon an initial payment of Four Million Dollars ($4,000,000) within &#91;***&#93; days of the A&#38;R Effective Date&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Within &#91;***&#93; days of the A&#38;R Effective Date, Paragon shall make a payment of the sublicense fee in the amount of &#91;***&#93; to &#91;***&#93; pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.7 (Sublicense Fee)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement. Paragon will provide Viridian with written confirmation thereof and will issue an invoice to Viridian for such amount Within &#91;***&#93; days of Viridian&#8217;s receipt of such invoice, Viridian shall make a one-time, non-refundable and non-creditable payment to Paragon to reimburse Paragon for the sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> fee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.7 (Sublicense Fee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement paid by Paragon to &#91;***&#93; with respect to this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestones Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.7pt">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall make the following one-time payments to Paragon on a Research Program-by-Research Program basis (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), based on the achievement of the corresponding milestone (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by Viridian, its Affiliates, or its Sublicensees with respect to the first Product within each of (i) the portion of the &#91;***&#93; Program other than the &#91;***&#93; Program, (ii) the &#91;***&#93; Program, and (iii) the &#91;***&#93; Program to achieve such Milestone, &#91;***&#93;. Notwithstanding anything to the contrary in this Agreement, the &#91;***&#93; Program and the portion of the &#91;***&#93; Program other than the &#91;***&#93; Program shall be deemed two separate Research Programs for the purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2 (Milestones Payment)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall, within &#91;***&#93; days after the occurrence of each Milestone, make the corresponding Milestone Payment to Paragon. Each Milestone Payment shall be paid no more than once per Research Program, for the first achievement thereof by any Product in such Research Program, irrespective of how many Products in such Research Program achieve each Milestone, and Viridian&#8217;s total Milestone Payments hereunder shall not exceed (i) Forty Million Dollars ($40,000,000) in the aggregate for all three Research Programs &#91;***&#93;.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.266%"><tr><td style="width:1.0%"></td><td style="width:7.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone Payment for First Products Within the First Two Research Programs with First Products to Achieve the Relevant Milestone</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone Payment for the First Product within the Last of the Three Research Programs with a Product to Achieve the Relevant Milestone</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">#1</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">#2</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">#3</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:11.95pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The obligation to make any Milestone Payment is independent of the occurrence or non-occurrence of any prior Milestone. If any Milestone is achieved without the achievement of a numerically lower numbered Milestone applicable to the same Product within such Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Program, then Viridian will pay Paragon the Milestone Payment applicable to such earlier Milestone at the same time Viridian pays the applicable Milestone Payment. For example, if the Milestone Payment for Milestone #3 becomes due before the Milestone Payment for Milestone #2, then upon achievement of Milestone #3, the Milestone Payments for both Milestone #2 and Milestone #3 shall be due and payable.</font></div><div style="margin-bottom:11pt;padding-left:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.02pt">Payment Obligations Pursuant to the &#91;***&#93; License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Payment Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In consideration for the rights granted by Paragon to Viridian with respect to a Product (as defined in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Section 4.2(b)(v)(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;***&#93;Related Definitions))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, including under the &#91;***&#93; IP pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(iii),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> following Paragon&#8217;s &#91;***&#93; pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4 (&#91;***&#93; Program Fee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement, and without limiting amounts payable by Viridian to Paragon pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1 (Initial Payments), Section 4.2(a) (Milestone Payments),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3 (Royalties),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Viridian shall make the following payments due to &#91;***&#93; under the &#91;***&#93; License Agreement as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4 (Fees and Payments)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement and in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(iii)(Payments by Viridian to &#91;***&#93;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement&#58;</font></div><div style="padding-left:42pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.36pt">each annual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Program Fee in the amount of &#91;***&#93; that becomes due to &#91;***&#93; under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font></div><div style="margin-bottom:11pt;padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt;text-decoration:underline">(&#91;***&#93; Program Fee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement arising from Paragon&#8217;s activities under this Agreement or the Research Agreement or activities conducted by or on behalf of Viridian, its Affiliates and Sublicensees under this Agreement or the Research Agreement, in each case with respect to Products&#59; provided, that (i) any such payments paid by Viridian pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (including the initial &#91;***&#93; Program Fee and any subsequent &#91;***&#93; Program Fees to be paid on each </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">anniversary of the date of payment of the initial &#91;***&#93; Program Fee), shall be creditable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4 (&#91;***&#93; Program Fee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement against the Development Milestone payments payable by Viridian to &#91;***&#93; on behalf of Paragon under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below, and more than one &#91;***&#93; Program Fee may be creditable towards the same Development Milestone payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below&#59; (ii) any such payments shall only be payable until the First Commercial Sale of a Product developed under the applicable &#91;***&#93; Program, after which, no &#91;***&#93; Program Fee will be due from Viridian for such &#91;***&#93; Program&#59; and (iii) any such payments shall only be payable once and on an annual basis per &#91;***&#93; Program&#59;</font></div><div style="margin-bottom:11pt;padding-left:42pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.02pt">the Development Milestone payments under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5 (Development Milestone Payments)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement, subject to any credits that may be applied to such payments as described under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4 (&#91;***&#93; Program Fee)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement, to the extent payable due to achievement of the applicable Development Milestones by Viridian, its Affiliates, or Sublicensees with respect to a Product&#59; and</font></div><div style="margin-bottom:11pt;padding-left:37pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.02pt">the Commercial Payments under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.6 (Commercial Payment)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement to the extent payable due to achievement of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the applicable milestones by Viridian, its Affiliates, or Sublicensees with respect to a Product.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.36pt">&#91;***&#93; Payment Buyout</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall have the right to exercise and fund on behalf of Paragon the buyout rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.11 (Product Payment Buyout)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement for each Product in lieu of Viridian&#8217;s ongoing payment obligations with respect to the Development Milestone payments and Commercial Payments under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i) (&#91;***&#93; Payment Obligations)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement . On a Product-by-Product basis, Viridian, or any assignee or Sublicensee of Viridian, may, after &#91;***&#93;, elect to buy out all remaining payment obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i) (&#91;***&#93; Payment Obligations)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that are payable to &#91;***&#93; with respect to such Product including &#91;***&#93;. Upon any such election by Viridian or any assignee or Sublicensee of Viridian, Viridian shall make a one-time payment to &#91;***&#93; of the sum of&#58; &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.03pt">Payments by Viridian to &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Unless directed otherwise by Paragon in writing, (x) Viridian shall, on behalf of Paragon, make all payments due to &#91;***&#93; under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i) (&#91;***&#93; Payment Obligations)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> directly to &#91;***&#93; in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(iii) (Payments by Viridian to &#91;***&#93;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Paragon will provide to Viridian a copy of any invoice received from &#91;***&#93; under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10 (Invoicing)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement that is relevant to any payments for which Viridian is responsible under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(ii) (&#91;***&#93; Payment Obligations)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> within &#91;***&#93; days of receipt, or direct &#91;***&#93; to provide such invoices directly to Viridian, and Viridian will make any applicable payments to &#91;***&#93; within &#91;***&#93; days of receipt of the applicable invoice, and will promptly provide Paragon with written confirmation of such payments. Viridian will not be responsible for any delay in making a payment to &#91;***&#93; as required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(ii) (&#91;***&#93; Payment Obligations)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the extent that Paragon fails to deliver the applicable invoice from &#91;***&#93; to Viridian within the time window as set forth in the preceding sentence and &#91;***&#93; has not provided such invoice directly to Viridian. Viridian will deliver to Paragon (i) notice of the successful completion of each Development Milestone payments or Commercial Payments by Viridian, its Affiliates or Sublicensees with respect to a Product within &#91;***&#93; days of such successful completion, and (ii) notice of the First Commercial </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sale of each Product within &#91;***&#93; days of such occurrence. Viridian will comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 5.1 (Tax Matters)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5.2 (Records&#59; Audits)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement to the extent applicable to the payments for which Viridian is responsible.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.69pt">Offsets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the extent that any Development Milestone payment or Commercial Payment owed by Paragon to &#91;***&#93; under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4.5 (Development Milestone Payments) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.6 (Commercial Payment) t</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">he &#91;***&#93; License Agreement is reduced, whether pursuant to and in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.9 (Offsets)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement, or as expressly permitted in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2 (b) (Payment Obligations Pursuant to the &#91;***&#93; License Agreement), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">then the corresponding Development Milestone payment or Commercial Payment due under</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be reduced by an equal amount. Paragon will promptly notify Viridian of any such reduction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:110pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;-Related Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For the purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b) (Payment Obligations Pursuant to the &#91;***&#93; License Agreement),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (a) a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Licensed Antibody, Derived Antibody and Product as defined under this Agreement, in each case that is also a &#8220;Product&#8221; as defined in the &#91;***&#93; License Agreement&#59; (b) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to any Product (defined in the foregoing clause (a)) in any country or jurisdiction in the Territory, the first sale of such Product by Viridian or any of its Affiliates or Sublicensees to a Third Party for distribution, use or consumption in such country or jurisdiction after the Regulatory Approval for the commercial sale of such Product has been obtained in such country or jurisdiction&#59; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Research Program that is also &#8220;&#91;***&#93; Program&#8221; as defined in the &#91;***&#93; License Agreement&#59; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Program Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selection Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meanings ascribed to them under the &#91;***&#93; License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.7pt">In consideration of the License granted to Viridian hereunder, but subject to adjustment as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3(b),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Viridian shall make quarterly, non-refundable, non- creditable royalty payments to Paragon, on a Product-by-Product basis, on each portion of Net Sales of each Product during a Calendar Year in the Field in the Territory at the applicable percentage set forth below during the applicable Royalty Term (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="padding-left:3.03pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.792%"><tr><td style="width:1.0%"></td><td style="width:68.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Increments of Worldwide Aggregate Net Sales within a Calendar Year</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:20pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty (Percentage of Net Sales)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">That portion of Net Sales in a Calendar Year for a Product up to &#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">That portion of Net Sales in a Calendar Year for a Product between &#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;text-indent:20pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">That portion of Net Sales in a Calendar Year for a Product exceeding &#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:11.95pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">On a country-by-country and Product-by-Product basis, if a given Product in a given country ceases to be covered by a Valid Claim within the Licensed Antibody Patents in </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such country, then for the purposes of calculating royalties due under this Agreement, Net Sales of such Product in such country shall thereafter be deemed to be reduced by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19pt">Payment and Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Within &#91;***&#93; days after the end of each &#91;***&#93;, Viridian shall provide to Paragon a written report stating the &#91;***&#93;. All Royalty Payments described in such written report shall be made by Viridian at the same time it submits such written report to Paragon.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Payment Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All payments due under this Agreement to Paragon shall be made in US Dollars by bank wire transfer in funds to an account designated by Paragon from time to time reasonably in advance of any payment due date.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties agree to cooperate with one another and use reasonable efforts to minimize obligations for any and all income or other taxes required by Applicable Law to be withheld or deducted from any Royalty Payments, Milestone Payments or other payments made by Viridian to Paragon under this Agreement, including by completing all procedural steps, and taking all reasonable measures, to ensure that any withholding tax is reduced or eliminated to the extent permitted under Applicable Law, including income tax treaty provisions and related procedures for claiming treaty relief. To the extent that Viridian is required to deduct and withhold taxes on any payment to Paragon, Viridian shall&#58; (i) deduct such taxes from such payment to Paragon, (ii) pay the amounts of such taxes to the proper government authority in a timely manner, and (iii) promptly submit to Paragon an official tax certificate or other available evidence of such withholding sufficient to enable Paragon to claim such payment of taxes. For the avoidance of doubt, Viridian&#8217;s remittance of such withheld amounts to the appropriate governmental authority, together with payment to Paragon of the remaining amount owed, shall constitute full satisfaction of the applicable payment due to Paragon. Viridian shall provide Paragon with reasonable assistance in order to allow Paragon to recover, as permitted by Applicable Law, withholding taxes, value added taxes or similar obligations resulting from payments made hereunder or to obtain the benefit of any present or future treaty against double taxation which may apply to such payments. Paragon shall promptly provide Viridian with any requested tax forms that may be reasonably necessary in order for Viridian to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral tax income treaty.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Foreign Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the exchange rates used by Viridian in accordance with applicable Accounting Standards consistently applied by Viridian.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any amount owed by Viridian to Paragon under this Agreement that is not paid within the applicable time period set forth herein will accrue interest at the per annum rate of &#91;***&#93; above the then-applicable United States prime rate as quoted in the Wall Street Journal (East Coast Edition) (or if it no longer exists, a similarly authoritative source), calculated on a &#91;***&#93; basis, or, if lower, the highest rate permitted under Applicable Law.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Blocked Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If by Applicable Law of a country in which Net Sales occurred, conversion of funds into Dollars or transfer of funds from such country to the United States is restricted, forbidden or delayed for more than &#91;***&#93; days, then Viridian can elect, at its sole discretion, that the amounts accrued in such country and owed by Viridian to Paragon under </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this Agreement shall be paid to Paragon in such country in local currency by deposit in a local bank designated by Paragon, unless the Parties otherwise agree in writing.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Records&#59; Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">Viridian shall, and shall cause its applicable Affiliates and Sublicensees to, create and keep complete and accurate records of its sales and other dispositions of all Products in accordance with Accounting Standards, including all records that are reasonably necessary for the purposes of calculating all payments due under this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Upon reasonable advance written notice to Viridian, Paragon shall have the right to retain a nationally recognized (in the US) independent certified public accounting firm acceptable to Viridian (which acceptance shall not be unreasonably withheld, conditioned or delayed) to perform on behalf of Paragon an audit, conducted in accordance with Accounting Standards, of such books and records of Viridian or its applicable Affiliates or Sublicensees as may be reasonably necessary to verify the accuracy of any reports provided pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4.4</a> (Payment and Reports)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for any Calendar Quarter ending not more than &#91;***&#93; calendar months prior to the date of such request. Such audits shall not occur more frequently than &#91;***&#93; in each Calendar Year and shall not be conducted more than &#91;***&#93; with respect to any reporting period, in each case except where the previous audit demonstrated material inaccuracies of reports provided pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4.4.</a> (Payment and Reports)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> All information disclosed or observed during any audit pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4.10 </a>(Records&#59; Inspection)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be the Confidential Information of Viridian, and Paragon shall cause the accounting firm to retain all such information as Confidential Information, including, if requested by Viridian, by requiring such accounting firm to enter into a customary confidentiality agreement with Viridian prior to the initiation of any such audit.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">Upon completion of any audit hereunder, the accounting firm shall provide both Viridian and Paragon a written report disclosing whether the reports submitted by Viridian are correct or incorrect, whether the amounts paid are correct or incorrect, and in each case, the specific details concerning any discrepancies. No other information regarding Viridian&#8217;s records shall be provided to Paragon.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Paragon shall bear its internal expenses and the out-of-pocket costs for engaging such accounting firm in connection with performing such audits&#59; provided, however, that if any such audit uncovers an underpayment by Viridian that exceeds &#91;***&#93; of the total owed for such payment or payment period, as applicable, then Viridian shall reimburse Paragon for the amounts actually paid to such accounting firm for performing such audit.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">If such accounting firm concludes that Viridian has in aggregate underpaid amounts owed to Paragon during the audited period, Viridian shall pay Paragon the amount of the discrepancy within &#91;***&#93; days of the date Paragon delivers to Viridian such accounting firm&#8217;s written report and an invoice for such amounts. If such accounting firm concludes that Viridian has overpaid amounts owed to Paragon during the audited period, then such overpayments shall be, at Viridian&#8217;s election, credited against any future payment obligation to Paragon hereunder or paid to Viridian within &#91;***&#93; days of Viridian&#8217;s request.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE V</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Other than the License granted to Viridian, nothing in this Agreement shall affect or limit Paragon&#8217;s rights in any Patents, Know-How, or other Intellectual Property Rights Controlled by Paragon, now or in the future. Nothing in the Agreement shall affect Viridian&#8217;s rights in any Patents, Know-How, or other Intellectual Property Rights Controlled by Viridian, now or in the future.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the License, no right or license under any Patents, Know-How or Intellectual Property Right of either Party or its Affiliates is granted or shall be granted by implication hereunder, and all such rights or licenses are or shall be granted only as expressly provided in this Agreement, and each Party reserves to itself all rights not expressly granted under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Patent Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.7pt">Prosecution Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For the purpose of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article V (Intellectual Property),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include any patent interference, opposition, pre-issuance Third Party submission, ex parte re-examination, post-grant review, inter partes review or other similar proceeding, appeals or petitions to any board of appeals in a patent office, appeals to any court for any patent office decisions, reissue proceedings, and applications for patent term extensions and the like.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.02pt">Prosecution by Viridian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, Viridian shall be solely responsible for, and have sole discretion over, preparing, filing, enforcing, defending, Prosecuting and maintaining the Licensed Antibody Patents, in each case, at Viridian&#8217;s sole expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:23.69pt">Consultation with Paragon. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Viridian shall provide Paragon with copies of all material correspondence from and to any patent office relating to the Licensed Antibody Patents, and Viridian shall provide Paragon with drafts of all proposed filings to any patent office with respect to such Licensed Antibody Patents in reasonably adequate time before submission of such filings for Paragon&#8217;s review and comment. Viridian will take into consideration Paragon&#8217;s reasonable comments prior to submitting such filings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.36pt">Paragon&#8217;s Backup Right to Prosecute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall notify Paragon of any decision not to prepare or file, or to abandon, cease Prosecution or not maintain any Licensed Antibody Patent anywhere in the Territory. Viridian shall provide such notice at least &#91;***&#93; days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licensed Antibody Patent. In such event, Paragon shall have a backup right, but not the obligation, to prepare, file, or continue Prosecution or maintenance of, such Licensed Antibody Patent in Viridian&#8217;s name, at Paragon&#8217;s expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:109pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.03pt">Cooperation in Patent Prosecution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall cooperate with the other Party in the preparation, filing, Prosecution and maintenance of Licensed Antibody Patents, including in each case by providing the Prosecuting Party with data and other information as appropriate and executing all necessary affidavits, assignments and other paperwork. Without</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> limiting the generality of the foregoing, upon the written request of Viridian, Paragon will promptly provide to Viridian any Paragon Know-How, Sequence Information and Results </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">generated by Paragon that (i) has not been provided to Viridian and (ii) is reasonably necessary and useful for the preparation, filing, and Prosecution of a related Licensed Antibody Patent to enable Viridian to timely prepare, file and prosecute any such Licensed Antibody Patent in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.3(b) (Prosecution by Viridian)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.7pt">Prosecution by Paragon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except with respect to Licensed Antibody Patents, Paragon shall be solely responsible for, and have sole discretion over, preparing, filing, Prosecuting and maintaining any Patents that it owns or otherwise Controls. Paragon&#8217;s Prosecution of such Patents shall be at Paragon&#8217;s sole expense.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.02pt">CREATE Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. &#167; 103(c)(2)-(c)(3) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CREATE Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) when exercising its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article V (Intellectual Property),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> without the prior written consent of the other Party. Where such Party intends to invoke the CREATE Act, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a joint research agreement (JRA) as defined in the CREATE Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19pt">Patent Enforcement and Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.7pt">Notice of Patent Infringement and Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall give the other Party notice of any known or suspected infringement by a Third Party of any Licensed Antibody Patent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and any known or suspected challenge by a Third Party against the validity or enforceability of any Licensed Antibody Patent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within &#91;***&#93; days after such Patent Infringement or Patent Challenge comes to such Party&#8217;s attention.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.02pt">Viridian&#8217;s First Right to Enforce or Defend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall have the first right, but not the obligation, to bring and control any legal action, including by declaratory judgment action, patent litigation or similar proceeding, in connection with any Patent Infringement or Patent Challenge with respect to the Licensed Antibody Patents in the Field and the Territory at its own expense and discretion as it reasonably determines appropriate. Viridian shall keep Paragon informed and reasonably consult with Paragon in the course of such legal action. Paragon shall have the right to be represented in any such legal action by counsel of its choice at its own expense.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.7pt">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In connection with any such legal action or proceeding, Viridian shall not enter into any settlement, consent to any judgment or make any admission in any way that would impose any obligation on Paragon, and Viridian shall have no right in such legal action or proceeding to deny the validity or enforceability of any Patent, Patent claim or Patent application included in the Licensed Antibody Patents or admit the invalidity or unenforceability of any Patent, Patent claim or patent application in the Licensed Antibody Patents without the prior written consent of Paragon, such consent not to be unreasonably withheld.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.02pt">Paragon&#8217;s Backup Right to Enforce or Defend. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Viridian does not initiate a legal action for Patent Infringement or Patent Challenge or take other reasonable action within &#91;***&#93; days after a notice from Paragon under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.4(a) </a>(Notice of Patent Infringement </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">and Patent Challenge),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> then Paragon shall have a backup right, but not the obligation, to initiate such legal action at its own expense.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.7pt">Allocation of Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any recoveries resulting from such legal action initiated by Viridian or Paragon hereunder relating to Patent Infringement or Patent Challenge, including pursuant to a settlement, shall be applied as follows&#58; &#91;***&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt">Cooperation with Patent Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At the request of the enforcing Party (and at the requesting Party&#8217;s expense), the other Party shall reasonably cooperate and provide any information or assistance in connection with any legal action under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.4</a> (Patent Enforcement and Defense),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> including executing reasonably appropriate documents, cooperating in discovery and, if required by Applicable Law, joining as a party to the legal action at its own expense.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19pt">Defense of Claims Brought by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Paragon becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization of any Licensed Antibody, Derived Antibody, or Product under this Agreement infringes, misappropriates, or otherwise violates the Intellectual Property Rights of any Third Party, Paragon will promptly notify Viridian. In any such instance, Viridian will have the sole right to undertake and control the defense or settlement of any Third Party infringement claim, using counsel of its choice, at its cost and expense. Paragon will provide reasonable cooperation and assistance to Viridian in connection with Viridian&#8217;s defense or settlement of such Third Parry infringement claim.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19pt">Common Interest Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties acknowledge and agree that, with regard to the Prosecution of the Licensed Antibody Patents, the interests of the Parties under this Agreement, are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Licensed Antibody Patents or their Confidential Information, including privilege under the common interest doctrine and similar or related doctrines. With regard to any information or opinions disclosed pursuant to this Agreement by one Party or its Affiliates to the other Party or its Affiliates regarding Intellectual Property Rights or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party Intellectual Property Rights may affect the Licensed Antibody, Derived Antibody or Products, and have a further common legal interest in defending against any actual or prospective Third Party infringement claims based on allegations of misuse or infringement of Intellectual Property Rights of Third Party relating to the Licensed Antibodies, Derived Antibodies or Products. Accordingly, the Parties agree that all such information and materials obtained by the Parties from each other will be used solely for purposes of the Parties&#8217; common legal interests with respect to the conduct of this Agreement. All</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party's prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against the other Party. At the request of either Party to conduct the activities under this<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article V </a>(Intellectual Property),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Parties shall cooperate in </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">good faith to enter into any necessary common-interest agreement intended to preserve attorney-client privilege with respect to disclosures and communications by or on behalf of either Party or its Affiliates in connection with such activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that Viridian has no right under this Agreement to prepare, file, enforce, defend, Prosecute or maintain the &#91;***&#93; Licensed Patents.</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VI</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROTECTION OF CONFIDENTIAL INFORMATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term, and for all time thereafter until one of the exception in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.2 (Exceptions)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is met, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#8217;s Representatives who have a need for such information, provided that the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party. Notwithstanding anything to the contrary in this Agreement, (a) all Licensed Antibody Inventions, Licensed Antibody Patents, and Deliverables, to the extent directly and exclusively related to the Licensed Antibodies, Derived Antibodies or Products, are the Confidential Information of Viridian and Viridian will be deemed the Disclosing Party and Paragon the Receiving Party with respect thereto, and (b) any Confidential Information included in the Deliverables, to the extent not related to the Licensed Antibodies, Derived Antibodies or Products is the Confidential Information of both Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Exceptions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Receiving Party&#8217;s obligations under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 6.1 </a>(Confidentiality) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence&#58; (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available&#59; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Party&#59; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure&#59; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.7pt">Compelled Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the provisions of this<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</a> (Protection of Confidential Information),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Receiving Party may disclose Confidential </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information, without violating its obligations under this Agreement, to the extent the disclosure is required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange, provided that the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the &#91;***&#93; request and expense, shall cooperate with the Disclosing Party&#8217;s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential Information.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.02pt">Other Permitted Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI </a>(Protection of Confidential Information),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> each Party is permitted to disclose the other Party&#8217;s Confidential Information to its actual or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> potential investors, investment bankers, acquirers, merger partners, and other potential or actual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> financial partners, licensees, sublicensees, or collaborators&#59; provided that, in each such case, such persons are bound by obligations of confidentiality and non-use at least as stringent as those set forth in this Agreement prior to any such disclosure, except that, where the disclosee is an investor, investment banker, or financial partner, such disclosee will only need to be bound by commercially reasonable obligations of confidentiality and non-use.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Confidentiality of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and its terms are considered Confidential Information of both Parties, and each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the other Party, except as expressly permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 6.3 </a>(Authorized Disclosure),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and except that both Parties may disclose this Agreement and its terms to its legal, financial and investment banking advisors&#59; bona fide potential and actual investors, acquirers, merger partners, assignees, collaborators, investment bankers, lenders, licensees, sublicensees, or strategic partners in connection with license or partnering transactions, due diligence or similar investigations by such Third Parties or in confidential financing documents&#59; and counsel or other advisors for the foregoing&#59; provided, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at least as restrictive as those set forth in this<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI </a>(Protection of Confidential Information)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (provided that the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Press Release</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party may issue a press release or other public statement disclosing any information relating to or regarding this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed. The Parties agree that after a press release or other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> public announcement has been issued in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 6.5 </a>(Press Release),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> each Party may make subsequent public disclosures of the information contained in such press release or other public announcement without the further approval of the other Party, so long as the information in such press release or other public announcement remains true, correct and the most current information with respect to the subject matters set forth therein. Notwithstanding anything to the contrary set forth in this Agreement, each Party may issue a press release or public announcement as required, in the reasonable judgment of such Party, by Applicable Law, including by the rules or regulations of the United States Securities and Exchange Commission or </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">similar regulatory agency in a country other than the United States or of any stock exchange or listing entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Use of Name in Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 6.5 </a>(Press Release),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> neither Party will use the name, trade name, service marks, trademarks, trade, dress or logos of the other Party (or any of its Affiliates) in press releases, advertising, public announcement, or any other publication, without the other Party&#8217;s prior written consent in each instance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Return of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly after the termination or expiration of this Agreement for any reason, each Party will return to the other Party or destroy, as such other Party will direct, all tangible manifestations of such other Party&#8217;s Confidential Information at that time in the possession of the Receiving Party, subject to the Receiving Party&#8217;s right to maintain one copy of such tangible manifestations of such other Party&#8217;s Confidential Information solely for purposes of monitoring its compliance with this Agreement, provided that the Receiving Party will not be required to delete or destroy any electronic back-up tapes or other electronic back-up files that have been created solely by the Receiving Party&#8217;s automatic or routine archiving and back-up procedures, to the extent created and retained in a manner consistent with its standard archiving and back-up procedures.</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VII</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Mutual Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party represents and warrants to the other Party that&#58; (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof&#59; (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder&#59; and (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Representations of Paragon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Paragon hereby represents, warrants and covenants to Viridian as of the A&#38;R Effective Date that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) Other than &#91;***&#93; IP, Paragon has not incorporated any Third-Party Know-How into the Product nor used any Third Party Know-How in performance of any Research Program without Viridian&#8217;s prior written consent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">There are no judgments against or awards or settlements against Paragon or any of its Affiliates, and there are no claims, actions, or proceedings pending or, to Paragon&#8217;s knowledge, threatened, nor to Paragon&#8217;s knowledge are there any formal inquiries initiated or written notices received that are reasonably likely to lead to the institution of any such legal proceedings, in each case (i) relating to the use of Licensed Antibodies, Derived Antibodies, or Licensed Antibody Technology&#59; or (ii) alleging that any Licensed Antibody Patent is unpatentable, invalid, unenforceable, or not infringed.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth a complete and accurate list of all Licensed Antibody Patents in existence as of the A&#38;R Effective Date.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Other than the &#91;***&#93; License Agreement, Paragon is not party to any inlicense agreements (other than in-license agreements for non-exclusive licenses to enable use of intellectual property owned or controlled by Third Party service providers) relating to (i) the Licensed Antibody Technology, or (ii) the Licensed Antibodies, Derived Antibodies and Products.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">As of the A&#38;R Effective Date, (i) Paragon Controls the Licensed Antibody Technology, Licensed Background IP, and &#91;***&#93; IP, and (ii) Paragon is the sole and exclusive owner of and Controls all of the Licensed Antibody Patents and is listed in the records of the appropriate governmental authorities as the sole and exclusive owner of record for each registration, grant, and application included in the Licensed Antibody Patents.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.03pt">Paragon has used commercially reasonable efforts to preserve the confidentiality and trade secret protections of the Paragon Know-How.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Other than &#91;***&#93; IP, Paragon has obtained from all individuals who participated in any respect in the research, invention or Development of any Licensed Antibodies, Derived Antibodies, Products or Deliverables or authorship or invention of any Licensed Antibody Technology effective assignments of all ownership rights of such individuals in Intellectual Property Rights generated by such individuals in the course of such work, either pursuant to written agreement or by operation of Applicable Law, in each case to the extent necessary to effectuate the license provisions of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">To its knowledge, Paragon has the right to&#58; (i) grant to Viridian the License that Paragon purports to grant hereunder&#59; and (ii) use and disclose and to enable Viridian to use and disclose (in each case under appropriate conditions of confidentiality) the Paragon Know-How.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.69pt">All activities conducted by or, to Paragon&#8217;s knowledge, on behalf of Paragon or its Affiliates with respect to the Licensed Antibodies, Derived Antibodies and Products prior to the A&#38;R Effective Date have been conducted materially in accordance with Applicable Laws and regulations (including good laboratory practices, as applicable).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.69pt">To the extent Paragon controlled the Prosecution of any Licensed Antibody Patents, Paragon has (i) filed and Prosecuted Patent applications within the Licensed Antibody Patents in good faith and complied with all duties of disclosure and candor with respect thereto&#59; (ii) paid all application, registration, maintenance, and renewal fees in respect of the Licensed Antibody Patents necessary to maintain the Licensed Antibody Patents as of the A&#38;R Effective Date (as applicable)&#59; (iii) filed all necessary documents and certificates with the relevant agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the purpose of maintaining the Licensed Antibody Patents&#59; and (iv) not received any information, except for the information disclosed to the U.S. Patent and Trademark Office during Prosecution of the Patent applications included in the Licensed Antibody Patents, that Paragon believes as of the A&#38;R Effective Date (without taking into account any other belief that Paragon may form after the A&#38;R Effective Date, whether due to the passage of time, the receipt of additional information, or otherwise) has a material adverse effect on the validity or enforceability of any of the claims of such Patent applications.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">(i) To the knowledge of Paragon and except with respect to &#91;***&#93; IP, the exploitation of the Licensed Antibodies, Derived Antibodies and Products as contemplated </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">hereunder does not infringe the Patents or misappropriate the Know-How of any Third Party&#59; and (ii) Paragon has not received any written notice alleging such infringement or misappropriation.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.69pt">Paragon has not entered into a funding relationship with a governmental authority that would result in rights to any Licensed Antibody, Derived Antibody or Product residing in the United States Government, National Institutes of Health, National Institute for Drug Abuse or other governmental authority (including counterparts of such agencies in any other countries), and the licenses granted hereunder are not subject to overriding obligations to the United States Government as set forth in Public Law 96 517 (35 U.S.C. 200 204) or any similar obligations under the Applicable Laws of any other country with respect to other governmental authorities.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.69pt">The &#91;***&#93; License Agreement is in full force and effect, and Paragon has provided a true and complete copy of it under Exhibit B. Neither Paragon nor its Affiliates is in default with respect to a material obligation under the &#91;***&#93; License Agreement, and &#91;***&#93; has not claimed nor has grounds upon which to claim that Paragon is in breach or default under the &#91;***&#93; License Agreement. During the Term, Paragon will maintain and not breach or terminate, and will cause its Affiliates to maintain and not breach or terminate, the &#91;***&#93; License Agreement. Paragon will promptly notify Viridian in writing of any material breach by Paragon or its Affiliate, and will promptly notify Viridian in writing if Paragon or its Affiliate receives a notice from &#91;***&#93; of Paragon&#8217;s material breach of the &#91;***&#93; License Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">During the Term, Paragon will not (i) grant any interest in, or take any action with respect to, the Licensed Antibody Technology and Licensed Background IP, including any sale, grant of license, assignment or transfer of the Licensed Antibody Technology or Licensed Background IP, or (ii) incur or permit to exist, with respect to any Licensed Antibody Technology or Licensed Background IP, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties or other restriction (including in connection with any indebtedness), in each case ((a) and (b)) that conflict with or would conflict with, limit, or restrict the rights and licenses granted to Viridian hereunder or that is otherwise inconsistent with the terms and conditions of this Agreement, and Viridian will use all reasonable precautions to preserve the confidentiality of the Paragon Know-How.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">During the Term, Paragon will not, and will cause its Affiliates not to, amend, modify, or terminate the &#91;***&#93; License Agreement in a manner that would restrict, limit, encumber, or adversely affect Viridian&#8217;s rights or obligations with respect to the &#91;***&#93; License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Agreement as set forth under this Agreement without first obtaining Viridian&#8217;s written consent, which consent may be withheld in Viridian&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Paragon covenants that it will provide &#91;***&#93; for the &#91;***&#93; Program (as such term is defined under the &#91;***&#93; License Agreement) directed to the Licensed Target related to this Agreement within&#91;***&#93; of the A&#38;R Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Other than the Licensed Antibody Technology and Licensed Background IP, Paragon does not own any Know-How or Intellectual Property Rights that is or was actually used in the course of performing any Development Activities under any Research Program. During the Term, other than Licensed Antibody Technology and Licensed Background IP, Paragon shall not, in performance of any Research Program, use or practice any Intellectual Property Rights or Know-How that Paragon owns but does not Control.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISCLAIMER OF WARRANTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EXCEPT AS EXPRESSLY SET FORTH IN THIS<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VII </a>(REPRESENTATIONS AND WARRANTIES),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. PARAGON MAKES NO REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE LICENSED ANTIBODY TECHNOLOGY, OR THAT ANY CLAIMS IN ANY PATENT APPLICATIONS WITHIN THE LICENSED ANTIBODY PATENTS WILL ISSUE OR ARE VALID OR ENFORCEABLE, OR THAT THE MANUFACTURE, USE, SALE OR IMPORT OF PRODUCTS WILL NOT INFRINGE THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VIII</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TERM&#59; TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The term of the Original License Agreement commenced on the Original Effective Date and continues, as amended and restated by this Agreement, as of the A&#38;R Effective Date and shall expire on a Product-by-Product basis on the expiration of the last-to-expire Royalty Term, unless earlier terminated by a Party as set forth in this<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII </a>(Term&#59; Termination)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Term of the Agreement will expire in its entirety on the expiration of the last-to- expire Royalty Term for the last Product for which there are Net Sales, unless earlier terminated by a Party as set forth in this<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII </a>(Term&#59; Termination)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon expiration (but not termination) of the Royalty Term, on a Product-by-Product and country-by-country basis, the License shall survive and become royalty-free, fully paid-up, perpetual, and irrevocable with respect to the applicable Products in the applicable country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Termination by Viridian</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall have the right to terminate this Agreement on a Research Program-by-Research Program basis, or in its entirety, for any or no reason upon sixty (60) days&#8217; notice to Paragon. Notwithstanding anything to the contrary in this Agreement, the &#91;***&#93; Program and the portion of the &#91;***&#93; Program other than the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91;***&#93; Program shall be deemed &#91;***&#93; Research Programs for the purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2 (Termination by Viridian)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.6 </a>(Effect of Termination of this Agreement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Termination by Paragon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Paragon may terminate this Agreement in its entirety upon notice to Viridian if Viridian or its Affiliate or Sublicensee, directly or indirectly, individually or in association with any Third Party, asserts, assists or directs a Viridian Patent Challenge, where a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Viridian Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any challenge by Viridian, or its Affiliate or Sublicensee, directly or indirectly, individually or in association with any Third Party, in a legal or administrative proceeding to the patentability, validity, ownership, enforceability, term or scope of any of the Licensed Antibody Patents (or any claim thereof), including by&#58; (a) filing or pursuing a declaratory judgment action in which any of the Licensed Antibody Patents is alleged to be invalid or unenforceable&#59; (b) citing prior art against any of the Licensed Antibody Patents (other than as necessary to comply with Applicable Laws in the course of exercising its rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.3 </a>(Patent Prosecution),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> filing a request for or pursuing a re-examination of any of the Licensed Antibody Patents without Paragon&#8217;s prior written consent, which shall not be unreasonably withheld, or voluntarily becoming a party to or pursuing an interference without </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Paragon&#8217;s prior written consent, which shall not be unreasonably withheld&#59; (c) filing, or joining in, a petition under 35 U.S.C. &#167; 311 (or any foreign statute or regulation that is equivalent or similar thereto) to institute inter partes review of any Licensed Antibody Patents&#59; (d) filing, or joining in, a petition under 35 U.S.C. &#167; 321 (or any foreign statute or regulation that is equivalent or similar thereto) to institute post-grant review of any Licensed Antibody Patents or any portion thereof&#59; or (e) filing or pursuing any opposition, cancellation, nullity, or other like proceedings against any of the Licensed Antibody Patents. Notwithstanding the foregoing, Paragon will not have the right to terminate this Agreement if (i) such Viridian Patent Challenge is brought by a Sublicensee of Viridian whose sublicense agreement includes a provision prohibiting such Sublicensee from, directly or indirectly, individually or in association with any other person or entity, asserting or directing a Viridian Patent Challenge, and where such Viridian Patent Challenge is withdrawn within &#91;***&#93; days of Viridian receiving notice thereof, or (ii) such Viridian Patent Challenge is asserted as a defense or counterclaim to an action first brought by Paragon against Viridian or if such Viridian Patent Challenge is asserted by Viridian in a declaratory judgment proceeding filed by Paragon pursuant to 28 U.S.C. &#167;&#167; 2201-2202 in response to a threatened claim that Viridian or its Affiliates or Sublicensees are infringing any Licensed Antibody Patent, (iii) such Viridian Patent Challenge was initiated by prior to a Change of Control of Viridian by a Third Party acquiror that subsequently acquires Viridian in a Change of Control transaction, thereby becoming an Affiliate of Viridian, or (iv) such Viridian Patent Challenge was brought by an Acquirer of Viridian prior to consummation of a Change of Control of Viridian, and where such Viridian Patent Challenge is withdrawn within thirty (30) days of Viridian receiving notice thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Material Breach</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall have the right to terminate this Agreement upon ninety (90) days&#8217; notice to the other Party upon or after the material breach of this Agreement by the other Party if the breaching Party has not cured such breach by the end of such ninety (90) day period&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the cure period for Viridian&#8217;s failure to make payment to Paragon hereunder shall be thirty (30) days&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, further,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if such breach is capable of being cured but cannot be cured within such ninety (90) day period despite the breaching Party&#8217;s efforts to do so, and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the breaching Party shall have such additional period as is reasonable in the circumstances to cure such breach, provided that such additional period shall in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> no event exceed one hundred twenty (120) days. Any Dispute regarding (a) the existence or materiality of a breach specified in a notice provided by a Party in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.4</a> (Material Breach),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (b) whether a material breach has been cured within the applicable cure period described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.4 </a>(Material Breach)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be resolved in accordance with the dispute resolution procedures described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10.7 </a>(Dispute Resolution)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No purported termination of this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.4 </a>(Material Breach)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall take effect until the resolution of such Dispute, and the period for cure of such alleged breach shall be tolled during the pendency of any Dispute with respect to an alleged breach. If it is ultimately determined that the breaching Party committed such material breach, then the breaching Party will have the right to cure such material breach after such determination within the remainder of the applicable cure period (or extended cure period as provided for herein) which will commence as of the date of such determination. Any termination by any Party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.4 </a>(Material Breach)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled. The right of either Party to terminate this Agreement as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.4 </a>(Material Breach)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will not be affected in any way by such Party&#8217;s waiver of or failure to take action with respect to any previous breach under this Agreement.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to the other Party. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankruptcy Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following&#58; (i) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any Section or chapter of the United States Bankruptcy Code, as amended or under any similar laws or statutes of the United States or any state thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within &#91;***&#93; days after they are instituted, (ii) the insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (iii) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (iv) appointment of a receiver for all or substantially all of a Party&#8217;s assets, or (v) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">The Parties agree that this Agreement constitutes an executory contract under Section 365 of the Bankruptcy Code for the license of &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code and constitutes a license of &#8220;intellectual property&#8221; for purposes of any similar laws in any other country in the Territory. The Parties further agree that each Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Bankruptcy Code, including, but not limited to, Section 365(n) of the Bankruptcy Code, and any similar laws in any other country in the Territory. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code and any similar laws in any other country in the Territory, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless such Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above, following the rejection of this Agreement by or on behalf of such Party upon written request therefor by the other Party.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">All rights, powers and remedies of each Party provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.5 </a>(Insolvency)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including under the Bankruptcy Code and any similar laws in any other country in the Territory). In the event of an insolvency event in relation to Paragon in which Paragon has rejected this Agreement in the applicable bankruptcy proceeding, Viridian, in addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity (including under the Bankruptcy Code).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Termination of &#91;***&#93; License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event the &#91;***&#93; License Agreement is terminated, this Agreement shall remain in full force and effect but the sublicense to &#91;***&#93; IP under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate, and Paragon will promptly notify Viridian of such termination. Pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement, provided that (a) at the time of such termination, Viridian is not in material breach of the terms of this Agreement related to the grant of sublicense under the &#91;***&#93; IP to Viridian under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)(iii),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and (b) </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Viridian agrees to be bound to &#91;***&#93; under the same terms as those included herein with respect to the &#91;***&#93; IP, Viridian shall have the option to enter into an appropriate agreement with &#91;***&#93; at Viridian&#8217;s sole discretion, in which case the Parties will enter into an amendment to this Agreement to effectuate the foregoing. In such event, Viridian&#8217;s obligations under this Agreement with respect to the &#91;***&#93; IP and &#91;***&#93; License Agreement (including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b) Payment Obligations Pursuant to &#91;***&#93; License Agreement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will also terminate, and any payments payable by Viridian to &#91;***&#93; in consideration for a direct license to &#91;***&#93; IP shall be included in the applicable agreement between Viridian and &#91;***&#93;. Paragon will use commercially reasonable efforts to provide Viridian with any necessary assistance for Viridian to enter into such direct agreement with &#91;***&#93; pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the &#91;***&#93; License Agreement as reasonably requested by Viridian.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Effect of Termination of this Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If this Agreement terminates for any reason (excluding expiration under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.1 </a>(Term))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then the following shall apply&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">The License shall automatically terminate (i) with respect to the applicable Research Program (and all Products under such Research Program), in the event of termination of the Agreement for a particular Research Program or (ii) in its entirety, in the event of termination of the Agreement in its entirety. Notwithstanding the foregoing, the License shall not automatically terminate to the extent (x) required for Viridian, its Affiliates, and Sublicensees to complete or wind down any ongoing clinical trials for any Product as may be required by Applicable Law or ethical principles or (y) to sell existing Product inventories for up to &#91;***&#93; months (subject to Viridian&#8217;s continued corresponding payment obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 4.3 </a>(Royalties))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">No later than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after the effective date of such termination, each Party shall return or cause to be returned to the other Party, or destroy, all Confidential Information received from the other Party and all copies thereof related to the terminated Product(s) in the terminated country(ies)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each Party may retain any Confidential</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Information reasonably necessary for such Party&#8217;s ongoing obligations and rights under this Agreement which do not terminate, and each Party may keep one (1) copy of Confidential Information received from the other Party in its confidential files for record purposes and such copy shall remain subject to<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI </a>(Protection of Confidential Information)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">Upon Paragon&#8217;s written request to Viridian, (which must be provided to Viridian within &#91;***&#93; days after the effective date of termination), Viridian shall exclusively discuss in good faith, for a period of up to &#91;***&#93; days following such written request, terms and conditions under which Viridian will grant to Paragon a royalty-bearing license under the Intellectual Property Rights Controlled by Viridian to make, have made, sell, offer for sale, have sold, import, export and otherwise exploit Products (but not including any Other Component) (or Products under a terminated Research Program, in the event this Agreement is terminated only with respect to a Research Program and not in its entirety) in the Field in the Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as well as, at no additional cost to Paragon, the transfer of materials, ongoing clinical trials, and applicable regulatory filings and relevant data generated by Viridian with respect to the Reversion Products and necessary for the Development and Commercialization of such Reversion Products, such agreement to include commercially reasonable financial and other terms, which terms shall take into consideration Viridian&#8217;s contributions made in the </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development, Commercialization and other exploitation of the Reversion Products. Notwithstanding the foregoing, Intellectual Property Rights Controlled by Viridian shall not include Intellectual Property Rights Controlled by Viridian as a result of a Change of Control of Viridian.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">The Parties shall negotiate in good faith the establishment of a transition and wind-down plan that will include a plan to transfer to Paragon any ongoing Product clinical trials, existing regulatory documentation and Regulatory Approvals pertaining to Products, trademarks that pertain to the Products, and any other Confidential Information of Viridian necessary or used as of the effective date of such termination to exploit Products.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Survival of Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon termination of this Agreement, at the written request of any Sublicensee who is not then in breach of its sublicense agreement, Paragon will negotiate in good faith the terms and conditions of a direct license with such Sublicensee that is consistent with the terms of this Agreement (as adjusted for the scope of license, products, field of use, and other provisions of the original sublicense).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Accrued Rights&#59; Survival</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The expiration or termination of this Agreement for any reason shall not release either Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article I</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Definitions)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 2.2</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Sublicenses) and Section 4.2(b) (Payment Obligations Pursuant to the &#91;***&#93; License Agreement) (with respect to any payments or other performance obligations prior to conversion (if any) to a direct license pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.8 </a>(Survival of Sublicenses))</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Reservation of Rights)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article IV </a>(Financial Term)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (with respect to any outstanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> payment obligations incurred prior to the date of termination or expiration or thereafter pursuant to Section 8.7(a))&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a>(Ownership)&#59;<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a>(Protection of Confidential Information) (for the duration set forth therein)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Disclaimer of Warranties)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.6</a></font><font style="color:#2b579a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#2b579a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></font><font style="color:#2b579a;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Effect of Termination of this Agreement)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.8</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a>(Survival of Sublicenses)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 8.9</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a>(Accrued Rights&#59; Survival)&#59;<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a>(Indemnification)&#59; and<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article X</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a>(Miscellaneous).</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IX</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">By Viridian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Viridian shall defend, indemnify, and hold harmless Paragon, its Affiliates and its and their Representatives (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paragon Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense and attorneys&#8217; fees (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to which any Paragon Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the extent such Losses result from&#58; (a) the gross negligence, recklessness or willful misconduct of any Viridian Indemnitee or Sublicensee in the performance of this Agreement or exercise of rights under this Agreement&#59; (b) Viridian&#8217;s breach of any of its representations, warranties or covenants under this Agreement&#59; (c) Viridian&#8217;s or its Affiliates&#8217; or Sublicensee&#8217;s research, testing, Development, Manufacture, use, sale, distribution, licensing or </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization of Licensed Antibodies, Derived Antibodies or Products&#59; or (d) any breach of the &#91;***&#93; License Agreement to the extent caused by the actions or omissions of Viridian or its Affiliates or Sublicensees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">By Paragon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Paragon hereby agrees to defend, indemnify, and hold harmless Viridian, its Affiliates, and its and their Representatives (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Viridian Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from and against any and all Losses to which any Viridian Indemnitee may become subject as a result of any Third Party Claim to the extent such Losses result from&#58; (a) the gross negligence, recklessness or willful misconduct of any Paragon Indemnitee in the performance of this Agreement or exercise of rights under this Agreement&#59; or (b) Paragon&#8217;s breach of any of its representations, warranties or covenants under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20pt">Indemnification Procedures</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Party claiming indemnity under this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX</a> (Indemnification)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) promptly after learning of the claim, suit, proceeding or cause of action for which indemnity is being sought (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Indemnifying Party&#8217;s obligation to defend, indemnify, and hold harmless pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.1 </a>(By Viridian) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.2 </a>(By Paragon)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as applicable, will be reduced to the extent the Indemnified Party&#8217;s delay in providing notification pursuant to the previous sentence results in material prejudice to the Indemnifying Party&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the failure by an Indemnified Party to give such notice or otherwise meet its obligations under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.3 </a>(Indemnification Procedures)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will not relieve the Indemnifying Party of its indemnification obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense, of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">days after receipt of the notice of the Claim, provided that (a) it agrees to indemnify the Indemnified Party from and against all Losses the Indemnified Party may suffer arising out of the Claim&#59; (b) the Claim involves only money damages and does not seek an injunction or other equitable relief against the Indemnified Party&#59; and (c) the Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> conducts the defense of the Claim diligently. The Indemnified Party will provide the Indemnifying Party with reasonable cooperation and assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Indemnifying Party will have the right to assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money and unconditionally releases the Indemnified Party. The Indemnified Party will not settle any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the Indemnified Party reserves any right it may have under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX </a>(Indemnification)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to obtain indemnification from the Indemnifying Party.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIMITATION OF LIABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OR FOR ANY LOSS OF PROFITS </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SUFFERED BY THE OTHER PARTY. NOTHING IN THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 9.4 </a>(LIMITATION OF LIABILITY)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> IS INTENDED TO OR SHALL LIMIT OR RESTRICT ANY DAMAGE (A) REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IX (INDEMNIFICATION),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (B) AVAILABLE WITH RESPECT TO A PARTY&#8217;S BREACH OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VI (PROTECTION OF CONFIDENTIAL INFORMATION),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (C) AVAILABLE WITH RESPECT TO A PARTY&#8217;S GROSS NEGLIGENCE, FRAUD OR WILLFUL MISCONDUCT HEREUNDER, (D) CAUSED BY A PARTY&#8217;S INFRINGEMENT OR MISAPPROPRIATION OF THE OTHER PARTY&#8217;S INTELLECTUAL PROPERTY RIGHTS (INCLUDING RIGHTS GRANTED TO A PARTY UNDER THIS AGREEMENT), OR (E) WITH RESPECT TO CONSEQUENTIAL DAMAGES, IS CAUSED BY BREACH OF SECTION 7.2(Q).</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE X<br>MISCELLANEOUS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Independent Contractor Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship between the Parties. Neither Party is an agent of the other Party or authorized to make any representation, contract, or commitment on behalf of the other Party.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Force Majeure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law. The Party affected will give prompt written notice to the other Party of the nature of the cause of any material delay or failure to perform, its</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give prompt written notice to the other Party of such resumed performance. If any such failure or delay in a Party&#8217;s performance hereunder continues for more than ninety (90) days, the other Party may terminate this Agreement upon written notice to the affected Party.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. This Agreement supersedes the Original License Agreement as of the A&#38;R Effective Date, and the Original License Agreement shall cease to be of any force and effect as of the A&#38;R Effective Date of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the terms of the Original License Agreement shall continue to apply with regard to the rights and obligations of the Parties from the Original Effective Date and to the A&#38;R Effective Date.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Non-Waiver&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of time and shall be signed by such Party. This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written instrument signed by both Parties.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither this Agreement nor any rights or obligations hereunder may be assigned by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent, but with prompt notice to the other Party, to an Affiliate or to its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10.6 </a>(Assignment)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any assignment not in accordance with this Agreement shall be void.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Dispute Resolution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties recognize that a bona fide dispute as to certain matters may arise from time to time during the Term relating to either Party&#8217;s rights or obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI </a>(Protection of Confidential Information)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights (hereinafter, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the Dispute or disagreement&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">The Party claiming that such a Dispute exists will give notice in writing (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notice of Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other Party of the nature of the Dispute.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">The Dispute will be referred to the then Chief Operating Officer of Paragon and the then Chief Executive Officer of Viridian who will meet no later than thirty (30) days following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve the Dispute.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">If, within &#91;***&#93; days of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10.7(b)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a>hereof has not been held within &#91;***&#93; days of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10.7(c)</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">. </a>The arbitration will be conducted by a panel of three arbitrators. Within &#91;***&#93; days after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">two arbitrators so named will then jointly appoint the third arbitrator within &#91;***&#93; days of their appointment, who will serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least ten (10) years of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical industry. If either Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such &#91;***&#93;-day period, JAMS will make the necessary appointments for such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ex parte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> communication with its appointed arbitrator. The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted in English translation accompanied by the original or a true copy thereof. The arbitrators have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;1 et seq., and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10.7 </a>(Dispute Resolution)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be deemed the Confidential Information of both Parties.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.02pt">Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.7pt">The Parties agree that any Disputes relating to<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI </a>(Protection of Confidential Information)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or Disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights shall be subject to the exclusive jurisdiction of the state and federal courts in Boston, Massachusetts and each Party hereby submits to such jurisdiction.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.03pt">THE PARTIES EXPRESSLY WAIVE AND FOREGO ANY RIGHT TO A TRIAL BY JURY.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of&#58; (a) the date of actual receipt&#59; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries&#59; or (c) if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to the other Party in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> 10.9 </a>(Notices), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Party shall send a copy of such notice by email to the other Party.</font></div><div style="text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Paragon&#58; Paragon Therapeutics, Inc.</font></div><div style="padding-left:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">221 Crescent Street</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Suite 105</font></div><div style="padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Waltham, MA 02453</font></div><div style="padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Evan Thompson</font></div><div style="margin-bottom:11pt;padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Viridian&#58; Viridian Therapeutics, Inc.</font></div><div style="padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">221 Crescent Street, Suite 103A</font></div><div style="padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Waltham, MA 02453</font></div><div style="padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Legal Department</font></div><div style="margin-bottom:11pt;padding-left:73pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93; </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8pt">Interpretation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#8217;s or entity&#8217;s successors and assigns, (f) the words</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, Section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;or.&#8221; The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8pt">No Third-Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8pt">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8pt">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8pt">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties hereto acknowledge and agree that&#58; (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision&#59; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement&#59; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. Nothing in this Agreement is intended to limit either Party&#8217;s rights under the Research Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt">Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Party may perform some or all of its obligations under this Agreement through Affiliate(s) or may exercise some or all of its rights under this Agreement through Affiliates. However, each Party shall remain responsible and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance as if such Party were performing such obligations itself, and references to a Party in this Agreement shall be deemed to also reference such Affiliate. In particular and without limitation, all Affiliates of a Party that receive Confidential Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in<a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i35760df1a6f24f949f724e3753244cc0_1" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI </a>(Protection of Confidential Information)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Party and its Affiliates shall be jointly and severally liable for their performance under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Remainder of Page Left Intentionally Blank&#59; Signature Page Follows&#93;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><div id="i35760df1a6f24f949f724e3753244cc0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:65pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In Witness Whereof, the Parties have by duly authorized persons executed this Agreement effective as of the A&#38;R Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PARAGON THERAPEUTICS, INC. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIRIDIAN THERAPEUTICS, INC. </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Evan Thompson</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Steve Mahoney </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Evan Thompson </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Steve Mahoney </font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; COO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; CEO</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; 9&#47;20&#47;2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:20pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; 9&#47;20&#47;2024</font></td></tr></table></div><div style="margin-bottom:65pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:488.95pt"><font><br></font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div><div id="i35760df1a6f24f949f724e3753244cc0_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:129pt;padding-right:129pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="padding-left:99.5pt;padding-right:99.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93; LICENSE AGREEMENT</font></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><font><br></font></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">148540263_3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex311_2024-09.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i77e97c63748541acab9f179dfeb80156_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Stephen Mahoney, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160; I have reviewed this Quarterly Report on Form 10-Q, or this report, of Viridian Therapeutics, Inc., a Delaware corporation&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160; The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.&#160;&#160;&#160; The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:27.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Stephen Mahoney</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen Mahoney</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex312_2024-09.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie4bda94dcbab488ea88eba8e837f676b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Harmon, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160; I have reviewed this Quarterly Report on Form 10-Q, or this report, of Viridian Therapeutics, Inc., a Delaware corporation&#59;</font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160; The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.&#160;&#160;&#160; The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Seth Harmon</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Seth Harmon</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President of Finance and Accounting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer&#59; Principal Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex321_2024-09.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id6e4f7b09e6c4a029de7feb2d0dc4ab6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned, Stephen Mahoney, Chief Executive Officer of Viridian Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Seth Harmon, Senior Vice President of Finance and Accounting of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended September&#160;30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Stephen Mahoney</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen Mahoney</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Seth Harmon</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Seth Harmon</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President of Finance and Accounting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer&#59; Principal Accounting Officer)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2024</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies and is being &#8220;furnished&#8221; with this Report, shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vrdn-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:bdb425b1-8ce6-48d2-af7c-3659fd6d6265,g:f76e6810-2604-4ff8-8a2b-997429168b4a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrdn="http://www.viridiantherapeutics.com/20240930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.viridiantherapeutics.com/20240930">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrdn-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.viridiantherapeutics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>9952158 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952159 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTS" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS">
        <link:definition>9952160 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDLIABILITIESANDOTHER" roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHER">
        <link:definition>9952161 - Disclosure - ACCRUED LIABILITIES AND OTHER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.viridiantherapeutics.com/role/DEBT">
        <link:definition>9952162 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONAGREEMENTS" roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS">
        <link:definition>9952163 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCK" roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCK">
        <link:definition>9952165 - Disclosure - CAPITAL STOCK</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTS" roleURI="http://www.viridiantherapeutics.com/role/WARRANTS">
        <link:definition>9952166 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>9952167 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE">
        <link:definition>9952168 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSTables" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables">
        <link:definition>9954472 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDLIABILITIESANDOTHERTables" roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERTables">
        <link:definition>9954473 - Disclosure - ACCRUED LIABILITIES AND OTHER (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.viridiantherapeutics.com/role/DEBTTables">
        <link:definition>9954474 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>9954475 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTSTables" roleURI="http://www.viridiantherapeutics.com/role/WARRANTSTables">
        <link:definition>9954476 - Disclosure - WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>9954477 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables">
        <link:definition>9954478 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>9954479 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails">
        <link:definition>9954481 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Debt Securities, Available-for-sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>9954482 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9954483 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails" roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails">
        <link:definition>9954484 - Disclosure - ACCRUED LIABILITIES AND OTHER - Components of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails">
        <link:definition>9954485 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofLongTermDebtInstrumentsDetails" roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails">
        <link:definition>9954486 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofFuturePrincipalPaymentsDetails" roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails">
        <link:definition>9954487 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONAGREEMENTSDetails" roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails">
        <link:definition>9954488 - Disclosure - COLLABORATION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>9954489 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails">
        <link:definition>9954490 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1">
        <link:definition>9954490 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKDetails" roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails">
        <link:definition>9954491 - Disclosure - CAPITAL STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTSStockWarrantsOutstandingDetails" roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails">
        <link:definition>9954492 - Disclosure - WARRANTS - Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WARRANTSStockWarrantActivityDetails" roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails">
        <link:definition>9954493 - Disclosure - WARRANTS - Stock Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9954494 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONBalancebyPlanDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails">
        <link:definition>9954495 - Disclosure - SHARE-BASED COMPENSATION - Balance by Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails">
        <link:definition>9954496 - Disclosure - SHARE-BASED COMPENSATION - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionActivityDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails">
        <link:definition>9954497 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails">
        <link:definition>9954498 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails">
        <link:definition>9954499 - Disclosure - SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails" roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails">
        <link:definition>9954500 - Disclosure - NET LOSS PER SHARE - Schedule of Potential Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vrdn_A2024PublicOfferingMember" abstract="true" name="A2024PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_September2022AtTheMarketOfferingMember" abstract="true" name="September2022AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtExtinguishmentExpense" abstract="false" name="DebtExtinguishmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_GoingConcernPolicyPolicyTextBlock" abstract="false" name="GoingConcernPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" abstract="false" name="ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vrdn_WarrantsPolicyPolicyTextBlock" abstract="false" name="WarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" abstract="false" name="AccruedOutsourcingClinicalandPreclinicalStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_AccruedLegalFeesCurrent" abstract="false" name="AccruedLegalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" abstract="false" name="AccruedLiabilityofWarrantsonTemporaryEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_HerculesTermLoanMember" abstract="true" name="HerculesTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_DebtCovenantPeriodAxis" abstract="true" name="DebtCovenantPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_DebtCovenantPeriodDomain" abstract="true" name="DebtCovenantPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_DebtCovenantPeriodOneMember" abstract="true" name="DebtCovenantPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_DebtCovenantPeriodTwoMember" abstract="true" name="DebtCovenantPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountFirstTranche" abstract="false" name="DebtInstrumentFaceAmountFirstTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentFacilityFee" abstract="false" name="DebtInstrumentFacilityFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentOtherExpenses" abstract="false" name="DebtInstrumentOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentPrincipalAmountTermFee" abstract="false" name="DebtInstrumentPrincipalAmountTermFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountSecondTranche" abstract="false" name="DebtInstrumentFaceAmountSecondTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountThirdTranche" abstract="false" name="DebtInstrumentFaceAmountThirdTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentFaceAmountFourthTranche" abstract="false" name="DebtInstrumentFaceAmountFourthTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_DebtInstrumentInterestRateMaximum" abstract="false" name="DebtInstrumentInterestRateMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vrdn_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_ZenasBioPharmaMember" abstract="true" name="ZenasBioPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_ParagonTherapeuticsMember" abstract="true" name="ParagonTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_FairmountFundsManagementMember" abstract="true" name="FairmountFundsManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_CollaborationArrangementInitialPayment" abstract="false" name="CollaborationArrangementInitialPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementUpfrontFeePayment" abstract="false" name="CollaborativeArrangementUpfrontFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementRightsAndLicensesFee" abstract="false" name="CollaborativeArrangementRightsAndLicensesFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementMilestonePayment" abstract="false" name="CollaborativeArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments" abstract="false" name="CollaborationArrangementFutureDevelopmentsMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborationArrangementMaximumMilestonePayments" abstract="false" name="CollaborationArrangementMaximumMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" abstract="false" name="CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" abstract="false" name="CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_ImmunoGenIncMember" abstract="true" name="ImmunoGenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_EnableInjectionsMember" abstract="true" name="EnableInjectionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_ThirdPartyCollaboratorMember" abstract="true" name="ThirdPartyCollaboratorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_ColoradoLeaseMember" abstract="true" name="ColoradoLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_MassachusettsLeaseMember" abstract="true" name="MassachusettsLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" abstract="false" name="CollaborationArrangementPotentialMilestonePaymentMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" abstract="false" name="CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" abstract="false" name="CollaborativeArrangementSharesIssuedForRightsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" abstract="false" name="CollaborativeArrangementValueOfSharesIssuedForRightsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" abstract="false" name="CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" abstract="false" name="CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrdn_OperatingLeaseAnnualBaseRent" abstract="false" name="OperatingLeaseAnnualBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_OperatingLeaseRightOfUseAssetDerecognized" abstract="false" name="OperatingLeaseRightOfUseAssetDerecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_OperatingLeaseLiabilityCurrentDerecognized" abstract="false" name="OperatingLeaseLiabilityCurrentDerecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_OperatingLeasesOperatingExpense" abstract="false" name="OperatingLeasesOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrdn_AtthemarketOfferingMember" abstract="true" name="AtthemarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_SeriesAPreferredStockConversionMember" abstract="true" name="SeriesAPreferredStockConversionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_SeriesBPreferredStockConversionMember" abstract="true" name="SeriesBPreferredStockConversionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_ViridianMergerMember" abstract="true" name="ViridianMergerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_CapitalStockSharesAuthorized" abstract="false" name="CapitalStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_CommonStockVotePerShare" abstract="false" name="CommonStockVotePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" abstract="false" name="SaleofStockCommissionFeePercentageofGrossSaleProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vrdn_SaleOfStockWeightedAverageSharePrice" abstract="false" name="SaleOfStockWeightedAverageSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" abstract="false" name="ClassOfWarrantOrRightConversionPercentageOfOwnership" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" abstract="true" name="LiabilityClassifiedWarrantsIssuedApril2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_EquityclassifiedWarrantsMember" abstract="true" name="EquityclassifiedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" abstract="true" name="EquityClassifiedWarrantsAcquiredOctober2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" abstract="true" name="EquityclassifiedWarrantsIssuedFebruary2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" abstract="true" name="EquityclassifiedWarrantsIssuedNovember2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_ClassofWarrantorRightRemainingTerm" abstract="false" name="ClassofWarrantorRightRemainingTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrdn_ClassofWarrantorRightActivityRollForward" abstract="true" name="ClassofWarrantorRightActivityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_ClassOfWarrantOrRightExercisedInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" abstract="true" name="ClassofWarrantorRightWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="vrdn_Amended2016PlanMember" abstract="true" name="Amended2016PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_FormerExecutiveOfficersMember" abstract="true" name="FormerExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrdn_InducementGrantsMember" abstract="true" name="InducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_A2020PlanMember" abstract="true" name="A2020PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_A2008PlanMember" abstract="true" name="A2008PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vrdn_CommonStockWarrantsMember" abstract="true" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vrdn-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:bdb425b1-8ce6-48d2-af7c-3659fd6d6265,g:f76e6810-2604-4ff8-8a2b-997429168b4a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_76dda8fe-40f3-40f5-a83c-f46ba4deab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f75d8ca2-2998-40c2-be3a-ab23cc1ee230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76dda8fe-40f3-40f5-a83c-f46ba4deab2f" xlink:to="loc_us-gaap_AssetsCurrent_f75d8ca2-2998-40c2-be3a-ab23cc1ee230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_01bb664f-ac68-4029-ac90-651a6810c460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76dda8fe-40f3-40f5-a83c-f46ba4deab2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_01bb664f-ac68-4029-ac90-651a6810c460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bbe06364-9fad-43cd-977d-f9305c22cd59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76dda8fe-40f3-40f5-a83c-f46ba4deab2f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bbe06364-9fad-43cd-977d-f9305c22cd59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8adb3b1b-5d50-4fd7-86dc-298cae7b2053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_76dda8fe-40f3-40f5-a83c-f46ba4deab2f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8adb3b1b-5d50-4fd7-86dc-298cae7b2053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ef99fbdd-5d21-4770-86c8-ee59593ec193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_aa8eff71-9f28-431b-a308-4a9d5793d8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef99fbdd-5d21-4770-86c8-ee59593ec193" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_aa8eff71-9f28-431b-a308-4a9d5793d8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d7812c1-a849-4d99-9689-5028b71c63dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef99fbdd-5d21-4770-86c8-ee59593ec193" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d7812c1-a849-4d99-9689-5028b71c63dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af2b8a8c-8e8b-42c6-8cc0-e006d3c8cbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef99fbdd-5d21-4770-86c8-ee59593ec193" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af2b8a8c-8e8b-42c6-8cc0-e006d3c8cbd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ac6a2307-0ff0-4daa-8f71-d4d4229909f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef99fbdd-5d21-4770-86c8-ee59593ec193" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ac6a2307-0ff0-4daa-8f71-d4d4229909f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_84a8da47-313f-47e9-a57b-36dcd6e2db56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_974101e5-2fbd-4c25-9b28-253c018a3df0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84a8da47-313f-47e9-a57b-36dcd6e2db56" xlink:to="loc_us-gaap_StockholdersEquity_974101e5-2fbd-4c25-9b28-253c018a3df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c5bcee4a-8a56-419b-b5fd-80360d340bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84a8da47-313f-47e9-a57b-36dcd6e2db56" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c5bcee4a-8a56-419b-b5fd-80360d340bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_640a4ae3-9aba-4ee4-b802-a9f8f31b6755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84a8da47-313f-47e9-a57b-36dcd6e2db56" xlink:to="loc_us-gaap_Liabilities_640a4ae3-9aba-4ee4-b802-a9f8f31b6755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1ca08056-9a75-466f-8867-9509854554d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dd5c57d1-165b-428a-a9e8-93d9557d6d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1ca08056-9a75-466f-8867-9509854554d9" xlink:to="loc_us-gaap_CommonStockValue_dd5c57d1-165b-428a-a9e8-93d9557d6d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d275b985-0302-4826-ac6b-16ef53062301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1ca08056-9a75-466f-8867-9509854554d9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d275b985-0302-4826-ac6b-16ef53062301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2bfa8fd3-632f-47db-950c-6e773497e054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1ca08056-9a75-466f-8867-9509854554d9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2bfa8fd3-632f-47db-950c-6e773497e054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_51357d34-a3a8-4f05-848d-595815b15a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1ca08056-9a75-466f-8867-9509854554d9" xlink:to="loc_us-gaap_PreferredStockValue_51357d34-a3a8-4f05-848d-595815b15a7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_83371399-fa2f-498b-96a5-a5556b267e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1ca08056-9a75-466f-8867-9509854554d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_83371399-fa2f-498b-96a5-a5556b267e75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef1da19e-917d-4ff6-8e9f-eebe0d2d5089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_13f8309f-91a8-4eee-a5bb-5c9a1b2dabb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ef1da19e-917d-4ff6-8e9f-eebe0d2d5089" xlink:to="loc_us-gaap_AccountsPayableCurrent_13f8309f-91a8-4eee-a5bb-5c9a1b2dabb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6f91d581-619e-4218-a6b7-4b74afe5bf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ef1da19e-917d-4ff6-8e9f-eebe0d2d5089" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6f91d581-619e-4218-a6b7-4b74afe5bf6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_771673ae-0309-4877-901c-d7e540be2b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ef1da19e-917d-4ff6-8e9f-eebe0d2d5089" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_771673ae-0309-4877-901c-d7e540be2b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_494e5b20-b191-4646-8aff-754cdaa98045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6116fe7b-c219-4f6a-b287-2d69ebb73659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_494e5b20-b191-4646-8aff-754cdaa98045" xlink:to="loc_us-gaap_LiabilitiesCurrent_6116fe7b-c219-4f6a-b287-2d69ebb73659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7b1ff59d-6e4c-4cf5-9f1b-7c8fa26c5a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_494e5b20-b191-4646-8aff-754cdaa98045" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7b1ff59d-6e4c-4cf5-9f1b-7c8fa26c5a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3fc20f9b-f942-4517-b5d1-37e6ca85bebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_494e5b20-b191-4646-8aff-754cdaa98045" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3fc20f9b-f942-4517-b5d1-37e6ca85bebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c7cb2af0-693c-4970-b450-54879a04fd96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_494e5b20-b191-4646-8aff-754cdaa98045" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c7cb2af0-693c-4970-b450-54879a04fd96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7cec77b-a079-4791-88d3-53887fe10e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1d353c57-dca2-44ab-9c99-f0dcd82d0c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7cec77b-a079-4791-88d3-53887fe10e5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1d353c57-dca2-44ab-9c99-f0dcd82d0c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d683ba6c-0fdd-473c-b0b6-3c1e09dcc9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7cec77b-a079-4791-88d3-53887fe10e5c" xlink:to="loc_us-gaap_NetIncomeLoss_d683ba6c-0fdd-473c-b0b6-3c1e09dcc9fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_675b3274-f44c-4f2a-81dc-00ffa30e167c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_9366757f-ee59-4bc2-885e-6555b20ebe11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_675b3274-f44c-4f2a-81dc-00ffa30e167c" xlink:to="loc_us-gaap_InterestExpenseNonoperating_9366757f-ee59-4bc2-885e-6555b20ebe11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_7621f91d-2dd0-414f-832a-fb589a8df299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_675b3274-f44c-4f2a-81dc-00ffa30e167c" xlink:to="loc_us-gaap_InterestAndOtherIncome_7621f91d-2dd0-414f-832a-fb589a8df299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5dcda1ed-4a6d-435b-93c1-66b30a33dd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f84bbca5-11f9-48cc-b7dd-f567b3e5fc64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5dcda1ed-4a6d-435b-93c1-66b30a33dd3a" xlink:to="loc_us-gaap_OperatingIncomeLoss_f84bbca5-11f9-48cc-b7dd-f567b3e5fc64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d24b5d15-b6e3-49ef-8e98-c26ce85b8a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5dcda1ed-4a6d-435b-93c1-66b30a33dd3a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d24b5d15-b6e3-49ef-8e98-c26ce85b8a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c63fc0c5-17e9-43a3-a46c-e8818f025046" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d3a91e34-5423-438f-aa45-04eb952b95dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c63fc0c5-17e9-43a3-a46c-e8818f025046" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d3a91e34-5423-438f-aa45-04eb952b95dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b288f632-ec2c-4105-82eb-d15d836d68c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c63fc0c5-17e9-43a3-a46c-e8818f025046" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b288f632-ec2c-4105-82eb-d15d836d68c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0573f9a4-fd46-4f11-8530-105a14b317fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_694ed3b4-ad5e-4bf7-982a-85e19252346c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0573f9a4-fd46-4f11-8530-105a14b317fe" xlink:to="loc_us-gaap_OperatingExpenses_694ed3b4-ad5e-4bf7-982a-85e19252346c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6946002c-faca-47bc-bfa4-9aab258d76a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0573f9a4-fd46-4f11-8530-105a14b317fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6946002c-faca-47bc-bfa4-9aab258d76a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b3dbef2-e8ba-4da8-856b-25498ce66b87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_24fbf63e-3a73-4f3a-bcd2-ca266544020a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b3dbef2-e8ba-4da8-856b-25498ce66b87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_24fbf63e-3a73-4f3a-bcd2-ca266544020a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4cb3779f-6149-4121-8c56-48f404815b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b62344ad-c613-4589-868d-c559eb277c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4cb3779f-6149-4121-8c56-48f404815b0b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b62344ad-c613-4589-868d-c559eb277c0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eada3fa9-0a19-4a66-a7ac-dbb71cdc0c27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4cb3779f-6149-4121-8c56-48f404815b0b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eada3fa9-0a19-4a66-a7ac-dbb71cdc0c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8d9148f5-0862-4b80-ac2a-d402bd41dd19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4cb3779f-6149-4121-8c56-48f404815b0b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8d9148f5-0862-4b80-ac2a-d402bd41dd19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92ece733-a680-4db7-ba3a-70fc86b908b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_92ece733-a680-4db7-ba3a-70fc86b908b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_113a771a-6e78-4758-9145-9c17ffa3ba14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_113a771a-6e78-4758-9145-9c17ffa3ba14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_daccccf3-5fc9-4372-9cfd-4278cc257453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_daccccf3-5fc9-4372-9cfd-4278cc257453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_fec5ec2e-8016-44a1-bba4-93401527e4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_ProceedsFromStockPlans_fec5ec2e-8016-44a1-bba4-93401527e4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_56aef754-72f8-4b82-9bdd-18849ff12183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_56aef754-72f8-4b82-9bdd-18849ff12183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7d98594f-876d-4b48-8888-c58be9067e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7d98594f-876d-4b48-8888-c58be9067e44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_c69273f2-9c8a-4385-b3e5-4da31d03d7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_c69273f2-9c8a-4385-b3e5-4da31d03d7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_54fd945c-33a8-426f-a133-5fa2f5c524bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ff1c92f-39b2-4dfe-8441-ef2fb7139791" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_54fd945c-33a8-426f-a133-5fa2f5c524bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fb12bb57-1f74-4fd6-9d88-4759b863c2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fb12bb57-1f74-4fd6-9d88-4759b863c2bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8a4331bc-7c8e-4218-89ca-de803d612ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8a4331bc-7c8e-4218-89ca-de803d612ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6c23fd57-24f4-430e-93a8-4b9be5875e45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_NetIncomeLoss_6c23fd57-24f4-430e-93a8-4b9be5875e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense_1c915dde-c2bf-4bd0-af40-6316bac1ea5c" xlink:href="vrdn-20240930.xsd#vrdn_NonCashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_vrdn_NonCashLeaseExpense_1c915dde-c2bf-4bd0-af40-6316bac1ea5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_38acb46f-cdd1-4332-85b5-8b22d5a4b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_38acb46f-cdd1-4332-85b5-8b22d5a4b2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ed359ea-98d2-4558-870a-4061f819e15f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ed359ea-98d2-4558-870a-4061f819e15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ce946af2-241e-423a-bcc6-dae20c57bf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ce946af2-241e-423a-bcc6-dae20c57bf18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a53e219b-df81-4e18-89de-27b980401aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a53e219b-df81-4e18-89de-27b980401aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_df1dc066-fb95-4aca-bcb7-9332306183bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_df1dc066-fb95-4aca-bcb7-9332306183bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0351819b-6836-4f8a-8e4c-c95641b8c626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_ShareBasedCompensation_0351819b-6836-4f8a-8e4c-c95641b8c626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_b24c8057-fca6-4b00-87a2-79749a04a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_b24c8057-fca6-4b00-87a2-79749a04a8d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a60a01a3-25f1-410e-87ff-efca65e20762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a60a01a3-25f1-410e-87ff-efca65e20762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_be30d2b5-5267-4754-837d-c261651a1ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_be30d2b5-5267-4754-837d-c261651a1ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b72c408-af00-47d0-8bcd-7128d98b43d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7b72c408-af00-47d0-8bcd-7128d98b43d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtExtinguishmentExpense_d8312d7b-60ae-4104-b303-b56a705559ed" xlink:href="vrdn-20240930.xsd#vrdn_DebtExtinguishmentExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_vrdn_DebtExtinguishmentExpense_d8312d7b-60ae-4104-b303-b56a705559ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d34b0dcb-90d8-4368-9a97-49ad5560f841" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b23da90-18e8-4c6d-ab88-d5b1e8e9f18d" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d34b0dcb-90d8-4368-9a97-49ad5560f841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92da60c2-c79f-40af-bd21-83e83feda72f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc3163ec-4537-4c8e-8413-fedef7dc5219" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92da60c2-c79f-40af-bd21-83e83feda72f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc3163ec-4537-4c8e-8413-fedef7dc5219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7953a053-447b-4955-8ade-0663e6226125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92da60c2-c79f-40af-bd21-83e83feda72f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7953a053-447b-4955-8ade-0663e6226125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56cd5bc9-80bf-4458-8a10-ef8fa5a96313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92da60c2-c79f-40af-bd21-83e83feda72f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_56cd5bc9-80bf-4458-8a10-ef8fa5a96313" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27ad8531-e9c2-4475-a4f4-3d4e2e0263a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d99202ea-6050-42a1-b272-3306013b228a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27ad8531-e9c2-4475-a4f4-3d4e2e0263a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d99202ea-6050-42a1-b272-3306013b228a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_000de8aa-ebab-43c2-8688-1e65046cd524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27ad8531-e9c2-4475-a4f4-3d4e2e0263a1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_000de8aa-ebab-43c2-8688-1e65046cd524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d0c7d268-5171-4d56-846d-f6b616ba344c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27ad8531-e9c2-4475-a4f4-3d4e2e0263a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d0c7d268-5171-4d56-846d-f6b616ba344c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8facdce1-7b24-4b2a-94e3-8301ee594d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_27764d9b-1b80-4617-a331-09f6646f857d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8facdce1-7b24-4b2a-94e3-8301ee594d63" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_27764d9b-1b80-4617-a331-09f6646f857d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f7dc9a68-813d-4c06-b01c-e42040306d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8facdce1-7b24-4b2a-94e3-8301ee594d63" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f7dc9a68-813d-4c06-b01c-e42040306d42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_77b608b1-b05b-42eb-be4e-03369190fe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_77b608b1-b05b-42eb-be4e-03369190fe9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b460a30b-4f42-4bff-a26c-fbd3cb5eff0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b460a30b-4f42-4bff-a26c-fbd3cb5eff0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_552eaa4a-e81a-483b-aedb-869f4aaf0cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_us-gaap_InterestPayableCurrent_552eaa4a-e81a-483b-aedb-869f4aaf0cfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_6d3e5743-97f0-43a2-bb53-a67563998b8a" xlink:href="vrdn-20240930.xsd#vrdn_AccruedLiabilityofWarrantsonTemporaryEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_6d3e5743-97f0-43a2-bb53-a67563998b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLegalFeesCurrent_fdc65379-27ee-4eca-9f87-565ee32b739f" xlink:href="vrdn-20240930.xsd#vrdn_AccruedLegalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_vrdn_AccruedLegalFeesCurrent_fdc65379-27ee-4eca-9f87-565ee32b739f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_99e28f11-9c25-42a3-8a0a-e49bb95d023b" xlink:href="vrdn-20240930.xsd#vrdn_AccruedOutsourcingClinicalandPreclinicalStudies"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_99e28f11-9c25-42a3-8a0a-e49bb95d023b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e42f1162-a323-406f-8213-2e4c7e825c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e42f1162-a323-406f-8213-2e4c7e825c8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d08075dd-2bd8-4594-a503-42e858c7bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f9b9215-4f31-4f45-9a32-4d1b236e3ec4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d08075dd-2bd8-4594-a503-42e858c7bdc8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d0b84e6e-0090-436d-9dc1-c45658bb89c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b20dd764-5221-4ab2-9e4a-3bcef7960b34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d0b84e6e-0090-436d-9dc1-c45658bb89c4" xlink:to="loc_us-gaap_LongTermDebtCurrent_b20dd764-5221-4ab2-9e4a-3bcef7960b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4d529946-9ef6-4673-a792-89b6d96d7240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d0b84e6e-0090-436d-9dc1-c45658bb89c4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4d529946-9ef6-4673-a792-89b6d96d7240" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ec2e5ab1-b53a-4d17-b111-d8c7808da423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b4da9576-5bd6-454d-b940-2005d942acd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ec2e5ab1-b53a-4d17-b111-d8c7808da423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b4da9576-5bd6-454d-b940-2005d942acd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98178136-14ab-4dc2-8a95-f49c8f173dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ec2e5ab1-b53a-4d17-b111-d8c7808da423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_98178136-14ab-4dc2-8a95-f49c8f173dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_af2f589e-b8fe-4989-b660-36f456af4188" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ec2e5ab1-b53a-4d17-b111-d8c7808da423" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_af2f589e-b8fe-4989-b660-36f456af4188" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85baa52c-36bc-4e08-ae73-8e9b44e35f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_de54b158-649d-4169-84cc-dad0d89972f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85baa52c-36bc-4e08-ae73-8e9b44e35f32" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_de54b158-649d-4169-84cc-dad0d89972f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9f4de458-48b4-48b8-a00b-4b2803d8c411" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85baa52c-36bc-4e08-ae73-8e9b44e35f32" xlink:to="loc_us-gaap_OperatingLeaseLiability_9f4de458-48b4-48b8-a00b-4b2803d8c411" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f7b11c4-0449-478a-9fbd-31c9bb57f281" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4031446b-0c5d-4007-a822-d8904d0cb24f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f7b11c4-0449-478a-9fbd-31c9bb57f281" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4031446b-0c5d-4007-a822-d8904d0cb24f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e3ac8f67-d54a-43a6-b63c-b4de64819f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f7b11c4-0449-478a-9fbd-31c9bb57f281" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e3ac8f67-d54a-43a6-b63c-b4de64819f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fd89fc93-b078-4d3c-9800-42f4101dc161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f7b11c4-0449-478a-9fbd-31c9bb57f281" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fd89fc93-b078-4d3c-9800-42f4101dc161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0da689cd-2498-434e-91a9-650165573012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f7b11c4-0449-478a-9fbd-31c9bb57f281" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0da689cd-2498-434e-91a9-650165573012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_759ba404-b01e-42d6-9aa5-f56bffa82398" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f7b11c4-0449-478a-9fbd-31c9bb57f281" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_759ba404-b01e-42d6-9aa5-f56bffa82398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e2369822-5e5f-4219-baae-1782627d2a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f7b11c4-0449-478a-9fbd-31c9bb57f281" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e2369822-5e5f-4219-baae-1782627d2a98" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vrdn-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:bdb425b1-8ce6-48d2-af7c-3659fd6d6265,g:f76e6810-2604-4ff8-8a2b-997429168b4a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ed7fa6c-7c89-4094-b3b6-a01e0e6f9bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:to="loc_us-gaap_StatementTable_3ed7fa6c-7c89-4094-b3b6-a01e0e6f9bde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb1ca902-caf5-4e40-959e-99c57fc43185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3ed7fa6c-7c89-4094-b3b6-a01e0e6f9bde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb1ca902-caf5-4e40-959e-99c57fc43185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bb1ca902-caf5-4e40-959e-99c57fc43185_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb1ca902-caf5-4e40-959e-99c57fc43185" xlink:to="loc_us-gaap_ClassOfStockDomain_bb1ca902-caf5-4e40-959e-99c57fc43185_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb1ca902-caf5-4e40-959e-99c57fc43185" xlink:to="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4888ec97-0437-4a99-9c25-778668e15a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4888ec97-0437-4a99-9c25-778668e15a48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_bb11b5b1-c0c0-4ad5-8e94-56720bdf1dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_bb11b5b1-c0c0-4ad5-8e94-56720bdf1dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:to="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ac724e1-4c08-416e-ace4-7ec0f619a031" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ac724e1-4c08-416e-ace4-7ec0f619a031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e074270c-24f7-47a6-9b73-81b427f9b2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e074270c-24f7-47a6-9b73-81b427f9b2d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_128ac07b-94c4-4167-a285-24bd924b3cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_128ac07b-94c4-4167-a285-24bd924b3cb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_71c3ccac-aa70-494a-be4b-1cf2f5b11c00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_71c3ccac-aa70-494a-be4b-1cf2f5b11c00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c4bc61ea-801f-40cd-939f-9d78a2b06350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_AssetsCurrent_c4bc61ea-801f-40cd-939f-9d78a2b06350" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_121f7eee-d732-4b91-806f-d44b2732cdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_121f7eee-d732-4b91-806f-d44b2732cdc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aac95184-0a8d-4300-8348-695a2746a1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aac95184-0a8d-4300-8348-695a2746a1a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0e14f823-cd8e-4fb0-b5fe-27e8ca71045f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0e14f823-cd8e-4fb0-b5fe-27e8ca71045f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1cca5f95-300e-4704-966f-b486bdc6aedb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_Assets_1cca5f95-300e-4704-966f-b486bdc6aedb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a25b778e-620e-4280-8d43-c802056cf5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_AccountsPayableCurrent_a25b778e-620e-4280-8d43-c802056cf5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_05c10458-6f2b-4e15-a36d-79a746360639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_05c10458-6f2b-4e15-a36d-79a746360639" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f2c5eb7-71ac-4453-8a58-ef79d3c4a4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f2c5eb7-71ac-4453-8a58-ef79d3c4a4e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_67a09e12-8b12-45d9-b362-e3f716423099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_LiabilitiesCurrent_67a09e12-8b12-45d9-b362-e3f716423099" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_accab3af-4448-4f8d-932c-d0fb5c0c6983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_accab3af-4448-4f8d-932c-d0fb5c0c6983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c171bba-b706-4f5f-a4d0-c99a34089eff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c171bba-b706-4f5f-a4d0-c99a34089eff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5fae0c3e-eec5-4233-9352-3c08fa570186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5fae0c3e-eec5-4233-9352-3c08fa570186" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d324510f-6829-4da7-ab5d-6eb4d47d75d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_Liabilities_d324510f-6829-4da7-ab5d-6eb4d47d75d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e88881fc-745a-4a0f-bc35-bdf222052bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e88881fc-745a-4a0f-bc35-bdf222052bd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e9cb0d0d-c506-43d6-b50f-e7af354c9e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_PreferredStockValue_e9cb0d0d-c506-43d6-b50f-e7af354c9e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_627d64cf-94bd-4b15-a51c-0da2ca008f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_CommonStockValue_627d64cf-94bd-4b15-a51c-0da2ca008f5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c89ade83-dd1f-428d-96f2-a988a5db9e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c89ade83-dd1f-428d-96f2-a988a5db9e87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_feb69328-2785-4488-8f15-9abb0a184c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_feb69328-2785-4488-8f15-9abb0a184c42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b404b6e6-f1ac-41c1-b286-fb7ff94e9eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b404b6e6-f1ac-41c1-b286-fb7ff94e9eec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7fb0e2f9-f3f1-4343-bb04-714bab9a3eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_StockholdersEquity_7fb0e2f9-f3f1-4343-bb04-714bab9a3eae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32b2944d-78e7-451c-92c4-54810c43b5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32b2944d-78e7-451c-92c4-54810c43b5ff" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_70968a79-1112-4396-8e3e-9646c5f40480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_70968a79-1112-4396-8e3e-9646c5f40480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_70968a79-1112-4396-8e3e-9646c5f40480_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_70968a79-1112-4396-8e3e-9646c5f40480" xlink:to="loc_us-gaap_RelatedPartyDomain_70968a79-1112-4396-8e3e-9646c5f40480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05614e89-dba9-4adf-8cb7-05cd15dfeb41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_70968a79-1112-4396-8e3e-9646c5f40480" xlink:to="loc_us-gaap_RelatedPartyDomain_05614e89-dba9-4adf-8cb7-05cd15dfeb41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f3a6fd97-cf74-4b2b-9370-cc2110bdc09b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_05614e89-dba9-4adf-8cb7-05cd15dfeb41" xlink:to="loc_us-gaap_RelatedPartyMember_f3a6fd97-cf74-4b2b-9370-cc2110bdc09b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7b752b2a-18f3-441d-9e68-6c90ce6ade6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7b752b2a-18f3-441d-9e68-6c90ce6ade6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7b752b2a-18f3-441d-9e68-6c90ce6ade6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b752b2a-18f3-441d-9e68-6c90ce6ade6d" xlink:to="loc_us-gaap_ClassOfStockDomain_7b752b2a-18f3-441d-9e68-6c90ce6ade6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b752b2a-18f3-441d-9e68-6c90ce6ade6d" xlink:to="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_550c575f-3292-4277-8721-2493d6076315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_550c575f-3292-4277-8721-2493d6076315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_ab41ce9c-baa9-4187-96df-0f035eddaa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_ab41ce9c-baa9-4187-96df-0f035eddaa0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f22fe200-75da-4bef-b2c6-3ec8c65de4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f22fe200-75da-4bef-b2c6-3ec8c65de4ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b79ff889-2ddb-40f0-9148-356c05e86b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b79ff889-2ddb-40f0-9148-356c05e86b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fd57a1e5-fee5-4b79-93b9-0de1f54baf53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fd57a1e5-fee5-4b79-93b9-0de1f54baf53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f33e810a-2654-44bd-8a23-ae8cec6c60d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f33e810a-2654-44bd-8a23-ae8cec6c60d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_abb40b98-fa67-43ec-82c0-b50f06f40bce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_abb40b98-fa67-43ec-82c0-b50f06f40bce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fae49c52-fd67-41a4-bca5-bf62422a918e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fae49c52-fd67-41a4-bca5-bf62422a918e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_51ca1480-4f87-4782-be6f-35fc3d4d332b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_51ca1480-4f87-4782-be6f-35fc3d4d332b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_777c401d-38f3-4453-b3bd-a5a43a1a167d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockSharesIssued_777c401d-38f3-4453-b3bd-a5a43a1a167d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c532bcdf-a54c-44c5-aba1-6c8e684f1a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c532bcdf-a54c-44c5-aba1-6c8e684f1a6b" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06d13535-885b-4484-9d01-c66bbed957c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6d92edb8-1a42-49a9-b9af-e157b55f8a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_06d13535-885b-4484-9d01-c66bbed957c9" xlink:to="loc_us-gaap_StatementTable_6d92edb8-1a42-49a9-b9af-e157b55f8a83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ba85b62-8005-41b1-ae0f-d929db20fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6d92edb8-1a42-49a9-b9af-e157b55f8a83" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ba85b62-8005-41b1-ae0f-d929db20fec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6ba85b62-8005-41b1-ae0f-d929db20fec0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ba85b62-8005-41b1-ae0f-d929db20fec0" xlink:to="loc_us-gaap_RelatedPartyDomain_6ba85b62-8005-41b1-ae0f-d929db20fec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_45fa3325-ad6a-46c6-b040-725c4f77882f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ba85b62-8005-41b1-ae0f-d929db20fec0" xlink:to="loc_us-gaap_RelatedPartyDomain_45fa3325-ad6a-46c6-b040-725c4f77882f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_ac7740dd-151b-415b-867c-c9460cdd3854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_45fa3325-ad6a-46c6-b040-725c4f77882f" xlink:to="loc_us-gaap_RelatedPartyMember_ac7740dd-151b-415b-867c-c9460cdd3854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6057915c-aa98-4d21-9d93-f249937903dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06d13535-885b-4484-9d01-c66bbed957c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6057915c-aa98-4d21-9d93-f249937903dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_531d6f15-579b-4c94-8836-37a5fa25f3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_531d6f15-579b-4c94-8836-37a5fa25f3b0" xlink:to="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c38dca7f-df5a-4851-be32-7874e59cfb72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c38dca7f-df5a-4851-be32-7874e59cfb72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c38dca7f-df5a-4851-be32-7874e59cfb72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c38dca7f-df5a-4851-be32-7874e59cfb72" xlink:to="loc_us-gaap_EquityComponentDomain_c38dca7f-df5a-4851-be32-7874e59cfb72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c38dca7f-df5a-4851-be32-7874e59cfb72" xlink:to="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_5f1c2f9c-f328-4b44-a895-ee17d2a0fc85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_PreferredStockMember_5f1c2f9c-f328-4b44-a895-ee17d2a0fc85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7b869700-223d-4259-b09c-7370b1589f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_CommonStockMember_7b869700-223d-4259-b09c-7370b1589f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fd027ef0-78be-4457-925b-6dcd8085095d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fd027ef0-78be-4457-925b-6dcd8085095d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ecd8b0f-6e80-44b0-aeb1-60f00203d717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ecd8b0f-6e80-44b0-aeb1-60f00203d717" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a043f7e4-d85c-45c1-8931-a2f7dab6c77b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_RetainedEarningsMember_a043f7e4-d85c-45c1-8931-a2f7dab6c77b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_64dde36a-1e2e-40ea-8eb8-7236820d67d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:to="loc_us-gaap_StatementClassOfStockAxis_64dde36a-1e2e-40ea-8eb8-7236820d67d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_64dde36a-1e2e-40ea-8eb8-7236820d67d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64dde36a-1e2e-40ea-8eb8-7236820d67d7" xlink:to="loc_us-gaap_ClassOfStockDomain_64dde36a-1e2e-40ea-8eb8-7236820d67d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64dde36a-1e2e-40ea-8eb8-7236820d67d7" xlink:to="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8014ead8-5ce9-4bca-9ec3-88985e1784ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8014ead8-5ce9-4bca-9ec3-88985e1784ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_504ec9a5-d7f4-4b3e-b3c1-6984bd139449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_504ec9a5-d7f4-4b3e-b3c1-6984bd139449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ac59e296-8c15-4c42-9744-af11a4bc6086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ac59e296-8c15-4c42-9744-af11a4bc6086" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac59e296-8c15-4c42-9744-af11a4bc6086_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac59e296-8c15-4c42-9744-af11a4bc6086" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac59e296-8c15-4c42-9744-af11a4bc6086_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac59e296-8c15-4c42-9744-af11a4bc6086" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2024PublicOfferingMember_0d3a2a59-0bb5-4707-a5f7-279ebc593d7e" xlink:href="vrdn-20240930.xsd#vrdn_A2024PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:to="loc_vrdn_A2024PublicOfferingMember_0d3a2a59-0bb5-4707-a5f7-279ebc593d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_September2022AtTheMarketOfferingMember_4a785ae0-8028-4be9-84f0-82619e171e90" xlink:href="vrdn-20240930.xsd#vrdn_September2022AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:to="loc_vrdn_September2022AtTheMarketOfferingMember_4a785ae0-8028-4be9-84f0-82619e171e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_531d6f15-579b-4c94-8836-37a5fa25f3b0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f4a08495-b243-48ac-ab7a-77b846f4d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f4a08495-b243-48ac-ab7a-77b846f4d1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2449dabe-253d-4709-8c91-0993e5ce7d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockholdersEquity_2449dabe-253d-4709-8c91-0993e5ce7d9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dcf223d8-f995-4b7e-aad0-bc6008499f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dcf223d8-f995-4b7e-aad0-bc6008499f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f36bd197-1feb-4b44-bbf6-91a2df5c7d21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f36bd197-1feb-4b44-bbf6-91a2df5c7d21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5bd74f6d-5bb1-487d-8ac4-98a687ce35de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5bd74f6d-5bb1-487d-8ac4-98a687ce35de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_3881ff5f-076d-4fd0-b81e-2fb577029955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_3881ff5f-076d-4fd0-b81e-2fb577029955" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7d87bb7c-716b-479b-ad3e-7133c104231e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7d87bb7c-716b-479b-ad3e-7133c104231e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5704148-323f-403a-998b-3589cb68d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5704148-323f-403a-998b-3589cb68d7c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3824290e-e863-449f-a207-f16b9ae05a31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3824290e-e863-449f-a207-f16b9ae05a31" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_03cca528-c1fc-4f2e-b125-f8e83b950eaa" xlink:href="vrdn-20240930.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_03cca528-c1fc-4f2e-b125-f8e83b950eaa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_f7be0ebf-996d-4812-99f3-bef2eeea6e4f" xlink:href="vrdn-20240930.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_f7be0ebf-996d-4812-99f3-bef2eeea6e4f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2a988746-8765-4add-b705-9d047073b572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2a988746-8765-4add-b705-9d047073b572" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ba03a9c9-dd69-45ee-a1e5-abcb715d0413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ba03a9c9-dd69-45ee-a1e5-abcb715d0413" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_776b8bda-b8af-4fb2-9595-6c77f8468fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_776b8bda-b8af-4fb2-9595-6c77f8468fd3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_07f6c409-8c47-4c7a-b4a0-fe9261c92b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_07f6c409-8c47-4c7a-b4a0-fe9261c92b4b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_64ce79c7-af9b-4ed3-88c7-1acc10b604fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_64ce79c7-af9b-4ed3-88c7-1acc10b604fa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_329d136c-23cf-491e-8f13-af7650ff84b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_329d136c-23cf-491e-8f13-af7650ff84b9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dde45ef-d138-4768-90cd-ea61712588e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dde45ef-d138-4768-90cd-ea61712588e4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f304d8d8-d0e7-48d5-ac83-fc852fb45132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f304d8d8-d0e7-48d5-ac83-fc852fb45132" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44747f47-496e-4799-a462-e3de9b6123e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_NetIncomeLoss_44747f47-496e-4799-a462-e3de9b6123e3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4b5bf1e2-edf0-468a-901b-b2414547100f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_126628d3-cf3f-49a0-8cff-79d16aa31a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2dd8c653-8add-4ea6-97ce-9c29e47f8001" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6aa43615-d396-4277-9eb8-85af0df69d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6aa43615-d396-4277-9eb8-85af0df69d90" xlink:to="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bfe19b0a-c457-4c44-9039-ae5e9dcce563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bfe19b0a-c457-4c44-9039-ae5e9dcce563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bfe19b0a-c457-4c44-9039-ae5e9dcce563_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bfe19b0a-c457-4c44-9039-ae5e9dcce563" xlink:to="loc_us-gaap_EquityComponentDomain_bfe19b0a-c457-4c44-9039-ae5e9dcce563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1274d2d5-0214-4aba-a326-b040bf7021ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bfe19b0a-c457-4c44-9039-ae5e9dcce563" xlink:to="loc_us-gaap_EquityComponentDomain_1274d2d5-0214-4aba-a326-b040bf7021ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2ad78242-a21a-4a0f-a9d2-c3e956de4664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1274d2d5-0214-4aba-a326-b040bf7021ea" xlink:to="loc_us-gaap_CommonStockMember_2ad78242-a21a-4a0f-a9d2-c3e956de4664" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_13b946af-3a1c-45c5-9d46-b54908d6175b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_13b946af-3a1c-45c5-9d46-b54908d6175b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13b946af-3a1c-45c5-9d46-b54908d6175b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13b946af-3a1c-45c5-9d46-b54908d6175b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13b946af-3a1c-45c5-9d46-b54908d6175b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13b946af-3a1c-45c5-9d46-b54908d6175b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2024PublicOfferingMember_ecf66844-2b9f-4df9-9d29-dd11bf9cfafe" xlink:href="vrdn-20240930.xsd#vrdn_A2024PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:to="loc_vrdn_A2024PublicOfferingMember_ecf66844-2b9f-4df9-9d29-dd11bf9cfafe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_September2022AtTheMarketOfferingMember_c852fea5-c101-4b34-8054-b34c51480a54" xlink:href="vrdn-20240930.xsd#vrdn_September2022AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:to="loc_vrdn_September2022AtTheMarketOfferingMember_c852fea5-c101-4b34-8054-b34c51480a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_47a3f68b-90c8-4306-9396-01e49b4bf326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6aa43615-d396-4277-9eb8-85af0df69d90" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_47a3f68b-90c8-4306-9396-01e49b4bf326" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3a6eab3-e357-403e-b0dd-56997b91309b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_StatementTable_e3a6eab3-e357-403e-b0dd-56997b91309b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c5938bc-5d38-4508-be8f-23c3cf17295f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3a6eab3-e357-403e-b0dd-56997b91309b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c5938bc-5d38-4508-be8f-23c3cf17295f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8c5938bc-5d38-4508-be8f-23c3cf17295f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c5938bc-5d38-4508-be8f-23c3cf17295f" xlink:to="loc_us-gaap_EquityComponentDomain_8c5938bc-5d38-4508-be8f-23c3cf17295f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c5938bc-5d38-4508-be8f-23c3cf17295f" xlink:to="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e862d950-fd90-47f2-983b-401776fd3d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:to="loc_us-gaap_CommonStockMember_e862d950-fd90-47f2-983b-401776fd3d5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_27b65faf-d72b-4ddb-84fe-318491542f03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:to="loc_us-gaap_PreferredStockMember_27b65faf-d72b-4ddb-84fe-318491542f03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb75d425-8b2e-4b04-b8fe-7e58d66d9083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:to="loc_us-gaap_NetIncomeLoss_eb75d425-8b2e-4b04-b8fe-7e58d66d9083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8ab27712-2eb3-4136-9650-fe8eb9ff2c06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_ShareBasedCompensation_8ab27712-2eb3-4136-9650-fe8eb9ff2c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9c65d916-ba18-4394-a881-d1fde2c20b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9c65d916-ba18-4394-a881-d1fde2c20b92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b7a8a13c-5297-4c7f-95d9-9d42d3d669f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b7a8a13c-5297-4c7f-95d9-9d42d3d669f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_807947b1-f2ec-4757-a0b0-aec58e67ba79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_807947b1-f2ec-4757-a0b0-aec58e67ba79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_703789b4-c9d7-4b75-9c56-606ca0b928b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_703789b4-c9d7-4b75-9c56-606ca0b928b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense_68088e73-3894-4a6e-b467-01831e40d2e0" xlink:href="vrdn-20240930.xsd#vrdn_NonCashLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_vrdn_NonCashLeaseExpense_68088e73-3894-4a6e-b467-01831e40d2e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92579ca5-14c1-4395-9656-f046d3db7f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92579ca5-14c1-4395-9656-f046d3db7f7d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtExtinguishmentExpense_6b202cf7-5e6d-4907-b03c-9722557aede9" xlink:href="vrdn-20240930.xsd#vrdn_DebtExtinguishmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_vrdn_DebtExtinguishmentExpense_6b202cf7-5e6d-4907-b03c-9722557aede9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5287ae3d-ac7c-45de-9870-b84c2090ea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5287ae3d-ac7c-45de-9870-b84c2090ea0a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9778b388-69ce-48c4-b244-e91ebfe5a94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9778b388-69ce-48c4-b244-e91ebfe5a94d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5a3f0c19-4629-4fa4-9c30-ca80c12bf8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5a3f0c19-4629-4fa4-9c30-ca80c12bf8ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7f06fbdc-7c98-4b97-89fb-ff5f35fbe668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7f06fbdc-7c98-4b97-89fb-ff5f35fbe668" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fb1d88f6-34cf-4a3a-9bcf-879ba10c6b62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fb1d88f6-34cf-4a3a-9bcf-879ba10c6b62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_94a2996b-eb59-4412-bffc-9671c2e4e345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_94a2996b-eb59-4412-bffc-9671c2e4e345" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92251452-6acf-41a3-a304-79182f9d3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92251452-6acf-41a3-a304-79182f9d3cab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fd43d43-a93d-426f-ad03-2452651019ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fd43d43-a93d-426f-ad03-2452651019ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2fb2674b-1a66-4600-9d90-cc619f20e9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2fb2674b-1a66-4600-9d90-cc619f20e9b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a3b698e5-bca5-4bcd-8e6c-0874f9a44285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a3b698e5-bca5-4bcd-8e6c-0874f9a44285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0ae91c20-f39e-49b0-b7ce-6a89855e6d59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0ae91c20-f39e-49b0-b7ce-6a89855e6d59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_065a52f3-3e5e-4afe-9590-c87e096a7379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_065a52f3-3e5e-4afe-9590-c87e096a7379" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4143dc38-acb8-4442-bde4-4c3a26b40324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4143dc38-acb8-4442-bde4-4c3a26b40324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f57f85e4-4847-4388-b2ed-1294442179f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f57f85e4-4847-4388-b2ed-1294442179f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_43a5390a-d6b3-4957-8513-bb06ace9ab49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_43a5390a-d6b3-4957-8513-bb06ace9ab49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8210f654-812f-464e-b2e5-45179fc83e76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8210f654-812f-464e-b2e5-45179fc83e76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_84b58759-c0bb-4ef5-b24a-b88059b6fc32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_84b58759-c0bb-4ef5-b24a-b88059b6fc32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_bff08dcf-0f4b-443a-8a80-77f350cfb8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_bff08dcf-0f4b-443a-8a80-77f350cfb8d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8ef9ce3a-e1b3-4d02-93f4-b92fa38c374f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8ef9ce3a-e1b3-4d02-93f4-b92fa38c374f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_36e8049d-f44a-4007-8fdb-a0357f7edfab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromStockPlans_36e8049d-f44a-4007-8fdb-a0357f7edfab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b04951a-7f75-4ca2-800f-58b43552064f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b04951a-7f75-4ca2-800f-58b43552064f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437d6e27-caba-4f00-90d6-e6b852ec0452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437d6e27-caba-4f00-90d6-e6b852ec0452" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36d8d0e2-e90a-4d8b-8438-0613a5c99aba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36d8d0e2-e90a-4d8b-8438-0613a5c99aba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5dda9e3f-3aaa-4d40-a3a4-101f231eb4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e151359-7338-4837-a026-0cdb30cd0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e151359-7338-4837-a026-0cdb30cd0a2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c0d6604c-03f7-4c4b-918e-c28ef290d3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e151359-7338-4837-a026-0cdb30cd0a2d" xlink:to="loc_us-gaap_InterestPaidNet_c0d6604c-03f7-4c4b-918e-c28ef290d3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_b11a014a-2e1c-41fb-b899-89a086e7fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_b11a014a-2e1c-41fb-b899-89a086e7fd2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2c8faa85-4c56-4972-bec6-a901bf8a515a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2c8faa85-4c56-4972-bec6-a901bf8a515a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_097022d4-838d-4a59-b920-cfd7783fb617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_097022d4-838d-4a59-b920-cfd7783fb617" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction_354c8f9b-fcfc-4fcc-8943-bc3eeb861406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_NotesReduction_354c8f9b-fcfc-4fcc-8943-bc3eeb861406" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_c811a749-345c-41a7-8579-f33d22e92a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_NotesIssued1_c811a749-345c-41a7-8579-f33d22e92a0c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1dcd015e-6ebb-49a7-818e-d96689d3938c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1dcd015e-6ebb-49a7-818e-d96689d3938c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd569ec1-13eb-4e2b-a009-c01023438644" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1dcd015e-6ebb-49a7-818e-d96689d3938c" xlink:to="loc_srt_RangeAxis_cd569ec1-13eb-4e2b-a009-c01023438644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd569ec1-13eb-4e2b-a009-c01023438644_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cd569ec1-13eb-4e2b-a009-c01023438644" xlink:to="loc_srt_RangeMember_cd569ec1-13eb-4e2b-a009-c01023438644_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cd569ec1-13eb-4e2b-a009-c01023438644" xlink:to="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7aa05668-5f9c-4741-9197-6f00cad5fa19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:to="loc_srt_MinimumMember_7aa05668-5f9c-4741-9197-6f00cad5fa19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85e12b6a-32b9-45b6-9e49-7eee6a5bd678" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:to="loc_srt_MaximumMember_85e12b6a-32b9-45b6-9e49-7eee6a5bd678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e619c521-81ef-42b3-bafe-4c7ddf7aa98a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e619c521-81ef-42b3-bafe-4c7ddf7aa98a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4cbcfed9-e6ec-4d89-ae64-c3ba01af3d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4cbcfed9-e6ec-4d89-ae64-c3ba01af3d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_593c44de-c031-41bb-bf54-e90e6fb35d85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_593c44de-c031-41bb-bf54-e90e6fb35d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_313956b1-f8d7-476a-8d57-8b2687e6f988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_313956b1-f8d7-476a-8d57-8b2687e6f988" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_8db32d8a-1802-4c24-a044-3a1b3da2d6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_8db32d8a-1802-4c24-a044-3a1b3da2d6d4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_745581bd-5f69-4358-bb0d-9a407663b281" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_745581bd-5f69-4358-bb0d-9a407663b281" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_703e3f96-8d9f-46ed-8693-e92517592e28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_745581bd-5f69-4358-bb0d-9a407663b281" xlink:to="loc_us-gaap_FinancialInstrumentAxis_703e3f96-8d9f-46ed-8693-e92517592e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_703e3f96-8d9f-46ed-8693-e92517592e28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_703e3f96-8d9f-46ed-8693-e92517592e28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_703e3f96-8d9f-46ed-8693-e92517592e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_703e3f96-8d9f-46ed-8693-e92517592e28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_24929725-662b-4f17-9a4e-5451b5dc4c71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_MoneyMarketFundsMember_24929725-662b-4f17-9a4e-5451b5dc4c71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5a0093cc-53c7-48a3-aa5a-f3dd6832357f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5a0093cc-53c7-48a3-aa5a-f3dd6832357f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_68241554-dc92-4b0b-8b44-7ad12d2985a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_68241554-dc92-4b0b-8b44-7ad12d2985a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_37e6fa18-e01a-458c-b443-8814ae598736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_37e6fa18-e01a-458c-b443-8814ae598736" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c13f0de-aaea-4cc7-bf85-4603da333954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c13f0de-aaea-4cc7-bf85-4603da333954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5c4847d-eba9-47be-a44a-3429e2579f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5c4847d-eba9-47be-a44a-3429e2579f64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1fd2fa1e-a770-4162-917b-10f8ddcc3309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1fd2fa1e-a770-4162-917b-10f8ddcc3309" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9599962e-b5d8-4e42-aea3-a893bb162329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9599962e-b5d8-4e42-aea3-a893bb162329" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_387ea5e4-56f4-431f-b5db-274cffcb7677" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_387ea5e4-56f4-431f-b5db-274cffcb7677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_387ea5e4-56f4-431f-b5db-274cffcb7677_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_387ea5e4-56f4-431f-b5db-274cffcb7677" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_387ea5e4-56f4-431f-b5db-274cffcb7677_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_682e6c45-f852-4de8-9c5f-c20d52d4e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_387ea5e4-56f4-431f-b5db-274cffcb7677" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_682e6c45-f852-4de8-9c5f-c20d52d4e0c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f578a7ad-9fb9-4cb3-9f76-049044304d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_682e6c45-f852-4de8-9c5f-c20d52d4e0c0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f578a7ad-9fb9-4cb3-9f76-049044304d8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26e2158-24ce-4ee3-a048-31055211878e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26e2158-24ce-4ee3-a048-31055211878e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e26e2158-24ce-4ee3-a048-31055211878e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26e2158-24ce-4ee3-a048-31055211878e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e26e2158-24ce-4ee3-a048-31055211878e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26e2158-24ce-4ee3-a048-31055211878e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4a5001a4-d2f5-443a-98eb-108e3029a29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4a5001a4-d2f5-443a-98eb-108e3029a29b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b8329bc9-704c-45a2-8015-0163efdeb092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b8329bc9-704c-45a2-8015-0163efdeb092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1e8204b4-9e57-4641-85b4-c05420c516af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1e8204b4-9e57-4641-85b4-c05420c516af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_47857513-f5e4-460c-871a-2e12f6d934bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_47857513-f5e4-460c-871a-2e12f6d934bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47857513-f5e4-460c-871a-2e12f6d934bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_47857513-f5e4-460c-871a-2e12f6d934bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47857513-f5e4-460c-871a-2e12f6d934bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_47857513-f5e4-460c-871a-2e12f6d934bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_dae497f1-5445-4cae-bb6c-90581247695f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_MoneyMarketFundsMember_dae497f1-5445-4cae-bb6c-90581247695f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8adfc8c3-9e6e-4a92-8593-f5787bb5f3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8adfc8c3-9e6e-4a92-8593-f5787bb5f3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c55f95c9-9198-4533-9c9b-3ad24eae081e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c55f95c9-9198-4533-9c9b-3ad24eae081e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_fa8c9712-fc73-42ec-a43a-e9dcfaffb19d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_fa8c9712-fc73-42ec-a43a-e9dcfaffb19d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:to="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6ee5ad6b-6604-478a-a53f-095a3571bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_6ee5ad6b-6604-478a-a53f-095a3571bc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f272409-8254-42e9-81d9-ec3ee0eb646a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6ee5ad6b-6604-478a-a53f-095a3571bc49" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f272409-8254-42e9-81d9-ec3ee0eb646a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_b94c07a5-d0d0-4070-a2bd-3ed8a91d579c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_b94c07a5-d0d0-4070-a2bd-3ed8a91d579c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b929f6c0-2c97-4bf7-9e13-7780012b8cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_b94c07a5-d0d0-4070-a2bd-3ed8a91d579c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b929f6c0-2c97-4bf7-9e13-7780012b8cae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_54c39082-4c8e-4b1f-925b-ebf4b5e1c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_54c39082-4c8e-4b1f-925b-ebf4b5e1c7c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d3fc200c-6ccb-4570-b80f-333e85e9253f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d3fc200c-6ccb-4570-b80f-333e85e9253f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3fc200c-6ccb-4570-b80f-333e85e9253f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3fc200c-6ccb-4570-b80f-333e85e9253f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3fc200c-6ccb-4570-b80f-333e85e9253f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_086eabe5-6c9e-4186-848a-7b482407eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3fc200c-6ccb-4570-b80f-333e85e9253f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_086eabe5-6c9e-4186-848a-7b482407eaa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_ec8a0990-cf97-40cc-9de0-8f7f5bb4e105" xlink:href="vrdn-20240930.xsd#vrdn_HerculesTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_086eabe5-6c9e-4186-848a-7b482407eaa4" xlink:to="loc_vrdn_HerculesTermLoanMember_ec8a0990-cf97-40cc-9de0-8f7f5bb4e105" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3bb794ce-1df2-47be-b9e2-97707120452e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3bb794ce-1df2-47be-b9e2-97707120452e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3bb794ce-1df2-47be-b9e2-97707120452e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3bb794ce-1df2-47be-b9e2-97707120452e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3bb794ce-1df2-47be-b9e2-97707120452e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9a801382-d8d0-46d8-82ad-c0e65f2ad65e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3bb794ce-1df2-47be-b9e2-97707120452e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9a801382-d8d0-46d8-82ad-c0e65f2ad65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3aca5298-7429-4a24-95a8-3c5a0b466f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9a801382-d8d0-46d8-82ad-c0e65f2ad65e" xlink:to="loc_us-gaap_SecuredDebtMember_3aca5298-7429-4a24-95a8-3c5a0b466f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodAxis_0c105a27-079d-403f-aa07-e162a66a85ea" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:to="loc_vrdn_DebtCovenantPeriodAxis_0c105a27-079d-403f-aa07-e162a66a85ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodDomain_0c105a27-079d-403f-aa07-e162a66a85ea_default" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrdn_DebtCovenantPeriodAxis_0c105a27-079d-403f-aa07-e162a66a85ea" xlink:to="loc_vrdn_DebtCovenantPeriodDomain_0c105a27-079d-403f-aa07-e162a66a85ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrdn_DebtCovenantPeriodAxis_0c105a27-079d-403f-aa07-e162a66a85ea" xlink:to="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodOneMember_16fa7fbc-5b6b-4991-8390-ac7a2df46401" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:to="loc_vrdn_DebtCovenantPeriodOneMember_16fa7fbc-5b6b-4991-8390-ac7a2df46401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodTwoMember_d7839ffd-67af-4794-97f0-902995c0a74a" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:to="loc_vrdn_DebtCovenantPeriodTwoMember_d7839ffd-67af-4794-97f0-902995c0a74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ef684090-a371-44fc-ab19-25b63f41058c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ef684090-a371-44fc-ab19-25b63f41058c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentNumberOfTranches_c0b480fa-57da-4c59-89e9-f606432b89f3" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentNumberOfTranches_c0b480fa-57da-4c59-89e9-f606432b89f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_b51802c5-e21a-4c0c-a82b-a4d6c5441c5b" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountFirstTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_b51802c5-e21a-4c0c-a82b-a4d6c5441c5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_6c36862f-aee3-427a-ac40-1f27b19bb15a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_6c36862f-aee3-427a-ac40-1f27b19bb15a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_c089ec83-45f5-47a7-aad3-16f3e1935e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_c089ec83-45f5-47a7-aad3-16f3e1935e92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFacilityFee_80f16e0a-7b94-40b5-b85c-ed1bbf8851bf" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFacilityFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFacilityFee_80f16e0a-7b94-40b5-b85c-ed1bbf8851bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentOtherExpenses_a34961de-0b15-48e8-8f14-922309231e95" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentOtherExpenses_a34961de-0b15-48e8-8f14-922309231e95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentPrincipalAmountTermFee_48f43fe5-4f5c-496f-aa0b-61ab9b3d1d24" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentPrincipalAmountTermFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentPrincipalAmountTermFee_48f43fe5-4f5c-496f-aa0b-61ab9b3d1d24" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_508dfdb3-a0b6-44a4-8f8e-81178ffdf0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_508dfdb3-a0b6-44a4-8f8e-81178ffdf0cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_912f5fcd-e27b-4e6d-9d58-897c0f9f4801" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountSecondTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_912f5fcd-e27b-4e6d-9d58-897c0f9f4801" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_7602a5ab-f5f5-4069-a3d9-1a3b5cf9d2a4" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountThirdTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_7602a5ab-f5f5-4069-a3d9-1a3b5cf9d2a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_b7ae6d98-8816-496b-a1ab-3e5e27117576" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountFourthTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_b7ae6d98-8816-496b-a1ab-3e5e27117576" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eff8fd1e-85c3-433e-b40d-1b9c32e5000d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eff8fd1e-85c3-433e-b40d-1b9c32e5000d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a95dacc9-a0f6-4104-a00b-ac737774a6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a95dacc9-a0f6-4104-a00b-ac737774a6c7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentInterestRateMaximum_c8ce23cb-3f6f-4b70-bb17-699c6f906143" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentInterestRateMaximum_c8ce23cb-3f6f-4b70-bb17-699c6f906143" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d3e67797-6cc2-4ac3-a75c-9518de616665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d3e67797-6cc2-4ac3-a75c-9518de616665" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_a32ba8a4-d2c1-4756-b4c4-49b949e4e8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_InterestExpenseNonoperating_a32ba8a4-d2c1-4756-b4c4-49b949e4e8e6" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fef3de6d-102d-42f9-80ef-7b37a13364e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:to="loc_us-gaap_DebtInstrumentAxis_fef3de6d-102d-42f9-80ef-7b37a13364e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fef3de6d-102d-42f9-80ef-7b37a13364e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fef3de6d-102d-42f9-80ef-7b37a13364e0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fef3de6d-102d-42f9-80ef-7b37a13364e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e732ee87-b75b-4c23-89d9-8da4f4c72f65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fef3de6d-102d-42f9-80ef-7b37a13364e0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e732ee87-b75b-4c23-89d9-8da4f4c72f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_65f620fb-e05e-42c8-8b05-cb3d0da3649a" xlink:href="vrdn-20240930.xsd#vrdn_HerculesTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e732ee87-b75b-4c23-89d9-8da4f4c72f65" xlink:to="loc_vrdn_HerculesTermLoanMember_65f620fb-e05e-42c8-8b05-cb3d0da3649a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_628dd4a4-298f-47e3-a236-c1354d9d69cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_628dd4a4-298f-47e3-a236-c1354d9d69cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_628dd4a4-298f-47e3-a236-c1354d9d69cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_628dd4a4-298f-47e3-a236-c1354d9d69cb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_628dd4a4-298f-47e3-a236-c1354d9d69cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42111de2-11a2-48e2-be4d-391147c4965c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_628dd4a4-298f-47e3-a236-c1354d9d69cb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42111de2-11a2-48e2-be4d-391147c4965c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f59ee5e3-b7ad-4a0b-8a0f-a24581c32171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42111de2-11a2-48e2-be4d-391147c4965c" xlink:to="loc_us-gaap_SecuredDebtMember_f59ee5e3-b7ad-4a0b-8a0f-a24581c32171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_56f71be7-50cd-4698-abe6-99766fc0e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_56f71be7-50cd-4698-abe6-99766fc0e7cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_628c12d7-6081-4e53-8bbe-14aca107b283" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_628c12d7-6081-4e53-8bbe-14aca107b283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_67b600e6-15b3-46a2-84a3-61430e16ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_LongTermDebt_67b600e6-15b3-46a2-84a3-61430e16ac4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4fbcc966-4dda-4257-a826-754036699192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_LongTermDebtCurrent_4fbcc966-4dda-4257-a826-754036699192" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be816f5a-2d95-4e62-9ae7-89706147eeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be816f5a-2d95-4e62-9ae7-89706147eeb2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_54b6c7ff-066c-4436-9ab1-86d1e8376e69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:to="loc_us-gaap_DebtInstrumentAxis_54b6c7ff-066c-4436-9ab1-86d1e8376e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_54b6c7ff-066c-4436-9ab1-86d1e8376e69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_54b6c7ff-066c-4436-9ab1-86d1e8376e69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_54b6c7ff-066c-4436-9ab1-86d1e8376e69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7b4906c-1ce3-4865-9b48-b28c0fadc079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_54b6c7ff-066c-4436-9ab1-86d1e8376e69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7b4906c-1ce3-4865-9b48-b28c0fadc079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_3b4e9b5d-d214-4d52-86e0-57ecc57b75e6" xlink:href="vrdn-20240930.xsd#vrdn_HerculesTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7b4906c-1ce3-4865-9b48-b28c0fadc079" xlink:to="loc_vrdn_HerculesTermLoanMember_3b4e9b5d-d214-4d52-86e0-57ecc57b75e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5814065a-09a7-4004-b235-b6f80bb10509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5814065a-09a7-4004-b235-b6f80bb10509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5814065a-09a7-4004-b235-b6f80bb10509_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5814065a-09a7-4004-b235-b6f80bb10509" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5814065a-09a7-4004-b235-b6f80bb10509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7714fbb7-2966-4adb-8230-83b809c1190f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5814065a-09a7-4004-b235-b6f80bb10509" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7714fbb7-2966-4adb-8230-83b809c1190f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5b67f97d-5dab-4482-9b79-60dfb7e95311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7714fbb7-2966-4adb-8230-83b809c1190f" xlink:to="loc_us-gaap_SecuredDebtMember_5b67f97d-5dab-4482-9b79-60dfb7e95311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6dfe6f87-a9e1-4d5b-9de2-5974ceb17191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6dfe6f87-a9e1-4d5b-9de2-5974ceb17191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a8feac7d-088a-4bf1-ac2f-38b25a5a4bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a8feac7d-088a-4bf1-ac2f-38b25a5a4bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e413d55b-ce6b-4b8d-8b93-b289017a1136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e413d55b-ce6b-4b8d-8b93-b289017a1136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a4161432-07a4-4083-a203-664ed3d4393e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a4161432-07a4-4083-a203-664ed3d4393e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COLLABORATIONAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ba7b186-ceaa-4b73-9525-66092e05b9cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:to="loc_srt_ProductOrServiceAxis_8ba7b186-ceaa-4b73-9525-66092e05b9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8ba7b186-ceaa-4b73-9525-66092e05b9cf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8ba7b186-ceaa-4b73-9525-66092e05b9cf" xlink:to="loc_srt_ProductsAndServicesDomain_8ba7b186-ceaa-4b73-9525-66092e05b9cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_07402f97-5bce-44a8-be5a-72ec0671a523" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8ba7b186-ceaa-4b73-9525-66092e05b9cf" xlink:to="loc_srt_ProductsAndServicesDomain_07402f97-5bce-44a8-be5a-72ec0671a523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationRevenueMember_3c3315a3-6863-4e23-97b2-5f6bf1aec25e" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_07402f97-5bce-44a8-be5a-72ec0671a523" xlink:to="loc_vrdn_CollaborationRevenueMember_3c3315a3-6863-4e23-97b2-5f6bf1aec25e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b817f37-0cc4-4963-a0c3-b54ee20f3865" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:to="loc_srt_CounterpartyNameAxis_7b817f37-0cc4-4963-a0c3-b54ee20f3865" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b817f37-0cc4-4963-a0c3-b54ee20f3865_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7b817f37-0cc4-4963-a0c3-b54ee20f3865" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b817f37-0cc4-4963-a0c3-b54ee20f3865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7b817f37-0cc4-4963-a0c3-b54ee20f3865" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ZenasBioPharmaMember_6c31a7ad-1cea-452c-8603-4ca6e97fa985" xlink:href="vrdn-20240930.xsd#vrdn_ZenasBioPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:to="loc_vrdn_ZenasBioPharmaMember_6c31a7ad-1cea-452c-8603-4ca6e97fa985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ParagonTherapeuticsMember_276456fa-3653-48a1-8f52-4849daf18459" xlink:href="vrdn-20240930.xsd#vrdn_ParagonTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:to="loc_vrdn_ParagonTherapeuticsMember_276456fa-3653-48a1-8f52-4849daf18459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c8667a27-fe9d-4841-8ea1-b3f78309a1a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:to="loc_srt_OwnershipAxis_c8667a27-fe9d-4841-8ea1-b3f78309a1a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c8667a27-fe9d-4841-8ea1-b3f78309a1a7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c8667a27-fe9d-4841-8ea1-b3f78309a1a7" xlink:to="loc_srt_OwnershipDomain_c8667a27-fe9d-4841-8ea1-b3f78309a1a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_be69bb97-18d5-4e0b-9d46-abfa468b0a75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c8667a27-fe9d-4841-8ea1-b3f78309a1a7" xlink:to="loc_srt_OwnershipDomain_be69bb97-18d5-4e0b-9d46-abfa468b0a75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FairmountFundsManagementMember_1ff7ad5a-84ca-4e5e-98b3-5e07fccfa304" xlink:href="vrdn-20240930.xsd#vrdn_FairmountFundsManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_be69bb97-18d5-4e0b-9d46-abfa468b0a75" xlink:to="loc_vrdn_FairmountFundsManagementMember_1ff7ad5a-84ca-4e5e-98b3-5e07fccfa304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_900b61e7-1e3b-4fb1-948b-98286d329ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_900b61e7-1e3b-4fb1-948b-98286d329ab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementInitialPayment_f2e8040d-c858-4d0a-af7f-db579130e8be" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementInitialPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementInitialPayment_f2e8040d-c858-4d0a-af7f-db579130e8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_54b1278a-bf28-4441-afa7-72d7199854de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_54b1278a-bf28-4441-afa7-72d7199854de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_06e4d4b8-6ff7-463b-af0e-360087d3feea" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementUpfrontFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_06e4d4b8-6ff7-463b-af0e-360087d3feea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_c6d764f5-a249-4fce-8a34-54664a649458" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_c6d764f5-a249-4fce-8a34-54664a649458" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment_9c713043-dd03-4ecd-839e-cd83b453c953" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborativeArrangementMilestonePayment_9c713043-dd03-4ecd-839e-cd83b453c953" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments_1667e738-b5b7-417c-9488-fd87ce0afe30" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments_1667e738-b5b7-417c-9488-fd87ce0afe30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementMaximumMilestonePayments_554e0e45-4306-4bf2-b2b3-09fff2d1a8f2" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementMaximumMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementMaximumMilestonePayments_554e0e45-4306-4bf2-b2b3-09fff2d1a8f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_6766e71f-49f5-46e5-a432-fca6641f142d" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_6766e71f-49f5-46e5-a432-fca6641f142d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_c6dfcd93-d2a5-4e75-b20e-1ef2f7e144e0" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_c6dfcd93-d2a5-4e75-b20e-1ef2f7e144e0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0627f670-0a50-464d-b32e-86399547ed40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0627f670-0a50-464d-b32e-86399547ed40" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_05f94cc0-55f7-4b40-a9d4-5943c237867e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_05f94cc0-55f7-4b40-a9d4-5943c237867e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_05f94cc0-55f7-4b40-a9d4-5943c237867e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05f94cc0-55f7-4b40-a9d4-5943c237867e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_05f94cc0-55f7-4b40-a9d4-5943c237867e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05f94cc0-55f7-4b40-a9d4-5943c237867e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ImmunoGenIncMember_4c84ea4f-d29e-4b33-be23-4548bd47150f" xlink:href="vrdn-20240930.xsd#vrdn_ImmunoGenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:to="loc_vrdn_ImmunoGenIncMember_4c84ea4f-d29e-4b33-be23-4548bd47150f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EnableInjectionsMember_fe717b53-4fe8-4dba-96ff-cedbf7bf8eb8" xlink:href="vrdn-20240930.xsd#vrdn_EnableInjectionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:to="loc_vrdn_EnableInjectionsMember_fe717b53-4fe8-4dba-96ff-cedbf7bf8eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ThirdPartyCollaboratorMember_4a276e16-7650-4aa6-9eab-b64d9b502d56" xlink:href="vrdn-20240930.xsd#vrdn_ThirdPartyCollaboratorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:to="loc_vrdn_ThirdPartyCollaboratorMember_4a276e16-7650-4aa6-9eab-b64d9b502d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2ce9dd9c-e388-4cd1-9335-c551f2882a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2ce9dd9c-e388-4cd1-9335-c551f2882a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_2ce9dd9c-e388-4cd1-9335-c551f2882a44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2ce9dd9c-e388-4cd1-9335-c551f2882a44" xlink:to="loc_us-gaap_LeaseContractualTermDomain_2ce9dd9c-e388-4cd1-9335-c551f2882a44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2ce9dd9c-e388-4cd1-9335-c551f2882a44" xlink:to="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ColoradoLeaseMember_511f0d0d-f48c-4c2d-af7b-b34619a21322" xlink:href="vrdn-20240930.xsd#vrdn_ColoradoLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:to="loc_vrdn_ColoradoLeaseMember_511f0d0d-f48c-4c2d-af7b-b34619a21322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_MassachusettsLeaseMember_609ecb5b-d374-4dca-8ea1-8bf80f6ba443" xlink:href="vrdn-20240930.xsd#vrdn_MassachusettsLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:to="loc_vrdn_MassachusettsLeaseMember_609ecb5b-d374-4dca-8ea1-8bf80f6ba443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_2caf1365-0d8f-4060-817e-b662fbe84d4c" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_2caf1365-0d8f-4060-817e-b662fbe84d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment_52b2365b-1375-42d2-9c9b-1ab87e1c77e5" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementMilestonePayment_52b2365b-1375-42d2-9c9b-1ab87e1c77e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_a3f8f33a-8258-41d3-b799-4d0b65f7ee50" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_a3f8f33a-8258-41d3-b799-4d0b65f7ee50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_587f3530-59bf-439b-a5e7-0015c22c1441" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_587f3530-59bf-439b-a5e7-0015c22c1441" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_b2124a24-7649-4d2f-90fe-83ee30b0b693" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementSharesIssuedForRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_b2124a24-7649-4d2f-90fe-83ee30b0b693" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_3ce48336-b183-4883-a070-c61351e92859" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_3ce48336-b183-4883-a070-c61351e92859" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted_a9d31224-1d76-4c39-ab12-06990dad832f" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted_a9d31224-1d76-4c39-ab12-06990dad832f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted_5c56aacb-e4a9-4475-8bbe-83e9c68d9603" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted_5c56aacb-e4a9-4475-8bbe-83e9c68d9603" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_9356838a-bf58-4af8-a6a9-d6856a22495d" xlink:href="vrdn-20240930.xsd#vrdn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_9356838a-bf58-4af8-a6a9-d6856a22495d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_293b3198-6f3a-4a87-b4d9-f0c0add341ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_293b3198-6f3a-4a87-b4d9-f0c0add341ef" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6cb91e6c-fe37-480e-88a5-2e5c9156ba90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6cb91e6c-fe37-480e-88a5-2e5c9156ba90" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c4756229-5d19-4d37-afdb-032aad57334f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c4756229-5d19-4d37-afdb-032aad57334f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1034621-4f22-42c3-bba6-3983fe4c03be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1034621-4f22-42c3-bba6-3983fe4c03be" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseAnnualBaseRent_d5e01de7-311f-48ff-8bae-c10219a73c3f" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseAnnualBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeaseAnnualBaseRent_d5e01de7-311f-48ff-8bae-c10219a73c3f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_f43d1215-8e8b-45d2-8466-d98381da4c76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_f43d1215-8e8b-45d2-8466-d98381da4c76" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5db7e202-a45e-49d7-ada8-d5f9c83e1557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5db7e202-a45e-49d7-ada8-d5f9c83e1557" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ffe038b-9dd7-4990-b503-f14b38570cce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ffe038b-9dd7-4990-b503-f14b38570cce" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseRightOfUseAssetDerecognized_c21a5df4-e666-4273-8d3c-cea031ada320" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeaseRightOfUseAssetDerecognized_c21a5df4-e666-4273-8d3c-cea031ada320" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseLiabilityCurrentDerecognized_5ad7021d-5148-4e14-9ed0-ce9e03de0306" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseLiabilityCurrentDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeaseLiabilityCurrentDerecognized_5ad7021d-5148-4e14-9ed0-ce9e03de0306" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_421d7aa8-5036-4cb5-9538-ee61175c703f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_421d7aa8-5036-4cb5-9538-ee61175c703f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db94f0ac-2d2a-4496-8a1b-1370879befde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db94f0ac-2d2a-4496-8a1b-1370879befde" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_26bfce7e-be5a-4e2c-9d14-9fe6a9ffd86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_26bfce7e-be5a-4e2c-9d14-9fe6a9ffd86c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d3029c0b-72c3-4daa-b95b-ae485b57295c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d3029c0b-72c3-4daa-b95b-ae485b57295c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeasesOperatingExpense_f738b6bb-9997-4526-b51f-2e3f0e76665f" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeasesOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeasesOperatingExpense_f738b6bb-9997-4526-b51f-2e3f0e76665f" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CAPITALSTOCKDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d41266d-fa03-413f-bb8c-073b4de1cd02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d41266d-fa03-413f-bb8c-073b4de1cd02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d41266d-fa03-413f-bb8c-073b4de1cd02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d41266d-fa03-413f-bb8c-073b4de1cd02" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d41266d-fa03-413f-bb8c-073b4de1cd02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d41266d-fa03-413f-bb8c-073b4de1cd02" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_2c00d175-8ead-411d-8832-72b603ba7b1f" xlink:href="vrdn-20240930.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_vrdn_AtthemarketOfferingMember_2c00d175-8ead-411d-8832-72b603ba7b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_0fe41087-e0e8-4a2d-b8a2-46559efabf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_us-gaap_PrivatePlacementMember_0fe41087-e0e8-4a2d-b8a2-46559efabf7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2024PublicOfferingMember_16553ece-aaaf-467d-b855-c2898f8d43f5" xlink:href="vrdn-20240930.xsd#vrdn_A2024PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_vrdn_A2024PublicOfferingMember_16553ece-aaaf-467d-b855-c2898f8d43f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_fa0050e1-afc3-477d-a42a-4528d8d50d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_us-gaap_OverAllotmentOptionMember_fa0050e1-afc3-477d-a42a-4528d8d50d6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_44e1b07f-a424-483d-9eee-2142a96c6bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_44e1b07f-a424-483d-9eee-2142a96c6bf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44e1b07f-a424-483d-9eee-2142a96c6bf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_44e1b07f-a424-483d-9eee-2142a96c6bf7" xlink:to="loc_us-gaap_EquityComponentDomain_44e1b07f-a424-483d-9eee-2142a96c6bf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_44e1b07f-a424-483d-9eee-2142a96c6bf7" xlink:to="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1b68c48e-9cef-4559-8020-ef7c21eb8542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:to="loc_us-gaap_CommonStockMember_1b68c48e-9cef-4559-8020-ef7c21eb8542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1c436b3e-c290-4c82-91df-2f78d5995739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:to="loc_us-gaap_PreferredStockMember_1c436b3e-c290-4c82-91df-2f78d5995739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aa109119-2b6e-4264-a118-7fd26bf6571d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aa109119-2b6e-4264-a118-7fd26bf6571d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa109119-2b6e-4264-a118-7fd26bf6571d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa109119-2b6e-4264-a118-7fd26bf6571d" xlink:to="loc_us-gaap_ClassOfStockDomain_aa109119-2b6e-4264-a118-7fd26bf6571d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa109119-2b6e-4264-a118-7fd26bf6571d" xlink:to="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_47afdfb8-6dca-41d8-be78-06869abdb66a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_47afdfb8-6dca-41d8-be78-06869abdb66a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c3bbe33d-356a-47b7-b6c1-68f0463adf29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c3bbe33d-356a-47b7-b6c1-68f0463adf29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_432c959c-4478-4e0b-993d-19b37a674ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_432c959c-4478-4e0b-993d-19b37a674ca8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_432c959c-4478-4e0b-993d-19b37a674ca8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_432c959c-4478-4e0b-993d-19b37a674ca8" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_432c959c-4478-4e0b-993d-19b37a674ca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_432c959c-4478-4e0b-993d-19b37a674ca8" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SeriesAPreferredStockConversionMember_a1c55222-bd0a-4734-a3c4-028e67a00833" xlink:href="vrdn-20240930.xsd#vrdn_SeriesAPreferredStockConversionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:to="loc_vrdn_SeriesAPreferredStockConversionMember_a1c55222-bd0a-4734-a3c4-028e67a00833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SeriesBPreferredStockConversionMember_d6dbb79b-6423-4b8a-9ba0-4cc49786ef61" xlink:href="vrdn-20240930.xsd#vrdn_SeriesBPreferredStockConversionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:to="loc_vrdn_SeriesBPreferredStockConversionMember_d6dbb79b-6423-4b8a-9ba0-4cc49786ef61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_b144bd26-6284-4bff-89d1-e3c007dd8926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_AssetAcquisitionAxis_b144bd26-6284-4bff-89d1-e3c007dd8926" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b144bd26-6284-4bff-89d1-e3c007dd8926_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b144bd26-6284-4bff-89d1-e3c007dd8926" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b144bd26-6284-4bff-89d1-e3c007dd8926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bef67da3-cbd5-43c8-a576-1dfcdfd5d653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b144bd26-6284-4bff-89d1-e3c007dd8926" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bef67da3-cbd5-43c8-a576-1dfcdfd5d653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ViridianMergerMember_ee3f2ccb-40e2-4d38-ad9d-b508b9fe5914" xlink:href="vrdn-20240930.xsd#vrdn_ViridianMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bef67da3-cbd5-43c8-a576-1dfcdfd5d653" xlink:to="loc_vrdn_ViridianMergerMember_ee3f2ccb-40e2-4d38-ad9d-b508b9fe5914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a4df4ca-bb61-4d10-9fa7-c10a4251caca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_srt_RangeAxis_2a4df4ca-bb61-4d10-9fa7-c10a4251caca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a4df4ca-bb61-4d10-9fa7-c10a4251caca_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a4df4ca-bb61-4d10-9fa7-c10a4251caca" xlink:to="loc_srt_RangeMember_2a4df4ca-bb61-4d10-9fa7-c10a4251caca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a4df4ca-bb61-4d10-9fa7-c10a4251caca" xlink:to="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca2d0b18-4b1a-424f-8471-4605b950599b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:to="loc_srt_MinimumMember_ca2d0b18-4b1a-424f-8471-4605b950599b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9da06254-7cc2-4176-9406-3e50c71f90e3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:to="loc_srt_MaximumMember_9da06254-7cc2-4176-9406-3e50c71f90e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CapitalStockSharesAuthorized_8a4590d0-5004-4518-8172-20e0caf49d00" xlink:href="vrdn-20240930.xsd#vrdn_CapitalStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_CapitalStockSharesAuthorized_8a4590d0-5004-4518-8172-20e0caf49d00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0bbd8d76-1213-447b-ba49-ea6e44cbae75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0bbd8d76-1213-447b-ba49-ea6e44cbae75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_297c8325-557d-4a28-b961-4e73bf4b1e65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_297c8325-557d-4a28-b961-4e73bf4b1e65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c6426477-0d5a-47b5-a38a-254920d8d6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c6426477-0d5a-47b5-a38a-254920d8d6b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_59362633-5683-44cb-8142-d0ad50892ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_59362633-5683-44cb-8142-d0ad50892ffd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockVotePerShare_b4803ffc-b6fe-4e9d-bc68-03eeb4cd224c" xlink:href="vrdn-20240930.xsd#vrdn_CommonStockVotePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_CommonStockVotePerShare_b4803ffc-b6fe-4e9d-bc68-03eeb4cd224c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c0ba9299-c7e3-4741-9cfd-582ca4eb9673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c0ba9299-c7e3-4741-9cfd-582ca4eb9673" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_acbf6c14-a001-4b0d-bdcf-57c398f21e6d" xlink:href="vrdn-20240930.xsd#vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_acbf6c14-a001-4b0d-bdcf-57c398f21e6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0f1abd-207b-44cf-b022-50a797ba6454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0f1abd-207b-44cf-b022-50a797ba6454" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockWeightedAverageSharePrice_12e137d9-d77d-440f-88f0-d2e4bb475eed" xlink:href="vrdn-20240930.xsd#vrdn_SaleOfStockWeightedAverageSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_SaleOfStockWeightedAverageSharePrice_12e137d9-d77d-440f-88f0-d2e4bb475eed" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38349b07-00c2-4ba1-95ec-1aaedffd36d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38349b07-00c2-4ba1-95ec-1aaedffd36d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2e52a28f-4488-4296-99e4-5475379c55d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2e52a28f-4488-4296-99e4-5475379c55d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_b567cd9f-5bcd-4a8f-8205-d5267a6fbfa8" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_b567cd9f-5bcd-4a8f-8205-d5267a6fbfa8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5a55a9a4-8e73-4eb8-abfc-31dcad0b1e84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5a55a9a4-8e73-4eb8-abfc-31dcad0b1e84" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_24ccf89c-cd74-427f-9353-7d5d74c0579d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_24ccf89c-cd74-427f-9353-7d5d74c0579d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_3b31bc56-28fc-4bb5-9a87-4ad964c29609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_3b31bc56-28fc-4bb5-9a87-4ad964c29609" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_d8a42e0f-0927-4b0a-9c32-e4f54d7af146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_d8a42e0f-0927-4b0a-9c32-e4f54d7af146" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#WARRANTSStockWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3a1f4ace-bf4d-438e-88e8-dc9739d4bbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3a1f4ace-bf4d-438e-88e8-dc9739d4bbb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f0d8d813-3d8c-4b73-83cf-18b49fcfe667" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3a1f4ace-bf4d-438e-88e8-dc9739d4bbb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f0d8d813-3d8c-4b73-83cf-18b49fcfe667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f0d8d813-3d8c-4b73-83cf-18b49fcfe667_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f0d8d813-3d8c-4b73-83cf-18b49fcfe667" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f0d8d813-3d8c-4b73-83cf-18b49fcfe667_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f0d8d813-3d8c-4b73-83cf-18b49fcfe667" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_17ea5ba0-a809-4f80-80f5-e4f4a3b9cd9b" xlink:href="vrdn-20240930.xsd#vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:to="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_17ea5ba0-a809-4f80-80f5-e4f4a3b9cd9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:to="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_91f98464-47ea-4368-a928-8017324223dc" xlink:href="vrdn-20240930.xsd#vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:to="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_91f98464-47ea-4368-a928-8017324223dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_c1d01fba-b5b7-42c8-9af3-cf7d6f179789" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_c1d01fba-b5b7-42c8-9af3-cf7d6f179789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_c008ea18-44b4-4189-9033-1cfec44a95f7" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsIssuedNovember2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_c008ea18-44b4-4189-9033-1cfec44a95f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_2bec93eb-f6d7-4960-bd37-978824c27781" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:to="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_2bec93eb-f6d7-4960-bd37-978824c27781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac462615-b6b2-4b9e-9264-489ee36fa4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac462615-b6b2-4b9e-9264-489ee36fa4e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightRemainingTerm_6fc2e1da-d23a-4df1-9b25-0656fd99ce45" xlink:href="vrdn-20240930.xsd#vrdn_ClassofWarrantorRightRemainingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:to="loc_vrdn_ClassofWarrantorRightRemainingTerm_6fc2e1da-d23a-4df1-9b25-0656fd99ce45" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8ec039c4-8c85-49ee-8980-88f45fe3576d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_us-gaap_PlanNameAxis_8ec039c4-8c85-49ee-8980-88f45fe3576d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8ec039c4-8c85-49ee-8980-88f45fe3576d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8ec039c4-8c85-49ee-8980-88f45fe3576d" xlink:to="loc_us-gaap_PlanNameDomain_8ec039c4-8c85-49ee-8980-88f45fe3576d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7b10b0f1-c5c9-42eb-b1c0-af2ba3775760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8ec039c4-8c85-49ee-8980-88f45fe3576d" xlink:to="loc_us-gaap_PlanNameDomain_7b10b0f1-c5c9-42eb-b1c0-af2ba3775760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember_3fbf429c-d74e-4016-974f-45cb6b0cb1f5" xlink:href="vrdn-20240930.xsd#vrdn_Amended2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7b10b0f1-c5c9-42eb-b1c0-af2ba3775760" xlink:to="loc_vrdn_Amended2016PlanMember_3fbf429c-d74e-4016-974f-45cb6b0cb1f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ee450de-437b-48ce-8dff-aaed7e4e7054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_us-gaap_AwardTypeAxis_2ee450de-437b-48ce-8dff-aaed7e4e7054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ee450de-437b-48ce-8dff-aaed7e4e7054_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2ee450de-437b-48ce-8dff-aaed7e4e7054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ee450de-437b-48ce-8dff-aaed7e4e7054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2ee450de-437b-48ce-8dff-aaed7e4e7054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_27976131-5537-4dfd-83f1-b3da6295eb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_27976131-5537-4dfd-83f1-b3da6295eb2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_47842164-62f3-447b-b5e6-8a5b98905e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_47842164-62f3-447b-b5e6-8a5b98905e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_77f44cbc-609a-40dc-96d7-91227e20486d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:to="loc_us-gaap_EmployeeStockMember_77f44cbc-609a-40dc-96d7-91227e20486d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7c98cb85-2266-4e1a-b578-4cc9b7e45929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_us-gaap_VestingAxis_7c98cb85-2266-4e1a-b578-4cc9b7e45929" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7c98cb85-2266-4e1a-b578-4cc9b7e45929_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7c98cb85-2266-4e1a-b578-4cc9b7e45929" xlink:to="loc_us-gaap_VestingDomain_7c98cb85-2266-4e1a-b578-4cc9b7e45929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7c98cb85-2266-4e1a-b578-4cc9b7e45929" xlink:to="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9ae68b38-3431-4aab-8d0c-e44cb10416e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9ae68b38-3431-4aab-8d0c-e44cb10416e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_78af8cfc-0869-4651-bdb5-9d9a38576de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_78af8cfc-0869-4651-bdb5-9d9a38576de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5d63bfc8-31c8-4c31-91d2-1941fab96d4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_srt_TitleOfIndividualAxis_5d63bfc8-31c8-4c31-91d2-1941fab96d4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d63bfc8-31c8-4c31-91d2-1941fab96d4b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5d63bfc8-31c8-4c31-91d2-1941fab96d4b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d63bfc8-31c8-4c31-91d2-1941fab96d4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c0f6471-8b08-4024-afdc-87da32c36666" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5d63bfc8-31c8-4c31-91d2-1941fab96d4b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c0f6471-8b08-4024-afdc-87da32c36666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FormerExecutiveOfficersMember_3c6b12d9-d051-49b6-bd73-afe2d487c570" xlink:href="vrdn-20240930.xsd#vrdn_FormerExecutiveOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c0f6471-8b08-4024-afdc-87da32c36666" xlink:to="loc_vrdn_FormerExecutiveOfficersMember_3c6b12d9-d051-49b6-bd73-afe2d487c570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b2f33301-9be5-4e49-8cfd-98062ea172a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b2f33301-9be5-4e49-8cfd-98062ea172a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b5911e15-fd87-4f7b-85fb-4fd5231158ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b5911e15-fd87-4f7b-85fb-4fd5231158ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_39885f93-8a32-4541-ad58-b1b6ed7c1232" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_39885f93-8a32-4541-ad58-b1b6ed7c1232" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97cc9ffc-1986-4acf-b152-e80a5032d8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97cc9ffc-1986-4acf-b152-e80a5032d8fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69c2c3f7-b802-4d34-b3c6-d8cbd2809c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69c2c3f7-b802-4d34-b3c6-d8cbd2809c62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a421261c-0ec8-47f9-ad28-02fa9bebab4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a421261c-0ec8-47f9-ad28-02fa9bebab4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90a31a2c-8824-45cd-94d7-1951c538e61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90a31a2c-8824-45cd-94d7-1951c538e61e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_75765f4f-b4e3-4cc5-8179-3317c7933f30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_75765f4f-b4e3-4cc5-8179-3317c7933f30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9f0c2068-a279-4cec-9bb2-f781c23da08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9f0c2068-a279-4cec-9bb2-f781c23da08d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9fc20295-4123-4018-9ab3-5d336a19ce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9fc20295-4123-4018-9ab3-5d336a19ce9a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f1690ea3-ca90-41be-8503-8e459a2b44c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f1690ea3-ca90-41be-8503-8e459a2b44c9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a210d63-5579-4184-96c3-2428dc79901d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a210d63-5579-4184-96c3-2428dc79901d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_71f5a0f7-a1d6-4149-bcf5-56b437e33b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_71f5a0f7-a1d6-4149-bcf5-56b437e33b06" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONBalancebyPlanDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:to="loc_us-gaap_PlanNameAxis_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f" xlink:to="loc_us-gaap_PlanNameDomain_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f" xlink:to="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_InducementGrantsMember_ef1f4801-035e-4b46-af62-6318074028cd" xlink:href="vrdn-20240930.xsd#vrdn_InducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_InducementGrantsMember_ef1f4801-035e-4b46-af62-6318074028cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2020PlanMember_24cfae44-69db-40a6-bfe3-33bb414b124c" xlink:href="vrdn-20240930.xsd#vrdn_A2020PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_A2020PlanMember_24cfae44-69db-40a6-bfe3-33bb414b124c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember_d9d09534-f12d-4ce1-b57d-211f2464e60c" xlink:href="vrdn-20240930.xsd#vrdn_Amended2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_Amended2016PlanMember_d9d09534-f12d-4ce1-b57d-211f2464e60c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2008PlanMember_9e9abb0a-5df5-45b0-8074-229348d80b61" xlink:href="vrdn-20240930.xsd#vrdn_A2008PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_A2008PlanMember_9e9abb0a-5df5-45b0-8074-229348d80b61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_167b7445-a7de-4479-850e-4a4d066e4866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:to="loc_us-gaap_AwardTypeAxis_167b7445-a7de-4479-850e-4a4d066e4866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167b7445-a7de-4479-850e-4a4d066e4866_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_167b7445-a7de-4479-850e-4a4d066e4866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_167b7445-a7de-4479-850e-4a4d066e4866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d42325-d18a-46b9-8792-e50c09f7c97c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_167b7445-a7de-4479-850e-4a4d066e4866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d42325-d18a-46b9-8792-e50c09f7c97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_be5ba7cb-7747-4984-9102-53e51984388b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d42325-d18a-46b9-8792-e50c09f7c97c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_be5ba7cb-7747-4984-9102-53e51984388b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67aff85a-7cc5-4612-ab32-e8d8644919b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67aff85a-7cc5-4612-ab32-e8d8644919b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8068cec-cef8-43f8-b790-adddf3554443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8068cec-cef8-43f8-b790-adddf3554443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02878e1e-1c87-4bf2-9b83-af865f8ee7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02878e1e-1c87-4bf2-9b83-af865f8ee7d5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da47afff-1407-4300-bc4d-736939bce079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da47afff-1407-4300-bc4d-736939bce079" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c4d5a368-69e1-438e-badd-328bbd1f302e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da47afff-1407-4300-bc4d-736939bce079" xlink:to="loc_us-gaap_AwardTypeAxis_c4d5a368-69e1-438e-badd-328bbd1f302e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4d5a368-69e1-438e-badd-328bbd1f302e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c4d5a368-69e1-438e-badd-328bbd1f302e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4d5a368-69e1-438e-badd-328bbd1f302e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd72cf5-d3a3-4913-b778-f4532be86839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c4d5a368-69e1-438e-badd-328bbd1f302e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd72cf5-d3a3-4913-b778-f4532be86839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00e05254-260d-4911-8613-4719f93e9214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd72cf5-d3a3-4913-b778-f4532be86839" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00e05254-260d-4911-8613-4719f93e9214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77aa6588-465a-4214-acf9-ff9e4f291a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77aa6588-465a-4214-acf9-ff9e4f291a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4083fcb-4393-4d09-8686-1408fd34511d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4083fcb-4393-4d09-8686-1408fd34511d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64c0a33b-5e17-497b-bee7-d87295f7e065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64c0a33b-5e17-497b-bee7-d87295f7e065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94f6d2fd-4ec5-48e8-82c3-13b518bd2bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94f6d2fd-4ec5-48e8-82c3-13b518bd2bda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4fbab6ea-3d78-4345-9707-142b0236626d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_27f8e989-5ea7-4a7d-8eb5-e29f36553933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_27f8e989-5ea7-4a7d-8eb5-e29f36553933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea72c9f5-ad67-4f9a-b1ce-841ec1a8e49a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea72c9f5-ad67-4f9a-b1ce-841ec1a8e49a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a11844c4-5e5d-46c7-bb0d-86af325e2374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a11844c4-5e5d-46c7-bb0d-86af325e2374" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_07ecf44a-e1f8-4ab6-adc3-0a6e99a41906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_07ecf44a-e1f8-4ab6-adc3-0a6e99a41906" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ba76c9c-4d32-4b36-a8eb-85ec78a72c35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd2f2e1-a050-440d-9ddf-6df1f505bde5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd2f2e1-a050-440d-9ddf-6df1f505bde5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_04b233ed-d475-4f7d-a87a-581b5bb49bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd2f2e1-a050-440d-9ddf-6df1f505bde5" xlink:to="loc_us-gaap_AwardTypeAxis_04b233ed-d475-4f7d-a87a-581b5bb49bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04b233ed-d475-4f7d-a87a-581b5bb49bee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_04b233ed-d475-4f7d-a87a-581b5bb49bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04b233ed-d475-4f7d-a87a-581b5bb49bee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861352b5-89fd-4404-9e5c-7c44e4aa16ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_04b233ed-d475-4f7d-a87a-581b5bb49bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861352b5-89fd-4404-9e5c-7c44e4aa16ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ff39cf48-ca31-4bf5-b483-d3c183d96bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861352b5-89fd-4404-9e5c-7c44e4aa16ae" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ff39cf48-ca31-4bf5-b483-d3c183d96bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3849455-8784-4579-8786-36225f6fdeec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3849455-8784-4579-8786-36225f6fdeec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbba9014-fed4-42a4-871f-8c81e716f3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbba9014-fed4-42a4-871f-8c81e716f3b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cbf1962d-0d41-4dd4-add8-228adf0f33a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cbf1962d-0d41-4dd4-add8-228adf0f33a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_04e5e49e-d9bb-4dd1-93df-46e47517946d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_04e5e49e-d9bb-4dd1-93df-46e47517946d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99c80d6f-0c55-4643-a001-32fb8f0aa45c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57ed1fb0-e807-444c-91bc-4ab840c1c5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57ed1fb0-e807-444c-91bc-4ab840c1c5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_af9a0728-398f-4ea1-85e8-0f5589e91ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_af9a0728-398f-4ea1-85e8-0f5589e91ceb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9d95c258-9583-4747-8622-a2974717f71c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9d95c258-9583-4747-8622-a2974717f71c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1dfdea26-3922-40b2-b543-7d775721c490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1dfdea26-3922-40b2-b543-7d775721c490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a4ab066-6a76-41e1-83f0-76cd8875e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a4ab066-6a76-41e1-83f0-76cd8875e9c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3262ea77-cfa0-4b16-8504-d204f8ba1f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3262ea77-cfa0-4b16-8504-d204f8ba1f86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f7d320ec-acfe-4b49-afd7-d70cbaa80e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f7d320ec-acfe-4b49-afd7-d70cbaa80e68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2874ee89-1079-417f-ab09-26993a945475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_29af2894-0d8a-4ac3-9c04-96d4de653cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_29af2894-0d8a-4ac3-9c04-96d4de653cb7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_23292776-b283-49f9-b8f3-5e1a12237ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_23292776-b283-49f9-b8f3-5e1a12237ee0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_abc9aa52-2ae9-4a5e-9837-0797015f0dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_abc9aa52-2ae9-4a5e-9837-0797015f0dbc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a267ced-fd99-40c8-9f54-48314b0db5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a267ced-fd99-40c8-9f54-48314b0db5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7215bc63-4071-4c7d-9965-0f5f65deaf24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7215bc63-4071-4c7d-9965-0f5f65deaf24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8f863e24-81e9-4f4b-bca4-c5e3501ef38c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8f863e24-81e9-4f4b-bca4-c5e3501ef38c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7c6676bc-ff6f-423d-ad74-896b3efaf21e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7c6676bc-ff6f-423d-ad74-896b3efaf21e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_54adc3e3-3033-409e-b1ce-2451511f56b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_54adc3e3-3033-409e-b1ce-2451511f56b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a782bed2-3241-4553-94c9-a95176e0f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a782bed2-3241-4553-94c9-a95176e0f1f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_47390050-3dbb-4b01-9f43-c89d68d2d26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_47390050-3dbb-4b01-9f43-c89d68d2d26c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5486a125-034d-4d92-acfa-71abe4dc590c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5486a125-034d-4d92-acfa-71abe4dc590c" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efaae5f1-be6c-44ea-9f1c-c49b257f794e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efaae5f1-be6c-44ea-9f1c-c49b257f794e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bef3598f-8baf-4048-8eb0-3a0348ca5aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efaae5f1-be6c-44ea-9f1c-c49b257f794e" xlink:to="loc_us-gaap_AwardTypeAxis_bef3598f-8baf-4048-8eb0-3a0348ca5aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bef3598f-8baf-4048-8eb0-3a0348ca5aaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bef3598f-8baf-4048-8eb0-3a0348ca5aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bef3598f-8baf-4048-8eb0-3a0348ca5aaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13468a27-2d20-4061-b849-06edb496bcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bef3598f-8baf-4048-8eb0-3a0348ca5aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13468a27-2d20-4061-b849-06edb496bcf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c4e5b5c-5f96-4953-9217-6ca49c3fc80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13468a27-2d20-4061-b849-06edb496bcf5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c4e5b5c-5f96-4953-9217-6ca49c3fc80b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99326d41-8a5f-491d-9ade-c2b823a5082c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99326d41-8a5f-491d-9ade-c2b823a5082c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_06c68624-68d8-431c-951c-8b16de84f857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_06c68624-68d8-431c-951c-8b16de84f857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7fed908-27a9-4e2a-a2e6-3d92edee8aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7fed908-27a9-4e2a-a2e6-3d92edee8aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fadd71b-fb67-4c30-86bb-7877570603e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fadd71b-fb67-4c30-86bb-7877570603e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8928e260-8967-4b61-855a-10014b035ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8928e260-8967-4b61-855a-10014b035ef7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f0b52ec4-6a54-4f70-b410-f398676f77f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_095066d6-14f1-47c8-a0dc-342faacdedcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f0b52ec4-6a54-4f70-b410-f398676f77f2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_095066d6-14f1-47c8-a0dc-342faacdedcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_095066d6-14f1-47c8-a0dc-342faacdedcd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c11b03b7-d935-4885-b6a3-2ed1f72cda4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c11b03b7-d935-4885-b6a3-2ed1f72cda4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5d01d7b0-8a9f-4f5d-9a99-4752ab7b4fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5d01d7b0-8a9f-4f5d-9a99-4752ab7b4fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ce0f08a-4eef-462e-844d-5c2545911977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f0b52ec4-6a54-4f70-b410-f398676f77f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ce0f08a-4eef-462e-844d-5c2545911977" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_74ebd7e6-9624-4800-8a06-de4491c24a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4241426-d090-4386-a266-8e2902670336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_74ebd7e6-9624-4800-8a06-de4491c24a7c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4241426-d090-4386-a266-8e2902670336" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4801b01f-e14d-46d1-af8d-774c2687835f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4241426-d090-4386-a266-8e2902670336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4801b01f-e14d-46d1-af8d-774c2687835f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4801b01f-e14d-46d1-af8d-774c2687835f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4801b01f-e14d-46d1-af8d-774c2687835f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4801b01f-e14d-46d1-af8d-774c2687835f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4801b01f-e14d-46d1-af8d-774c2687835f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_73332219-2ca6-431c-92c2-b97b2dede52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_73332219-2ca6-431c-92c2-b97b2dede52c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_083ad068-8c99-4e41-952c-4140c9908c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_083ad068-8c99-4e41-952c-4140c9908c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4235b6ef-1e6c-4640-a7a9-461cda3e92c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4235b6ef-1e6c-4640-a7a9-461cda3e92c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockWarrantsMember_5da54890-a297-4a32-8dff-04e40e135e7b" xlink:href="vrdn-20240930.xsd#vrdn_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_vrdn_CommonStockWarrantsMember_5da54890-a297-4a32-8dff-04e40e135e7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3baa0f44-8b73-4954-ad2d-32ef26a8091b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3baa0f44-8b73-4954-ad2d-32ef26a8091b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_104c84c9-4643-467b-89a0-c9515022c74b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_74ebd7e6-9624-4800-8a06-de4491c24a7c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_104c84c9-4643-467b-89a0-c9515022c74b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vrdn-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:bdb425b1-8ce6-48d2-af7c-3659fd6d6265,g:f76e6810-2604-4ff8-8a2b-997429168b4a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_a41a1b3d-3f4e-4ace-87d4-acb9ce861886_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock upon the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e10081b3-150d-498f-9ff5-215842118626_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_17950ddf-f022-4649-b19c-725fa221ae5e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or expected to vest (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4e9c6b79-c2a8-4b6f-acc1-a5ae640241e6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9111b714-3982-4869-b2ce-32adc250e9a0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5e46f6a6-26e4-48eb-ab1a-3f86135a3c3d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_96e63df0-545a-484f-a958-2001d6d80b17_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_794c3609-d014-4f65-a3a9-89673d9c77af_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9043ade4-cbf4-4bab-b396-e2462729c875_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Lease Payments under Noncancelable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFourthTranche_a70565ee-1a00-4f2e-a341-d71b724c4b28_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount, fourth tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFourthTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Fourth Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFourthTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Fourth Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountFourthTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountFourthTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2024PublicOfferingMember_0247fcc8-befe-43c0-a1d8-ea718017a393_terseLabel_en-US" xlink:label="lab_vrdn_A2024PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Public Offering</link:label>
    <link:label id="lab_vrdn_A2024PublicOfferingMember_label_en-US" xlink:label="lab_vrdn_A2024PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Public Offering [Member]</link:label>
    <link:label id="lab_vrdn_A2024PublicOfferingMember_documentation_en-US" xlink:label="lab_vrdn_A2024PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2024PublicOfferingMember" xlink:href="vrdn-20240930.xsd#vrdn_A2024PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2024PublicOfferingMember" xlink:to="lab_vrdn_A2024PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d2833717-f627-4848-9fc7-afea29d716ff_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_55ffd9e9-1467-4666-883b-ec9a32be1d8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2eee96ba-4005-4e18-bb79-428d98b2df76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleOfStockWeightedAverageSharePrice_910329e0-3a25-44be-bad9-de770b2b3bb3_terseLabel_en-US" xlink:label="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average share price (in dollars per share)</link:label>
    <link:label id="lab_vrdn_SaleOfStockWeightedAverageSharePrice_label_en-US" xlink:label="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Weighted Average Share Price</link:label>
    <link:label id="lab_vrdn_SaleOfStockWeightedAverageSharePrice_documentation_en-US" xlink:label="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Weighted Average Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:href="vrdn-20240930.xsd#vrdn_SaleOfStockWeightedAverageSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:to="lab_vrdn_SaleOfStockWeightedAverageSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_adab9059-18a7-4682-ac21-20f231976338_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial milestone payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Commercial Milestone Payment, Intellectual Property Rights Development, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Commercial Milestone Payment, Intellectual Property Rights Development, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:to="lab_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9f3481a7-efff-45c8-a300-c002e66dc9f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon the conversion of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_FairmountFundsManagementMember_091516bf-f3dd-46a2-be0c-d9f1183d27f8_terseLabel_en-US" xlink:label="lab_vrdn_FairmountFundsManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fairmount Funds Management</link:label>
    <link:label id="lab_vrdn_FairmountFundsManagementMember_label_en-US" xlink:label="lab_vrdn_FairmountFundsManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fairmount Funds Management [Member]</link:label>
    <link:label id="lab_vrdn_FairmountFundsManagementMember_documentation_en-US" xlink:label="lab_vrdn_FairmountFundsManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fairmount Funds Management</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FairmountFundsManagementMember" xlink:href="vrdn-20240930.xsd#vrdn_FairmountFundsManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_FairmountFundsManagementMember" xlink:to="lab_vrdn_FairmountFundsManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_721b4eb2-ae94-43dc-8a95-6dc2b14fe18c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6df03914-4dd6-4255-8721-370cfb73472d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationRevenueMember_75cd21dc-84cd-49fe-87b4-c690a0ff251b_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:label id="lab_vrdn_CollaborationRevenueMember_label_en-US" xlink:label="lab_vrdn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_vrdn_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_vrdn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationRevenueMember" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationRevenueMember" xlink:to="lab_vrdn_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtCovenantPeriodTwoMember_8cfe9bb1-1beb-47c5-a43b-d50897e02a65_terseLabel_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 1, 2024 through December 15, 2024</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodTwoMember_label_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Period Two [Member]</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodTwoMember_documentation_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodTwoMember" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtCovenantPeriodTwoMember" xlink:to="lab_vrdn_DebtCovenantPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_a3da227d-36d8-4b88-aa37-41480c603ef1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock upon the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ZenasBioPharmaMember_ddf00e1e-f532-43d4-9fc9-3267e20aec76_terseLabel_en-US" xlink:label="lab_vrdn_ZenasBioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zenas BioPharma</link:label>
    <link:label id="lab_vrdn_ZenasBioPharmaMember_label_en-US" xlink:label="lab_vrdn_ZenasBioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zenas BioPharma [Member]</link:label>
    <link:label id="lab_vrdn_ZenasBioPharmaMember_documentation_en-US" xlink:label="lab_vrdn_ZenasBioPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zenas BioPharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ZenasBioPharmaMember" xlink:href="vrdn-20240930.xsd#vrdn_ZenasBioPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ZenasBioPharmaMember" xlink:to="lab_vrdn_ZenasBioPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c28c508e-a79f-47b4-8763-e094c0992522_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f1a5c54c-452e-4d1a-9855-b3254fc2a562_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3e33c9dd-8712-47af-8afe-053b3b8576b6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_OperatingLeaseLiabilityCurrentDerecognized_01c9e350-6549-47f0-aceb-6d4d314385bf_terseLabel_en-US" xlink:label="lab_vrdn_OperatingLeaseLiabilityCurrentDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability derecognized</link:label>
    <link:label id="lab_vrdn_OperatingLeaseLiabilityCurrentDerecognized_label_en-US" xlink:label="lab_vrdn_OperatingLeaseLiabilityCurrentDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current Derecognized</link:label>
    <link:label id="lab_vrdn_OperatingLeaseLiabilityCurrentDerecognized_documentation_en-US" xlink:label="lab_vrdn_OperatingLeaseLiabilityCurrentDerecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseLiabilityCurrentDerecognized" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseLiabilityCurrentDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_OperatingLeaseLiabilityCurrentDerecognized" xlink:to="lab_vrdn_OperatingLeaseLiabilityCurrentDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_44b8bb57-deea-4252-adda-5f32734cc21a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_70dab403-bf97-4e3f-afe3-03e2ded33bdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability, noncurrent, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7a679c33-78d6-4995-9883-0a7c53c9c73b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_80aeadba-c771-4aaa-be5a-ad0fe4d8aa6f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term lease obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ea28285f-36ec-4ba7-b4ab-9adc5db50c50_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_4a034e18-ac32-45ce-b3ed-f1dfeea1c0e3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f317fa08-2080-491f-974d-b8646a30680a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue - related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5ddf542b-bfdc-4402-b536-813cda5a3593_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_bc72e68e-3c68-4721-9cfb-5fdfd970da2f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d744cb11-8747-4397-959d-2a96431ca3bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_84906ba7-b71b-4e97-a26b-cbcf33a4b03a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_cfacf2a8-e0ac-40d1-94dc-499e1ab68997_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a9162e09-ec56-4a84-9e9d-7e4bfd4e385f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d3a78c10-a855-4cd5-8891-58c7ef06893b_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ab6e3b60-9cf7-4c41-8fa8-f20f0ba31b26_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_da7d08ed-4b9b-4e25-af37-7aeee5917632_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1a4e3ee0-abf6-4714-8d11-226be0287f56_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_52e69af9-fcc5-4948-8539-2c42a954b056_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_GoingConcernPolicyPolicyTextBlock_6bdf2757-881a-42b0-9375-f17da54350e7_terseLabel_en-US" xlink:label="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_vrdn_GoingConcernPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern Policy [Policy Text Block]</link:label>
    <link:label id="lab_vrdn_GoingConcernPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:href="vrdn-20240930.xsd#vrdn_GoingConcernPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:to="lab_vrdn_GoingConcernPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a3347eb0-d39c-4bb6-aa76-43af1d9cd238_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_2c09fd47-3f3b-45e0-bfc6-ec91e770cd3f_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_3f40acbb-f458-4756-8b2a-88623fdd167d_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_93e235e6-6066-42f3-9b8a-0ab2d8f9b8a7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_982db25e-d67e-46c0-af3a-321d8c4e1572_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_15f655ef-7dfd-4f68-a486-1cc0a11a417d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_10e7b397-4fb4-4f80-9749-b15c11a1bfa2_terseLabel_en-US" xlink:label="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued outsourced clinical trials and preclinical studies</link:label>
    <link:label id="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_label_en-US" xlink:label="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Outsourcing Clinical and Pre-clinical Studies</link:label>
    <link:label id="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_documentation_en-US" xlink:label="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Outsourcing Clinical and Pre-clinical Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:href="vrdn-20240930.xsd#vrdn_AccruedOutsourcingClinicalandPreclinicalStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:to="lab_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5306f3fb-ff54-4b11-930e-05537873c6b6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d0e91fe0-73b4-4d74-85d3-d4e122fc0a79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_045c581c-79d8-44bf-a30c-4c3f8b8bbb3c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c939d51f-b563-44e4-959e-1f636c9c11b8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c362298e-cfdb-4322-bd95-2300d88ab124_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b4397e1a-6282-4cac-b75b-8d7d8eabe7fb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in share)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_59990f60-7ff6-466e-b5f4-e6eb30e95cca_terseLabel_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercises of warrants</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_label_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Value</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_documentation_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:href="vrdn-20240930.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:to="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ed2b0422-a98f-4a19-ab0e-9f6f58132fa8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtCovenantPeriodDomain_25a342f5-2aa9-4f40-8674-0677dbd37a9c_terseLabel_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Domain]</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodDomain_label_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Domain]</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodDomain_documentation_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodDomain" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtCovenantPeriodDomain" xlink:to="lab_vrdn_DebtCovenantPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_eab1f030-424f-4ad6-a73a-bc3d73e02214_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_cfdc5341-3584-46ee-8a92-bbc905cc8f9e_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16d9a7be-ffaa-415f-ad75-58cac5c46c57_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_6f02946b-fccb-49bc-9a28-3a6907456d1a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fe92b536-df28-4ace-a191-e530200a3d89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized (loss) gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ed628468-ed15-4f01-9ae3-ac1250031cc7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9d12b223-5033-400d-bccf-5619593b6cf0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_40488e39-4e03-43cf-8bf8-f42d3ce98fdc_terseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_458ad65b-846e-47c9-9208-5362ebb4a2bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_263bad89-29b6-4bfe-93f6-7a20445a4ca5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1e87ea36-1415-4dc5-bb20-aac1dde152fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_93d33f74-bd2f-4834-8397-e77d89dedbca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9a9e67b5-a23b-45c6-a9dc-22275426bc7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other (including related party of $3,725 and $374 as of September&#160;30, 2024 and December&#160;31, 2023, respectively)</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b7a81739-2777-442d-a330-16ffe9bc8b49_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_52e01953-7435-45da-ae0d-40ba62d67dd5_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bfcdcb15-5393-4602-9c4b-7968b684deb0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_e3f340de-c840-42c9-ad98-bcb1c064a2c7_verboseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of underlying shares (in shares)</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:to="lab_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e289eaf7-16e5-4918-8255-2272c449ac2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Vesting Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_77a84f53-ad07-48e4-b4e6-603140e405f7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_16b127a5-bfb5-4bda-b90d-573489bc6d79_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_6f0ba8e9-b580-47c5-bf2c-14a45a7db65a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6499328-44e5-4bda-9495-bcaaad5714bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_837af263-bd1b-426d-8410-9a65ac78d112_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d881201-767f-4ae4-b0d5-fcd957350244_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_08bac917-50a6-4c41-8e78-2b7008dcd9af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion and amortization of premiums and discounts on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ParagonTherapeuticsMember_1d0e8a02-5c11-437e-967c-ab0757f4c200_terseLabel_en-US" xlink:label="lab_vrdn_ParagonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paragon Therapeutics</link:label>
    <link:label id="lab_vrdn_ParagonTherapeuticsMember_label_en-US" xlink:label="lab_vrdn_ParagonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paragon Therapeutics [Member]</link:label>
    <link:label id="lab_vrdn_ParagonTherapeuticsMember_documentation_en-US" xlink:label="lab_vrdn_ParagonTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Paragon Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ParagonTherapeuticsMember" xlink:href="vrdn-20240930.xsd#vrdn_ParagonTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ParagonTherapeuticsMember" xlink:to="lab_vrdn_ParagonTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7cff1fd3-e125-4a3d-ad30-7d41dd53d617_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassofWarrantorRightActivityRollForward_61e63b02-2011-4d89-b92e-7e26b08c5b4c_terseLabel_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightActivityRollForward_label_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Activity [Roll Forward]</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightActivityRollForward_documentation_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Activity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightActivityRollForward" xlink:href="vrdn-20240930.xsd#vrdn_ClassofWarrantorRightActivityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward" xlink:to="lab_vrdn_ClassofWarrantorRightActivityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_70fe0955-4e3b-4170-8b61-f12ebb7c8d07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_99dfe5bc-42bc-4291-9d28-1b16ab00ccec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsMember_0b799a0c-9a63-4f11-abca-e5258aff7b0b_terseLabel_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsMember_label_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants [Member]</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsMember_documentation_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsMember" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember" xlink:to="lab_vrdn_EquityclassifiedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9c344ca0-2fd3-42cf-a275-b43b0fb193a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid common stock issuance costs included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d0b03d86-b928-4e86-bee4-54aec59e5535_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AccruedLegalFeesCurrent_1d9a423d-a746-4a46-b173-3151bf5e4df7_terseLabel_en-US" xlink:label="lab_vrdn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal fees and expenses</link:label>
    <link:label id="lab_vrdn_AccruedLegalFeesCurrent_label_en-US" xlink:label="lab_vrdn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:label id="lab_vrdn_AccruedLegalFeesCurrent_documentation_en-US" xlink:label="lab_vrdn_AccruedLegalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLegalFeesCurrent" xlink:href="vrdn-20240930.xsd#vrdn_AccruedLegalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AccruedLegalFeesCurrent" xlink:to="lab_vrdn_AccruedLegalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2bc4eb11-4d9c-4943-a7a2-9600270db31d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1b95e13d-023a-4349-b4f5-81983b71408c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_5a5210cb-feb9-4c5f-8410-80772c702a75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_729055d7-ad84-4838-b136-9f87ec737029_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8e4ed0e9-2d8f-4dd0-b476-d501319499d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_726544b0-1123-4c08-9c3a-7a8d07c0617b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8b6e88e8-0645-475d-ae5e-1dae2f659a76_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_332456ef-7643-415d-9e40-b0b644c226b1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_252e7d0f-66fb-4f9f-b2e4-b82d674eb37c_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c7ec0c1d-bec2-41dc-93cb-6352adafc33a_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c0476a73-f656-4c7a-a7dd-b2a49610b7e2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fb06c6e6-be51-4a5c-aafc-21ddc9a1a095_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_71664bd1-a050-4bee-aff1-288bf8e94d93_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_013bff37-63c1-48c0-a3ab-ec916c31d305_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentInterestRateMaximum_07daa26f-194c-4303-9ca7-6701083627f6_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum interest rate</link:label>
    <link:label id="lab_vrdn_DebtInstrumentInterestRateMaximum_label_en-US" xlink:label="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Maximum</link:label>
    <link:label id="lab_vrdn_DebtInstrumentInterestRateMaximum_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentInterestRateMaximum" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentInterestRateMaximum" xlink:to="lab_vrdn_DebtInstrumentInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_19933f74-275b-42e6-ba99-3b629f2455e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_da39349c-8962-4b12-b402-20ec28aaaa4f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1fa1dcb7-ce80-4445-8f1f-9969f41668ed_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9f51fec2-05aa-48c9-b2c0-b54fbb27a7f2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6060b2b3-41b1-499a-a070-58a51a52538b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_19c9dfa3-68db-40f8-8b51-490358b18d07_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b271d169-ff59-442f-bc0b-2f3e56c9fd06_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7f9f209b-84b9-42fb-a141-21ca3f5b5fc2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt Securities, Short-term Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b9853d0-5d2e-467d-b913-59b1ec49b9a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1cad066-36bf-4458-aa81-4ad428916d97_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_98ea2323-9c6e-42fb-bf5d-ee7062f87663_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of Series B preferred stock, pursuant to September 2024 Public Offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8cc2e4af-417f-474a-916c-5159ee8368f6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by each warrant or right (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_19f66005-76a0-4347-a3e3-b31ce56549f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, short-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_73b7f4c7-40fa-459b-a5d9-1ebba9640d58_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtCovenantPeriodAxis_f4ea1166-0ab8-4c37-834b-fac3bc37e617_terseLabel_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Axis]</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodAxis_label_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Period [Axis]</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodAxis_documentation_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodAxis" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtCovenantPeriodAxis" xlink:to="lab_vrdn_DebtCovenantPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_f1c7dc92-1b62-4fe3-9a7d-af770fb54430_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9fdc81d5-f1a0-429b-ba43-06b2d57d3f21_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1b9b1761-5289-4521-829e-1291b97f461f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_bc0c86b1-882b-459d-9ae9-4bc88719d80b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d81b9f60-7143-461d-a8a3-477418f1fb7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ab20ffa7-14bd-403f-af65-ae94f2aa391f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_ab83c5f5-b422-40f1-9ac7-ccd390a321b6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d9df55bd-f1ce-41e2-ad1d-5e257c8ae03b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_401195dd-a7f7-4b63-941c-ae993a2644ac_terseLabel_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued February 2020</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_label_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants, Issued February 2020 [Member]</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_documentation_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants, Issued February 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:to="lab_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_b68a1b95-c43a-4835-bb01-b904ee5729df_terseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial ownership</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Conversion, Percentage Of Ownership</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Conversion, Percentage Of Ownership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:to="lab_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6346a25b-f53e-4e43-856c-0a012cc2b32b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_d6c59582-3df0-4b3e-8f91-e17fa2e34c4b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7c3f1d4e-cb94-4c7e-aded-e3912ce3ba3a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b8528fa1-f83e-471f-a254-b95962b5149d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8c9af675-8393-41aa-9897-058b18bbe7df_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentOtherExpenses_88aa224c-f769-4977-8180-823a1b7ef2bc_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_vrdn_DebtInstrumentOtherExpenses_label_en-US" xlink:label="lab_vrdn_DebtInstrumentOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Other Expenses</link:label>
    <link:label id="lab_vrdn_DebtInstrumentOtherExpenses_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentOtherExpenses" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentOtherExpenses" xlink:to="lab_vrdn_DebtInstrumentOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted_fdf85657-59f8-4ba6-b061-c5f43846276d_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, value of shares to be issued for rights granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Value Of Shares To Be Issued For Rights Granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Value Of Shares To Be Issued For Rights Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" xlink:to="lab_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c79331f8-74f4-463f-86f1-0659590539dc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_6e0a4af4-839d-43cb-9410-5140bc43e0f1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_fa0bffa6-ef06-40a7-bf58-0562736ceded_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_ff30004c-c666-4d44-8473-f8924b73bb49_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_0b9727b3-988e-4df0-bc84-191ea43cd9bd_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest and other expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_a040af3b-3cc0-4296-831c-95a628517b9e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c2d36799-6561-4f96-a27b-d262dd13b95a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ImmunoGenIncMember_366941bf-efd8-4190-bfb8-de823d692956_terseLabel_en-US" xlink:label="lab_vrdn_ImmunoGenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ImmunoGen, Inc</link:label>
    <link:label id="lab_vrdn_ImmunoGenIncMember_label_en-US" xlink:label="lab_vrdn_ImmunoGenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ImmunoGen, Inc [Member]</link:label>
    <link:label id="lab_vrdn_ImmunoGenIncMember_documentation_en-US" xlink:label="lab_vrdn_ImmunoGenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ImmunoGen, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ImmunoGenIncMember" xlink:href="vrdn-20240930.xsd#vrdn_ImmunoGenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ImmunoGenIncMember" xlink:to="lab_vrdn_ImmunoGenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e7cd535d-1c5c-4a88-b9d4-588b1db1168a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f182b30e-e74e-4d8f-bd66-887040ad1492_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_5f67ef3c-c538-40b1-a983-8703fd45bceb_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_da5043ba-e6d5-4e87-b746-f18940206d76_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_351bdfd0-9647-407c-939e-2a64612eab27_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_05bd261c-8fd2-448f-b7b2-98d2863d6699_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_18dcb9d7-353e-475b-a6a0-5838458f3b61_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7f1d533c-823b-4e0e-9eb7-d8680522b649_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5573ffe6-889e-4d1d-9ea1-9f3a857b6672_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_79fd3f48-748c-4bfd-9760-52e7bf736ebd_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_9a1191e3-58a2-41dc-92d0-4acb3d85a428_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_565ab840-afc9-45cb-b3c8-d1ba3b1e1228_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_34a72ba6-1039-40fe-9817-c8e4c6a11dca_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6f0dab4e-cf2b-4590-a3b1-adcd35c42601_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_88512a15-031c-46c5-8477-076aefb786ed_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c289fb58-69dc-4fa6-bae6-f965d65d1af5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c990f437-196a-4f6e-9590-f4f889a504ae_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_OperatingLeaseRightOfUseAssetDerecognized_ec430619-497e-4e12-8b60-8dbb041699c9_terseLabel_en-US" xlink:label="lab_vrdn_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset derecognized</link:label>
    <link:label id="lab_vrdn_OperatingLeaseRightOfUseAssetDerecognized_label_en-US" xlink:label="lab_vrdn_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset Derecognized</link:label>
    <link:label id="lab_vrdn_OperatingLeaseRightOfUseAssetDerecognized_documentation_en-US" xlink:label="lab_vrdn_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseRightOfUseAssetDerecognized" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_OperatingLeaseRightOfUseAssetDerecognized" xlink:to="lab_vrdn_OperatingLeaseRightOfUseAssetDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_123aca11-0142-44b8-8e17-15b361efb429_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11f82e5f-73be-49fd-9d7a-5305bd1909bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_37181ab8-3ac9-40c8-89ef-fff405f5d42c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8f3c4cf4-7cf5-400a-bd16-30360b4140c6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b3a26be7-e13f-4a4f-868f-e17b63cf63a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_08f9536b-ee69-4acd-852f-1f4aebf8060e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9a0ee04c-77ac-41eb-b309-966e7cadca36_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_09d6e3d3-81a4-4fd2-a854-58ac86b0696a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Assumptions for Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments_bde94e1a-56af-4564-9336-32037f5d0cd3_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future developments milestone payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Future Developments Milestone Payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Future Developments Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments" xlink:to="lab_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4fef0bce-878a-4162-900f-d36d4adcf5b6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f98c355a-a859-4533-bd28-d6ebb01d8804_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_aabd62f7-8f7e-4084-8457-9230146b7126_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7b85420e-dfc5-4a23-8e51-71dd64891513_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_bc7fc21d-316b-44b0-9319-0453bddb441e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_fd616007-2132-4bb1-a66e-d87405a1a2ec_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bbabab0-b8b2-48fc-9e01-0802319f3621_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ViridianMergerMember_5cc17ce5-ad0b-4927-ac13-6dd6262e9daa_terseLabel_en-US" xlink:label="lab_vrdn_ViridianMergerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Viridian Merger</link:label>
    <link:label id="lab_vrdn_ViridianMergerMember_label_en-US" xlink:label="lab_vrdn_ViridianMergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Viridian Merger [Member]</link:label>
    <link:label id="lab_vrdn_ViridianMergerMember_documentation_en-US" xlink:label="lab_vrdn_ViridianMergerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Viridian Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ViridianMergerMember" xlink:href="vrdn-20240930.xsd#vrdn_ViridianMergerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ViridianMergerMember" xlink:to="lab_vrdn_ViridianMergerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_349d0f38-e6d7-4ee6-935f-d5a44dd76085_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b305c16-273b-4242-8a8b-debbdbe4aded_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for exercises of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_075ccaba-66df-4e2e-9712-f34278c6db9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_b48e9741-c76c-4fdd-838b-34adc3bd501b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0ecab059-04b9-4646-92c6-007d74e224e1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_32caf4fc-95d4-4687-ba4b-d450a2413ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_e5b87286-5093-4a7b-a48f-b45d59d5d1ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue - related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_4bf87e7a-a21d-4c41-8c99-91355e3320af_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential royalty payments</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Royalty Payments, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Royalty Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:to="lab_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_556aa1a0-9f75-4aa6-9ab0-f307f2db74f3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e449853f-6c4e-4617-9ddd-9a2e0fc96b96_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements - To Be Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_feb86934-31dd-4cf3-9f35-d507214b76ee_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_f2d4faa9-fe7c-47f7-8049-78691c2f25e1_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_38989a33-2746-47e2-af66-698d7ea1b8a1_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock (as converted to shares of common stock)</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9971060a-7021-4a95-9d39-3df949c2850f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_c1d0d579-c002-4e4c-8c0a-c6f802c6432a_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_bf098f82-de2f-4167-94af-895a28550900_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_55333a2b-5254-4abc-bf39-08f3d8a034df_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_85ab5511-be22-4d88-801d-a54fdee452b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense relating to operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_526d8c07-a23a-4520-b09f-25c47a4b0b6c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c63dc1b9-4332-4637-844f-24a53064b877_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue - related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8c5fcc83-1ebb-4526-9960-c24d71210135_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_65776289-6b73-4b9d-ba85-6dbe0fb350ca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (Weighted Average Remaining Contractual Term)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_84a96491-6fb6-48db-904a-a823710bd520_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_6b74c6fa-b9b6-4797-a2cb-352afdad0bd7_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_596b2bd4-66ed-4edf-a6f8-e65d08f4d120_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ba207b9e-4be1-4651-85b3-6695c3eee8a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_324b9bb7-e55c-4271-8e58-0b4ca4813346_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountThirdTranche_d4bcffa0-2963-45d3-96ed-a8fe1e6a5395_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount, third tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountThirdTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Third Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountThirdTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Third Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountThirdTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountThirdTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fec58f75-15eb-4bf5-99f9-258a6e7bb285_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9c366256-de36-4959-97f6-f899df94db31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_40ef846f-4e81-4636-8800-3aa2786fe103_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e4fd45f0-a88a-4794-a1d2-92d66cf67530_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b6baf327-b162-4f1c-9de1-32689b7bdcf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Vesting Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AtthemarketOfferingMember_30d354a7-0a0f-4907-b18e-524aff3da926_terseLabel_en-US" xlink:label="lab_vrdn_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_vrdn_AtthemarketOfferingMember_label_en-US" xlink:label="lab_vrdn_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:label id="lab_vrdn_AtthemarketOfferingMember_documentation_en-US" xlink:label="lab_vrdn_AtthemarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember" xlink:href="vrdn-20240930.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AtthemarketOfferingMember" xlink:to="lab_vrdn_AtthemarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_757988d9-3211-4ca1-bd3c-e74a1fa2d030_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4ffcd96c-057e-4399-b323-ab7002d04a9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b3342f0a-d0a6-49d8-876c-3923dbb3d4db_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SeriesBPreferredStockConversionMember_90f459ee-53cc-48e2-ace2-b3478e14e3af_terseLabel_en-US" xlink:label="lab_vrdn_SeriesBPreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock Conversion</link:label>
    <link:label id="lab_vrdn_SeriesBPreferredStockConversionMember_label_en-US" xlink:label="lab_vrdn_SeriesBPreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock Conversion [Member]</link:label>
    <link:label id="lab_vrdn_SeriesBPreferredStockConversionMember_documentation_en-US" xlink:label="lab_vrdn_SeriesBPreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SeriesBPreferredStockConversionMember" xlink:href="vrdn-20240930.xsd#vrdn_SeriesBPreferredStockConversionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SeriesBPreferredStockConversionMember" xlink:to="lab_vrdn_SeriesBPreferredStockConversionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_0027016a-a208-4700-a238-1c8079f19b03_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d551ec77-9873-4f78-a50b-456b374e1d50_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ac0ab574-77de-472b-8183-dbcd243e5060_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining weighted-average period for stock options and RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_44f0b2ab-0e4b-4e9f-8dac-5a4ae7c33980_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementMilestonePayment_193788ff-dcb5-480d-8c59-d0fc20797b4f_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, milestone payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementMilestonePayment_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementMilestonePayment_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementMilestonePayment" xlink:to="lab_vrdn_CollaborativeArrangementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_dfa4a904-4231-44a8-937d-5b981472fc6a_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">International corporate bond holdings</link:label>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_8fa03eaf-e675-4c34-8162-2205e5dc331b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International corporate bond holdings</link:label>
    <link:label id="lab_us-gaap_ForeignCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Corporate, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_770d7637-556a-437a-8c51-2046cea400fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bec57983-4873-4cfa-85ff-f79213a471df_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3a317ea9-172f-475f-8faa-b6c56670a204_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares authorized for plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_959f8303-02d5-45a1-b10f-9971feccec48_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development (including related party expenses of $7,725 and $10,937 during the three and nine months ended September 30, 2024, respectively, and $1,099 and $6,521 during the three and nine months ended September 30, 2023, respectively.)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d2f18f48-c302-43c8-a0e0-12a4246f76dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development - related party expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_49268326-f299-41f5-981d-b6ddfdc7a604_netLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a386c233-ecd4-4772-a130-ee7c045b89ba_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_dac3cb6f-5a0d-4279-afb2-2a56fbc96693_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee compensation and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e887f82-9e83-4824-a5c6-fd281113aacd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ec802692-7d6f-4e1e-ab99-8ea0d04fe6a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_11dee16a-e493-45d8-8b79-fde48dc6b29f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ff6d6887-d32b-4c91-8c6e-00742fe9e905_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51e24114-cae7-4e58-a5b8-fa03f35418d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementInitialPayment_ce732ed0-c233-4347-9cf7-61647eccf943_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementInitialPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration arrangement, initial payment</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementInitialPayment_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementInitialPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Initial Payment</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementInitialPayment_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementInitialPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Initial Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementInitialPayment" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementInitialPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementInitialPayment" xlink:to="lab_vrdn_CollaborationArrangementInitialPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1e1c8319-3574-4f8f-9698-b8817f728267_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Principal Payments of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_c03ecd77-c287-414b-b8b3-87bc4fb7c3e5_terseLabel_en-US" xlink:label="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued April 2017</link:label>
    <link:label id="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_label_en-US" xlink:label="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability-Classified Warrants, Issued April 2017 [Member]</link:label>
    <link:label id="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_documentation_en-US" xlink:label="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability-Classified Warrants, Issued April 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:href="vrdn-20240930.xsd#vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:to="lab_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a6cbb44d-b85e-44f5-a0c2-1610972a5dbb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a67bb744-7ad3-4114-977c-4b29e761634f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_788a5659-ae0e-47e6-8701-4a6da24f72d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_df977892-627a-4afa-a6f4-764c2b0379ff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod_48b4124c-ea2f-477c-982b-70ad0ddef5d5_negatedTerseLabel_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod_label_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised in Period</link:label>
    <link:label id="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod_documentation_en-US" xlink:label="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:to="lab_vrdn_ClassOfWarrantOrRightExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7c9ee202-63ab-49b7-8fa3-791203778c23_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d4f47414-0601-450a-a5a3-c5a056f0b524_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_39e19811-0a64-4122-b097-95da3194fe7c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_33a7cb17-3561-4440-8843-cbd67bf71a8e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b9a887dd-9b6b-488a-a6c5-d0e2f595f8f9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1323f59c-f479-46a0-bb40-99ca07f2a160_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_badb62a3-b0da-4692-aa6d-3a5262019b0e_terseLabel_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:href="vrdn-20240930.xsd#vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:to="lab_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d550ea83-3e0c-40ec-a860-4d6aa251dcdb_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_1d747bb5-043f-4083-aa2b-faf8047e74b9_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d222525a-4493-4d8f-8284-331065cea7e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c3e70914-5424-48da-8baa-677396b39710_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cbf88b07-7734-4208-bf4d-1319796d4dcb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_07608fe4-fc68-408f-a22d-31bb8555b3ff_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a3d7883a-4145-4190-a577-6a5edeb2b369_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested or expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_835f8f38-0fcd-4702-b24f-199dd3e2322a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, term (less than)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_604cb55b-88a7-4591-b870-1508420bd494_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue - related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a55fa93-5787-4343-a72b-698b04d43ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec125c60-d64f-4420-9b43-bbf09619cf84_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d14275e-00ac-4489-8cd0-0fc8be84db95_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_78d00aef-fa16-4365-8d99-35049c54f530_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dfc60f5f-be97-4573-b335-709af7cc19b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a3ea3ee-2069-4832-9c8b-4ae68755fa41_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b325c4b8-d3a9-410a-91ff-893e8bdfdb1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_97e15fd1-94d6-44d3-94cc-420846d97e97_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Balances by Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2008PlanMember_838451e5-c554-493c-b9b4-340e2d393c2d_terseLabel_en-US" xlink:label="lab_vrdn_A2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2008 Plan</link:label>
    <link:label id="lab_vrdn_A2008PlanMember_label_en-US" xlink:label="lab_vrdn_A2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2008 Plan [Member]</link:label>
    <link:label id="lab_vrdn_A2008PlanMember_documentation_en-US" xlink:label="lab_vrdn_A2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2008 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2008PlanMember" xlink:href="vrdn-20240930.xsd#vrdn_A2008PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2008PlanMember" xlink:to="lab_vrdn_A2008PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9591f9d0-6eab-48fe-99e1-2c9e54cf6765_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross term loan proceeds</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e5bfaa67-3cb7-44b4-831e-86ac9fa3b9ce_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtCovenantPeriodOneMember_40460ee8-59af-415a-a22c-d89592ef8b58_terseLabel_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Through December 15, 2023</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodOneMember_label_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Covenant Period One [Member]</link:label>
    <link:label id="lab_vrdn_DebtCovenantPeriodOneMember_documentation_en-US" xlink:label="lab_vrdn_DebtCovenantPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Covenant Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodOneMember" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtCovenantPeriodOneMember" xlink:to="lab_vrdn_DebtCovenantPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_185736ee-5a2a-4e3a-80c6-0339ce915fee_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6a599cc1-2dd7-4723-9829-df220647bd6a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9a2a6b7b-4b3d-48a2-a98d-bbbb2510e1cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_FormerExecutiveOfficersMember_b2cfb135-8f7d-4cf3-9313-c0fbdeb2d377_terseLabel_en-US" xlink:label="lab_vrdn_FormerExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Executive Officers</link:label>
    <link:label id="lab_vrdn_FormerExecutiveOfficersMember_label_en-US" xlink:label="lab_vrdn_FormerExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Executive Officers [Member]</link:label>
    <link:label id="lab_vrdn_FormerExecutiveOfficersMember_documentation_en-US" xlink:label="lab_vrdn_FormerExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Executive Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FormerExecutiveOfficersMember" xlink:href="vrdn-20240930.xsd#vrdn_FormerExecutiveOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_FormerExecutiveOfficersMember" xlink:to="lab_vrdn_FormerExecutiveOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_26d3669c-12b8-4a75-a7de-0b676e923375_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5945a958-9af0-4c3b-99fe-f59fe936ad95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFacilityFee_7ef3bcd6-12b2-4d74-ac24-67b3ecc0ecf2_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFacilityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lenders facility fee</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFacilityFee_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFacilityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Facility Fee</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFacilityFee_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFacilityFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Facility Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFacilityFee" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFacilityFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFacilityFee" xlink:to="lab_vrdn_DebtInstrumentFacilityFee" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_September2022AtTheMarketOfferingMember_c7957d7d-f910-4e4d-80af-4d92245084d4_terseLabel_en-US" xlink:label="lab_vrdn_September2022AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 At The Market Offering</link:label>
    <link:label id="lab_vrdn_September2022AtTheMarketOfferingMember_label_en-US" xlink:label="lab_vrdn_September2022AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September 2022 At The Market Offering [Member]</link:label>
    <link:label id="lab_vrdn_September2022AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_vrdn_September2022AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September 2022 At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_September2022AtTheMarketOfferingMember" xlink:href="vrdn-20240930.xsd#vrdn_September2022AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_September2022AtTheMarketOfferingMember" xlink:to="lab_vrdn_September2022AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7106969e-6b91-48c5-9cd1-1aeee2905245_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_MassachusettsLeaseMember_d62ee8db-b982-4421-81b5-8a90c1f5a1db_terseLabel_en-US" xlink:label="lab_vrdn_MassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Massachusetts Lease</link:label>
    <link:label id="lab_vrdn_MassachusettsLeaseMember_label_en-US" xlink:label="lab_vrdn_MassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Massachusetts Lease [Member]</link:label>
    <link:label id="lab_vrdn_MassachusettsLeaseMember_documentation_en-US" xlink:label="lab_vrdn_MassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Massachusetts Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_MassachusettsLeaseMember" xlink:href="vrdn-20240930.xsd#vrdn_MassachusettsLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_MassachusettsLeaseMember" xlink:to="lab_vrdn_MassachusettsLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_73666bd2-d8c4-4685-aa86-dd1b162bdc30_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_208cdf83-c3de-4787-a77d-5149d9b6d31a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CommonStockVotePerShare_1374e8f4-2e16-4f20-8221-0a5584a5c317_terseLabel_en-US" xlink:label="lab_vrdn_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, vote per share</link:label>
    <link:label id="lab_vrdn_CommonStockVotePerShare_label_en-US" xlink:label="lab_vrdn_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:label id="lab_vrdn_CommonStockVotePerShare_documentation_en-US" xlink:label="lab_vrdn_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockVotePerShare" xlink:href="vrdn-20240930.xsd#vrdn_CommonStockVotePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CommonStockVotePerShare" xlink:to="lab_vrdn_CommonStockVotePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_WarrantsPolicyPolicyTextBlock_5eb96065-09a4-43f4-8f99-9dfe0917fcde_terseLabel_en-US" xlink:label="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_vrdn_WarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Policy [Policy Text Block]</link:label>
    <link:label id="lab_vrdn_WarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_WarrantsPolicyPolicyTextBlock" xlink:href="vrdn-20240930.xsd#vrdn_WarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_WarrantsPolicyPolicyTextBlock" xlink:to="lab_vrdn_WarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_fd7073ad-5241-44e1-aa36-62272edff63a_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. corporate paper and bonds</link:label>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_0aae9e44-a0b8-4081-8dc6-96d934fd357f_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. corporate paper and bonds</link:label>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Corporate, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a0d9b5bd-5ca4-4164-9859-1490f0350d18_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_765ee97f-dd17-4786-a04e-edd9f10da9f5_terseLabel_en-US" xlink:label="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal terms (up to)</link:label>
    <link:label id="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:label id="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="vrdn-20240930.xsd#vrdn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_561ecc80-1e9d-4e79-b16d-95b13e7f359e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1ce134e5-1164-4ad0-b1cc-17ff053028f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized employee stock-based compensation costs related to unvested RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1d89ac61-7312-42d7-8874-2337cd465655_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0e4e659f-9724-4123-9970-957e946bbd40_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remainder)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesIssued1_72a17795-d25a-45b0-86b8-7e1cd2020416_terseLabel_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_NotesIssued1_label_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_OperatingLeaseAnnualBaseRent_e6719367-8bec-441a-852d-1efbaf97de97_terseLabel_en-US" xlink:label="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, annual base rent</link:label>
    <link:label id="lab_vrdn_OperatingLeaseAnnualBaseRent_label_en-US" xlink:label="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Base Rent</link:label>
    <link:label id="lab_vrdn_OperatingLeaseAnnualBaseRent_documentation_en-US" xlink:label="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseAnnualBaseRent" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseAnnualBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_OperatingLeaseAnnualBaseRent" xlink:to="lab_vrdn_OperatingLeaseAnnualBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92b0a4e1-f29e-4d61-bafb-f501b20c6986_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_f8f456c5-d01f-4941-a43b-2921005dc935_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted_f0f66fc4-cb51-4e8d-ad4e-608aa50de920_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued exchange for rights for granted (in shares)</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Additional Shares Issued For Rights Granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Additional Shares Issued For Rights Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" xlink:to="lab_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9826aba8-29e3-49ce-b404-02e841f07a65_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReduction_7360da9b-341d-4405-b469-ecde2544ca8a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of long-term debt</link:label>
    <link:label id="lab_us-gaap_NotesReduction_label_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReduction" xlink:to="lab_us-gaap_NotesReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9ee1a04a-afa1-4e51-9ea1-66f954613f4b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_94853d2d-47b2-4801-a6df-c31b65ca3ee2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_04f2a980-0285-4d50-806b-e31c10f12ca2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_957b69fd-a134-4f92-be23-c3f42eb5191c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_8d17f5d3-1eaf-4988-9123-31e8662a051b_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0baabb27-265b-40dd-92ca-c9eea4ef3bda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term and Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_88df6507-8412-4eed-ad9b-572aef3ca206_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ThirdPartyCollaboratorMember_52a47429-734b-499e-a678-9e13e7c49449_terseLabel_en-US" xlink:label="lab_vrdn_ThirdPartyCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Party Collaborator</link:label>
    <link:label id="lab_vrdn_ThirdPartyCollaboratorMember_label_en-US" xlink:label="lab_vrdn_ThirdPartyCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Party Collaborator [Member]</link:label>
    <link:label id="lab_vrdn_ThirdPartyCollaboratorMember_documentation_en-US" xlink:label="lab_vrdn_ThirdPartyCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Party Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ThirdPartyCollaboratorMember" xlink:href="vrdn-20240930.xsd#vrdn_ThirdPartyCollaboratorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ThirdPartyCollaboratorMember" xlink:to="lab_vrdn_ThirdPartyCollaboratorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_81d403d2-2f85-4257-add4-472827115c2e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock, percentage of fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6371c8ad-023a-4d9e-befa-65a9abf6ad4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_1a350a21-9a58-4418-864f-7a84361b8c7c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_60e4ddc1-f323-4097-bbd6-76901d0bee15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d1bfeb0e-6fb6-4635-a7ee-853ed59692e1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_af894a00-eeee-4350-9826-437e573c25ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_75429123-0693-4c45-8c86-1b486f78b646_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d320a244-4a90-48b2-97a3-f1441d4725a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7d847e36-40e0-4f7e-8c26-329547c6f69f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under license agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_e27fdbfd-806d-4377-b0bb-2105d3860b88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_A2020PlanMember_b25302f8-85d2-4e04-84d5-4772444c9903_terseLabel_en-US" xlink:label="lab_vrdn_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Plan</link:label>
    <link:label id="lab_vrdn_A2020PlanMember_label_en-US" xlink:label="lab_vrdn_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Plan [Member]</link:label>
    <link:label id="lab_vrdn_A2020PlanMember_documentation_en-US" xlink:label="lab_vrdn_A2020PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2020PlanMember" xlink:href="vrdn-20240930.xsd#vrdn_A2020PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_A2020PlanMember" xlink:to="lab_vrdn_A2020PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e4c924b5-f785-42d9-be7e-0e517349244d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fd19d19e-3e7a-47b3-a0d9-7b634405c7cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_021c3a3f-199c-4c8c-bac9-75a4697f6d3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0157176e-0457-4bf4-a0bd-db02d24d6922_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_153d6323-8c88-4d5c-a592-16dcb2936804_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9a701157-9efb-4e2c-be11-df7f35b71b9f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_6f2b72e1-fd41-4926-9cca-87e957364bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, acceleration of vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_78970ad8-5b2d-40a1-b075-c187736b7742_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_7e98bf79-b7d0-4b7b-978c-eb3549073f4a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_d7d60af2-c85f-424f-a400-226148c18553_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED LIABILITIES AND OTHER</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_Amended2016PlanMember_95706ac9-878e-4566-890d-b233f4c97849_terseLabel_en-US" xlink:label="lab_vrdn_Amended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_vrdn_Amended2016PlanMember_label_en-US" xlink:label="lab_vrdn_Amended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended 2016 Plan [Member]</link:label>
    <link:label id="lab_vrdn_Amended2016PlanMember_documentation_en-US" xlink:label="lab_vrdn_Amended2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended 2016 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember" xlink:href="vrdn-20240930.xsd#vrdn_Amended2016PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_Amended2016PlanMember" xlink:to="lab_vrdn_Amended2016PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_fb2d6108-a061-4c7d-af44-b264c7fa7d91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4f0836d1-97f9-494b-8673-8125f93f4674_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAPITAL STOCK</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_210ae058-ea33-46d0-911f-cae311083cd1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">WARRANTS</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5ee00182-3ce6-48c6-b14b-45ffd2d56ae2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6b187fa5-f780-43db-bba1-44dca12c5e67_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8a681fb6-f136-46fd-a364-fce7b2b2b694_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee_77c47b54-6499-4b2f-ab13-16e8d765685c_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, rights and licenses fee</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Licenses Fee</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Licenses Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:to="lab_vrdn_CollaborativeArrangementRightsAndLicensesFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9877ab7d-5adc-410c-a175-aeeaf6e0c298_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8fc0173-6558-4434-addc-72c5850cca28_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4f34b2e4-cc16-4811-82ee-17aca6408a53_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_81cc72e1-c766-4f43-a66c-c2d03827e286_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fe03083c-815f-4f8e-b25f-fa6f69a2a6b9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2f279c21-721b-4688-b8e9-c498ee89811e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_69f1ed3b-3a33-4532-865e-a648225bf940_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_15df1eab-c760-449d-a033-212b34226c27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_71702700-29cf-444c-8ca2-9155daf81293_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4e328e02-2091-4377-87ae-753c24bec98f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ColoradoLeaseMember_edb07736-8044-440b-84e1-dd4f73ef52a3_terseLabel_en-US" xlink:label="lab_vrdn_ColoradoLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Colorado Lease</link:label>
    <link:label id="lab_vrdn_ColoradoLeaseMember_label_en-US" xlink:label="lab_vrdn_ColoradoLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Colorado Lease [Member]</link:label>
    <link:label id="lab_vrdn_ColoradoLeaseMember_documentation_en-US" xlink:label="lab_vrdn_ColoradoLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Colorado Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ColoradoLeaseMember" xlink:href="vrdn-20240930.xsd#vrdn_ColoradoLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ColoradoLeaseMember" xlink:to="lab_vrdn_ColoradoLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d4e4d24a-954f-45ba-bdfd-66134586e2f2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_817c10ec-c649-4670-bc72-ba934f6dc9f4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f2e8ac4e-4da0-4559-b255-6cd006fc5970_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d9d86d96-b279-47a5-8048-2463922012a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_945dc03a-4924-489c-9ce5-2cc476c01b14_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_84e2e6bb-2c9e-492b-9b69-21392dbe17f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_086a7b02-c6f9-41bd-86c8-266bd2f23802_terseLabel_en-US" xlink:label="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired October 2020</link:label>
    <link:label id="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_label_en-US" xlink:label="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants, Acquired October 2020 [Member]</link:label>
    <link:label id="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_documentation_en-US" xlink:label="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants, Acquired October 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:href="vrdn-20240930.xsd#vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:to="lab_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_93884f5b-900b-4210-aac9-194c26217e47_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_1f9709e8-2ae9-4b72-abef-bf14a658926d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a55bd0d7-32c5-401f-84d8-c3d1753a4044_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a9d94f5c-e42c-47a1-b6f8-9bcbd05536de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_37e41aef-a769-405f-83b3-431abf95a457_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_60ad61da-187a-44e8-a92a-aeb4446dfee0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_45813a87-2ff5-4b17-a451-8cf09df7e419_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca9bf008-0c2e-417a-863c-384c344796fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac485ee4-e8d6-4dd5-b42d-0b6727fd1319_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value per option (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5d380190-f082-4578-9887-f631dc8d645e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_52426641-94af-4a76-9653-b632d6f38962_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_87002d77-c357-4ff4-92cd-e4d0a1587314_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e8ad67d0-c6aa-4cf7-acc1-04e88271963c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_360643b6-520f-4b57-98b0-b0b9ab639125_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentNumberOfTranches_c43d1246-fe09-4b13-b207-6c739501b194_verboseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, number of tranches</link:label>
    <link:label id="lab_vrdn_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:label id="lab_vrdn_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentNumberOfTranches" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentNumberOfTranches" xlink:to="lab_vrdn_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f5192fb4-62d5-4fde-a521-8969e97994c1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_25668b7a-f1b1-4161-b275-4a35c5b2f799_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_375624fc-d006-4c6d-a95a-b53581459f08_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CommonStockWarrantsMember_852c48a4-5ae2-44d9-b626-96ef8b417052_terseLabel_en-US" xlink:label="lab_vrdn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_vrdn_CommonStockWarrantsMember_label_en-US" xlink:label="lab_vrdn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_vrdn_CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_vrdn_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockWarrantsMember" xlink:href="vrdn-20240930.xsd#vrdn_CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CommonStockWarrantsMember" xlink:to="lab_vrdn_CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8b36c420-211f-4d07-ba72-8b5d1c4dc581_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9200763-1239-4eb7-977b-a686f8fc39e0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_5d5d610b-664b-43f0-b7b8-b5bff8ed0ffe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt and Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_c78f5f59-8d22-4e0b-83dc-03bf3f8b81ae_terseLabel_en-US" xlink:label="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission fee percent</link:label>
    <link:label id="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_label_en-US" xlink:label="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</link:label>
    <link:label id="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_documentation_en-US" xlink:label="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:href="vrdn-20240930.xsd#vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:to="lab_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_66b8ca5f-0415-4b10-bbe4-ac3c3296f10b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_506f5043-6d26-42ab-a39f-43197d692db4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued end-of-term fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dba4d992-859b-463c-b92d-e200391b8a02_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_18c86199-1c22-4e1f-9913-b5372baab92f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt extinguishment costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_dabf4ac4-2098-4d68-b630-c76cd9c22b37_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFirstTranche_430a174d-f74a-464b-9c1d-df00e5b6e37e_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount, first tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFirstTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, First Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountFirstTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, First Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountFirstTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountFirstTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b1c427ea-1742-4425-8eba-f83bacad43d9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_746c2f3e-587c-4053-9384-bbd795b26424_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6ee52896-a2bf-4e3e-ba38-8d1c7ff65b22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementMaximumMilestonePayments_202d0d8d-c9c9-4dc2-9d53-5fef6f7d996f_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration arrangement, maximum milestone payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementMaximumMilestonePayments_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Maximum Milestone Payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementMaximumMilestonePayments_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Maximum Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementMaximumMilestonePayments" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementMaximumMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementMaximumMilestonePayments" xlink:to="lab_vrdn_CollaborationArrangementMaximumMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fd58111b-b6b2-4a19-bbc7-059bc8b5a0f4_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22b5320c-1564-4060-bcd0-4927c3d2a366_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_da900c59-40f2-4f51-865c-fc5c1c528f9d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1fb4eca3-946a-4fba-86ff-04dd481e76ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6250f10a-28ec-46e0-b2e4-56fe285a8828_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_436251b8-ae74-4f64-8f32-98d11aa4592e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4eb52548-8024-44b5-b5b2-e104030c667d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_702aef17-3aa0-4a66-b479-7ee316a14393_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_94501c43-362f-4cd9-b405-933f28dd03f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a9d53770-ebe6-4a63-98b4-2d12b437be7e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b7177e21-a2a8-4944-b4e7-c2776cbe5add_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_20db58eb-1df6-4948-a52b-c0a6fcab0f52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_07cd3ccf-a236-4c3b-96a0-8560f2cf4f05_terseLabel_en-US" xlink:label="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial and Preclinical Study Accruals</link:label>
    <link:label id="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_label_en-US" xlink:label="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trials And Pre-clinical Study Accruals [Policy Text Block]</link:label>
    <link:label id="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_documentation_en-US" xlink:label="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:href="vrdn-20240930.xsd#vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:to="lab_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc65fb39-dc29-4235-a27d-ebbbd98299d3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6f923019-7ba5-4686-8b87-e51aae220ca3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_21cb1f30-6caf-4ccc-98ea-7b1263307785_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; 200,000,000 shares authorized; 79,181,445 and 53,986,112 shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4ecf2e0-753c-4cfb-86fc-d19e76e96c28_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_dee8115b-c5cc-41c2-9ff4-6823c7f54d8f_terseLabel_en-US" xlink:label="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of liability-classified stock purchase warrants</link:label>
    <link:label id="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_label_en-US" xlink:label="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liability of Warrants on Temporary Equity</link:label>
    <link:label id="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_documentation_en-US" xlink:label="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liability of Warrants on Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:href="vrdn-20240930.xsd#vrdn_AccruedLiabilityofWarrantsonTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:to="lab_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4f1371fe-7748-4d06-817c-01290f3af5ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c8e33776-be9f-4761-be35-049d1c2bea33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6d63d452-c432-497c-8746-be80e15521ba_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a1d6a947-eb98-4cf8-800c-96b100b55d00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40cd63ff-6795-47e6-80ba-f05490171dba_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_89948075-97ac-4f1e-bcac-55bdf28c9440_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c5fadca5-442f-4dcb-8c5f-f4a47f6b6e57_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability, current, statement of financial position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_884a2ed6-d30a-404b-8e05-44d7d8b50534_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a5fa22eb-5202-486f-a0ef-7407b8c01303_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_b10f6aed-c102-4573-b190-a683cc3eb938_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d27a978e-d518-40cd-a7e9-9502209ac28d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_c14fbed5-5b7f-430b-aaed-ef3ab5591996_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_0ddd061b-921d-4027-989f-5a91bee88ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock for cash under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d43e36b9-bf1a-41d3-b25d-53fc8a7270d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock, pursuant to January 2024 Public Offering, September 2024 Public Offering and September 2022 ATM Agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a105adc6-f9b6-4c37-b82b-fbcd178f6433_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_610b18ed-3dfb-4356-997d-bec42b644cc3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_c479a661-ac4c-4261-89a7-f06054ccbc0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_f28565b5-c6c6-4763-be63-01a4eb8e4c50_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aef86fc7-5a24-4fda-8cbe-daced6d011fa_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_OperatingLeasesOperatingExpense_928f5d9a-ed56-4238-8e08-03a6f86ce32c_terseLabel_en-US" xlink:label="lab_vrdn_OperatingLeasesOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expenses</link:label>
    <link:label id="lab_vrdn_OperatingLeasesOperatingExpense_label_en-US" xlink:label="lab_vrdn_OperatingLeasesOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Operating Expense</link:label>
    <link:label id="lab_vrdn_OperatingLeasesOperatingExpense_documentation_en-US" xlink:label="lab_vrdn_OperatingLeasesOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeasesOperatingExpense" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeasesOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_OperatingLeasesOperatingExpense" xlink:to="lab_vrdn_OperatingLeasesOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b5e6998e-7091-4173-994a-aa01de07580e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4753f5d1-21e6-4f02-b3d6-1d10c6d1a0fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_aae067c6-f9ec-4884-a9cd-02605bc205b6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_780b7d82-5143-40a9-bb79-d295a429aa17_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized option employee stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_ClassofWarrantorRightRemainingTerm_e82fbf72-46e5-45f8-8459-b96e86b17d66_terseLabel_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining contractual life</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightRemainingTerm_label_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Remaining Term</link:label>
    <link:label id="lab_vrdn_ClassofWarrantorRightRemainingTerm_documentation_en-US" xlink:label="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Remaining Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightRemainingTerm" xlink:href="vrdn-20240930.xsd#vrdn_ClassofWarrantorRightRemainingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_ClassofWarrantorRightRemainingTerm" xlink:to="lab_vrdn_ClassofWarrantorRightRemainingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9170f8b6-e291-43f6-a3d7-07c64479adfe_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_e392a441-3c86-4b12-813f-f4864bccb61f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan modification costs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_676efc00-32c2-4fdd-b093-6d3797da2171_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c77c42ae-4191-4ee3-8693-fdf4b95bb697_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountSecondTranche_88e701f4-3932-48ea-b7cc-4ed27fa3ba70_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount, second tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountSecondTranche_label_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Second Tranche</link:label>
    <link:label id="lab_vrdn_DebtInstrumentFaceAmountSecondTranche_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Second Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountSecondTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:to="lab_vrdn_DebtInstrumentFaceAmountSecondTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_56f4f72b-32ed-45b0-afdf-ea4b3e538bf7_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_a0abeaff-d04c-4047-9ce2-91a4e1c78135_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_56c20279-237e-450f-8024-bcd7bcfe7399_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ca399775-f04e-4f47-83ed-5af0fd97545f_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under license agreement</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_49e139a9-4097-4125-8115-b0da884be95e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d0050040-0699-45b1-98c6-7b4ad718a0f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_66a430b9-8ef2-49aa-824a-f7b42718272f_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in exchange for rights granted (in shares)</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Shares Issued For Rights Granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Shares Issued For Rights Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementSharesIssuedForRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:to="lab_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_284d5f90-9525-4254-9202-372f4b666286_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_SeriesAPreferredStockConversionMember_1da3f282-4fc7-467c-b508-1e74a0431691_terseLabel_en-US" xlink:label="lab_vrdn_SeriesAPreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock Conversion</link:label>
    <link:label id="lab_vrdn_SeriesAPreferredStockConversionMember_label_en-US" xlink:label="lab_vrdn_SeriesAPreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock Conversion [Member]</link:label>
    <link:label id="lab_vrdn_SeriesAPreferredStockConversionMember_documentation_en-US" xlink:label="lab_vrdn_SeriesAPreferredStockConversionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SeriesAPreferredStockConversionMember" xlink:href="vrdn-20240930.xsd#vrdn_SeriesAPreferredStockConversionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_SeriesAPreferredStockConversionMember" xlink:to="lab_vrdn_SeriesAPreferredStockConversionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_57ec9d09-1b89-42a8-b68f-415324be4712_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3f3ec051-0e0f-4cad-b9fa-9c29e1067805_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d14291dc-4a88-41d8-937e-f26bf857dd6a_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ebcd00e0-c0e6-43a9-b405-cdfd7e9a7275_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4d9ef3c4-9c9f-48cc-a3e8-76ecc9616d37_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9f9b82d5-3080-46da-9cf4-53162f9a1c2c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_0010d3dd-7abd-48bf-9b32-3bbd19f8d3b2_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Potential Milestone Payment, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Potential Milestone Payment, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:to="lab_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_705f47e5-03ec-48e4-b948-ee715e58bec5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0b52c215-3998-410f-b94b-99f69cb7d7d9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_NonCashLeaseExpense_81737413-d70b-4e33-bed7-ccc9262f0afd_terseLabel_en-US" xlink:label="lab_vrdn_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_vrdn_NonCashLeaseExpense_label_en-US" xlink:label="lab_vrdn_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_vrdn_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_vrdn_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense" xlink:href="vrdn-20240930.xsd#vrdn_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_NonCashLeaseExpense" xlink:to="lab_vrdn_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0562fb1d-bf7e-438c-b570-64ff527dd4e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9d69edc8-516e-485b-87a5-7ede9c6488d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt, net of costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_6673c7bb-5223-42ca-a292-8ac23c702553_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Right-of-Use Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6bb441ff-46a8-4991-a2d5-5bef69f477c2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under license agreement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c54192dd-aae7-4c18-bc6a-9523f718e429_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e08d2e61-c2f7-465a-bb52-2a1f1a7e83e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cdabf428-d3e6-4aed-b559-5e8e0ef18340_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3ce13036-b5d6-4c1f-b8bc-a1e549a32997_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b7d2a4f0-9d3f-44ad-8a7d-c91dfc017fa5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b29cb41e-9f4a-4362-87ee-058c3afa1a44_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d3395f54-14af-4e71-bde1-94213d8d9949_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue - related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a2cfa17a-2bc9-4328-a200-5d2f4351719f_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_00ccd837-be5f-4f26-945a-d037f9fc12d7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon the conversion of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c6f62441-257d-471f-879d-b96a74793d76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24357ec3-7fc1-4842-b31a-8fa44c8e6872_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CapitalStockSharesAuthorized_a3e38a64-7530-4a6e-8c1b-4d722642560a_terseLabel_en-US" xlink:label="lab_vrdn_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_vrdn_CapitalStockSharesAuthorized_label_en-US" xlink:label="lab_vrdn_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Stock, Shares Authorized</link:label>
    <link:label id="lab_vrdn_CapitalStockSharesAuthorized_documentation_en-US" xlink:label="lab_vrdn_CapitalStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CapitalStockSharesAuthorized" xlink:href="vrdn-20240930.xsd#vrdn_CapitalStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CapitalStockSharesAuthorized" xlink:to="lab_vrdn_CapitalStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_fd0f30e1-dcc5-4254-b77d-456c6f1448eb_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_50f98849-a815-45dd-8e5c-45e5dc8c773c_terseLabel_en-US" xlink:label="lab_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future developments milestone payments</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_label_en-US" xlink:label="lab_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Milestone Payment, Intellectual Property Rights Development, Maximum</link:label>
    <link:label id="lab_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_documentation_en-US" xlink:label="lab_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Milestone Payment, Intellectual Property Rights Development, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:to="lab_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9e7fa2a6-62f2-47d8-86de-e64b5370589f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_aa1bd355-99ec-4134-9276-b11f397c0b1d_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_99402bdc-6603-4832-b360-ab9b97a38ae7_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock (as converted to shares of common stock)</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_00b62357-f6ba-4f89-afc9-6a3c33a5ddb4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4b70ac7e-d6da-4b21-ac3e-a2e765ab9392_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cb9f61b9-ff0f-48e8-855c-392763e503d6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2223f393-b786-4965-a8cf-d48b4ad7a9fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_56cf4503-c0ba-4533-8984-b61ee71f36fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2d93ad7d-6ad9-4aac-96e0-1bbc40157d62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_66f96665-d84e-4658-a7e9-49535c5f8663_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c597a29f-13ae-4a1c-91f2-2778e1d32094_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (Aggregate Intrinsic Value)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5695faa7-60f9-4bd7-be42-8e75c9fdf5d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remainder)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e4531891-93f2-4a0e-bd0b-05b48fdeeec9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease remaining term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fadae32e-f027-43be-9571-c21441f8143f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_14597886-3bda-445b-96d2-daf642f67786_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_f236ff32-5b01-4594-9165-b761623fe35a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_be7db98a-8709-4411-8132-7d2fbad97a47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtExtinguishmentExpense_b2833269-e05f-40e3-a711-43fde81e6972_terseLabel_en-US" xlink:label="lab_vrdn_DebtExtinguishmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees paid directly to creditor related to extinguishment of debt</link:label>
    <link:label id="lab_vrdn_DebtExtinguishmentExpense_label_en-US" xlink:label="lab_vrdn_DebtExtinguishmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Extinguishment Expense</link:label>
    <link:label id="lab_vrdn_DebtExtinguishmentExpense_documentation_en-US" xlink:label="lab_vrdn_DebtExtinguishmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Extinguishment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtExtinguishmentExpense" xlink:href="vrdn-20240930.xsd#vrdn_DebtExtinguishmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtExtinguishmentExpense" xlink:to="lab_vrdn_DebtExtinguishmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_062e2998-45ed-4c1a-a3aa-f57f7d2b23c7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b8c0e6b9-59c3-46a8-809a-1dcbbac3bf6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_43a9afcc-b69e-4ff1-9008-21343a5ae0d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_da871c1a-d189-4890-9d54-ba50f2ccb596_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_DebtInstrumentPrincipalAmountTermFee_6d359f7e-9969-4963-8d50-72619e527f68_terseLabel_en-US" xlink:label="lab_vrdn_DebtInstrumentPrincipalAmountTermFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term fee</link:label>
    <link:label id="lab_vrdn_DebtInstrumentPrincipalAmountTermFee_label_en-US" xlink:label="lab_vrdn_DebtInstrumentPrincipalAmountTermFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal Amount, Term Fee</link:label>
    <link:label id="lab_vrdn_DebtInstrumentPrincipalAmountTermFee_documentation_en-US" xlink:label="lab_vrdn_DebtInstrumentPrincipalAmountTermFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal Amount, Term Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentPrincipalAmountTermFee" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentPrincipalAmountTermFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_DebtInstrumentPrincipalAmountTermFee" xlink:to="lab_vrdn_DebtInstrumentPrincipalAmountTermFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_be7769aa-1eb9-4904-95a4-632475dd021b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue - related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_InducementGrantsMember_d872aeae-d1e8-42c0-b34f-70c68c8dfb16_terseLabel_en-US" xlink:label="lab_vrdn_InducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_vrdn_InducementGrantsMember_label_en-US" xlink:label="lab_vrdn_InducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Grants [Member]</link:label>
    <link:label id="lab_vrdn_InducementGrantsMember_documentation_en-US" xlink:label="lab_vrdn_InducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_InducementGrantsMember" xlink:href="vrdn-20240930.xsd#vrdn_InducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_InducementGrantsMember" xlink:to="lab_vrdn_InducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2bca300d-e79c-4a8b-8476-98a651a40949_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7256634f-ec9b-4ef4-bfe1-260d524fde72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_5f158038-9a94-4153-abec-80ae0af995d5_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares issued in exchange for rights granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Value Of Shares Issued For Rights Granted</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Value Of Shares Issued For Rights Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:to="lab_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_e8c80a5d-643c-43a4-ad5d-0c971095ede2_terseLabel_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued November 2017</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_label_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants, Issued November 2017 [Member]</link:label>
    <link:label id="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_documentation_en-US" xlink:label="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity-classified Warrants, Issued November 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsIssuedNovember2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:to="lab_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_acbf9600-f51c-4cb1-9205-68a25ef1f8b6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_CollaborativeArrangementUpfrontFeePayment_74909854-dcab-445b-9679-0b7c913e8140_terseLabel_en-US" xlink:label="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, upfront fee payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementUpfrontFeePayment_label_en-US" xlink:label="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Fee Payment</link:label>
    <link:label id="lab_vrdn_CollaborativeArrangementUpfrontFeePayment_documentation_en-US" xlink:label="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Fee Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementUpfrontFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:to="lab_vrdn_CollaborativeArrangementUpfrontFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1dd3da2e-3a22-4ea3-9731-adcbd124d5c5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b0f6445c-ae73-4827-9ad7-89df92ca9550_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_6e480db1-8f82-4139-ab8f-dfe604e71d1a_terseLabel_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercises of warrants (in shares)</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_label_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Shares</link:label>
    <link:label id="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_documentation_en-US" xlink:label="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:href="vrdn-20240930.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:to="lab_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2cb55bdf-281b-4d16-a910-627b0809461b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive gain</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9d09a6ef-70c0-42c1-bae9-656d734ef717_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c4936092-7a6e-4a53-9d3b-e94f95f1e269_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_65cc3db5-1651-4e0b-9f70-2b796557ceb3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_ca881be2-ce9a-45e6-a155-90e829115c6b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_96e5999a-ddb8-4a8a-b231-633846e1f1c5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c110996a-c01b-4843-853e-a757e990fdd1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_EnableInjectionsMember_b3c06aa9-66e3-43b1-a28e-0ba928640efb_terseLabel_en-US" xlink:label="lab_vrdn_EnableInjectionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enable Injections</link:label>
    <link:label id="lab_vrdn_EnableInjectionsMember_label_en-US" xlink:label="lab_vrdn_EnableInjectionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enable Injections [Member]</link:label>
    <link:label id="lab_vrdn_EnableInjectionsMember_documentation_en-US" xlink:label="lab_vrdn_EnableInjectionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enable Injections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EnableInjectionsMember" xlink:href="vrdn-20240930.xsd#vrdn_EnableInjectionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_EnableInjectionsMember" xlink:to="lab_vrdn_EnableInjectionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a73f9c0f-5ca7-47b4-8ab1-9a1dbea4f1f0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0b95ffb0-687e-45ca-801c-a7a7241e2f26_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrdn_HerculesTermLoanMember_ffab53f3-932c-4934-890c-0be7deecc206_terseLabel_en-US" xlink:label="lab_vrdn_HerculesTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hercules Loan and Security Agreement</link:label>
    <link:label id="lab_vrdn_HerculesTermLoanMember_label_en-US" xlink:label="lab_vrdn_HerculesTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hercules Term Loan [Member]</link:label>
    <link:label id="lab_vrdn_HerculesTermLoanMember_documentation_en-US" xlink:label="lab_vrdn_HerculesTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hercules Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember" xlink:href="vrdn-20240930.xsd#vrdn_HerculesTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrdn_HerculesTermLoanMember" xlink:to="lab_vrdn_HerculesTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_90a270bd-ab8b-49a0-bec9-aa6807a3da29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains (losses) in available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_d2251a5c-1b9c-449d-82c5-f1c7095828fe_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense and amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_fcaee6d9-9568-4509-a9cd-4801e283c8b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3d8506d6-b371-4ff0-be46-76a784b44d06_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_be32d2c5-9aed-4643-ad33-bf400c1887ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other professional service fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_876af5ab-43ab-4a6a-bfcf-d686ac210c3b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f06278b2-f6ae-4b3a-80a4-a8d4e38198c1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a0027367-f011-4e89-b7d8-f9163f638da6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_991a3fe1-aa0d-4e14-bb8d-a2d11710f5be_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_a0761692-ef02-40dd-b111-2c2300f4f5ff_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vrdn-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:bdb425b1-8ce6-48d2-af7c-3659fd6d6265,g:f76e6810-2604-4ff8-8a2b-997429168b4a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6c4cb074-69ea-4e63-a0d9-4fe751c973c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_DocumentType_6c4cb074-69ea-4e63-a0d9-4fe751c973c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_20df92c7-e2d5-40e6-8032-b848c7481bcc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_DocumentQuarterlyReport_20df92c7-e2d5-40e6-8032-b848c7481bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8763f792-5200-459d-b3c0-c49e416cae21" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_DocumentPeriodEndDate_8763f792-5200-459d-b3c0-c49e416cae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4b0a6854-c64e-454d-9d91-fab8595b4222" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_DocumentTransitionReport_4b0a6854-c64e-454d-9d91-fab8595b4222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1bb726af-0764-4125-8393-8d71aa7f5d9b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityFileNumber_1bb726af-0764-4125-8393-8d71aa7f5d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4f065097-7257-4732-994d-8524c9ca5635" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityRegistrantName_4f065097-7257-4732-994d-8524c9ca5635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_47212051-dd81-4cc2-92eb-05616ae409ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_47212051-dd81-4cc2-92eb-05616ae409ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a3f611d1-f8d8-4816-82fd-194ac48be351" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityTaxIdentificationNumber_a3f611d1-f8d8-4816-82fd-194ac48be351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8103ce1e-9c6b-4a9b-a943-7d8e37ed15d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityAddressAddressLine1_8103ce1e-9c6b-4a9b-a943-7d8e37ed15d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b1572ffb-dcc7-49ea-892d-fe77fcdaf84c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityAddressCityOrTown_b1572ffb-dcc7-49ea-892d-fe77fcdaf84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_20f2ca34-fedc-4a27-a823-690303c8058d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityAddressStateOrProvince_20f2ca34-fedc-4a27-a823-690303c8058d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1cfb2749-5d3e-4a4f-8db3-ae685b695f46" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityAddressPostalZipCode_1cfb2749-5d3e-4a4f-8db3-ae685b695f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0c40f25a-d467-475f-973d-360aa2034ad7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_CityAreaCode_0c40f25a-d467-475f-973d-360aa2034ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_571bed1d-8444-4d23-ba30-8732ffba43eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_LocalPhoneNumber_571bed1d-8444-4d23-ba30-8732ffba43eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a2da2c8b-c5dd-453f-a6a7-b5e6af03b903" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_Security12bTitle_a2da2c8b-c5dd-453f-a6a7-b5e6af03b903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dc59b8c0-898a-4bc0-a5b7-fa963d645c04" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_TradingSymbol_dc59b8c0-898a-4bc0-a5b7-fa963d645c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a3833b9e-685c-4793-8b9a-eeb58e351908" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_SecurityExchangeName_a3833b9e-685c-4793-8b9a-eeb58e351908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2ba62495-6e12-451e-9f96-733b228edc9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityCurrentReportingStatus_2ba62495-6e12-451e-9f96-733b228edc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2ba38edb-229b-450b-8f71-ec5b04f37d98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityInteractiveDataCurrent_2ba38edb-229b-450b-8f71-ec5b04f37d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d3eb9104-50cb-49f2-b70d-3553631a5407" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityFilerCategory_d3eb9104-50cb-49f2-b70d-3553631a5407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_25160b68-bf96-42e8-a194-26c28fe22887" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntitySmallBusiness_25160b68-bf96-42e8-a194-26c28fe22887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_25241e06-1f63-46c0-a362-a510c38d8213" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityEmergingGrowthCompany_25241e06-1f63-46c0-a362-a510c38d8213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_82c39946-3600-479d-af08-a97e5e877edd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityShellCompany_82c39946-3600-479d-af08-a97e5e877edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4583fd24-e85f-407f-a143-09780bf8b08f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4583fd24-e85f-407f-a143-09780bf8b08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d96e0871-b28b-43cc-9a8e-63b4c7f5e555" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_EntityCentralIndexKey_d96e0871-b28b-43cc-9a8e-63b4c7f5e555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_02d7714e-6c87-418a-891d-1e5ba82b6d5b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_AmendmentFlag_02d7714e-6c87-418a-891d-1e5ba82b6d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8fd335f4-5296-4e99-a5dc-7aec9b7535a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_DocumentFiscalYearFocus_8fd335f4-5296-4e99-a5dc-7aec9b7535a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ce21dcad-3253-40dc-a299-4eccc08538be" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ce21dcad-3253-40dc-a299-4eccc08538be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d332068c-c5cf-465e-8a0f-2a3d9514d5dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74971485-8720-4c37-a996-c287c14c14c0" xlink:to="loc_dei_CurrentFiscalYearEndDate_d332068c-c5cf-465e-8a0f-2a3d9514d5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b0adc917-d4a5-4bf0-ab8c-bcdc4c69a1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ed7fa6c-7c89-4094-b3b6-a01e0e6f9bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0adc917-d4a5-4bf0-ab8c-bcdc4c69a1bf" xlink:to="loc_us-gaap_StatementTable_3ed7fa6c-7c89-4094-b3b6-a01e0e6f9bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb1ca902-caf5-4e40-959e-99c57fc43185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ed7fa6c-7c89-4094-b3b6-a01e0e6f9bde" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb1ca902-caf5-4e40-959e-99c57fc43185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb1ca902-caf5-4e40-959e-99c57fc43185" xlink:to="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4888ec97-0437-4a99-9c25-778668e15a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4888ec97-0437-4a99-9c25-778668e15a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_bb11b5b1-c0c0-4ad5-8e94-56720bdf1dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4f8eede4-2a57-4b66-b763-5c2e57baa4d0" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_bb11b5b1-c0c0-4ad5-8e94-56720bdf1dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ed7fa6c-7c89-4094-b3b6-a01e0e6f9bde" xlink:to="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:to="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ac724e1-4c08-416e-ace4-7ec0f619a031" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ac724e1-4c08-416e-ace4-7ec0f619a031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e074270c-24f7-47a6-9b73-81b427f9b2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e074270c-24f7-47a6-9b73-81b427f9b2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_128ac07b-94c4-4167-a285-24bd924b3cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_128ac07b-94c4-4167-a285-24bd924b3cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_71c3ccac-aa70-494a-be4b-1cf2f5b11c00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_71c3ccac-aa70-494a-be4b-1cf2f5b11c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c4bc61ea-801f-40cd-939f-9d78a2b06350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ec6843e-98a2-405c-8612-56168c460df3" xlink:to="loc_us-gaap_AssetsCurrent_c4bc61ea-801f-40cd-939f-9d78a2b06350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_121f7eee-d732-4b91-806f-d44b2732cdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_121f7eee-d732-4b91-806f-d44b2732cdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aac95184-0a8d-4300-8348-695a2746a1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aac95184-0a8d-4300-8348-695a2746a1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0e14f823-cd8e-4fb0-b5fe-27e8ca71045f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0e14f823-cd8e-4fb0-b5fe-27e8ca71045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1cca5f95-300e-4704-966f-b486bdc6aedb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7ce5f53a-c049-4633-8deb-d5fcbf0ace03" xlink:to="loc_us-gaap_Assets_1cca5f95-300e-4704-966f-b486bdc6aedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f443ca6c-c352-47c9-ab3e-93035818aa3f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a25b778e-620e-4280-8d43-c802056cf5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_AccountsPayableCurrent_a25b778e-620e-4280-8d43-c802056cf5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_05c10458-6f2b-4e15-a36d-79a746360639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_05c10458-6f2b-4e15-a36d-79a746360639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f2c5eb7-71ac-4453-8a58-ef79d3c4a4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7f2c5eb7-71ac-4453-8a58-ef79d3c4a4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_67a09e12-8b12-45d9-b362-e3f716423099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f577498-5303-4761-a3a4-3aee13ac64fc" xlink:to="loc_us-gaap_LiabilitiesCurrent_67a09e12-8b12-45d9-b362-e3f716423099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_accab3af-4448-4f8d-932c-d0fb5c0c6983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_accab3af-4448-4f8d-932c-d0fb5c0c6983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c171bba-b706-4f5f-a4d0-c99a34089eff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2c171bba-b706-4f5f-a4d0-c99a34089eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5fae0c3e-eec5-4233-9352-3c08fa570186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5fae0c3e-eec5-4233-9352-3c08fa570186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d324510f-6829-4da7-ab5d-6eb4d47d75d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_Liabilities_d324510f-6829-4da7-ab5d-6eb4d47d75d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e88881fc-745a-4a0f-bc35-bdf222052bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e88881fc-745a-4a0f-bc35-bdf222052bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e9cb0d0d-c506-43d6-b50f-e7af354c9e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_PreferredStockValue_e9cb0d0d-c506-43d6-b50f-e7af354c9e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_627d64cf-94bd-4b15-a51c-0da2ca008f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_CommonStockValue_627d64cf-94bd-4b15-a51c-0da2ca008f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c89ade83-dd1f-428d-96f2-a988a5db9e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c89ade83-dd1f-428d-96f2-a988a5db9e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_feb69328-2785-4488-8f15-9abb0a184c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_feb69328-2785-4488-8f15-9abb0a184c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b404b6e6-f1ac-41c1-b286-fb7ff94e9eec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b404b6e6-f1ac-41c1-b286-fb7ff94e9eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7fb0e2f9-f3f1-4343-bb04-714bab9a3eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ac77f8aa-1639-4ea5-8a21-4ceab1233d6e" xlink:to="loc_us-gaap_StockholdersEquity_7fb0e2f9-f3f1-4343-bb04-714bab9a3eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32b2944d-78e7-451c-92c4-54810c43b5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9593ba9a-5bfb-4323-a3d5-25d484752b62" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32b2944d-78e7-451c-92c4-54810c43b5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6bb91483-8733-4e6b-8669-89b8e557ecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6bb91483-8733-4e6b-8669-89b8e557ecbc" xlink:to="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_70968a79-1112-4396-8e3e-9646c5f40480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_70968a79-1112-4396-8e3e-9646c5f40480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05614e89-dba9-4adf-8cb7-05cd15dfeb41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_70968a79-1112-4396-8e3e-9646c5f40480" xlink:to="loc_us-gaap_RelatedPartyDomain_05614e89-dba9-4adf-8cb7-05cd15dfeb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f3a6fd97-cf74-4b2b-9370-cc2110bdc09b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_05614e89-dba9-4adf-8cb7-05cd15dfeb41" xlink:to="loc_us-gaap_RelatedPartyMember_f3a6fd97-cf74-4b2b-9370-cc2110bdc09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7b752b2a-18f3-441d-9e68-6c90ce6ade6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7b752b2a-18f3-441d-9e68-6c90ce6ade6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b752b2a-18f3-441d-9e68-6c90ce6ade6d" xlink:to="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_550c575f-3292-4277-8721-2493d6076315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_550c575f-3292-4277-8721-2493d6076315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_ab41ce9c-baa9-4187-96df-0f035eddaa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4125d139-a06a-4613-9933-34bbd63e96a4" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_ab41ce9c-baa9-4187-96df-0f035eddaa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4d139706-6a32-4412-ac22-9c1192a6098d" xlink:to="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f22fe200-75da-4bef-b2c6-3ec8c65de4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f22fe200-75da-4bef-b2c6-3ec8c65de4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b79ff889-2ddb-40f0-9148-356c05e86b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b79ff889-2ddb-40f0-9148-356c05e86b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fd57a1e5-fee5-4b79-93b9-0de1f54baf53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fd57a1e5-fee5-4b79-93b9-0de1f54baf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f33e810a-2654-44bd-8a23-ae8cec6c60d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f33e810a-2654-44bd-8a23-ae8cec6c60d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_abb40b98-fa67-43ec-82c0-b50f06f40bce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_abb40b98-fa67-43ec-82c0-b50f06f40bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fae49c52-fd67-41a4-bca5-bf62422a918e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fae49c52-fd67-41a4-bca5-bf62422a918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_51ca1480-4f87-4782-be6f-35fc3d4d332b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_51ca1480-4f87-4782-be6f-35fc3d4d332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_777c401d-38f3-4453-b3bd-a5a43a1a167d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockSharesIssued_777c401d-38f3-4453-b3bd-a5a43a1a167d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c532bcdf-a54c-44c5-aba1-6c8e684f1a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b530a0a-c757-42b2-b542-c9d6ea42a63b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c532bcdf-a54c-44c5-aba1-6c8e684f1a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_449bcbb7-6775-466e-9f8b-fc9bb677e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_RevenuesAbstract_449bcbb7-6775-466e-9f8b-fc9bb677e56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8eb2b1b3-4a00-4c0a-a784-beaf2607286e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_449bcbb7-6775-466e-9f8b-fc9bb677e56c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8eb2b1b3-4a00-4c0a-a784-beaf2607286e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ac2d5523-5750-431a-b8b3-f23d373b6456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ac2d5523-5750-431a-b8b3-f23d373b6456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8a7beaa0-6569-4266-ab7f-3fb43f28bc75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac2d5523-5750-431a-b8b3-f23d373b6456" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8a7beaa0-6569-4266-ab7f-3fb43f28bc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_83ba82fe-9e94-4adb-bb1d-296e46a47555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac2d5523-5750-431a-b8b3-f23d373b6456" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_83ba82fe-9e94-4adb-bb1d-296e46a47555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b631d561-8c74-4569-99eb-50b66a9d3f54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac2d5523-5750-431a-b8b3-f23d373b6456" xlink:to="loc_us-gaap_OperatingExpenses_b631d561-8c74-4569-99eb-50b66a9d3f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6410df39-7f4b-4c6c-a483-d77726a54bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_OperatingIncomeLoss_6410df39-7f4b-4c6c-a483-d77726a54bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00527ea7-1df5-4b43-bb7f-ab1b0f8831a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00527ea7-1df5-4b43-bb7f-ab1b0f8831a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_0560a8cf-77a1-4566-9966-623acef3086f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00527ea7-1df5-4b43-bb7f-ab1b0f8831a9" xlink:to="loc_us-gaap_InterestAndOtherIncome_0560a8cf-77a1-4566-9966-623acef3086f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_b17ad016-8f05-4679-9dbe-cd29b51602f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00527ea7-1df5-4b43-bb7f-ab1b0f8831a9" xlink:to="loc_us-gaap_InterestExpenseNonoperating_b17ad016-8f05-4679-9dbe-cd29b51602f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1a23c909-21e7-4ffa-bdd4-6c31355c4797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_00527ea7-1df5-4b43-bb7f-ab1b0f8831a9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1a23c909-21e7-4ffa-bdd4-6c31355c4797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e8f0109-2713-4e99-98e2-2cf5321178f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_NetIncomeLoss_3e8f0109-2713-4e99-98e2-2cf5321178f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_75bdc9ba-fac5-4fac-b27f-b6778369f819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_EarningsPerShareBasic_75bdc9ba-fac5-4fac-b27f-b6778369f819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_adccfdca-3e36-40ee-a28f-90b2968d1c38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_EarningsPerShareDiluted_adccfdca-3e36-40ee-a28f-90b2968d1c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_24a9b577-fe0c-4833-a28a-707e734ba65e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_24a9b577-fe0c-4833-a28a-707e734ba65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4daa80fb-070e-4014-b2bd-a1e7f56bd154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4daa80fb-070e-4014-b2bd-a1e7f56bd154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fe637c63-d57c-4e52-bf2b-2664649ef99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69df9e7a-664a-4f3f-949c-42397ad3bf86" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fe637c63-d57c-4e52-bf2b-2664649ef99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_724bb16d-ced3-4988-b4f8-0797e995b54e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fe637c63-d57c-4e52-bf2b-2664649ef99d" xlink:to="loc_us-gaap_NetIncomeLoss_724bb16d-ced3-4988-b4f8-0797e995b54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7897fc8d-801f-4e51-aed9-de362f08b088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fe637c63-d57c-4e52-bf2b-2664649ef99d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7897fc8d-801f-4e51-aed9-de362f08b088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e1aaaaf-e68f-4d45-9c0a-5a5fd2a31dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7897fc8d-801f-4e51-aed9-de362f08b088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e1aaaaf-e68f-4d45-9c0a-5a5fd2a31dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e2e03279-f0ab-451e-bb64-7df4b03279f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7897fc8d-801f-4e51-aed9-de362f08b088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e2e03279-f0ab-451e-bb64-7df4b03279f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7d8889ec-c713-4cf1-b6ae-4172fd0a37c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fe637c63-d57c-4e52-bf2b-2664649ef99d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7d8889ec-c713-4cf1-b6ae-4172fd0a37c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c5c0117a-b4a5-4142-8271-bd420865b2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6d92edb8-1a42-49a9-b9af-e157b55f8a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c5c0117a-b4a5-4142-8271-bd420865b2d8" xlink:to="loc_us-gaap_StatementTable_6d92edb8-1a42-49a9-b9af-e157b55f8a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ba85b62-8005-41b1-ae0f-d929db20fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6d92edb8-1a42-49a9-b9af-e157b55f8a83" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ba85b62-8005-41b1-ae0f-d929db20fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_45fa3325-ad6a-46c6-b040-725c4f77882f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ba85b62-8005-41b1-ae0f-d929db20fec0" xlink:to="loc_us-gaap_RelatedPartyDomain_45fa3325-ad6a-46c6-b040-725c4f77882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_ac7740dd-151b-415b-867c-c9460cdd3854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_45fa3325-ad6a-46c6-b040-725c4f77882f" xlink:to="loc_us-gaap_RelatedPartyMember_ac7740dd-151b-415b-867c-c9460cdd3854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06d13535-885b-4484-9d01-c66bbed957c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6d92edb8-1a42-49a9-b9af-e157b55f8a83" xlink:to="loc_us-gaap_StatementLineItems_06d13535-885b-4484-9d01-c66bbed957c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6057915c-aa98-4d21-9d93-f249937903dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06d13535-885b-4484-9d01-c66bbed957c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6057915c-aa98-4d21-9d93-f249937903dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6864037b-f554-4235-b3aa-7b14b9aa3c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6864037b-f554-4235-b3aa-7b14b9aa3c7d" xlink:to="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c38dca7f-df5a-4851-be32-7874e59cfb72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c38dca7f-df5a-4851-be32-7874e59cfb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c38dca7f-df5a-4851-be32-7874e59cfb72" xlink:to="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_5f1c2f9c-f328-4b44-a895-ee17d2a0fc85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_PreferredStockMember_5f1c2f9c-f328-4b44-a895-ee17d2a0fc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7b869700-223d-4259-b09c-7370b1589f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_CommonStockMember_7b869700-223d-4259-b09c-7370b1589f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fd027ef0-78be-4457-925b-6dcd8085095d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fd027ef0-78be-4457-925b-6dcd8085095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ecd8b0f-6e80-44b0-aeb1-60f00203d717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4ecd8b0f-6e80-44b0-aeb1-60f00203d717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a043f7e4-d85c-45c1-8931-a2f7dab6c77b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa518f2c-720b-457c-8cb2-50a7308fe3ce" xlink:to="loc_us-gaap_RetainedEarningsMember_a043f7e4-d85c-45c1-8931-a2f7dab6c77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_64dde36a-1e2e-40ea-8eb8-7236820d67d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:to="loc_us-gaap_StatementClassOfStockAxis_64dde36a-1e2e-40ea-8eb8-7236820d67d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64dde36a-1e2e-40ea-8eb8-7236820d67d7" xlink:to="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8014ead8-5ce9-4bca-9ec3-88985e1784ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8014ead8-5ce9-4bca-9ec3-88985e1784ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_504ec9a5-d7f4-4b3e-b3c1-6984bd139449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4a5c9da0-1abf-4d92-bbb8-38a92ac8fc0f" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_504ec9a5-d7f4-4b3e-b3c1-6984bd139449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ac59e296-8c15-4c42-9744-af11a4bc6086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ac59e296-8c15-4c42-9744-af11a4bc6086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac59e296-8c15-4c42-9744-af11a4bc6086" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2024PublicOfferingMember_0d3a2a59-0bb5-4707-a5f7-279ebc593d7e" xlink:href="vrdn-20240930.xsd#vrdn_A2024PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:to="loc_vrdn_A2024PublicOfferingMember_0d3a2a59-0bb5-4707-a5f7-279ebc593d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_September2022AtTheMarketOfferingMember_4a785ae0-8028-4be9-84f0-82619e171e90" xlink:href="vrdn-20240930.xsd#vrdn_September2022AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70538648-acf0-4a2e-9524-b44c96a28b5f" xlink:to="loc_vrdn_September2022AtTheMarketOfferingMember_4a785ae0-8028-4be9-84f0-82619e171e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_531d6f15-579b-4c94-8836-37a5fa25f3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cef1cde3-e9e4-481b-a7a8-b52ab32f9169" xlink:to="loc_us-gaap_StatementLineItems_531d6f15-579b-4c94-8836-37a5fa25f3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_531d6f15-579b-4c94-8836-37a5fa25f3b0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f4a08495-b243-48ac-ab7a-77b846f4d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f4a08495-b243-48ac-ab7a-77b846f4d1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2449dabe-253d-4709-8c91-0993e5ce7d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockholdersEquity_2449dabe-253d-4709-8c91-0993e5ce7d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dcf223d8-f995-4b7e-aad0-bc6008499f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dcf223d8-f995-4b7e-aad0-bc6008499f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f36bd197-1feb-4b44-bbf6-91a2df5c7d21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f36bd197-1feb-4b44-bbf6-91a2df5c7d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5bd74f6d-5bb1-487d-8ac4-98a687ce35de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5bd74f6d-5bb1-487d-8ac4-98a687ce35de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_3881ff5f-076d-4fd0-b81e-2fb577029955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_3881ff5f-076d-4fd0-b81e-2fb577029955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7d87bb7c-716b-479b-ad3e-7133c104231e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_7d87bb7c-716b-479b-ad3e-7133c104231e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5704148-323f-403a-998b-3589cb68d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5704148-323f-403a-998b-3589cb68d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3824290e-e863-449f-a207-f16b9ae05a31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3824290e-e863-449f-a207-f16b9ae05a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_03cca528-c1fc-4f2e-b125-f8e83b950eaa" xlink:href="vrdn-20240930.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares_03cca528-c1fc-4f2e-b125-f8e83b950eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_f7be0ebf-996d-4812-99f3-bef2eeea6e4f" xlink:href="vrdn-20240930.xsd#vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue_f7be0ebf-996d-4812-99f3-bef2eeea6e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2a988746-8765-4add-b705-9d047073b572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2a988746-8765-4add-b705-9d047073b572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ba03a9c9-dd69-45ee-a1e5-abcb715d0413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ba03a9c9-dd69-45ee-a1e5-abcb715d0413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_776b8bda-b8af-4fb2-9595-6c77f8468fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_776b8bda-b8af-4fb2-9595-6c77f8468fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_07f6c409-8c47-4c7a-b4a0-fe9261c92b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_07f6c409-8c47-4c7a-b4a0-fe9261c92b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_64ce79c7-af9b-4ed3-88c7-1acc10b604fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_64ce79c7-af9b-4ed3-88c7-1acc10b604fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_329d136c-23cf-491e-8f13-af7650ff84b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_329d136c-23cf-491e-8f13-af7650ff84b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dde45ef-d138-4768-90cd-ea61712588e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dde45ef-d138-4768-90cd-ea61712588e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f304d8d8-d0e7-48d5-ac83-fc852fb45132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f304d8d8-d0e7-48d5-ac83-fc852fb45132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44747f47-496e-4799-a462-e3de9b6123e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_NetIncomeLoss_44747f47-496e-4799-a462-e3de9b6123e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4b5bf1e2-edf0-468a-901b-b2414547100f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4b5bf1e2-edf0-468a-901b-b2414547100f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_126628d3-cf3f-49a0-8cff-79d16aa31a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_StockholdersEquity_126628d3-cf3f-49a0-8cff-79d16aa31a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2dd8c653-8add-4ea6-97ce-9c29e47f8001" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3a318747-f39f-4d47-b01c-2e1899138496" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2dd8c653-8add-4ea6-97ce-9c29e47f8001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c1c0fb50-d145-4e22-9ac4-c5fc5ca99218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c1c0fb50-d145-4e22-9ac4-c5fc5ca99218" xlink:to="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bfe19b0a-c457-4c44-9039-ae5e9dcce563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bfe19b0a-c457-4c44-9039-ae5e9dcce563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1274d2d5-0214-4aba-a326-b040bf7021ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bfe19b0a-c457-4c44-9039-ae5e9dcce563" xlink:to="loc_us-gaap_EquityComponentDomain_1274d2d5-0214-4aba-a326-b040bf7021ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2ad78242-a21a-4a0f-a9d2-c3e956de4664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1274d2d5-0214-4aba-a326-b040bf7021ea" xlink:to="loc_us-gaap_CommonStockMember_2ad78242-a21a-4a0f-a9d2-c3e956de4664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_13b946af-3a1c-45c5-9d46-b54908d6175b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_13b946af-3a1c-45c5-9d46-b54908d6175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13b946af-3a1c-45c5-9d46-b54908d6175b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2024PublicOfferingMember_ecf66844-2b9f-4df9-9d29-dd11bf9cfafe" xlink:href="vrdn-20240930.xsd#vrdn_A2024PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:to="loc_vrdn_A2024PublicOfferingMember_ecf66844-2b9f-4df9-9d29-dd11bf9cfafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_September2022AtTheMarketOfferingMember_c852fea5-c101-4b34-8054-b34c51480a54" xlink:href="vrdn-20240930.xsd#vrdn_September2022AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_82dddaf9-d43c-41b7-85c5-5af183457d08" xlink:to="loc_vrdn_September2022AtTheMarketOfferingMember_c852fea5-c101-4b34-8054-b34c51480a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6aa43615-d396-4277-9eb8-85af0df69d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7176cc1c-85e1-4f59-be36-10ce8f2c06c9" xlink:to="loc_us-gaap_StatementLineItems_6aa43615-d396-4277-9eb8-85af0df69d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_47a3f68b-90c8-4306-9396-01e49b4bf326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6aa43615-d396-4277-9eb8-85af0df69d90" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_47a3f68b-90c8-4306-9396-01e49b4bf326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2281a7cd-1088-44e9-8a8a-ebb2f2024463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3a6eab3-e357-403e-b0dd-56997b91309b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2281a7cd-1088-44e9-8a8a-ebb2f2024463" xlink:to="loc_us-gaap_StatementTable_e3a6eab3-e357-403e-b0dd-56997b91309b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c5938bc-5d38-4508-be8f-23c3cf17295f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3a6eab3-e357-403e-b0dd-56997b91309b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c5938bc-5d38-4508-be8f-23c3cf17295f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c5938bc-5d38-4508-be8f-23c3cf17295f" xlink:to="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e862d950-fd90-47f2-983b-401776fd3d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:to="loc_us-gaap_CommonStockMember_e862d950-fd90-47f2-983b-401776fd3d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_27b65faf-d72b-4ddb-84fe-318491542f03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d55d1f67-f5f3-4573-8bfa-58173a195457" xlink:to="loc_us-gaap_PreferredStockMember_27b65faf-d72b-4ddb-84fe-318491542f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3a6eab3-e357-403e-b0dd-56997b91309b" xlink:to="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb75d425-8b2e-4b04-b8fe-7e58d66d9083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:to="loc_us-gaap_NetIncomeLoss_eb75d425-8b2e-4b04-b8fe-7e58d66d9083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8ab27712-2eb3-4136-9650-fe8eb9ff2c06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_ShareBasedCompensation_8ab27712-2eb3-4136-9650-fe8eb9ff2c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9c65d916-ba18-4394-a881-d1fde2c20b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9c65d916-ba18-4394-a881-d1fde2c20b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b7a8a13c-5297-4c7f-95d9-9d42d3d669f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b7a8a13c-5297-4c7f-95d9-9d42d3d669f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_807947b1-f2ec-4757-a0b0-aec58e67ba79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_807947b1-f2ec-4757-a0b0-aec58e67ba79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_703789b4-c9d7-4b75-9c56-606ca0b928b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_703789b4-c9d7-4b75-9c56-606ca0b928b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_NonCashLeaseExpense_68088e73-3894-4a6e-b467-01831e40d2e0" xlink:href="vrdn-20240930.xsd#vrdn_NonCashLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_vrdn_NonCashLeaseExpense_68088e73-3894-4a6e-b467-01831e40d2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92579ca5-14c1-4395-9656-f046d3db7f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92579ca5-14c1-4395-9656-f046d3db7f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtExtinguishmentExpense_6b202cf7-5e6d-4907-b03c-9722557aede9" xlink:href="vrdn-20240930.xsd#vrdn_DebtExtinguishmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_vrdn_DebtExtinguishmentExpense_6b202cf7-5e6d-4907-b03c-9722557aede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5287ae3d-ac7c-45de-9870-b84c2090ea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5287ae3d-ac7c-45de-9870-b84c2090ea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9778b388-69ce-48c4-b244-e91ebfe5a94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9778b388-69ce-48c4-b244-e91ebfe5a94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09432339-1031-44ba-a1ef-6179d2764049" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5a3f0c19-4629-4fa4-9c30-ca80c12bf8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5a3f0c19-4629-4fa4-9c30-ca80c12bf8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7f06fbdc-7c98-4b97-89fb-ff5f35fbe668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7f06fbdc-7c98-4b97-89fb-ff5f35fbe668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fb1d88f6-34cf-4a3a-9bcf-879ba10c6b62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fb1d88f6-34cf-4a3a-9bcf-879ba10c6b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_94a2996b-eb59-4412-bffc-9671c2e4e345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_94a2996b-eb59-4412-bffc-9671c2e4e345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92251452-6acf-41a3-a304-79182f9d3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12cdf57a-7b0c-4547-8a5f-ed175fbc47d1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92251452-6acf-41a3-a304-79182f9d3cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fd43d43-a93d-426f-ad03-2452651019ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_267dfab2-ff01-48b2-9268-ea32d57feb57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3fd43d43-a93d-426f-ad03-2452651019ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2fb2674b-1a66-4600-9d90-cc619f20e9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2fb2674b-1a66-4600-9d90-cc619f20e9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a3b698e5-bca5-4bcd-8e6c-0874f9a44285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a3b698e5-bca5-4bcd-8e6c-0874f9a44285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0ae91c20-f39e-49b0-b7ce-6a89855e6d59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0ae91c20-f39e-49b0-b7ce-6a89855e6d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_065a52f3-3e5e-4afe-9590-c87e096a7379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_63649b2c-3a56-42bd-8f28-057c5a0dd7d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_065a52f3-3e5e-4afe-9590-c87e096a7379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4143dc38-acb8-4442-bde4-4c3a26b40324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4143dc38-acb8-4442-bde4-4c3a26b40324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f57f85e4-4847-4388-b2ed-1294442179f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f57f85e4-4847-4388-b2ed-1294442179f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_43a5390a-d6b3-4957-8513-bb06ace9ab49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_43a5390a-d6b3-4957-8513-bb06ace9ab49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8210f654-812f-464e-b2e5-45179fc83e76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8210f654-812f-464e-b2e5-45179fc83e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_84b58759-c0bb-4ef5-b24a-b88059b6fc32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_84b58759-c0bb-4ef5-b24a-b88059b6fc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_bff08dcf-0f4b-443a-8a80-77f350cfb8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_bff08dcf-0f4b-443a-8a80-77f350cfb8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8ef9ce3a-e1b3-4d02-93f4-b92fa38c374f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8ef9ce3a-e1b3-4d02-93f4-b92fa38c374f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_36e8049d-f44a-4007-8fdb-a0357f7edfab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_ProceedsFromStockPlans_36e8049d-f44a-4007-8fdb-a0357f7edfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b04951a-7f75-4ca2-800f-58b43552064f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71447b67-085d-48c3-9c8f-cfea9ac5c454" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b04951a-7f75-4ca2-800f-58b43552064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437d6e27-caba-4f00-90d6-e6b852ec0452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437d6e27-caba-4f00-90d6-e6b852ec0452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36d8d0e2-e90a-4d8b-8438-0613a5c99aba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36d8d0e2-e90a-4d8b-8438-0613a5c99aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5dda9e3f-3aaa-4d40-a3a4-101f231eb4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5dda9e3f-3aaa-4d40-a3a4-101f231eb4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e151359-7338-4837-a026-0cdb30cd0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e151359-7338-4837-a026-0cdb30cd0a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c0d6604c-03f7-4c4b-918e-c28ef290d3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5e151359-7338-4837-a026-0cdb30cd0a2d" xlink:to="loc_us-gaap_InterestPaidNet_c0d6604c-03f7-4c4b-918e-c28ef290d3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9daa620a-aafa-4763-b26f-ae7170cd4d1d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_b11a014a-2e1c-41fb-b899-89a086e7fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_b11a014a-2e1c-41fb-b899-89a086e7fd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2c8faa85-4c56-4972-bec6-a901bf8a515a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2c8faa85-4c56-4972-bec6-a901bf8a515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_097022d4-838d-4a59-b920-cfd7783fb617" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_097022d4-838d-4a59-b920-cfd7783fb617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction_354c8f9b-fcfc-4fcc-8943-bc3eeb861406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_NotesReduction_354c8f9b-fcfc-4fcc-8943-bc3eeb861406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_c811a749-345c-41a7-8579-f33d22e92a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_68d551e6-756b-4507-8885-8b8bc60ad480" xlink:to="loc_us-gaap_NotesIssued1_c811a749-345c-41a7-8579-f33d22e92a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e6a1b2e-3bad-4123-9b50-b09eb1a432b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_15f14dfa-5795-459e-a185-ccf11b207dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e6a1b2e-3bad-4123-9b50-b09eb1a432b5" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_15f14dfa-5795-459e-a185-ccf11b207dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3e727189-7589-4f8f-a24e-eb65feb8d581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0f893ca2-cd79-44c6-9abe-094b71cd5860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3e727189-7589-4f8f-a24e-eb65feb8d581" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0f893ca2-cd79-44c6-9abe-094b71cd5860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_07491f81-77e1-4541-859d-4aa2bea97f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_5ec03a98-1ecd-45a2-8991-e70fd329c7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07491f81-77e1-4541-859d-4aa2bea97f71" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_5ec03a98-1ecd-45a2-8991-e70fd329c7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHER" xlink:type="simple" xlink:href="vrdn-20240930.xsd#ACCRUEDLIABILITIESANDOTHER"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9e6dbd2e-41a4-4da2-bf96-d42c708bc82e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_eaba1cc8-eb1f-4a2a-b7c8-c760f546a95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9e6dbd2e-41a4-4da2-bf96-d42c708bc82e" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_eaba1cc8-eb1f-4a2a-b7c8-c760f546a95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBT" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6d74fb25-29a2-4f67-8991-6baf2031a984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_24e856da-de31-475e-ac31-4f45fdc52f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d74fb25-29a2-4f67-8991-6baf2031a984" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_24e856da-de31-475e-ac31-4f45fdc52f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COLLABORATIONAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef218305-d13c-43d6-86f5-cb0d7ef702e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ca9f6e10-6d05-434a-bc42-e4b2ff411c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef218305-d13c-43d6-86f5-cb0d7ef702e9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ca9f6e10-6d05-434a-bc42-e4b2ff411c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7b8b9be-33c0-4ed9-8e2f-43b41d139255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b2affd8-9261-4cda-9c2a-5b5f540e53c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7b8b9be-33c0-4ed9-8e2f-43b41d139255" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b2affd8-9261-4cda-9c2a-5b5f540e53c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCK" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CAPITALSTOCK"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CAPITALSTOCK" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6dae1ee6-7d9c-4c2f-8d28-c604c9ba3e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_63923618-2b33-4a2a-b7f2-5723dd9f47e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6dae1ee6-7d9c-4c2f-8d28-c604c9ba3e82" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_63923618-2b33-4a2a-b7f2-5723dd9f47e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTS" xlink:type="simple" xlink:href="vrdn-20240930.xsd#WARRANTS"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_9c0682b5-a102-400e-8756-7f673fbe5719" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9219172a-bdcb-4ef7-a781-15a3cb883ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_9c0682b5-a102-400e-8756-7f673fbe5719" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9219172a-bdcb-4ef7-a781-15a3cb883ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41a252e7-f015-4a36-9103-609a3d15d2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_acb5aba2-1e2a-46f7-8c8c-1167e4fc3488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41a252e7-f015-4a36-9103-609a3d15d2ff" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_acb5aba2-1e2a-46f7-8c8c-1167e4fc3488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="vrdn-20240930.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_286c5f4c-4355-4050-8e61-c4288032d26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ae037642-42e0-4841-b66e-a945640a09dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_286c5f4c-4355-4050-8e61-c4288032d26b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ae037642-42e0-4841-b66e-a945640a09dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_24878691-1a25-458b-851c-8d3e1ab4024d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_24878691-1a25-458b-851c-8d3e1ab4024d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_GoingConcernPolicyPolicyTextBlock_e64d7aca-ccd1-4cbf-8416-a430c2775373" xlink:href="vrdn-20240930.xsd#vrdn_GoingConcernPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_vrdn_GoingConcernPolicyPolicyTextBlock_e64d7aca-ccd1-4cbf-8416-a430c2775373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_757e0700-6477-4ef0-99c1-d8b22b74666f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_UseOfEstimates_757e0700-6477-4ef0-99c1-d8b22b74666f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_00e24197-e5fa-4186-b4b4-c091537ccc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_00e24197-e5fa-4186-b4b4-c091537ccc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d9f9411c-0365-4b77-8cdb-dd9c1fc293cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d9f9411c-0365-4b77-8cdb-dd9c1fc293cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_90b18edc-8d0d-4bfa-a7af-60978834f5ef" xlink:href="vrdn-20240930.xsd#vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_90b18edc-8d0d-4bfa-a7af-60978834f5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14eaa16a-d1cb-4320-bb0e-619d2a16eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14eaa16a-d1cb-4320-bb0e-619d2a16eafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c040976-f1db-44a8-a991-1981d4c68b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c040976-f1db-44a8-a991-1981d4c68b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_e0707486-4ea0-4a43-b649-112961f13f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_e0707486-4ea0-4a43-b649-112961f13f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7d23bd50-672b-4f4a-9e7d-75a57f192a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7d23bd50-672b-4f4a-9e7d-75a57f192a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_61f02b70-c783-49fa-bca3-dee5721a2256" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_61f02b70-c783-49fa-bca3-dee5721a2256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5cb69ff3-74b9-4924-be03-fab765daa2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5cb69ff3-74b9-4924-be03-fab765daa2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8484289a-c4ca-4b16-8c86-e39ff65c3251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8484289a-c4ca-4b16-8c86-e39ff65c3251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_8a88921b-b59c-4761-86c3-245bc5251ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_DebtPolicyTextBlock_8a88921b-b59c-4761-86c3-245bc5251ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_8d56501e-06be-40a2-a0c6-fe896777bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_8d56501e-06be-40a2-a0c6-fe896777bdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_76ad8b82-3076-417d-9fb6-d846ba9ce507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_76ad8b82-3076-417d-9fb6-d846ba9ce507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3d339c84-cc09-4cb4-b0ce-4153afef7b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3d339c84-cc09-4cb4-b0ce-4153afef7b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e1fc6d2d-5a76-435b-bcbb-ec1f61e417b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e1fc6d2d-5a76-435b-bcbb-ec1f61e417b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3976894e-8176-4e60-aa77-3b26fe5f303d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3976894e-8176-4e60-aa77-3b26fe5f303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_WarrantsPolicyPolicyTextBlock_0909ce52-54f3-4bcd-9f1f-8d9d042e5e89" xlink:href="vrdn-20240930.xsd#vrdn_WarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_vrdn_WarrantsPolicyPolicyTextBlock_0909ce52-54f3-4bcd-9f1f-8d9d042e5e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7e8e9ad0-f4a6-495e-a0f9-c5eeea82f605" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7e8e9ad0-f4a6-495e-a0f9-c5eeea82f605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7548a806-190d-44a5-bfe4-9ed5604b7433" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e7774a5-c3be-4556-a09d-2a5d7be9a7d7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7548a806-190d-44a5-bfe4-9ed5604b7433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b2990585-70f2-490f-b84e-38042aad0891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a4e7e51a-141a-4b11-b68d-f11bc9e72f22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2990585-70f2-490f-b84e-38042aad0891" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a4e7e51a-141a-4b11-b68d-f11bc9e72f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_504f5edb-27a0-41a9-b644-99d229f49b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2990585-70f2-490f-b84e-38042aad0891" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_504f5edb-27a0-41a9-b644-99d229f49b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERTables" xlink:type="simple" xlink:href="vrdn-20240930.xsd#ACCRUEDLIABILITIESANDOTHERTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_503685d2-1493-4f09-9463-d29e5250c8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eb917407-453b-4c5a-871c-37f28a5e1b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_503685d2-1493-4f09-9463-d29e5250c8fc" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eb917407-453b-4c5a-871c-37f28a5e1b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTTables" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8b2b7ba5-fc74-4473-9b2b-3ddef2499561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_713df47a-a38e-43bd-b2d6-3d3b109269f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8b2b7ba5-fc74-4473-9b2b-3ddef2499561" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_713df47a-a38e-43bd-b2d6-3d3b109269f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ced69fe3-fb8d-4bb3-93cd-864d9f9b294a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8b2b7ba5-fc74-4473-9b2b-3ddef2499561" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ced69fe3-fb8d-4bb3-93cd-864d9f9b294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd208f4e-8d09-4914-a58a-82ea96eec6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8d6de128-dde1-4a38-99d1-3b6376fcef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd208f4e-8d09-4914-a58a-82ea96eec6d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8d6de128-dde1-4a38-99d1-3b6376fcef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSTables" xlink:type="simple" xlink:href="vrdn-20240930.xsd#WARRANTSTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3bc31904-62aa-4725-b6df-d0bb0081c6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bdcdf2a0-8092-4321-acb6-0984aba60dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_3bc31904-62aa-4725-b6df-d0bb0081c6ea" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bdcdf2a0-8092-4321-acb6-0984aba60dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1916c79-e03c-4c36-82e9-7463620e778e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_cfa854c1-0cb7-4df5-b45f-d0861ccec827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1916c79-e03c-4c36-82e9-7463620e778e" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_cfa854c1-0cb7-4df5-b45f-d0861ccec827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f033254f-07a2-4179-8435-cd7afb2ffd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1916c79-e03c-4c36-82e9-7463620e778e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f033254f-07a2-4179-8435-cd7afb2ffd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bf47f246-0c45-47b2-9122-ca605008a76a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1916c79-e03c-4c36-82e9-7463620e778e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bf47f246-0c45-47b2-9122-ca605008a76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_315d0357-1978-4f88-b08c-ea377a009104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1916c79-e03c-4c36-82e9-7463620e778e" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_315d0357-1978-4f88-b08c-ea377a009104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f7a3e78a-a4ee-4d7e-a6c9-176f516084b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1916c79-e03c-4c36-82e9-7463620e778e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f7a3e78a-a4ee-4d7e-a6c9-176f516084b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="vrdn-20240930.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8264c542-c075-4c8d-9f70-ceb44a789306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a2b3c947-3ad2-4f6a-97d6-87f8940802df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8264c542-c075-4c8d-9f70-ceb44a789306" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a2b3c947-3ad2-4f6a-97d6-87f8940802df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f6c86ab-e6ca-4dab-b8cb-934b11ae3a15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f50d902a-0013-441e-957a-efbdff1a4c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f6c86ab-e6ca-4dab-b8cb-934b11ae3a15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f50d902a-0013-441e-957a-efbdff1a4c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_cf3f8f54-7d84-4881-9dce-1f0604aec266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f6c86ab-e6ca-4dab-b8cb-934b11ae3a15" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_cf3f8f54-7d84-4881-9dce-1f0604aec266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6cc59ecb-c495-48e2-b4c3-34fc7e720fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1dcd015e-6ebb-49a7-818e-d96689d3938c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6cc59ecb-c495-48e2-b4c3-34fc7e720fb0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1dcd015e-6ebb-49a7-818e-d96689d3938c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cd569ec1-13eb-4e2b-a009-c01023438644" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1dcd015e-6ebb-49a7-818e-d96689d3938c" xlink:to="loc_srt_RangeAxis_cd569ec1-13eb-4e2b-a009-c01023438644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cd569ec1-13eb-4e2b-a009-c01023438644" xlink:to="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7aa05668-5f9c-4741-9197-6f00cad5fa19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:to="loc_srt_MinimumMember_7aa05668-5f9c-4741-9197-6f00cad5fa19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85e12b6a-32b9-45b6-9e49-7eee6a5bd678" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_07eea8aa-c418-4817-b7bf-2ac55e7006f8" xlink:to="loc_srt_MaximumMember_85e12b6a-32b9-45b6-9e49-7eee6a5bd678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1dcd015e-6ebb-49a7-818e-d96689d3938c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e619c521-81ef-42b3-bafe-4c7ddf7aa98a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e619c521-81ef-42b3-bafe-4c7ddf7aa98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4cbcfed9-e6ec-4d89-ae64-c3ba01af3d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4cbcfed9-e6ec-4d89-ae64-c3ba01af3d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_593c44de-c031-41bb-bf54-e90e6fb35d85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_593c44de-c031-41bb-bf54-e90e6fb35d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_313956b1-f8d7-476a-8d57-8b2687e6f988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_313956b1-f8d7-476a-8d57-8b2687e6f988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_8db32d8a-1802-4c24-a044-3a1b3da2d6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_52226fb4-31d7-4aee-9fb7-9dd5042d0464" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_8db32d8a-1802-4c24-a044-3a1b3da2d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3d5045f4-e44b-499a-a56b-8f15082e44e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_745581bd-5f69-4358-bb0d-9a407663b281" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3d5045f4-e44b-499a-a56b-8f15082e44e3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_745581bd-5f69-4358-bb0d-9a407663b281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_703e3f96-8d9f-46ed-8693-e92517592e28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_745581bd-5f69-4358-bb0d-9a407663b281" xlink:to="loc_us-gaap_FinancialInstrumentAxis_703e3f96-8d9f-46ed-8693-e92517592e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_703e3f96-8d9f-46ed-8693-e92517592e28" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_24929725-662b-4f17-9a4e-5451b5dc4c71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_MoneyMarketFundsMember_24929725-662b-4f17-9a4e-5451b5dc4c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5a0093cc-53c7-48a3-aa5a-f3dd6832357f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5a0093cc-53c7-48a3-aa5a-f3dd6832357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_68241554-dc92-4b0b-8b44-7ad12d2985a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_68241554-dc92-4b0b-8b44-7ad12d2985a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_37e6fa18-e01a-458c-b443-8814ae598736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_403d4fe9-86a6-4fb4-acc3-babc5f609f79" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_37e6fa18-e01a-458c-b443-8814ae598736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_745581bd-5f69-4358-bb0d-9a407663b281" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c13f0de-aaea-4cc7-bf85-4603da333954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c13f0de-aaea-4cc7-bf85-4603da333954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5c4847d-eba9-47be-a44a-3429e2579f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5c4847d-eba9-47be-a44a-3429e2579f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1fd2fa1e-a770-4162-917b-10f8ddcc3309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1fd2fa1e-a770-4162-917b-10f8ddcc3309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9599962e-b5d8-4e42-aea3-a893bb162329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfa62192-e6cf-4e3b-8adf-4ffc9f9d95bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9599962e-b5d8-4e42-aea3-a893bb162329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7d7c1b97-1c68-4bb1-8d55-cb1b8bacfea7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_79629dd8-ed39-4db9-9a23-5fd6742beb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7d7c1b97-1c68-4bb1-8d55-cb1b8bacfea7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_79629dd8-ed39-4db9-9a23-5fd6742beb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2c2b4862-7a5a-4d26-848d-8dd76b60d690" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7d7c1b97-1c68-4bb1-8d55-cb1b8bacfea7" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2c2b4862-7a5a-4d26-848d-8dd76b60d690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_02fd8d23-b1d0-4dfa-9514-75b6ec93decb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7d7c1b97-1c68-4bb1-8d55-cb1b8bacfea7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_02fd8d23-b1d0-4dfa-9514-75b6ec93decb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_155ae457-2686-4d50-ac95-3bd464446880" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_155ae457-2686-4d50-ac95-3bd464446880" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_387ea5e4-56f4-431f-b5db-274cffcb7677" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_387ea5e4-56f4-431f-b5db-274cffcb7677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_682e6c45-f852-4de8-9c5f-c20d52d4e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_387ea5e4-56f4-431f-b5db-274cffcb7677" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_682e6c45-f852-4de8-9c5f-c20d52d4e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f578a7ad-9fb9-4cb3-9f76-049044304d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_682e6c45-f852-4de8-9c5f-c20d52d4e0c0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f578a7ad-9fb9-4cb3-9f76-049044304d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26e2158-24ce-4ee3-a048-31055211878e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26e2158-24ce-4ee3-a048-31055211878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e26e2158-24ce-4ee3-a048-31055211878e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4a5001a4-d2f5-443a-98eb-108e3029a29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4a5001a4-d2f5-443a-98eb-108e3029a29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b8329bc9-704c-45a2-8015-0163efdeb092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b8329bc9-704c-45a2-8015-0163efdeb092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1e8204b4-9e57-4641-85b4-c05420c516af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31f4fc89-7e83-48bb-9a2f-698f388ba64d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1e8204b4-9e57-4641-85b4-c05420c516af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_47857513-f5e4-460c-871a-2e12f6d934bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_47857513-f5e4-460c-871a-2e12f6d934bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_47857513-f5e4-460c-871a-2e12f6d934bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_dae497f1-5445-4cae-bb6c-90581247695f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_MoneyMarketFundsMember_dae497f1-5445-4cae-bb6c-90581247695f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8adfc8c3-9e6e-4a92-8593-f5787bb5f3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8adfc8c3-9e6e-4a92-8593-f5787bb5f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c55f95c9-9198-4533-9c9b-3ad24eae081e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_c55f95c9-9198-4533-9c9b-3ad24eae081e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_fa8c9712-fc73-42ec-a43a-e9dcfaffb19d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_45ffa200-75af-4f84-b95c-e6c231d7d012" xlink:to="loc_us-gaap_ForeignCorporateDebtSecuritiesMember_fa8c9712-fc73-42ec-a43a-e9dcfaffb19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e9a74d3e-e635-4ad0-a829-40bc88f4aab5" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:to="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6ee5ad6b-6604-478a-a53f-095a3571bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_6ee5ad6b-6604-478a-a53f-095a3571bc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f272409-8254-42e9-81d9-ec3ee0eb646a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6ee5ad6b-6604-478a-a53f-095a3571bc49" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f272409-8254-42e9-81d9-ec3ee0eb646a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_b94c07a5-d0d0-4070-a2bd-3ed8a91d579c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_84b5d31a-6c9e-4bfc-a7e4-ddd81cbae055" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_b94c07a5-d0d0-4070-a2bd-3ed8a91d579c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b929f6c0-2c97-4bf7-9e13-7780012b8cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_b94c07a5-d0d0-4070-a2bd-3ed8a91d579c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b929f6c0-2c97-4bf7-9e13-7780012b8cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_54c39082-4c8e-4b1f-925b-ebf4b5e1c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a61d1e87-fb68-4b1c-aa0d-0f30ebddc940" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_54c39082-4c8e-4b1f-925b-ebf4b5e1c7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_9cba99d3-1e88-4ee2-aae5-d00538123859" xlink:href="vrdn-20240930.xsd#vrdn_AccruedOutsourcingClinicalandPreclinicalStudies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies_9cba99d3-1e88-4ee2-aae5-d00538123859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0a78b529-9a19-4e3f-b716-a29d6796be60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0a78b529-9a19-4e3f-b716-a29d6796be60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_df50026e-a20f-4246-add1-c684ab5c9b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_df50026e-a20f-4246-add1-c684ab5c9b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLegalFeesCurrent_fe86ddab-828d-4755-b19b-5d24c99d167c" xlink:href="vrdn-20240930.xsd#vrdn_AccruedLegalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_vrdn_AccruedLegalFeesCurrent_fe86ddab-828d-4755-b19b-5d24c99d167c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6037e839-ad30-48d1-b3d0-2e750266196e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6037e839-ad30-48d1-b3d0-2e750266196e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_15600e1c-39cd-49c9-8bd4-761012f20815" xlink:href="vrdn-20240930.xsd#vrdn_AccruedLiabilityofWarrantsonTemporaryEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity_15600e1c-39cd-49c9-8bd4-761012f20815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_e2f72646-b718-40cc-a451-bdbd1404955e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_us-gaap_InterestPayableCurrent_e2f72646-b718-40cc-a451-bdbd1404955e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_355de197-faed-4159-9391-934b994a085c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_355de197-faed-4159-9391-934b994a085c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2dbbb6bf-5e1b-4b93-a3eb-ca37b77680d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2dbbb6bf-5e1b-4b93-a3eb-ca37b77680d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7ef1b36f-4e6c-45ed-b100-41b3c3a68190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_35cd2473-cbe2-4e3a-913a-92514d5f2a2f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7ef1b36f-4e6c-45ed-b100-41b3c3a68190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f2650101-69b9-4bb8-bbf7-8a20fbe3f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f2650101-69b9-4bb8-bbf7-8a20fbe3f0d9" xlink:to="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d3fc200c-6ccb-4570-b80f-333e85e9253f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d3fc200c-6ccb-4570-b80f-333e85e9253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_086eabe5-6c9e-4186-848a-7b482407eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3fc200c-6ccb-4570-b80f-333e85e9253f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_086eabe5-6c9e-4186-848a-7b482407eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_ec8a0990-cf97-40cc-9de0-8f7f5bb4e105" xlink:href="vrdn-20240930.xsd#vrdn_HerculesTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_086eabe5-6c9e-4186-848a-7b482407eaa4" xlink:to="loc_vrdn_HerculesTermLoanMember_ec8a0990-cf97-40cc-9de0-8f7f5bb4e105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3bb794ce-1df2-47be-b9e2-97707120452e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3bb794ce-1df2-47be-b9e2-97707120452e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9a801382-d8d0-46d8-82ad-c0e65f2ad65e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3bb794ce-1df2-47be-b9e2-97707120452e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9a801382-d8d0-46d8-82ad-c0e65f2ad65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3aca5298-7429-4a24-95a8-3c5a0b466f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9a801382-d8d0-46d8-82ad-c0e65f2ad65e" xlink:to="loc_us-gaap_SecuredDebtMember_3aca5298-7429-4a24-95a8-3c5a0b466f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodAxis_0c105a27-079d-403f-aa07-e162a66a85ea" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:to="loc_vrdn_DebtCovenantPeriodAxis_0c105a27-079d-403f-aa07-e162a66a85ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_DebtCovenantPeriodAxis_0c105a27-079d-403f-aa07-e162a66a85ea" xlink:to="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodOneMember_16fa7fbc-5b6b-4991-8390-ac7a2df46401" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:to="loc_vrdn_DebtCovenantPeriodOneMember_16fa7fbc-5b6b-4991-8390-ac7a2df46401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtCovenantPeriodTwoMember_d7839ffd-67af-4794-97f0-902995c0a74a" xlink:href="vrdn-20240930.xsd#vrdn_DebtCovenantPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_DebtCovenantPeriodDomain_e93c471d-feeb-4691-8471-7fa1d605c121" xlink:to="loc_vrdn_DebtCovenantPeriodTwoMember_d7839ffd-67af-4794-97f0-902995c0a74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_40bb33e8-afa7-44d3-944a-5974c44b823f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ef684090-a371-44fc-ab19-25b63f41058c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ef684090-a371-44fc-ab19-25b63f41058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentNumberOfTranches_c0b480fa-57da-4c59-89e9-f606432b89f3" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentNumberOfTranches_c0b480fa-57da-4c59-89e9-f606432b89f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_b51802c5-e21a-4c0c-a82b-a4d6c5441c5b" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountFirstTranche"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFirstTranche_b51802c5-e21a-4c0c-a82b-a4d6c5441c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_6c36862f-aee3-427a-ac40-1f27b19bb15a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_6c36862f-aee3-427a-ac40-1f27b19bb15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_c089ec83-45f5-47a7-aad3-16f3e1935e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_c089ec83-45f5-47a7-aad3-16f3e1935e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFacilityFee_80f16e0a-7b94-40b5-b85c-ed1bbf8851bf" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFacilityFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFacilityFee_80f16e0a-7b94-40b5-b85c-ed1bbf8851bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentOtherExpenses_a34961de-0b15-48e8-8f14-922309231e95" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentOtherExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentOtherExpenses_a34961de-0b15-48e8-8f14-922309231e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentPrincipalAmountTermFee_48f43fe5-4f5c-496f-aa0b-61ab9b3d1d24" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentPrincipalAmountTermFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentPrincipalAmountTermFee_48f43fe5-4f5c-496f-aa0b-61ab9b3d1d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_508dfdb3-a0b6-44a4-8f8e-81178ffdf0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_508dfdb3-a0b6-44a4-8f8e-81178ffdf0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_912f5fcd-e27b-4e6d-9d58-897c0f9f4801" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountSecondTranche"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountSecondTranche_912f5fcd-e27b-4e6d-9d58-897c0f9f4801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_7602a5ab-f5f5-4069-a3d9-1a3b5cf9d2a4" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountThirdTranche"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountThirdTranche_7602a5ab-f5f5-4069-a3d9-1a3b5cf9d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_b7ae6d98-8816-496b-a1ab-3e5e27117576" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentFaceAmountFourthTranche"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentFaceAmountFourthTranche_b7ae6d98-8816-496b-a1ab-3e5e27117576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eff8fd1e-85c3-433e-b40d-1b9c32e5000d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eff8fd1e-85c3-433e-b40d-1b9c32e5000d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a95dacc9-a0f6-4104-a00b-ac737774a6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a95dacc9-a0f6-4104-a00b-ac737774a6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_DebtInstrumentInterestRateMaximum_c8ce23cb-3f6f-4b70-bb17-699c6f906143" xlink:href="vrdn-20240930.xsd#vrdn_DebtInstrumentInterestRateMaximum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_vrdn_DebtInstrumentInterestRateMaximum_c8ce23cb-3f6f-4b70-bb17-699c6f906143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d3e67797-6cc2-4ac3-a75c-9518de616665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d3e67797-6cc2-4ac3-a75c-9518de616665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_a32ba8a4-d2c1-4756-b4c4-49b949e4e8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7bc0621f-779a-4401-a14d-1648603eea61" xlink:to="loc_us-gaap_InterestExpenseNonoperating_a32ba8a4-d2c1-4756-b4c4-49b949e4e8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTScheduleofLongTermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3b449d5f-8eb2-487d-ba3a-56f08bb4fb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3b449d5f-8eb2-487d-ba3a-56f08bb4fb9e" xlink:to="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fef3de6d-102d-42f9-80ef-7b37a13364e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:to="loc_us-gaap_DebtInstrumentAxis_fef3de6d-102d-42f9-80ef-7b37a13364e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e732ee87-b75b-4c23-89d9-8da4f4c72f65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fef3de6d-102d-42f9-80ef-7b37a13364e0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e732ee87-b75b-4c23-89d9-8da4f4c72f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_65f620fb-e05e-42c8-8b05-cb3d0da3649a" xlink:href="vrdn-20240930.xsd#vrdn_HerculesTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e732ee87-b75b-4c23-89d9-8da4f4c72f65" xlink:to="loc_vrdn_HerculesTermLoanMember_65f620fb-e05e-42c8-8b05-cb3d0da3649a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_628dd4a4-298f-47e3-a236-c1354d9d69cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_628dd4a4-298f-47e3-a236-c1354d9d69cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42111de2-11a2-48e2-be4d-391147c4965c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_628dd4a4-298f-47e3-a236-c1354d9d69cb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42111de2-11a2-48e2-be4d-391147c4965c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f59ee5e3-b7ad-4a0b-8a0f-a24581c32171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42111de2-11a2-48e2-be4d-391147c4965c" xlink:to="loc_us-gaap_SecuredDebtMember_f59ee5e3-b7ad-4a0b-8a0f-a24581c32171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2b310377-f389-4b4a-941b-bc6e3df1ca01" xlink:to="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_56f71be7-50cd-4698-abe6-99766fc0e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_56f71be7-50cd-4698-abe6-99766fc0e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_628c12d7-6081-4e53-8bbe-14aca107b283" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_628c12d7-6081-4e53-8bbe-14aca107b283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_67b600e6-15b3-46a2-84a3-61430e16ac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_LongTermDebt_67b600e6-15b3-46a2-84a3-61430e16ac4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4fbcc966-4dda-4257-a826-754036699192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_LongTermDebtCurrent_4fbcc966-4dda-4257-a826-754036699192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be816f5a-2d95-4e62-9ae7-89706147eeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75e2c9d8-354d-49cd-984f-ff9f55fcf15d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be816f5a-2d95-4e62-9ae7-89706147eeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#DEBTScheduleofFuturePrincipalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5bfa60dc-1fdd-4cb0-a6c4-abc0a6292d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5bfa60dc-1fdd-4cb0-a6c4-abc0a6292d0e" xlink:to="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_54b6c7ff-066c-4436-9ab1-86d1e8376e69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:to="loc_us-gaap_DebtInstrumentAxis_54b6c7ff-066c-4436-9ab1-86d1e8376e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a7b4906c-1ce3-4865-9b48-b28c0fadc079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_54b6c7ff-066c-4436-9ab1-86d1e8376e69" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a7b4906c-1ce3-4865-9b48-b28c0fadc079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_HerculesTermLoanMember_3b4e9b5d-d214-4d52-86e0-57ecc57b75e6" xlink:href="vrdn-20240930.xsd#vrdn_HerculesTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a7b4906c-1ce3-4865-9b48-b28c0fadc079" xlink:to="loc_vrdn_HerculesTermLoanMember_3b4e9b5d-d214-4d52-86e0-57ecc57b75e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5814065a-09a7-4004-b235-b6f80bb10509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5814065a-09a7-4004-b235-b6f80bb10509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7714fbb7-2966-4adb-8230-83b809c1190f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5814065a-09a7-4004-b235-b6f80bb10509" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7714fbb7-2966-4adb-8230-83b809c1190f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5b67f97d-5dab-4482-9b79-60dfb7e95311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7714fbb7-2966-4adb-8230-83b809c1190f" xlink:to="loc_us-gaap_SecuredDebtMember_5b67f97d-5dab-4482-9b79-60dfb7e95311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f7dfc13b-df3a-425b-b9b7-8c0f902ba144" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6dfe6f87-a9e1-4d5b-9de2-5974ceb17191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6dfe6f87-a9e1-4d5b-9de2-5974ceb17191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a8feac7d-088a-4bf1-ac2f-38b25a5a4bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a8feac7d-088a-4bf1-ac2f-38b25a5a4bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e413d55b-ce6b-4b8d-8b93-b289017a1136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e413d55b-ce6b-4b8d-8b93-b289017a1136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a4161432-07a4-4083-a203-664ed3d4393e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5507b4-929d-4edc-b9b4-ea69e888e7f5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a4161432-07a4-4083-a203-664ed3d4393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COLLABORATIONAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e839f2b-929b-4286-a2d7-b0b203a5e3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e839f2b-929b-4286-a2d7-b0b203a5e3c5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ba7b186-ceaa-4b73-9525-66092e05b9cf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:to="loc_srt_ProductOrServiceAxis_8ba7b186-ceaa-4b73-9525-66092e05b9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_07402f97-5bce-44a8-be5a-72ec0671a523" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8ba7b186-ceaa-4b73-9525-66092e05b9cf" xlink:to="loc_srt_ProductsAndServicesDomain_07402f97-5bce-44a8-be5a-72ec0671a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationRevenueMember_3c3315a3-6863-4e23-97b2-5f6bf1aec25e" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_07402f97-5bce-44a8-be5a-72ec0671a523" xlink:to="loc_vrdn_CollaborationRevenueMember_3c3315a3-6863-4e23-97b2-5f6bf1aec25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7b817f37-0cc4-4963-a0c3-b54ee20f3865" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:to="loc_srt_CounterpartyNameAxis_7b817f37-0cc4-4963-a0c3-b54ee20f3865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7b817f37-0cc4-4963-a0c3-b54ee20f3865" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ZenasBioPharmaMember_6c31a7ad-1cea-452c-8603-4ca6e97fa985" xlink:href="vrdn-20240930.xsd#vrdn_ZenasBioPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:to="loc_vrdn_ZenasBioPharmaMember_6c31a7ad-1cea-452c-8603-4ca6e97fa985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ParagonTherapeuticsMember_276456fa-3653-48a1-8f52-4849daf18459" xlink:href="vrdn-20240930.xsd#vrdn_ParagonTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_089115d7-ddef-46e4-9ff3-8a0ea4021f09" xlink:to="loc_vrdn_ParagonTherapeuticsMember_276456fa-3653-48a1-8f52-4849daf18459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c8667a27-fe9d-4841-8ea1-b3f78309a1a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:to="loc_srt_OwnershipAxis_c8667a27-fe9d-4841-8ea1-b3f78309a1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_be69bb97-18d5-4e0b-9d46-abfa468b0a75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c8667a27-fe9d-4841-8ea1-b3f78309a1a7" xlink:to="loc_srt_OwnershipDomain_be69bb97-18d5-4e0b-9d46-abfa468b0a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FairmountFundsManagementMember_1ff7ad5a-84ca-4e5e-98b3-5e07fccfa304" xlink:href="vrdn-20240930.xsd#vrdn_FairmountFundsManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_be69bb97-18d5-4e0b-9d46-abfa468b0a75" xlink:to="loc_vrdn_FairmountFundsManagementMember_1ff7ad5a-84ca-4e5e-98b3-5e07fccfa304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79bad3af-c1ff-41c4-9cf1-0a2a77943641" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_900b61e7-1e3b-4fb1-948b-98286d329ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_900b61e7-1e3b-4fb1-948b-98286d329ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementInitialPayment_f2e8040d-c858-4d0a-af7f-db579130e8be" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementInitialPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementInitialPayment_f2e8040d-c858-4d0a-af7f-db579130e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_54b1278a-bf28-4441-afa7-72d7199854de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_54b1278a-bf28-4441-afa7-72d7199854de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_06e4d4b8-6ff7-463b-af0e-360087d3feea" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementUpfrontFeePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborativeArrangementUpfrontFeePayment_06e4d4b8-6ff7-463b-af0e-360087d3feea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_c6d764f5-a249-4fce-8a34-54664a649458" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_c6d764f5-a249-4fce-8a34-54664a649458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment_9c713043-dd03-4ecd-839e-cd83b453c953" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborativeArrangementMilestonePayment_9c713043-dd03-4ecd-839e-cd83b453c953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments_1667e738-b5b7-417c-9488-fd87ce0afe30" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments_1667e738-b5b7-417c-9488-fd87ce0afe30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementMaximumMilestonePayments_554e0e45-4306-4bf2-b2b3-09fff2d1a8f2" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementMaximumMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementMaximumMilestonePayments_554e0e45-4306-4bf2-b2b3-09fff2d1a8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_6766e71f-49f5-46e5-a432-fca6641f142d" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_6766e71f-49f5-46e5-a432-fca6641f142d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_c6dfcd93-d2a5-4e75-b20e-1ef2f7e144e0" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum_c6dfcd93-d2a5-4e75-b20e-1ef2f7e144e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0627f670-0a50-464d-b32e-86399547ed40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_59eff182-8873-4dfb-9d45-1072153441b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0627f670-0a50-464d-b32e-86399547ed40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4fd0c91-47fe-47b9-83f5-5ffb9475009a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4fd0c91-47fe-47b9-83f5-5ffb9475009a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_05f94cc0-55f7-4b40-a9d4-5943c237867e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_05f94cc0-55f7-4b40-a9d4-5943c237867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_05f94cc0-55f7-4b40-a9d4-5943c237867e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ImmunoGenIncMember_4c84ea4f-d29e-4b33-be23-4548bd47150f" xlink:href="vrdn-20240930.xsd#vrdn_ImmunoGenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:to="loc_vrdn_ImmunoGenIncMember_4c84ea4f-d29e-4b33-be23-4548bd47150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EnableInjectionsMember_fe717b53-4fe8-4dba-96ff-cedbf7bf8eb8" xlink:href="vrdn-20240930.xsd#vrdn_EnableInjectionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:to="loc_vrdn_EnableInjectionsMember_fe717b53-4fe8-4dba-96ff-cedbf7bf8eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ThirdPartyCollaboratorMember_4a276e16-7650-4aa6-9eab-b64d9b502d56" xlink:href="vrdn-20240930.xsd#vrdn_ThirdPartyCollaboratorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0284b9e3-9f28-4007-97d3-be6019cdb55a" xlink:to="loc_vrdn_ThirdPartyCollaboratorMember_4a276e16-7650-4aa6-9eab-b64d9b502d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2ce9dd9c-e388-4cd1-9335-c551f2882a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2ce9dd9c-e388-4cd1-9335-c551f2882a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2ce9dd9c-e388-4cd1-9335-c551f2882a44" xlink:to="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ColoradoLeaseMember_511f0d0d-f48c-4c2d-af7b-b34619a21322" xlink:href="vrdn-20240930.xsd#vrdn_ColoradoLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:to="loc_vrdn_ColoradoLeaseMember_511f0d0d-f48c-4c2d-af7b-b34619a21322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_MassachusettsLeaseMember_609ecb5b-d374-4dca-8ea1-8bf80f6ba443" xlink:href="vrdn-20240930.xsd#vrdn_MassachusettsLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_096acee4-2793-4e08-bdba-63db9b47ee8e" xlink:to="loc_vrdn_MassachusettsLeaseMember_609ecb5b-d374-4dca-8ea1-8bf80f6ba443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f7ebba9a-c348-4dab-b6a9-f6b62bc7d2d8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_2caf1365-0d8f-4060-817e-b662fbe84d4c" xlink:href="vrdn-20240930.xsd#vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum_2caf1365-0d8f-4060-817e-b662fbe84d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementMilestonePayment_52b2365b-1375-42d2-9c9b-1ab87e1c77e5" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementMilestonePayment_52b2365b-1375-42d2-9c9b-1ab87e1c77e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_a3f8f33a-8258-41d3-b799-4d0b65f7ee50" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum_a3f8f33a-8258-41d3-b799-4d0b65f7ee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_587f3530-59bf-439b-a5e7-0015c22c1441" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementRightsAndLicensesFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementRightsAndLicensesFee_587f3530-59bf-439b-a5e7-0015c22c1441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_b2124a24-7649-4d2f-90fe-83ee30b0b693" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementSharesIssuedForRightsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted_b2124a24-7649-4d2f-90fe-83ee30b0b693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_3ce48336-b183-4883-a070-c61351e92859" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted_3ce48336-b183-4883-a070-c61351e92859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted_a9d31224-1d76-4c39-ab12-06990dad832f" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted_a9d31224-1d76-4c39-ab12-06990dad832f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted_5c56aacb-e4a9-4475-8bbe-83e9c68d9603" xlink:href="vrdn-20240930.xsd#vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted_5c56aacb-e4a9-4475-8bbe-83e9c68d9603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_9356838a-bf58-4af8-a6a9-d6856a22495d" xlink:href="vrdn-20240930.xsd#vrdn_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms_9356838a-bf58-4af8-a6a9-d6856a22495d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_293b3198-6f3a-4a87-b4d9-f0c0add341ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_293b3198-6f3a-4a87-b4d9-f0c0add341ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6cb91e6c-fe37-480e-88a5-2e5c9156ba90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6cb91e6c-fe37-480e-88a5-2e5c9156ba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c4756229-5d19-4d37-afdb-032aad57334f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_c4756229-5d19-4d37-afdb-032aad57334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1034621-4f22-42c3-bba6-3983fe4c03be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1034621-4f22-42c3-bba6-3983fe4c03be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseAnnualBaseRent_d5e01de7-311f-48ff-8bae-c10219a73c3f" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseAnnualBaseRent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeaseAnnualBaseRent_d5e01de7-311f-48ff-8bae-c10219a73c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_f43d1215-8e8b-45d2-8466-d98381da4c76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_f43d1215-8e8b-45d2-8466-d98381da4c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5db7e202-a45e-49d7-ada8-d5f9c83e1557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5db7e202-a45e-49d7-ada8-d5f9c83e1557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ffe038b-9dd7-4990-b503-f14b38570cce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ffe038b-9dd7-4990-b503-f14b38570cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseRightOfUseAssetDerecognized_c21a5df4-e666-4273-8d3c-cea031ada320" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeaseRightOfUseAssetDerecognized_c21a5df4-e666-4273-8d3c-cea031ada320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeaseLiabilityCurrentDerecognized_5ad7021d-5148-4e14-9ed0-ce9e03de0306" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeaseLiabilityCurrentDerecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeaseLiabilityCurrentDerecognized_5ad7021d-5148-4e14-9ed0-ce9e03de0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_421d7aa8-5036-4cb5-9538-ee61175c703f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_421d7aa8-5036-4cb5-9538-ee61175c703f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db94f0ac-2d2a-4496-8a1b-1370879befde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db94f0ac-2d2a-4496-8a1b-1370879befde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_26bfce7e-be5a-4e2c-9d14-9fe6a9ffd86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_26bfce7e-be5a-4e2c-9d14-9fe6a9ffd86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d3029c0b-72c3-4daa-b95b-ae485b57295c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d3029c0b-72c3-4daa-b95b-ae485b57295c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_OperatingLeasesOperatingExpense_f738b6bb-9997-4526-b51f-2e3f0e76665f" xlink:href="vrdn-20240930.xsd#vrdn_OperatingLeasesOperatingExpense"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bab3855-468b-41a1-b68f-25938846e300" xlink:to="loc_vrdn_OperatingLeasesOperatingExpense_f738b6bb-9997-4526-b51f-2e3f0e76665f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_adf769bb-bdb7-40d2-ad58-201b948d83ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_adf769bb-bdb7-40d2-ad58-201b948d83ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_57b9c664-1d96-4907-9045-6436311d3fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_57b9c664-1d96-4907-9045-6436311d3fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e5d4050c-0729-4ef7-885d-8f72b2dc8787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e5d4050c-0729-4ef7-885d-8f72b2dc8787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b9f8e642-bd81-41ce-8e97-17ebebad3c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b9f8e642-bd81-41ce-8e97-17ebebad3c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_25596457-bd26-4cff-a9fa-8e083483cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_25596457-bd26-4cff-a9fa-8e083483cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d3539c06-1054-40ad-91ce-2e06743ff70b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d3539c06-1054-40ad-91ce-2e06743ff70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5cc1be82-da6c-4f92-bef0-5c5c387d8667" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5cc1be82-da6c-4f92-bef0-5c5c387d8667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8ee0f1d1-fdaa-4839-b694-6280c396148c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8ee0f1d1-fdaa-4839-b694-6280c396148c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6a132f73-7685-48ff-9676-f7d3f0d6446b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6a132f73-7685-48ff-9676-f7d3f0d6446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c84eba6c-da66-47d9-b92a-a855568af622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_599c7d35-d886-45ca-a1c5-229385ae739a" xlink:to="loc_us-gaap_OperatingLeaseLiability_c84eba6c-da66-47d9-b92a-a855568af622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#CAPITALSTOCKDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a53adde8-70ba-4e58-9fc6-292cc834e6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a53adde8-70ba-4e58-9fc6-292cc834e6b0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d41266d-fa03-413f-bb8c-073b4de1cd02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d41266d-fa03-413f-bb8c-073b4de1cd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d41266d-fa03-413f-bb8c-073b4de1cd02" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_AtthemarketOfferingMember_2c00d175-8ead-411d-8832-72b603ba7b1f" xlink:href="vrdn-20240930.xsd#vrdn_AtthemarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_vrdn_AtthemarketOfferingMember_2c00d175-8ead-411d-8832-72b603ba7b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_0fe41087-e0e8-4a2d-b8a2-46559efabf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_us-gaap_PrivatePlacementMember_0fe41087-e0e8-4a2d-b8a2-46559efabf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2024PublicOfferingMember_16553ece-aaaf-467d-b855-c2898f8d43f5" xlink:href="vrdn-20240930.xsd#vrdn_A2024PublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_vrdn_A2024PublicOfferingMember_16553ece-aaaf-467d-b855-c2898f8d43f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_fa0050e1-afc3-477d-a42a-4528d8d50d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3098c795-215e-409c-a05e-61cd028b4ccb" xlink:to="loc_us-gaap_OverAllotmentOptionMember_fa0050e1-afc3-477d-a42a-4528d8d50d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_44e1b07f-a424-483d-9eee-2142a96c6bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_44e1b07f-a424-483d-9eee-2142a96c6bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_44e1b07f-a424-483d-9eee-2142a96c6bf7" xlink:to="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1b68c48e-9cef-4559-8020-ef7c21eb8542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:to="loc_us-gaap_CommonStockMember_1b68c48e-9cef-4559-8020-ef7c21eb8542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1c436b3e-c290-4c82-91df-2f78d5995739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bec68396-c480-4a4b-9ee0-624038300f27" xlink:to="loc_us-gaap_PreferredStockMember_1c436b3e-c290-4c82-91df-2f78d5995739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aa109119-2b6e-4264-a118-7fd26bf6571d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aa109119-2b6e-4264-a118-7fd26bf6571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa109119-2b6e-4264-a118-7fd26bf6571d" xlink:to="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_47afdfb8-6dca-41d8-be78-06869abdb66a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_47afdfb8-6dca-41d8-be78-06869abdb66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_c3bbe33d-356a-47b7-b6c1-68f0463adf29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45b7aa80-cb70-4aa8-a4b5-24858c254ce1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_c3bbe33d-356a-47b7-b6c1-68f0463adf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_432c959c-4478-4e0b-993d-19b37a674ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_432c959c-4478-4e0b-993d-19b37a674ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_432c959c-4478-4e0b-993d-19b37a674ca8" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SeriesAPreferredStockConversionMember_a1c55222-bd0a-4734-a3c4-028e67a00833" xlink:href="vrdn-20240930.xsd#vrdn_SeriesAPreferredStockConversionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:to="loc_vrdn_SeriesAPreferredStockConversionMember_a1c55222-bd0a-4734-a3c4-028e67a00833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SeriesBPreferredStockConversionMember_d6dbb79b-6423-4b8a-9ba0-4cc49786ef61" xlink:href="vrdn-20240930.xsd#vrdn_SeriesBPreferredStockConversionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_f4978aca-b670-43bd-b9fb-06dcc14a3ca5" xlink:to="loc_vrdn_SeriesBPreferredStockConversionMember_d6dbb79b-6423-4b8a-9ba0-4cc49786ef61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_b144bd26-6284-4bff-89d1-e3c007dd8926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_AssetAcquisitionAxis_b144bd26-6284-4bff-89d1-e3c007dd8926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bef67da3-cbd5-43c8-a576-1dfcdfd5d653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_b144bd26-6284-4bff-89d1-e3c007dd8926" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bef67da3-cbd5-43c8-a576-1dfcdfd5d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ViridianMergerMember_ee3f2ccb-40e2-4d38-ad9d-b508b9fe5914" xlink:href="vrdn-20240930.xsd#vrdn_ViridianMergerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bef67da3-cbd5-43c8-a576-1dfcdfd5d653" xlink:to="loc_vrdn_ViridianMergerMember_ee3f2ccb-40e2-4d38-ad9d-b508b9fe5914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a4df4ca-bb61-4d10-9fa7-c10a4251caca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_srt_RangeAxis_2a4df4ca-bb61-4d10-9fa7-c10a4251caca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a4df4ca-bb61-4d10-9fa7-c10a4251caca" xlink:to="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca2d0b18-4b1a-424f-8471-4605b950599b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:to="loc_srt_MinimumMember_ca2d0b18-4b1a-424f-8471-4605b950599b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9da06254-7cc2-4176-9406-3e50c71f90e3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c489be89-01ac-47ba-97ff-1a32bf863e75" xlink:to="loc_srt_MaximumMember_9da06254-7cc2-4176-9406-3e50c71f90e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f4262961-b1b6-4382-a68f-3c34d0455c66" xlink:to="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CapitalStockSharesAuthorized_8a4590d0-5004-4518-8172-20e0caf49d00" xlink:href="vrdn-20240930.xsd#vrdn_CapitalStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_CapitalStockSharesAuthorized_8a4590d0-5004-4518-8172-20e0caf49d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0bbd8d76-1213-447b-ba49-ea6e44cbae75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0bbd8d76-1213-447b-ba49-ea6e44cbae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_297c8325-557d-4a28-b961-4e73bf4b1e65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_297c8325-557d-4a28-b961-4e73bf4b1e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c6426477-0d5a-47b5-a38a-254920d8d6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c6426477-0d5a-47b5-a38a-254920d8d6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_59362633-5683-44cb-8142-d0ad50892ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_59362633-5683-44cb-8142-d0ad50892ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockVotePerShare_b4803ffc-b6fe-4e9d-bc68-03eeb4cd224c" xlink:href="vrdn-20240930.xsd#vrdn_CommonStockVotePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_CommonStockVotePerShare_b4803ffc-b6fe-4e9d-bc68-03eeb4cd224c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c0ba9299-c7e3-4741-9cfd-582ca4eb9673" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c0ba9299-c7e3-4741-9cfd-582ca4eb9673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_acbf6c14-a001-4b0d-bdcf-57c398f21e6d" xlink:href="vrdn-20240930.xsd#vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds_acbf6c14-a001-4b0d-bdcf-57c398f21e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0f1abd-207b-44cf-b022-50a797ba6454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4d0f1abd-207b-44cf-b022-50a797ba6454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_SaleOfStockWeightedAverageSharePrice_12e137d9-d77d-440f-88f0-d2e4bb475eed" xlink:href="vrdn-20240930.xsd#vrdn_SaleOfStockWeightedAverageSharePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_SaleOfStockWeightedAverageSharePrice_12e137d9-d77d-440f-88f0-d2e4bb475eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38349b07-00c2-4ba1-95ec-1aaedffd36d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38349b07-00c2-4ba1-95ec-1aaedffd36d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2e52a28f-4488-4296-99e4-5475379c55d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2e52a28f-4488-4296-99e4-5475379c55d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_b567cd9f-5bcd-4a8f-8205-d5267a6fbfa8" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership_b567cd9f-5bcd-4a8f-8205-d5267a6fbfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5a55a9a4-8e73-4eb8-abfc-31dcad0b1e84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5a55a9a4-8e73-4eb8-abfc-31dcad0b1e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_24ccf89c-cd74-427f-9353-7d5d74c0579d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_24ccf89c-cd74-427f-9353-7d5d74c0579d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_3b31bc56-28fc-4bb5-9a87-4ad964c29609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_3b31bc56-28fc-4bb5-9a87-4ad964c29609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_d8a42e0f-0927-4b0a-9c32-e4f54d7af146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9dd0b549-167f-480c-9059-2a3938f86b35" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_d8a42e0f-0927-4b0a-9c32-e4f54d7af146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#WARRANTSStockWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c80e0efb-af6d-4d9a-9f74-af1f06ee0d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_3a1f4ace-bf4d-438e-88e8-dc9739d4bbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c80e0efb-af6d-4d9a-9f74-af1f06ee0d93" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_3a1f4ace-bf4d-438e-88e8-dc9739d4bbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f0d8d813-3d8c-4b73-83cf-18b49fcfe667" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3a1f4ace-bf4d-438e-88e8-dc9739d4bbb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f0d8d813-3d8c-4b73-83cf-18b49fcfe667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f0d8d813-3d8c-4b73-83cf-18b49fcfe667" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_17ea5ba0-a809-4f80-80f5-e4f4a3b9cd9b" xlink:href="vrdn-20240930.xsd#vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:to="loc_vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member_17ea5ba0-a809-4f80-80f5-e4f4a3b9cd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1c4e9b75-1aa7-4938-9279-9a4c96f11fb0" xlink:to="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_91f98464-47ea-4368-a928-8017324223dc" xlink:href="vrdn-20240930.xsd#vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:to="loc_vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member_91f98464-47ea-4368-a928-8017324223dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_c1d01fba-b5b7-42c8-9af3-cf7d6f179789" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member_c1d01fba-b5b7-42c8-9af3-cf7d6f179789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_c008ea18-44b4-4189-9033-1cfec44a95f7" xlink:href="vrdn-20240930.xsd#vrdn_EquityclassifiedWarrantsIssuedNovember2017Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_EquityclassifiedWarrantsMember_2e0964ad-a62a-4105-bab7-aa3cd8b18cc5" xlink:to="loc_vrdn_EquityclassifiedWarrantsIssuedNovember2017Member_c008ea18-44b4-4189-9033-1cfec44a95f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_3a1f4ace-bf4d-438e-88e8-dc9739d4bbb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_2bec93eb-f6d7-4960-bd37-978824c27781" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:to="loc_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet_2bec93eb-f6d7-4960-bd37-978824c27781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac462615-b6b2-4b9e-9264-489ee36fa4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ac462615-b6b2-4b9e-9264-489ee36fa4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightRemainingTerm_6fc2e1da-d23a-4df1-9b25-0656fd99ce45" xlink:href="vrdn-20240930.xsd#vrdn_ClassofWarrantorRightRemainingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_dced6ff1-08a4-4503-a9b9-4f1b26f934ac" xlink:to="loc_vrdn_ClassofWarrantorRightRemainingTerm_6fc2e1da-d23a-4df1-9b25-0656fd99ce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#WARRANTSStockWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_65518c77-c05e-4d78-98c7-938bbe2daf36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightActivityRollForward_010920c2-52c0-4d9f-9650-a1d7c2357302" xlink:href="vrdn-20240930.xsd#vrdn_ClassofWarrantorRightActivityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_65518c77-c05e-4d78-98c7-938bbe2daf36" xlink:to="loc_vrdn_ClassofWarrantorRightActivityRollForward_010920c2-52c0-4d9f-9650-a1d7c2357302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8abfbc37-1b2f-4df3-8deb-c1bd2f60ee72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward_010920c2-52c0-4d9f-9650-a1d7c2357302" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8abfbc37-1b2f-4df3-8deb-c1bd2f60ee72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod_f5aeb4f8-bfaa-4ef6-a102-ab2f1b6af4c9" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward_010920c2-52c0-4d9f-9650-a1d7c2357302" xlink:to="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriod_f5aeb4f8-bfaa-4ef6-a102-ab2f1b6af4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_098712a9-2063-4b41-8d0c-dcea604c4548" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightActivityRollForward_010920c2-52c0-4d9f-9650-a1d7c2357302" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_098712a9-2063-4b41-8d0c-dcea604c4548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_beeced69-3a02-4e6a-85f7-ae55369d48ae" xlink:href="vrdn-20240930.xsd#vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_65518c77-c05e-4d78-98c7-938bbe2daf36" xlink:to="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_beeced69-3a02-4e6a-85f7-ae55369d48ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_791bd592-7386-40d1-85cb-fa73aa43625d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_beeced69-3a02-4e6a-85f7-ae55369d48ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_791bd592-7386-40d1-85cb-fa73aa43625d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_770b7d9c-9b1b-4419-bf33-6c0d0af19b73" xlink:href="vrdn-20240930.xsd#vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_beeced69-3a02-4e6a-85f7-ae55369d48ae" xlink:to="loc_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue_770b7d9c-9b1b-4419-bf33-6c0d0af19b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_de696d2f-d790-4b79-b58d-41e451d4ddd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_beeced69-3a02-4e6a-85f7-ae55369d48ae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_de696d2f-d790-4b79-b58d-41e451d4ddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfa9374c-d778-4263-b6f9-0e3b4215d1be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfa9374c-d778-4263-b6f9-0e3b4215d1be" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8ec039c4-8c85-49ee-8980-88f45fe3576d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_us-gaap_PlanNameAxis_8ec039c4-8c85-49ee-8980-88f45fe3576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7b10b0f1-c5c9-42eb-b1c0-af2ba3775760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8ec039c4-8c85-49ee-8980-88f45fe3576d" xlink:to="loc_us-gaap_PlanNameDomain_7b10b0f1-c5c9-42eb-b1c0-af2ba3775760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember_3fbf429c-d74e-4016-974f-45cb6b0cb1f5" xlink:href="vrdn-20240930.xsd#vrdn_Amended2016PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7b10b0f1-c5c9-42eb-b1c0-af2ba3775760" xlink:to="loc_vrdn_Amended2016PlanMember_3fbf429c-d74e-4016-974f-45cb6b0cb1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ee450de-437b-48ce-8dff-aaed7e4e7054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_us-gaap_AwardTypeAxis_2ee450de-437b-48ce-8dff-aaed7e4e7054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2ee450de-437b-48ce-8dff-aaed7e4e7054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_27976131-5537-4dfd-83f1-b3da6295eb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_27976131-5537-4dfd-83f1-b3da6295eb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_47842164-62f3-447b-b5e6-8a5b98905e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_47842164-62f3-447b-b5e6-8a5b98905e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_77f44cbc-609a-40dc-96d7-91227e20486d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db7a614b-a761-4c4e-aa0a-a7499bcfdc2f" xlink:to="loc_us-gaap_EmployeeStockMember_77f44cbc-609a-40dc-96d7-91227e20486d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7c98cb85-2266-4e1a-b578-4cc9b7e45929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_us-gaap_VestingAxis_7c98cb85-2266-4e1a-b578-4cc9b7e45929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7c98cb85-2266-4e1a-b578-4cc9b7e45929" xlink:to="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9ae68b38-3431-4aab-8d0c-e44cb10416e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_9ae68b38-3431-4aab-8d0c-e44cb10416e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_78af8cfc-0869-4651-bdb5-9d9a38576de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b85899e7-3454-463b-a6ef-278e70f0eb8a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_78af8cfc-0869-4651-bdb5-9d9a38576de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5d63bfc8-31c8-4c31-91d2-1941fab96d4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_srt_TitleOfIndividualAxis_5d63bfc8-31c8-4c31-91d2-1941fab96d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c0f6471-8b08-4024-afdc-87da32c36666" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5d63bfc8-31c8-4c31-91d2-1941fab96d4b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c0f6471-8b08-4024-afdc-87da32c36666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_FormerExecutiveOfficersMember_3c6b12d9-d051-49b6-bd73-afe2d487c570" xlink:href="vrdn-20240930.xsd#vrdn_FormerExecutiveOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c0f6471-8b08-4024-afdc-87da32c36666" xlink:to="loc_vrdn_FormerExecutiveOfficersMember_3c6b12d9-d051-49b6-bd73-afe2d487c570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e72dd9d-78f5-4132-8a22-7fb6340a067a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b2f33301-9be5-4e49-8cfd-98062ea172a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b2f33301-9be5-4e49-8cfd-98062ea172a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b5911e15-fd87-4f7b-85fb-4fd5231158ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b5911e15-fd87-4f7b-85fb-4fd5231158ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_39885f93-8a32-4541-ad58-b1b6ed7c1232" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_39885f93-8a32-4541-ad58-b1b6ed7c1232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97cc9ffc-1986-4acf-b152-e80a5032d8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_97cc9ffc-1986-4acf-b152-e80a5032d8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69c2c3f7-b802-4d34-b3c6-d8cbd2809c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69c2c3f7-b802-4d34-b3c6-d8cbd2809c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a421261c-0ec8-47f9-ad28-02fa9bebab4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a421261c-0ec8-47f9-ad28-02fa9bebab4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90a31a2c-8824-45cd-94d7-1951c538e61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90a31a2c-8824-45cd-94d7-1951c538e61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_75765f4f-b4e3-4cc5-8179-3317c7933f30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_75765f4f-b4e3-4cc5-8179-3317c7933f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9f0c2068-a279-4cec-9bb2-f781c23da08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_9f0c2068-a279-4cec-9bb2-f781c23da08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9fc20295-4123-4018-9ab3-5d336a19ce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_9fc20295-4123-4018-9ab3-5d336a19ce9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f1690ea3-ca90-41be-8503-8e459a2b44c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f1690ea3-ca90-41be-8503-8e459a2b44c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a210d63-5579-4184-96c3-2428dc79901d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0a210d63-5579-4184-96c3-2428dc79901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_71f5a0f7-a1d6-4149-bcf5-56b437e33b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c6f0d161-f9d3-426d-a5ff-bb167016461c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_71f5a0f7-a1d6-4149-bcf5-56b437e33b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONBalancebyPlanDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1e99c49-c4df-4202-b56b-3c35803c85ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1e99c49-c4df-4202-b56b-3c35803c85ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:to="loc_us-gaap_PlanNameAxis_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_341b8ebb-0038-4f75-a5eb-7ae408ac6c1f" xlink:to="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_InducementGrantsMember_ef1f4801-035e-4b46-af62-6318074028cd" xlink:href="vrdn-20240930.xsd#vrdn_InducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_InducementGrantsMember_ef1f4801-035e-4b46-af62-6318074028cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2020PlanMember_24cfae44-69db-40a6-bfe3-33bb414b124c" xlink:href="vrdn-20240930.xsd#vrdn_A2020PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_A2020PlanMember_24cfae44-69db-40a6-bfe3-33bb414b124c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_Amended2016PlanMember_d9d09534-f12d-4ce1-b57d-211f2464e60c" xlink:href="vrdn-20240930.xsd#vrdn_Amended2016PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_Amended2016PlanMember_d9d09534-f12d-4ce1-b57d-211f2464e60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_A2008PlanMember_9e9abb0a-5df5-45b0-8074-229348d80b61" xlink:href="vrdn-20240930.xsd#vrdn_A2008PlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_70053b1c-7c92-4b72-8cda-8c93169c3765" xlink:to="loc_vrdn_A2008PlanMember_9e9abb0a-5df5-45b0-8074-229348d80b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_167b7445-a7de-4479-850e-4a4d066e4866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:to="loc_us-gaap_AwardTypeAxis_167b7445-a7de-4479-850e-4a4d066e4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d42325-d18a-46b9-8792-e50c09f7c97c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_167b7445-a7de-4479-850e-4a4d066e4866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d42325-d18a-46b9-8792-e50c09f7c97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_be5ba7cb-7747-4984-9102-53e51984388b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d42325-d18a-46b9-8792-e50c09f7c97c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_be5ba7cb-7747-4984-9102-53e51984388b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cfa0f41-46a3-47c1-bd60-10c31393be34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67aff85a-7cc5-4612-ab32-e8d8644919b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67aff85a-7cc5-4612-ab32-e8d8644919b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8068cec-cef8-43f8-b790-adddf3554443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8068cec-cef8-43f8-b790-adddf3554443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02878e1e-1c87-4bf2-9b83-af865f8ee7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06360e68-1598-439d-89c3-4c05be630e41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02878e1e-1c87-4bf2-9b83-af865f8ee7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89a5eed0-efd8-4eac-b373-6e0b2423c724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da47afff-1407-4300-bc4d-736939bce079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89a5eed0-efd8-4eac-b373-6e0b2423c724" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da47afff-1407-4300-bc4d-736939bce079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c4d5a368-69e1-438e-badd-328bbd1f302e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da47afff-1407-4300-bc4d-736939bce079" xlink:to="loc_us-gaap_AwardTypeAxis_c4d5a368-69e1-438e-badd-328bbd1f302e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd72cf5-d3a3-4913-b778-f4532be86839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c4d5a368-69e1-438e-badd-328bbd1f302e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd72cf5-d3a3-4913-b778-f4532be86839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_00e05254-260d-4911-8613-4719f93e9214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fd72cf5-d3a3-4913-b778-f4532be86839" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_00e05254-260d-4911-8613-4719f93e9214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_da47afff-1407-4300-bc4d-736939bce079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77aa6588-465a-4214-acf9-ff9e4f291a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_77aa6588-465a-4214-acf9-ff9e4f291a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4083fcb-4393-4d09-8686-1408fd34511d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b4083fcb-4393-4d09-8686-1408fd34511d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64c0a33b-5e17-497b-bee7-d87295f7e065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64c0a33b-5e17-497b-bee7-d87295f7e065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94f6d2fd-4ec5-48e8-82c3-13b518bd2bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94f6d2fd-4ec5-48e8-82c3-13b518bd2bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4fbab6ea-3d78-4345-9707-142b0236626d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6bee3d1e-79f7-4276-88dd-fd5f7ead3cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4fbab6ea-3d78-4345-9707-142b0236626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_730ce3fb-54d3-43fc-b6d2-bfdf3143cda3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_27f8e989-5ea7-4a7d-8eb5-e29f36553933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_27f8e989-5ea7-4a7d-8eb5-e29f36553933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea72c9f5-ad67-4f9a-b1ce-841ec1a8e49a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea72c9f5-ad67-4f9a-b1ce-841ec1a8e49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a11844c4-5e5d-46c7-bb0d-86af325e2374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a11844c4-5e5d-46c7-bb0d-86af325e2374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_07ecf44a-e1f8-4ab6-adc3-0a6e99a41906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_07ecf44a-e1f8-4ab6-adc3-0a6e99a41906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ba76c9c-4d32-4b36-a8eb-85ec78a72c35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_435cb1ef-44d2-42e9-9b69-8641feafcbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ba76c9c-4d32-4b36-a8eb-85ec78a72c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5495b2c-2214-4287-8e58-0c30dd75b730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd2f2e1-a050-440d-9ddf-6df1f505bde5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5495b2c-2214-4287-8e58-0c30dd75b730" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd2f2e1-a050-440d-9ddf-6df1f505bde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_04b233ed-d475-4f7d-a87a-581b5bb49bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd2f2e1-a050-440d-9ddf-6df1f505bde5" xlink:to="loc_us-gaap_AwardTypeAxis_04b233ed-d475-4f7d-a87a-581b5bb49bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861352b5-89fd-4404-9e5c-7c44e4aa16ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_04b233ed-d475-4f7d-a87a-581b5bb49bee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861352b5-89fd-4404-9e5c-7c44e4aa16ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ff39cf48-ca31-4bf5-b483-d3c183d96bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_861352b5-89fd-4404-9e5c-7c44e4aa16ae" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ff39cf48-ca31-4bf5-b483-d3c183d96bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd2f2e1-a050-440d-9ddf-6df1f505bde5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3849455-8784-4579-8786-36225f6fdeec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3849455-8784-4579-8786-36225f6fdeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbba9014-fed4-42a4-871f-8c81e716f3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbba9014-fed4-42a4-871f-8c81e716f3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cbf1962d-0d41-4dd4-add8-228adf0f33a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cbf1962d-0d41-4dd4-add8-228adf0f33a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_04e5e49e-d9bb-4dd1-93df-46e47517946d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_04e5e49e-d9bb-4dd1-93df-46e47517946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99c80d6f-0c55-4643-a001-32fb8f0aa45c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cf6e7335-6c58-49cd-bfae-251b48b5d4cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99c80d6f-0c55-4643-a001-32fb8f0aa45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57ed1fb0-e807-444c-91bc-4ab840c1c5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_57ed1fb0-e807-444c-91bc-4ab840c1c5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_af9a0728-398f-4ea1-85e8-0f5589e91ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_af9a0728-398f-4ea1-85e8-0f5589e91ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9d95c258-9583-4747-8622-a2974717f71c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9d95c258-9583-4747-8622-a2974717f71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1dfdea26-3922-40b2-b543-7d775721c490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1dfdea26-3922-40b2-b543-7d775721c490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a4ab066-6a76-41e1-83f0-76cd8875e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2a4ab066-6a76-41e1-83f0-76cd8875e9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3262ea77-cfa0-4b16-8504-d204f8ba1f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3262ea77-cfa0-4b16-8504-d204f8ba1f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f7d320ec-acfe-4b49-afd7-d70cbaa80e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f7d320ec-acfe-4b49-afd7-d70cbaa80e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2874ee89-1079-417f-ab09-26993a945475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce70e013-65eb-4e2c-861a-f8f5f86951d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2874ee89-1079-417f-ab09-26993a945475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_29af2894-0d8a-4ac3-9c04-96d4de653cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_29af2894-0d8a-4ac3-9c04-96d4de653cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_23292776-b283-49f9-b8f3-5e1a12237ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_23292776-b283-49f9-b8f3-5e1a12237ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_abc9aa52-2ae9-4a5e-9837-0797015f0dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_abc9aa52-2ae9-4a5e-9837-0797015f0dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3380019-dcf2-424a-b20a-e2685537af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a267ced-fd99-40c8-9f54-48314b0db5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a267ced-fd99-40c8-9f54-48314b0db5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7215bc63-4071-4c7d-9965-0f5f65deaf24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7215bc63-4071-4c7d-9965-0f5f65deaf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8f863e24-81e9-4f4b-bca4-c5e3501ef38c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8f863e24-81e9-4f4b-bca4-c5e3501ef38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7c6676bc-ff6f-423d-ad74-896b3efaf21e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7c6676bc-ff6f-423d-ad74-896b3efaf21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_54adc3e3-3033-409e-b1ce-2451511f56b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_54adc3e3-3033-409e-b1ce-2451511f56b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a782bed2-3241-4553-94c9-a95176e0f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a782bed2-3241-4553-94c9-a95176e0f1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_47390050-3dbb-4b01-9f43-c89d68d2d26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_47390050-3dbb-4b01-9f43-c89d68d2d26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5486a125-034d-4d92-acfa-71abe4dc590c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b9510997-ccf9-488e-806f-a3edcaa3bdef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5486a125-034d-4d92-acfa-71abe4dc590c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24c8ac3b-892a-44bc-8265-6c07e863ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efaae5f1-be6c-44ea-9f1c-c49b257f794e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24c8ac3b-892a-44bc-8265-6c07e863ff08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efaae5f1-be6c-44ea-9f1c-c49b257f794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bef3598f-8baf-4048-8eb0-3a0348ca5aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efaae5f1-be6c-44ea-9f1c-c49b257f794e" xlink:to="loc_us-gaap_AwardTypeAxis_bef3598f-8baf-4048-8eb0-3a0348ca5aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13468a27-2d20-4061-b849-06edb496bcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bef3598f-8baf-4048-8eb0-3a0348ca5aaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13468a27-2d20-4061-b849-06edb496bcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6c4e5b5c-5f96-4953-9217-6ca49c3fc80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13468a27-2d20-4061-b849-06edb496bcf5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6c4e5b5c-5f96-4953-9217-6ca49c3fc80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efaae5f1-be6c-44ea-9f1c-c49b257f794e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99326d41-8a5f-491d-9ade-c2b823a5082c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_99326d41-8a5f-491d-9ade-c2b823a5082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_06c68624-68d8-431c-951c-8b16de84f857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_06c68624-68d8-431c-951c-8b16de84f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7fed908-27a9-4e2a-a2e6-3d92edee8aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7fed908-27a9-4e2a-a2e6-3d92edee8aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fadd71b-fb67-4c30-86bb-7877570603e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9fadd71b-fb67-4c30-86bb-7877570603e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8928e260-8967-4b61-855a-10014b035ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48bac5de-3024-46e4-aca1-46431960ebe6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_8928e260-8967-4b61-855a-10014b035ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3134aff5-7cd1-4ba0-9fc5-f7a909f57c39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_095066d6-14f1-47c8-a0dc-342faacdedcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3134aff5-7cd1-4ba0-9fc5-f7a909f57c39" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_095066d6-14f1-47c8-a0dc-342faacdedcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_095066d6-14f1-47c8-a0dc-342faacdedcd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dfd2d8b2-15b2-403b-9b3a-9bb95a429bae" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c11b03b7-d935-4885-b6a3-2ed1f72cda4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c11b03b7-d935-4885-b6a3-2ed1f72cda4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5d01d7b0-8a9f-4f5d-9a99-4752ab7b4fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9be14167-de3f-497d-afa5-eed078c8839a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5d01d7b0-8a9f-4f5d-9a99-4752ab7b4fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f0b52ec4-6a54-4f70-b410-f398676f77f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_095066d6-14f1-47c8-a0dc-342faacdedcd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f0b52ec4-6a54-4f70-b410-f398676f77f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ce0f08a-4eef-462e-844d-5c2545911977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f0b52ec4-6a54-4f70-b410-f398676f77f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ce0f08a-4eef-462e-844d-5c2545911977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="vrdn-20240930.xsd#NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_826858a5-4b0a-4ef6-9d8a-305a5b281300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4241426-d090-4386-a266-8e2902670336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_826858a5-4b0a-4ef6-9d8a-305a5b281300" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4241426-d090-4386-a266-8e2902670336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4801b01f-e14d-46d1-af8d-774c2687835f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4241426-d090-4386-a266-8e2902670336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4801b01f-e14d-46d1-af8d-774c2687835f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4801b01f-e14d-46d1-af8d-774c2687835f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_73332219-2ca6-431c-92c2-b97b2dede52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_73332219-2ca6-431c-92c2-b97b2dede52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_083ad068-8c99-4e41-952c-4140c9908c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_083ad068-8c99-4e41-952c-4140c9908c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4235b6ef-1e6c-4640-a7a9-461cda3e92c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4235b6ef-1e6c-4640-a7a9-461cda3e92c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrdn_CommonStockWarrantsMember_5da54890-a297-4a32-8dff-04e40e135e7b" xlink:href="vrdn-20240930.xsd#vrdn_CommonStockWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_vrdn_CommonStockWarrantsMember_5da54890-a297-4a32-8dff-04e40e135e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3baa0f44-8b73-4954-ad2d-32ef26a8091b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f0962084-0d14-476d-bbaf-8aeff2864b77" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3baa0f44-8b73-4954-ad2d-32ef26a8091b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_74ebd7e6-9624-4800-8a06-de4491c24a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c4241426-d090-4386-a266-8e2902670336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_74ebd7e6-9624-4800-8a06-de4491c24a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_104c84c9-4643-467b-89a0-c9515022c74b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_74ebd7e6-9624-4800-8a06-de4491c24a7c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_104c84c9-4643-467b-89a0-c9515022c74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_X0_=17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  %N-@   G
M$  6XV   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,#DZ,3 Z
M,C(@,#DZ,C(Z,30      Z !  ,    !  $  * "  0    !   ->J #  0
M   !   )]@         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   ZG
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ =@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MV6 ;BQCVN=M!V[MK3]'=[5GY[7NZ[@!@:7?9\D^_5L"S!<[_ */T4>K$SZ[
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M-R,;%R+AGU/W6[J6[8:&DM)=4WUC2^]C'?:/S'_]_5RIF75O#:ZR'.EH]0@
M?1#1^A_DI*2VUWO<#7;Z8'(VAT_>F97>'@NNW-'+=H$_--OS/]%7_P!N._\
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MZ'^$5G%MM96&"O>W>_W[@W\]WYCE)MEEF327U^G ?&H=,@?N_124V]K? )
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M]C7?O_T?_!_S2FVGI3<^N<CJ;LCU*XD9?I[X'I^KMJ;B^GM_GO5_0?S?VG_
MKYV224_0#*>@AK(OZP0.-PZCJ=WN^E7^_P#^!_\ ==6;Z.E?;#ZF1U,7FP$%
M@R]@<6M]-OZ.K[-Z;6?0W_\ "?X7U%\[))*?J7&:&X];6N>\!H =9.\Z?2LW
M!ON_LHJ^54DE/U4DOE5))3]5)+Y5224_522^54DE/__9_^T5ZE!H;W1O<VAO
M<" S+C  .$))300$       '' (   (  @ X0DE-!"4      !!&#/*))KA6
MVK"< :&PIY!W.$))30/M       0 )8    !  $ E@    $  3A"24T$)@
M    #@ !     #X]-Z<^]-Z<.$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))300*       !   X0DE-
M)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$         @!(.$))300"      "Z
M
M
M
M                                            .$))300P      !=
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! #A"24T$+0      !@ !    J#A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      -3    !@
M   )]@  #7H    / #  .0 P #4 ,@ Y %\ 3 !A 'D ;P!U '0 7P Q
M 0                         !              UZ   )]@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   )]@    !29VAT
M;&]N9P  #7H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M 3_P        .$))3004       $    J#A"24T$#      .PP    $   "@
M    =@   >   -U    .IP 8  '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!
M9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1
M%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ =@"@ P$B  (1 0,1 ?_=
M  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$!
M 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A
M$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$
MDU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%1
M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4
MHQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G
M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I) &966AX986D;@=CN/N4
M!DVAQ+VG9/ 8_=!W?R?I?024VDD'[56#[PY@F-SVEK>)^D44$$2-04E+I(65
ME48F/9DY#ME-0W/=!,#^JP.<[^RJ3^O8H'LJRB[L#AY8$3[M1BO0) W(7QQS
MD+C"4AM<09.DDJ&'UC'RKQC%ME5[FE[&64W5!S6;&V%C\JC'W;'V?FJ^D"#L
M;1*$HFI1,3_6'"I#L=>"/28QX[ESRT_**[$1)%:BK=D%Q%K&-;&A:\N,_P!4
MUU_]4BI))*4D@Y3G-I):[:9:-P[2X-0#A58[3;6][2T<B./SOS$E-U) H=+W
M!KG/9 U>(UEW\EJ,9D!)2Z2B9'=.TR-4E/\ _]#U51?P/B/RJ2B_@?$?E24B
MQ!NPZ@X$S6)GS"*6@B")&BJT67#%I8RE[BZLP\%D-+1[-^]V[])^9[+/^%17
MV7[3MJ<':099\^Z2F5U/JAH#W5ECP\.;$Z?F^X.]CV^QZB*+0 !>\ "!HS_R
M"F7V28K<1\6^$_O?V4)F1>88^@BT,:ZQK7@M!=N&UCW>GO\ H?N,24PS>GG,
MQ+<6V^P,N;M) 9([[F^Q9/2<[J-G6/LN3>ZRLTWN!=Z!.ZJVBMKV?96[ZM]=
MGOIR/TBVS;D3I0?\YO\ >J)WGZP8A>S8?LF7 D'_  F#QM^BFR'7KI^;+BD3
M<#1C625$ ^KVY?I?H_)%6;973US!LML#*VX^47.>0UH&[";J[3\XJ_5FX=UG
MI4WUV6 ;BQCVN=M!V[MK3]'=[5GY[7NZ[@!@:7?9\D^_5L"S!<[_ */T4>K$
MSZ[ _P!3''O&Y[:2'&KZ3ZY]3^<>_P#/^A_P:%FS0Z_L9#&!QPXI<,N \/\
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MFXXHOO<ZUE5-;7WV>FTDNV^MNVNI8U[WL8[=Z3*_["TZ;?5:7;2T3 DM,_\
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M?2LW!ON_LHJ^54DE/U4DOE5))3]5)+Y5224_522^54DE/__9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, ,@    $
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MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
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M Q$!_]T ! &P_\0!H@    8" P$             !P@&!00) PH" 0 + 0
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MSOLW8^[ZML#N&KPFW]G8Z;'[UQN4@22>MRTS TJ*^JG92^EE#>Z]UEKOF/\
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MLA2T]=05]#415=%7457$*BEK*.JIRT<L4L;*\<B,592""0??NO=$4[J_F?\
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M29W=_,Z_EQ;$PLVXMU_//X?8G#P34]/+5M\C>I*PB:JD$4$:4V/RTLS%F/\
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MI3[FS4D$F:S%/@,7%%B\!0559.\]954\")!3NVIP2 H)'NO=%Z_X?J_E/?\
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MYYY7IP7DFFEB+,Q/))))]^Z]T[=8HD6S*"*)$CCCR6YDCC10B(B;HK51$1>
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M61F&KH,A30UE%51$W,512U*LCK< Z64CW[KW2+_T3=5_\^TZ_P#_ $#=N?\
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M5&2HL]0[7WQC<F^/:EFHIA M/)3NS([R:M$?NO=&@_X;D[V_[SZ'_I9&S_\
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M %M]^Z]U!R7PZ^(V9HJC&9?XL?''*XVK54JL?DND.LJZBJ41Q*BU%)58MHW
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M^J-G1O=>ZK&_X9(^(G_/U/G_ /\ IQ[YK_\ V;>_=>Z]_P ,D?$3_GZGS_\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ!_D*_]NGOBG_Y7/\
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MAJ!XJ?*Q02^2(?N(^FZV)]U[HK^X_P#M_ITW_P",@/DK_P#!G]3^_=>ZM_\
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]T ]9_P 7=O\ M:2?^]OG_?NO="U4?\?/A_\ M0[C_P#=ABO?NO=/
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#O=5'25
MV\=@4U;2T]93N=U%Z>J@BJ(7*8J-D+13 J;$ BXX/OW7NN&-Q]!CNR<E!CZ*
MDH(7V/B96AHJ:&EB:5L]6HTC1P*H+$*H)M>P _'OW7NA']^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$_P#@Z2>E]ZW%O^<P/YA0MP>!
M\^^RP#Q_7Z^_=>Z.![]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__
MT=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%N^8VP=V]J_
M$[Y)=9["Q/\ 'M[;^Z0[-VAM+"??XS%_Q;<6X=H5>+P^._B69FIZ2#S3RI'Y
MJFHCB2^IW502/=>ZU]?B/MK^>Q\,>EL3T5U?\*^A\]M'#9K<&<I<COWL#KW*
M;CDJ]QY Y*NCGJ]O=IXNF,:.Q$06C5@O#,QY]^Z]T9O^7W\#/F!+\T^P/YA7
MSI3:>T>S]QX?*XS;_76U<OALS54V2K\/#L>*LR,VV:G(XVEQN/P%''18VFAR
ME742B59*F2*2!A/[KW18-H_'S^;O\4?F?\T>\_C/\5.L]_[<^0/<7:65Q63[
M+[!ZUFHJW966[6RF\-L9C&8K&[_V_74DM3!51R/%7IY$5@CPQR!@/=>ZM ^(
M';G\W'>7<E+A?F3\7>BNI^EGV[G:FKW=U_N#"Y+<,6Y*>.,X#'I34/8NY9/#
M.QD$K?PL@6%Y(_J?=>ZJ8^,'0W\Z#X.;W^0^0Z%^(74^\,-W;OR//UU9V;V+
MUGDI$H]OY?,3[?FPT6W^Q\$\ GBRTK3I5QR/<1@",JX;W7NC:_'#X"_-'Y!_
M,_:/SK_F/2[%VME>KHZ.3J[H[9=;B\U3X3)8"LJJS:D+OA*K*45)C<975,F;
MIG_C=?6SUAC^XDC1"C>Z]T,G\P_^6QVUVWWAL#YK?#'L'%=9?*?KV/'TU?#G
MJB2BPF]:3#T[T&*KH<EX*N*&NCH99L564E;2R4>0HF2"<PK&_P!Q[KW15NT<
M!_/\^5NP,M\?-^=3_'GHW8^\,!5;2WUV#0;DV4)-VX#*+#A\Q2YN3$;EWC6T
MZ54#33U!PV!I6,1F1 K&& ^Z]U<+\ /B5-\)OC)LWH2LWG'OW*8;(9[<&:W#
M38EL+CY,QNC(ME:^AQ=%+-/(::F=O##-*X>4+Y6CB+^)/=>Z*#_.1ZN^<G?G
M3FS^C/B!L"KW1MG>V1S%9WCEJ#?O7FR:ML%AUI3MK9;-O;,8N6>DR4\M14UP
MI0X84D4,K>*5XY/=>Z)U\6(/YU'QGV=U]TMU_P#R]?BCL?JW"Y'$4^XLA0;I
MVI/N/)Q3U$-/N7>>X,C#VY))7Y>>%6FEJ'IW)*I'%$(8XH%]U[H9/F'\+_FE
MU=\Y4_F"?R_\'L#L3>&\=HT^U.SNI]\Y'$X2ER%3!A*7:TE>KYC)X*FJ*&IH
MZ+'5,JQ9BDJHJRD\H-0D[1K[KW0K?RO?@]W[TWV/\A/EU\O*K 1?(KY(5VJK
MVEMG(4F4H=D8&ORYW+G:"NK\7)/0M-/6+104]+0U51#2T]%&%JIVF81>Z]U<
MU[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[K6_\ YB'_ &64?_$@?$;_ -P=T^_=>Z.#U_\ ]NX_Y47^O_+)_P#=
M7MCW[KW5O_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZJ _DD?]DB=J?\ B_\ _,>_^#7WM[]U[I4_+;>^],%_,\_E%[,P>[]T8;9^
M_/\ 9^/[\;4Q6?RV.VUO/^Z_Q\QN5VS_ 'KP5)*E+D?X=5.]30_>12?;RL9(
MM#DGW[KW5JWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZJI_DD;WWIV/_ "P_C+O/L/=^Z-^;PS/^F?\ B^Z]YY_+;HW+
ME?X=\@]V8K'_ ,2SN<EGJI_!2P04T/EE;1%&D:V1% ]U[HN76W?G6/R+_G\9
M<]-9/<F\\?\ &'^77\E_CCWCN-.NNQ\#LS9/>*?+CJ[/OUJ-\;GQ-%A\GDA1
MTM34%,/75::(I#K]#6]U[J^/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%_QNT-Q[LDJ<[!N^/$1P;AST$./
M3;\58A7'[GK:B/SSO51E[R33'A5L&TW-@??NO=+&B&XZ#?6&HLWG*/-1U.W-
MPR0M3X5<0:?178\R Z:B?7J*I;Z6L?K?CW7NA/\ ?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@]P?\?OU]_Y-G_NH3W[KW2>WC2X_
M*[K3'#9']Y\I3[>I*V2L_O V$\./FR53!#3:=2A[2)(][W]7OW7NF3^Z7_?H
MO_7^_P"POOW7NHO]VI?^?*U7_HP*+_ZJ]^Z]UQ;:8J-,<_2<A34#>??M%)&A
MM;45%2Q_)^@]^Z]UR_N)1?\ /EZ7_P!#:+_H_P!^Z]UX;(I8W#)TO &4J5=-
M\0*5):UP?("+?4_[Q<\>_=>ZE?W2_P"_1_\ K_?]A/?NO=<!M*Y!/3Y!TGU'
M?J77D>@D2G_7XX]^Z]US_NE_WZ/_ -?[_L)[]U[KW]TO^_1_^O\ ?]A/?NO=
M!+\!8/M>@MR4_P!A_"_#\M/Y@<?\.^Z^]^RT_/?LL?;_ '=SY-/TUWY]^Z]T
M=+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]+?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW6M__,0_[+*/_B0/B-_[@[I]^Z]T<'K_ /[=Q_RHO]?^63_[J]L>_=>ZM_\
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MU[_9[_C-_P ]1V!_Z(#Y"_\ V+>_=>ZIF^&_5WP#_F5_S'?YMG>F[>@/C_\
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M;0MCLRU)GSC*=ME1Q+]S !0T( ^W]_P2'(__ "BWW_.*W_[:NO?\F5/O3_\
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M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HN?\
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MP>#3+%-[KW0W?[(IWM_WB1\@/_0_V=_]C7OW7NO?[(IWM_WB1\@/_0_V=_\
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M[V_[Q(^0'_H?[._^QKW[KW7O]D4[V_[Q(^0'_H?[._\ L:]^Z]U[_9%.]O\
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MK<RQ(/PI(ZC/' (&>BO=^0>1.8+UMRW[9;"]N6 !EN+.WFD(444%Y(V8A1@
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M]NBB:H&+!$#%;>W12X10[!6@E*AG#, 9&I7%!10L'M3]\U;BY,&Z0K ]S=/
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\O\
MPW;\G?\ H'(3^7#_ ';VV/E,WQ)CZG;:_P#?#"_W;CWL^Y1F&QS[R#_8>-(B
M0U0LABU A686)]U[K8:]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW50'\]W
M_MV=VA_XG_X!?_#".K/?NO=>_F2_]E=_R6?_ !?_ 'S_ / 4=H>_=>ZM_P#?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U\W7_A2?\ ]O*.P/\ Q+/PY_\ >)VI[Q YQ_Z>US'_ -*FZ_[MB]?1
MM]V__P"1Z^R__GPMA_\ )YEZIS^1>-H<SM?8^&RE-'6XO+]R=5XO)T4US!6X
M^OW7#35E),%()22-F5A?Z'W%WMA=7%CNVX7UHYCF@VS<)(W'%72W9E8?,$ C
MK/#[].P[/S7[>\H<J\Q6ZW>W;GSQRA:74#U\.>VN-X@BFAD ()22-F5A48."
M#U<Q\3?^$V&\_F/T/L[Y"]8T'Q6P6R][U&YJ;$XS?>Y.T,9NBG?:FZ:S:.1.
M0HMO[8RE(@>IH97A\=;)>(H6",6197Y4VKWMYPV*'F#;-^1(9RX5999%<:':
M,U"6SKQ4D48XI6AQUS\]_P#G[^Z[^[C[J[E[0<[^TUU=;GM:VS2RV-C9RVS"
MZM8;N/PWN-ZMI21'.BOJA2CA@NI0&)CO^@1+O'_E8^$W_H9]T_\ V$>Q%_43
MW\_Z:&#_ )S3?]LG4-?\%?\ W1__ (1[=?\ N6[;_P"7#U[_ *!$N\?^5CX3
M?^AGW3_]A'OW]1/?S_IH8/\ G--_VR=>_P""O_NC_P#PCVZ_]RW;?_+AZ<L5
M_P )*._\+5BNQU7\'XZE8WC5ZC<W;E>BK(+/:#(;$ECO;C5IN.;'D^TMY[;^
M^E_#]/<\P0E"0:+<7*''#*6JG\JTZ/N7/OJ?W4W*>YC>-C]H-Q2X564-)LVR
MW"@-AJ1W.^RQU(QJT:@"0"*FJG_Z!6?D_P#\[3X)_P#G;V%_]KSV4_ZSGO%_
MT?8_^RV^_P"M'4A?\G)O[MS_ ,)1=_\ CL<K_P#>SZBUO_"4SY+Y&DJ*&KR/
MP6>FJ8S%,L>4[)IW9&^H2>FZ^21#_1D8$?@^WK?VC]Y[69;B'?HPR&HK>7C"
MOV- 0?L((Z+MW_O$?[L[?-MFVC<O::\>"X4HX7ESEJ)BIXTDBW9)$/HR.K#R
M(Z2'_0(EWC_RL?";_P!#/NG_ .PCV=?U$]_/^FA@_P"<TW_;)U&'_!7_ -T?
M_P"$>W7_ +ENV_\ EP]*C%?\)1/DCA:-:''9#X,Q4R.\BK/F.S:V37(VIR:B
MNZ_DD//T!>P^@L/93>>U'O5?SFXN=_B+D 8N[M!CAA+=5_EU(?+G]X%_=B<J
M;8NS['[2WT=NK,P$G+W+L[58U8F2XWB64YX N0!@ #'3C_T"L_)__G:?!/\
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MM!:++IEY@=(J6]M#'H@6.,Z-90NSLSY_T#4?.K_GZ_Q,_P#0Z[A_^P3V7_\
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M[KG49+'8WLRL?(U]%0)+L7$)&];504JR,,_7$JC3LH) YL/?NO=*O^]6V/\
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MDKJC$RK7/-48R60P2SPTTS*9*>(K[KW1#/\ AF_KK_O/C^;_ /\ IS[Y3?\
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MBID8:5*JONO=#5[]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/Y)'_ &2)VI_XO_\
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MOB!_Z/#9/_U5[]U[KW_#UO\ */\ ^]C7Q _]'ALG_P"JO?NO=>_X>M_E'_\
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MZK_T7>2_^HO?NO=>_C?7?_/'U7_HN\E_]1>_=>Z]_&^N_P#GCZK_ -%WDO\
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M/_M6>_=>Z]_P^[_+._Y^AW__ .D!?S"/_M6>_=>Z]_P^[_+._P"?H=__ /I
M7\PC_P"U9[]U[KW_  ^[_+._Y^AW_P#^D!?S"/\ [5GOW7NO?\/N_P L[_GZ
M'?\ _P"D!?S"/_M6>_=>ZAY#^?=_*^Q&/KLMENWN\\9B\91U.0R62R'P+_F
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\W7_A2?_V\H[ _\2S\.?\
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M_P#_ -#GX4?_ &T/?NO=>_X<E^7?_>EGY_\ _H<_"C_[:'OW7NO?\.2_+O\
M[TL_/_\ ]#GX4?\ VT/?NO=>_P"')?EW_P!Z6?G_ /\ H<_"C_[:'OW7NGO>
MGRLVI\W?Y,_R,^46R-I[NV+MKM3X9?+FJHMH;[7"+NW 5&UME;LV-EJ#,_W<
MJZ^A+BLQE0T;4]7(K1E&)#$JONO=&E_E[?\ 9 OP>_\ %0/C3_[YC"^_=>Z-
M_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^;K_PI/\ ^WE'8'_B6?AS_P"\3M3W
MB!SC_P!/:YC_ .E3=?\ =L7KZ-ONW_\ R/7V7_\ /A;#_P"3S+U4!WQ_Q:NM
M?_$Y]0?^]E![B;V[_P!S-U_Z5.Y?]HS]=!_OD?\ *N\@_P#GP.2O^[Y;]?2.
M_D2?]NP/CW_VM>YO_?V[A]Y>^QO_ $[+;_\ 37'_ &DR]?.A_>I_^)Q\W_\
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MY=_&#>6[MR9"GQ.W=J[5[]ZIW#N//96K?QTN,PN#Q&6FJJJHE;TQPP1,['@
M^_=>Z,_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/^V?\
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MMB]?1M]V_P#^1Z^R_P#Y\+8?_)YEZKS]XS==QNMK/_A+7_Q=OG[_ *WQ5_\
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ5]Q_#+/\
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M%[2;-_R3MV_YY$_[3K+H0>Y?_*Z>WO\ XL%S_P"2KS+U]1SX#_\ 9"OPM_\
M%3/CG_[Y[#>^AO(?_*C[-_SPVG_:/'U\<7WL?_$I_<O_ ,6OF'_N[WG1L_8K
MZQ_Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUO\ ^8A_V64?_$@?$;_W!W3[]U[H
MX/7_ /V[C_E1?Z_\LG_W5[8]^Z]U;_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NJ@=T?]NGOYBO\ YF?_ /@DNY??NO=$^_EX?\SG
M3_QI_P#+G_X 7:_OW7NMC_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'G7U+32X2N>2F@D
M<[HW9=WAC=C;<-0!=F%_?NO=<JR"&'L;;?AABBU;7W+J\<:1ZK5U!:^D"_OW
M7NA!]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%KO\ @%6?
M]0M1_P!:C[]U[I+]>?\ 'B[3_P"U#C?_ '&7W[KW2;RNXL)MSLFIGSF2I\;#
M4['Q44$E26599$SU<[HI4'D W/OW7NGK_2?L#_GJL7_U,D_Z-]^Z]U[_ $G[
M _YZK%_]3)/^C??NO=>_TG[ _P">JQ?_ %,D_P"C??NO=+.CK*7(4E/744Z5
M-)5PQU%-41F\<T,JZXY$)_!!O[]U[J3[]U[KWOW7NO>_=>Z][]U[KWOW7NB@
M?![_ )DQO7_Q;_\ F$__  ?79?OW7NC?^_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO_0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0#^9S_V
M2)E__$__  H_^#7Z]]^Z]T?_ -^Z]U[W[KW7O?NO=>]^Z]U[W[KW10/C3_S.
M?^83_P"+?[*_^ %Z/]^Z]UI<;0_F2?*;I;^4MEOY3F9_EP;RRN7K/@E\EOCX
M/D10?(;8*]=1K4?&T[\W9N\XT8E_7AMO[YV]DY\0<D)Y6K*:F619YM*>Z]UO
M7="[0S/7O1G3&P=QI3Q;AV/U/UUM#/1TDZU5+'F=M;/H\+E$IJI0!)&)X'"2
M 686/Y]^Z]T+'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[JH#^>[_ -NSNT/_ !/_ , O_AA'5GOW7N@K_G*=V]5_
M&_N#^4SWKW?O7#]=]4=7?-OL?=F^-Y9V25,?AL-0?"?L\,PAIUDGJ*B>5HZ:
MCHZ:*2HJ:B2*GIXI)Y8XV]U[K5/^0/P"^37\Y#L7Y*_S:/@U\.MI]7?$NIW)
ML;)[=^+N\<WOWKG<W\UK&]7;^DW1OWLC>.T=HY/'4<,F6DBO']M4T3UDT>FC
MJZG.)55\ONO=3?YG'\P;XU_/[N#_ (3A9GH+:T/2VX.E/ESNSJ7N/XHY#&4N
MV=V_%W>6W.W.C,+%UKDMIP4]&(,5$*&H@P-9#100SP4\D/AI:RDK:&D]U[KZ
M.WOW7NO>_=>Z][]U[K7"^#W_ '#2[U_\5 _F$_\ O5]E^_=>ZM^_E[?]D"_!
M[_Q4#XT_^^8POOW7NC?^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDGOW,5NW
MMC;TS^-:-<A@]I[CS% TT8EB6MQF'FK:5I8CPRAT74I^HX]^Z]U0)\&]A?S;
MOE_\//C3\H\E_-TI=BU_?O3.Q.U:S9U%\ /CEGJ/;-1O+!19B7"TV:GK:5ZI
M(#)XUG:FC+@7*+]/?NO=&)^(N^_FIUK_ #).XOA;\G/ECC_EEM#%_!_I_P"4
M.TMT?[+_ -<=$97;>Y-\=\[RZHRF ^RZ^EG6LI_M=M0U'EJ9R=<NE(X]#-+[
MKW5SWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJL_YKG<WR(ZGZY^*6
MVOC+VS0](=@?(SYV_'OXSY+LRMZ[VMVF=L;/[4I\VF:KZ+9N\1]C4SQR45-(
M@=XVLK*)$U$^_=>Z1O\ LFG\V'_O<_\ ^TZOC;_]=/?NO="O_*,[[[F^2_P'
MZH[;^06[\?O[MVL[ ^3VP]V;TQ>U<-LFCW*G3/RLWOTSMW+C:NWE6BHI)<5@
M*%IXJ<:3+K;DL3[]U[JR?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
M%N\L_P#S ODO_,A^:?QTZ$^=5'\3^J?BYU)\-]V8;!Q?%OJ'O*MW1F_D3BM\
M56XJFLS>^9:2KIEI7VG"8HQ+,K?<, (Q&-?NO=!O\DX/YHGPJS7Q#[ W;_,X
MH^_MD=H?/OX8?&[?W65;\)^ANLUSFP^^N\L7L/>'V^\MOU-;6T<PH*B=(I*:
M)9%9PR21LH;W[KW6PU[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z^;5_PI?H*++?S&.S\5DZ6"NQN4[-^(6.R-#4QK+2UM#6;#VK3U=)
M4POP\<B,5=2+$&Q]XC<T7,]G[Q[_ 'EJYCEAVNX='4T977;5*LIX@J0"".!Z
M^B/V*V7:>9/[MOVDY;W^WCO+#<>>]GMKJWE4/%/;S\[31S0RH:J\<L;,CHP(
M920>J5>R^E]B[>@V)GMB]9XFDRV%[7ZURE;5[5VR)LK2X*BW5!/EZD18R)IC
M#'$NN;2ILH)/ )]Q_P J\]\P[G)N.W<P[M(\,^WWT:K<3TC:5K=Q&M9&"ZBQ
MHM3DF@R>LOO?[[J'L]R1:<G<Y^SWM_9VVY;5SCRM=SS;1M6N\AV^#=[>2]ET
M6D3SF&.)=<^A2%C4LU%4D;,OPK_GY;R^%_QOV%\<]O?'?%[XQ>Q:C=U3#N?,
MU78>*K\B^[=YY#>,PDQ]#AY(XQ"U>8%M(VH)K)!;2!)R9[M[SR;RY!R[;V5K
M.L!D.MKR)2?$D>3@'(%-5./E7J%/O+_W>/MI]Y3WGW;WDW?F;?=KGW5;13;0
M\M[A+'&+2SM[,4D>W5F+B#6:J*%M(K2I-3_T%,=F_P#>)>UO_/UV?_\ 63V*
M?^"#Y@_Z-MI_V6Q_]!=0/_R9[]H?^FVYB_\ '7O?^M/7O^@ICLW_ +Q+VM_Y
M^NS_ /ZR>_?\$'S!_P!&VT_[+8_^@NO?\F>_:'_IMN8O_'7O?^M/7O\ H*8[
M-_[Q+VM_Y^NS_P#ZR>_?\$'S!_T;;3_LMC_Z"Z]_R9[]H?\ IMN8O_'7O?\
MK3U[_H*8[-_[Q+VM_P"?KL__ .LGOW_!!\P?]&VT_P"RV/\ Z"Z]_P F>_:'
M_IMN8O\ QU[W_K3U[_H*8[-_[Q+VM_Y^NS__ *R>_?\ !!\P?]&VT_[+8_\
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M"_[Q_P _3_GS?\H#_P!*5^9__P!J?W[KW1B/Y;7RK[)^8OQG;M;N#9&Q^O\
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M #L__&_?NO=>_O/_ -G7L/\ \[/_ ,;]^Z]TS_WIW/D<_P#P+;M9LG)%,/\
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M>]^Z]U4!_/=_[=G=H?\ B?\ X!?_  PCJSW[KW0C?S.OY9WQ#_F6["ZHV?\
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MW[KW7O\ 9B/E+_SV/\P#_P!)T[&_^[8]^Z]U[_9B/E+_ ,]C_, _])T[&_\
MNV/?NO=>_P!F(^4O_/8_S /_ $G3L;_[MCW[KW7O]F(^4O\ SV/\P#_TG3L;
M_P"[8]^Z]U[_ &8CY2_\]C_, _\ 2=.QO_NV/?NO=!Y_+[@S'S3_ )I7?M-\
MW>X/E/B-D_!7'_#CO3XM]:]O]K=H=/; W+V143;CSE5VSN#HK=_8O8F&KJJE
MKC/AH*RDW/7!H:-@STLLM30P>Z]UN _Z6>J_^?E]?_\ H9;<_P#JGW[KW6E1
ME<SV'\./YF_RW^(OQ'[,^86X_B7CNK>K>]L'A^N-R]K_ "*V=T_VGW'O+<F]
M]];?VKMO%=R=4X/;M)NK)97+Y:9(\E4S33T#LE(Y-95)[KW1F?\ 9B/E+_SV
M/\P#_P!)T[&_^[8]^Z]U[_9B/E+_ ,]C_, _])T[&_\ NV/?NO=>_P!F(^4O
M_/8_S /_ $G3L;_[MCW[KW7O]F(^4O\ SV/\P#_TG3L;_P"[8]^Z]U[_ &8C
MY2_\]C_, _\ 2=.QO_NV/?NO=>_V8CY2_P#/8_S /_2=.QO_ +MCW[KW2'[-
M^4GR_P!L=;=A;EVWN3Y\9/<6WMC[LSF QM7T%VCC*7(9K$X&HK\715.2H/F+
MFIZ>.6>..-YX<-7R1@ETHJI@(']U[JSO^1/UWTKUY\/NL?E[NSY"]@=H?)WY
MO?'CXT[N^1^_?D/\D,UVSNG(YC8FULK6;:PF)DW_ )&HJ<70T$NY<P(J"-]*
M"54X6-%7W7NCW?/?K#XR?+KXY;BZ^['[:;"1[*S6![MV'NGJKNQ.M^PMG=J=
M/U+;RZ\W;M/>.V*V.MHZV@R,$4\$T#B1'"R1,DJ1R)[KW6J/_+Z^8WS=[.^&
M7Q]WMV-OGY\9#=V6V.(*_.4O6?<?:D6ZZ+"9FKP. WLW8>X_E3L.KRTF<QU+
M29B:K;:E%&9*EA :N!8ZVI]U[HX_^S$?*7_GL?Y@'_I.G8W_ -VQ[]U[KW^S
M$?*7_GL?Y@'_ *3IV-_]VQ[]U[KW^S$?*7_GL?Y@'_I.G8W_ -VQ[]U[KW^S
M$?*7_GL?Y@'_ *3IV-_]VQ[]U[KW^S$?*7_GL?Y@'_I.G8W_ -VQ[]U[KW^S
M$?*7_GL?Y@'_ *3IV-_]VQ[]U[HG7;VYMX_)?YS_ ,K_ .-GRNA^26[?B]V;
MWUVUD>T'[WQ/;W1.T3EMG="9JIV5MN/.T7?O9]//+725=;6^JHPU3'_#PM.U
M=#-5K3>Z]UL"_P##-W\DK_GSW7__ *5+W?\ _9U[]U[K2H_GJ=0_';XS?+7/
M;"Z(QN)VGT;USVQ\9MP8""AW?N'>F+PZY#;>$W!NVM&Y=Q9#)UM2OW%7D)9%
MFK)1&69$5%C15Q,YBAO+OWBYAV^P4O+<[5<1*@ )=FV^/0HKYEPM.&<5H3U]
M"?LSN?+?+O\ =N>SO.'-<R6MCLG/VTW\MQ(S*EO%!SA=_43OIXK';-.6!# +
M5@NI5((7_LR_0_\ S\_;/_4^I_Z]>X:_UJO<3_HTS_L7_H+KI5_P?GW-O_"A
M;5_SDE_ZU=>_V9?H?_GY^V?^I]3_ ->O?O\ 6J]Q/^C3/^Q?^@NO?\'Y]S;_
M ,*%M7_.27_K5U[_ &9?H?\ Y^?MG_J?4_\ 7KW[_6J]Q/\ HTS_ +%_Z"Z]
M_P 'Y]S;_P *%M7_ #DE_P"M77O]F7Z'_P"?G[9_ZGU/_7KW[_6J]Q/^C3/^
MQ?\ H+KW_!^?<V_\*%M7_.27_K5U[_9E^A_^?G[9_P"I]3_UZ]^_UJO<3_HT
MS_L7_H+KW_!^?<V_\*%M7_.27_K5U[_9E^A_^?G[9_ZGU/\ UZ]^_P!:KW$_
MZ-,_[%_Z"Z]_P?GW-O\ PH6U?\Y)?^M77O\ 9E^A_P#GY^V?^I]3_P!>O?O]
M:KW$_P"C3/\ L7_H+KW_  ?GW-O_  H6U?\ .27_ *U=>_V9?H?_ )^?MG_J
M?4_]>O?O]:KW$_Z-,_[%_P"@NO?\'Y]S;_PH6U?\Y)?^M77O]F7Z'_Y^?MG_
M *GU/_7KW[_6J]Q/^C3/^Q?^@NO?\'Y]S;_PH6U?\Y)?^M77O]F7Z'_Y^?MG
M_J?4_P#7KW[_ %JO<3_HTS_L7_H+KW_!^?<V_P#"A;5_SDE_ZU=>_P!F7Z'_
M .?G[9_ZGU/_ %Z]^_UJO<3_ *-,_P"Q?^@NO?\ !^?<V_\ "A;5_P Y)?\
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M 7_O![X@?^DT],?_ %E]^Z]U[_AO;X"_]X/?$#_TFGIC_P"LOOW7NO?\-[?
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M\M0'>.%Z@QH[ $@ D7]^_P!8R[_Z:2^_:W_6WKW_ "=6Y>_\(KRI_P XXO\
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M_P#B,_MU_P"*MR]_W:K;HK/L*]3YU])_^5M_V[M^'/\ X@C9'_NO]],.1_\
ME2MG_P">*T_ZL1]?#W]Z;_Q)WW'_ /%HW_\ [NUWT??V*.H'Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7N@_[9_YE7V7_ .(_WE_[SE3[]U[KY;G8W_,P
MM^?^'GNC_P!W<_OFESY_RO&\_P#/==_]I$G7V^_=._\ $6/;3_Q5.7O^[19]
M5]=!?\"ML_\ :LV3_P"Z;?7N2_<?^QN_]/=?]7=IZP?^Y=_R4>7_ /GEV'_M
M!]P>OK:_ ?\ [(5^%O\ XJ9\<_\ WSV&]Y;\A_\ *C[-_P \-I_VCQ]?/%][
M'_Q*?W+_ /%KYA_[N]YT;/V*^L?^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5?Y
M2_%SY??S$/YEWS9ZVZ<^174O0&R?B95?"[+TB;BZN[.W3NC=V>WGTCF]SXRK
MJ-S]?;YVK/!!05-;6R?;(-,K+2%O\S()O=>Z4G</77\S7X0=>_RV^O\ M7Y0
M_$[N3X_[5^</\MWXP0;2V?\ %GL#KSL6?;%9V]@.LL+F'WWD>PLO2"KIJ*(2
MRM_"-,LUFT*MT/NO=;0GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZU;_CIUO_ #0_G'\8/EGM;KCY4_$;J#X_]J_)W^9ETRVR]T?%
M'L/?O8>(V]NWY5]@[?WI4IOVA[%Q=+)/--DJ^:@<XC]A#$D@G,;._NO=-OQ?
M^,7R_P#Y>G\PGX.]&=R?(;I_OSK;Y5=N?-/O:I_NQU3V9M+>FU^R]G?$C$;1
MR=5_>_?^^-U35>/KZ.EHW%'*EXIS4NDOCDBBA]U[K:B]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=(/KK_BQ5O_ (=&[?\ WHJCW[KW7LA_S,?;7_AK[F_]SJ#W[KW2\]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%KO^ 59_U"U'_6H^
M_=>Z2_7G_'B[3_[4.-_]QE]^Z]U%A_YF=D/_  P\/_[T%=[]U[I>>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__U-_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=$ _F<_]DB9?_Q/_P */_@U^O??NO=/FWOY>_Q]VS\R]U_.;'IO
M23N'=O\ $JZJQ%9N"DGV#B]U9WKC;W4.X=[87#"C6NBR%?MO:V$Q<\,F2DH5
M$,E1#115E34U$WNO='C]^Z]U[W[KW7O?NO=>]^Z]T4#XT_\ ,Y_YA/\ XM_L
MK_X 7H_W[KW6H#VW_P R_J__  P/Y@/_ ,+ ^+WOW7NM[WW[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T#_=_1VQ?D!LE=D[Z3.4:
MX[.8C=^S]V[0SN0VIOSKK?FW)6J-L[]V%NO%,M1C\I02.X1QK@J())Z*N@JJ
M"JJJ6?W7NBV8[MWY,_':-,!\C>M-T?(7K[%^>*A^3WQQV;-NG>4^'A:-,94]
MT?%;:,4FXX\TX?P553UECL_1UDR/7#$[>I91CZ3W7NJZ_GS_ #3?@QTOVST!
MN/N;M_<'3^-R/3_S&VK11=K]'?(+K?,U&X<SMK:M!C\6NV]Z;5H<B)&E*+)>
ME"Q"2)I2BRQ%_=>ZM[^'M?1Y7XD?%O*8ZHCJ\?DOCGTC7T%7"28JJCK.L\94
M4M1$38Z71E9>/H??NO=&,]^Z]U4!U-_QYO\ +._\7_\ EI_[XKY->_=>ZM_]
M^Z]U[W[KW7O?NO=!_P!L_P#,J^R__$?[R_\ ><J??NO=: ?_  E(_P"WS_\
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MI]^Z]T(GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNB0H+,0JJ"68D
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MM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\
M]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N
M_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J
M#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[K
MW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OX
MAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_
M ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\U
MM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\
M]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N
M_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J#W[KW7OXAV/_ ,\UM?\ ]":N_P#J
M#W[KW7.*O[#,D8EVYME(BZ"1UW)7,R1EK.RK]AR0+D#W[KW4W>M'+4[>R51!
MD\KBY\90U^2AFQ-8:.266EH9'CAJ& .J,M8E>.0.1[]U[ISV[/-5;?P5342-
M-/48;&3SRN;O+-+1)))(Y_)9B2??NO=//OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU$_YI?QV[+E^>?:N_OCI\QOE+\1
M-Z]UY[XA[8[.K.C>Q:K![=W=04VR-P[3QM;E=M((Q)6T=-1TBTL_W.A%$P\1
M:=W'NO=#;LKX!)N?X]_RO?E#VQ\TOY@'>^Y<_P!S?RY>^LCUQW3\DZC>W3DG
M9&9S^W=_0Y8;+?$P2Z*#)S&:@C:N8H $D:52P;W7NMG_ -^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6KE6_R]5V/\+?G?\E.IOF__
M ##^D\YL[LS^:QVSMOK/J/Y-2[/Z:Q6[NLODGV?+B)J794.'EE6&MGP]/4Y-
M!7!IY9)W5X]8">Z]T$?\KSX[=C_[-CTWW+\A/F-\J_EEV3T;\P_E]\=.O:KO
M'LF7<.T,#L>J^&&$WAD,EC-ISQ2M3Y:JJJ^:.IJXZ[QR0) AA#1!S[KW6W3[
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z!C9^$W%6X_(U&/WG78:E?<VZ0E!!AL#61Q%<]4
M*[">N@>0ZB"Q!;B]AQ[]U[J?28[+8_L3!+E=PU.X&EVSN(PO4X_&4!I0E;0A
MU08V*,-JN"2][6X^I]^Z]T+'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NHM=_P"K/\ J%J/^M1]^Z]T$FR<)N^?:&VYJ/>_V-+)AJ%Z>C_N
MUC*G[:)H 4A^XE<,^D<:F%S[]U[IRP%'E:+L7)Q9?,?QNI;9>*D2K_A]-C?'
M <Y5JM/X*4E39@S:R;G5;Z >_=>Z%/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1 /YG/_9(F7_\
M3_\ "C_X-?KWW[KW1_\ W[KW7O?NO=>]^Z]U[W[KW7O?NO=!3UYOC96[-W=[
MX':N#FQ.=ZQ[6P^Q^RJ^7%8S'IN;>N0Z/V;V309RGJZ"626N2/;FX<!C355J
MQS*](U,J&GIX))/=>ZTF.V_^9?U?_A@?S ?_ (6!\7O?NO=;WOOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT _\
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MKNT]8/\ W+O^2CR__P \NP_]H/N#U];7X#_]D*_"W_Q4SXY_^^>PWO+?D/\
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M_G3MW_ZM]^Z]U[^]V=_Y][NC_P Z=N__ %;[]U[KW][L[_S[W='_ )T[=_\
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M^N7OW7NO?[-A\IO^\E>__P#T<G8O_P!<O?NO=>_V;#Y3?]Y*]_\ _HY.Q?\
MZY>_=>ZVRO\ A%1D<AE_YA/R]RV6KJS*93*?$S(Y')9+(U,U;D,CD*WN[;%3
M65U=65+-)---(S22RR,69B68DDGW[KW0??.G_LM_YD?^+3?('_W[F9]\T>>?
M^5SW?_GNN_\ J^_7W ?=7_\ $9_;K_Q5N7O^[5;=%9]A7J?.OI/_ ,K;_MW;
M\.?_ !!&R/\ W7^^F'(__*E;/_SQ6G_5B/KX>_O3?^).^X__ (M&_P#_ '=K
MOH^_L4=0/U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!_VS_S*OLO_P 1
M_O+_ -YRI]^Z]U\MSL;_ )F%OS_P\]T?^[N?WS2Y\_Y7C>?^>Z[_ .TB3K[?
M?NG?^(L>VG_BJ<O?]VBSZKZZ"_X%;9_[5FR?_=-OKW)?N/\ V-W_ *>Z_P"K
MNT]8/_<N_P"2CR__ ,\NP_\ :#[@]?6U^ __ &0K\+?_ !4SXY_^^>PWO+?D
M/_E1]F_YX;3_ +1X^OGB^]C_ .)3^Y?_ (M?,/\ W=[SHV?L5]8_]>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2#W_P#\!-L?^'YLW_W=1^_=
M>Z]N#_C]^OO_ ";/_=0GOW7NEY[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H!]W?\SLZ]_[5=3_
M +U6^_=>Z'CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UJ0_S'-I_.7I[^8'\@NR?@A\Y<A\7-P?)3.?#K;G9F#R
M_071_<^V,B,/UMG=DX#*TK]E8;(5]--2)0K((Z6HBCD\\_E#E8#'[KW0N0?%
M[YF=Y='_ ,L;Y&_)W^9KVYWSM+<WR,_EP_)>NZ,K?C9\1^M]MC?%9O/;W9F%
MI5WKUAM+%YW[6@K93$$6J7S17$@U$,ONO=;07OW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU;]N?%;YL] ?#OYN]]_&O\ FB]N]*[(
MZ\[F_FG=T;7Z)I/C'\0.P-N4><ZW^3G9F1J*";?'9.TLIGIHLM58?[BI:6K;
MPF=TIT2-(T'NO=!Q_+HVG\WNX?F3\=>]/G3\Y,M\HMV?&OY2_,?XV=>[9QO0
MO1?36SL?0YCX=8;>6=WFTO66%QV1J*NK-<M*U+6U,T,:4\;Q:'>77[KW6VO[
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z+[0;7W7NF6IS='N3'8JG@W#G((Z$X7[ORKC]SU
MU2GW,\DVHWDGF_S>CTL ;D ^_=>Z6E#+N:EWSAZ+/9#$Y%*C;FX9(&QV,J,<
MT.FNQYE$GFJ)M5RJ6^EN?K?CW7NA.]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]UAJ)##3SS* 6BAED4&]B40L ;?CCW[KW0+8?#[ZW+LG!Q
MQ[EP>.HJK&82HIA'M^>:LI5H6AJZ-3--5-&[ Q(&)BL>>!?W[KW3GLC'YC;V
MY:K;65R5)EA3;8ILC3UD%":&2U?N&LDDBF02.I(?605"\$"W!)]U[H7/?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_0W^/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U7=_-2S.(V[\+=V;@W!E<;@L!@N[?AMF<WF\S74N,Q&&Q&,^
M9O7];DLKE<E6LD-/34\*/-//,ZI&BL[L%!/OW7NA2_X<)^ O_></Q _]*6Z8
M_P#KU[]U[H:]L]Z=);TZZR_;^SNXNJ]V=2[?H\]D,]VCMGL+:6=ZZPF/VM2M
M7;GKLOO;%UDN,IH<; CS5\LU2JTZ*SRE%!/OW7N@4_X<)^ O_></Q _]*6Z8
M_P#KU[]U[H:9^]^CZ7JQ>\ZGN7JFGZ3:EIZY>X9^P]HQ=6-15>87;U)6+V#)
M6#$F*6O=*&.3[O2U0RP@F0A??NO= M_PX3\!?^\X?B!_Z4MTQ_\ 7KW[KW5?
M'47\V3^63UIWE\\*/?7SV^*&W9=Q_*?:.X-O/6=W["EI,[@Z7X4=/[0J<MAZ
M^DK9(*FGCRN*R>.DEAD95J:6HA)$D3J/=>ZU\.JOY/OQF[1_D79K^:/O3LKY
M:97YAT?\N#Y%=V0;^?Y,=A_:)NO:?1VXJ*@Q0QSRLXPLU!C*3$UF(6H$$V/!
MHG7[<^,>Z]UNT_&G-Y?<OQRZ W'N#)5F9SVX.D^JLWF\OD9WJLAE<OE=BT%?
MDLE75,I+233S2/++(QNS,2>3[]U[H;/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=: ?_"YS_NEW_Y>S_\ ,C]^Z]UJ)8G^
M4G_,WSVT]K[\P_P1^3^1V7O7!T.YMI[JINI-UO@-P;>R>W7W;C\WB\I]OX9:
M67%QO7I.K:# IEOI!/OW7NL-%_*=_F4Y.LIL?C?A)\B<A7UDT=/1T-%UUF:N
MLJJB5M,4%-30(SN['A5522?H/?NO=*J@_DQ?S8\G3_=4'\NWY=U5.*BLI&DC
MZ0WO9*K'5DF/KZ:16I05DAGBDAE1@"KJRD @CW[KW4S_ (92_FX?]ZY?E_\
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M/XZXKY38/X9UV\<U#WYN/"_Q?%8,=>]B2;.EJI-K9+?=)M*7M:/%':T6X:C
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MRYNFQVH@1Q9QWZ7R1V5EOT%JD&N"*!]<^]N]PTU3X<2B,A@0V^'3_*7^;?\
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M28Y<I55V6QF'I:1ZT8]'J,I4BEA9ZHQ2Z0&(OZ#[]U[IH_C>_P#_ )X3%_\
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MBJ()D#Q3P2)+#*C<J\<D9*L#^"#[]U[K+[]U[KWOW7NO>_=>Z][]U[J+7?\
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M_P#LA7X6_P#BIGQS_P#?/8;WEOR'_P J/LW_ #PVG_:/'U\\7WL?_$I_<O\
M\6OF'_N[WG1L_8KZQ_Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7ND'O\ _P" FV/_  _-F_\ NZC]^Z]U[<'_ !^_7W_DV?\ NH3W[KW2\]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=!LM5+-VP*=Z*IITH]D9%(:J7Q?;UZ39?'SM+2E&+61V:)PZCU+
M<7!]^Z]U-W=_Q?>O?_#HJ?\ WG:WW[KW2\]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:?G\W7YO=0]-_.?>FSSM
MONOM7??7NZ/B7N'>FRNE>E>P>PLGMS!1;/W!N?\ B.3S=)1PX2/735M#XJ8Y
M;[B1IUT0LD52\'NO=#_U'_-&^%V?^,O\K+XMP;X[5Q'=V*[&_EP=2Y#:^\?B
MI\L]@X6F[$P>3VULW([9?L3?&Q\=MHRC)HU+%*N8,,Q&J&22,A_?NO=;0GOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU<-\?S5?A+
M0?!S^8%\88]]=LYONG-;V_FS]=8C;FT/B9\N][X'([R['^2':K[.PU)V-L[8
ME=MES5?Q6@5YQF/#3M(5J9(6CE">Z]T"7\H_YM=/=P?)K8764>#[EZQ[4[(^
M</RV[XV?UWW+TIV1UYELOU7)\)L%M0;FI=QY''OMV5UR%!64\F.AS;UT8C\L
ME,L$D4LGNO=;?GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I!]=?\6*M_\ #HW;_P"]%4>_
M=>Z]D/\ F8^VO_#7W-_[G4'OW7NEY[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[J+7?\ JS_ *A:C_K4??NO=)?KS_CQ=I_]J'&_^XR^_=>Z
MBP_\S.R'_AAX?_WH*[W[KW2\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U__U=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$ _F<_]DB9?_Q/_P *
M/_@U^O??NO='_P#?NO=>]^Z]U[W[KW18?F9VGV;TK\:.T>S.FZ/8M;V;MNAV
M^NTD[.I-QUG75)79O>&/V[49;?$6T9Z;)+BJ&GJYJVNFI)E>&*)I;,J%&]U[
MHC__ &/S_P#!0/\ [.?[]U[H*^O>K_Y\FP-V]Z;KHZS^4;4U'=_:F([0RT-3
M4?,B:''Y#$]);.Z7CH\?'%3PM%"U+M"FJ&CDDG8RRRN)0CI!#[KW52E-_+P^
M87;'QFW5\^?DIW9T)M+ ]+_RS>XNM.M^HN@]D[USS]@[*Q77O9NZ*^7L?=?9
M-132X;(+E<]CYT?#Q5D<\5$L6FD!G-7[KW6Y[[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZHWZBZI_GG=)[ Q'6NT*S^4WD<#@Z[
M<M?3Y+<<_P PJG/Y.MW5NFMW?F<GF9L;#34QJ:FMKZB>;[:GBB#,1%%&@5![
MKW0E?]C\_P#P4#_[.?[]U[JB+^<C_-1_F0_RL]__ !5WQ\P>H/A%W'%VWU[\
MN-A]?87XU[I[XV=)B6DQ>Q\7NS,[RR_:%)D XB3*4!QU+14?[K"H,T\02-9?
M=>Z/;\9/^%-O\E3:7QM^/FU-^_,;^Z>^ML]']3[>WIM;_9>_ECG?[M;LPNPZ
M#&[CV_\ QS#;!EHZS[.LCFIONZ21X9M'DB9D92?=>Z'#_H*._D4?]YS?^RS?
M,/\ ^U][]U[HFFT/^%/_ /+23"_%U=T?.FL.6I/D1W!4_(C7\=OD5(S]'3[!
M[2CZO6J:BV&8YXQFINNRD.(+UJ$(U2HACKRGNO=&!WQ_PK(_DH;3K<?2X'O_
M +*[.@K*6:HJ,EL?X]=QX^BQ,L4JQI0Y"/LK$[>J&ED!,B&EIYHPH.N1&LI]
MU[I$_P#07E_)M_Y[3Y ?^B)SG_U5[]U[J#D_^%;_ /);S5!5XK,;D[RRV+KX
M6IZ[&Y/X_92OH*VG?]<%71U50\<B'\JZD'^GOW7NE5M7_A2=_P )Z=P;*S-+
MD>\L7UQ2;[P>5VKO'8V:^)'?T.3R.VZF.;#3X?<<O7&S,KC:FEJJ5F*11Y&4
M"&4*XCDUQK[KW6J%_('_ )C_ ,!/@+_-(_F ]V=[]\UFP_COVCMOMK:_2/8&
M0ZV[;WGD-Z8_)_(B@W;LZ:NV_P!>;;KLI135>#I36RM7XJC5&!C=(I2(??NO
M=0ODKV;LCNOY(_('N3K+-_WEZW[:[J[2[-Z^W'_#<OAO[P;(WYOS([JVGF_X
M/N"GI*^D^[H*NGG^VK:6&HBU:)HHY%9!S1YY_P"5SW?_ )[KO_J^_7W ?=7_
M /$9_;K_ ,5;E[_NU6W0*^PKU/G7TG_Y6W_;NWX<_P#B"-D?^Z_WTPY'_P"5
M*V?_ )XK3_JQ'U\/?WIO_$G?<?\ \6C?_P#N[7?1]_8HZ@?KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z"7OW-T^V>B>ZMR5<4U12[?ZE['S=3!3Z/N)J
M?%;.K*^:*#RE5ULL9"ZF N1<@>_=>Z^4+NWMO<>[8</V1L?JW-[JH>S(JC>[
M8V'<NT\/5;9I=R)#GL;0U\N>J:9*B1DJWC+4VH Q,6L&2_/+?MKV7<N>-^_>
M^YQ[=HOKG1KAGF\2MQ-JIX"/IT46NJE=0TUH:?8[[2\]^YG)7W6/:7_6ZY&N
M^<_J>5-D^H^EW+:=N^C\/:-N\+7^]+JV\;ZCQ)=/@:_#\!O%TZX]15NE,9VS
MM+=.T<3V#UF^V<?D*G&X2@S<&Z]KYF#[C;NT=V90I546,J99PTZUA"%4*+XS
MJ8%@/8WY\N^3=ZVB]O.6]U%W+&KRO$;>XB-)KG;HZJTD:H0ABS4@G4*#!ZQ<
M^Z9R_P#>4]L_<7ECEOWLY ;E^RO9;6PM[^/>-IOH_$VS9><;LK+!:7<MPK7"
MWQ$95&C3P&\1P74=?7*^ _\ V0K\+?\ Q4SXY_\ OGL-[RKY#_Y4?9O^>&T_
M[1X^N OWL?\ Q*?W+_\ %KYA_P"[O>=&S]BOK'_KWOW7NO>_=>ZI/_G_ /:R
M]=?RZMY;9AK$I<CW-V%UWUM2A99(ZN2EILP>Q<NM.(C?0]-@9*><MZ#'*4;F
M1087]^]U_=WMY-; T:\EBA'K0-XS4_VL1!\J&GF.NFG]TGR$><?OB[;O<D9D
MAY;V_<-Q:H!0,T(V^'57S$E^LD8'=KC##",0%G_"<KJU-E_!S=79-8GCK.WN
MY=TY6GJ6E/B;;&R<91[/QZ&-@%4QY"GS#,US<,M_T^RO[N^UBRY(EW%^-W<.
MP/\ 0C58Q^QQ)^WH>?WR?/3<R_>BL.2[<UCY=V>UB9:9^IO9)KR0UXD-;R6@
M \B#3CU1W_+P2;YC?SL*;MJI<UN&F[G[D^0U1,88Z@4F&P3Y+-;%BB252JQP
MULN%I8W/J1;,IUA3[A+V^#<X>] W9NY#<7%V3QHJZVB_(,8U'H/GUU"^^"T7
MW<O[LM_;^ >%<KL^S\OJM2NN:<6T-\20:EGA2\E8<&:H(TDCK?$DDCACDEED
M2**)&DEED94CCC1=3R2.U@  "22; >\Z"0!4X Z^4]$>1Q'&"S,0  *DDX
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MVP^Y5ZP#Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND'O_\
MX";8_P##\V;_ .[J/W[KW7MP?\?OU]_Y-G_NH3W[KW2\]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(.;
M_F9V/_\ ##S'_O04/OW7NO;N_P"+[U[_ .'14_\ O.UOOW7NEY[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU7?D
M1\Z^WOY8G\S+^8'V&/@WW7\I-B?*6H^#N-V7G.E=V=?29/&YW:'1N6VU_",G
MLNKJ9LV?NZFGKDBJACUIU:!4>4/4TPD]U[I0?(KY/_,_YX;2_ERY6H_EF=I]
M"](;E_F!_P M[Y&8_O7>GR7^)^\,(>O,5W;@NP\94ML/8FZ*K<PFR.-D62&!
ML6)8F(2>.-K@>Z]UM!>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[K5O^(_RG^;7P2^-_RA,G\KOMGNOI;J_P"6O\R;MC+][[0^3WQ$
MVM@:W9N$^66_=Q;QR-)L/>.ZX-S XK[.OIWA.+\U0T!:FBE62+7[KW43X^?.
M3N'^9K_,7_EZ=S2?!SN7XN=5_&3L+YR=1;PW-W+O7K=\MD.U-V_%K&9T[*I>
MO\=5Q[BA>DQ[T=7)D)L7]BXG\4=29XI8T]U[K:;]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO= QL_<.5Q^/R-+2[/SN7A3<VZ2M=0S8=*:4OGJAV5%K*F.2ZDZ3=!R.+CW[
MKW4^DRU=E.Q,$U;@,G@C#MG<0C3)28^1JD/6T19HOL)I@ M@#J(^HM?W[KW0
ML>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZBUW_  "K/^H6
MH_ZU'W[KW02;(W/F:7:&VZ>'8^XJZ*'#T,<=93U&#6"I1( %FA6>K1PK?4:E
M!_J/?NO=.> R-7D^Q<G45F&K\'*FRL5"M)D7HI)Y(USE6XJ%-#+*F@EBH!8&
MZGBUB?=>Z%+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__6W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0#^9S_V2)E__$__  H_^#7Z]]^Z]TG]
ML]'?/*@_F&[S[KS_ ,BMMY#X5Y;!UM'MWI.+*5DF1HH)>N]O8/#[:3KZ;;"4
MU!64.YZ#/;EJ-YQ[WJJBO@R8Q#8>EIJ:&5/=>ZL?]^Z]U[W[KW09]T=6;=[R
MZ?[3Z6W<:A-K]M==[SZWW!+1N8ZZGQ&]=NU&W*^KH)E*M'40QU+2P2*P9)%5
ME(8 CW7N@B^'?<VX>WNGJ6A[+2EQOR Z@RU5TS\D=LPH:9L+W+L>EAI\YF**
M@E5)(\-NBCEH=X;6F=!]U@\MCJI>)N/=>ZE=!;JW'N'M;YNXC.9K(93&;$^3
M^T]J[.H:VH>:FVWMRL^%_4.]ZK"XF-N(J>3+YG*Y%HUX,]5,_P!7/OW7NB/U
MG_;CSMS_ ,4 ^17_ +Z;<7OW7NK?_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-><BS51A<O!MO(8O$[BFQ>0BP&4SF(J]
MP87&YJ2D=,7D,O@*"NQD]=2PSF.2HHX<E2231AHTJ8&82I[KW5#/\UG^1HO\
MX*+HB/Y,?)V+9#_'J3LU]D3]&])R[9EKU[77;Z[FAW*-^[QW,DZH=MXYJ0TR
M4[(3-K:0.H3W7NJ$-X?\(VOC1MKO'I7J>#YE]YU6/[3VWV]G*_+2["V"E9BI
M>MJ?!344%' CZ'6I.6D$I<W7QKI^I]^Z]U[KW_A&U\:-Z=K?(#KRI^9?>=%1
M].;DV#@\;D8-A;!DJ<S%O#K7';ZJ9ZZ*1]$;0RUKP((^"B@GDGW[KW0)U'_"
M2WX\0_#C>GR;'RV[H.<VO_I.^WVP=D['_A-5_<+M+)]?TGFK-?F7[B&@2HDT
MCTNQ5?2![]U[H['_ $!#?%G_ +SA[_\ _1=]=?\ 7SW[KW7O^@(;XL_]YP]_
M_P#HN^NO^OGOW7NO?] 0WQ9_[SA[_P#_ $7?77_7SW[KW7O^@(;XL_\ ></?
M_P#Z+OKK_KY[]U[KW_0$-\6?^\X>_P#_ -%WUU_U\]^Z]UKL_*+:\'PH[ [.
MZ3P.#WGVCL_X\[L[(ZLEW?2KMN@R!VYTEFI]I4^X]P4-95TZK-6TM$U4\5&L
M@5ED4 #1JY]7W+4',_N!N^WF_@LYGW&:.)9A*3,\MS(H5#'&X%&T@ZRH[A0\
M:?8+RK[V[K[%?=#]N^<(^4=TYEVRVY,VR\OY]N?;U7;K:PV6SGDEN%O;RU=P
M\1E=!;K,U() R@F,.6SJ'Y1[>[FW&VW]M;-W52)3Q-+D<KDYMOQ46-1J6:>E
M,T,58U1)YF@:)?!$^EB"^E;L'^=?:/<^1=K_ 'ENM];N6-$CC$Q9SJ4-0F((
M-(8,=;+4 A:G'17]V'^\0Y(^]7SV>2N0>5MXME@0O=7ET^VI!:J8IY(M:)>M
M<2>,T#1+]/#+H=E:71'5Q]1K^6OO;8^T_@)\0<#N/?.Q\1F:/H/KJ:KQM7O+
M;2U5(N1P$63I4J8DJCXY##-&SQ/9XR2DBJZLHS6Y'_Y4K9_^>*T_ZL1]?,-]
MZ;_Q)WW'_P#%HW__ +NUWT=S_2SU7_S\OK__ -#+;G_U3[%'4#]"![]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7N@=^1&#?<_P ?^\]M1U*T;[AZ=[-P:5;Q
MF9*5\MLJNH%J6A5E+A#)J*AA>UKCZ^_=>Z^3[E]A=J];X3:O6^R<[U]-6]>8
MJ/9&Y,ENG";CKJ7*U6U:2GP-/782'$UM&\,<CT]1(ZSZS9HP-)5M7/+?GY53
MGC?OZS1W<G^/7/A_2R0QT_QB;7K\6*2M>S3ITTHU:U%/L=]I;;W]N/NL>TO^
ML=><OVE.5-D^M_?MGN-WKKM&W?3?2_N^_LO#TTN/'\7Q=>J'P]&E]9>>J>P>
MX^R]V;+JM\TW7.-P.*R=-GH(-LT6XURU8V?V7NG%T6JHR5=/#&L1I)C*GB);
M4A5A8@BSG#EKD?E79K^'E][V6XF1H29W@\-?!NK"1L)$C$MXBZ3J %&J#CK'
MS[M_O;]Z7W]]R>5-Q]W[?EBPV;;;J+<8X]JM]S%Y,=QV+FZT@K)=7]Q!&L1L
MYS-'X3,^N(I(M&!^MO\  ?\ [(5^%O\ XJ9\<_\ WSV&]Y;<A_\ *C[-_P \
M-I_VCQ]?/+]['_Q*?W+_ /%KYA_[N]YT;/V*^L?^O>_=>ZKK_FC]@_*[K+XF
MYS=7PQH-[Y+O"#>FRJ/&TO7W6='VWN1MO5F1:/<+P[.K\3FHY(A%;RSFA)B'
MJ#I]?<>^Y^X<U;9RH]UR:LC7PDC $4(G?03W_IE) 13B=./4=9B_<6Y1]@^=
M_?\ M=A^\G+90\KM9WKR-N&Y/M-O]0D8-N#>)=6;*Q>NA/' <X*MPZTD?G/\
MH_YCG;M+LSK3YY5?9F*7"3S;ZV7M#LOH[;G2>2=JV.; /N2DH,9MS 55; ?'
M44L<THEB5A*J6?7[PKYXYG]Q-V6';>>C,N@^+''-;);'-4U@+#$S#!4$U -:
M9KU].7W6O8O[FOM[/N7.WW4H]MG-THL;R[VW>[C>HQH*3BW>27<;^*%QJCE9
M%\.1E,9:JZ>AQVI\F/YS'QG^,U'L7 ;9[_ZI^+VUMJ5])3Y#,_$C;^/V9B=J
M;XR,U95UU1V1N?9;3"/(564DDCKYLH7>2H4QRZF3V=VO,OO%RURT+&"*ZM=L
MB0@%K!!&J2$DDS/;UH[.2&+U);!X=1?O_LG_ ';GO;[VR<T[M?;#O_/-_=1N
MT</-EQ)>2W5E&B(B[=;;R$+6\5JJM EKI5(2'CH&Z+)\'-P_/WJW=FZ>W?@A
ML3N'-;D7 3==[LW9UET+_ILI,=ALUD*/<<F R,>0V_GJ*BEJ)L;25"MXHYRL
M5E?QM(K!KDBXY]VN[EW;D6"X>308I)(;7ZD!6*OI-8I54DHIX!J#!I7J;OO1
M;/\ =*Y[V"P]O?O5;KM%M9&==PM+7<M]_<KR30QS6XGC,=_8S3+&EQ+&1J>(
M,]676$(W"/YU_3_R8^07P\ZJZL^..V=^;MW_ +Q[ZV-2;SV_L_(';\-;LR7J
M[=9S4>_*^>HHL?383^)'&_<G+3QT:U'VP<B3Q>\N_>C:.9=_Y0M=KY=BEEN)
MKJ(2)&=%8_!GU>*2501Z]&KQ"$U::YIU\ZW]V7[B^R7M%]XO?N>_>:]L=OVG
M;MBOGL[B[C^H*7@W/:_!-C&L<UQ)>_3"X\,6B/<F'Q](*>)UK_\ R)_DO9/X
M9_ +M#Y']][SH,[WA!E>N,3M?8^R:NHGV9L.CW)OO'X[+569SM1'#)E\G)22
M/3>.*%*.F+2E'K6,,\,"<P^S<O)W(5US%OTP>^#0JD<9)CB#RJ&+,0#(Y4E:
M !%J:%S1AUM]G?[RFQ^\E][38O9GVGVV2UY7>+<9;F]O45;R^>WL9Y(EA@5G
M6TMEE59-3.US/1 RVRB2*0;O^$RO_91GR/\ _$*87_WNJ7V=?=J_Y6+<?^>9
M?^KJ]1C_ 'W/_3F^3/\ I=3?]H,O6W'WIO.HZXZ2[B[#I)DIZO8?5G86\Z6H
MDT>."HVOM*KSD,TGE!6RM &.H$6'(M[RRWR\;;MEO-P0T,$$L@/H4C9A_@Z^
M?#VLY;AYS]SN7.3[A2\>Z[IM]FRBM66ZNXH& I0U(<@4-?3KYX7\K+9=!V?_
M #%OBA@=Q1?Q6E?MRAWA61UI>I%;5[%H*KL"!JW6'\H:HQJ-*L@*N+A_26/O
MGU[7V<>Y^X>U07 UCQQ(:YJ8@THKZY05KQ\^OL%^_=S+=\C_ '.>?MUV=O <
M;2]HA2BZ$OI(K!M%*:2([A@I6A4T*Y ZWW_GAL+%=F_"SY5;*R]%'74^6Z#[
M1J***5#((,]A-HU6?VQD40$7DI,E2TE5%S^N-?>=W/5A%N?)FZ64RZ@]K.1\
MF6-F0_:KJK#YCKY//NJ<V7_)'WE^0^9MND,3V^^[8KD&FJ":[B@N8R?X9;:6
M6)OZ+GK2Q_D([_K-E?S*>J<+3S20T79^SNU-@9<1Z],U'%L:KW]10S*GU4U^
M!HB+@@,%8V U##3V(OWLO<BUA4T6ZCGB;[/":4#_ 'J)>OI<_O8>4K;F7[E>
M_P"Y2J&EV.\VN_AK2H<WT5@Y!/ B"^F]"02!4FAW=N\_B3\:/DO48&L[ZZ4V
M!VE7[7AJJ;;^2W5A(JO)XJDKG66KHJ7)Q&.H$#NHD: R&/6->G5S[S5WSE/E
MOF1HWWVRBNFBJ$+K5E!X@-@T/&E:5S3KYA_:W[P7O7[)PW=M[4<S7^Q17Q5K
MB.UF*12N@(1VC.J,R*"5#Z=>GMU4QT7_ 'MVS\%_Y271.QMEYB?_ $*=4U&5
MW=!UYM/$8GL;L7*9[<5553;PW#20Y'1EZUII9JIBE1F*Z."-6BIUFBACBC0@
MO=UY']I]C@LIC]%:EI!$BK-,S.29'%?U&J2W&1@HJ%!   EOECD#[TW]X+[J
M;IS+MR?UFW](K1MPNII=NV^*"W54L[=S'6TA"*D0!CM('E<K),T;R.[MI*=X
MU_8G\UK^8;V1N3X\=899\MW5NO$G;>W'ACC.WMF[5V_C=B4F\M_5U!YJ;'1"
MDHJ>OS-297BBGF>-))W:,R86[W)N'NG[@W-SR]:MKO770G\$:(D0DE(J$&E0
MTAJ0&) +&E?IP]KK7D_[A'W/]EV7W@WR(6_+-K+]3< D_47EU<7-\]G8(^B2
MX;Q9I(+.,*LDD4:NR1*'T;[=#UE3=*_#>CZ;H\C)F*3J7XS4_65+EIHA#-E*
M;8?5@VM!D985)"-.M()64$V+6]YVIMJ[+R>-G1M8M+,0AN&H10: ?STUZ^3^
MZYWF]S/O'R>X]Q"+>3F#F1MR:('4(FOMT-TT8/F$,I4'S KU\YKX8=@[0ZG^
M7/QF[/[ R_\  -C=?=Z=7;RW?G/L,GE?X1MO;N\:3*YG(_PS"PU-94>&GBDD
M\-+3R2O;2B,Q //#DW<+3:N;-MW._?PX+>YADD:C-I1)%9C106- ":*"3Y G
MK[(_O*<H\P\__=[YVY'Y2M_J]TW?8]SL[2#Q(HO%N;BSEBAC\29XX8]<C*NN
M61(UK5F4 GK>8_X?*_E:_P#>4/\ [!3Y$_\ V(^\WO\ 7N]L/^CG_P!FUW_U
MHZ^6[_DUQ]^S_IAO^ZUR]_WMNJ!_YX'\T#XW_,W9/5_2?QUFS.]L5LS?3]BY
M[L_)[9RVU,7).FW:W;=!MG;>.W/%2Y60.*V6HKY*J@IXP8J81&8F3Q0+[V>Y
MO+G.-E:[+R\6F6&7QFF9&1:Z&0(@<*YKJ)8LJC"TKFG6C^[ ^XW[S_=MYGWW
MW-]XUAVR?<K$;?!MD5S%=2A3<0W#W-S);/+:KI,*QP+%/*Y#S&01@)KMG_X3
MZ_$;L3X[?&G?W9_:&"R6TMQ?(G<FV\[@MK9FEGH<O1]?;-QE53;6S.4H*DK)
M3R9*?)9&HAADB5C2_;S$D3*$E?V!Y2W#E[EN?<]S0Q2;@Z,J,"&$488(S Y!
M<NY (!TZ3YXY_P#][I]X3D_WB]Z]IY&Y&NH]PL^3K:Y@GNH65X7O[R2)KJ&*
M1:K(MNEM;QNZL5$_C1@ QDM?O[GGKDQU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=(/?_P#P$VQ_X?FS?_=U'[]U[KVX/^/WZ^_\FS_W4)[]
MU[I>>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7ND'-_P S.Q__ (8>8_\ >@H??NO=>W=_Q?>O?_#HJ?\
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M(^Q7N5]VC[H$O*N^[3X'-\\N[;B]@MS:2EKU@8;&'ZA)WLM4T%K:=WU'@IK
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M/'-%-'%#-Y(H<3.;]EW_ -E^:H_ZNW\BQSH)(W!IK56(,<\8[)-+?Q*48$,
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MA*NO5Z@IJ=(;R^\DN?\ WNY1W'DVYV_E^62:ZOHFBT&)T\)9!ID,C, I.@L
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M\"564W))DGFKJ>/)01453' (,H>1_P#E2MG_ .>*T_ZL1]<(_O3?^).^X_\
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M"^Y>YJMK6.*UDV>P,@>2WN/$F29EB,:BC^)5?K1? ?\ [(5^%O\ XJ9\<_\
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MJRD>.HI*NFE5)Z2LI)HYX)562*1'4$/;QLVV;_MTFT[Q"L]O**,C?M!!%"K
MY5E(93D$'HM]N/<GGGVBYRLO<#VXW*7:MWV]BT-Q"145!5T='#1RQ2(2DL,J
M/%*A*2(RDCK7-[1_X3(=2YW<<^0Z>^4F^>N-M3S3S#;N^>M\/VK5T8F6-HZ6
MASV*S&UB(8G\P05%--(8S&KRN\;RRX\;I]VG:9[@R;1NDMM&:]DL*SD<,!ED
M@P,TJ":4J202>R/(O]]Y[@[5LR6GN+R+9;S>H%'U%EN,VUH]-56>"6SW,:V&
MC5X<D:!PY5%5U2,V'PZ_D'_%/XR[LP/978>>W#\CNQ-M5-/D,$V\<3C-O=;X
MC,4JJU/FZ3KJCDK6J*F*77) ,KE*R"(^-TA$\23^Q5RA[$<K<M7<>Y;A(^XW
M$1!7Q%5(58<&$0+5(.1K=U&"!J ;J OO&?WL7OW[W<OW?)7)]I;\F;/>JT<X
MLY9;C<986)U0ON#K"(XV6BN;6UMI7&M6D,4C1=76[RV__>W:&ZMJ_=_P_P#O
M-MO.;?\ O_M_N_LOXSC)<;]W]KKC\GC\FOQ^1-5K:EO<3/>6_P!7:2VM=/BH
MR5I6FI2*TJ*TKPJ/MZYF\N;O_5_F&PW[P_&^AN8+CP]6C7X,JR:-6EM.K335
MI:E:Z3PZU6/^@7?_ ,#C_P#99_\ ](/O%S_@8_\ I-_]F?\ V]==Y/\ D^=_
MYR[_ ,B3_O@=>_Z!=_\ P./_ -EG_P#T@^_?\#'_ -)O_LS_ .WKKW_)\[_S
MEW_D2?\ ? Z6FQ_^$PO7=!E5F[)^7>]-V8/R4A;';'ZDP?7N5,*5(:OC7,Y[
M.;GA#20ZDA?[ B-R'995'C*RR^[/M\<M=RW:25,8C@6)N.>YI9AD8';@YSPZ
M#7-']^)SC=V!CY+]O+/;[JCTDO=VGW"*I4B,^#!9;:]%>C./'!=:J#&3K&PQ
M\:_C!TG\1^L,;U'T1LREV=M&BG?(UQ$]1D,WN7/U%/'3U^Y=T9NM9YZVNJ%B
MC5Y'8(B*D,"14\<429!<M\L[+RGMB[3L4(AA4U.26=B "[L<LQH,G  "J H
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M?MJA2PTFZW)YM<>_=>ZGTE?FJ[L3!',X'^!-'MG<0@3^*4F3^Y5JVA,C:J4
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MW%\E-G2[6[3W_P!B[I^-%1M+$YN@RDN'1Q'$N2JZ"!Y6H8Y98Q5SO2>Z]U]
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M>Z][]U[KWOW7NO>_=>Z][]U[I!S?\S.Q_P#X8>8_]Z"A]^Z]U[=W_%]Z]_\
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M9' 4&+HI:EWF<NU-CZ>/Z!8UM[]U[JPWXF_]DL?&C_Q7_IK_ -]UC??NO=&
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW5%O\KWMOO+;WQ8HL5M#XH[V[!P=-V%OU:;=-#V
MCTMMRDR)7)JGDIL7N+-PUB(5"NIGA1K-8J""/?NO=6)?Z=ODS_W@WV!_Z._X
M]?\ U_\ ?NO=>_T[?)G_ +P;[ _]'?\ 'K_Z_P#OW7NJN/YR':G=>Z/@)W#B
MMZ_%W>'66%>""1MT93LWI_<]%#4+1U,:TTN,VIF*FL]4;22!TA8>C2;%@??N
MO=%@KOF)_)Z'RB^?N(^;OS6DVQVAM/YC[HV5MO;2_+SY2["QVW=E;/Z>V5MZ
MMV_BMK=0[GH,+2K0;HI]RT=9%'3+,E='5QS_ +B$#W7NM6KY Y;KK/\ ?O>&
M=Z?SO]Z.I,UVWV-ENKMR_P <SNY_[Q==9+>E?6;)SO\ >7=$U1D\C]WC'I:C
M[[(U$M5/K\M1(\KNQYH\\_\ *Y[O_P ]UW_U??K[@/NK_P#B,_MU_P"*MR]_
MW:K;H)/85ZGSKZ3_ /*V_P"W=OPY_P#$$;(_]U_OIAR/_P J5L__ #Q6G_5B
M/KX>_O3?^).^X_\ XM&__P#=VN^C[^Q1U _7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T&O<];1XSI[M?)9"IAHZ#']:[ZK:ZLJ)%BIZ6CI-KU4]34SRM
MPJ(BLS,>  3[]U[KY2O;/=?56&W'7;IRF^,)1;>W[F]PY_9V6FEF%+N##5->
M,C!D*!E0DQM!5TT@+ &TB\>^>6_<J<Q<S\\;]^X+22Z\"^N?$T '3KN)M-:D
M?%H:GV'K['?:7W^]FO8W[K'M+_KM\PVFP_O3E39/I/JF9?'^FVC;O'T:4:OA
M?40ZJT_M%I7HBGQM['V5FMQ[8V]C<]!/FC1[<IDQSTU=2SRS8;;V\JK*" 5<
M48D$,=53L[(2OK O>X$E>Z7*^_6&UW>YW5N5@U3L7#(P EFVQ8ZZ6)&HQN #
M0]IQUA']POWW]IN;.>^7^2-AWF.;=C#M<2VS17$4CO8[;SQ-=B/QH8Q((([N
MV9WC+(/%4!B:@?2S^%?\YW^5EL[XX_$OHC=?S?Z.V[VWM;I+H?J3<FR<SG:_
M'Y+!=C8/8F*V=F-JY6HJ:5::">ER<4E).\DXB1U8LX0%O>3'(?\ RH^S?\\-
MI_VCQ]</OO8_^)3^Y?\ XM?,/_=WO.K[/8KZQ_Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7ND'O\ _P" FV/_  _-F_\ NZC]^Z]U[<'_ !^_
M7W_DV?\ NH3W[KW2\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(.;_F9V/\ _##S'_O04/OW7NO;N_XO
MO7O_ (=%3_[SM;[]U[I>>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[HCWRH_F1?"KX4;LVAL3Y.=WT/6>\-^;=R>[=I[>.
MR^R=Y9++;:PV2BP^3S*P=?X;*^&"*JFB@+5!CN[ +?W[KW5$_07Q8_EM_P Z
M;^8)_,S[][7ZOC^4W3VWI/A9@.D-V;GD[UZYPE'+3='Y+&]ATF!P4]1MR5VC
MR-(J3R3T;%6N8V"S$O[KW2V^>7\K'X'_  R/\OOMGXS=%MU9O['_ ,UG^6UL
MVCS>.[0[FSL,&U]P_)C"8W,81,)NW<60Q_@GIU$+*:4D)Z5*@GW[KW6T'[]U
M[KWOW7NO>_=>Z][]U[KWOW7N@OG[OZ7I>V:'H2J[>ZOIN],IM>?>^,Z6GW_M
M2'MG([+I9FIJG=]#US)5C,38N.1'C?(1T9@5E*F0$$>_=>Z%#W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3'N?<^V]D[;W#O/>>X<'M+9^TL'EMS[KW
M7N?+4&!VWMC;>!H),KG=P[ASN5DBI:*AHJ6*6IJZNIE2*&)'DD=44D>Z]TS]
M=]D==]O;+V_V3U/OW9?9_7>[*-\CM7?W7>Z<'O79>YL>E2]&]=M_=.VIZFAK
M81-%)$9::=U#HRWU*0/=>Z6GOW7NO>_=>Z][]U[KWOW7NO>_=>ZU</Y;W\J+
MX"?,+I/O?N7Y(]#-VAV1NWYV_P PK#[CW%DNU.ZL*F6QF&^8.\L'CZ.HPFUM
MQT./"+2QK$X2D'DY:36S,Q]U[I*_(#XL?RV_Y+O\P'^6-WQU9U?'\7>FLU6?
M-3&=T;HVW)WKV3@9LA5=$8_!=>C,;?BJ-QR0S2UE=+3P3T]$C-J(D<QQ@I[K
MW5\GQ1_F)?#7YOYO?FVOB]W50]H;@ZQQNV\QOK#IL[L79V1P&+W?45M)MNOF
MI>P,1BGFBJI<=6HCTPD"F(A].I=7NO='5]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1:VNHL;32UN1K*6@HX='F
MJZVHBI::+R2"*/RSSE474S*JW/)( Y/OW7NF'^^^R_\ GK]K_P#G_P 3_P!?
MO?NO=(O8>[=JT>%K(JO<VWJ65MQ[GG6.IS6-@D:"HST\T$RI+("4="&1K6((
M(N#[]U[J:N:P^9[%V^V(RV,RJP;8W&L[8VOI:Y86DK:$QB4TKMI+6-K_ %L;
M>_=>Z$_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW46N_P"
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M3X;%3;@JZ"@2IJG400-75U/3AV4S3PQZI%]U[H4O]F6[G_[U[?+_ /\ 0U^
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND'O\ _P" FV/_  _-F_\
MNZC]^Z]U[<'_ !^_7W_DV?\ NH3W[KW2\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(.;_F9V/\ _##S
M'_O04/OW7NO;N_XOO7O_ (=%3_[SM;[]U[I>>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JOCY5_RV^FOEKV]LCOC<G:?R
MHZ8[7V%UOG^H\/O7XN?([L/X\9^MZ\W/N>CWEF]K9[+]<STM56T<^2Q]#5O3
M33F(R4\#LA>*-E]U[K72^=?PJ[.ZX[S;J;J/^9O_ #:>O\5_?+H'%C+G^8+\
M@MUY48[L7&;A&Y*;3N7*S07:6CHYH7\6I#$5!*NX/NO=&PV!_+NV?EOCG_*Y
M^3_8?RG_ )@O=>]\YV]_+?[RR6TN\_FWWKVUU+4=D9;/;;WZ<X_6F],E58XF
MFR<C3489"81Z5-B;^Z]UM">_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[K5PS/\N#9FVOA/\]ODKUO\K_YB/3.[MJ]C?S7^T]N;*Z6^
M<O?75W4&&W?UM\E.TI,!5X[K+:&3IL=$DTN(I9\@J(#52F665B\K-[]U[HL'
MP9^%O9/9.[*39';'\S'^;/OLQ?-OY =$U&=7^83\AMK5]7L#KOXHX+MO;5.]
M-MW+0TR529FNJ9)JE(@9(F$1 50??NO=;&OQ'_ET]-_#OL7M/MW:'9/R:[@[
M.[@VKL39&[]^?)[Y"=@_(/=?]TNM\CELKM3;V(S_ &%45-534E/49O(2B!92
M@:0E%0L^KW7NC\^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H!ZS_ (N[?]K23_WM\_[]U[H6JC_C
MY\/_ -J'<?\ [L,5[]U[I^]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U%KO^ 59_P!0M1_UJ/OW7NDOUY_QXNT_^U#C?_<9??NO=18?^9G9
M#_PP\/\ ^]!7>_=>Z7GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__6
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0#^9S_V2)E__$__  H_^#7Z
M]]^Z]T?_ -^Z]U[W[KW7O?NO=>]^Z]U[W[KW1?NF>R-R[Y[&^6>V,ZU"V+Z;
M^0.V^M]F"DI/MZA-M93XK=9]O52Y.;4WGG_C&ZLL5ELMH3%%;]O4WNO=:8?;
M?_,OZO\ \,#^8#_\+ ^+WOW7NM[WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=5@?SK?^W1_P#,:_\ %0.\/_>)JO?NO= !_,>_YE7_ "=O_&GW\OG_ -YS
M.>_=>ZN^]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:@/_=FU_P"6
M _\ R]>_=>ZV_O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=5?_P H7_LC7"_^) WW_P"YT7OW7NK0/?NO=>]^Z]U4!_/2_P"W<?<O
M^O2_^ZNN]^Z]T8#X/?\ ,Q?YC?\ XO\ [D_^!9ZH]^Z]UH'?.G_LM_YD?^+3
M?('_ -^YF??-'GG_ )7/=_\ GNN_^K[]?<!]U?\ \1G]NO\ Q5N7O^[5;=%9
M]A7J?.OI/_RMO^W=OPY_\01LC_W7^^F'(_\ RI6S_P#/%:?]6(^OA[^]-_XD
M[[C_ /BT;_\ ]W:[Z/O[%'4#]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW0?]L_\ ,J^R_P#Q'^\O_><J??NO=?+.[*R>-BW[O2>3(44<%7N_<\M+,]7
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M /YG/_9(F7_\3_\ "C_X-?KWW[KW1_\ W[KW7O?NO=>]^Z]U[W[KW7O?NO=
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M) WW_P"YT7OW7NK0/?NO=>]^Z]U4!_/2_P"W<?<O^O2_^ZNN]^Z]T8#X/?\
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M_02O\ZO^?4?$S_T!>X?_ +._?O\ @D.>/^46Q_YQ7'_;5U[_ ),J?=8_Z/\
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M?,/_ '=[SHV?L5]8_P#7O?NO=>]^Z]UKT?SDOYNN ^-FV-S_ !B^/.X(,O\
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MM3'HV;Q1BI]$U4U70?:QW?QU<Z122+A'S1[/<\<LR.QM6O+=:D36X,@TCS9
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MB6-Q;2MIBN9TT-(8SKU%"RH5._\ \/E?S2O^\H?_ &"GQV_^Q'V-O]>[W/\
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1 /YG/_9(F7_\3_\ "C_X-?KWW[KW1_\
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MZ][]U[KWOW7NO>_=>Z >L_XN[?\ :TD_][?/^_=>Z%JH_P"/GP__ &H=Q_\
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1 /YG/_9(F7_\3_\ "C_X-?KWW[KW1_\
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M_JGW[KW7O]+/5?\ S\OK_P#]#+;G_P!4^_=>Z]_I9ZK_ .?E]?\ _H9;<_\
MJGW[KW7O]+/5?_/R^O\ _P!#+;G_ -4^_=>Z]_I9ZK_Y^7U__P"AEMS_ .J?
M?NO=>_TL]5_\_+Z__P#0RVY_]4^_=>Z]_I9ZK_Y^7U__ .AEMS_ZI]^Z]U[_
M $L]5_\ /R^O_P#T,MN?_5/OW7NBDX[LOKD?.[>.2._]DC'-\2>MJ%<@=U8+
M[)JU.XMUU#T:U7G\9E$;*YCU:@I!M8@^_=>Z-M_I9ZK_ .?E]?\ _H9;<_\
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M2=/=>Z/?_P -0=B_][A?YO\ _P"CK^+/_P!IOW[KW7O^&H.Q?^]PO\W_ /\
M1U_%G_[3?OW7NO?\-0=B_P#>X7^;_P#^CK^+/_VF_?NO=>_X:@[%_P"]PO\
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M%G_[3?OW7NO?\-0=B_\ >X7^;_\ ^CK^+/\ ]IOW[KW7O^&H.Q?^]PO\W_\
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MG>W;WQOR.T<CG]H;=FR^-H]QT&"ZIQM9-1O)&JSQTM?3R,MPDJ'U#W7NFO\
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M /TOW^81_P#;3]^Z]U3=_.S^"/Q&^#'Q(?L+X5579.R?F]C^YOC&W2FU<O\
MS!_F'E-Q[BDW7W[A]K?:Q;0WWVJ5-!D/\IH9LF@@:F FFAK:2:#SQ>Z]TD?/
M_,K_ .='V!_Z<^^;G_V:^_=>Z]Y_YE?_ #H^P/\ TY]\W/\ [-??NO=>\_\
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M%(34CW7NA=\_\RO_ )T?8'_IS[YN?_9K[]U[KWG_ )E?_.C[ _\ 3GWS<_\
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MRZ_^RSW[KW7O]%OS7_Y\Q_[4,^77_P!EGOW7NO?Z+?FO_P ^8_\ :AGRZ_\
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M'BL9F/LH,E4U[U\P@26:H:=WD]YL<A_\J/LW_/#:?]H\?7R__>Q_\2G]R_\
MQ:^8?^[O>=;9/L5]8_\ 7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T@]__P# 3;'_ (?FS?\ W=1^_=>Z]N#_ (_?K[_R;/\ W4)[]U[I>>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7ND'-_S,['_^&'F/_>@H??NO=>W=_P 7WKW_ ,.BI_\ >=K??NO=
M+SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=$2^57\ROX:_"O?FS>L/D1V5N[;78&_]HYC?NU=I[)Z&^0O=N7R&SL!F8-O
M9?<53!T9M7<@HJ:&MJJ>F+UQAN\B!0U_?NO=:S_SM_F:_&WL7Y$_Z2.HL=\@
M>P]O'>7Q]RGW ^(7S#VFHQW7N"W-4;FJ&CW1U_3U%XZBHH*.-!3EI)*E'4&&
M.>6+W7NCD]1_S1OA=G_C+_*R^+<&^.U<1W=BNQOY<'4N0VOO'XJ?+/8.%INQ
M,'D]M;-R.V7[$WQL?';:,HR:-2Q2KF##,1JADDC(?W[KW6T)[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7#?'\U7X2T'P<_F!?&&
M/?7;.;[IS6]OYL_76(VYM#XF?+O>^!R.\NQ_DAVJ^SL-2=C;.V)7;9<U7\5H
M%><9CPT[2%:F2%HY0GNO=%(^"_\ ,R^-/6^_*;=7;-+W_L&G?YU_(3NF>#_9
M/OF1ND4_7'8/PYV[UOMC/&7;77T[.TNX*6LQ4E(L7W$;PM.\0HWBJ9/=>ZV9
M?B=_,<^'_P WMT]B;(^-_8^ZMU[PZIPNT]Q[]VUO/H[OWI/,X/!;YJ\A0;5R
MT=!WGM?;<E9!5S8K(1K)0+,$:$B31J35[KW1X??NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6*>>"E@FJ:F:*GIJ>
M*2>HJ)Y$B@@@B0R2S32R$*J*H+,S$  7/OW7NDHW8.QD8J=V[?)4V)7*4CK_
M +!T8@_[ ^_=>Z#O:.+W=F\?D,MA.P#B<97[DW-4TU)#MK#9.+3+G9W:HCK*
MHZW$I)<?@7L.![]U[IWQF/W%BNPL0F<W0VY#5;7W L+MAL?B/M8X\A022(%H
M>'UL$-VY&FP^I]^Z]T+OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NHM=_P"K/\ J%J/^M1]^Z]T$FR,!NBHVAMN>EWYD:"FEP]"\%%'@MN3
MQTL;0 I DU33M(P4<!G8D_D^_=>ZX4U?!M+L"N_O;NZ*J:JV=C/M<AEH<9B;
MJ,W5WHXHZ%(HVTD,]R"WJL38#W[KW0B4.\=IY.7P4&Y,)53<6ABR5(TK7_U,
M9;4?]@/?NO=*3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__6W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U7=_-2S.(V[\+=V;@W!E<;@L!@N[?AMF<WF\
MS74N,Q&&Q&,^9O7];DLKE<E6LD-/34\*/-//,ZI&BL[L%!/OW7NLE'\G?Y4&
M.[5RW>N/^0O\O*A[OS^W:;:&=[DH^V?C=3=JYK:=&T34FU\MV'#D%R]3CHC!
M 8Z*:L:%3''I0:%M[KW1N=L]Z=);TZZR_;^SNXNJ]V=2[?H\]D,]VCMGL+:6
M=ZZPF/VM2M7;GKLOO;%UDN,IH<; CS5\LU2JTZ*SRE%!/OW7N@4_X<)^ O\
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M -M/W[KW7O\ AB+^6=_SZ_O_ /\ 2_?YA'_VT_?NO=>_X8B_EG?\^O[_ /\
MTOW^81_]M/W[KW7O^&(OY9W_ #Z_O_\ ]+]_F$?_ &T_?NO=5[-TY\ /Y.G\
MVGXRR;2[$POQ Z0[Z^)/S)W%VID._OE[V;4]<[\[:QG9/6*;6R>0S'R;WGDZ
M 9UZ:;),AIIHZBI02,_E\(*>Z]T?+YI?S5_Y<U?\.?EE0];_ ,R+X45O8E;\
M:.]Z385'LCYA=%5.]*O>E3U;E8=K4VT*? [B:NDRDE<T"8]*(&=IS&(09"OO
MW7NBW_!W^1]_+;W?\./BYV!FNJ>YUW7V?T!U!VGONNPGS<^=.UJ//]@]D]?X
M_>F^MT2X/:_9-'00U&3RM;5UU2*:EC0RRL511Q[]U[HT_P#PQ%_+._Y]?W__
M .E^_P PC_[:?OW7NO?\,1?RSO\ GU_?_P#Z7[_,(_\ MI^_=>Z]_P ,1?RS
MO^?7]_\ _I?O\PC_ .VG[]U[KW_#$7\L[_GU_?\ _P"E^_S"/_MI^_=>Z]_P
MQ%_+._Y]?W__ .E^_P PC_[:?OW7NO?\,1?RSO\ GU_?_P#Z7[_,(_\ MI^_
M=>Z9\W_(!_E7[FHXL?N/I/N?<%!!D,;EH*'-_.OY]Y6CARN&KDR>(R<5-7]G
MR(M125,4=133!=<4J+(A5E!'NO=%2_E2_-OX+?$[K'Y:?'#NGYQ?'GJ'*=+_
M ,R7Y[];;#Z[^1_R^V?3=E;6ZBV5\@<GMGK7$SR=W[FEW)4T4&-I8XJ2LR$\
MSSA6E>:61G=O=>Z2GSIWQ_+[_FI?/W^53\8L)\B^G?E?U,V>^8>_NTM@?&[Y
M9M5U.*W#L'IG&[NZ@W5N;+_&W=5)E\=/09>BEJ\/4O60_NQ3",L/*I]U[H^'
M_#$7\L[_ )]?W_\ ^E^_S"/_ +:?OW7NO?\ #$7\L[_GU_?_ /Z7[_,(_P#M
MI^_=>Z]_PQ%_+._Y]?W_ /\ I?O\PC_[:?OW7NO?\,1?RSO^?7]__P#I?O\
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MJ-6U6U=PTNZL!4TVY-BU^+RU))3UU'3S!Z*OB+JK12%X9)(W]U[JB?X2=G?
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M#[]U[HZO^R(?&;_GE^P/_1__ "%_^RGW[KW7O]D0^,W_ #R_8'_H_P#Y"_\
MV4^_=>Z 3MS^3G_+W[SW#M7=O9G4O9&9W3LG%Y_";6W'B?E;\N]EYS$X;=%1
M1U>X,5%E=C[[QL\E/52X^CDDAF=UU1*0 ;W]U[JH3^5K_.9_EQ_$+X:;$^,/
MRB^7-1LGO/JGM/Y>8',[+[%P/?W8&]\3M*A^7?8&0Z_BR&ZY\/F)LC#!M?\
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M_ASM63>727\Q#XN;L[!W_P#'7XKTF\^[L%T;MF3/YG>$,7^B3 U6Y9L-'/\
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4!_)(_[)$[4_\
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M?:;_ *=7RS_TJMN_[0X>OJ$_ ;_LA7X6?^*F?'+_ -\]AO?1OD?_ )4K9_\
MGBM/^K$?7Q=_>F_\2=]Q_P#Q:-__ .[M=]&S]BCJ!^O>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[H/^V?^95]E_P#B/]Y?^\Y4^_=>Z^6YV-_S,+?G_AY[
MH_\ =W/[YI<^?\KQO/\ SW7?_:1)U]OOW3O_ !%CVT_\53E[_NT6?5?707_
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$
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M^T.'KZA/P&_[(5^%G_BIGQR_]\]AO?1OD?\ Y4K9_P#GBM/^K$?7Q=_>F_\
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1 /YG/_9(F7_\3_\
M"C_X-?KWW[KW1_\ W[KW7O?NO=>]^Z]U[W[KW7O?NO= 5U'VCG=_]@?*/:>6
MHL32T'1_>NW^KMKSXZ*LCK,E@LM\9NNNZ:BMSSU,\J25:Y/=^1ID>GCAC^UB
MIE,9E66:7W7NM+?MO_F7]7_X8'\P'_X6!\7O?NO=;WOOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZT0?E3_S-3._^*@_S&/\ WH]R^_=>ZWOO?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U\H+^;5G>R\)\W/DR.N-TX[;<U;\LOD53949'!T68BK$J^]9,+0R(U4CF
M,P25K.0@]:DW-U7WA!M^W<JW_.O,G]:+-[I8[RZ:/1*T94J]W*X.D@-K$0 K
M\)I3!/7U*\X<X^_O*7W8O9,>Q/,=ML,MWRYL<5X+JP@O4G6:#E^QMV4S)(T1
MMY+]G8( )4+!CJ1.B^]?8/M"0;;W)N7M<;AQ-=BJ?(UNW%V)M_$+.V2Q7DAC
M&6HI#*@@ED22ZIZ]&D@!C[ /,NX<I+]5M>U;-]--'(46?ZN:2FB2A/AN-)U*
MI&3VZJC(ZRW]DN4/O#3#8>?.??<D;YMMY9QW,^V#E[;;(2&ZL]4:B\@D,R""
M:1) 53]7PM# *YI]2[^7'@8MN? /X98Z&HDJ4F^,W3&:,LJJC"7<NPJ'<<\(
M5.-,3U;1H?J54$\D^\]>1_\ E2MG_P">*T_ZL1]?)7]Z;_Q)WW'_ /%HW_\
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MU[I?^_=>ZC/--YFAABC<I''(YEF:(6E9U4+H1[_H-[V_'OW7NNM=;_RKTO\
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M4IH8559%=B1K'%QS[D+L,^V7-[M6ZVMT2TI\-9$\4^+-8:="JSZP%@D9B2I
M_#UBO]RF;W9VOGK9>6N?>0-]V)$BV^,7LUE<"Q0;?MW-QF-U//!;?3N\F[6D
M,"(LZ22$CQ0: _17^/7\X;K;XX?#?XT4O;WPS_F+[5ZZZYZ0^.W7VY/D!/\
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MU%KO^ 59_P!0M1_UJ/OW7NDOUY_QXNT_^U#C?_<9??NO=18?^9G9#_PP\/\
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M[.:KCJVITP@RL.[7V9]U(@$Z.=W?;",@-4++>,>Z]T!G^S+=S_\ >O;Y?_\
MH:_ 7_[>'OW7NJ6/B!\F_EE\;NYOYG."IOY5_P Q^V%[)_F+[T[G6MV/O;X>
MB/:5'O[XP]4RX3:&Y9*[LP4SY08ZFH\K*<955=*L%=3Q_<?<I40P^Z]T<_Y-
M?*/9?S6_D(?+_P"5?7>!W1MC9?>/\LCY=;WP&WMZ0XF#=&(I:OX^;HI)*',1
MX.JK:3R)+#(%:&I<,FECI)*+[KW5B_Q-_P"R6/C1_P"*_P#37_ONL;[]U[HP
M'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ&OY5_=FW?C3_))W/\CMWXO-
M9S:?0&9_FF]V;HPNVTH9=Q9C;O57S1[AWWF\7@8\G-34S5M134$L5*M1411&
M5E$DB)=A[KW0&?*GY$?+[^8OT[T!UOUU_*R^7O7&W=U?*'X1=YIVSV/O3XJ1
M[&Q/6G7/R%VMV_FMQ9*GVUV!7Y4(^&H99HHX\>TER R*;V]U[K98]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\HK^;
M!_V7%\E?_%NN]?\ X)BD]X-VG_*Y<S?\]5[_ -6]QZ^J/F#_ ,1L]D/^E#RO
M_P!IG)W0<;*_X\W:7_ALX'_W51>X@W[_ )+E[_S7F_ZN-UT9]IO^G5\L_P#2
MJV[_ +0X>OJ$_ ;_ +(5^%G_ (J9\<O_ 'SV&]]&^1_^5*V?_GBM/^K$?7Q=
M_>F_\2=]Q_\ Q:-__P"[M=]&S]BCJ!^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[K2"_X6\_]DL_![_Q/_8G_ONH_?NO=6M_'3_A/#_)FWE\
M?.B=W[F^"^P\MN3=?3?6&Y-P92;?G=$,N2S>=V30Y3+9"6*EW*D2M-/+)(RQ
MHJ@FRJ!8>_=>Z&3_ *!O?Y)7_>!'7_\ Z,'N_P#^RCW[KW0-_(O_ (3P_P F
M;9OQ\[VW?MGX+[#Q.Y-J=-]G[DV_E(=^=T32XW-X+9-=E,3D(HJK<KQ,T,\4
M<BK(C*2+,I%Q[]U[JF7_ (0Z?\RK_F)?^) ^./\ [SF\/?NO=;WGOW7NO>_=
M>Z][]U[KWOW7N@_[9_YE7V7_ .(_WE_[SE3[]U[KY;G8W_,PM^?^'GNC_P!W
M<_OFESY_RO&\_P#/==_]I$G7V^_=._\ $6/;3_Q5.7O^[19]5]=!?\"ML_\
M:LV3_P"Z;?7N2_<?^QN_]/=?]7=IZP?^Y=_R4>7_ /GEV'_M!]P>OK:_ ?\
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MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@'K/\
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M>_=>Z]_<"D_YZ??G_H99K_KY[]U[KW]P*3_GI]^?^AEFO^OGOW7NO?W I/\
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M:$]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$ _FQ?\
M;K+^99_XH!\R/_@==Q^_=>ZH!_X14_\ ;K+OS_Q?_M/_ .!UZJ]^Z]UM^^_=
M>Z][]U[KYO/RK[9V1T5_PM/@[-[,R]+MK8^,[:^.6(S6Y,K7XC#87 4^]_@-
MM;8-)N'.YC/U-'1TN,HJK(QU&2JY:@"&FCFD"R.@C;W7NM\?_APGX"_]YP_$
M#_TI;IC_ .O7OW7NO?\ #A/P%_[SA^('_I2W3'_UZ]^Z]T/O6?;?5/=6VCO/
MISLWKWMG9ZY*MPS;KZSWIMO?FVAF,;H_B.*.=VM4U5+]S!Y$\T'EUIJ74HN/
M?NO="%[]U[KWOW7NO>_=>ZU;_A3\^=Y_ SX]?)7;79'\NC^8CV3M'K3YB_S'
MNR-Q]U=+=:]"[CZ@;:%+\MM];CS^5QV=W?V1@<C(F*B@JH<@7Q2!9:>41&5
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M/PMEI9X:F)?BC\>J=I*>5)HQ/2=38FDJH"\9(UQ2H\<BWNKJRD @CWG[R/\
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M46G_ ,[7?]12?^X4/OW7NO5W_ *L_P"H6H_ZU'W[KW36_P#Q\]/_ -J&L_\
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M:_Y;[,JZ&6:&2*.MI4^"'2="]32.X DC$\,T)="0'C=+ZE8#W7NM/GYJ_P#
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M'GGVSE6XVEX[1N6>8E9);Y]HLHU260)2!IPTQ2JH_AL5^M7\!_\ LA7X6_\
MBIGQS_\ ?/8;WEYR'_RH^S?\\-I_VCQ]?.E]['_Q*?W+_P#%KYA_[N]YT;/V
M*^L?^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[I,[LW =O8L34T K,M7U$.,PF/U$&NRE6VB",D?1$%Y96XLBGD&WOW7NN
M.U=N_P!WZ&7[F?[_ #63F-?G<H1ZJ[(2#U:+@%88A^W E@%4?0$GW[KW2H]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
M%T21'CD19(Y%9'1U#(Z,-+(ZMP01P0??NO=!KA&EV3G(]I5+.^W,Q)/-M"KD
M9G_A]0+SU>V*B1KFRB\M&6Y*W2[%0![KW0F>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7N@W[&H:?)P[>Q]4'-/6;@QM--XY'BD\4]=##)HE0@J2K$7'^]>_=>
MZP0;<V[B9HL?G\%B7BFE6#'9X4<45/6.YTPTN31 %IZIN%4BT4S?YO0["$>Z
M]T_U>U=DT%-+5UF&PU-30+KEFF@C2- 2%%R?R20% Y)( N2/?NO=(O*;4QM9
MCZK,)A*? T-"@JL;31TXILK6RQN##5Y)AZH(K^I*52';CS%?5#[]U[H1MJ_\
M>QMS_M0X?_W7Q^_=>Z?O?NO=>]^Z]U!5IH9JK_)9Y5EG21'C>ETE?M8XSQ)(
MI%BI'(]^Z]U#RU>:7%Y*IFHZM8:?'UD\K T;%8XJ=I'(59KFP!X'OW7NDE@M
MUTFX=TTRP8W-8_R;6JJZG.6H11K5TC9&E"STS!WUJ=:V/^/OW7NA']^Z]TFM
MQ4T4$!SL5;#BLABX2R5TP<TM13ZKG&9**/U2PR,;(J@R(Y#1>OTM[KW39A9I
M-T2K79JF;'RXV>*6GVQ.7$]#,%O3Y+*K(J>9V-WI;+XTM<$S*?'[KW2X]^Z]
MT'/9/_ +;/\ X>6&_P"M4_OW7NG3KS_CQ=I_]J'&_P#N,OOW7NEE[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU?/YI_;W4_
M4_RYDS':?9_7?6N)C[ ^)/DRF_\ >NVMFXY/'AMV5TFNNW%4TT0TP12S-=N$
M1G/I4D>Z]T=KK/?6R,A_+W_E28.@WCM6NS:3_P L^G?#T>X<14Y5:BFQNV4J
M(&Q\,S3!XR"'4I=2""!;W[KW5U/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[H@'\V+_MUE_,L_\ % /F1_\  Z[C]^Z]U0#_ ,(J?^W6
M7?G_ (O_ -I__ Z]5>_=>ZV_??NO=>]^Z]U4!FO^RBNQO_&O_2O_ ,*RV#[]
MU[JW_P!^Z]U71W5O.J^96X]U?$+I7*Y!^I:>HS&SOF?WUMO[=\#MW;II?LMS
M_%SK;<T@>&JWQN*&=L?N.JQGE?:N+:JDFFH<]4X91[KW5AM#0T6,HJ/&XVCI
M<?CL?2T]#04%#3Q4E%0T5)$*>EHZ.EIPL<444:JD<:*%50   /?NO=2O?NO=
M>]^Z]U[W[KW5*N\M^[&H?Y6G\Q; UN]-IT><%1_.8I#AJK<>'I\L*JI^27<?
MVU,<=+,)O))K30FB[:A8&X]^Z]T2S^5KVMU=VCVM0YCK+LG8/8N)K_YF/RXR
M=#E-B;QV]N['5N-;X%;7@7(4E;M^IJ(I("YT"5&*:N+W]^Z]UL^^_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7N@8V?F]Q46/R-/C]F5V9I4W-NDI7P9G T<<I;/5#.H@KITD
M&DDJ25YM<<>_=>ZGTF1RV0[$P397;U3M]HML[B$*5.0QE>:H/6T)=D.-ED"Z
M; $/:]^/H??NO="Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[K'+(L,4DK E8HWD8+8L512Q !MSQ_7W[KW0'T^7W?F-C86DQ&Q*RH7[#;<
MM'6RY[;\%-4IC)Z:J$AB><2H)!";!DN+BX]^Z]TZ==RY>ER<N"SV&DP^3H\!
M]Z8S6T-=%/3U^XZVHCDCEHG<"Q8II8@W4FUB+^Z]T,'OW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT0#^9S_V2)E__$__  H_^#7Z]]^Z]T?_ -^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M01=;=K)V)O/Y!;07!-B#T1V[A>J9,@V2%<-T/F.A=D=X#.I2B"'[,1KO-<9]
ML9)]1I#4>4>?PP^Z]UI/_-7_ (&[?_\ &(6)_P#@R<K[]U[K>]]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=5N?S(<7W7E-K=&)L2+Y*5G2D';E?+\H<?\-MRS
M[3^3=1U]_HQSPV/+LC*XNIHLO)B4W?\ P)=Q4FVJR#+O \4T,IH(,E!-[KW0
MV?!:E[^H_B]UU!\F?[T)VL,AV+(U+OVNVQENR<=UO-VAFINC\5VIFMERS8FN
MW92[);;U/NBMQ[^&;*)5R+RQ)]U[HV_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZHIZEQ?SR7^8:DFXH_E6F.IOD9\B:KN?/[NSV J_@5EO@A
M7[9W)/\ $[ =(;26O1:?L2FR4FRX<Q58NA_BXJ*?<<N=GDQ4^&@]^Z]U>M[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZT0?E3_S-3._^*@_S&/\ WH]R^_=>ZWOO?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\HK^;!_V7%\E?_%N
MN]?_ ()BD]X-VG_*Y<S?\]5[_P!6]QZ^J/F#_P 1L]D/^E#RO_VF<G=!QLK_
M (\W:7_ALX'_ -U47N(-^_Y+E[_S7F_ZN-UT9]IO^G5\L_\ 2JV[_M#AZ^H3
M\!O^R%?A9_XJ9\<O_?/8;WT;Y'_Y4K9_^>*T_P"K$?7Q=_>F_P#$G?<?_P 6
MC?\ _N[7?1L_8HZ@?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>ZT@O\ A;S_ -DL_![_ ,3_ -B?^^ZC]^Z]UM^_$W_LECXT?^*_]-?^^ZQO
MOW7NC >_=>Z+_P#++_LECY+_ /BO_<O_ +[K)>_=>ZTP_P#A#I_S*O\ F)?^
M) ^./_O.;P]^Z]UO>>_=>Z][]U[KWOW7NO>_=>Z#_MG_ )E7V7_XC_>7_O.5
M/OW7NOEN=C?\S"WY_P"'GNC_ -W<_OFESY_RO&\_\]UW_P!I$G7V^_=._P#$
M6/;3_P 53E[_ +M%GU7UT%_P*VS_ -JS9/\ [IM]>Y+]Q_[&[_T]U_U=VGK!
M_P"Y=_R4>7_^>78?^T'W!Z^MK\!_^R%?A;_XJ9\<_P#WSV&]Y;\A_P#*C[-_
MSPVG_:/'U\\7WL?_ !*?W+_\6OF'_N[WG1L_8KZQ_P"O>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H.,(AW1NS)[FJ/5C=M
MSUNV]MPZM4;5D9$>>S0MQJ=O\EB8&VA6_J#[]U[H1_?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)K=N";
M<.$J:&"44V1B>&OP]9]#19>A?[B@J0P!( <:7(%]#,/S[]U[KEM3._WBP=)D
M9(OMJT>2CRM$>&H<M12&FR-(RDDC3(K:;\E2I_/OW7NE'[]U[KWOW7NO>_=>
MZ][]U[KWOW7ND'O;_@1M/_PZ,/\ ^[*#W[KW2DS5=CZ6E^WKX/OCD==)3XI(
M4JJC)NR^NGBI7X90O,C/9$6[2,J@GW[KW2+I\9D\/-1Y/.QR97%4K,])CH99
M\@^T-3$QS@,->0$:$(:@J9H!<1J8R[#W7NE3N">"JVSD*FFFBJ*>>B\L,\+K
M+%+&Y!5XY$)!!'T(/OW7NLNU?^/8VY_VH</_ .Z^/W[KW3][]U[IHR.7CH9H
M*.&EJLED:E))8:"B^W\HIXB%DJJB:JDBBBB4D+J>0%B=*!VX]^Z]UGQ^1BR"
MS 13TM32R>&KHJM8TJJ64J)$$@A9XV5E(9)(I&1A]&)! ]U[J#NK_CV-Q_\
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MFR(NPCM#;9Q];LQ*$X>A-(E;B\W+5K!X!XQ4205B(SV_454"_P! /?NO=.>
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MPFI(=T9C&URJ?J!/11M_5?</3_>%]OX93'']5*!^)80%/V:Y$;]JCKH[M/\
M<[?>^W&PCO+P['82.*F"?<I&EC/HYMK.Y@)_YIS./GTS?]!'7P"_YYKY'_\
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M7.7[D.Y[;N6Y;&NWW$4YAM]A23PY$?0_T'N =+Z2=+4(.EJ&A!IU];WX#_\
M9"OPM_\ %3/CG_[Y[#>\LN0_^5'V;_GAM/\ M'CZ^?#[V/\ XE/[E_\ BU\P
M_P#=WO.C9^Q7UC_U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW2<W=F6P&V\OE8AJJ:>D9*%+7\F1JG%)CH[?G5/)&#_A[]U[K)M;
M"C;VWL1A@Q=Z&CC2HD+:C-62DSUTY;\ZYG=[G^OOW7NG_P!^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW0>8FV%W]N#$\)2;GH:;=% HN$&0I-.*S<8OP7<"GF(']2?\ 6]U[H0_?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T'_ &!#E6I</58C&RY2JQ^8HJT4T0<@_:U"
M5/[IC!(4B,BX'UL+B]_?NO=-6,S61HGDK:K9^ZLAEZE--5D9:2F0^.X84E%"
M'(@IU(&F)2;VU2,\A+GW7NGG^^62_P">(W1_YST__1_OW7NDADJW-.M3%A=I
M[AH:;*.1D\?54J''AIWO-D:(0%F@FO>2144I,;ZE61C+[]U[H4]O4\U)M_!T
MM1&T5138?&4\\36U1S0T21RQM;\JP(/OW7NGCW[KW2=K:3(TN7.9QM/!7"IQ
M\&.R%%+.*68I15$U50U%'.ZLA*FHF5XWTA@RG6-%F]U[K-BJ2N6JR62R*4\%
M1D&I8HZ2FE>HCIJ2A1E@$E0ZIKD=I)'<A  "J#5IU'W7NN.ZO^/8W'_VH<Q_
M[KY/?NO=!OB:^DQN>V?65LPA@CZF1;Z7=Y))<GC(X888HP7DD=B$CC12S,0%
M!)M[]U[H0:/'U61K(\QFH_%]NQ?#X<LLB8T,I7[VM*W62M=21<$K"I*1DDO(
M_NO=*7W[KW7O?NO=,N7Q'W_@JJ6?['+T.ML?D%37X]=C+25<0(\M-+8":$D7
ML&4K(J.ONO=!UO7+?>TNWZ*KA%%EZ+>&"-;0ES(NB2*H$=90S$+YJ:0@B.4*
M"""KJDBLH]U[I6]>?\>+M/\ [4.-_P#<9??NO=++W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK1_P S#;.V]V?+IL3NK;^#
MW-BSV)\1Y3C=P8F@S./,IQ6[*8RFCR,<D>KQR21ZM-]+,OT8@^Z]T=WK_P#[
M=Q_RHO\ 7_ED_P#NKVQ[]U[JW_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]T0#^;%_VZR_F6?^* ?,C_ .!UW'[]U[J@'_A%3_VZR[\_
M\7_[3_\ @=>JO?NO=;?OOW7NO>_=>Z^>'V7_ -QQF-_\2!U-_P#"S,-[]U[K
MZ'GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH'='_;I[^8K_ .9G_P#X)+N7
MW[KW1)OY:>WL!M?M:FP^V<'A]NXBF_F?_+K[?%8+&46(QL%_@)M93X:''I'$
MO  ]*CZ#W[KW6RO[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z >L_XN[?\ :TD_][?/^_=>
MZ%JH_P"/GP__ &H=Q_\ NPQ7OW7NG[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW46N_X!5G_4+4?]:C[]U[I+]>?\>+M/\ [4.-_P#<9??N
MO=18?^9G9#_PP\/_ .]!7>_=>Z7GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO_0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0#^9S_V2)E__$__
M  H_^#7Z]]^Z]T?_ -^Z]U[W[KW7O?NO=>]^Z]U[W[KW0(=3]I97L'?GR;VG
MD,;CZ&DZ-[PP'5N"JJ(U)J<SBLO\;>O>ZYLEEA.S**A:[>%91J(0J>""$E?(
M79O=>ZTL?FK_ ,#=O_\ C$+$_P#P9.5]^Z]UO>^_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[K1!^5/_,U,[_XJ#_,8_\ >CW+[]U[K>^]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UH]=)P_
M\)X(.UOYA*?S-HOBQ#\I&_FC_P P>;(IW.F[(]['851\D<U/L*65<<!%]F]&
MVNB8?6(@BZD>_=>ZUR/FI_LDW^FC?/\ "/\ 1W_H&_TF]J?[+7X/XA_=C_0_
M_>MO[F?W0O\ N?8?P;^$?;^7U>+Q7YO[P17_ %Q?ZZ<Q?U"\>GUTWC^#I_W_
M #^'JK_S<I^?7UA3?\!G_P #-[-_\%K^ZM7]5ML_=7[S\7A^ZMJ^M\#P_G])
MXE?Z%//HO?6G^RF?WTQ'^C#^X_\ ??3D?X-_!OO?XCI_A<W\2^W\WI_X"^?7
M?^S?VEYJ_P!>7]Q3_P!;/J_H.SQ?%TZ/[1=%:9_M--/G3H^]@O\ DVI_KK[7
M_P #Y^X/ZW4N?H?H?'^JI])/]5X>OM_W#\?77_0]5,TZ^J;_ "NO+_PW?\./
M-Y-?^@385O+JU>+^%+X+:^=.C3H_&FUN+>\T.1_^5*V?_GBM/^K$?7S+_>F_
M\2=]Q_\ Q:-__P"[M=]'S]BCJ!^O>_=>Z][]U[KWOW7NJ#/^%'4\\/P"VW'%
M-+%'5?([KN"J2.1T2I@79VYJI89U4@.@DCCD"M<:E5OJH(@?[Q+,.0HP#2MW
M$#\QX<QS^8!^T==9/[FF**3[VMZ\BAC'R[N#*2 2K?6;:M5)X'2S+49TL1P)
MZ^?'C^U*_95+EJGOFLVUL1:S<^1H]EL:B!?XMA:6GBE,GCH:NOUB-W(6:1H)
M'4J9*6!K!L8[GE"WWZ:&+V[2?<2D"-==I_3E8L*5>.&E0,JHD52"$FD&1W.V
M3[QF\^T^V[E?_?+NMJY.6ZW:Y@V(^+&/K+"*.)RVFWO-QUB-W(2>5K2>6-D,
M^W6;T63-_LR_0_\ S\_;/_4^I_Z]>V_]:KW$_P"C3/\ L7_H+I7_ ,'Y]S;_
M ,*%M7_.27_K5U[_ &9?H?\ Y^?MG_J?4_\ 7KW[_6J]Q/\ HTS_ +%_Z"Z]
M_P 'Y]S;_P *%M7_ #DE_P"M77O]F7Z'_P"?G[9_ZGU/_7KW[_6J]Q/^C3/^
MQ?\ H+KW_!^?<V_\*%M7_.27_K5T2WYH]O;$WQMC95)L+>E!FZNASV0J*^+$
M5-0LD%-)CQ'%)-Z4]);@<_7W._L3R5S#R_NU_-S'8/;I)"BH9%6A8/4@9.:=
M<G_[U[[SOL[[O>WW*>V^S/-EONUS9[C<R7*64LH:.)K8*C/VIVE\#)ST;3:O
MR/Z0I-L;<I*SLO;D592X'#T]5%+/4F2.IAQ\<<\<G[9]08$'GZ^X9WCVOY_F
MW:ZF@VJ<H\TC*0%H5+L01W<".NEOMS]^[[HNV>WNP[;NG/\ MD=U;[=913(\
MDNI98[:)9%;](]RN"#DY!Z?O]F7Z'_Y^?MG_ *GU/_7KV7?ZU7N)_P!&F?\
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M?516D9M?!:=NC/?\.*?]^>_]B#_^0_<3?\#'_P!)O_LS_P"WKKH1_P GSO\
MSEW_ )$G_? Z]_PXI_WY[_V(/_Y#]^_X&/\ Z3?_ &9_]O77O^3YW_G+O_(D
M_P"^!T9#K+Y#9'LW:T6Z:; ]>[;BEK:RB&,W'VO/1Y-6HW"&9H8]ON-#WNAO
MS[B[FSVTM>5-W;:);F\NBJJWB0;>&C[A6E3>#(\\=9X_=]^_!OGW@/;J+W$L
M-FY:V&.2>>#Z3=.<9(+H&!@I<QKRVXT/6J&N0#T(7^D7,_\ ?H/_ $<-5_\
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M3Y%4_8>WLMTGA]FYC?\ 7]A;=GFW-A5VG@**6OS.1I4V\E545$E.D$J24E/
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M<Z^^.72'\S[MG(9?(]N_('Y2G?,:UXEAC@V[-15._=E99HPY$9S$^+KJRCB
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M/=>ZO$_X0Z?\RK_F)?\ B0/CC_[SF\/?NO=;WGOW7NO>_=>Z)-\EMH[\Z\[
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M!$><2)2Q/W#B/2_NO='9ZY_X1W?S/LUMS.;P[AWO\9NB\+M[ Y'.5V)RN_\
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M,)@C,1%M!8GZD6P)DYQWSE'G7F!]DMH;@SWMP',L)ETA9Y@ M&&D,'8-6NH
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M;^MGO_A'W_S/#%?^*W]X?^_NQ'L8;+_XD7N__/&G_5FRZQQ]SO\ Y#)[=?\
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M[1ZRR?4^*W#3TD_<.+FES<U3W)NC:6)-+"T:12)'E&J2TL9CIY$$KQC+9O\
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MX:MS'6&,R^2G)E+&\M3/+*1>P+$*   ,\.1_^5*V?_GBM/\ JQ'U\G/WIO\
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M7O?NO=>]^Z]U[W[KW10/YA/_ &0+\X?_ !4#Y+?^^8S7OW7NOFE_\)'\SOO
M_P TC=V2ZWV1B^P]U1?$CMA*7:^8WDFPZ*KIIM_;.CK9VW')C\FL;0QDR+&:
M4^2VG4I(/OW7NOI9_P"E;YE?]XA=?_\ I5%#_P#89[]U[KW^E;YE?]XA=?\
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ME7OS:$+5E/1[AR&,IWBAN&FM4ZPO(1@#;W7NOI:_[-AN/_O#SY@?^@5U7_\
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M_"'YL;FEPN)DW)1?"[Y08:CW!)CJ-\W28>NZ@RU76XJFRK(9XZ::6&&66!9
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M9?\ #PFX_P#O+/X@_P#I/_5?_P!VC[]U[KW_  \)N/\ [RS^(/\ Z3_U7_\
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M .D_]5__ ':/OW7NO?\ #PFX_P#O+/X@_P#I/_5?_P!VC[]U[KW_  \)N/\
M[RS^(/\ Z3_U7_\ =H^_=>Z]_P /";C_ .\L_B#_ .D_]5__ ':/OW7NO?\
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M-3X^ODD&,,%.\\RFEED2LB/FIXP?=>Z2_P#PQO\ )?\ [V-=?_\ IM[X]_\
MU\]^Z]U[_AC?Y+_][&NO_P#TV]\>_P#Z^>_=>Z]_PQO\E_\ O8UU_P#^FWOC
MW_\ 7SW[KW7O^&-_DO\ ][&NO_\ TV]\>_\ Z^>_=>Z]_P ,;_)?_O8UU_\
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M/HJ:6HA9XG]U[I>?\,V=.?\ >0G?_P#Z+[X*?_:6]^Z]U[_AFSIS_O(3O_\
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M\%/_ +2WOW7NO?\ #-G3G_>0G?\ _P"B^^"G_P!I;W[KW7O^&;.G/^\A._\
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M:*:+NC:V[<=3K+19JMBDJ:/'PUFEC"E4E/+4PS^Z]T9O_AFSIS_O(3O_ /\
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MK*HH9ZEX:>)&D9BD:*0H]U[IX_G;_P#9(G5?_B__ /+A_P#@U]D^_=>ZM_\
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M=>]^Z]U[W[KW7O?NO=:87_"T?_LC;X[_ /A_[R_]S]J^_=>Z #_A#I_S*O\
MF)?^) ^./_O.;P]^Z]UO>>_=>Z][]U[KWOW7NO>_=>Z#_MG_ )E7V7_XC_>7
M_O.5/OW7N@_^)O\ V2Q\:/\ Q7_IK_WW6-]^Z]UK _RJ/^Y;?^#?R\__ )ZG
MW[KW6W][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5+Y2_,?Y;?RU_Y
ME/SI['Z@^"F/^9VUOEA6?"/$X6'$?)O!]);GVKF=H=*YC:5+2U6"SNU,['5P
MUM535BFH%9!X=,%TD$[&'W7NE7W;WE_,2^=^Q?Y;^[-^? 'J/X\]";I^=G\M
M_P"3=+VG1?.6@[BW)%L_'=Q8'LO#8MNL*3K?;TQJJ^AE6,WRBB"6RN&6[+[K
MW6T%[]U[KWOW7NO>_=>Z][]U[KWOW7NB@?S"?^R!?G#_ .*@?);_ -\QFO?N
MO=?-+_X2/U_9.,_FD;NJ^I]I['WKO1/B1VPM#@.P^PL]UAM>HI7W]LY<A-5;
MOVUMC=]7#)%%J>&),'*)7 1I(03(/=>Z^EI_?7Y]?]XT_$#_ -+A[G_^Y[]^
MZ]U[^^OSZ_[QI^('_I</<_\ ]SW[]U[H"^Y=E_-7M^?!'=/170FWZ+;>'W7+
MBVZX^3V[>Q,CDMQ9.;&_PW'YFCWYUEL:"AQ[14U2TV0I:NNG1Q&@H9%D:6+W
M7NAT_OK\^O\ O&GX@?\ I</<_P#]SW[]U[KW]]?GU_WC3\0/_2X>Y_\ [GOW
M[KW17?FKNSYIU?Q8[JI=Z= ?%[;^TI]HF+<>;VO\O>U]W[BQ6(?)TXKJ["[7
MRW1^#ILA4QI=HJ2?,4:2-96J(@=0]U[KYDW_  F]_P"WVOP(_P#$@=@_^^0W
M1[]U[K['7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5S^//8W\T#X-?&/Y:[
MHZS^+?Q&[D^/?57R=_F8]S_WWW3\J^Q.ONQ<QMW:?RJ[!W%O2E_T?T7765I8
MJF";'5]/11_QAEG58G9XO(0GNO=,GQ7^3OS/_F%_S!/@YWGWQ\9.I?C3L+XJ
M=O?-?HBMQ^W^Z]R]C[YW'V5N[XF8G=61IS@,AM;$4]/CJ.BJ:()6??,TLWW"
M"(+'')-[KW6U/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!C9^S<5F,?D:^JJ<[%-+N;=*
MLE#N#,8^F BSU1&NBEHYDC4V')"\GD\^_=>Z><;M^AP&_P"@2BFR<PJ=GY]I
M#DLKD,HRF+-8P+XFKY)"@]1N%M?B_P!/?NO="=[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KBZ+(CQN-2.K(Z\BZL-+"X_P]^Z]T!<FRL;3
M;%P]=0Y#<5%5ST>U0'@W%F5@A_B59205(AI//XU!65PJA;"_%K#W[KW3GUEB
MXJ6=J]ZBNK:^LP\T515U]=5ULK14NY:VF@C3[EWT*%1?2O%[GZDD^Z]T,?OW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]??X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW10/@]_S)C>O_
M (M__,)_^#Z[+]^Z]T!?:?QG^2]+_,2QGS4Z2/1><V_-\,/]E9S.UNT]X;_V
MIF,;E5[OE[<_O5C(MI;<S,%;3O$(:'PRUE*Z,SR^L(L<GNO="1D_C%W9WG(F
M.^7/>VW]S]6+JDJN@/CQL3=726Q=YB95UXGNS?.:W3N/<FZ\;%I9?X3C:G;V
M*KHI98,UB\I 4C3W7NCH[<VWMW9V PVU-HX'"[6VOMW&T>&V_MO;F+H<'@,%
MB,? *:@Q6&P^,CBIZ6F@C58X8((U1% 55  'OW7NI66Q.*S^*R>"SN,Q^:PF
M:Q];B<SALM14V1Q66Q61IFH\AC,GCZQ7AGIYX7>*:&5&1T8JP*DCW[KW1(L/
M\5>V.B':@^'G>>)V#UB85CH_COWQL//=X]1[)C@(>.BZ1S&(W+MC=&T*24WA
M&(J,SF<%00".'#X/&QQE']U[H-^J?C-\FJG^8?D?FIWB_1.%P<'PN'Q8Q.V>
MJ=W=@;GRV3R[=VQ=N-NS(T^[]NXB&AIEC,]"((JZK=F5);H'9(_=>Z,Y\M-X
M[GV+U9M7-[1S%5@LK7?)GX5;.JZVC\1EGVQV+\R-A]?;VP[^97'BR.&R=?CY
M[#5XYGTE6LP]U[HS/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^3=_-\R>:QOS<^2,F&V1
MO7>LA^6OR(GJ(=G;>K\X:"+&=_+FF:O>D5EA,R4LD< <@NU[<(Y&%FR6EC=<
MZ\SK?;A:V ^KN@IN9DBUF0WL78&(+:3("]/A%*Y(!^G/W/Y@YKV#[L?L;-RK
MRCOW-CGE[8I)4V3;;C<#;I:KRQ?DW#0HRPF9+22.W#D&5]17LCD90+ZU[+I\
MG3[4VC)L?M/#5\>$HZ*?(;BZ[W)@\%33XO#ZYUJ<Q7PI#&&,3)$6(UN54<L!
M[CGFKE62TEO-Z7<-OGC,K,$AO8)96$DN-,2,6--0+4':H). >LS_ &$]_;+F
M"QY;]LYN4.;MJO(["""2YW/EG=-OV^*2TL@9!+?7,*01AS"T<)=AXLK1QKW.
MHZ^I_P#R[\Q0YSX$_#"NQTK2T\?Q=Z*Q3N\<D1%;@NM<;@\E'HD -DJ:>5 W
MT8 ,I*D'WGCR/_RI6S_\\5I_U8CZ^37[TW_B3ON/_P"+1O\ _P!W:[Z.-[%'
M4#]>]^Z]U[W[KW7O?NO=4#?\*/O^R!-J?^+)]>?^\/NGW WWBO\ E0XO^>R+
M_JW/UUH_N9O_ !+._P#_ !7-P_[3=LZ^:)_,/_XLW5O_ &L]U?\ N+0^P#]V
M;_<[=_\ FG;_ /'I>LMO[\7_ )57VZ_YZ]X_ZL[?ULX_\(\_^9ZP?^*\]V_^
M_@P7L;;3_P")$;G_ ,\*?\<M.L8/<'_Y#;R-_P"+7<?]I7,'7T0_>0/7(#KW
MOW7NO>_=>Z][]U[KWOW7NM([_A;?D:^A^*GPPIZ2JD@ILQW?V%B\I3JD+1UM
M$FSJ',Q12,ZEUT5-'!("C+RMC<&WOW7N@T_X0Z?\RK_F)?\ B0/CC_[SF\/?
MNO=;WGOW7NO>_=>Z][]U[KWOW7N@O[ORM!@^ENWLWE9_M<9A^K]_Y7(U/BFG
M^WH,?M2KJZR?PTZO(^B-&;3&C,;64$V'OW7NJ7/B]_.L^(%!\:/CO01=?_./
M-Q471?4E)%F=L?R_?F'N;;67CIM@8^%,GM[<F$V=/19"AJ HEI*ZCFD@GB9)
M8G>-U8^Z]U2'_*L^6F-VYV;\8.J>Y/CU\O?CAN#.]I_"#I_9^7[]^-O86P]E
M;SWMLNG[\ERN/PF]8X:S'0F67>^ IJ*+*3TD]1)),8H6BIII5]U[K>O]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6M__,0_[+*/_B0/B-_[@[I]^Z]T
M<'K_ /[=Q_RHO]?^63_[J]L>_=>ZM_\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4
M#^83_P!D"_.'_P 5 ^2W_OF,U[]U[KYN/_".JBJJK^;U53T^1FHHL;\4NZJV
MNIHHU=,O2OG]M8Y,=4,Q!1%GGAJPP!.N!5M8DCW7NOJF^_=>Z][]U[KWOW7N
MO>_=>Z][]U[HG/\ ,%J*>D^%OR,JZN>&EI:7KG(5%34U$J0T]/3PU<$DT\\T
MA"HB*"S,Q  !)-O?NO=?*+_X3>_]OM?@1_XD#L'_ -\ANCW[KW7V.O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW50.Z/^W3W\Q7_S,_\ _!)=R^_=>Z)]_+P_
MYG.G_C3_ .7/_P  +M?W[KW6Q_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0?77_%BK?\
MPZ-V_P#O15'OW7NI51_S,'#_ /AF[C_]W>*]^Z]TLO?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'-1_S+K;__ %"[&_\ =E0>_=>Z
MB]>_H@_[5==_[UN0]^Z]T*'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T%/3796"[7VCF-T;=PU5@J#%]K=[]:U%#6)1QRSYWIGO#<7
M3^Z,RBT+,GBR.3P57D(&8^0QSH90)2X'NO="M[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z!SO7JJ7N39.$VC#FX]OOA^Y/CKVJ:^7'MDEJ(NB?D%MCO"?""G
M2: JV33;K8U*C61 TXG,<HC,3^Z]T,?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^5)_-+
M[1W/UK\W?E*=M]?)OULY\K?D73U,9W;1;6?&R+W55XW'E374M0LXGGKDC)#)
MX[!B"I9DP-/*.T\U<Z<PC=-R_=PM[VY93].UP''B7#O\$B%="1%N!U9 H0 W
MUFI]XCW!]@_NR>SK<A\DCG-MWY:V2*5?WS!M#6K"RV:UMJ?46ERLXN+B_2(D
M-&82%=@T;.\18]D[T[2W)586?.]687;FVLM1"O?-TW9$.>K*6"?'M64%L*N)
MI3(97,<3#SKH#%O5ITD'[]L7*.UPSQ[?N\MU=0MH$36)A5B'"O\ J_42 :1J
M8=AU4 Q6HR-]I?=?[Q//NX[5=\X>W5CL.P;E +AK^+FA-PGACDMFGMZ6(V:T
M:0RN8HG'U">$)&D.O1H;ZC/\M3!U>W?Y?GPTQU;)3RSS?''JC,JU*\CQ"EW)
MM&FW%0QLTJ(?(D%5&DH"V#A@K,H#'/KD?_E2MG_YXK3_ *L1]?([]Z;_ ,2=
M]Q__ !:-_P#^[M=]'>]BCJ!^O>_=>Z][]U[KWOW7NJ!O^%'W_9 FU/\ Q9/K
MS_WA]T^X&^\5_P J'%_SV1?]6Y^NM']S-_XEG?\ _BN;A_VF[9U\T3^8?_Q9
MNK?^UGNK_P!Q:'V ?NS?[G;O_P T[?\ X]+UEM_?B_\ *J^W7_/7O'_5G;^K
MZO\ A,;\LOCC\-=Y8WMCY0]N[2Z5ZXK^H>V]ET>[MYU%538FHW3F.T<;E,9A
M(Y*.*9_/-3T-7*@T6TQ-S]+C;:?_ !(C<_\ GA3_ (Y:=8P>X/\ \AMY&_\
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M9A\=M;<NX*O*9#"+*)H8%I9Z5P\@6YJ:95N9X@WNO=&4Z/\ YDGP#[ ^(O\
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MS?\ B6=__P"*YN'_ &F[9U\T3^8?_P 6;JW_ +6>ZO\ W%H?8!^[-_N=N_\
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M\YO_ &6;YA__ &OO?NO=>_Z"COY%'_><W_LLWS#_ /M?>_=>Z]_T%'?R*/\
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M_P"R>#_K7U[_ )-2?<A_Z9>Y_P"YONO_ &V=>_X?F_F;_P#/[]M_^B=ZE_\
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M9'/9;#TM7EJ:I-,9JK'T<IJ:41SKXPJ2JK.K#3:%"_>)W4CSL4)_YQV8_P
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M_?(;H]^Z]U]CKW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4#NC_MT]_,5_\
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MC?RLO_NEO?NO=>_V<CY%?]ZG?G__ .C&_E9?_=+>_=>Z]_LY'R*_[U._/_\
M]&-_*R_^Z6]^Z]U[_9R/D5_WJ=^?_P#Z,;^5E_\ =+>_=>Z]_LY'R*_[U._/
M_P#]&-_*R_\ NEO?NO=>_P!G(^17_>IWY_\ _HQOY67_ -TM[]U[KW^SD?(K
M_O4[\_\ _P!&-_*R_P#NEO?NO=>_V<CY%?\ >IWY_P#_ *,;^5E_]TM[]U[K
MW^SD?(K_ +U._/\ _P#1C?RLO_NEO?NO=>_V<CY%?]ZG?G__ .C&_E9?_=+>
M_=>Z]_LY'R*_[U._/_\ ]&-_*R_^Z6]^Z]U[_9R/D5_WJ=^?_P#Z,;^5E_\
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MC?RLO_NEO?NO=>_V<CY%?]ZG?G__ .C&_E9?_=+>_=>Z]_LY'R*_[U._/_\
M]&-_*R_^Z6]^Z]U[_9R/D5_WJ=^?_P#Z,;^5E_\ =+>_=>Z]_LY'R*_[U._/
M_P#]&-_*R_\ NEO?NO=>_P!G(^17_>IWY_\ _HQOY67_ -TM[]U[KW^SD?(K
M_O4[\_\ _P!&-_*R_P#NEO?NO=>_V<CY%?\ >IWY_P#_ *,;^5E_]TM[]U[K
MW^SD?(K_ +U._/\ _P#1C?RLO_NEO?NO=>_V<CY%?]ZG?G__ .C&_E9?_=+>
M_=>Z]_LY'R*_[U._/_\ ]&-_*R_^Z6]^Z]U[_9R/D5_WJ=^?_P#Z,;^5E_\
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M7O\ 9R/D5_WJ=^?_ /Z,;^5E_P#=+>_=>Z]_LY'R*_[U._/_ /\ 1C?RLO\
M[I;W[KW7O]G(^17_ 'J=^?\ _P"C&_E9?_=+>_=>Z]_LY'R*_P"]3OS_ /\
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M7O\ 9R/D5_WJ=^?_ /Z,;^5E_P#=+>_=>Z]_LY'R*_[U._/_ /\ 1C?RLO\
M[I;W[KW7O]G(^17_ 'J=^?\ _P"C&_E9?_=+>_=>Z]_LY'R*_P"]3OS_ /\
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M7O\ 9R/D5_WJ=^?_ /Z,;^5E_P#=+>_=>Z]_LY'R*_[U._/_ /\ 1C?RLO\
M[I;W[KW7O]G(^17_ 'J=^?\ _P"C&_E9?_=+>_=>Z]_LY'R*_P"]3OS_ /\
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M7O\ 9R/D5_WJ=^?_ /Z,;^5E_P#=+>_=>Z]_LY'R*_[U._/_ /\ 1C?RLO\
M[I;W[KW7O]G(^17_ 'J=^?\ _P"C&_E9?_=+>_=>Z]_LY'R*_P"]3OS_ /\
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M\F\A;/RMR%97MGLMC9V\-C ]CRH7BM5C7P4?ZR!KH,L= PN29P:B3O!'3_\
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M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0?\
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MNO?\-._RLO\ O6G\ /\ TC?XZ_\ V.>_=>Z]_P -._RLO^]:?P _](W^.O\
M]CGOW7NO?\-._P K+_O6G\ /_2-_CK_]CGOW7NO?\-._RLO^]:?P _\ 2-_C
MK_\ 8Y[]U[KW_#3O\K+_ +UI_ #_ -(W^.O_ -CGOW7NO?\ #3O\K+_O6G\
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M^.O_ -CGOW7NO?\ #3O\K+_O6G\ /_2-_CK_ /8Y[]U[KW_#3O\ *R_[UI_
M#_TC?XZ__8Y[]U[KW_#3O\K+_O6G\ /_ $C?XZ__ &.>_=>Z]_PT[_*R_P"]
M:?P _P#2-_CK_P#8Y[]U[KW_  T[_*R_[UI_ #_TC?XZ_P#V.>_=>Z]_PT[_
M "LO^]:?P _](W^.O_V.>_=>Z]_PT[_*R_[UI_ #_P!(W^.O_P!CGOW7NO?\
M-._RLO\ O6G\ /\ TC?XZ_\ V.>_=>Z]_P -._RLO^]:?P _](W^.O\ ]CGO
MW7NO?\-._P K+_O6G\ /_2-_CK_]CGOW7NO?\-._RLO^]:?P _\ 2-_CK_\
M8Y[]U[KW_#3O\K+_ +UI_ #_ -(W^.O_ -CGOW7NO?\ #3O\K+_O6G\ /_2-
M_CK_ /8Y[]U[KW_#3O\ *R_[UI_ #_TC?XZ__8Y[]U[KW_#3O\K+_O6G\ /_
M $C?XZ__ &.>_=>Z]_PT[_*R_P"]:?P _P#2-_CK_P#8Y[]U[KW_  T[_*R_
M[UI_ #_TC?XZ_P#V.>_=>Z]_PT[_ "LO^]:?P _](W^.O_V.>_=>Z]_PT[_*
MR_[UI_ #_P!(W^.O_P!CGOW7NO?\-._RLO\ O6G\ /\ TC?XZ_\ V.>_=>Z]
M_P -._RLO^]:?P _](W^.O\ ]CGOW7NO?\-._P K+_O6G\ /_2-_CK_]CGOW
M7NO?\-._RLO^]:?P _\ 2-_CK_\ 8Y[]U[KW_#3O\K+_ +UI_ #_ -(W^.O_
M -CGOW7NO?\ #3O\K+_O6G\ /_2-_CK_ /8Y[]U[KW_#3O\ *R_[UI_ #_TC
M?XZ__8Y[]U[KW_#3O\K+_O6G\ /_ $C?XZ__ &.>_=>Z]_PT[_*R_P"]:?P
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MP _](W^.O_V.>_=>Z]_PT[_*R_[UI_ #_P!(W^.O_P!CGOW7NO?\-._RLO\
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M?\JNP#U=T'W%-O\ WTN"R6Y9,+%UIV[MQ(<%B)88,AD:C+;NP&/H8T22H@C
M>I#,[JJ!F('OW7ND!V+_ #=?Y>'4^_-X=9;]^0\.%WOL'<66VGNW#0=7=U9Q
M,1N+!5CX_+XMLMM[;=713/3SQO%(U/4R('5EU7!]^Z]T9/X[?+WXU_+'#Y+-
M_'OMW;'9$&%:(9O&T(RF%W/@XZB62"DJ<WLW<]/0Y>C@J'BE6FGJ:)(YM#>)
MGTFWNO=(+Y(_S"/A_P#$7=N$V+\ANX8>O]V;CV['NS#X5=D=D[MJ*G;LV3J,
M/#E)9=C8;)Q0(]325,2+/(CL8W*J0+^_=>Z+M_P]M_+#_P"\FO\ V#'R#_\
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M7G:G:_4=3O[J_P"*-%O/KK=6?Z<[)RO5>Z\MLK=-!N4)78U\IAZP4D[1QR%
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MM'^#C-U/86]-JXF2CGJJI!-/ECD_O8WD-0GDF6_OW7NC-?R%NH^Q^A/AAO\
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M#=B5VR.INK-RSOE-DXA<;20YIZ*LP\X6.LQ>#H:^AQV,HY$---,U;4544U2
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MJ-T[3VMOG;V6VCO;;6 WCM//TCX_.[8W3AL=N';V:H)"&DHLMA<M'-35,+$
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M][]U[KWOW7N@_P"V?^95]E_^(_WE_P"\Y4^_=>Z#_P")O_9+'QH_\5_Z:_\
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ) !)(  N2>  /J2??NO=
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW0?]L_\ ,J^R_P#Q'^\O_><J??NO=!_\3?\
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M?NO=>]^Z]U4#NC_MT]_,5_\ ,S__ ,$EW+[]U[KK;_\ V\ W+_XO_OK_ .%
M]7>_=>ZM_P#?NO=$.R^*/QG^6>U]S[;@:#I_YL;JK=H=FX&*I2/&[0^4&W]@
M5&?V'VOBL<RA88MX[>V]7;:W.8Y+2Y.BVW/% )ZO*U4WNO='Q]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JWU3M'YX_
MR=.[.\]K]6?$C>'S ^,/:^Z(MP;+;K.#/56;QWVXJFV]-45>SL5GJS&5-/1S
M?P_,4^1PK03R4\$E'41HP:?W7NC:_%W!_P T+Y9?+?;?R?\ D"^^OAY\;-FX
MVE3#?'.BW5G<7+OV.'5DL9BMT[#JY$:25YZ@29K+YK'4M0T<:T%+31J9#3>Z
M]TA?FU\:_F!\7OGE_P .0?#/KC_3?C=Z;:IL'W)U+B:6JK]P2K1;?I-N9>FA
MV[BR*^KI<E38W'5U+48E*BHAR4#//2R0LJS^Z]T'G=G9W\TO^:-MZ#XY;2^'
M>ZOA)TQNFMIJ?N+>_;U;N6CRE?A,?64]>]#!6[HP^VJV7'NQB,V.Q&&J)JUU
M\,E5%1K6H?=>Z.K\O_Y:-;FOY8N)^&'QGDAJ,_U;-M;=6V:7-U=#A'[.W'A,
MA49+=:YG)U#I24M;F9ZZNKH6GD2F2J\,+R04X\L7NO=$IV7\[?YH>T^AMI?%
M?9?\KWMC!=I[/ZXQ74.![BEQV^:'KW'#:^V%VYC-RTE!58&GP\4T5+3Q20RG
M=QI#4J"@9&6G]^Z]T,W2_P *NV_@#_*D^3^"QVW,UV#\I.Z=G9ZHSFV^LL/F
M]^9W&Y7>V+AZ[V[M;;]#MN*IFR,V"IZ^IR-55TM.T2S/4R:Y*2!9C[KW0_\
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M_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\
MMO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_
M +]U[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_
M=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7N
MO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^
MAC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_
MF.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG
M_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG
M?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW]
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MZAZUPJ7 C)-_?NO="A_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW]
M?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I
M!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[HLWRTZ._F*5?5FU8JKY
MD=-;MB3Y,_"JJ7%8'X,YFAKJ2HHOF1L.MH]SSS0=J5K-182:-,SDH3"JRTE+
M/$\]*KFIA]U[HS/^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3
M_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\
MMO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_
M +]U[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_
M=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7N
MO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^
MAC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_
MF.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG
M_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG
M?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW]
M?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I
M!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG?T!_Z0;E
M/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[
M;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[
M]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>
MZ]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?
MZ&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC
M^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.
M?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>
M=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T
M!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^
MD&Y3_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N
M4_\ MO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_
M +;_ +]U[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V
M_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\
MOW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U
M[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]
M_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&
M/YCG_>=_0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8
MY_WG?T!_Z0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]
MYW] ?^D&Y3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_
M0'_I!N4_^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG?T!_
MZ0;E/_MO^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW] ?^D&
MY3_[;_OW7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I!N4_
M^V_[]U[KW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG?T!_Z0;E/_MO
M^_=>Z]_H8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW
M7NO?Z&/YCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[K
MW^AC^8Y_WG?T!_Z0;E/_ +;_ +]U[KW^AC^8Y_WG?T!_Z0;E/_MO^_=>Z]_H
M8_F.?]YW] ?^D&Y3_P"V_P"_=>Z]_H8_F.?]YW] ?^D&Y3_[;_OW7NO?Z&/Y
MCG_>=_0'_I!N4_\ MO\ OW7NO?Z&/YCG_>=_0'_I!N4_^V_[]U[HN'Q7V'_,
MAWEUCNC+R_/7J2=J/Y'_ #'VH'W5\-L_O')K%L3Y=[XV/##2Y:M[9@>'&QIC
MECPV*5#'C,>*;&Q22Q4B2O[KW1C_ /0Q_,<_[SOZ _\ 2#<I_P#;?]^Z]U[_
M $,?S'/^\[^@/_2#<I_]M_W[KW7O]#'\QS_O._H#_P!(-RG_ -M_W[KW1V]G
M4.Z<9M/;>.WON'%[MWC08/&4>Z-TX3;DNS\1N+/4U&D.5S>-VK-7Y1L=#53!
MYDHCD:GPAM'FDTZC[KW18_B?_P ?'\P__%P-Z_\ OJ]F^_=>ZI!_FL_\S%H/
M_&OW\N__ .!8K_?NO=7_ 'Q-_P"R6/C1_P"*_P#37_ONL;[]U[I ?R]O^R!?
M@]_XJ!\:?_?,87W[KW1O_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1/_ )W_
M /9,VZ/_ !('0'_P0NUO?NO=%!_D*_\ ;I[XI_\ E<__ ()+>/OW7NK?O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!_VS_P R
MK[+_ /$?[R_]YRI]^Z]T'_Q-_P"R6/C1_P"*_P#37_ONL;[]U[K6!_E;?\?A
MLG_Q8#X^?^_T^97OW7NMFCY=[VW3UWT1G]U[,R\V"W#2;RZ<QM-DX(:2HEBH
M=R=T;?VSFZ<15L<L9%10UE33L2A(#DJ58*P]U[HRWOW7NO>_=>Z][]U[KWOW
M7NBV?,S?&ZNL?A_\K>RMBY>3 ;WZ]^-G>F^-G9Z&FHJR7";JVGU?E,_M[+Q4
M>2BFII6IJNGAF6.HADC8KI=&4E3[KW1D_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW10/Y>W_9
M OP>_P#%0/C3_P"^8POOW7NC?^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HN72&P-U[.[,^8FXMQ8Q:#$=K_
M "-VQO\ V'5+78^K.:VICOB-U9U;69-X*.622E*9S;69H_!5I%*1 )@A@EAD
MD]U[HQOOW7NO>_=>ZI!Z_P"]?YBOQOD[9ZKVO_*"[?[CVM!\G_E[OO:7:VU_
MEQ\'-G83L'9_;_RFWAV[L[=%'M?>>]:3+T/W.+SE&STV3I8:J-@5FBC<%%]U
M[I?_ .SV?S,?^]'/?_\ Z6[_ "]__L]]^Z]U2_\ +O\ F/\ =O2WR63M[Y;?
MRZ^^?CWU]3=B]=XK-UV.[B^,'=>=Q6YL[\$OD9L+K_ 1X#K/=M0:@YI\U5UP
MJEG6&EAQL\<S?=U-!35/NO=7OY?_ +(U_EV?^) _E]_^YV!]^Z]U:![]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HFWS^VGV5O?
MXI=A;<ZEZMKN[]X5.XNGJ^;I[&;HV3LO(]G;)P/=FW,_VCL>AW1V16X_!4<N
M2VQ2YBE23*5:4Y+A7$FH1O[KW12?]GL_F8_]Z.>__P#TMW^7O_\ 9[[]U[KW
M^SV?S,?^]'/?_P#Z6[_+W_\ L]]^Z]U7KT5\\\KV#_,_V5\6N[_B[W)\9?DC
MN[^8?N'Y!5.QMS;BZ@[0V?MS86&_DK5W6]#3Y+L_J7<.4H)LI6O1)D%I*2&2
M."GJ:=*BHCJ7\ ]U[K:)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5 [H_[=
M/?S%?_,S_P#\$EW+[]U[JI+J/^8Y\@_DA\I\EWK\.OY=_;7:W6FX/FSV'/@%
M[N[;ZV^*W8=1V'M[^6YL+K;?/7^7Z\WTN2J*%,;1XU,W!EY*AH*M)Q21HE1%
M)[]U[JVW_9R_YL/_ 'I@_P#:BOQM_P#K7[]U[H/]_=N_S/OD%5]/]>;N_E3?
MZ'MK0_)_XF;[W7VPGSE^.^_JGKS9/6'R7VIV)V#N*FVCCJ2CK*__ '[^,RE+
M/2T-0M3-!-+#"DSR""3W7NKOO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= /6?\7=O^UI)_P"]OG_?NO="
MU4?\?/A_^U#N/_W88KW[KW3][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[J+7?\  *L_ZA:C_K4??NO=)?KS_CQ=I_\ :AQO_N,OOW7NHL/_
M #,[(?\ AAX?_P!Z"N]^Z]TO/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=?_U-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4@
MYKKOJ+??\W#Y0_Z4>P.P-C_8?$#XP?PK^Y'R>[K^.WWWDWMO+S???Z(=U;:_
MB.G^S]YYM']G3[]U[HW_ /LN_P 1/^\@._\ _P!.=_-?_P"VI[]U[KW^R[_$
M3_O(#O\ _P#3G?S7_P#MJ>_=>Z*Q\.NA/BM7]2[NGRO>G>=#4Q_*?YT444-#
M_,>^8>W(7QN-^;786.P]8^/P_9E-%)-44D4%145[QF>NE=ZVIEGJ:B6>3W7N
MD]4];].;%_FE?#&;J_L3L3>\]7UOW?'D(M[?*?O+Y#Q4D)V)FF,E)1=N;MW)
M'0MJ2,>6F2)K,RZK2.&]U[J\?W[KW7O?NO=>]^Z]U[W[KW7O?NO= YWKVK+T
MWLG";NAPD>X'S'<GQUZJ-!+D&QJT\7>WR"VQT?/FQ4)#.6;&)N)LDE/H G:
M0&2(2&5/=>Z&/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=$HQ'P_W=M&7=--US\TOE/UQM;<_9':O:";(V]M_P"&^:P&WL_W)V7ENVMY
MT>#R'8/4>;S+4;9G-Y"6FCR&6JI(HW6+RLJ+;W7NAVZIZRWKUV^=;=_R'[B[
MW&77&KCX^UL)T!ATVN:$SFJ?!'H_8VS&D-9YHQ4_Q-JL+X(OMQ!>;S>Z]T&.
M6^.O;^1RN3R%'\\_E?@*2OR%964N"Q.S_@U-BL+3552T\&)QDV=Z8K:YZ>F5
MA#"U963SE%!EFEDU.WNO="WUMU[NW8N R^&W1WIVIW-D<E62U-%NOLG$=)8O
M/[?ADHDI4Q^(ING]G;4Q;PQNK5*-7XVIE\CL&E:$)$ONO= I_LM/<_\ WL)^
M7_\ Z!7P%_\ M'^_=>ZI*^!GPQ[E^4Z_-KLK=/\ -$_F2]<9G!_S)?FYU V*
MZ:W[\8]C[6R^'Z1[=GZIVIN+([>FZIK8(\K48C$T$>0>@%-2N\8:"DIU.CW[
MKW0N=S?\)V>K/D)#+#W%_,M_FR[T6;?VV.TI'J._/CWB9SV)LO;$FS-I;Q%3
M@.J*205^-Q<LE'1SJX,2,VBS$M[]U[H5<C_*7WIU1U-74>R_YN7\W/'XGK7K
MNJIMIX:7NSXR5./H<=L[;318'&2L_4/GDABBIHHF)G\C*.7U'5[]U[K2<^.&
MW_\ A6[OCH#I?=?QOW!\JLE\?\SUCLN?I:LP/9G1&.PDO6,6 @I=E+B*#-Y2
M&LAIDQ\<"0QU,22*@ =0;^_=>Z&K_1I_PM&_YV7S _\ 1L_'3_Z\^_=>Z]_H
MT_X6C?\ .R^8'_HV?CI_]>??NO=>_P!&G_"T;_G9?,#_ -&S\=/_ *\^_=>Z
M]_HT_P"%HW_.R^8'_HV?CI_]>??NO=>_T:?\+1O^=E\P/_1L_'3_ .O/OW7N
MJ_N\_P"8#_PI0^-.P'[1[U^2/RZZQV#'VM7='/N/=M1@,- W;.*V^VY\OLJE
MHJZCCJJF6DHTD::LI8):(.CQ+4M*I0>Z]U7[VS_.=_FG]Y]?;AZK[5^<O?6[
MM@[J7&)N#;M1N>#&PY),/F:?<&.62MPE/352".LI*>:T<ZZM&E]2,RGW7NOH
M=_\ "1#L2+>O\H+;N"GWJVZ<UUWW]W3MS)XFJS\F8R.S8<MEJ;>6.PT]'42R
M24,52N2?)0PZ41S423*"TCL?=>ZVA/?NO=>]^Z]U[W[KW7O?NO=>]^Z]T1#Y
M8_.(?%CMWXO]4GX\]Y]PCY*;XAV8N\>KMJU.<VQUU)/OG;6QQ4[HK8HWC$T:
M[D;<$U++)!IP>'SN065VQ_V\WNO='O\ ?NO=>]^Z]U[W[KW7O?NO= C\F<M7
M8#XW_('.XR18<EA>D>ULMCYGCCF2*NQVPZ^LI)&AE!5PLB*2K @_0BWOW7NJ
M/_@9\6?YE'</P:^&/;E'_.<[OV)1]I?%#XZ]C4NQ\3\-/@9F<5LVFWOU!A]S
M0;5QF8SNQ9:ZKI\<M4*.&IK)7GE2,/*S2,Q/NO=)/I+_ (3^]X_':MJ,CU+_
M #>/DW@:RHWIM_L$2YKH+XR[]%'NC:M7NK(X&IQ,/86%RJ45+!4[WW54_P ,
MHUBHGFR,TLE.\BQ-'[KW2=_F@]"?S'OC7\'^W^\\O_-Y[=[DH>N,UTOG&ZUW
M9\0/A'MG;FZ*E^^=L8['P9;-[&V;09:&*GJ)XJRU'61-(8A&SB-W!]U[J[S_
M $4_,K_O+WK_ /\ 25Z'_P"S/W[KW0V9K;7;%9UG1;=PG:>#PO:$-'B(J[LN
MIZUAR^&K:VEEC;,UD?7K9:!(5JT61(XOXHW@+!@TFFQ]U[H$_P#13\RO^\O>
MO_\ TE>A_P#LS]^Z]T-G8>VNV,[M7#8OKCM/!]?;KI*RBES6ZLSUK#ORES-%
M!CI:>MHZ?;CY;&)2-/4O%4B45,F@1F(*0Y8>Z]T5GM#XP_)_N3K3L3J'?GRY
MVK-L;M78N[>M]YQ8'XT8O#YV7:F^<!4;8W%'A<M4;LJHZ6K:CJIA35+TLRQR
M:7,4@4H?=>Z/U[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IKSF8HMO8
M7,9_)-(N/P>+R&8KVAC,LJT6,I'K:IHHARS!$;2H^IX]^Z]T33:?R_[*WSM7
M;.]MK? 3Y?Y3;&\-OX;=.W,G_>OX)47\1P.X,='EL17?99'NR&HA\U/-')XI
MXDD2^ET5@0/=>Z,3D.P]W4?5T._Z?HCM;+;LEI<?4/T?C\QT?'VC3RUN22AJ
M:&;+93>5-LHRTD3M6U!CW>T9A1E@DFJ"D#^Z]T"W^S+=S_\ >O;Y?_\ H:_
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M-VIVCOCKVJP]/M'XW]T=ZPY.GJYJVNZKSOQXQ%+MZ2FD1(:3,)W=OW9L[R5
M9GB./AJ4 1O*\;%%;W7N@UVI\H\UD^R]B=8]A?&'Y ]'9#LMMS4NS-Q=D97X
MT9W;67RVT]O3;KRF%8]+=C;NR-/.:"GJ)XI*G'1T[>,H9UD:-']U[HV/OW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB@?R]O^R!?@]_XJ!\:?\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K6 _F,_]E4;]_P#$_P#QB_\
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MT_CK_P#:J]^Z]U[_ * J?Y67_/\ SY__ /HT_CK_ /:J]^Z]U[_H"I_E9?\
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M^U5[]U[KW_0%3_*R_P"?^?/_ /\ 1I_'7_[57OW7NO?] 5/\K+_G_GS_ /\
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MC_L@7XH_^+?T_P#[YC='OW7NMC[^4[_VZR_EI_\ B@'PW_\ @==N>_=>Z/\
M^_=>Z][]U[K#45%/1T\]75SPTM+2PRU%34U$J04]/3P(99IYYI2%1$4%F9B
M "2;>_=>Z^;I_P (^*4]Q?S7?G#\C:V%IC+\?NQ\C&:R&DCJ*7,=T?(';VYD
MK/ DDICG^VQE; WA=T599$+G4I;W7NOI(^_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z+_\ ++_LECY+_P#BO_<O_ONLE[]U[H /Y3O_ &ZR_EI_^* ?
M#?\ ^!UVY[]U[H /YN__ '3!_P#&OWPK_P#EE]^Z]U;][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I!]I
MPRU'6/8\$$4D\\^P]WPPPPHTDLTLFWZA(XHHT!+,Q("J!<G@>_=>Z0?Q9I*J
M@^,7QRH:ZFJ**NHNA^H:2LHZN&2FJJ2JINOL=#44U33S!7CDC=2CHX!4@@@$
M>_=>Z'CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW13>[<9DJSY'?"RO
MH\?75=#A]]=SU&6K::DJ)Z3%T]5T+G*"EGR-1$I2!))Y(X8VE*AI&5 2S 'W
M7NC9>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*!_+V_[(%^#W
M_BH'QI_]\QA??NO=&_\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:X'
M\P'_ ++[ZD_\6_\ Y7G_ +^>?W[KW1P.O_\ MW'_ "HO]?\ ED_^ZO;'OW7N
MK?\ W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$ _FQ?\ ;K+^
M99_XH!\R/_@==Q^_=>ZH!_X14_\ ;K+OS_Q?_M/_ .!UZJ]^Z]UM^^_=>Z][
M]U[KWOW7NO>_=>Z][]U[JFK^9YT1T?WQV+MC&]X]-=4]RX[9/\NK^9KOK9E!
MVMUYM'L2BVCO?$YWI"#%;QVQ2[OHZQ*#*TR33)3Y"D6.HC5W"2 ,U_=>Z8.M
M/Y$7\J?(]<; R%9\5EDJZ_9.U:VJD3N[Y&0))456"@GG=8*?=Z1H"S$A$4*/
MH !8>_=>Z6W_  PK_*>_[Q3_ /8Y_)+_ .S'W[KW6/X1_";XK_%KYR_*5?BQ
MUE_<#;&T_C_\=]@[NJ(-V]E;TI)NTMY;KWAV)NS:M1E>P<SE/!78_;<>P\K-
M24H6U-EZ.5S^XH/NO=7!>_=>ZJ!W1_VZ>_F*_P#F9_\ ^"2[E]^Z]T3[^7A_
MS.=/_&G_ ,N?_@!=K^_=>ZV/_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0#UG_ !=V_P"U
MI)_[V^?]^Z]T+51_Q\^'_P"U#N/_ -V&*]^Z]T_>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZBUW_ *L_ZA:C_K4??NO=)?KS_CQ=I_]J'&
M_P#N,OOW7NHL/_,SLA_X8>'_ />@KO?NO=+SW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=5@=5?]O</E[_XJ!\6/_>VWE[]U[JS_ -^Z]T77NWY+;*Z8RFV]
MCPX;=7:?=6^Z6OK.N^A^KJ/&9GLO=U#C'6'([AGCS-708K!8"DE>*"NW/N;)
MX[$4\TL--)6BJJ*:";W7NJZ?B[5_/"K^-G;&]L'NWXO=&T6*^0O\PK</]R<[
MU9V7\CMT4V5IOF3V7D\[CI]^XO>O76,A>ER*S0TTL> K8I8@DC#ZHWNO= 1\
M7.^^P/E!W/\ RF.^NU/[OGL+L?I#OS+;J;:N*J,'M^3)46&W=A/+B\155-9)
M3QO'2HQC:IDLQ/JM[]U[K87]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1?ODQV1N7J
MKKG;>Y]J-0IE,I\@?B9UO5'(4GWE.=M=R?*G9G4.\UCAU+:=L/G*X4LM_P!J
M8QRV;1I/NO=&!]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6E5_.JV%V5T!W5\@_E7\<_E?
M\K_CWOWO/^8G_+VZ$[4V[T]W!6;,V#NC9F\?B]C=HUV5DV_CJ82+FH*7$T"T
ME>]5(B!9%,#>6Z^Z]U>;7?R>Z/)T59C<A_,U_F\5E!D*6HHJZCJ/FBLM/54=
M7$8*FFGB;;5F1T9E93P02/?NO=&?_E@;.P^P/Y;WP*VC@!5?PG$?#[XYK2FM
MG%35,:WJ;%9&H>:8*H):69SPH !L!8>_=>Z/3[]U[KWOW7NO>_=>Z][]U[KW
MOW7NM,+_ (6T?]D"_%'_ ,6_I_\ WS&Z/?NO=;'W\IW_ +=9?RT__% /AO\
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MS4B2V65891&[20SI%[KW3M\8OYG72?RB[XKOC7B>HOEYTCW!2]1Y[O&AVO\
M*;XN]I_'>7<76VV=Y8?86>S^V).QJ2E^^6FRF>QE/(L(/,A()\;Z?=>ZL;]^
MZ]U[W[KW7O?NO=$X^8WSBZB^$>$ZNR?9VV.Z-^9CNCL1^K>LM@=!=1;O[L[*
MW?O"':62WQ5T.'V/LF&>NF6#%XFNJYFCC8JD9:U@Q'NO=%!3^=3\?\;GMC8G
ML/XO_P R7I/"[^[&Z_ZLQG8?>/P"^0G5O66*W?V?NZDV-LNDW)OC=.+AHZ)*
MS)UU+2QM(Y+.X5%9B ?=>ZN%]^Z]U[W[KW7O?NO=!+WUW;U[\:^E.U?D#VSE
M*K"]9],[!W1V3OK*4.-K,Q7T>V-HXB7-9:2@Q./5YZF<Q1,L,$2EG<JHM>_O
MW7NJTJ3^<YUA7TM-74/P1_F[UM#6T\-71UE)_+'^4532U=+4QB:GJ::HAP[)
M)'(C!T="0P(()!]^Z]U8S\;OD+UA\L.B.K/D?TQE:[-]6]Q;1QV]-E9/)XFM
MP62J,/D=2JF0Q&159J>>*1)(I8G'#J=)9;,?=>Z&[W[KW7O?NO=>]^Z]U3Q_
MP]5T!E,WO;&=>_%S^9/W1A]A]B;_ .K<IO\ Z1^ ?R"[3ZUR.\.L=VU>Q]Z4
M.W=\;2QM10UJT64H:JDD:*2X>-E8*01[]U[HX7PY^<'4/S<P/:&6ZPVWW-L3
M-=,=C?Z+.SNO._.HMX])]F[.W?)M'&;YHZ3-;'WO!!60I48S+T-5 SH"R.&*
MA2A;W7NCB^_=>Z][]U[KWOW7NJWODA_-!Z0^-W>M9\<*GJ#YA=[]M8?KG:G:
MFZ=O_%7XJ=M_(F/9>SM\YO*[?VC7;PKNNJ&JCH'R%1A,D*:.8^I82;WX]^Z]
MU#Z _FF]'=^=[[2^.$O3/S.Z#[2[!VCOS>G7F,^57Q*[@^/&-[ P_6/\-;?J
M;-R_8E!2PU\^+CR^/EK(H2?$D\6LAI8E?W7NK+??NO=>]^Z]U[W[KW11OF/\
MU.H_@]L;K_?';.#[:W<W:O;6 Z/ZWV1T?U9NSN3LK>W96Y-L9G>6,V[MW8NR
MX9ZZH=L;@,K4LR)8"'2+NZ*WNO=$ERO\[?X_;37$9#LOXJ?S,^G-H9/=FR=F
MU?9'<7\OGY#];=:;:R_86\*'86U&W7O;<^,@H:"&JRV2H:&)YI+O--'%&KRR
M(C>Z]U<G[]U[KWOW7NO>_=>Z0_9O8>U^H>MNPNV-[U510[+ZPV/NSL/=]=24
M=1D:JCVOLK U&Y<_54V/I TL\D=)32ND,2EW("J"2![]U[JIK;?\\KXP9P=5
M9;,?'O\ F&]==>]R[NZLV;L?N?L_X*][['Z3K,AW3N&@VQUGD:CM#+X]<4M!
MEZO)T*T57'.Z3+-&T/DU+?W7NKG??NO=>]^Z]U[W[KW2=W?NO![$VGNC?&Z*
MQL?MK9NW<WNO<->E-55KT.#V]C9<OEJQ:.B22:4Q4\,CB*&-G:VE%9B ?=>Z
MINQ'\^/XJ9+:FP^RLC\>OYB>T.F>QZSK"';/?.]O@EWMMGHNHQG<N?QFVNL]
MT2]KU] ,-_"<S5YC%QX[(1U3Q57W4 IC,TT2O[KW5V?OW7NO>_=>Z][]U[KW
MOW7NJ/*_^?O\1J3K_</<E+T#_,3S?0VV8]TUV2^0>!^!O?F2Z+&WMEY:JPNY
M=WQ=HQXX8K^$TD]'5+45LDZI%XG670Z.J^Z]U=CALM0Y_#XK.XR1IL;FL;0Y
M;'S/')"\M#D:5:RDD:&4!D+1NI*L 1]"+^_=>Z<O?NO=>]^Z]U[W[KW5,&X?
MYY?QAPL?:>8Q/QX_F']@]?=.;L[1V=OGN3K+X+=Z[YZ6Q^1Z7W!7;9[-KHNT
M<)0/B6H</5XRN2NK&J%CA$,C2E K6]U[JVGK3L+:W;?7.P.UMC5LV2V5V;LG
M:O86S\C4455C:BOVMO3!0;DV_6SXZN2.>!Y:2IAD:&9%="2KJ&!'OW7NEM[]
MU[KWOW7NO>_=>ZJ<WO\ SA>AMJ]K=P]1;4^.?\P/O?,=$=B5G4_9.ZOCA\(>
M\N\.NL)V+C,!CMS97:/]]]BX^IHFKJ6BRN/GGIV975)XI IBEBD?W7NCX_&C
MY$]8?+7H3JOY)=,9+)9?J[N/:./WILROS.'K<!EI,37EHO%DL/D%66">&6.2
M&5#J74I,;O&5=O=>Z'+W[KW7O?NO=>]^Z]U55V=_-WZ'Z[[J[?Z(V_\ '[YZ
M]];MZ(W-A]E]GYOXS_"KO#O78>VMWYK9N-W[3;9JMX[$Q]12"M3&9:AGE@8@
M@2 KJ0J[>Z]TA<M_.GZEP&*R>=SOP:_FWX7"87'UN6S.9RW\LWY.X[%8G%8Z
MF:LR&3R>0K,0D,%/!"CRS32NJ(BEF(4$^_=>ZM#Z6[;V7W]TYU-WOUM65F1Z
M[[KZSV'VWL'(9''U.)R%=LOLC:U+O':U978JL"S4TTM#6P/+3R@/&Q*, P/O
MW7NA,]^Z]U[W[KW7O?NO=5&=G?SF_CEUOV#WIU_0]#?//MV/XW;TS/7O<787
M0WPM[J[>ZEV=O#;>UZ#>6YL'D^R-HT,V-AFQN-R5%65RSRQF*&6.=OV)(Y7]
MU[JR?I;MO9??W3G4W>_6U969'KONOK/8?;>P<AD<?4XG(5VR^R-K4N\=K5E=
MBJP+-332T-; \M/* \;$HP# ^_=>Z$SW[KW7O?NO=>]^Z]U4YO?^<+T-M7M;
MN'J+:GQS_F!][YCHCL2LZG[)W5\</A#WEWAUUA.Q<9@,=N;*[1_OOL7'U-$U
M=2T65Q\\].S*ZI/%(%,4L4C^Z]T?'XT?(GK#Y:]"=5_)+IC)9++]7=Q[1Q^]
M-F5^9P];@,M)B:\M%XLEA\@JRP3PRQR0RH=2ZE)C=XRKM[KW0Y>_=>Z][]U[
MKWOW7NJJNSOYN_0_7?=7;_1&W_C]\]>^MV]$;FP^R^S\W\9_A5WAWKL/;6[\
MULW&[]IMLU6\=B8^HI!6IC,M0SRP,00) 5U(5=O=>Z.M\6ODOU?\P^@^NODC
MTS/N"HZU[/Q^5R&VVW7M[(;4W)#_  /<59M3,46:V[E )Z2HIZ^@JJ>2.0?5
M+J2I!/NO=#_[]U[KWOW7NO>_=>Z][]U[KWOW7NM0'^?[_P >=NO_ ,:_?RR/
M_?$CW[KW6W][]U[HH'\O;_L@7X/?^*@?&G_WS&%]^Z]T;_W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=:87_"VC_L@7XH_^+?T__OF-T>_=>ZV/OY3O_;K+^6G_ .*
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M,A%5XVG7*];[AQ5+N*@=9'#3QUV+B>&+5/,L<"M(/=>Z/M_L\/3'_/%?+_\
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MZ[[1S?7&:WG_ '/P?QKV-UG49+)OUCFL[CXQ)DL)6K&OWA8J ;?6WNO=$:^
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M_P#_ $.?A1_]M#W[KW7O^')?EW_WI9^?_P#Z'/PH_P#MH>_=>Z]_PY+\N_\
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ME$RTT_=,N-II=MRUN-.,QV)I#6-54$U-2>Z]U:7_ +/?E/\ O$'O_P#]'/\
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MK_CY1P2.B$LJ35<$;$ /-&I+K[KW14OE1GH-K?\ "5?XD[GJJC#TE+MSXO\
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MLU*RGHJO(S4E)-)M?'3&".,5%.*@2,WNO=&S_P"&YODO_P!XY=@?^B.^/?\
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M+W5LK9VZFV3N7/83/_%7!T^*W2N(ILZV(EI]X=@8Z=W^TJZ:;7%$R6<#5J!
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M6G[%RN]MVYRIH,)\C>N#2BG2+%Q4,T&8KE8352U-)$PI93[KW0P_\-S?)?\
M[QR[ _\ 1'?'O_[O#W[KW16/DA_+'^8U'O;X:]\;'^)7=&_,Q\3_ )M_&SY(
MY#86U-E?&3KO);NVCUEV)29W>&+I<]E?EAV/JJC0Q2?8TZ82%7J"AGK:>!9"
M?=>ZOF_X<E^7?_>EGY__ /H<_"C_ .VA[]U[JN[^:)E_F+_-0^*DGPD3^55\
MV>E\-VUW5\>6WKV?NS?7P\&+V=UWMGN?"[B[ S47\)["R4OW<&(IZR2B#44D
M?F">4>/5[]U[I3[P_DE;"VSASD\+COG3V'6_=04_]WMG]I]2T68,4H8R5PGW
M_P!LX/'^**P#C[[R'4-$;^JWNO=!5_PT;0_]X\?S/O\ T=7PU_\ NB_?NO=>
M_P"&C:'_ +QX_F??^CJ^&O\ ]T7[]U[I#_-C^0)'V'\-.^\+U#2?+/<7<64Z
MHS.5ZZZ]W7V7ULU%F=_XFD3<6V]H[@FK=_9'&:9ZZGBI*AU:6/EC#,#HF'NO
M=6H[*_F%?,/;.S=I;;J_Y+_SYJ*K;^V<#A*F>GWS\*_MYJC%8J*@FE@\O9ZM
MH9HR5U*#8BX!]^Z]T!WS2^7'S:^2_P .?EE\<=J?R;_G/@=T_(#XT=[]);:S
MFX=]?#48#"Y_M;JW*[$PV6SAQO9<]0*.FJ*^.:I^W@DD\:MH1VLI]U[HN'QR
M_EY?)#IGH+IGJBDI?YSVW(NONL]F;4? ;3^7?QEPNU\+58? P4E;C-N8G!?(
M[%T=/0PS+)'2Q4^.ID6,*!#'^D>Z]T,_^R??)G_G8?SOO_2S_CU_]T[[]U[H
M#_Y9U%\R/Y6."^8O2A_EA?/?O[;7;OSC[6^3&Q>R).S/AIF=S97:W9G7.S<)
M(F_,I4]H.L^:.3PF2GJ98:NK5HY83)52U!GM[KW5E_\ PY+\N_\ O2S\_P#_
M -#GX4?_ &T/?NO=>_X<E^7?_>EGY_\ _H<_"C_[:'OW7NJ(^C?Y;/S'W9W)
M\W?DOO?X@]W=;Y/Y6_+7LKN'!=>[OV?\8>Q\CMK9&7J$J=LK69O$_*OK8Q5L
MAJ*E*VE;%542F-'@K9%<HGNO=&=_X;F^2_\ WCEV!_Z([X]__=X>_=>Z![J/
MXB_,[X/_ ,S/KOYS[?\ @9\DN^-JUGQ*[+^.NZ]H]<8_XI=:UV"RM1V+BM[;
M2SE-09OY&]CFJ%0DN4BKII\Q0JHAI5IJ25C52CW7NKH/^')?EW_WI9^?_P#Z
M'/PH_P#MH>_=>Z]_PY+\N_\ O2S\_P#_ -#GX4?_ &T/?NO=4T_(CXK_ #/_
M )@'\SB@^;&9^ ?R8Z!V5U[\)-I_&[";<[)I/B?V17[EW<G=FZNP\[E),3A/
MD1UYX*6*AR]%'25$.>J&\JU"3T2H8)C[KW0K_P##<WR7_P"\<NP/_1'?'O\
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MH%OY8C?,G^5KUE\A?CD_\K7YX]W[<W'\P>[NZ-@=B1=C_#')9O-;#[ CQ,.
MDWI73=G".7-M]A+-D'IIIXB\@M42MK/OW7NK*/\ AR7Y=_\ >EGY_P#_ *'/
MPH_^VA[]U[H#OD[\U/FEWC\:_D+TIM_^35\[<1G^X.CNV>K<)E<SOKX9#$8S
M+]@;"R&T\;D,J:+LV6;[:&:K22?PQ.^A6T(S6!]U[JLCXX?RIOE7U5T!TOUO
MG/CKV-)G=D]8[*V[G3/U+\<=P.F<QNWX(,Q"N>HOFQM^*M2.I$L<=6F"Q_F0
M+(:.F+&)?=>Z&G_AN;Y+_P#>.78'_HCOCW_]WA[]U[K!_*OPWS8_E1;)^6G0
M^4_E>_,?O;#]I_-OM7Y([(W[L/<'PZV[C9MH]D==[.P4&+R&!R/<&8^SJJ>N
MP=?:GAS>25*=H ];+/Y@ONO=6C?\.2_+O_O2S\__ /T.?A1_]M#W[KW09]T_
M._YE=F=.=L]<8G^3)\\Z#*=@=9[\V1C:[(;Y^%_\/HLANO:U5@:.KKOMNSGD
M\,<E0KR^-&;2#I4FP]^Z]U7+\(/Y;7RA^/\ \1/COU%DL)_.&V/N':/5>UAO
M/9_6?RR^,VVNN]N=@YVB&Y>Q,3L;"8?Y#X.&#$PYRLR"T ?$TT[0Z'JH_N6E
M9O=>Z-/_ +)]\F?^=A_.^_\ 2S_CU_\ =.^_=>Z+]\&]B?,7^67\H/Y@.Y\?
M_+K_ )A/R>V/\L]W=%=A[;W[N?MKX=[H[*_CFTMCY+';\CWWFZ_M>O$Y;(Y$
MICG.5K)S3Q@U#H^E??NO=6@?\.2_+O\ [TL_/_\ ]#GX4?\ VT/?NO=>_P"'
M)?EW_P!Z6?G_ /\ H<_"C_[:'OW7NJ[OYK>_OG!_,J^!W<OPDVE_*6^;/6&9
M[RSW1M$=_;OWI\-9\!MC#;(^0FU.S-S9&J@H.SF>27^&86KCI$8I&U0T0FEA
MA+S)[KW2#QG\M?Y)XO&X_&1?'?L:>+'4-)0135'1_P =C431T<"TZ2SF#YVQ
MIK8*"VA%6][*!Q[]U[J=_P -S?)?_O'+L#_T1WQ[_P#N\/?NO=.W\IK._-O^
M5Q\-=O\ PLW#_*C^;/;TG5G:7>=1A.Q=I[O^&5%B]T[1W7VUEMR[1R<M%5=H
MN(*N3'5-,U;#!/40),76"IJ(@DS^Z]U93_PY+\N_^]+/S_\ _0Y^%'_VT/?N
MO=!GW3\[_F5V9TYVSUQB?Y,GSSH,IV!UGOS9&-KLAOGX7_P^BR&Z]K56!HZN
MN^V[.>3PQR5"O+XT9M(.E2;#W[KW5=/PE_EK?*'X\_$KX^=.Y+$?S@ME[AV;
MU?MF+>>U.K?EK\9MN];8#L'-4G]X^Q,9L'#X?Y#8*&'#QYRLR QVO$4L[P:)
M*J/[EI6;W7NC1_[)]\F?^=A_.^_]+/\ CU_]T[[]U[H&_@!C_FC_ "R]\?.?
M:DO\M?Y]_)+:WR'^4\WR%V7V7D.U_A[N;>^1H-U=6;>Q>XHNQ,UE.U:HSY1<
MW1Y+]Q<C6,U/X6FJ'G,EO=>ZLC_X<E^7?_>EGY__ /H<_"C_ .VA[]U[JFK^
M7S_PG_J>O_A-T-@N\J#Y6[+[FH]DU^8["Z_VOV/UY%CL%NS/[@K]S5^W\.<9
MOK'T "/5"-"4C&HWFD9_),WNO="M_P -&T/_ 'CQ_,^_]'5\-?\ [HOW[KW7
MO^&C:'_O'C^9]_Z.KX:__=%^_=>Z%'9?\DW8NZ<3+D<YB?G;UO61UTU(F!WI
MVIT_79:>GCACE3)Q3=>=MYZA$$C.T:*]:LP:-RT2H8V?W7ND)_+ZZW^4G\H#
M>_SKZ8V3_+D^:/RBZH[A^5M7WQU=VMM;?GQ2>;)X/>/5VWH\_1Y]MW=@8ZJ^
MYI\Y#E((RR2N8$B,\\M1Y7/NO=64_P##DOR[_P"]+/S_ /\ T.?A1_\ ;0]^
MZ]UK_P#P8_E'?,+J'X^8C$;\^,_:6+WMNO=V_NQ=RX')=>?&S?1VY6;TW959
M2BPE-NB@^7VPC4I%1&E:03[7I98YFEB)F5%E?W7NC@_\-S?)?_O'+L#_ -$=
M\>__ +O#W[KW3#\$^J?FO_+&^7GSV[.;^6_\I?D#LOYB;=^(N1VU7=6UGQ)V
M,FU,ST/M;=VS-TXO+;9SW>V]# E0F4QU13-_>JLDD?[B1XJ2)J>'W[KW5KO_
M  Y+\N_^]+/S_P#_ $.?A1_]M#W[KW7O^')?EW_WI9^?_P#Z'/PH_P#MH>_=
M>Z,-\)?G8GS"W#\C-@Y[X[=S?&3M3XO;VV)LCL_K;NBJZUR.<I:WLCK>A[5V
MG64&1ZNSN?Q\L4^'R-'4,/NPR>5%(UZU3W7NC<]L_P#,J^R__$?[R_\ ><J?
M?NO=$ _DI?\ ;H_^7+_XJ!T?_P"\32^_=>ZL_P#?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW1(.DZY>K?EA\G.ALI4T=-C^TI-M_+OIVG9XZ5JW%;JQ5+U?WQ
MM?#4Q1#4R8/=.#H]S9B9#)XSO*A5W&M47W7NCO\ OW7NJ@?F7_V]A_DP?^9%
M?_@;<7[]U[JC3_A;5V"F,^"_Q(ZM%1&DV]/E?4;[%/Y(%GJ*?K7J+/8&9UC+
MB5HXWW3%KT1L@9H];*WC#>Z]U?\ ?R1.ODZR_E%?RZ]M)3QTOWWQ0ZDWW+#'
M'!$!4=J;<C[/JGD2G2-1(\F8=Y=2ZRY8R,TFIC[KW5I?OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NB__++_ +)8^2__ (K_ -R_^^ZR7OW7N@ _E._]
MNLOY:?\ XH!\-_\ X'7;GOW7NC_^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[K4"_X6K?]NLN@_P#Q?_JS_P"!U[5]^Z]U\P3W[KW7O?NO=?3[
M_P"$5/\ VZR[\_\ %_\ M/\ ^!UZJ]^Z]UM^^_=>Z][]U[HGG\PZ&*H^ 'SE
M@GBCG@G^'GR9AFAF19(IHI.E<VDD4L;@AE8$AE(L1P??NO=4*_!'_A.U\+<[
M\+/BINNJ[+^0BY#??0'5/8^6B>F^+N4CI\WV1LRDWWG*6BK<_P!7UE<U+%69
M&>.D6JJYY4@6-'ED*ES[KW1C:_\ X33_  BK-X]6;[A[>^2V,W%T]V%ANS-H
M24.-^'CXR7<F!#B@AW+@LEU#4465H+N3-CZZGD@EL-:,!;W[KW1X?^&M^O\
M_G^6_P#_ -)F_E@?_<^^_=>Z]_PUOU__ ,_RW_\ ^DS?RP/_ +GWW[KW7O\
MAK?K_P#Y_EO_ /\ 29OY8'_W/OOW7NO?\-;]?_\ /\M__P#I,W\L#_[GWW[K
MW03]W?R4NC^_^M\MU9OSOKN>EVUF,QLO/5%3LSI'^6[LG<4&3V!OC&]A;<EH
M]Q;<Z#@JHXUR6*I#54XD,553^6EJ4EIII8G]U[H",3_PFX^$&&Q6,Q%+V?\
M(B2EQ6/H\;325>,^)%35204-,M+"]34R=3ZI)"J@N[<L;D\GW[KW1:,+_*XZ
M!^ /\Y7^57OKI[=O:&XLOVGM?YT[2W!3;Z3J&EQ5)C=F]!)F,9/BZ/JW:&V#
M]Q)+DZA9Y:QZBZ+&L:QV8O[KW6U+[]U[KWOW7NO>_=>Z^4)_PKQ_[?);U_\
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MW#XS!8JG_P!)?1)\&-Q%$F/H8;KUN!Z8HU7@#Z?3W[KW3Q_PSULW_O.'Y_\
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MRV<W]TCG-T9ELED-JXK"T31QSU#1TZI0(RQ*H=I&!<^Z]T4O^3E_*RV/VW\
M^J>ZW^5/S#ZZS/;^Y.UMT[CVIUGO/IG![(Q^3V]V=E>L:'^!X_+[$R%:JMC-
MOX_RM69"HE:4.WD"%(T]U[JT+_AGK9O_ 'G#\_\ _P!&7T5_]KCW[KW1-/C7
M\*=G_$+^?UB*[;W;/=_;V8[6_E&=U56X,YW?N'96X<K00[,^8'6./PV.P<NR
M]OX"..GTUD[R+/',Q<W5U'I/NO=(_K?^7SLGY3?S?_YTO;&3[U^1_3FY]O\
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M>63QN4R]3GLAOKLW;,A67$T5!3QPI1XFCC2..F'*LS%F<GW[KW0 ?!7^6/\
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M?;>0AQ>;I,CL?XN=@;_VW6X^MJ8:B)6@R>+HY626"2.15:.1&1F!]U[H:_\
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M '@]\P?_ $FGL#_ZR^_=>Z"[O'^6W_+CW-TKW!MO9_P9^851NW<'5W8&#VM
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M=-%N*,Y.LQ51)/:L$X$K3/J'.HBQ]^Z]T*__  WM_+ _[P>^8/\ Z33V!_\
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MZ]U[W[KW7O?NO=: ?_"YS_NEW_Y>S_\ ,C]^Z]UN>_R]O^R!?@]_XJ!\:?\
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MW7O?NO=>]^Z]U[W[KW7O?NO=5 ?%3_M\E_-Z_P#$ ?RL/_=%W-[]U[KVX_\
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M#ZTW#B(YI/'N#:^4Q^4P^X,?"\C4E90U<3G]EF]^Z]T%.Z/^W3W\Q7_S,_\
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M+H3J42Q.EP-2L+@^Z]T@T_X2%_R;E55.SOD%(54 N_>N9#.0+%V"4BK<_4V
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MDJB*-5)M##*L=RS:=3,3[KW0J?\ #>WP%_[P>^('_I-/3'_UE]^Z]T'/9_\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT0_P#A<7_S*O\ EV_^) ^1W_O.;/\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TC>O/^/%VG_P!J'&_^XR^_=>ZBP_\
M,SLA_P"&'A__ 'H*[W[KW2\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7RA/^%>/_;Y+>O_ (@#HG_W157OW7NC ?\ "*G_
M +>F]^?^* =I_P#P1757OW7NOI]^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU@?^%>7_ &YM
MWI_XL!T3_P"[RJ]^Z]T4#_A$O_V0+\KO_%OZC_WS&U_?NO=;GOOW7NO>_=>Z
M][]U[KWOW7ND7V/U[L[MK8&].K^PL)3[DV+V%M?.;-W=@:J2>&'*[>W%CI,5
ME:(U%(\<T+/#*X2:"1)8VM)&Z.JL/=>ZUNNT_F7T#\+/A!\R_P"6M\H^\-R2
M_+^CZ[^:5+M[([DZX[&R,OR$HOE/E][=D=0=LT>ZMI82IV_ VXY-Q_89=)Z^
M&/'YFDRE-*PIZ9*B7W7NAL[Q_G6?RRMX=G?#C<.W/DM_$</U5\C]T;]W[6?Z
M&_D!2?P':>1^(G:G5]'E?MZ[:D4M5KSNY,+0^"B2:8?<>9HQ3PSRQ>Z]U[:_
M\ZS^65COEWWCVA6?);P[%WA\</BOL+;F<_T-_("3^([LZW[.[CW#O3%?PR+:
MC5D/V5'NK 3>>>G2&;[K1!)*\%0L/NO=)+J7^<-_*JH^K/DCL+MSY*28O;G:
MG<GR:S%5##U'\A9)<AUEVCN?(34F4BK<+M69J5JK&U+2*CLE1"3:2..0:1[K
MW1_?Y.^8Z.W-_+X^.>Z^B]RT.Z*#</574+=D5E#7UU8E#V[MOI+;&QMZX:HI
MLBJ24DM-_"J9&IP@0\31:HYE=O=>ZL]]^Z]U[W[KW7O?NO=?)$^=W_<47NC_
M ,:?] _^_,VM[]U[KZE/Q9V?T)LGK#'8;XY9ZAW%UQ'A>JX,76X[<IW72#"X
M3H+:&UNMVARS,[.E1LO'[8KHY'=C/'.M46/W%_?NO=&2]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW09U/3G6-7W'AOD%4;.Q<G<NW^L]R].8CL"]4F:I.L=X;IQ.]MQ;.LD@@DI
M:C*X/%UMY86>.2#]IT6299/=>ZX[<Z9ZPVEVEV;W7MS9^-Q7:?<F%Z[V[V=O
M*GDK6R>[\+U-#E:?KK'Y*.:5H%3%)F\JM.88D)^Y?R%[+I]U[H3O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U2/M/^65\X.F=V=^U7QI_FGUW376O>?R9[\^3K=;5_PHZ3[-?:FZ/D
M#V-6]C;EP]/O/=V5^^K(*>HK/!"\B1@H@81H21[]U[JB?YE?+/\ X43?%_Y3
M=N]2[,[N[7[\Z+ZK[4^,&P?].767P ^,&?3/4/R QVTHZ^)=NTV96MI]P4V7
MW)+AL'@THYQDJB.F,E51150EC]U[HP69^2W\U//X?*X+)]N_S@)L;FL;78G(
M0I_(:^.$+RT.1I6HZN-9HM]!D+1NP#*01]0;^_=>Z;OCWT_\'>D^C>INHMP?
MRA_YJO:.=ZWV#MG9V8[&SO\ +4ZAI<QO?)8+%QT-;N;(TM;5Y&:*6LD1IFCE
MKZAUU:6FD(+GW7NK,?B+\,/Y<'S VAV#NG _"[?G261ZP[0JNI=X=??)#XV=
M(]8=CXW<M/L';W94-6VV(L/D2*&HQ6YL9+33R3*SL9!XPJJS^Z]T:_\ X9Y^
M O\ SXG8'_HL.F/_ +&/?NO=$S^9/P&^+WQAVSLKLWIWJC8&V]V83L?HJJHL
MG%UCU/35]-497Y>=7=?BLQ>9PV!H\ACZJFI\_55--68ZL@F$L:([O2O4T\_N
MO=;!?OW7NO>_=>Z+Y\?/BG\>/BIC-[X?X]=5;;ZMQW8^]*OL#>=-M\Y&49K=
M%90PXS[EI<K/4/!2T]-3Q4]#C*5HZ*CC!2EIX59PWNO=&#]^Z]U[W[KW7O?N
MO=?-G^7D[_(O_A9KU5MF#R9#&]8?)SXE08N.1YZC[=.B>G-N]MY[1$E1IB6#
M+4.2E C95%O))$SF5&]U[KZ3'OW7NO>_=>Z][]U[HGW;WP'^)7?7?.Q/DQV]
MU)#OGN7K7"[0V]LW<64WIV)!@\=B-@]B?Z6]GTM;UYC<O!MO(&@W,(,W#+D<
M1/(:JFHY'=C14GA]U[HX/OW7NO>_=>Z][]U[KWOW7NB__++_ +)8^2__ (K_
M -R_^^ZR7OW7N@ _E._]NLOY:?\ XH!\-_\ X'7;GOW7NJ0?^%DG_;H_;G_B
MW_37_O$[O]^Z]T%W\ASNKYQ=:?RPOB95=%?RCML]S86;KW=.%H?D-1?+OX\=
M3;F[,P5+V]N+(1IEL%N+%29JG@HJR:IIH:6OJI!>,S1@+*/?NO=7(?[.7_-A
M_P"],'_M17XV_P#UK]^Z]U7%VYE/^%"F;^1'8W>_Q^^'N!Z,I>RME=7;(R^S
MMQ]W?$/NB>BQ?5)S=7@J7&;KS&2Q,L=(:W<6:R I/M;)/63L'8. ONO=)W^^
M/_"J#_GU&P/_ #X_"W_[)??NO=63?RD/D7\]>U\O\P^G?YA6"VG@NX_CMV7U
M=C<73;<IMDI5P[7[0ZDH=^45'EZWK>OK\)4Z2_W%/)3L)D6=HIRQ1%C]U[JS
M'NWHC87?FW,5@]YKGL7E=JYZ+=_7F_\ 9.>K]H]D=8;WIL;4X>EWEU_O#%%:
MB@K11UE905,9\E+745358[(4]7CZNJI9O=>Z+]0[N^;/1ZQXC??6&+^9>RZ+
M32T'972F<V)U9W_54WE:.EJ=_P#2?9];M_9=7-# (Y,GF-M[THONI?*U!M:D
M4Q4OOW7NE/U]\V^H-\=TX#XX9G ]P=3]\[KV/O/LG;'6O;?4>]-K5&XMC=>Y
MG'[?WGN'![WHZ:MVM5QT%5EL9'+#3YYYB*F)TB="S+[KW1P/?NO=>]^Z]U[W
M[KW7O?NO=:(7_"VC_F5OQ1_\/^G_ />=W1[]U[KYXGOW7NOM\_RG?^W67\M/
M_P 4 ^&__P #KMSW[KW1_P#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW6B'_P +B_\ F5?\NW_Q('R._P#><V?[]U[K=\[9_P"95]E_^(_WE_[SE3[]
MU[K0#_X0Z?\ ,U/YB7_B/_CC_P"]'O#W[KW7T//?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=?,$_P"$5/\ V]-[\_\ % .T_P#X(KJKW[KW7T^_?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW5>GSTZCVMVKO'^7=7[F[CV'U)/U%_,+ZV[<VMCM[U,
M5-5]R;IPG1'8^VJ/IS82RSP>7/5U/EZK*T\2^1C38ZJ(B;3<>Z]UQ[*ZCVSF
M/YGWQ3[KJ>XM@X;=VR/B5\LMBXKHS)5D<?9&^L'O3L'K?)Y;L':]'Y09,9@I
M<;34F38PG3)74VEB->GW7NK#??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U\E_9&V>JNRO\ A2/\HNL?DCW1U;TI\5T_FN?)?O'O3-]S
M=A;2ZRZ\S^/^/O?>^-X[6V?FMR;OK*"G<YJLJ&PD=&E2'?[YIE6\ >/W7NKV
ML#D_CI0_\*W_ (O=@_$WY,="]U]!?+>E[*[ZWC3=']N=<]F;6VE\AL'\+^T^
MH\[C,M6;*R602CR>6,PS>F9XVK)LPR(CF% GNO=;(_\ .0_YEU\!_P#QK_\
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M2Q)-@/=>ZW^O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?,$_X14_\
M;TWOS_Q0#M/_ ."*ZJ]^Z]U]/OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4!_-?\ ^9B_
MR>O_ !K_ -*?_ L]R>_=>Z]W/_V_#^"'_B@'SR_]^SU![]U[JW_W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:SG?G_"4'^5Y\C>].YO
MD)O[.?*6FWWWMVMV%W'O:#;G;.TL=M^/=_9N[:O>FYEP>/K=KU4L%)][6SFG
M@DJ)#&FE"[6O[]U[HJO7W\C;X5_RI_YM'\H7?WQEK^Y\KF^U^U_F!M/<\7;&
M]=O;PQL6-V[\%-^[BQD^)I<5A,6T-0E4 WE>1_H-*JPU>_=>ZN._G(?\RZ^
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M ,5 ^-/_ +YC"^_=>Z-_[]U[KWOW7NO>_=>ZJ _DD?\ 9(G:G_B__P#,>_\
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M2TL,M14U-1*D%/3T\"&6:>>:4A41%!9F8@  DFWOW7NOFV?\) Z>;NO^;?\
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M%(=\9/.XW!R.\-3AH=TT1F:/W7NB:_.B?Y5?%C&?#7?&%^<W>^\JSL7^8_\
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M"_![_P 5 ^-/_OF,+[]U[HW_ +]U[KWOW7NO>_=>ZJ!W1_VZ>_F*_P#F9_\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M?B<AV#MO9&#G@Q>TZ^AI\9@X*5%RF53(3ID&AI*3R1RTR0J]Y4,G[MAS8GB_
MNO=.>QJW-Y[<=3N7,TF.H#5[9I\=3T=#43U#HF/W#61.]2TJ!0QD#V".PTZ3
M<$D#W7NA=]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]/?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=4 _S7?\ BU?/C_Q7_P#D]?\ PQSLOW[KW0@?R^O^/_\ BE_XC_\
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M][]U[J#DL9C<S0U&,S&/H<KC:M52JQ^2I*>NH:E$D$J+44E4KQN RJP#*;$
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MJP/Y _\ VYM_E[?^( Q'_N]K_?NO=6_^_=>Z][]U[JL#^:7_ ,R8P?\ X?\
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M4DT$<Q16]U[JV_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'_6G_ ![F2_\
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MD<TWE$<7NO=?3G]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!_P!:?\>YDO\
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MW!DFK:1:O%8A*BNAJI#'4I,[R0R03-$_NO=?6"]^Z]U[W[KW0"?*+9_>._\
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MF!W92XZJFC\T5-75&!J*A(9&3UJDA!(Y M[]U[H-_P#9LOBQ_P!Y+_'_ /\
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M++=V8#.;6W&?EQE]O;EP^3P&>Q-7VO\ '5J3*8;,T3X[*8ZJ5<T"8YX)'B<
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MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[HK7S2^*FU?FS\;=^_&C>VY\]M#;&_\
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MG^9=\L^INM>S?EW_ #'^KL[TAUCM'XOIL"'9V0^6.^]M;GQM%6;IV)D,RO\
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M[KWOW7NO>_=>Z][]U[H/^V?^95]E_P#B/]Y?^\Y4^_=>Z#_XF_\ 9+'QH_\
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MOW7NO>_=>Z][]U[H-=@XO&56&KYJG'4-1,VY]V!I9Z2GED8+N&H507D4DV'
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M?^//^)__ )=A_P"^+]^Z]UL_>_=>Z][]U[KWOW7NO>_=>ZJ!W1_VZ>_F*_\
MF9__ ."2[E]^Z]T3[^7A_P SG3_QI_\ +G_X 7:_OW7NMC_W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T@^NO\ BQ5O_AT;M_\ >BJ/?NO=2JC_ )F#A_\ PS=Q_P#N[Q7O
MW7NEE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@YJ
M/^9=;?\ ^H78W_NRH/?NO=1>O?T0?]JNN_\ >MR'OW7NA0]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U_];?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _S7?\ BU?/C_Q7
M_P#D]?\ PQSLOW[KW0@?R^O^/_\ BE_XC_\ G;__  S[KWW[KW5WWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZJ W'_V_TZ;_ /&0'R5_^#/ZG]^Z]U[XJ?\ ;Y+^;U_X@#^5A_[H
MNYO?NO=6_P#OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NM,+>/_<:/U1_XJ!D?_@<MR^_=>ZK@VMW-\<*[_A2
MK2?S-J7HF3_9 =U_,/-_"C;7R1:8#K#_ &>%.DJ/:;]O_;-_D4<>2R<WW5/5
M,1 ].[[B:1:V%T7W7NMKGX7[-VAN?^9M_._GW)M7;>X9Z7OOX214TV<P>,RT
MM/$_\OG83O%!)7Q2%%)Y*J0">??NO=62]K=4]71]7=DR1];;!1TV#O%T=-G;
M=5T==NU+*RLM-<$'D$>_=>Z)]_)2_P"W1_\ +E_\5 Z/_P#>)I??NO=6?^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NOG8_\+A>POXCW
M7_+^ZI6H4_W0ZM[T["DI%>'6G^D?=FWMMPU$L:_N6;^ZLBQL_I]+A+'R7]U[
MK?8^+FP3U3\9?CKU<86ISUMT3U'L$P.LR- =G]?X_;WA9*E(Y 5^WTD2(K"W
MJ4&X]^Z]T.WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@_[9_YE7V7_
M .(_WE_[SE3[]U[H/_B;_P!DL?&C_P 5_P"FO_?=8WW[KW0?_+#_ (^/X>?^
M+@;*_P#?5[R]^Z]T<#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=$,[?;='RA[HS'Q>VUN'*;3Z,ZMQ^T]P?*[=NT\WEL
M%O'?.:W;329[97Q;VKN3!-#/AXZK&1T>XM_5T%7%7#"5^(QM& F?J*V@]U[H
MZNUMK;9V/MG;^S-F;?PNT]H;3PN,VYM?:^W,91X7;^W=OX6C3'8?!X/#XY(Z
M>EI*6GCC@IZ>"-4C1555"@#W[KW1'>J/^/._F'?^+ =T?^^)VM[]U[HP'Q-_
M[)8^-'_BO_37_ONL;[]U[I?=I=M]4]';*RO97=?9O7O3_7.!:C3.;_[2WIMO
MK_96&?(U:8_'KE=U;LJ:2AIS//)'!")IUUR,J+=F /NO=1>L>Z>G.[,55Y[I
MGMGK/MS!T%0M)7YGK'?>UM^XJBJGUZ*:KR.U:JKACD/C>R.X)TMQP??NO="9
M[]U[KWOW7NO>_=>Z+5N7YG_#S9>]J/K7>/RP^-6T^QLAN+';0H-@;E[UZNP6
M]J[=F8JOL<1M>CVKE,K%7RY&JG_9IJ)(#-*_H1&;CW[KW1E??NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$/??<.%Z"Z?W[VYG,9DMP1;.POGQ
M&T\&(VW%OO>&5K(L#L3KG:T4UDDR^X\W58_!8F)R%DK*N!"0&N/=>Z"KXU_'
MO,;!K-R]V]UU>#WE\K.W:>!^SMYXF?(9/;NR-N0U!K-O="]-U.;BAJ:+9>W0
M0D"+3TSY:O\ N<[D(%R%?*L?NO=&S]^Z]U4!\1/^9P_$'_Q '\V#_P"#LZD]
M^Z]U;_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ0_FH9;*XKL/^44F,R>0QJ9;^;?TSB<
MHE!6U-&N2Q51\7NX)Y\9D%IV434[O%$[PR70LBD@E1;W7NO=QY;*P_SLO@SA
MH<GD(L16? CYV5=7BHZVI3&U553]L=0K3U-30JPB>1 2$=E)7\$>_=>ZMO\
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW50'SL
M_P"WF/\ (Y_\3_\ -W_X7OOWW[KW7OYR'_,NO@/_ .-?_P"6#_\ !38;W[KW
M5O\ []U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU!/^%9OR1ZY^/FROA*-[C/5N2WEDOE50
M8'";<QU/79&II_\ 1;B=K9#+R29&>DI8Z:CK,YBTJ U3YBLX:&&8))H]U[K;
M-V!OO:G:6P]D]F[#RRY_8_8NT=M[[V9G4H\ACTS6U-W8:'<&W<LM!EHH*J 5
M-'40S"&I@CE35IDC1P5'NO=*[W[KW7O?NO=>]^Z]UJW]0YK^;+\QOBA\Q>L/
MCMUM_+NQ?0?:?R&_F?=)8G<O=/=WR4V]V_CZ???RE[&P>ZLOD=N[&Z^SF%#T
ME5E:HX\19%Q+%%$TRQ.[QK[KW2<^&74OS[^$7SQ^(GQ^^7T_QRWUMKY4]\_,
MOY%;<W]U7VAO'>_86(WEM?X?X;9VYMO;HHZSK+K;!C&21TE/54$E!CC.'FEC
MF.F%'E]U[K:S]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= QL_;V5R&/R-52[PSN(A?<VZ0
MM#0PX=Z:(IGJA&9&K*:22[$:C=SR>+#W[KW4^DQ-=B^Q,$M;G\GG3-MG<1C?
M)1X^-J8)6T098OL(800UP3J!^@M;W[KW0L>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZP53M%35,B&SQP3.AL#9DC+*;'_'W[KW0-;=V=D=
MR[*P!K]YY\4E;BL34''QT^#-+%]N(ZFEB3R4I<K&T:$:F-[<WY]^Z]TY[1PT
MFV-Y5VWH\I69&@BVG1Y&G6LBHHS32UVX*PSQQ"BBB707#. 1P6('%@/=>Z%G
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__U]_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK
M9]A_!#H[^9!_-=_F9=:_*C+]W;CZZZJ^.7\MO&;5V%LGY =P=6[,DQV\I.UM
MVY>AW'MCK[,8^BRL293'09&B3(P3"EJ7J)X!')43,_NO=.WQ.^%/3/P"_G-=
M9=$_'/)=P8_J+*_RK/DQO>+8/87>/:W;.V=O[FG^8O5-)79+:&([%RN1@Q#5
M0=WK!CHX1/(3)+K<W]^Z]UL;>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I-R;-VA-N^C[!FVKMN7?
MN.VWD]FX_>\F#QC[OH-H9K)TF;S&U:/<K1&MBQM76T%#5U-"DPAEFIH)71I(
M8V7W7NN..V5L[$;HW+OC$[2VSC-Z[SH=NXS>&[\=@<51;HW7C=H+5KM/'[EW
M!31+5U\&+%?7#'154SI3"IG\(3S2:O=>Z4WOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NOFK_ ,_7N_N_HO\
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MKJ5EO<$>_=>Z1?\ LV7Q8_[R7^/_ /Z.7KK_ .N7OW7NO?[-E\6/^\E_C_\
M^CEZZ_\ KE[]U[H9-M[GVUO+"8_<VT-PX/=>V\M')-B]P;;RU!G<)DHH9WI9
M9<?EL7)+!,JRH\;-'(0&5E/((]^Z]T^>_=>Z#O?/;W4W6$N.@[*[0Z[Z\GS$
M=3-B8=\[UVUM*7*14;(E9+CH\_4TYG6(R1B1H@P4LH:VH7]U[I!_[-E\6/\
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MN@__ -FR^+'_ 'DO\?\ _P!'+UU_]<O?NO=>_P!FR^+'_>2_Q_\ _1R]=?\
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M<PE++63K2TD53ELQ+# C2RLL<:M("S$*MR0/?NO=!'_LV7Q8_P"\E_C_ /\
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M^1Q&(V=GMMSX_&_;=FN/N6ERL,B>4HFA'NP.D'W7NAR_X<E^7?\ WI9^?_\
MZ'/PH_\ MH>_=>ZB];?S6^Q]Y?(JF^+>Z_Y8GS=ZY[AR?2NYN_L%MK-[I^%\
MCY?K79^^<+UWN#.19*M[6HL>@@RF?QU/X#6FH?662!HTDD3W7NCE?[,MW/\
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MGQ?PPH<=3(JHR;V^2>PL/DI9R27:FI=FXS<=.T 70!)+61R%]8,(55=_=>Z
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MY3N7=%5E]QOUSE5B Q.(J_ C0*'DTH'!(!]U[J#T'_,/^;_:7R([S^+78_\
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M0Y";#Y*"#+;?Z\JZ.62EK*>HI*D05#A)HI(R=2$#W7NA(_V>'IC_ )XKY?\
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M_%W9>[:O<FT*/N+.TN'KI-S+\;>Q36J@1Z:&5MUU)6.)(Q%3*BT\?NO='_\
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M'GL[[ZFQ^8.8PM 6W&@@I**"DAHH*>GA>;W7NK ?]E][V_[UX= _^D=[._\
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M)R54TDM55M,(?=>Z.?\ [+[WM_WKPZ!_]([V=_\ <:^_=>Z*-G.E<:/YIO\
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MR^Z]T*/^R^][?]Z\.@?_ $CO9W_W&OOW7NF+^2/T%_+RWQT=\L,I_,4^,?\
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M%NJE^//9WWU-C\P<QA: MN-!!244%)#104]/"\WNO=6 _P"R^][?]Z\.@?\
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M;V#H-I4^2V]AJ*HDI\Q).N-K*)JA8JF&9X)KQR,#[KW0;?[+[WM_WKPZ!_\
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M5]@YWM_J[XKYGLS)Y]LQ6++4[RRF\Z&3*35AC$89ZUVDTA;FUO?NO=7&Y_\
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M&/B?F\Y\ NB\Z^0Z)Z\EP6Y*_P")>RLOD=V;'7;\,77>\<IFX_C#ODY"KS&
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MW3L;X$_RTMY[9AFJJ>7<>U/BW\7-Q8**HH4$E;!)E\1@IJ=7A5E:53)= 06
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M?-5/0C.;.^+'Q>W-AS6TH4U-&,GA<%/!Y8PRZX]>I;BX%Q[]U[HH?R3^*_\
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M7;.#^"WS?KFZ3V55T-7'E>S,AMZ&BK9\I3T(8:\?3*DTI*K&VJRGW7NKEO\
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MAX4IJJ"HA%"8:FF$B>>H]U[JQ3_9X?YQG_/%?$#_ --[?SR/_M:>_=>Z#?\
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M5G!9/X_;UQ78E=2T"8O..TE'MJ?+U:2183)21-$)8\?72(M++[KW3-_LP_\
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M\52RU4D:0O4R4]!@8T:1DC1"Y%R%47L![]U[IX_X;V^ O_>#WQ _])IZ8_\
MK+[]U[IASG\LS^6]N=*:/<O\OOX1;A2C:1Z1,Y\4>A\LE*\P59FIEK\#($+A
M5#%;7L+_ $'OW7NJCODMU[_+P_EN?S8/Y6G8V#V/\,/@1U[N_I#^9+B=_;[Q
M6V>C_BULW=&5QV%ZFBV1C-W[HHX,%0UM1 U=D5Q4-;.[H:BH%. 99=7NO=>^
M-/7O\O#^9'_-@_FE]C9S8_PP^>_7NT.D/Y;6)V#OO*[9Z/\ E+LW:^5R.%[9
MBWOC-H;HK(,[0T51.U#CERL-%.CN:>G%0"8HM/NO=6UX/^6)_+6VQ+//MO\
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MS.<SF9R6WY:BKK*NHEDJ*FIJ)'DED=G=F9B3[KW1Y_\ AO;X"_\ >#WQ _\
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M&E/_ "IOY75'405=)_+:^ U+54LT5135-/\ #OX\05%/40.)89X)HMNAD=&
M964@@@$&_OW7NEU_PWM\!?\ O![X@?\ I-/3'_UE]^Z]U[_AO;X"_P#>#WQ
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M_P#V4^_=>Z]_LB'QF_YY?L#_ -'_ /(7_P"RGW[KW7O]D0^,W_/+]@?^C_\
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M(ONO=;;/^R(?&;_GE^P/_1__ "%_^RGW[KW7O]D0^,W_ #R_8'_H_P#Y"_\
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M?:U+\7NRMHU\VZMF3&JBEHDR^2QE!**F!HQ45$"$:G7W[KW5]/\ PWM\!?\
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M Y$:.3X.?#YT=61T?XS]+LCHPTLK*V$L01P0??NO=%-I/Y"O\G6AR%-DZ?\
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MC?B%\?:&NIG>,Q.U/5TNWDD0E692587!(^A]^Z]TLO\ AO;X"_\ >#WQ _\
M2:>F/_K+[]U[KW_#>WP%_P"\'OB!_P"DT],?_67W[KW5,7\\G^7E_+AZ2_E+
M_.3M#K[X+?"KJC?6UNGC)M#L'8_Q?Z/V7N_;>Y,KNO&8+#5&W-T[=P5/7457
M-/5)30RTTZ/>32&LQ]^Z]TE?EC\Z?Y</\ROYA?RE>A^DNY>D/EPF/^9^^=W]
MC=6PX==\X?\ N5COB'V+!_&=S;;W-CVHYZ."ODHS>:-PDOC>P*AA[KW5X_\
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M;E#%C-O;4VEA,;MS;6!QL%_#C\-@L/%#2TL"7.F*")4%^![]U[K0E_X7.?\
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M+[@^-_QWW9F<CN/=/0O2^Y=PY>H-7EL]N#JW8^9S.4JF4*U3D<ID:&2>>0@
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M&)&"EM(9K7/NO=+S_H.+[4_[UV]?_P#I1VX__L/]^Z]U[_H.+[4_[UV]?_\
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MCY+_ /BO_<O_ +[K)>_=>Z #^4[_ -NLOY:?_B@'PW_^!UVY[]U[H /YN_\
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MC\G#C=Q8!*>MHIFB=A'4TLZ2H?4C B_OW7N@6^ O\LSX?_RS=G;^V)\0.O\
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MU%@\]4U5)AJ^O?:>,KHH!4O150B2:1781E@ND@GW7N@Q_P"'2/@G_P _S_\
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M7?\ Y>S_ /,C]^Z]UMD_ ?XO?&?+_!7X6Y;+?'?HO*93*?$SXY9')9+(]2;
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MM^- M]" >/?NO=,,_;'VU3%22[*W7YYI6@58X\9.BRI72XXK+-!4,D?[T$R
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M2X0R:0Q47M>P^GOW7NE%_H8_F.?]YW] ?^D&Y3_[;_OW7ND_U+O3Y9[#^:&
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M-+*RMP01P0??NO=('_1-U7_S[3K_ /\ 0-VY_P#4WOW7NO?Z)NJ_^?:=?_\
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M9\,-O+7;IS.W^IMXYK )O_<6,E>LQ^2S@V[7[7[)RU7BI)5I<94S/H@662"
MG4\"!/=>ZVK??NO=%$^2>\]Z=@["[-Z-^(??736S_F'_ '>Q6;VS0[EW5MS)
MY/9FWZ/?6/QF[=T;AV=#19ZOBI/M35XR&JDP4T:5TT$;-$Y\D?NO=4K_ ,EG
M(87HGY4?+'XH=V;/RT?S/J\AE=Z;[[>JMYP[OPG8>)Q66@R%1B</$:6EFHFE
M.9CSHFE>HFR FFDJC2-2P4H]U[K9C]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=%VR>7Q5/G!#/D:**63+3*D;U,2L63>^<+BQ/%A)&3
M?\,#^??NO=#$*VCK=S8LT=7358BP6X!*::>*<1F3(8PQB0Q$VU:6TW^MC;Z'
MW[KW2G]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%KO^ 59
M_P!0M1_UJ/OW7NDOUY_QXNT_^U#C?_<9??NO=18?^9G9#_PP\/\ ^]!7>_=>
MZ7GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__6W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4#^83_V0+\X?_%0/DM_
M[YC->_=>Z'_J;_F5?6G_ (C_ &;_ .\Y3>_=>Z$#W[KW1 -Q_P#;TWIO_P 4
M ^2O_P $5U/[]U[JL#HS_N)<^4O_ (I_W#_[ROPW]^Z]U=]\LO\ LECY+_\
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MS1X?!XB@>6>2+'X\U58\+3S/---43SR%!(D$/NO=$+['_E$?(+I7O#>'??\
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M??NO=>_X85_E/?\ >*?_ +'/Y)?_ &8^_=>Z]_PPK_*>_P"\4_\ V.?R2_\
MLQ]^Z]U[_AA7^4]_WBG_ .QS^27_ -F/OW7NO?\ #"O\I[_O%/\ ]CG\DO\
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MA\UMZDQT_F;=YD7QQUU4NE7"MKNP8JA7W7NEA_PPK_*>_P"\4_\ V.?R2_\
MLQ]^Z]U[_AA7^4]_WBG_ .QS^27_ -F/OW7NO?\ #"O\I[_O%/\ ]CG\DO\
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M2Q(TT0AC<$0QE?=>ZV\/?NO=>]^Z]U[W[KW50'\Y#_F77P'_ /&O_P#+!_\
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M /SGZ8_^RCW[KW7O^@VCX"_]XH_+_P#\Y^F/_LH]^Z]U[_H-H^ O_>*/R_\
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M]N?\ZWL#_P!%-VI_]9O?NO=>_P!)>W/^=;V!_P"BF[4_^LWOW7NO?Z2]N?\
M.M[ _P#13=J?_6;W[KW7O])>W/\ G6]@?^BF[4_^LWOW7NO?Z2]N?\ZWL#_T
M4W:G_P!9O?NO=>_TE[<_YUO8'_HINU/_ *S>_=>Z]_I+VY_SK>P/_13=J?\
MUF]^Z]U[_27MS_G6]@?^BF[4_P#K-[]U[KW^DO;G_.M[ _\ 13=J?_6;W[KW
M2!R/9.W3VCLY_P"';^LNP>R5(/5/:(>[[BVH05C.'U$>DW(%AP"1<7]U[I??
MZ2]N?\ZWL#_T4W:G_P!9O?NO=>_TE[<_YUO8'_HINU/_ *S>_=>Z]_I+VY_S
MK>P/_13=J?\ UF]^Z]U[_27MS_G6]@?^BF[4_P#K-[]U[KW^DO;G_.M[ _\
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M\PHJ>H>HDD3W7NCE_P U]$C_ )5_\RF.-51$_E_?,=$1%"HB+\=-QJJJJ\
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M)NS^Z?7?S-W]L796*RN]=]/D<QD?X=A\=0XZ"?(UT\WA@C5I&T@^_=>Z-_\
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MR"1%GI*OKA)8G /JCE174W5E!!'OW7NLW_05I_X 9_[-%_\ HZ]^Z]T\9/\
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M(3[V_P#NC/?NO=>_X;-WA_SL?@!_Z0GWM_\ =&>_=>Z]_P -F[P_YV/P _\
M2$^]O_NC/?NO=>_X;-WA_P ['X ?^D)][?\ W1GOW7NO?\-F[P_YV/P _P#2
M$^]O_NC/?NO=>_X;-WA_SL?@!_Z0GWM_]T9[]U[KW_#9N\/^=C\ /_2$^]O_
M +HSW[KW7O\ ALW>'_.Q^ '_ *0GWM_]T9[]U[KW_#9N\/\ G8_ #_TA/O;_
M .Z,]^Z]U[_ALW>'_.Q^ '_I"?>W_P!T9[]U[H%*G^4'\BMO?(S!_*3H+YK]
M-_%3M+$=)[JZ"K&Z/^"M+7[:W+L#>&^L-V)EAG\#WCV=O1#7#(X'&^&KHWIR
MD4;1Z2)')]U[HA_S!WS_ #K^@NU&ZGZU_FC[#WCEANCI[!+E=\_"+HW;6.-+
MVECLU/-5&+ )D9?)1SXVG54M:1))&+(R*K^Z]T*]5\=/GA\@^E/Y9'R(^3/\
MQQNW=@[H^37\M[Y.5G1^.^(?3/6T*;HJ=][=[/P^'3L?:58N0\%%42FF9Q2@
M3)ZFC4V ]U[K:#]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0 5GQ7^.^1^06)^55=U
M'L^J^0N"V_)MG$=J34,K[CH,7)C*G!:X 9/MA6)CJZOQD62,!JXZ*JJJ*.=:
M6IGAD]U[H?\ W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW23W[L79_:.
MQMZ=9]A[=Q>[]@=B[3W%L7?.TLY3K687=&S]W8>;;^YMNY>D;B6EK:*HGIJB
M,\-&[+^??NO=)_I[ISK+H#KG;O4O3NS\7L/KO:G\7?![9Q!JY*:FJ=PYVJW1
MN'(U%7D))JFJK,CDZVLR.0K:J:2>IJIYJB>2261W/NO=:)__  N<_P"Z7?\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM
M/_A<Y_W2[_\ +V?_ )D?OW7NMSW^7M_V0+\'O_%0/C3_ .^8POOW7NC?^_=>
MZ][]U[KWOW7NJ@=T?]NGOYBO_F9__P""2[E]^Z]T3[^7A_S.=/\ QI_\N?\
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MU'W[KW02;(H=^/M#;;T&X-NT]$V'H6I8*C;]943Q0& >..:=*U [ <%@@O\
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MKWOW7NO>_=>Z][]U[KWOW7NJ=/YR%;%C>CZO(S#5#0?'3^8=6RKYJ2FO%2_
MW?<\@^XKY(8(^%/KGF2-?J[JH+#W7NB=?R ,G39+<_R8BIJK UPV[\=_Y?NQ
M*K(;6WSUYV7MC(Y/KK"=D["R^1VYOSJC+YW 92@J*K&S34=3C\I->)D$RP5
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M,KF=V;F^(^)W=F]R9K<_96YLU338Y::JI8*2&GHZ>998YFD,B2)X_=>ZVO\
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MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YO_\
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MYO+R[ S?\0H_X+657\+^SJ*SPU-XI?\ -^BS^Z]ULW?!#_LF;:__ (D#O_\
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MA_\ L8]^Z]U[_ACGY)_]Z[_Y0'_IPC^;#_\ 8Q[]U[KW_#'/R3_[UW_R@/\
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MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H.:C_F76W_\
MJ%V-_P"[*@]^Z]U%Z]_1!_VJZ[_WK<A[]U[H4/?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=?_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO= ;\F?D#LCXH_'KNGY+=E4FXLAL#HKK7=W:6[\?M&@H<INFOP.S<-+FLA
M0[=Q^3JJ*FFK9DB,5-'4UD$1D9?)-$FIU]U[JN;'_P V_?&6Q]#E,=_*"_F]
MUF/R5'39"@JX>E?BT8JJBK(5J*6HB)[C%U=&5EX^A]^Z]U,_X=?[%_[T]?S?
M_P#T2GQ9_P#MR>_=>Z]_PZ_V+_WIZ_F__P#HE/BS_P#;D]^Z]U[_ (=?[%_[
MT]?S?_\ T2GQ9_\ MR>_=>Z]_P .O]B_]Z>OYO\ _P"B4^+/_P!N3W[KW4W^
M3]MCM;&==?,W?_;'2/:GQ]K._P#^8G\F._\ 977/=&*P&$[%HNNNR*7;]3MF
MMW#C-KY+,4$,SF"HBD2FR50@>-PLC@!C[KW1I?YCO7V\^VOY>?SQZJZXV]7;
MM[#[-^&7RAZ^V'M3&>'^);FWGO/I#.;<VOM['_</''YZVNJ8*:+R.JZW&I@+
MGW[KW5?O2'\RGMKK7I;J'KG._P H+^;?5YO8'5^P-DYFJQ/3/QBGQ53E=J[4
MI,%D*C&3UG;T$ST[S0.T+RP1N4(+1HUU'NO="A_PZ_V+_P!Z>OYO_P#Z)3XL
M_P#VY/?NO=%&^2'\V2A[[R%'_+TJO@W_ #">A>YOE+@<72+MWN#K/H[ 97>'
MQNG[!QFUODR^P*C9G967D&7.SZG-T>.GE, I:B5*T.XI3&_NO=6X4GRES%!2
MTU#0_#+Y<45#14\-)1T=)L/J>FI:2EIHQ#3TU-3P[Q5(XXT4(B( %    'OW
M7NI'^S8;C_[P\^8'_H%=5_\ V9>_=>ZUTOY+'\VW#[4^$6R/C?UY\!OYA_R0
MW?\ ''*;RP?:VY.@NK^B-P;'P>;[-[&SO;6U\3'DM[=DX"M>9L-EZ226^.55
M?6JLX74?=>ZMN_X=?[%_[T]?S?\ _P!$I\6?_MR>_=>ZI9_X4+?S"=_=X?RB
M?EGU9DOY:O\ ,7Z%P>ZH^BCDNX>_NN.A]L]7[-EP?R?V/N&@3<E=LCL7<615
M<D]*V-I&@QTA^\GI8W412RSP>Z]UJ@=)_P ]#MA/BC\;/Y;^_>V>[?B5\)NH
M=H[BVYVUO#X6[0VIO3Y5=YTNX=Z9'>&4VXV[>Q=S;3HMNXRJ3(28\#&5)*1F
M0U\.9@D^R3W7NK2\1_--_P"$HF(^*E7\0E_EB?,'(;!R"PUV0[ RG5/Q\J^_
M*O=\%$:.'?P[O_TK+GX,FA:1XX:2JBQ\:R2TL="M#+)2M[KW57W:'\\3>^Q?
MCK\C?Y>OQ[[8^0GR>_E_]V=7UVP^NL=\[-I;*V_\E/CLE15)-B\'M+L;K'<V
MY:;-XF@2FI8UIL@L%*85\&/QV("M+-[KW6V[_P (J?\ MUEWY_XO_P!I_P#P
M.O57OW7NMOMT21&CD571U9'1U#(Z,-+*RMP01P0??NO=5Y=15& ^&O<F^OC;
MD\QC]L?&W/=9[T^3GQZGS=318K;G36WMD;@IJ/Y*]+TN1FD2"@VKMN?-[=W/
MM:GG*)14.7R>+HUAP^WZ."G]U[IPV?O3Y0?+6C7?/7>X8_B?\<<S)4MU_N+*
M]>4NZ?E!VUM=Z=/X/V=C]O\ 9$;;>V!B\@S2U.)Q6X=LY[*55%]K55T&$GFE
MQL7NO=%D^'7S)W]L;XQ?S/>ZOE7V;OSO3;7P)^5_S;V[#N:39W4N'[)R'0WQ
M@V/C]YT^&CPW6F(V=M^OS'VJ5[13/24GGGE5)9HH@IC]U[KGM[^;]NS=F P>
MZ=N?RB_YN^7V]N7#XS/X'+4G2OQ;:DRF&S-$F1Q>1I6;N,$QSP2)*A(!LPX]
M^Z]T\?\ #K_8O_>GK^;_ /\ HE/BS_\ ;D]^Z]U[_AU_L7_O3U_-_P#_ $2G
MQ9_^W)[]U[H+^[_YE/;7972W;W7."_E!?S;Z3-[_ .K]_P"R<-59;IGXQ08J
MFRNZMJ5>"Q]1DYZ/MZ>9*=)IT:9XH)'" E8W:RGW7NK OY<77V\^I?Y>?P.Z
MJ['V]7;2[#ZR^&7Q>Z^WYM3)^'^);9WGLSI#![<W1M[(?;O)'YZ*NIIZ:7QN
MRZT.EB+'W[KW1&/YX/8FT.H.N?Y?G;78>4FP/7W6?\U3X@[VWSN"+$9K.# ;
M6P5/N6IRN7FQ>W:>KK9DA3DI3TTCL2%568@'W7NEM_P_5_*>_P"\K/\ V!GR
M2_\ L.]^Z]U[_A^K^4]_WE9_[ SY)?\ V'>_=>Z]_P /U?RGO^\K/_8&?)+_
M .P[W[KW7O\ A^K^4]_WE9_[ SY)?_8=[]U[IXVW_/,_E7[LW3M+9>#^55'-
MN/?6[-M;&VK0UW4'?V%ARVZ]X9J#;NV<,F3S6U*>DBDK*VI@IXVGG1-3C4RB
MY'NO=6S>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NJ>OYP]13T?2\E75SPTM+2_'K^8345-34
M2I!3T]/!\$-]2S3SS2D*B(H+,S$  $DV]^Z]T2[_ (3Z;AP&Z<CWOF-LYS#[
MCQ#_ !-_EI8],K@LG19?&MD,'U_O[!YJA6NQ[R1&:CK::HHZJ(-JBGBDBD"R
M(RCW7NME;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'^2_P"9J;-_\1_V7_[T
M>T_?NO=/%)A*J#>F?W&\E.:'*[7VAA*>)7D-4E5@,MG*^LDF0H$$;)DX!$5<
MDE9-2J I;W7NL.Y,M78[,]?T=)(J09_=U;B<FK1QN9J&'8>;SL<:,X)0BIHJ
M=]2V-E*WTL0?=>Z5WOW7NO>_=>Z2/7^6KL_L/9.=R<BS9+-;1VWELA,D<<*2
MUV1PT-95R+#$ J!I'8A5  ^@%O?NO=:EWS+_ .WF/S<_UH?_ (7OM+W[KW6Q
M_P#!#_LF;:__ (D#O_\ ^"%W3[]U[HX'OW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU"?YJ_REW#
MM[YX=G;&Z9^)'S+^6N].G=R?$7<79&(^,/QXWYVMC]HXV78^?W=0+G-R;?II
M:*EJ*NFK:7[2GGE1Y292EQ3S%/=>Z'+8'\Q'9^)^.?\ *Y^,'8?Q8_F"]*;W
MP?;W\M_HW);M[S^$G>O4O4M/V1B<]MO81P;]E[TQM+C@:G)QM#1EG!F'J46!
MM[KW6T)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU@?\ A2S_ ,>?\3__ "[#_P!\7[]U
M[K9^]^Z]U[W[KW7O?NO=>]^Z]UJZ;N_F;?'>?X2_/WXQ;8V3\L>QNR]P;^_F
MP]98.LZN^&?R=[%Z]RV\NR?DAVG_ '8Q>/[+VEM>JPDH+Y:CAJI5K2E/(729
MD:-[>Z]T"G\I[Y@[7[#^476O5NZ^EOE'\>^S.V/FO\N>_=B;+^2'Q]WWU94Y
M[K9?A5@]ISY&@W)5PU."FJH:R@JEGH*?+23Q(J2.BI-"9/=>ZV]O?NO=>]^Z
M]U[W[KW50'\Y#_F77P'_ /&O_P#+!_\ @IL-[]U[HX'\PG_L@7YP_P#BH'R6
M_P#?,9KW[KW7OY>W_9 OP>_\5 ^-/_OF,+[]U[HW_OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[JH#^5!_S,7^<+_XU_[K_P#@6>F_?NO=6_\ OW7NBC?/KX[;
MB^7/PG^5/QAVCGL+M?=7?'179'5^V]P[C2NDV_B,[N[;,^)Q5;G!C(Y:D4B3
MR)]P\$,DBIJ9(Y& 1O=>Z)!MO"?SZ]L[=P&VZ27^4/44NW\+B\)33U'^SF?<
M34^*H8Z"&6?Q!5ULL8+:5 N38 >_=>Z>O^Q^?_@H'_V<_P!^Z]U[_L?G_P""
M@?\ V<_W[KW7O^Q^?_@H'_V<_P!^Z]T@/A'\I/YI?R\Z7RW:!V[\ =L5VVNZ
MN_>DLS0 _(G[2ISO0O<.9ZDR^7QB^:H<4E9/B'J*82R>0QL"ZQL3&ONO=&]_
M[&G?^"__ /V8OW[KW7O^QIW_ (+_ /\ V8OW[KW1$ZGY2?SB=V?,WMSX?=7[
M=_EI4N;Z8Z)Z7[LW)N??I^49Q66HNZ-U;KVUB<7A#MZ8S"6D.UYGJ5GIU6TJ
M%)'NRQ^Z]T-W_8_/_P % _\ LY_OW7NO?]C\_P#P4#_[.?[]U[KW_8_/_P %
M _\ LY_OW7NB/_-+XM;J^$W_  F [J^*6^-R;?W?N[H[X8R;*W%N3:B9&/;>
M6RM/NFGKJJHPHR\4%4:<-/HC>>&-V"ZC&E](]U[HP6V?YJ_=.\MM[>W?MGJO
MKO*[<W5@\3N3;^4AVS\H(8LEA,Y01Y/%5\455LQ)56:"6.15D16 -F4&X]^Z
M]T^?\.9_(7_GSG7_ /Z#OR9_^P_W[KW0#?"#YT?S?_YC?1$/RI^-6$_E@X'H
M_=G8G:^UNNZ?L]/EU'O3(;>ZZ["R&QZ'/9:/#K'$O\02A6LB5J>"54D42T\$
M@:)?=>Z-W_V/S_\ !0/_ +.?[]U[KW_8_/\ \% _^SG^_=>Z]_V/S_\ !0/_
M +.?[]U[KW_8_/\ \% _^SG^_=>Z]_V/S_\ !0/_ +.?[]U[HOORN^._\\SY
M;_&KO/XQ;TS?\I_;6TN^>L=V]6[CS^US\OUW%A\1O#$R8BNR&%.6AJ:85,22
M%HO/!(FH#4A''OW7NKVME82HVSLW:6VZN6&HJMO[9P.$J9Z?7]O-48K%14$T
ML'E"MH9HR5U*#8BX!]^Z]U5-W/\ ]OP_@A_XH!\\O_?L]0>_=>ZM_P#?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8YI!##+,06$4;R$#ZD(
MI8@?[;W[KW0(T=9OG.['PE)B]IXM('Q^WIJ+(5.YE;R1XR:GJXI)L>M*A7RB
M&Q03>G5]6MS[KW3IU_\ QK'9F?;V>QU-15M'MY:]9:2O%9#44^0W'6SJVG0O
MC*LS)IU-?3JXU6'NO="][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__
MT]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M_P"W1_\
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M_)#E[PQE;31;D[XVOUYUIFX(&AC6AWY4;MI\7VQAHZ=5X15Q6<2!2L9: QS
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M#[8V+,V.R78@KA/2XL9"EJ-,%1D<A0I)DJZ?*P5<.-BGAHX*1S/+,?=>Z&;
M_P LWY5_R_/DYT?O#^7UO'L?M7H#<F?$7R!ZY[,["Z^P]!B\*E;CJ/-5V8IY
MFPU'DY*^@>=\;5XO R5U!+1 .TB2HK^Z]T]?S!/D9\D?E/\ ,W;W\L3X>;]J
M>LJ>EQ%/F/D3VQ@ZFNI<IA\?58M,[F,0<OB7CGAQ^/Q=31BH@HZB&2OR%7'C
M)IH(TE$GNO=!#\E/Y)6+^,O2>_\ Y.?&;Y-?("A^0?4.U\[VIF\]G]R86DBW
MA3[7ISNG=YQ60VM1X[)XZKDBIZBMA-5D<@)ID2"4$R&=/=>Z,K2_/?=?9_\
M(^[*^2N]:Z"@[3?K'>?3.<S-+!'2#*;\RV>_T28K<^-IJ8(B5-7'D*3)RI#&
ML4-0TVB,01 >_=>Z'G^1YU9_HR_EV]45L\,,&3[3SN]^T\FL4>EG_C.>?;^"
MFFD_W8[XC%XY]5A8$)R$N?=>Z(3_ "Z*FD[[_G!_S"_E!7U"U.VNKZ7=&RL/
MEJB'PTU/$^Y*?8.ULL]0?3&IV_M2O55>S,CEC8HP]^Z]T2;X$?!3K7^;-W7\
MUN_^[=U=K[<VNW;39S:%5L#+[5PV0R>1[%S^;W'6X_)MNC#9A!%C<?%C8XX8
M8HM F502JZ1[KW2\VWU-M;^7K_-L^,/1/PI[V[#[#P>_LMM;"]\[*S&X<'N1
ML;09K-U>-W9@MX_W-I,;C*B2BP\3YN*GJ<>*G'-%%4EKF)A[KW0W?SCOY:?Q
MFZKZJ^0?S=K=_P#>N4[GWWV%B:[";=R.Y-@-L!]T[[WA!%4XI<91[8AR"X_'
MXK[UJ2-LH9M-/$LD\C%F;W7NG_\ EY?R2/CIOOHSXP?*'LS=O=\/9F;I-K=Q
M3[6Q>=V'0]?54*;C.Z-FT$N&R6VZO(M156,3'_>#^*ZYO)(\3P*Z+'[KW6SS
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>ZH;_FF_'GI;Y6?S!_Y/\ T1\B>O,#VST_NG)?
M/7,;BZ]W4M7/MS,93:GQ_P 5E]MU];24DL1>6BJ1Y:=]5U):W#,#[KW3'\ ?
MBK\=_AQ_-\^>_4'Q@ZFVKTMUG5_";X.[RJ=F;,AJZ7#3;HRW9W:]!D<W)#5R
MS,9Y8:6"-FU6TH  .;^Z]UL >_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z!?O\ [^ZU^,W661[9[7K\Y2;7HMP;'V?0T.U-I;GW]O'<^]>S-ZX_KCKS
M96S-C;*I*[+9?+9G.97'XV@H:"CED>68$A8U=U]U[I1=0=L[ [XZLZ[[JZJS
MZ[IZU[5V;M[?VQMPK093$ME]K[IQD>7P];-B,Y#35M'*T,J>:DK::*H@?5%-
M%'*C(/=>Z$;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15-@?-3X[]G
M?)'LKXG;.W=F,CW3U5C\[D=SXFHV+OC&;7K$V?'M=]_4>T^P\ECXL#F:K;C;
MWVA#GZ7&9&:6AFRU+#,JRB9(?=>Z-7[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[HO\ \D_DWU)\3NN8^S^Y,EN2CV_6;DP^SL)CMF;&WGV3O#<N[,^)
M9,5M_;>R]@T.1R=94/%3U-0_BIBD4$,LTSQQ1NX]U[H6-D;TVOV1LO:'8FR,
MQ3[AV7OW:^ WIM#/TB5$5+G-K[IQ,6<P&8IHZM(Y5CJ:2>*9%EC5P& 95-P/
M=>Z5'OW7N@_R7_,U-F_^(_[+_P#>CVG[]U[J=0Y*NE[!W/AY*AFQM#LW8F2I
M*4K&$AKLKF]QTN0J%<#43+'14JD%B!XQ8 EK^Z]T]9O;V W+2QT.X\'A]P4,
M50E7%1YO&465I8JJ.-X4J8Z>O21%D5)'0.!<!F%[$^_=>ZAX/9NT-L2SS[;V
MKMO;T]5&L-3-@\'C,3+41(VM(IY*"*,NH/(5B0#S[]U[IMK>M.N,G65.0R6P
M-DY"OK)I*BLKJW:N"JZRJJ)6U2SU-3/ SN['EF9B2?J??NO=+*&&*GBB@@BC
M@@@C2&&&%%CBABC4)'%%&@ 55  50+ <#W[KW6E-\D-G?S&_E'_,0^>G9'P@
M^'^S^X.I^OOD?D/CCV/N/?7?G7O6V7DW9M?XB]?;)W12[9P>>JH)ET4.03(4
MM7,DT+F>&-@'BG3W[KW6QE_*&[@F[Y^ ?4_:=7M"LV#DMP]@?)^AS6RZ_+X_
M<%1MK<&T_E;O?9VX<3_'<6JT];'%78^H$-5$BK+'I?0A;2/=>ZLK]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW6JE\I?F/\ +;^6O_,I^=/8_4'P4Q_S.VM\L*SX1XG"PXCY-X/I
M+<^U<SM#I7,;2I:6JP6=VIG8ZN&MJJ:L4U K(/#I@ND@G8P^Z]TK>Z^\?YB/
MSPV-_+@W7OWX"=0_'7H/='SI_EQ?)VD[5I/G+1]Q[CCVAB^W\%V;A<2>L*'K
M; 3FKR-%(L(U9-1!,0) 4U.ONO=;0'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K11_P"%
MLO<?9'6V _EP;<V)NG);5HMW9+Y>Y/.U&&F:AR=6^ P?7VW*2C_B,!$BTTE)
MN#)Q5, .B76A<'QK[]U[K;&V1\B?E%F=E[0S%9\)]^9"LRNU\!DJJOA[G^/=
M)%75-=B8JJ>LBI3G4,2RLY=8](T@VL+6]^Z]TJ/].WR9_P"\&^P/_1W_ !Z_
M^O\ []U[KW^G;Y,_]X-]@?\ H[_CU_\ 7_W[KW7O].WR9_[P;[ _]'?\>O\
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MGZM&K:TI#!!30>Z]UM&_RVO^RN_YTW_B_P#L;_X"CJ_W[KW7NY_^WX?P0_\
M% /GE_[]GJ#W[KW5O_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NHM=_P"K/^H6H_P"M1]^Z]TE^O/\ CQ=I_P#:AQO_ +C+[]U[J+#_ ,S.
MR'_AAX?_ -Z"N]^Z]TO/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_5
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;W\X?;&<WC_*J_
MF';<VW0-D\UD/A]WVU'0I/2T[SBAZ[KLC5!9:QXXP5AAD< N"UM*@L0#[KW5
M?75'\^G:4F^Z7XFX_P#EA_S9\OWQUAL? P[OV50=!?']?LH\1AH*2IJZ?,U_
M:L%%-&S))XQ'4&1O',- :"=8_=>Z3G\CWYP=7?S$?F;_ #>/E%T]M3LS9.R-
MT;D^$VU*?;7;V'VO@=^8W+]==.[@V1N"/+8S9V8SU BFMH9C 8LG(6CTEQ&Q
M*#W7NMDGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UH_\ _"W'OMMO_&3X8?&:CK_'-VGW
M9O?N7-4<#R+,^,Z7V6FT<7'7&,@?;S5.]9)4BDNKRTP<#5!=?=>ZV<?Y2G0D
MGQB_EF?!KI*KH8\9F]H_&OK"MW?CXD5(Z3?V\]O1;[["A6P&JV<R>0O(5#.?
M6P#,0/=>ZL/]^Z]U[W[KW587S#^./07<7S"^&>8^1/4VQNS]D9[8/R=Z*P=/
MO?$0Y>CINV-T1;/[HV'XHJL^)7_@.PM\I$=.LM+H4^H@^Z]TOO\ AJO^7'_W
MAAT!_P"@%B_^*>_=>Z+#\H?Y:WP!V;CNA\MMWX??'ZAK9_E=\<\-4F7K7;F1
MIJS$YOL:FQF7QM;C\G#-3SP5-/))#-%+$RLK$$>_=>Z./_+RP.#VM\3=A[<V
MSA<3MS;V#WEWOC,+@<%CJ/$8;$8VC^0&Z8:3'XO%X](X*>") $CBBC5%4 *
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MZ4D]-,TST@2T].M]51"LGNO=&;Z/_F2? /L#XB_RJ_CYLGYA_'K<_>%)N?\
MEN[,J>JL-VAM>LWS!NW"MMG Y7;<FWXJCSBM@K5-))3Z-8F_;MK('OW7NMEC
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]UH!_\+G/^Z7?_ )>S_P#,C]^Z]UO>=3?\RKZT
M_P#$?[-_]YRF]^Z]T('OW7NO>_=>Z][]U[KXW.U_C9%\P?YXOR<^,_V\=1DN
MXOD/_,<VGM7RHLL=+OV3:W9%?UYDVB<@-]GG8,=5!=2W,=@RGU#W7NDQ\@E[
M1^5/\O3=7S][JIY&S'6WR'_E_P#\N#JVK>&I<P[9Z&^$V_G[!IJFLK?W#65C
M8O:6:R27)-76SLUAX[^Z]U]:[^7M_P!D"_![_P 5 ^-/_OF,+[]U[HW_ +]U
M[KWOW7NJ@/YR'_,NO@/_ .-?_P"6#_\ !38;W[KW7OY_'_;FW^83_P"( R__
M +O:#W[KW5O_ +]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[JL+XD_'KXXU;_);K/>_0_3.X.S.K?ES\B<CNO([CZMZ^RF4RF ^0
MO95?\K.K<K25E5CC-44$>V=\XS#1U!+*M7CJVCUM+1S*GNO=&]_V4WXL?]XT
M?'__ -$UUU_];??NO=%S[ Z6Z<ZS^5'PFRW7'4W6?7^4K]Z=WX^NR6R-A[6V
MID*W'_Z <Y4_8U=9@:6GDDA\B))XG8KJ56M< ^_=>ZP?R_L#UJ_QS^!&YYLC
M1KW!2_R[.BL#C<2<UHR$W6M?L7:.0S>13;Q?]R&+*4V/C:M$?[;2+$6'E4'W
M7NK$_?NO=$6P/SFPN<[8H=GCIKLVBZAS_>6]?C+M+Y)39/K&?KC/=[=;5.=P
MV]=J2[<I,^^YJ.@BSFW<KM2BR\^&\<^<I9Z.2.GA-%5UONO='I]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7S1/@]_W&C[U_\ %O\ ^83_ / Y=E^_=>ZW^?B_V3MB
MDV=M+KC)YW;N,SJ[9BW%BL;6Y['TN;S";G[+W3AECHL-4.LTB))B@J21AM;N
MR6!3GW7NC32;FV_#N6BV=+F,>FZLA@\GN:BV^:F/^*U&W\-7TF+R>82C!U_;
MPU-?20-(0!KE51<WM[KW53FW/^W^G<G_ (R ^-7_ ,&?VQ[]U[JH#NO_ )GM
M\KO_ !Y^_E$?^\=TM[]U[K8]^;7PIZH^='3R]8=C56XMH[EVON+&=B=*]T=?
MY&3;_;'07<>V@\NSNV.K]STY$M'D\?*Y#QZO#50-+35"/#*P]^Z]T5#X'?-G
MM)^R\Y_+U^?QQ.U/GKU9B<AE]J[QHL/#M;K?YP](8JJDI<+\C>CX4EEIA7M3
M1HV\]JT\@FQ-<)VC@2D#QT?NO=6U5%13T=//5U<\-+2TL,M14U-1*D%/3T\"
M&6:>>:4A41%!9F8@  DFWOW7NM>_/9#<O\]+LNNV/M>MK-M_R=.E>R)<=V3O
M;%Y2:FR_\S#M#KO,F.MZRV16XB=3%TSA<G !G<RKEMQ5<(I,>5IX9JJ#W7NC
M!_SW<'A=L_R4_GCMO;>(Q>W]N[?^-D^#P& P>/I,3A<)A<3DL;08O$8C%T"1
MP4U+301QPT]/#&L<<:JB*%  ]U[IT_EM?]E=_P Z;_Q?_8W_ ,!1U?[]U[KW
M<_\ V_#^"'_B@'SR_P#?L]0>_=>ZM_\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF
M,CNJBQFX<-MR:EKY*K-)*\-3# KTD C#:1.Y8,;E"#H5M%U+Z5-_?NO=*?W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3?E<C%B,9D,K/'/-#CJ.HK98
MJ:/RU$D=/$962&,D L0+"Y _J0.??NO=8,#F(,_B:++TT-13PUL;ND-4J+,A
MCE:!PWB9E(U*2K*Q#+9@;'W[KW3O[]U[KWOW7NO>_=>Z][]U[J+7?\ JS_J%
MJ/\ K4??NO=!)LC=U31[0VW2KLS>=:M/AZ&(5=%0XF2DJ D  FIWEK48HWU4
ML@-OP/?NO=9$SV57>-5N$[&WK]E/MF@PR1"AQ/W0JJ7*5-=)(R?>Z/&4F4 A
M[W!NH%B?=>Z43=A45*0V9V[N_ 4Q_P"4[)8-IZ)?Q:6?#R5?C_Z>!?Z_0&WN
MO=*G$Y["YZ(SX;*T&3C0*9#1U,4[0ZKZ1/&AU(38V#@'W[KW3M[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW10/YA/_ &0+\X?_ !4#Y+?^^8S7OW7NJ?\ XX?]OYODY_X8"?\ 6W/^
M_=>ZK"_X1F_]U7?_ !8#J3_Y>/?NO=;OGOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KYM7
M_"C5YOG=_P *)OB%\&\=*U;A]ITOQ7Z W%C(ION8,9D>Z=_GLW?6>JJ>X\17
M;.X<3+4*#<P4J.+W ]^Z]U])&&&*GBB@@BC@@@C2&&&%%CBABC4)'%%&@ 55
M  50+ <#W[KW63W[KW7O?NO= WWWTQA^^^LLQUYD\[G-H5\N0V[NC9F_=K''
MKNSKGL38^X*;=_7_ &!M@Y:&II'K,1EJ*DK%IJVFFI*I$>DK8*BCGG@D]U[H
M$ND?E%D)=T4GQY^4E)MWJ7Y2T2U%/C*"G>MQ?6'R-P^.4 =G_&S-YYW_ (C3
M3QE9LSM%ZN?-[<G8TV02HH7QN9RONO=./S)_X]SH/_Q<#XO_ /OU*+W[KW7O
M@A_V3-M?_P 2!W__ /!"[I]^Z]U4%_,)_P"R^OG#_P".X7R6_P#?SYKW[KW7
M7\H__LLJN_\ &(/\G?\ ]P>Q??NO=7R=Z]%=1_)GJ/?G1'>^P\#V7U-V7@:G
M;F\]F;CIC48[*XZH*RQ2Q2Q,DU+5TLR15=!7TDL=325,<5332Q3Q1R+[KW5.
MO17>O;G\K3MS8?P=^<6_,]V7\3^R\]3;(^!/SVWO4BHR-'D:@,-N_$/Y>;B*
MI#2[MI84^WVAN^H\=-N*FC$4IBR,4T*^Z]T>GYZ?/3:OPPVKLW;VWMFYCOCY
M6=\9BJV/\5OBML>JIX]_=U;^CI_-43SU$VJ/";5PD;+7[KW77JM%BZ)6DD9Y
MW@@F]U[H-_@7\"]U=-[JWE\O_E_O+#]\?S#N^,/2X_M#M#'TM1'L'I?8,=1_
M$L+\9?C+A<EJDPFR<)(P\TUEK<Y6J^3R;O,\44'NO=")_-B_[=9?S+/_ !0#
MYD?_  .NX_?NO=5__P N;_MXYVQ_XR _E4?^[3LWW[KW1@/YV_\ V2)U7_XO
M_P#RX?\ X-?9/OW7NK?_ '[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3U_.'J*>CZ7DJZN>&E
MI:7X]?S":BIJ:B5(*>GIX/@AOJ6:>>:4A41%!9F8@  DFWOW7NB7?\)]-PX#
M=.1[WS&V<YA]QXA_B;_+2QZ97!9.BR^-;(8/K_?V#S5"M=CWDB,U'6TU11U4
M0;5%/%)%(%D1E'NO=;*WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/\E_S-39
MO_B/^R__ 'H]I^_=>Z$#W[KW7O?NO=>]^Z]U[W[KW7O?NO=:9/SE[,ZXVW_-
M3^:.T=Q;^V7@-U9"+;DN/VWF]SX3%9ROCW1\%-J;7VTU#BJ^>.>;^(9-3CZ(
M1HWFJ;01ZI2%/NO=;.WP0_[)FVO_ .) [_\ _@A=T^_=>Z.![]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NM5+OKYX=#_ ,M?^:#_ #&][_+#XS_(/LW9OR%C^#474V].J>B<'V]M
M\UFU>A\K@LQA*W(9+(TC4=9/54]2(*5$9Y12RN0%5"_NO=<ODY\OMD_-2D_E
MW4'1'\O/YJ]68K-_S(?Y<G=.,[L[1^*>W^K>J9>L<'WWA-Z5>:3L3'Y:J4Q5
MF,9:FB5$*U*V"$LRAO=>ZVJ_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6@'_PN<_[I=_^
M7L__ #(_?NO=;WG4W_,J^M/_ !'^S?\ WG*;W[KW0@>_=>Z][]U[KWOW7NOC
MX]'?('%?%+^?[WU\E,S)3I1]'?)/^8_V9##4C5'D<KM/9G9F5P.&5/[4E=71
MT]'$G]IY56XO?W[KW0;=J=G=I[$_E+]G?#3OF"JQ6^,E_,!^%O\ ,!V'#E)%
MEK]W;'^7?P;[#S>3W=23+97@:AAVA45"QC3#55TT+Z9DE4>Z]U]9C^7M_P!D
M"_![_P 5 ^-/_OF,+[]U[HW_ +]U[KWOW7NJ@/YR'_,NO@/_ .-?_P"6#_\
M!38;W[KW7OY_'_;FW^83_P"( R__ +O:#W[KW5O_ +]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HD7R#VAO_JKM'!?+[IG;VXM]
MUM!MW#=9_)/I?;2-D,WVWTCC,Q6Y;;6[NO\ #32*C[SV!7Y;*9;&TM.5?-8F
MLS&',=3D9,"]![KW1F>J^V>N>[MCX?LCJK=N+WILS.?=1T>7QAGB>FK\=5/C
M\S@LWBZ](:S&Y3'54<M%E,3D:>"LHJJ.6FJX(:B*2-?=>Z /O;_LIGX-_P#B
M0.[_ /X'K/\ OW7NB@? CZ_R[/\ QD!UI_O?7'OW7NK?_?NO=4T_&W^7S\:N
MX1O?Y ;[7Y!U/:*_-_Y][LH,KMKYG_,SK_;F W1COE)V#T=2[CVGUUU_O[%[
M;P]<-HT<& >JQ6)IY7I/(DC,9IC)[KW1U_\ 9'NF/^>U^7__ *<)^?7_ -LO
MW[KW7O\ 9'NF/^>U^7__ *<)^?7_ -LOW[KW7O\ 9'NF/^>U^7__ *<)^?7_
M -LOW[KW0>[5ZWQW1WS3Z?V7L?>O>.1VEV'\7OE3NC=>W.TOD?\ (+O7$5FX
MNN.U^F,3LS-8^A[PW-N),=4T5-N;.P>7&B!I4JW6<RA(O'[KW5@/OW7NOFB?
M![_N-'WK_P"+?_S"?_@<NR_?NO=;Y/QTPFXL[MB.@H,ALU,)5=:[;@R6*W7L
MFNW;%7.>V-_,=8AS..A\172/%) _(+:N0![KW0G8CXWQ8')9O+8:;K?$9',Y
M"&NAK<-U_O+!UFV(8\7#C)<+L:MPF\:>;!XVH:.>NJ\=BI(*>HK:ROK)HWJ*
MZJ>7W7NJ\.HMKY#:?\][NS'9+-R9Z>;^4A\;:Q*R2KWE6-'"?F'VC2)3^3>^
M<S]6+&$N1'6)$2Q80B1I9)?=>ZJT[K_YGM\KO_'G[^41_P"\=TM[]U[K;^]^
MZ]T1SYX_!G9'SBZSVYA:K=>X.G^\>G]V4W:?QB^2>PT@7L?H#N'$P&/%;KP7
MG*QY#%U:VH]Q;=K'^SRM$3#,$FCIJFG]U[K7=Z/^9??'\\/LVH_EA=P[UZOZ
M8V'\=9-T/_,#WST7V?.*O^8M@.N>R,KU8NS_ (CRX\T^0HNKMPU6-2N[!S5-
M4-50BHBP$+PQ32R57NO=;;>QMC;-ZRV;M;KOKO:V!V1L39&!Q>U]G[/VOBZ/
M";=VUMW"4:4&)PN%Q- B0T]-3PHD<44:!54  >_=>ZJJ_G\?]N;?YA/_ (@#
M+_\ N]H/?NO=>_EM?]E=_P Z;_Q?_8W_ ,!1U?[]U[KW<_\ V_#^"'_B@'SR
M_P#?L]0>_=>ZM_\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT54E6*@LM]+$ E=7Z
MM)_%_P ^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW70
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M='_4["__ %#[]U[KW]W*O_GK-T?]3L+_ /4/OW7NO?W<J_\ GK-T?]3L+_\
M4/OW7NO?W<J_^>LW1_U.PO\ ]0^_=>Z]_=RK_P">LW1_U.PO_P!0^_=>ZR[4
MJ*JJP<$E94RUE0E9EZ9JF81":5*+,5%' TOA5%U:(U!(47^OOW7NE'[]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[HH'\PG_L@7YP_^*@?);_WS&:]^Z]U3_\ '#_M_-\G/_# 3_K;G_?NO=5A
M?\(S?^ZKO_BP'4G_ ,O'OW7NMWSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\V#^4KXOY
MA?\ PJZ^0OR;;QYW9O4W8'RN[SPDKZ:BEJME;.U_'+IBLFD'D7R4T>;V_70^
M.0 30*48HNEO=>Z^D_[]U[KWOW7NO>_=>Z][]U[JL[?^[\W\_<5N;K/I3K/H
MG>?QGI<M6X'='R(^3G6\?=?3_8F?P=?)B,_A.@>CXLABCNZ"@=:RBJ-ZY',4
M&&AJPJXI-R)'7)2^Z]T6O=/\OW&?&2M^/N]*/Y2_+WLWQ?+;XY4M/UGV!W"9
MN@,%3Y7L;'TCX_9W2>#H:3%8RDI70SX^,&6:&1G9JB4LQ/NO=6"_!#_LF;:_
M_B0._P#_ ."%W3[]U[JH+^83_P!E]?.'_P =PODM_P"_GS7OW7NNOY1__995
M=_XQ!_D[_P#N#V+[]U[K8^]^Z]U55_-I[_\ CSLGX\U7QH[6Z1A^8?:?S#AR
M?4G1'PCQ1@DW;W_NV2!:MZQZTD-MO ;;80YK.;ZE>&/ QPI6Q3K7+2))[KW5
M/W\O'K'L3^4-\I=K8[^:QDJ/MWL7Y8[#ZJZ2^.7\R3)[OWEOG9G5U5MW;-/3
MQ_R\=T9KL*267:,8R,-17[:W#>"'>$EY<@_\3A^W@]U[K;6]^Z]T0#^;%_VZ
MR_F6?^* ?,C_ .!UW'[]U[JO_P#ES?\ ;QSMC_QD!_*H_P#=IV;[]U[HP'\[
M?_LD3JO_ ,7_ /Y</_P:^R??NO=6_P#OW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JGK^</"*G
MI>2G:2:(3_'K^83"9:>5X*B(2_!#?2&2">.S(ZWNK*;@V(]^Z]T5+^1-EMP[
MC[ ^4.Z]W[HW)O7=V]?CC_+NWWNS=F[LM49S<.?W1OK:?8>[MPY'(9*I]3:Z
MRMF\48 2*+1%&%1% ]U[K8R]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!_DO^
M9J;-_P#$?]E_^]'M/W[KW0@>_=>Z][]U[KWOW7NO>_=>Z][]U[K2]^9_7BI_
M-Q_F =AXO>W8>W*[>6QNNNN]X8';6Z9<)M?=>U>M?B!MGM;;>-W%CJ&)9:N/
M^+S:ZF&:H,,L:+&8P"Y?W7NMH+X(?]DS;7_\2!W_ /\ P0NZ??NO=' ]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW6M__,0_[+*/_B0/B-_[@[I]^Z]T<'K_ /[=Q_RHO]?^63_[
MJ]L>_=>ZM_\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=%.^7OSF^*'P)V'MSLWY==S8'I78^[MW0[$VW
MG<YBMT9I,MNNHPU9N"/$TU!M&@R-4#]G054S3/ (ET!6D#O&K^Z]U7E_T$A?
MR2O^\]^O_P#T7W=__P!B_OW7NM.+_A6E_,A^$O\ ,&_V0'_9.>_-O]X?Z(_]
MFI_TB_P+;^^,%_=C^_O^C?\ NC]U_?/%XWR_>_P7*:/MO)I\#>31J35[KW6\
M9\4?YK7P+[SZ3VCN'ISN[(=F8+;&+P>Q=P9?9?3G>^?QV)WA@MJX^JR^W:VK
MQ^V'1*J"*JII7CO?1+&XNKJ3[KW1C_\ 9[_C-_SU'8'_ *(#Y"__ &+>_=>Z
M#+MS^:O\#^A-F578G='=.6ZRV-1UU!C*G=.\>EN^\-AXLCE)OM\=1&KJMK@&
M69[A$6Y-B;6!(]U[HIW_ $$A?R2O^\]^O_\ T7W=_P#]B_OW7NOE3=S0;4^4
M/\R3MFDV5OK X_8GR,^;N_J+:W969R$.V=KTFSNX>]JNFPV]<QD]RFCCH,<M
M#D8ZZIFR)A2&#4U1XU5[>Z]UL$?\*V-D?%1^\_AGV]\3.X.E.Q]I5GQTC^/&
MX]O=/=J[$["&TT^/61C'7==N*CVG75<T#56%W",;2SU "O'C-"V9&U>Z]UNV
M_P MC^9I_+PW%\%_BGAJ/YM?&#'9OKKX\=%];[VP6Z>Z=A[)SVW=Z[3ZBPE#
MN'!UV$WC6T%5JIIKPM,D+0LZNJ2,R.%]U[H\?_#A/P%_[SA^('_I2W3'_P!>
MO?NO=)'??\T+^7!UKM3+;VWA\Z_B=1;<P:T;9&JQO?/6VYJZ,5^0BQ=**?![
M8R-97U!:>>-2*>F<J"78!%9A[KW5,W\P/^:U_+J^74_\O[ISXU?+;JCN+L^M
M_FS_ ,M?<%+LO:&0RE1F9\-@OE#A)\OD4BJZ6%/'3HZM(==['@'W[KW5@_\
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MJJA,3CH?-,I*QP(BV -_=>ZNR_V3;;G_ #_SY@?^E0=J?_5OOW7NJ[/YD/\
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MU[KWOW7NO>_=>Z][]U[KWOW7NB@?S"?^R!?G#_XJ!\EO_?,9KW[KW50'6/\
MV^$[0_\ %P.B?_@&?F'[]U[JL'_A&;_W5=_\6 ZD_P#EX]^Z]UN^>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KY]?\ PMD[ER&Z^SOY?_P]VJ)*_.+A^Q>Y<M@*9T>KRF0W_N#'
M]7]7B&$N-+&;$;D@0NMF,EE8:6]^Z]UO2?&7I?%_'#XX=!?'O"O3RXGHSI?K
M#J+'STJR+3U5-USLJBVC'61^8!SYA2>4M)ZV+%GNQ/OW7NAP]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW6L#_PKR_[<V[T_P#%@.B?_=Y5>_=>Z #XU?\ <&WN/_Q0
M#Y8?^]SO+W[KW6R1V5U=G>\/@EO_ *6VO6XG&[E[?^)6ZNKMNY'/2UE/@L?G
M=_\ 3L^T\36YJ?'P5-0E)%45<<E2\%-+((PQ2-VLI]U[K67[?_EB_)-L3\?\
MG\POC7_(XS_8?4O0'6OQHV7V[V5\]OGUTYN3<^Q>F]NIAL=2)'MK9F$HY9!Y
MY*FI6&-V4U 1F,8B ]U[H'_^&ZL7_P ^&_D ?^G;?YCG_P!:??NO=!_UY\&\
MMVS\I]V_$OK/X(?R@-^[VV5\?]F?(K-;WV=_,>_F7;IZL3:N]^Q<YUIC=JQ;
MEP&.J:L;@IZO!3U=90RXU(4HZBDE6ID>5HH_=>Z.!_PQS\D_^]=_\H#_ -.$
M?S8?_L8]^Z]U[_ACGY)_]Z[_ .4!_P"G"/YL/_V,>_=>Z*-\N?Y<.>^+]%T%
M1=__ ,M_^4-5;7^27R*VI\;=MY*J^?O\S&?:&V=[[EV-N3LC%;C[&K-ZXC'T
M]%A(*7:M='+60"JJ$J9*94I61Y)8?=>ZMN_E5[G[8W+_ #1?FS#V^?B4N:VI
M\%O@ELG;5'\+NU]Z=R=-XS8NVM_=H46VL4V[]^8C#5XRM.GDCJJ0TK)'"*=A
M,[2.%]U[HY/\[?\ [)$ZK_\ %_\ ^7#_ /!K[)]^Z]U;_P"_=>ZU)?F=MOY(
M;M_GJX[ _$O?^T>L.^*SJW#ML_>N^:*ER&V<534W2U?5;FCKZ6MPFXHV-1BT
MK*:'5B9K2.A!B($J>Z]TA/YB'4O\R;K7:W4/:'\Q_L/8WRW^,VR^UL+5Y[KO
MIS<6+ZVB&9J:2>FQ_P#>*JQFQ=ORJ*R!JNAAKHZ2L>$2R0AZ4U"NWNO=#I_/
MFW]L[M3X2_!GLKKRE^PV+OO-4VZ]HXTT\%&^*V]G.L(<ABL3-14I:."2DA=:
M:6!"5C=&0<+[]U[K:A]^Z]UK1_SU_P#LJ7^5]_XE#<O_ +\38?OW7NKE_P"8
M7'@Y/@E\PEW"*1J ?&[N.2G%:0(?XY%L2MEVP4O_ +N&2%(:?_F[H]^Z]UJD
MTXWF?^$^]<:-JT8,?,]#E@-7@?9GV\(C5M (\/\ >$TQ]=AY1];Z0?=>ZV..
MAMQ]I;;_ )3_ $#N#X4;$V;V'VYC_CKTK_<39&Z*NAH=KYO=3QXJB[-3.UDN
M7P$(J(I&SE5.QRM-JJXS^MCX7]U[HAGQ-^<_S,J_YE6WOBY\I_C'\6.F>PNR
M-O;@SW8^X>MMJS3=FY2AQ'4\^X]IRUW8&&WCN"BJU>'"XNF:.I:=DIH(H0(C
M%$8_=>ZV,IIH:>&6HJ)8X(((WFGGF=8H888E+R2RR.0JJJ@EF)L!R??NO=:R
M&S/Y%7Q\[KQG>6ZJ'YW9WNK?61["W+5TVX.I9=@4.Q]F=HJ)\G/C.T<%C:W<
MTU;DZ6HKQ)/'!DL7410RL!$AE#>_=>Z-#_(6^2_:O>OQIW]L7MC/9#>&3Z'W
MU1;0VUN_+UL^3R]=M',X@Y#&X/)96I9Y:ML;-#4QT]1(Y84LE/ /3 I/NO=7
MI>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[JH#^;_\ \R>3_P 0!_,%_P#@$]\^_=>Z*!_(2_X^/OG_ ,5!_E??
M^^KWQ[]U[K8^]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3+E,W3XJNVW031322;FS4^
M$I'BT:*>HI]NU^Y&EJ-9!T&+'RQC2"=;+Q:Y'NO= [W+#+42Y2""*2>>?H/O
MJ&&&%&DEFED;;:1Q11H"69B0%4"Y/ ]^Z]T)V)Z_V'@*Z/)X+9.T<+DH5D2'
M(8G;>&QU=$DT9BF6.KHX4D4.I*L W()!X]^Z]UDS.Q=D;CK!D-P[.VKGJ]84
MIQ79G;V(RE8*>-BT< J:Z%WT*68JNJP)-AR??NO=>PVQ=D;<K#D-O;.VK@:]
MH7IS78;;V(Q=8:>1@TD!J:&%'T,54LNJQ(%QP/?NO=8<KUYL#.5\^5S>Q]GY
MC)U7B^YR.5VSA<A7U'@A6GA\]95P/(^B-$C74QLJA1P /?NO=1^L?NO]&W7O
MWWW'WW]Q]I_>?=^3[K[K^ T_W'W/F]?DUWUZ^;WOS[]U[K4X^9?_ &\Q^;G^
MM#_\+WVE[]U[K8_^"'_9,VU__$@=_P#_ ,$+NGW[KW1P/?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5:?
M+/X)?)+MCY;=9_,7XJ_,?:?Q:[)V/\<^P/C1G:'>WQ=HODCA=T['W]V9@.TJ
MJKI*>LWKM(8ZJAK]NT2:]-3KCU &.[!O=>ZJ/^5'<7\[?X]]JMU1M7^83\9.
MQ,H-R=1X$93<'P.H>O<>8NU*'+U K2F.WQN*0-0R8R./PZ;3+,S^2(Q!)?=>
MZ7>3Z+_F&_)'IW^6;\A/D]\_^KNQ^K-U?*+^7'\H:CI#9/P@Q'5F<I]PU&_-
MO]H;=V^O;L'8659H*&HF%-43#;Z_<H"PBIRP"^Z]UM >_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTPO^
M%M'_ &0+\4?_ !;^G_\ ?,;H]^Z]U?\ ?R4O^W1_\N7_ ,5 Z/\ _>)I??NO
M=6?^_=>ZI$^/&>[6Z"^;/\S;+5OQ5^3?8M#V_P!Q]2[BZUR6P]A8#&;7W?B,
M#U?'B<G5XCL/MG,[7VRZQ551' Q.: 5_)J*B&<Q^Z]T<+)]2_)?Y2)2T'R+R
M>%^/O0]2LDNX/CSTQO7-;C[/[2HY K4NWNYOD#CX<.N(PS*77-;5V31LU8X6
MGEW55XEZW'5_NO='=VSMC;>RMN8'9^S=O8/:6T=K8?&[>VQM;;.)H,#MS;F
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M#<5"R+)=]>H6EE\8]U[KZ0'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J@_\
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MZ]U[_2SU7_S\OK__ -#+;G_U3[]U[KW^EGJO_GY?7_\ Z&6W/_JGW[KW7O\
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M]^Z]TP[9QV=FQ1EI=Q?9T[Y7<!CIOX11U'B W!5 CS2,&:YN>?ZV]^Z]T_\
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MPX=T?Z+<_L#%Y"#8M1G1BQ+18?>>YZ6G=:5;-D:F;2)'!7W7NH/\@/X+4O\
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M_%B#$NBI+R*8H5J?=>Z%S&?,GO[J;H?^6%\:?D#_ "W_ )8]$T>V_D%_+?\
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MO_\ #7S_ /[J9O?NO=.&X<:^7PF4QL3^*>JHYDI9;V$56J^2DE/^"RA&(/U
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M]I?$C%;GVSN#!9JC2NQ^4P>X<'NJ>CK::6-PT5133/&XY5B/?NO=++_AW?\
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MLD-'E=X4SRI495J;%Q" /(]754E-&CS5$:'W7NC5?\.[_P#@L'^;]_Z17_\
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M+N?NG;]!!!_>2:K^WH<+MS<-)14\?EFED\=/3HNIV-KD^_=>ZO*_V1#XS?\
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M;^2<71.(Q>YMV_&W8'7F)VYDHIMC[I0PF6@6=\@U5&%$F@P^C6WNO=7@=-;
M_F#]Y_S)ND?E?\G_ (C]5?%CK?H[XM?(OIVGBV?\L\=\C\QO#<_<V^=C;BQ;
M"CH=F;3;'Q4L.V:K6S"=7UCU1D!9/=>ZNY]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW0<U'_,NMO_ /4+L;_W94'OW7NHO7OZ(/\
MM5UW_O6Y#W[KW0H>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__6W^/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]TE][_\>7N__P -?/\ _NIF]^Z]TJ/?NO=(NA==
MO;@J\3,?%B]PSR93"2-Q#%EY;R9K$!OHK2L/O85/+EYP/T6]^Z]TM/?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW2+SC#/Y.#:L-Y**$PY'=$B\QK1HPEH,)(P
M^CUC@/(H-_ CA@!*E_=>Z6GOW7NDOL[_ (L2?]K3<7_O157OW7NE1[]U[H/L
M;M[!Y?);JJ<GBZ.NJ$W') DM3"LKK"F'HW6-6;Z %F('^)]^Z]T\_P!RMI?\
M\]B__.5/?NO=>_N5M+_GGL7_ .<J>_=>Z]_<K:7_ #SV+_\ .5/?NO=>_N5M
M+_GGL7_YRI[]U[KW]RMI?\\]B_\ SE3W[KW7O[E;2_YY[%_^<J>_=>Z]_<K:
M7_//8O\ \Y4]^Z]U[^Y6TO\ GGL7_P"<J>_=>Z]_<K:7_//8O_SE3W[KW7O[
ME;2_YY[%_P#G*GOW7NFVGP^+PV\L.F*H:>@2JVSNEJE:6,1+.U/E<,(&D5>"
M4$CA2?IJ/]3[]U[I=>_=>Z2^/_X^W<O_ &J]L_\ 0]?[]U[I4>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*!_,)_[(%^</\ XJ!\EO\ WS&:
M]^Z]U3_\</\ M_-\G/\ PP$_ZVY_W[KW587_  C-_P"ZKO\ XL!U)_\ +Q[]
MU[K=\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1#/G[\1-Q_+
MC9'4%#M+)],-N+I/N>G[EQ6Q?DIU)5]Y?'CLVI'5VZ.JVVSVOUMCLO@YZN&C
MBW1)GL-51US?9Y>@H*OP2M"I3W7NAF^(OQ]3XJ?&GIOX[IO3)=A#J?9M'M<[
MMR./&%3)/%42ULE/@]NBIK?X5AJ-IC0X'#??57\/QL-+1&JJ?!YY/=>Z,;[]
MU[KWOW7NO>_=>ZT\/^%HG?S[ _EV=(="XZN6FRWR$^2.*K\M2L23D=@=.[3K
MMQ9J!$%K&//9#:\VLD@!2NDE@R^Z]U=%_(BZ!7XU?RB/@9UL]"V/R>1Z*P?;
M.?IYK&LCW#WQ7U/=F7@KW_49:>7/FETL3XUB6(66-0/=>ZMM]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW1"/Y@?P\SWS#Z]ZPP^V,]U7#G^G>W*'N'$=?_ "%ZNJ>[
M/C7VU74&R,YLF+9O>/5=#E<+/D\? ,VV7Q-1'D+X[+T=!D1353TJ1'W7NAN^
M)'0"?%;XS])?'./>N6[$3ISKW [%3>69HQC)\RF&I_$IH,*L]6,=CH ?ML3B
MQ5U'V5%'3TGW$_A\K^Z]T8GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=5 _*S_LI+N'_S M_\-AWS[]U[HG_P._[<]_&;_P 7 ^ '_P '-U-[
M]U[K8^]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=5<_/KXM?+'M?O7X4_)KX>[G^/&,[-^)F4
M^02U&V?DK3]DML3=&%[YZYH]A5<T-7U>KY!*J@6E:6.)M$;F0,T@$9CE]U[I
M#_\ 8_/_ ,% _P#LY_OW7NJ\=M_R,^_.SNY?DS\EOEW-\'MX=S_)+M+#;XR5
M%LS:_>>;V;M/"[;ZUPNP,5A<!5;ER&.JU$AQDU7.DL,A#RFT[KICB]U[H3?^
M&'-O?\\;\0/_ $7W:G_U_P#?NO=9H_Y%,%-B-W[>H*;XZX?;78,.Q*??NU\#
M3?(/ ;6WO3]8[VB['V%!N_;6%W9!0Y-,7FX8\A3+6T\@\BZ6#1W0^Z]UA_X8
M<V]_SQOQ _\ 1?=J?_7_ -^Z]U[_ (8<V]_SQOQ _P#1?=J?_7_W[KW6:J_D
M4P9.7'U&?IOCKNZKQ.U=G;'Q5?OFF^0>^\CC-G]?;=@VELO;./R.\=V5T\-%
MCL=30TM-3QR! JZB"[,Q]U[K#_PPYM[_ )XWX@?^B^[4_P#K_P"_=>Z0'67\
MG'YE?#'YEQ_,;X*5'P PNY-P_&S=/QRW]M+M/&_)'#[7R.*SG9>W^QZ#<F,Q
MVT*O(,*ZGDP$=+Y!/ C12OY(IG$3Q>Z]TKOE/_+2_F7?S$NQOC#6?-G+?RWX
MNJ?C;OG?/8]-M7J*A^460KMY;AW-U]5;.P]%GJ?=D](AI*&JFILD!#61EG@$
M<J31.\9]U[IQ_P"&'-O?\\;\0/\ T7W:G_U_]^Z]UY/Y#V'@J<=7T&WOBQA\
MGALQA=P8;,;?VOW5MW.8?.;=RT.=P>6Q.<P>Y:>KIJBEJZ>&>*6"96#*.;7!
M]U[K#!_(6V_"C*^U_BE72R35%345V8VEW/G,M75=74-55=;DLQF=R3U=5/+*
M[R2SU$SR.Q)9B3[]U[K-_P ,.;>_YXWX@?\ HONU/_K_ ._=>Z\/Y$- M-68
MZ+'_ !PIL%DLQMC<.5VI14/R H=E9C/[+Q.X,%M7.9K9%)NM,165E!2;IST-
M-4U5%)(HJB=6J* Q>Z]U[_AAS;W_ #QOQ _]%]VI_P#7_P!^Z]T!'R+_ .$[
M.?[%Z\HZ?J./X@;$[9V7O_K3L[K?=4NU.Z,/08_<W7>^J#=#4>8FQ67JV>CR
M-#!68RH1Z*H"K4>:.-9XH98_=>Z.A\D.DOYZGR7^/'?7QQW7EOY3.!VM\@.E
M^T>DMRYS;Q^80S^%P':VQZ[8F9RV#.2BGIQ64U/7R34WW$$D?D5=:.MU/NO=
M%OZS_P"$]NWNO^N]C;';;'Q(R$NTMIX#;]1D*K9G<.3J<A58K&14=7735^0S
MYGF::5'D+R6)U?0?0>Z]TM_^&'-O?\\;\0/_ $7W:G_U_P#?NO=>;^1#031X
MJ"OQ_P <,W1X##U.WMMXW<E#\@-SXG:N K-ZYOL6JP>T<1N'==338FCDS6X\
MS7M38Z*&,O4E=/CBA2/W7NO?\,.;>_YXWX@?^B^[4_\ K_[]U[K-1_R)Z+%Y
M/$YS!8OXR[7SV!R5/E\)N':&$[TV?N'$Y&F#+%58_/[8W125D1TNZ.J3!75F
M1PRD@^Z]TVX_^0;M3%8^AQE%LKXB1T>.HZ:@I$EV+VY5RI34<*T\"2U57N&2
M65@B@-)*[.QY9B23[]U[J9_PPYM[_GC?B!_Z+[M3_P"O_OW7NLGP>^"_\X'^
M7+T/#\5OC;FOY7^<Z1VGV-VUNGKN?LV7Y=S;SH-M]B]BY'>^-P67EQ&J)C01
M5R4B%IYY"L8\M342:IG]U[H'MK?R)N]^R^^/E/\ *GY=GX/;N[N^3O8VU=TY
M.#9>#[^W!LS;&V]E==8W9&"P6"BW3D,;+ 3+35M74$P2R2-,-=2\:0PT_NO=
M"[_PPYM[_GC?B!_Z+[M3_P"O_OW7NO'^1#0+0;AQ%)C_ (WXK"[OH]LX_>&!
MP5#\@-O[>WAC]F;ZQW9>UJ'=V PFZZ>CRD-#G<3C\E!%7P2JLL(%BC.K>Z]U
M[_AAS;W_ #QOQ _]%]VI_P#7_P!^Z]U[_AAS;W_/&_$#_P!%]VI_]?\ W[KW
M7F_D0T$Z8A,IC_C?N0[?V?LGK_ S;QH?D!O6JPFQ^M]LT^SMB[2Q%7NW==;+
M38_%XRE@HZ2EA=8T1+Z2Q9C[KW7O^&'-O?\ /&_$#_T7W:G_ -?_ '[KW2$V
M;_)I^7GQ,^66P_EY\&LC\$,#O#%=2=G]0;TV7VAB_D=A]CYC&;\S.W,S0[BH
M*':F0R3KD*;^!&G=HOM5>-U\WW)6/P>Z]T?S_L?G_P""@?\ V<_W[KW1B?Y9
M7Q:[&^&/PNZR^/G;FY=D[N[*V[N[OO?&\,[UQ#G8=CS9?N[Y$;K[SDQ^VDW,
MD5>::A3<B4*O51J[F$N0 P]^Z]T?7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:W_\ ,0_[+*/_
M (D#XC?^X.Z??NO='!Z__P"W<?\ *B_U_P"63_[J]L>_=>ZM_P#?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=:87_"VC_L@7XH_P#BW]/_ .^8W1[]U[J_[^2E_P!NC_Y<O_BH'1__ +Q-
M+[]U[JS_ -^Z]U[W[KW7O?NO=>]^Z]U[W[KW7S@_^$\G_<33_,$_\O[_ /@G
ML5[]U[KZ/GOW7NO>_=>Z][]U[KWOW7NJ@/YR'_,NO@/_ .-?_P"6#_\ !38;
MW[KW7OY_'_;FW^83_P"( R__ +O:#W[KW7QAO?NO=>]^Z]U]?K_A,5_VYM^,
M/_DW_P#N\;W[KW5Y78O8NQNH]B;L[-[,W3A]E; V-@Z_<F[-U9^J6CQ.$PN-
MA,]765<S7)L!ICC16DD<K'&KR,JGW7NBP?%+:.^-U[A[+^6W;>W\IL[?7R H
M]G8?K_K3/1B+/=-?'+8<5;6]8;'W32BZP;FRE=F,WNO=<4?-+59*'"/)5)@X
M*N;W7NCI^_=>ZT0_^%Q?_,J_Y=O_ (D#Y'?^\YL_W[KW6S[_ "4O^W1_\N7_
M ,5 Z/\ _>)I??NO=#_T3_V4S\Y/_$@=(?\ P/6 ]^Z]T%7RP^ D_P G/DQ\
M1OD92]Z;NZW?XO[NHMPUFR<;BZS+X[>-!C]^83L$T^W*ZFR^-BP.1R;X-=N9
M_)55#EDK=MU^3Q24E+-5)7P>Z]U2O_PLD_[='[<_\6_Z:_\ >)W?[]U[K5!_
MEO\ _";[_AP7^7%O'^8%_LY?^B/^Z7^FW_C$G^R\?W]_B'^AS%29/_C_ '^_
M.%\7\1T:/^+*_P!O>_[]K>_=>Z#O^2+_ ,)_8OYR'6'=G8S_ "[C^-\O3_8&
M V+#@&Z(7MV3=/\ &]MMN&3*1UYWIM<TO@"^(P"GGU ZS(OZ??NO=7A_] ,?
M_@T3_P!DF_\ TN>_=>Z(A\T?^$?GR/Z#SO06T/C9\G]G_)O=_>6Z-\[5CQ^]
M^M*?XX8? 9+9VR)NP::BI=P56[=VID*ROQE!FJN.D,5-IBQ\[AY#Z1[KW1;_
M /H$._G)?\\5T!_Z/;!?_4OOW7NC+?&#_A&1\^NR-Y9C&?*7N+J;XP[&H<"]
M9BMW;0@@^1.=SFX361Q08./9N.RVV(Z>#PF6::NFRHTE41()2[-'[KW1G^Y?
M^$:C_&+J3L[Y)K_,<7>Z?'S8.[>[JC9K?#PX)MTT75."GWU7X"',#L[)"GEJ
MX*"2"&1J"=0[+JC*W]^Z]UNC?[*CWM_S_+X__P#I$NSO_LJ]^Z]U[_94>]O^
M?Y?'_P#](EV=_P#95[]U[KYN'_"H#H[=6S/GMV/V!O#?>T]SY7%93K/IB.BV
M;U31=78B6BQ_0FW>UHL\V-Q^6R$2S,^XY*%XU0:A LQD)<QK[KW2%^%'QL^1
M'PE[0_DR_,C)83I&JZ_[7^9O4=1U3N:CZR^1&'[![!HN_?X)B-[;?WKN_>.U
M<!@:NBV53T$U'C(Z7,LKY#)5==A&W!AVJJVE]U[KZA/Q/_X^/YA_^+@;U_\
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M>Z]T0S^=ML1LQ_*N_F?[]["RG][-^;3ZDS&SL#5XK)[OQ6Q,%MIJ3:^X8J7
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M1,B!']U[H"?^@B[8'_>'78'_ *6?_+!_^W7[]U[KW_01=L#_ +PZ[ _]+/\
MY8/_ -NOW[KW0\?$[^>3U3\I/E)U9\4V^/G9'6F\>X\/V/E-F;CJ.Y_B'W#M
MH2=8;5;>.?H]PQ_'OL+=5?C?)1(XI)JNC1)I;1H3:1H_=>Z$C^;O_P!TP?\
MQK]\*_\ Y9??NO=6_>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4OH]W_ "X^
M&'\T3YI?(79?P$^1OR+VKV=D-X[.P,^U]D]F8';U7CLINO$;E@W/B-W8K:>X
M*:NA/\,,*)#&%;R:Q-Z-+>Z]TV?+0_/C^;_O;HKJ:H^!/9/Q1V1L;<F0R6?W
MUVMCMV"EQL.Y33T&7SK[FWGM_:R-34=%3&3^#X^FJ*FIF">HGQ*ONO=&1_G"
M]>=]8OY>? ;NCIKX\]T?(;%_'N3 ;TRU%L#9F]=TKD*K879V,W72[>SNZ=L8
MK*)05.1CHBGW$U-(RZC,(9 ND^Z]T*/_  [_ /-__O2Y\J__ #K[=_\ M5>_
M=>Z G^9E@_D?U[_-:^/GRGZD^*7=WR+VQU1T_LV6HI>NMC;[R&"RF8@W%NZG
MJMO3;UVSA,U3T=3%%7P5$D;4TKJC1DQ@2*WOW7NDW\H.X/YE7\TG9N+^+&UO
MY?W8GQ8V)N+=&V\MV)O7M^?>-#C)J#!US9.@6?/[QV[MB%*&FJ(HJZHI:&BK
MJR66G@6$ OXY?=>ZL/\ E_\ RJ\+W-_+]ZK^*76F<HZ'?GQTQ&WZWJS=&?$M
M+0;DW'B<+)C-UT>Y&A$[4L&XFJ*BJD:%66GJOMV ,$31M[KW10.NOY@O\UCX
M^[!PW2/;'\LKMCNCL?9V(I=K8OM;:4&\:K;65@Q6K#8O([EJ-A8#<.(R$]H5
M-3546<I$F4"?3&LHD/NO="=_*K^(OS$VU\I_D/\ .'Y:;2VMUCG>^MLYW%1]
M?8VMADS*97<F\L5NJHR:8>AJLBF-Q]/'C!304]=D9*UBP,J#3Y)/=>ZN6^1/
M8V[.H^CNT>R-A; S_:F^=H[/RV3V;UWMC"YG<.9W;NGQ?;;?Q$.(V]'-72PO
M5R1&K--$TB4XED ]/OW7NM1#XK;X^6_2_>>^?E/W_P#RL/EQ\L?DGNO/297!
M=D;MVQVSM+&;!II*983'M;9[=?YF&*L0 P4U:*A124BQ4M#!2HLS5'NO=77[
MU^$O7W\WKK3I?Y _*SK[Y&_$_L/ 8K>^UXNG,;N+"8K,X/'1;VJ:6"LW&O8^
MR(ZZ22MBI(:ZF84%,HAF4 2C3*WNO=4[[V_DK87"_P QKK3XZ[<VK\J\M\1]
MR[77*;Q[U_@=)7_P#-'9V:S!QW^DZ@VJFV:7_<A18ZE\-50M)^_X[^26)E]U
M[K<6VY@Z3;&WL#MJ@DJ9J#;V%Q>#HI:QXI*N6DQ-#'04TE5)"D:-(R1J7*1J
MI:]E X'NO=//OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM;_^8A_V64?_ !('Q&_]P=T^_=>Z
M.#U__P!NX_Y47^O_ "R?_=7MCW[KW5O_ +]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z^:'_/H_P"XHSXJ?^) _EY_^_*QWOW7NOI>>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NB@?);_F<_\ +V_\6_WK_P# "]X>_=>ZZ^ 7_9&OQZ_\1_1_
M^YU1[]U[HX'OW7NB'?'S*TWR*^0_:?RNQTTV1ZIV7ME_C)\9\RRU\.+W9A8L
MY3;Q^2';^U#4I"*G$;DW+0[>VQ0U>B2&JCV:N3Q\\V/R<$\WNO='Q]^Z]T0#
M/9:3XD_)[<&],ZDD?QP^9>[-C0;EW2(E:DZ;^6U-MS&=1[6K=UU(/^3;;[%P
M>)VUM^CJF5(:#<F-IX9GEEW5$:7W7NC_ /OW7NJ@?BG_ -E)=/?^9Z?_ (;#
ML;W[KW5OWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_,NO@/\ ^-?_ .6#_P#!38;W
M[KW7OY_'_;FW^83_ .( R_\ [O:#W[KW6JA_PB>V+@NQ-O\ \TS;N?6J2%V^
M%,]%7X^9(,CBJYJ7N&A%;1M,DL,@:&>:GJ:2K@FI*RFEFHZZGJ:*HJ*>7W7N
MMVC.?'3;FS]M;YWYF]T;V["W1MWJ7>>W]H5&]MS9G/X[9]#)M2KH<CD]OX[,
M5%5X<KDJ=O'E,CY27#20TL=%1R&D'NO='&]^Z]U[W[KW4')9/&X:AJ,GF,A0
MXK&TBJ]5D,E5T]#0TR/((D:HJZIDC0%F50687) ^I]^Z]T&._P#O_H?JCK>K
M[C[2[LZCZUZBQ]9!CJ_M3?\ V1LW9W6]#D*G,_W<IJ&KWQN*MIL9%-)D?\@2
M)ZH,U1^P 9?3[]U[JGOY5_SMOBWM3N#X@]2_&SY[_P MZ?"]];^[7V_W)W9O
M7NOKOM_8_0>V-A=*YCLC:V<W+A]A=B;4BI1N#-8ZDVU1U&5W!2Q&HK(UA$\^
MB"3W7NHM1\H/Y</<&9I,K\ROYS_P([ZVYB<AA\GA^A.O/DC\?^AOB_-D<'/#
M7T.8WYUI_I"W1G]Y3?=PK4OB]X[RR> 5T@EAP<-3"*AO=>Z.[D_YIW\J#-XW
M(8;,_P QO^7EE\/EZ&KQF6Q.3^7OQMK\;D\;7T[4E=C\A0U>X7BF@FB=XY8I
M$9'1BK @D>_=>Z+G+\L/Y,/^Y''T/\SWXC8C9N<RU5GMQ==XK^8;T[3;-S^;
MK)DJI\G60ONIZ^!S/%!/HH*^GCUQJ=%C(']U[JO+^<?\U/Y?.:_E<_/?KSX\
M_P Q#X2;ZK^R^H,@^/Z7VM\A.C^Q]^;DW<TV(Q\QV"=J;H7+U==D4HWK<I]_
M2Y:IJJII:KR1EI1)[KW03_\ ";[_ +AQNX__ "]O_P!Y:H]^Z]T2#_A'#O'>
MW77Q)^;&^\5C=MYOKS;'>^RLKVI05CYFCW?B]HT/6DE9E-V[-FQZ5<-?-C*=
M):F;"2TD<M9&K+352U CIY_=>ZW/ZCY2X%*?+Y2@ZF[ZS6VL2TQ.Z\5UK-)A
M*^FID1ZVLH4JZJ&L"4VJ1*I)Z2*6&2&>&6-)HF3W[KW1&/Y@O6WP_P#E#M7X
MM?(KN_K+K;Y!_'?HGN;*Q]PKV3LFFW+A]@]2]Q=:5NU*W?N6VKNNGCJ,=!B-
MR3[!W%E\G40QBBVY'7960&A!G'NO="-_PRE_*/\ ^]<OQ _]$?LG_P"I??NO
M=& ^//\ +]^$/Q+W/E]Z?&;XI=$=%;NS^'_N_F=S=8];[:VGG,C@_NDK6Q-3
MD\5!',U.TT:2-%KTLRJ2#I%O=>Z-_P"_=>Z][]U[KWOW7NHL-#14]15UE/1T
ML%7D&A>OJH:>**HK7IH13T[5<Z -*8XP$0N3I4 "PX]^Z]U*]^Z]T'^-_P"9
MJ;R_\1_UI_[T>[/?NO=4@_\ "H[_ +<4?.;_ ,MF_P#@P^OO?NO=?)%ZT_X^
M/)?^(_[9_P#?5YGW[KW7WN/?NO= 1\BN]L5\?NO4W0^ R&^=[[HW!BNO>GNJ
ML%54U)N;MWMO="3?W1Z^V_458:*G\P@J*[*Y2H7[7$XJER&8KVCQ^/JIH_=>
MZ@?%GIG+=%=*;7V9N[,XW=79^4JL_P!@]U;UQ---28_>_=G96=J-\=J;GQD%
M6!/%CILS7546%I)R6H\9'1T*VBIHU7W7NC#>_=>Z][]U[KWOW7NJ@/Y;7_97
M?\Z;_P 7_P!C?_ 4=7^_=>Z]W/\ ]OP_@A_XH!\\O_?L]0>_=>ZM_P#?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1:[_@%6?]0M1_UJ/OW7
MNDOUY_QXNT_^U#C?_<9??NO=18?^9G9#_P ,/#_^]!7>_=>Z7GOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[H/I>R,-&*V1,3NNJI<?/6T]37T>VLE4X]7QTK0
MUCBMB4QZ49&U-?BQO;W[KW2XHJN&OHZ2NIRS4];305<!92C&&IB$T193]#I8
M7'OW7NI/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T1OX>=I[U[*^.WQRWOVGV?+5[K
M[%^+WQ^[2W#EY\?L/;S97=N_NO:3.[JJH:&BQL%+'&]5*9!#30(D>O2JJNE1
M[KW1J/XEB/\ GYO_ *O[(_\ J'W[KW2;W'F"#@:+"=BSU-7EMQXS%S)33[1J
MJF.BJBXJ)X8J2C#74A?4;J+V(Y]^Z]U[(-D]M;EVY09'L'*+C<U1Y]JBHR:[
M9IA%/C%I7I4@EGH_&"_F:X()('%N??NO=*3^)8C_ )^;_P"K^R/_ *A]^Z]T
MD-^5^,DVIDXX=^C*RNV/"8\UFTY/NC_%(3HT8^ECF-AZO0X/'/%Q[]U[I0]@
M2PP9#8DM1DAB(5W/,&R)DHHA3%L%5HI\F022$%B0@UH;WL.;>_=>ZG?Q+$?\
M_-_]7]D?_4/OW7NH>0S&-IJ"NJ(.RP\]/25,T*&MV2X>6*%GC4JM$";D 6!O
M[]U[I(5C[FQ^Q,7O)]]YO[BIH]JUU3!/3;?6@C&:K*2*L!+4EPD:SN5U,1P-
M5Q>_NO=+O^)8C_GYO_J_L?\ ^HO?NO=>_B6(_P"?F_\ J_L?_P"HO?NO=(2D
M;<V0V)E=Y)OO-^>GH]U5U-!!3X!J&086LJXJ.Q6DN4D6!"Q5A]3IL+6]U[I7
MX_,XVIH**IG[+"33TE--,BUVR5"2RPAY$"M1$BS$BQ-Q^??NO=3/XEB/^?F_
M^K^R/_J'W[KW4'K^6&?(;[EI\D,O"VYX0N1$E%**DK@J1&/DQZ1PDJ04.A!:
MUCS?W[KW2=V%7XR/:N,CEWZ,5+&^063'"MVG']JW\3F.@I7TLDPN"&M(Y//'
M%O?NO=+#^)8C_GYO_J_LC_ZA]^Z]TG,>V4W+N7<6/QW8&4;&X6CP#T]1C%VS
M4B6?*+5/4K/-!1Z"4\*:0 " >;\>_=>ZZV_EG6?<F.SG8E135.&W%4XZE6KF
MVE25,U E#3U$51+'5T98WDDE4,ME.FP%P??NO=*3^)8C_GYO_J_LC_ZA]^Z]
MTFZFLJ\MNK$X'"]AUTU--A\MD:V;'-M6KGBEI:BGAI4<TE&%56$DA]:W)'!X
M/OW7NO8S(5%!N'<V"S?8E93IC/X-)0/7R;4I*FH2NHC451(JZ,Z@C:0-  %^
M>3[]U[I2?Q+$?\_-_P#5_9'_ -0^_=>Z3.>K*"?+;%BIMXC<$O\ ?2B?['[K
M;DQCC7$UJM5A,13PR^DLJ$LQ7U\BY4CW7NI^?J*6F[%Q35>>&WD?9>51*PS8
MJ#S2?QND<4@;,131FZAGLJZO1<&P8'W7NG?^)8C_ )^;_P"K^R/_ *A]^Z]T
MF]V9Y*+!S2X;L9ZG)R5F(I::".IV?4RR+6Y>"DJC%!34:R,RPO(XTGBVH\ ^
M_=>Z]EER^V,WM:&M[ RXQF9K,G25U1DDVU3Q4XIL3+5TICGFHQ&K/,J)ZP;W
ML.2/?NO=*3^)8C_GYO\ ZO[(_P#J'W[KW3;F<W04>(RE72=E"2KIL=6STL9K
M=E/Y*F*F9Z>/QI1!FU. -*FYO8<^_=>Z3E>=QXC:^"W/)OO-$UDNUVK8JJGV
M^M%#!F*J".M8L])Z5C25BK,2!:YO[]U[I:_Q+$?\_-_]7]D?_4/OW7NNCD\.
MH+-V<  "23D-C@ #DDDT7OW7ND)_S0'_ ,E?_P".??NO=+L9/#L R]G @@$$
M9#8Y!!Y!!%%[]U[KO^)8C_GYO_J_LC_ZA]^Z]TE<)'G=QT^Y,G!O[,BFQV<R
M^/Q[4$6W9:6HI*"-'IYO*E(58MJY9+ _4 >_=>ZF;7S]+DMNX6NR79'@R%5C
MJ:6MA^[V9$8:IHQYXC%/1EU*M<%7)(/UY]^Z]T_?Q+$?\_-_]7]D?_4/OW7N
MDWCVR>Y=R[BH,=V#E&QN%H\"U/48Q=LU*S3Y(535:3304?C)0PJ   1<@WX]
M^Z]U[;6:\L.7ILUV++35F*W'G<0J5$^T::H>EQV0>GI9IXJNC9]3J+D\ _@
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M139!MJTE1+-55%1#5(C55&0RJ(XS91P3S]1[]U[I1_Q+$?\ /S?_ %?V1_\
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M_P"^N9&1R6/V94Y%9X,$*(PU];3QR(^NEX2%:N8J2?\ @UQ[]U[H1/XEB/\
MGYO_ *O['_\ J+W[KW7OXEB/^?F_^K^Q_P#ZB]^Z]TD\,ROTKG7285"-A^Q&
M2<&-A.K9')%9@T0"G4.;J .>!;W[KW3WB,EB?X3B[]DB$_PZBO$*_98$1^V7
M]L"2B+>GZ>HD_P!3?W[KW3C_ !+$?\_-_P#5_9'_ -0^_=>Z3>#CS&Z,CN=J
M7L#,?P_%9B+'4,N.CVU/#/$,9!4R.TT5&49A)(ZG0 .+'D'W[KW7MH;B@RFV
ML/7Y;L?[;)5-&KUD!JMFP&&<,49&BJ*-G4@ 7#DG^OOW7NE)_$L1_P _-_\
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M2['\&0JL=2RUL'W>S8C#5-$//&T4]&SJ0UP5<D@_7GW[KW3]_$L1_P _-_\
M5_9'_P!0^_=>Z:]FST]1O/?4E+F1GHOL-GK_ ! 2XV;4Z+D%>'7BHXH?0>"
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MW2^R*-<-/3T=4LHW8C5 IZZ5(86--]A>]W6ZZO\ 8^_=>Z7_ -[N#_G0TO\
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M+&E^Y$^JPJQ'I*V_M?3W[KW2NAVYCJ>&*"*O[&6*"*.&-10PC2D:!$%A0@<
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M>W<%'M[?%,L.<PU3D*AMLY*C^WHZ.&1:F6&HJ8FC#K<:0RFY_!^GOW7NGO\
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M2R5/85++#04PGIXJ&/Q05#1!ZB**]&3I5RP6Y/'Y/OW7NG;^ T7_ #L.QO\
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M^_=>Z]_',+_SN,7_ .?"D_Z/]^Z]U[^.87_G<8O_ ,^%)_T?[]U[KW\<PO\
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M5TT-/1T5;2U=-DJ2M.8KY#3O%%44M+625%/0>Z]T6W_A-]_W#C=Q_P#E[?\
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MO?NO=>]^Z]U4!_.0_P"9=? ?_P :_P#\L'_X*;#>_=>ZM_\ ?NO=?&9_EO\
MP _G,?)'9>\^R?Y:^*[@I-I9C,1X?>N8ZQ^577OQYGW5E-GW9$R.,W-O7;%;
MF%Q1RY'G6GGCI6K@I>-JH"3W7NK(1_*&_P"%99K6H/M_F3YUI5K#(?YD76 H
MO$\IA"+DCVO]L9;J28!+Y MG*!2"?=>ZK8^7#_SM_@KV/MGJ7Y2_(/Y@];=@
M;Q60[:P5%\T<WV-'E98:N"@J*.',]6;TS= E3%-4P1S4LM4LT;2*'1;CW[KW
M1U8OY=?_  J,J,/3;AI)OG37X&NDI(L?F\=\YL;DL3DVR%>F,QS8O(T/8LD-
M2E3/)''320.ZRET\98,I/NO="'M_^4Q_PK W/AZ'.XF+YG?P[(I)+2')_P Q
M?KO 5KQQS-!Y),5GNU*:KC5BA:,RPJ'0K(FJ-U8^Z]U67WSL3^<EM+Y38G^7
MYW_VE\H:[Y)3[BV#EL5TQNCY:5&^L=3[CGI:?L38&XANFEW?D-KTTM'&E/F*
M?)295!0-&M0\L#Q%E]U[JT>G_E!_\*R:RG@JZ1OES54M5#%44U33_P S3J">
MGJ*>=!+#/!-%VX5='4AE920000;>_=>Z+C\@?Y47_"C/X]];=@]_=]8+Y#[<
MV+LO![BWSOS=D_SHZHWEFAB-LX&IW1NC,K@=J]D9+-922BQ=!69*K6BHJB9*
M2FGJ'40P2NGNO=)GXW?RP/\ A0)\O^KZ;NOXV4/?/:/5-?N;>>T<9O.G^:O7
M.SJ?(YK8&Z*K9VZ(8,%V-O\ PV61(,A1U$*R5&/C$@4/'J1E8^Z]T/#_ ,A_
M_A3W(K(_5O?KHZE'1_GYT RNK"S*RGM*Q!'!!]^Z]T'ORM_EA_\ "DKI_P".
MO;?9ORRC^38^..S=IU&8[=.[_GOUKV7MD;2CJHH:C^,[#Q'967J<I#Y7BO30
MXVH8FQ\9M<>Z]UM@_P#";[_N'&[C_P#+V_\ WEJCW[KW5>7_  CHRE>W0_S.
MVO@:#>53N#<.9W+14F2V?C_)5[86MV/M^DI]R?Q&JR.&B$M//H,%+2Y6.NED
MTFG4!9)HO=>ZW(=XYW+[XZJH>I]J_&')2YQ,+#B,%19[ Y/9W5^Q*JFQ#X6E
MW5LO<F4I,77PG$&9:C&)]OA<B\"N*>2CK D1]U[HUW6&ULELGK[:>U,O7QY+
M)83#T]'65%.Q>BBE!,G\/QC-% ?LZ0,*2CO#&?!'&#&A](]U[I>>_=>Z][]U
M[HJ7<GSI^''QZWLG6O=OR8Z:ZR["; T&Z6V/NS?6$QNZX-MY6JGHL5G:O /*
M:J"DJIJ6JCI9YHE25H91&6\;V]U[H+?^'5/Y<?\ WF?T!_Z'N+_XK[]U[HKG
MS=_F)? #M3X??)K8>T/EYT!EM^YOI#LA^LJ9-[4E354W;&(VO4YSJC,8N.B=
M9Q78_<=-BZ^@>G82I4PQ/$0ZJ1[KW5Q&V\]1;IV[@-SXU9EQVX\+B\]0+4"(
M5"T67H8\A2K.*=Y(PXCD74$D9;WLS#D^Z]T]>_=>Z#FFIZ>L[,WS25<$-52U
M77/7%/4TU1$D]/44\^?W;%-!/#*"KHZDJRL"""01;W[KW5$/_"FG96S=F_R)
M/G=#M#:6V=JQ5:_%M*N+;>!Q6#CJDH/E]U_!0K4)BXH@XA1F2(,#H4D+8'W[
MKW7SZ?\ A-[_ -OM?@1_XD#L'_WR&Z/?NO=?8Z]^Z]U[W[KW7O?NO=4F]?;?
M_ER56UJ:H[<^$/\ I([(ERFY6W;OC_AK+O7NS^\>2_O-6 5W^E3;/5V:H,U^
MUXX_NZ;*U*>GQZ[H57W7NEI_=?\ E/?]ZZO_ &C!\DO_ +37OW7NO?W7_E/?
M]ZZO_:,'R2_^TU[]U[K0@KA@1_PJE^-(VKAVV]M<?)WX!#;> ?;5?LM\'@1T
MCL 8?#ML[*4U%58DTU/XX3C*FC@EI=/@DAB="B^Z]U]5WW[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=% ^#W_,F-Z_^+?_
M ,PG_P"#Z[+]^Z]T;_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_
M_]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4#^7M_P!D"_![_P 5 ^-/_OF,
M+[]U[HW_ +]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J)
M74-)DZ2HH*^GCJJ.JC:&HIYEU1RQM]58>_=>ZB8;!8?;U*]%A<?3XZEDG>JD
M@IE*H]0\:Q/*VHGDJB#_ %@/?NO=.WOW7NJP/YUO_;H_^8U_XJ!WA_[Q-5[]
MU[H__4W_ #*OK3_Q'^S?_><IO?NO=5@_#3_M[#_.?_\ ,=7_ ,#;E/?NO=6_
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K5A_P"%@'?W^B;^4A7]74=;XLI\F^^^J>L)J2)]%3+MG:%55=UYJL!M?PI5
M[9QE--I8$_<HINC.#[KW1QO^$UOQ_?X]?R9?ASC*ZB6EW#VOMG<WR W!,*<T
MQR"=R[OK=W;+K71AJ)&UY<#!Y"3K$8=2$957W7NKV/?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UK _P#"O+_MS;O3_P 6 Z)_]WE5[]U[JNS_
M (1,Y/'8;XI?.O+Y>OHL5BL7W9LK(Y/)Y&JAHJ#'T%'UPU15UM;65++'%#%&
MK/)([!54$D@ ^_=>ZMD[8_F+?)S^8WV%N;XL_P G*GH*+8FWJ^HVYWS_ #*=
M[8F>IZ5ZS99C297;O0U(X']\=RHNOQ2TMZ.!P&>70"P]U[JQWX$?RS?CM\ =
MOYVLV)3YKLKO;L21<GW;\GNU:I=S]V=O;BE/FKJ[.;EJ];T= 92S4V'H62FA
M4(I61T$A]U[JQ#W[KW7O?NO= =\B?C9T9\LNJ=R])?(CK3:_:O6>ZZ5J?*[:
MW3CHJR&.8*13Y/%57$]%6P$ZZ>LI9(YHVY5QS?W7NM?EL=\Z?Y$58:G$/V7\
M_P#^4]25K&HQ+F;=?RT^&6W9Y2YFI6_SV\-I8Y38Z?\ *J>(7*J +^Z]T>;Y
MB?)WHGY>_P LG='>/QU[(VYVAUKNK(=>38[/;=K8ZC[6I7?6/^ZQ&9HC:>BK
MJ=CXZFCJHTEC;AE'OW7NM53_ (0Z?\S4_F)?^(_^./\ [T>\/?NO=;/O_"A#
M_MWA3?\ BW_P4_\ @M-I>_=>ZG]>T7\JH[!V.<GU+')DCL_;/\0DA^//R)FB
MDK?X+!]V\4U#MYH74R:BK0DH1RA*V]^Z]TL/L?Y3G_/HO_9=/DG_ /8[[]U[
MI%]D47\J@==[]./ZE\=>-E[I^RD_V7GY'0^.K_@<_P!L_FGV\J)9])U.0H^I
M('OW7NK;.F_MAU#U4*-(XZ/_ $;[&^UCAC$,24W]V*7P)%" -"A;!5L+#BP]
M^Z]T)'OW7NBX='97:&1[.^8])MK:E1MW-8+Y'[7Q78.7FSM7EX]^;OF^(G5>
M<HMUTF/J55,7'#@*S!X,T-.6C=\<]:3Y:N15]U[HQ_OW7NO>_=>ZI_\ YJ7_
M # __BO_ ,M/_E$]^Z]UKA?S%/\ MQ;\RO\ Q;_J'_X6YUU[]U[K;^_E[?\
M9 OP>_\ %0/C3_[YC"^_=>Z-_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU0/FEW9_,0^"W\QOYA=G_#/K_X
MK=QXSY8Y+X5X')[6[ORO8V#W)MO*[7ZBS.S,-5X^NVW68_'FDEFHZDU/EFDE
M_>@**%2;W[KW2\[$'\U3YC]7_P M7MSY!M_+ZVKT#NOYE?RW?E)_#>FU^1I[
M@IZ*/M/;_:& V[IWL:C"B4PS?;5G[K*'YCD*BY]U[K:#]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=?-#_GT?]Q1GQ4_\2!_+S_\ ?E8[W[KW7TO/?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW6NK_ ,*"/D)U;\5I/Y:O?7=.:K-N]9[$^7_9
M?]Y<Q08;*[AJZ/\ O1\+^R]FX;Q8C"13U4WDR&1I8F\43:%8NUD5B/=>Z/7_
M "4O^W1_\N7_ ,5 Z/\ _>)I??NO=6?^_=>Z][]U[KWOW7NJL_YU?8_8W4W\
ML?Y0;\ZFW]N[J[L#$T/55#@-_;#S-1M[>&VQN3O+;&U\M58#-TO[E-/)0UM3
M )4Y"N??NO=(W_AHC_P9]_-^_P#2U/\ \VO?NO=%,ZK_ .$R_P ,.CNX=T_(
M+I[Y/_S$^M.[][_WG_O?VKLWY*X#!;ZW)_?7,IN'=O\ &-Q4.U$J)_XC71QU
M=9K<^650[7(O[]U[HV?_  T1_P"#/OYOW_I:G_YM>_=>Z]_PT1_X,^_F_?\
MI:G_ .;7OW7NO?\ #1'_ (,^_F_?^EJ?_FU[]U[KW_#1'_@S[^;]_P"EJ?\
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M6V:[J[-;=V;'!NS*UV*Q643!9^KH<DVU\]EZ#&US:*N>J$V-IH)_=>ZU]O\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NF,[CQ0SPVWYY/XJ:7[SQ"GG,(B(+!34A=
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M;GQO<W=76-76_*WMC&UM%UEGMH87'5O\/V1M04E;61YK!Y&66=!*ZJSS%0+
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M6DQN*^./=^2R%4ZNZ4U%0]992JJZADB#,0D:LQ"J2;< GW[KW6NA_P (V_\
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M[9WSM>EW/@J'*T&.FJ:>"IBI:J*.>&"HEC1PRI(Z@,?=>Z$KW[KW7O?NO=5
M?RVO^RN_YTW_ (O_ +&_^ HZO]^Z]U[N?_M^'\$/_% /GE_[]GJ#W[KW5O\
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MHQ_OW7NO>_=>ZJ!^9?\ V]A_DP?^9%?_ (&W%^_=>Z]_-W_[I@_^-?OA7_\
M++[]U[JW[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=:W_P#,0_[+*/\ XD#XC?\ N#NGW[KW1P>O_P#M
MW'_*B_U_Y9/_ +J]L>_=>ZM_]^Z]U[W[KW7O?NO=>]^Z]UQ=TC1I)&5$16=W
M=@J(BC4S,S<  <DGW[KW11LK_, ^#&&W)C-F5OS"^-#;QR^[,5L7'[1Q_=G7
M>8W3-N[-UYQ6*P#[=Q&0GK(JB>J4TJ++"H\Q$1(=E4^Z]U\_[^?1_P!Q1GQ4
M_P#$@?R\_P#WY6.]^Z]U]+SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIA?\
M+:/^R!?BC_XM_3_^^8W1[]U[J_[^2E_VZ/\ Y<O_ (J!T?\ ^\32^_=>ZL_]
M^Z]T 7R/Z0?O3K^GQ&#W35=>=H;&W%0=E=']I4%*<A6=9=N[=H*JAVYN:7%"
M6 9'&5%-6UV%W'AGGCCRN$K\EBY)8XZQY%]U[I'_ !_^3]#V;D6ZE[4VY-TK
M\I]K;=ILKV%T?N&>0FMIZ>1<;E.P>E=S5"14^]-D35A"T6X<3J:G$L-)F:;$
MY?SXV#W7NFSY^_\ 9&OR%_\ $?UG_N=3^_=>Z)_N;_LD/Y2?^- -P_\ P;&"
M]^Z]U<![]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_,NO@/\ ^-?_ .6#_P#!
M38;W[KW1P/YA/_9 OSA_\5 ^2W_OF,U[]U[J@'_A&W_VZ/W'_P"+?]R_^\3M
M#W[KW6U[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HCO16]=O[*KOE/
M4UE/55>5R_S"WOA\)M[!!LKN7>>Y9.LML5E/B<-BG,:K/]K"TDSR2QTM+2P2
MU];44U)'4SQ>Z]T)F2Z-J>T,EA>PNT<KEL'V#MMI:KK6EV7GYXL;U"U744==
M5B#5&M'N*OJI:&D.0GS=!44FB,4U)2PPM4R5GNO=5B?SRM\Y0_R@_P"8-L+L
M2DH<+V!%\=L[54-3BTJTVEV%BJ+-8P5.YMDS5K2/$5,@_B&"JIY*S'275I*R
MB:CRE=[KW5:7_";[_N'&[C_\O;_]Y:H]^Z]U4#_PE)_FD? ?X"= _+#97S ^
M1.WNE-R=@]O[+W/L_&9W:W86=_CF"QFRWQ.0K8:K9V(R4$8CJ&$9CGD1S>ZJ
M5!(]U[K:83_A1_\ R7\3JQF.^=O7]92R ?PFIFV'W:E-B8['RT>0 VP)&AA
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M=_3XAFWA+C=H=I;GQ>;\"0U$$\3_ &3+(KA49I%=%]U[JR?XC?(K!?+KXO\
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M8]^Z]UMP^_=>Z][]U[KWOW7NO>_=>Z][]U[JH#^<A_S+KX#_ /C7_P#E@_\
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MFP601!(]#F<#F<K#54LP5E8Q3Q*P!!MS[]U[I-_\.$_ 7_O.'X@?^E+=,?\
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M;&0W'!B#LZF^QBS==B=RTU-+4A+"5X*>-"URJ*./?NO=60_PWY]_\]E\/_\
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M\!0>??NO=6)_PWY]_P#/9?#_ /\ 1:=T?_99[]U[HF'SR^2_\P_X>]$XWM/
MM\+]\;@W'W9\?ND<!A<OLKO#"X>'-=]]R87J/&YG,5U'N:HG%+0RY=:J=88F
MD*H=*L?2WNO=!97_ "?_ )OG5WRW^)GQD[QQ?\MPTWRSI^_?[M;JZIQ?R=S,
M^UJKH?KR#L#)?QW'[OR>-5XZZ.HCIH/MW8JVIGL% ;W7NK(OX;\^_P#GLOA_
M_P"BT[H_^RSW[KW18OFIWU\^/B'\2/D=\H7KOB#O%>A.GM]=IC:R;![GQQS[
M;/P,V73&?>G=3>,2M&%+6^E^1]1[KW12^Q_E[_.0Z';XC;A[=V]_+-R6Q?E7
M\C^D/CI0?Z.*;Y35>[-K97O.AK*W"[CK*3<];1T<M/0+1N:J)*@NY(2.P8R+
M[KW5J/\ #?GW_P ]E\/_ /T6G='_ -EGOW7NO?PWY]_\]E\/_P#T6G='_P!E
MGOW7NM<'_NS:_P#+ ?\ Y>O?NO=;'W\-^??_ #V7P_\ _1:=T?\ V6>_=>Z]
M_#?GW_SV7P__ /1:=T?_ &6>_=>ZIX7YY_SA-V=>_/;NCKK:G\M8=9?!7MWY
M-]5[AHMZT?RAHM][V?XQ;7CW7N++X:BP>1JL?$,E3R!**.>L33)=92JC6?=>
MZLJ^/O87SX[TZ%Z1[MCSGQ!P$?<?476W:B8%^O.YZQ\(G86S*+=JXAJM=UJ)
M33"L\)D"C5IU6%[>_=>Z%W^&_/O_ )[+X?\ _HM.Z/\ [+/?NO=5K[>^4'\X
M3M_Y3_,OX\=(XG^6M%C/AUO+IC9&?W/VKC?E#B*[=^2[@Z$P/>=-68?';1R.
M2CB@HX<V*!Q-*'9XBX&EK#W7NA?^ ?R7_F#_ #2^+&R?D/DG^&NQ,GN3>7>6
MR,GMBAV/W;F:&CR72/?>Y^C,A64.1GW/#))!73;;>OA$D2NB3*C#4I/OW7NC
MD_PWY]_\]E\/_P#T6G='_P!EGOW7NJ^.C(.WH/YZO=Z=TY/K?*[I/\ICXXM0
M5'5^#W/@, F /S"[0%+#64>[,CDZAJP5 JFDE2=8S&8E$8979O=>Z2OPLI?D
MK4?-+^<JW2F>Z-Q. 7YV[&7+0]I;2W]N#+R9?_9,NLB9<?4[3S6,A2F\/B&B
M2)WUACKTD >Z]U9C_#?GW_SV7P__ /1:=T?_ &6>_=>Z(1\FODY_-#ZN^3WQ
M*^*74M)\"-S;X^4NS_DQO>DW/V+MWY#;<VIM3%?&VAVA696AJ(MM9O(UD]1D
M_P"]L7V[+&$C^V8/?R I[KW7'XR?)O\ FB]H_*'Y;?%+MNF^ VV=Z_%K9OQE
MWO4[DZYVU\A]Q;7W5C?DE1;PK,;1P+N;.8ZKAGQHVDXG+0Z'-0ND^@D^Z]T?
MG^&_/O\ Y[+X?_\ HM.Z/_LL]^Z]T27YQ?)C^8_\6-N?'U]FCX1[UW=\B?E7
MT_\ %K;-/N;9_>^!VY@<UVVN2-%N?.UF*W'5U34M*V.TRQT\#2$2:E#:=)]U
M[I$]>_)[^;+3_.C"?";NV@_EW8W,;J^)W87RFP6]>K,)\E,_C8,;U]W!M7J6
MKVMEJ+=N7QDJSU$NYUJXY80R*D!5N7%O=>ZL0_AOS[_Y[+X?_P#HM.Z/_LL]
M^Z]U57_.SH?F)%_+'^2LG8^Y_C37;)6;I(YZDV3L3M'%;IFIS\B-I"G7$9#.
M[CK:2)Q/XBYFI9 8PX #$,/=>Z&O^:Y'O>7Y)?R<8^N*O:M#O9OGSO,8&KWM
MC\OE=K0U ^&79IJ&R^/P551U<J&#RA!#4QD.5))4%3[KW1Z?X;\^_P#GLOA_
M_P"BT[H_^RSW[KW2![6W/\^.L>KNR>RI-Q_$'+1]>[!WCOA\6G77<],^23:>
MWJG/-CTJ6W6PC,PI_&'*G3>]C:WOW7NB+_&_NW^>I\E_CQT+\CMJ8G^4S@=K
M?(#I?J[NW;6#W"/F$,_A<!VML>AWWAL3G!C99Z<5E-3U\<-3]O/)'Y%;0[K9
MC[KW0K?#S^7[W!3_ "#^9/R?_F'[1^%W:O97R:JOC_#MK"]1;)W1NW:.QL1T
MIU]6[$J4AF[PQ\E?!+DDEI)Y4IYG1GC8G2 BCW7N@0_G,==_%[XY]/\ PS[I
M;KOH_I;"=>?S3_Y<^ZMY=F4.R-D[&AVEL;;_ ,C\7F]W9K,[FQ])3M38^EH:
M>6IK9'E$:Q1LS^E??NO=' _X>M_E'_\ >QKX@?\ H\-D_P#U5[]U[KW_  ];
M_*/_ .]C7Q _]'ALG_ZJ]^Z]U[_AZW^4?_WL:^('_H\-D_\ U5[]U[IRZF[5
MZH^>GR7V[V[U+O\ V%W)\:?BYLFGS/7&\-D9S';NVGO'Y+]NQY+ 9K<^/RN/
M:2G:78VT*6?$T<T,C U&ZLM!,J5.-C*>Z]U9;[]U[JF;^>%N/;^SOC/T%N[=
MN<Q.V=J[5^<OQ@W'N;<F>R%+B<%M_;^#W%6Y/,YS-96N=(*:DI*:*2>IJ)G5
M(XT9W8*"??NO=:+?\YSY7?&KN?\ X43?&[Y$]3]Y]8]B=$[;WM\':[/]M;1W
M;B<WL+#T>Q]_T-?O"IR&Y**1J:),9!&\M:S.!$JDM8#W[KW7T1.I?YJ'\MWO
MCL+;?4W3?SB^,79/9F\JJ>AVGL7:/<&S<MN?<E?34<F0FH,'B:>J,M5.((99
M1#"K.51B%-O?NO='Y]^Z]U[W[KW7O?NO=(?LKLSKSIO86ZNTNV-[;7ZXZXV-
MAZG/[PWQO3-T&W=K[;PU(!Y\AF,SE'C@AC!*HI=P6=E10790?=>ZKX_X>M_E
M'_\ >QKX@?\ H\-D_P#U5[]U[K5$_P"%;_S_ /A+\M_A9\;-E_&+Y4='=\[M
MVU\H8=T9_;G5O86W]X9?#[=7JC<6).:R%#B)I'BIA4U,$'E8!=<B+>Y'OW7N
MK6/BQO':>]?Y4_\ PG+KMH;DP>YZ/"_*3X;[.S%5@<G1Y2'%[LV=TAOK;FZ]
MMY&2C=Q#78ZOIYZ2MI9+20RHR.H(M[]U[K:B]^Z]T1+Y:;1RW4^17YQ]3XR:
M;?\ TUM66+O/:6%QDU;7_('XP;>DJ=Q;PV(^/QL;U%=N7;$<V0W+UZR*THR(
MJL.C0T>X,@_OW7NEUWG\\OA;\9<+UWN+Y"_*7HOIG"]N8NISG5^0[&[(VSM:
M+?\ A:.DHZZLS&TURM1&]=2PQ9"@>6HIU:-!40:F!E0-[KW5'?\ ./\ YI_\
MN#OK^7%\A>H^E_F[\:NT.S]Z572U%M+8>R>U]J;@W3N*LH?D#M3+UE-B,/05
M#S3O'2T\]0ZHI(2-F/ /OW7NCY_S\JBGH_Y2WRSJZN>&EI:6'I&HJ:FHE2"G
MIZ>#Y'[/EFGGFE(5$1069F(  ))M[]U[H29OYU'\I&"66%_YC?P\9X9'B<P]
MZ[#J(BT;%&,4\%8R.MQZ71BI'()!O[]U[K'_ ,/6_P H_P#[V-?$#_T>&R?_
M *J]^Z]TN-C_ ,V;^6#V/55U#LS^8)\/,Q68VGCJZRG/R%ZOQLL=-+)X5G1,
MMDH/(H:RL8]6DE=5M2W]U[H2/^'"?@+_ -YP_$#_ -*6Z8_^O7OW7NO?\.$_
M 7_O.'X@?^E+=,?_ %Z]^Z]U5Y_-*^6WQ4[BP'P"V7U'\FOCYVGO&?\ FY_R
MS,C#M/KCN?KC>^YIL?0?*/"R5U=%@=LY*JJFAA4AII1%I0$%B+^_=>Z/_P#S
M9IHH/Y6'\RMYI8X4;X"?,.$/*ZQJ9:CX];B@@B#.0-3NRHB_4L0!<D>_=>ZU
M>?\ A,(\\_\ *9DHGH:?/5%)\L^R,MM'9U?GIMO83=>2JMT]3[1WG+G<S3PU
M+T'V>(RBT%/6"EE1*?*Y"230(0X]U[K:+W3M/9O7_='>.&V128W:5-N_XBY[
M=VX]G[=HJ/$8;+9K#9"7:..W;68ZCC5#4PT$,..A==(6-6&DL[-[]U[H_P![
M]U[JJ3J3XF?$7?/R5^>.W>W?C%\>.P^P*;OC9?;&)RW9/2_6N]MXY+JWN7HG
M;$N-W)/G-PXN>=J&HWOA.PL91IY/2V.F# OJDD]U[HSG_#>WP%_[P>^('_I-
M/3'_ -9??NO=*3:'PH^&G7VYL-O38/Q(^,FR-X[=K%R.W]V;0Z%ZKVUN;!9!
M$,:5V&SV&Q4-52S!691+!*K $B_/OW7NA]HMU;8R>6K<#CMQX'(9W&K,^1PM
M%F,?59:@2GF6GJ&K<=!(TT0CD=(W+H-+,JFQ('OW7NG[W[KW7O?NO=$YV5N[
MNKO?*;PSFU=\[5ZNV+MG=60VIAJ'&X;%[YW=73T-+#450WO19<H,;5A)J:H2
MF!@DA\LT#T]7 */*U7NO=4I_\*&Y^RJO^3U\P8-S]F29A-G;@PNT<G#@\7@*
M.GW/5G)4>7%3D<GCH81]F*2II <,M%%-0URU<$^0RJ0TU4?=>Z+G_P )OO\
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M?N;K-L14^Y<?44]-E*#&RT=<&:B9FAJK1R):0'W7NC%?[)C\6?\ O)KX ?\
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MVY2UV2J\-0_Q"MFR<%10T-9DH$J(Z2KE#C[8@^Z]T5#_ *#5OY67_/@_G_\
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M4/>>,Q>,HZ;'XW&X_P">G\P&BQ^/Q]%"M-1T-#1TW:*QQ0Q1JL<44:A54!5
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MG/Y:_P H<-1KLWI7Y*;:[/WQ-%5S81@U1'BL75O30 7FD"Q@@L#[]U[JP?\
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M;X[TV[?YAC=!Y'LROS55_,+[/J?D8G8R85*3'?(A^DNO(]R8[K4X:"'5ME<
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MOW7NMO'_ $#?S</^]D/Q _\ 386]O_NB_?NO=>_T#?S</^]D/Q _]-A;V_\
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MI(?=>ZK\^9'_ !^'\QO_ ,4 ^%7_ +_;OWW[KW1P/C3_ ,SG_F$_^+?[*_\
M@!>C_?NO=&_]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW50&W/^W^G<G_C(#XU?_!G]L>_
M=>Z]_*@_YF+_ #A?_&O_ '7_ / L]-^_=>ZM_P#?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'_;/_,J^R__ !'^\O\ WG*G
MW[KW7S@_^$7'_997R'_\1_L[_P!P=T^_=>Z^EY[]U[KWOW7NO>_=>ZJ _GO_
M /;K+Y@_^( ^0/\ \#KO#W[KW6M!_P (D:;=E1U=_,*.VLWMW$HN_OCL*M<Y
MM?);A>=SMW=WA:F>@S&+$04:M099-5Q8K8@^Z]UNX9RBWY#O#J*3.[DVCD<:
M-_9834F)V3F<+7.YZHW,(6CR%9N"OC0*UBP-*VH7 *DZA[KW0W>_=>Z O^(Y
M#_99_P"+??5G\4_T%_Q'^)?<S?Q#^(?W ^Y^^^\U>3S>3]SRZM6KU7OS[]U[
MH=/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5C
M?)3I>@P'RGZ,W[MW<.6V?B/E!OX=9=J8O%_Y/M^O[EZSZ:W'V)T)W5E7HGI*
MF')T^,VWDMD5U12U]-59*&JV_3"JBFPN*,?NO=#/7]$]V;HW-LW([OWAU3D)
M=BUU%E*?L*IV-+D=^[MK]O2&LVS#G<=AOX%24-!3U]369*GHJ&L+T[:*=ZFM
M@GK_ +OW7NM;#_A672[LV9_)PZSZMSVV=P5U/L;Y-]&[7H^S'S6U\GA=TXW;
M/7FZ<3@\OD8FK*?,193(4J1SY" X<T\%6*B*.JG@6&IG]U[JQ#O?=_S@PW<.
MT,?U%DOES35+]<_"J/XC;:ZIZGPN[OA_NZIR&?,/R<7Y:]@IM_(C!1'%C[>K
MGSV:Q[46.6FK=L)4YEY8W]U[I(_SY_\ LF?^9W_XS V7_P#!"YWW[KW10/\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IKRK9188SBHX9)O+^X)2O\
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M=X?^\35>_=>Z/_U-_P RKZT_\1_LW_WG*;W[KW58/PT_[>P_SG__ #'5_P#
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M#\=ND][U^/H>DN@'HJ"MW7UKC,]545&]1@6D,43U#)&78L5 N2;^_=>Z)/\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=% _E[?\ 9 OP>_\
M%0/C3_[YC"^_=>Z-_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZK _G6_]NC_YC7_BH'>'_O$U7OW7NC_]3?\
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M=X/0TF,?=?9'3/7.^=ROC:#5]CCVSNY\;551@AUOXHC+H34=(%S[]U[I _\
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MNO>_=>ZJ VY_V_T[D_\ &0'QJ_\ @S^V/?NO=>_E0?\ ,Q?YPO\ XU_[K_\
M@6>F_?NO=6_^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[H/^V?\ F5?9?_B/]Y?^\Y4^_=>Z^<'_ ,(N/^RROD/_ .(_V=_[
M@[I]^Z]U]+SW[KW7O?NO=>]^Z]U4!_/?_P"W67S!_P#$ ?('_P"!UWA[]U[K
M6@_X1(YO)8GJ[^84M!M#<6YQ/O[X[-+)@ZG:=.E&4V[NX*E2-RY3',2]R5\*
MN.#J*\7]U[K=PSFY,SD=X=14E9U_N[ 0/O[+,V3RU;L.:AA*=4;F=4DCP6;K
M:DER-*Z*=A<C456Y'NO=#=[]U[I#_P!QZ7_1M_HV^^J/L?[C_P!Q_P")>./[
MK[7^ _P'[[Q?H\FC]S3]+\?3W[KW2X]^Z]U[W[KW6B5\RZ2JH?G;_*]I:VFJ
M*.JB^7_P%\M-50R4\\>O^<%W!(GDAF 874AA<<@@_0^_=>ZWM??NO=>]^Z]U
MHN_RW/\ A3I_+@^#?PTZH^*?=&#^2M5V?T]ENW<-NVHV3UAM3.[6DK,SW9N/
M=E&<1EJ_<M%-,@I<A '9Z6,A]2@$ ,?=>Z/+_P!!DG\H_P#YYSY?_P#HFMD_
M_9?[]U[KW_09)_*/_P"><^7_ /Z)K9/_ -E_OW7NO?\ 09)_*/\ ^><^7_\
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M)6GBGE5@\:W]U[HQ7OW7NO>_=>Z][]U[KWOW7NM<'_A6!_VY*^1O_B0/CO\
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M>_=>Z][]U[H/^V?^95]E_P#B/]Y?^\Y4^_=>Z^<'_P (N/\ LLKY#_\ B/\
M9W_N#NGW[KW7TO/?NO=>]^Z]U[W[KW50'\]__MUE\P?_ ! 'R!_^!UWA[]U[
MK6@_X1(U.[*?J[^84-M83;N61M_?'8U;9S=&2V\\#C;N[O"M,E!A\H)0PU:B
MS1Z;"P:Y(]U[K=PSE;OR;>'44>=VWM''8T[^RQFJ\3O;,YJN1QU1N8PK'CZS
M;]!&X9K!B:I=(N0&(TGW7NAN]^Z]T ?FE_V5WS^63S_Z _-YM;>7R_Z/-?E\
ME[ZK\ZKWOS[]U[H?/?NO=>]^Z]UKB_SHOBG%7_)O^7;\S%WU)"^,^??\K;HJ
MIZY.VUE6KEQ7S8;=6(W9!NT5RF%53<.1IJG'MC)#*RTTJ54(BEBG]U[K8Z]^
MZ]UJW_RS_P"4Q_+@^673/>'=_P C_B'U-V_VSN;YZ_S!J+/[\W?09:JSV5I<
M!\P]XX7#0U<]-5Q*PIZ6&*!#HOI47)//OW7NK$?^&!_Y-O\ WKVZ _\ /1G?
M_J_W[KW7O^&!_P"3;_WKVZ _\]&=_P#J_P!^Z]T63YK_ ,C;^4EU[\-/EMO[
M9?P/Z,V[O'8_QD[ZW?M/<&/Q6:3(8+<VVNJ\KFL#F:%Y*YE$U+5013Q%E(#*
M+@_3W[KW6OS_ ,)._P"6I\$/FO\ #3Y';^^5GQBZS[QWCM3Y-S;0V[N#>U#D
M:K(8C;*]5[>S(PU(]%4PJ(15551/8J3JD;GW[KW6U#_PP/\ R;?^]>W0'_GH
MSO\ ]7^_=>Z]_P ,#_R;?^]>W0'_ )Z,[_\ 5_OW7NO?\,#_ ,FW_O7MT!_Y
MZ,[_ /5_OW7NJE?YZW\G7^6+\</Y3GS)[LZ-^&'3G6G:VPME[+R&SM\[;QN7
MAS>WZW(=M[?P=;44$M162(&DI*JH@;4A]+M^>??NO=%C_P"$S?\ *E_EU?+K
M^5SM7N/Y*_$GJCN+L^M[H[@V_5;TW?C\I49F?#8++T\&(QSRTE5"GCIT=EC&
MB]CR3[]U[JQ_^8!_*,_E+_'CIS"93K7^7/T)N+N+L?=F:ZNZ9V7'C=RPP[J[
M(S746Z<[@Y<Y4TE9)+3X/ +C9MV;DK8D9Z7$XJMJ(TDDC2*3W7N@5Z._X3I_
MRMTZP^1U)O7HN'?FZOC_ +ZWCU]BMY5V3K<+5;K_ +F]28#='\?W#B,*\=*D
M]9DJ^KGEAI%BBCC988U58P3[KW6#/?R OY5>,^(WQT[EI_C-B6WKV9NGX#X;
M=$LN=S38V2D^1/?.P.NNQC14"2J(7?';CR7V3!B()3&]FT:3[KW0L;D_X3I_
MRDL7\J>F>H:7XQT(V?OGX_?)CLC.I)N3./DFW+U5V-U+MC:C4E=Y!XX!2[RS
M(J(M!\CF%KKXK-[KW7NF?^$Z?\I+?/8WRSVQG?C'0MB^F_D#MOK?9@I-R9RG
MJ$VUE/BMUGV]5+DYO(WGG_C&ZLJ5ELMH3%%;]O4WNO=#^_\ PF)_DW,C*OQC
M:,LK*)$W=F2Z$BP=1(66X^HU*1_4'W[KW1@?^&!_Y-O_ 'KVZ _\]&=_^K_?
MNO=>_P"&!_Y-O_>O;H#_ ,]&=_\ J_W[KW7O^&!_Y-O_ 'KVZ _\]&=_^K_?
MNO=$LJ/Y=G\B/<V9JMO_ !U_E=[8^8.0Q=1E:+.Y3XW[1Q.5ZUP.2PLYI,G@
MJ_OGM'=NU>OI,M!,LD-3A*/=<^2IW6U320ZH]?NO=:T_\_+H'^73C?Y:$_=?
MQ"^!=#\-NU.I_P":[/\ "GLH96+:K[SKFV'T+O+=F[L5]]L3<6Y,3)CIJ]<6
M3X*^2]11,8WD@$<TWNO=7Z?R9OY,W\KCOW^5Q\*.Y.Y/A1TQV#V?V#TQC,_O
M3>F?QF8ES.XLS+F*R"3(9"2"LC0R%(T4E4 L!Q[]U[JS?_A@?^3;_P!Z]N@/
M_/1G?_J_W[KW7O\ A@?^3;_WKVZ _P#/1G?_ *O]^Z]U[_A@?^3;_P!Z]N@/
M_/1G?_J_W[KW2^ZW_DL?RK.H-RKO#K3X/]);/W.E#58V/-8G$Y9:V.AKM/W=
M/')45CA1($4,5 -KB]B0?=>Z,#_L@7PU_P"\>NO_ /SCKO\ ZH]^Z]U[_9 O
MAK_WCUU__P"<==_]4>_=>Z]_L@7PU_[QZZ__ /..N_\ JCW[KW5-O2?\K+^4
M?VMW5\_<E\@/C#\<-P;JVW\T\UM;;[[UK$QN3QNT(OCKUQN"DQU+329&G/VY
MK\CD:D.4):6:4EB3Q[KW567\Q+X7_P J?XC?*_M;?'6_PH^-79'6W3G\F_Y/
M_)&#J&.;*9+8&>[VVC\GNMMB=>9_=!P.4%4AAI\Y54<QAJ8W^TGGT6<JZ^Z]
MU>I_PG=P.0VE_+8QNS,GB]IX"JV5\I_FYM%MM=?U.3JNO=L';_RMW9CI=N]?
M2YF26J_@='(CPXO[B1I#3B,R$N6)]U[H3.Y_^WX?P0_\4 ^>7_OV>H/?NO=6
M_P#OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB@?
M![_F3&]?_%O_ .83_P#!]=E^_=>Z-_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z__]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6_P# /<-7B_AW
M\-<'D]V9F*C;X6?%[,8R"DQFWV: 5/4N+BJ:8S24+EHX@(5C,C%S<DLQN??N
MO='0_O)0?\]=NC_SV[:_^MWOW7NF+,[JF^YV]C<-O#/I6YG/T&-<U.*VVZK1
M3EEJ9(O]QX4.IT:=1M]>#[]U[J5GLEE]J[@VS0Y+>V<GQV<AS@E88C; J$J<
M='3O2K"8<?8!O*^O4/P+$?GW7NG/^\E!_P ]=NC_ ,]NVO\ ZW>_=>Z8-S[Q
M_A^%JJG%;MW <CKI(:056+VXT!DJ*R.%O($QX_L,Q'-KVO[]U[J?NBLSFTJG
M;4M;OC-SX_*YH8NM!Q&U_*B2T4LE.8#!C[AC,L:DD$6)O;ZCW7NG#^\E!_SU
MVZ/_ #V[:_\ K=[]U[J'D=UT=)CZZJCW=N7R4U'55$?DQFW#'KA@:1=83'7(
MN.0.;>_=>Z:<ED-U8SKZ@WK+O?*M+-C]L9"KICA]KFF1,Q4TL=:L82@\ED2=
MS'ZB;@7O^?=>Z4*[EQ[*&7=VZ"K ,#_#=MBX(N#SCO?NO=>;<N/52S;NW0%4
M%B?X;MLV %R>,=[]U[I/8W(;JR?7U?O6+>^566''[GR%)3##[7%,Z8>IJHZ)
M9 ]!Y+.D"&3U W)M;\>Z]TZ8S=M%68ZAJWW?N8R5%)3S2%,9MQ4\DD0:30K8
MZX&J]K^_=>ZG?WDH/^>NW1_Y[=M?_6[W[KW3?M>LSF[:G<LM%OC-P8_%9HXN
MB Q&U_*Z1444E09S/C[EA,TB@@ 6 M?ZGW7NF[:^\QD<+35&4W=N#^)++5P5
MHI<7MQ(%E@JGC01A\>?]UA"2"1>_OW7NE#_>2@_YZ[='_GMVU_\ 6[W[KW3=
M@LCF-T;AW+08[>N;I\?@Z? F)CB=L&HDJ,G%435(F:;'V(41QZ-('U-[GZ>Z
M]U$Q6Z)X\AN7$YO>&>>KPN<DHZ=J7%;;3R8XTD4E/+.1CRID,AF!TVX X'U/
MNO=/G]Y*#_GKMT?^>W;7_P!;O?NO=-$6=K\UNW'[=PV\\[#"^%R&4KI)L3MI
MIU>*JAIZ-8FDQX32UY=0L3<#Z?GW7NN,6X:S&[GW#M[-;SSTO\.BQ,] \&*V
MTLLD592>:J,Y3'E/2Y4*!8V_K[]U[IY_O)0?\]=NC_SV[:_^MWOW7NF3*[GJ
M)*_;>*PF\,^E5F<Y%15#U.*VXXCQ_P!I-+/)"?X>%$@D$(&J]P6L#:X]U[K-
MD\ME-N;LQ^&R^]<Y/C\E@ZZLA>/$[8%3_$::LB2.(-#C](3P^9CJ'U Y_!]U
M[IU_O)0?\]=NC_SV[:_^MWOW7ND_N;>)HL8&Q.[]P#)U.0Q=%1BJQ>W'@)JL
MC%%5:@N/'(@\K*20-0'U^A]U[IPW'6YO:F4VPM?O;-U&,S%?745:?X1MCSQ>
M/'/-1FG^WQ_!:<1JQ8$!23Q]1[KW3A_>2@_YZ[='_GMVU_\ 6[W[KW39F=WT
MM!B<E60;OW(*BGH:F6F\N,VXT1J5B/VPE5,=?27TAK?C\CW[KW47+UVY\-M#
M$;JFWOEI!4G;4U= V(VOXDILK40+7>+Q4&NZ)(VCDFX%[^_=>Z??[R4'_/7;
MH_\ /;MK_P"MWOW7NL<NZ,9!%)-+N_="Q0QO+(W\,VVVE(U+NUEQQ)L!] /?
MNO=)HY'>/^C7^^W]]<D*_P#A'\1^T&(VO]F)?-X_'S0^33;_ &N_^/OW7NE-
M'N?&RQQRQ[OW24E19$)QFW%)1UU*2K8X$<'Z$7]^Z]US_O)0?\]=NC_SV[:_
M^MWOW7NFO;-7N#=&.SV7I=\9F*DHLSEJ+'*N(VO^Y1T4:24[S^;'ZM9U6;Z?
MX >_=>ZC;9WG%E,!BJ^OW=N+[ZHI(S6BGQ>W$@6L0F*J6%7QY.D.K <G_ D>
M_=>Z??[R4'_/7;H_\]NVO_K=[]U[IMP.1S&ZL_N2CQN]LY3XS#087P.V(VQ]
MQ+45WW2UBRF?'V*HT "%0/SR??NO=0\'NR21LY19C>&?:NP^X\UB":7%;;1&
MIJ"M:"D=_P#<>079 &?2;7_ ^GOW7NG[^\E!_P ]=NC_ ,]NVO\ ZW>_=>Z:
M*3-Y'/;P7;V'WIG8:6';E5EZMY<3MEJ@5,>2@I*=$:7'Z=!25R; FX'(_/NO
M=<J;<-10YW<V!S.\L_+-AJO&BF>#%;:1GH\AAX*X-.5QY4MY6E4:;>D"X_)]
MU[IU_O)0?\]=NC_SV[:_^MWOW7NF:IW%5UVXMK8#"[QST39FHRPK):C%;:>2
M.GQV)DK4-.6QX0$R*BMJ!X/']??NO=<)\I7;<WC)M_+;VW%44L^W*7+4K_8X
M"2H-2^2GI)T)-"R! D:$< DD\GZ#W7NGS^\E!_SUVZ/_ #V[:_\ K=[]U[I/
M;@W2_P#N#H,3O'<25N9W'A<3JFQVWU"TU=6K#5O&\5 MG5"674;7^H/T]^Z]
MU(S=3E-H[@VW2Y#>^XZG&YFGS8G9J' RS15%#]JM&(@M$R@,TY#%E_I8CF_N
MO=//]Y*#_GKMT?\ GMVU_P#6[W[KW3#NC>,.-V_EZVAW=N/[V&BE^R\^-V]X
M35R6BIED,6/5@"[*"0PM];CZ^_=>ZY;C;.;4H,!F:C?>X9J6LS6(HL@DM'@9
M%CI*V-Y*AX42B)+C39;@C^H/OW7NGS^\E!_SUVZ/_/;MK_ZW>_=>ZX2;GQL4
M<DLF[]TA(D:1R,9MQB$1=3$*N.)/ ^@%_?NO=(_S;L_T:_WW_OQG/XA_"/XE
M]I]K@_L_+YO'X[?:Z]/_ "%[]U[I7Q;HQD\4<T6[]T-%-&DL;?PS;:ZDD4.C
M6;' BX/T(]^Z]UD_O)0?\]=NC_SV[:_^MWOW7NDUBI-Q9S:68W9%OG/Q^!MR
MST-/'1X)('I\543K0B1&H]0U)&NL"W)-@/?NO=.6%W=25V(QE7/N_<IJ*BAI
M9*GQ8W;HC%281]R(Q)CRVD/J N3Q^3]??NO=.?\ >2@_YZ[='_GMVU_];O?N
MO=-& ER^[\MN?[+?&XJ;&X>NH:&B\=#@8I9->.2:K-0KT0%Q,9%4JH!4 \_4
M^Z]U$VMN[[K$VRN[]Q')4E?E:&K\&.V^8@:7(RQTUFFH&))@\3,=1%R1Q:P]
MU[I1?WDH/^>NW1_Y[=M?_6[W[KW3)05^1W1NW(8C%;WW%3T&,P5#5RN*' 15
M'\1J*V59(V_R%5*>'PL"%O<D7_ ]U[K'B]PST.8W1@LQO+<4LV&R=-'3/'C]
MON[T=5CHIT>9Y*%QJ\GE "D6 %QS<^Z]T_\ ]Y*#_GKMT?\ GMVU_P#6[W[K
MW3#59RJR^YMN;=P^]-Q0C(1Y:HKW>@P$<R14E)YJ4PNE"J^IPP8-?CZ6^OOW
M7NN7\7K,!NW([=R^]=Q3PC"X[*44@H,!).7DJIJ>L5V:A9 JVBL  22?K;CW
M7NGS^\E!_P ]=NC_ ,]NVO\ ZW>_=>Z8,QN26IKMM8;#;QW#'59K.14=0TV/
MV^K1XY:262HE@>.@0!Q((0 Q(()X/U'NO=2,Q4Y7:6XMM45?O?<-309VFSPE
M+T6 DFCGQD=--3B "B*C4)'UEE/  !%^?=>Z=_[R4'_/7;H_\]NVO_K=[]U[
MI.;KWBM!@ZJ;&;OW$,B\E)3T8J,=M\1-+/5)&X9H:!6'H+D'4.;?ZWOW7NIF
MY7S&SJO;-15[ZW%44&4S7\+K1+18&1T2:AF> PJE$1J,JQK=E( )/%KCW7NG
M?^\E!_SUVZ/_ #V[:_\ K=[]U[J#D]V45'CJ^J3=^YE>GHZB6,OC-N%!(D1:
M/4$QU[:K7M[]U[IBR$NY<7U_C][2[YSS32T&U\C54S4F#:E1,Q54L=:J(M(7
M(1)W* D\@7OR#[KW2J7<N/90R[NW058!@?X;ML7!%P><=[]U[KS;EQZJ6;=V
MZ J@L3_#=MFP N3QCO?NO=)7'R[ERG7^0WM%OG/+-%0;HR-+3+28-:5TP]55
M1T2NC4@<!T@0N 1R3:W 'NO=/^.W71U>/H:J3=VY?)4T=+42>/&;<$>N:!9&
MT!\=<"YX!YM[]U[J9_>2@_YZ[='_ )[=M?\ UN]^Z]TT;:?,;QJ]S5%)OK<5
M/08O-?PNB$5%@8W=(:&%YS,KT0&H2M(MU4 @ \WN?=>ZA[1WFF3V[BZS([NW
M%_$)("M:*?&[?\*U,<A218S-0,Q M]2QO_7W[KW2C_O)0?\ /7;H_P#/;MK_
M .MWOW7NF;"563W=N+<U'C]\;BI\?@X,$L12BP$4SU.0CJ7JEF!HE4A?$FDJ
MOY-R?Q[KW6#![FDBGW!B\OO'<4E9AMP9#'1M#C]OMJHH2HII)7EH&N['7?2;
M#C@>_=>Z4']Y*#_GKMT?^>W;7_UN]^Z]TQ?Q>MS^[L=MW$;UW%!"<+D<I6N:
M# 1SJ\=5#!1A&6A5"K7EU @D6'TOS[KW62+<-9C=S[AV]FMYYZ7^'18F>@>#
M%;:662*LI/-5&<ICRGI<J% L;?U]^Z]T\_WDH/\ GKMT?^>W;7_UN]^Z]TQY
M7=$\F0VUB<)O'/I5YK.1T=0U3BMMN$QPI)9*B6$G'A0XD\(&J_!/!^H]U[K/
MD\ME-N;LQ^&R^]<Y/C\E@ZZLA>/$[8%3_$::LB2.(-#C](3P^9CJ'U Y_!]U
M[IU_O)0?\]=NC_SV[:_^MWOW7NF'<&[9*>EHH\/N[/C(5^9P^-B-5B]N/$L=
M=7I#4L ,>!J$1<KJ-K@?7Z>_=>ZD;AJ\MM3/;93([XW!/C\W)E*>J_W';=UQ
MRTM(CT8IXH:'0-3L Q*?3G@\^_=>Z=O[R4'_ #UVZ/\ SV[:_P#K=[]U[IHS
M^[X*#!Y>LH]V[C-;3XVLEHA/C=NF%JU:=OLTF\>/#:3)I#68<?D?7W[KW43.
MR9[;>!P.Y*C?6X)(*G([=7)1R4>"DCCH<C*AKWA1*,L61"V@$-S]0??NO=*+
M^\E!_P ]=NC_ ,]NVO\ ZW>_=>ZQR[HQD$4DTN[]T+%#&\LC?PS;;:4C4N[6
M7'$FP'T ]^Z]TEH#NN7KAMZ-OG.BO&"J,M]J*7!_9^:%681V^TUZ3IY]5_\
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MZ[-XB@KXY:/ R*E+7QNT[PHM&;N-(T:@1_4'W[KW3U_>2@_YZ[='_GMVU_\
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MC5D:E\08>0:OW"!S8GZ'W7NEE_>2M_[,W_T,Y?\ ZV^_=>Z]_>2M_P"S-_\
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M>T]X08W"TNX342U.,KJ"5*FO2E2B:FEQ\ODO^U(&LPX/Y!/OW7NE'_#=N?\
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M.>KI-,.=H)GQ@H:>.F%1%C)E2XE$]M5R+_6Q'OW7NE-_#=N?\ZC>7_G3N_\
M^J/?NO=)J6*FP6\<5GL9MC=]72C!Y7'5TD=%ELC5>66JIYJ*.^4E)" "8V5@
M+D\$GW[KW7L?2TF6W1NC/97;.[J2.N3"0XYFI<SCJHQ4M$8:Q9%Q<J@KK"D:
MF/\ 46Y]^Z]TI?X;MS_G4;R_\Z=W_P#U1[]U[I-YJ@PT.:V)/0X[.TU4N\:2
M'[C+29R2(4\N+JWEAB.4ED0,S)&WI 8A?Z ^_=>Z<=RTN.JNQ,.,C1Y"LCAV
M?E9H%QAR"U4-1_&*:'S!\:Z2!?&\B$ZK>JQ^H]^Z]TY_PW;G_.HWE_YT[O\
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MZX28G;,L;Q2X7=\D4B-')')/NUXY(W&ET=&J"""#8@_7W[KW20_YH#_Y*_\
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M287$TT^#W;!40XVB2IBADW5#$E4*=?N0D4$ZHH\FHV50/Z#W[KW3K_#=N?\
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MS%5,D6VHX9<2V7C:.)\66DCF?%21\$A2 ]_IQ[]U[I^_ANW/^=1O+_SIW?\
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M_OH:=]ST\2UCKY*HK#23K&I9RS-I4<DGZ^_=>Z47\-VY_P ZC>7_ )T[O_\
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MWUG,7@OXCMJ6H%%!55\L5(M1-)*(E0222."[>Z]T"O\ T!+_  %_[RN^7_\
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MR'_\1_L[_P!P=T^_=>Z^EY[]U[KWOW7NO>_=>ZJ _GO_ /;K+Y@_^( ^0/\
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MRGZ_1@1_4'W[KW25HMS[9I>FZK -GL8,JF"S=&E U7"*QYGJI_#'X+WU."I
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MJ@\Z&$F^I &)!^EO?NO=*N'"[8@ABA7?V,*PQI$I.>K5)6-0@)$>551]/HH
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M\%0&:X:)C?CW[KW2BV-BZ["[5Q.-R4205U.E4U1"DJ3K$U172U*H)8_2Q"N
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M]TX/_P )K_\ A2)(C1R?S6NO71U9'1_G/\\&1T8:65E;8EB"."#[]U[H0O\
MA@O_ (5-?][J/_:C?\Q3_P"PWW[KW0I=%_R&?^%$V#[RZ9WA\D_YIF)[SZ:V
M#V=M'?F\NK\O_,*_F'9%-TT6U<HN5CH:!WVSCY:2K9T ILA2U]/44KD303)*
MBGW[KW6Q7_LF'R3_ -4/_3JG\V'_ .O_ +]U[KW^R8?)/_5#_P!.J?S8?_K_
M ._=>ZT8?^%&7\K[YS_#G ;T^1V_.^MLU/PA[[^8.W,GM'XP[;^2WRF[A?;O
MR+WQTUFLSN'MK<>W^\Z%J*LR=7%@-PQ5&YI\W591DK8Z8*M-)(D'NO=;#_\
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JN#
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MD%!8$^Z]U0'_ ,*"4W)D>Y/D=4;FQ>#Q$N#_ )&O>>Z8*?![CS&<CR-/L_\
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MK-X]G]C;@")+EMQ9VLUUV6R<XUS3.;!(UCC3W7NF/Y9?]DL?)?\ \5_[E_\
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M ! &(_\ =[7^_=>ZM_\ ?NO=>]^Z]U[W[KW7O?NO=?.$_EV?]QDGR-_\3_\
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M_P"W1_\
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M(JBFGC8-#54E5#'44\R203Q1S1O&ONO=+;W[KW5>7R*_E3? 3Y8]I9#NGO\
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M $JO*?\ VK??NO=$*_F(_P T+Y6=$=.]<=K?(3^7G%U/USLSY+= 9VHW-/\
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M_P#-#^(M53P54'\V_P"830U,,4\+/U[_ "]HF:*9!)&6BFZ;5U)!%U901]"
M??NO=9O^'//B5_WMM^8'_H ?R\O_ +3GOW7NB1=/;]^;/R6_E/?+S^:3L?\
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M9U%/3=9TVW9\10T>:Q^6@K*/%M6?=5E1!/72)"E+3>Z]TE?A?\G>I_AOW/\
MS.OC]WO_ #-OE9L_L_ ?S$^P=R97*8_8OPVJJ[LO%YOHOK["X_LO=53O[K#*
MQ)EJR?%5N/J*7#24M%'#14[BBBFFEFJ?=>Z/W_PYY\2O^]MOS _] #^7E_\
M:<]^Z]T6;</S:S/RY^=WPI^%_P 0?YM7R^@I.W,3\CMV=TYRGZS^%"Y_!8;K
MGK1=S]>MM[*;>ZHHZ&]7D*:O@K8*SSOX@K(D1*R-[KW66F^9&Y?A?_,$^67P
MS^8'\VSY@56W]G=2?&3L_HK/576?PJDW#FVWO3;F'<5/G\IG>J*S'I'0RKM=
M<=3TZT\KK-4.PJ!&S0>Z]T93_ASSXE?][;?F!_Z '\O+_P"TY[]U[HJGR$_F
M*4W</;WP8^,'P]_FR_+B;L;Y+?+C;G7>_*J;K/X1R56#Z3AZVW-E=V9[ 9+:
MO4U%%!DH<VFV8((Z^=XY89J@K32F-I(/=>Z5_>7??:?\M_\ F(]0_'WY0_S<
M_F1F.C.\/B/VIV)@MP9KK3X8UNY(.[-G]K;>Q> P,%76=5U6,I<;+MP[CJII
M*BE21JB*")*D%U@F]U[H?/\ ASSXE?\ >VWY@?\ H ?R\O\ [3GOW7NB>?/'
M^;5L3:'QDWQ+\7/YJORTW!\AL]D-H[<ZLP^3ZM^#V2Q57D:_=='4;JFR3;,Z
MBI:RFCI=NP9FL6J-93QK)"BM(6=8I/=>Z&7Y[YSY&?RN-_?!?L#M3^;Y\T=R
M])=X_*&;HSMV;=/6OPYRDV#P.=Z?W-FMM9' 4])U=+3K4R;@HL32R5%?2S4\
M$$LLSB+QBHB]U[H7O^'//B5_WMM^8'_H ?R\O_M.>_=>Z#7N3^:Y\;-J]4=B
MY_9_\V+YA9#>>.V;N!]E8\=6_ G,C([TGQLE+M#'R8S ]-M63)/DGI8I%I[,
M%8G4@!8>Z]T6;M/M#YG?&#^6W_+L_F7=F_S:_E_4X+O?<'\N_=/R*VQ4]:_$
MO*[6VIUE\E*;!;F[PJ-G8R#K2IK9IL5C*W('#157WA)2,315+75O=>Z/'_PY
MY\2O^]MOS _] #^7E_\ :<]^Z]UAJ/YH?Q%I:>>JG_FW_,)8::&6>9DZ]_E[
M2LL4*&20K%#TVSL0 ;*JDGZ $^_=>Z(ULW<?\P'L+^2-O;^:U0_S:?EW!V)1
M="=_]WX#8%/U[\2Z7KFHJ.M=X[AP^U\=44;]=+DHZ6II<53254:5<;J[N(S&
MNE5]U[HW?7O\UWXH;NV!L?==3_-M^8 J-S[/VSN&<?Z,O@!B[39K"P9*4?PS
M*=-1U5-ZI3^Q4QK+'^B10X('NO=+#_ASSXE?][;?F!_Z '\O+_[3GOW7N@(^
M#&1^5?\ ,:Z9^87RJV'_ #>OF?M_KGKKY1_([K7I*AVYUK\0,50YWK#J["8W
M-;(S&X:#(=81NE=5)6LM9]M#3Q$*ICAC))/NO=(WX/\ \W7J7L?XD?'O>'?O
M\U?Y;8'O+,=4[+J.W,-C^K?@OBL7CM_R8&"7<,&)@W?U!-D):3S-KIJF>IG,
M\9643S!_(WNO=&I_X<\^)7_>VWY@?^@!_+R_^TY[]U[H#_B)VKW5_- ^9?SJ
MV-T!_-W^9>W^A_BIL_XDT^U,OMOK3X:8_,YS>G<V+WQD>PZ3/R+U93X^IAHF
MV]COL)Z"E7B:9)9IF11%[KW0<?$_^9SM_;%5\JNDOEC_ #8OEI2=N?&CYM_*
MCX\0M1]9?""F?)]>]4=K5VT^N\YE:S=W4M8]3D*W'4R5%=)25!IUE9HXXX O
MB7W7NC;_ /#GGQ*_[VV_,#_T /Y>7_VG/?NO=%]P'RD[ ^=G\P#I7XL?$O\
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ME'C85V)WAN#!]?U%/+O#J2KJJF2JVG'@*NLJ$K)HONI9XT,?C:"'W7NCA_\
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MIJ.JIO5*?V*F-98_T2*'! ]U[I8?\.>?$K_O;;\P/_0 _EY?_:<]^Z]T$_\
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M.ZMN8RC^0G6L"]E[PV]_>G8.5JQ704.WL71T:U4D]*D<0DD@9]<A]U[JS_\
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MW7OQ^VSM+"TV_,)\=-TXVBJ109\[F?&FOEJ7B6JG,4B":1![KW5B/\'^.O\
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M3?\ [/O?NO=$8_F9]"=3=_\ P"^6?4?7'Q[_ )H_9O9>[NF-UIUCLKL?>_\
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M/3B9'7QD^_=>Z&O^#_'7_GW'\W__ -'3_--_^S[W[KW0*_(_JKX[]H= ]R[
M@Z/_ )K.],ENCK7>&.V_MC>79G\RS<VV<INO^!S5&T$RV"W9O>IQM0D>42DF
M5:VG>(.BLRD+[]U[JK'?VYNQ/D1_+9_E:?R\]]?RT/YE$55T1OK^6!@?DY5[
MH^,6Z]N=<S];?'%]N8#Y"_P?>.V<O_%VBDQ]%DOX?-2TU/4R(5:,P3%;>Z]U
M=Q_!_CK_ ,^X_F__ /HZ?YIO_P!GWOW7NH]7MSXUU]+4T-=U=_-WK:&MIYJ2
MLHZON/\ FDU-+5TM3&8:BFJ:>;?K))'(C%'1P0P)!!!]^Z]U1ML_LGO'8?\
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M78+>6S]B]B_S(]G[2P>^Z79M&=]TN"VSL?>M'AZ.%LPU;+X<;2Q4^IF,2*I
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MJEJ)))&DD=BU_?NO=$/_ ))NROCA@OY6GPX#=4_S'Z3+9GJ\[CW-4]#]A_S
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M;656!,GM[<W0?56>P>12FJDK:9:_$Y7$RT\PCFBCF021G2Z*PLR@CW7NJ?\
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M .U?[]U[KW_#;7R[_P"]TWS_ /\ T!OA1_\ :O\ ?NO=>_X;:^7?_>Z;Y_\
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M-49G*9/)4&RSF-V8[<&9FJ*1\GE*^*)Z:MKB<C+%!624]+"\7OW7NC']C_\
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M2UU;G4N; 4+$AK:6]U[JLO\ X2!_$?\ T!_ROZCOG.8O[/>?S$[4W%V&E3-
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M)4NZ\7V%!G9\PZ0^.MV5-NC&T,2ZIY<C4T,-*IJ9(2/=>Z=^F/\ M^'\[_\
MQ0#X&_\ OV>W_?NO=>[G_P"WX?P0_P#% /GE_P"_9Z@]^Z]U;_[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__3W^/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW1'OYFNU,'O?^7+\\=K[DHVK\+E/A]\CEK*5*FJH
MW<TG4>7KZ5UJ*-XY%*311R"S6-K,"I(/NO=:QW\S/^6[L;I+N_JG873GRG_F
M%]=;!GV52U>X-EXWYQ]][BP>[(FZS[;WP^-S+;]RF7JX*5GZ_P 1CC#BZJC'
MV=17*")Y*:HI?=>ZV<?Y96U,'LC^7+\#MK[;HVH,+B_A]\<5HZ5ZFJK'0U?4
M>(KZIVJ*QY)&+S2R2&[6%[* H 'NO='A]^Z]U[W[KW7O?NO=>]^Z]U\]'X*6
M_FU_\*O._?E'4#^\/27PSRN]MQ[-J'$<^!GQ?1U+#\?^DYL7+Z])R&>F;>](
MH(9GAG<Z;,H]U[KZ%WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ*_P">QLOL7*];_#KL7I7N
M7-="=W=1?*7>6[^K^S\5LW8W8L&W,Y2_"[MG*U$N2V-V'1UF,R44\5#]F\4Z
MKICFD="LPBDC]U[JL3K7J3^8%\NOC1UMV7\P/YG^_N[=H[/^;O\ *FS&3Z@Q
M/Q2^*/5&U=TIW)N/X]?(/!QU>Y-D;?CW!2S[?J.RFHA-2Y415S8R.>6GABJI
M*./W7NMP_P!^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4L?SR-D
M[1[*Z&^&W7/8&W,/O'8>_P#^:O\ RX-D[VVCN&A@R> W3M'=7R0Q>"W)MS.8
MVI#1U%'74<\U+4P2*5DC=D8$$^_=>Z))_.I_E1_RU.E?Y5GS?[5ZD^#7QDZY
M[)V/TID\WL_?&T.I-IX3<VVLO%F**&/)8;+45.LL$RH[J)(V!L3_ %]^Z]U8
M!\OW_A?\WK^39F)#&8<QL?\ F9=<1)))X",AGNGMC]AP3P2,")9%@VE5)]J+
M,R.\P;33NK>Z]U$_D0&GQ/\ +PPW6ST\V+W%TO\ *7Y\]4[RVS4T\U+4;.W%
M@/G%V#DX]J302@!#1XZNQZB.,E(U(C%BA4>Z]U<;[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[JG#^<TM)E=D?R\]D34DF4J^P/YO?\N[#4>"2EEJUS='
MM;N ]I[Q@JH4!7[>EV[M[,Y.I,MD$5*_U;2#[KW577\X+HWLO/?S$_[Y= _+
M+Y&_$3?^]NCOA9L#>FY^B-[U6 AW=M?.]K=VT24NX<0I03RT+X^EEH)!.JQW
MJ T;F<NGNO=&E_EV?%$;3^17\NWY1;Z^27RQ^17:7=7\K?NG?F7G^1W<C]G8
M79V8W1F_C]G\_3=>4,V/I9<=254^X:SS025$^H14UV+0ZF]U[K8O]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_U-_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]T4#^83_P!D"_.'_P 5 ^2W_OF,U[]U[JG_ /G
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M1B:%E['[#K>B=UTU;!,CB2.?;V[<Q"EM+)*\<RL&C /NO=%'_F8_]E];9_\
M# ^!W_OY^^O?NO='!^%?_=(C_P 9 ]E__.P>_=>ZM^]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7__5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW1,/YCN6Q6#_ )>_SHRN;R>/P^,I?B!\D?N<CE:VFQ]!3^?I
M[,4\/GK*MDC37(Z1KJ879@HY('OW7NM8#^;)_-E_EP;M^2/3]9LKY?\ 3^_L
M;7[.I,5_&NO,O7[_ ,!C*_\ T4]W;&,&X]P;-IJZBQ5LGO+;<+/DYX%$=6:D
MD4M-5S0>Z]UL^_RW\SB=P?R]/@KF,'DJ'+XJM^'WQL:DR.-JH:RCJ!%T[AH)
M1%40%E)21'C<7NK*RL P('NO='1]^Z]U[W[KW7O?NO=://\ PL^^2^;J^M_A
ME_+WZZ:IRV]>]^S:KN'=&V<2ZME<AC=J'_1WU/@9J4'5+%FLYFLG+3I^DU&*
M0GE1[]U[K;@^$'QIPGPX^('QM^+F!^U>EZ.Z<V-L"OKJ,,(,WN;#X.(;QW*-
M2J=64RS5N1D.A;O.QTK]![KW1IO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4Z?SH\AC\1T;T
M3ELM74>,Q>,[S[*R&2R60J8:+'X_'T7P-[JJ:RNKJRI98XH8HU:2661@JJ"S
M$ $^_=>Z)?\ !S=.V-Y?R\:+.[/W'@=UX0_-'^21AAF-MY?'YW%'+[8ZT^&6
MV-RXK^(8N26'[G'9*CJ\?70:]<%3!-!*J2QNB^Z]ULM^_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_,NO@/\ ^-?_ .6#_P#!38;W[KW7
MOY_'_;FW^83_ .( R_\ [O:#W[KW35\P_)'_ #D_Y+\K-70TLG6/\TBA\U.9
M:>CJ,A-U9UQ6TN+KZN*&02B2"FJJF*ADDB21J?[G4ST<<;>Z]UB_D&U%-2_R
MV]H;)DF8;FZO^2OSRV!OO%SXR;"U^!W=0?.+L+-U.*RN(ECC%+4FDR%'52TT
M:A(O,(PJ%3&GNO=7,^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIP_G-
MRO5;&_EZ[5Q\]1%N?>G\WO\ EUX[:@H\=/E*P5VU.Y1VCN'(04L:/%IQN V_
MF,O4-5 0B"DEU'5I!]U[JK3^=G\ROC'\6?GAM2H[W[=V_L:6?K#X49>+$+1Y
M[=.Y6Q&W.VN],AG,L=J;+I,CDQ2TL533&6H-((PT\$>KR31*_NO='(_EF_,?
MXJ=_;X_EE]9]*?(7J/M'L+J7^4[V=MGLO9FR=[X//;DV/N&*K^.%!)A-R8FA
ME::FJEFQ.31H)%#@TE1Q:)R/=>ZV$O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U_];?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M5@?SK?\ MT?_ #&O_%0.\/\ WB:KW[KW1@_]%G6/^RN^?_1QL/S_ .@/S>;^
MZ&W_ "^7_1YK\OD^WOJOSJO>_/OW7NB^?R4O^W1_\N7_ ,5 Z/\ _>)I??NO
M=6?^_=>Z][]U[KWOW7NOG_\ \V"GH=S_ /"N7^6]@MRXZDW%B\;/\09J&BS<
MN3K:2E^R[ SFXL5'2TBU*11)19-&R=/'&@0U3N]0DZ,T9]U[KZ 'OW7NO>_=
M>Z][]U[HE7SZV]\TMR_'^JH/@;O;;NQ.\8]W;=JI\GG3LVFK*[9""HAW!B]K
MY7L7;F[<#19$S24=3YLIMZKBDI8:FFC^WJ9X*N#W7NC1]=4N^J'K[8E%VAE,
M#G.RZ/9NV*7L3-;6HZG';8S&^J?"01;MRFW,?66F@H*C("HEHX91K2)D5O4#
M[]U[I9>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NB;?/'#?,3._'C,T'P8W-A=J=\'<VTIJ7)96OV5B*N7:,>77
M^]=%MW,]D;8WE@*2O> JRS97;5;'X%GCB2.I>":/W7NC']7TW8-'UIUW1]M9
M' YCM6DV+M*F[,RVUH):7;&4[!@P%/%O/([<I9TCDCH)\D*F6CC>-66)D!52
M+#W7NEU[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JC#^<CTMU9\C>Y/
MY1?1G>.RL/V5U%V#\]]T4N]=@;C6HFV_N2#$_#OLS,8R/)4U-)&S^"JACFC(
M<%6'!L2#[KW1//YF?\I7^6]\4>END>[/CI\0>I.I.UMN?//^7WC\'OG:>.RM
M/F\;1;A^86SL)FZ>FEJJN5 M323RP270W5C:WU]^Z]UM)>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_,NO@/_P"-?_Y8/_P4V&]^Z]U[
M^?Q_VYM_F$_^( R__N]H/?NO=8/F7)/_ ,.W?R7*<4W^2''_ ,R*KER#3($2
MLI_CS@*>DQ:TZWD:2HCGJ)UDL(D6F=7<220I)[KW2:_D+Q5:?"_M.;)PR',5
MGS[_ )@M3FLK7Y'(YS<>XLJ/EAN>GJ\UN[<=8Y@R>28QBGFKZ!(X)DBC)3[@
M3N_NO=75^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB =H?+ON38GSOZ.^*6!
M^+&]-X=0]G[/I=P;I^2%%#V7)M_:61R&.WK65-'2S8+9V1VE'#@)=JX6GW"N
MY=[X6M9MUX0XBARA2J1?=>Z/_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)!_,"^4?:OQ#Z%C[7Z=^.
MVY/DQNV7?&W]K-L3;E/VC5G&XS*4-;7S[@RM/TQL[?NY##)-1T^&I3C]KU:K
M79"C:I,%()YX_=>Z-WLW.5^Y]H;5W+E-NY3:&3W#MO!YS([3SGA.:VO7Y;&1
M5]9MW+FG)C^ZHI)&IJCQDKY$;22+>_=>Z4GOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[JEW^<DACRW\HW(^*LG7&?SHOAP[14%?6XFI(S.R]^;664Y:DCD6*&
M)L@LU5!/ICKH$DQVM7K$]^Z]UEZTVKMC<_\ /!^<T>Y=N8'<*4?P"^"+TB9S
M#X_+)2O-VQVZLS4RU\<@0N%4,5M>PO\ 0>_=>Z]V7M7;&V/YX/P9CVUMS [>
M2L^ 7SN>K3!X?'XE*IX>V.HEA:I6@CC#E S!2U[7-OJ??NO=7.^_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__7W^/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW58'\ZW_ +='_P QK_Q4#O#_ -XFJ]^Z]T;_ /[E
M8_\ +?\ _P"9U[]U[HH'\E+_ +='_P N7_Q4#H__ -XFE]^Z]U9_[]U[KWOW
M7NO>_=>ZT _YHG_<7Y_+M_\ +2/_ 'J=P>_=>ZW_ #W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=5 ?S)?\ LKO^2S_XO_OG_P" H[0]^Z]U[^=O_P!DB=5_^+__ ,N'
M_P"#7V3[]U[JW_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4!_
M.0_YEU\!_P#QK_\ RP?_ (*;#>_=>Z]_/X_[<V_S"?\ Q &7_P#=[0>_=>ZC
M?,V-\S_-P_DLX",-$<!0_P R/MF:IC^WB:6FVU\=L#U8V*EF9'E>*67?,-2:
M9"BN]-'*[W@1)/=>ZQ?R/#+EOB1W%V%CZ)L-L#MK^83_ #&>Q^I=LO41L^T^
MN<E\QMW86@VVV.IBU/0FGR&/R)-)2LT(U>523*??NO=7&^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>ZIO_G#1?:U'\JK=-;C5R^W-H_SD/A9+N/'&2'6
M_P#?S&[NZ<V5DHJ6I(CG.-W5N; 91E)#1I3-41:IH8U;W7NG'IC_ +?A_.__
M ,4 ^!O_ +]GM_W[KW7NY_\ M^'\$/\ Q0#YY?\ OV>H/?NO=6_^_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__T-_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M_P"W1_\ ,:_\5 [P_P#>)JO?NO=&_P#^
MY6/_ "W_ /\ F=>_=>Z*!_)2_P"W1_\ +E_\5 Z/_P#>)I??NO=6?^_=>Z][
M]U[KWOW7NOG:?S)^V-N[@_X6*?#["45%FHJOJ3L_X/\ 4^XY*JFH4IZW<6[<
M;2=A8VMPCQ5+M)1)1;PQD4\DZ0RB>*J587C2*2;W7NOHE^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[JH#^9+_V5W_)9_P#%_P#?/_P%':'OW7NO?SM_^R1.J_\ Q?\
M_EP__!K[)]^Z]U;_ ._=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MJ@/YR'_,NO@/_P"-?_Y8/_P4V&]^Z]U[^?Q_VYM_F$_^( R__N]H/?NO=1/E
M[30R_P XO^3745J^.FI>K_YH1QM4*:$-)N:;K+K>.BQ9R'C,JK+C/XQ4FE$J
MQRFF65U=Z:(I[KW4;^0ECDIOY:VQ<Q4B.3<>[/D7\[]P;TR,)ECI\UNU/G/V
M+@,GEZ6A=F2DAE2@A$-+%Z8T50S22>263W7NKD_?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=4T?SH<4:K97\NK/4<\=+N+:/\X/^7=6[6JZRBILMB:/+
M;O[:DZIK:O+X.K 2MCBQFXLA)3QB2*2&J%/5P30ST\4B^Z]T\=,?]OP_G?\
M^* ? W_W[/;_ +]U[KW<_P#V_#^"'_B@'SR_]^SU![]U[JW_ -^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=5@?SK?\ MT?_ #&O_%0.\/\ WB:KW[KW1O\ _N5C
M_P M_P#_ )G7OW7NB@?R4O\ MT?_ "Y?_%0.C_\ WB:7W[KW5G_OW7NO>_=>
MZ][]U[KYOOR>IZ>J_P"%LVVHJF"&HC7Y#?$6H6.>))D6HH_A1LJKI)U20$!X
MI426-OJKJK*00#[]U[KZ07OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ _F2_\ 97?\
MEG_Q?_?/_P !1VA[]U[KW\[?_LD3JO\ \7__ )</_P &OLGW[KW5O_OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH#^<A_S+KX#_P#C7_\ E@__
M  4V&]^Z]U[^?Q_VYM_F$_\ B ,O_P"[V@]^Z]U"^9VNN_FZ_P E;%4LDT55
MC\;_ #*-[5IB:G1*C;V'^/&W]G5E'4&I8:D.0W%BIA' AG+Q*P98$J _NO=0
MOY$\HS'PKW_OS!T-5@^K.TOG3_,$[$Z+VA6U3O6;&ZCSGR]W;2X/:%9C"\BX
MV>EKJ;)&HQZNQCE=VD(E>0#W7NKF??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=4W_P XB!$?^5?G<G139/:6V_YR'PFGW9C(JD1BI?=-/NKKGKBMFHGD
MC2K3&[WS>ULL8W)\1I15HCRTR*?=>Z<>F/\ M^'\[_\ Q0#X&_\ OV>W_?NO
M=>[G_P"WX?P0_P#% /GE_P"_9Z@]^Z]U;_[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW58'\ZW_ +='_P QK_Q4#O#_ -XFJ]^Z]T;_ /[E8_\ +?\ _P"9U[]U
M[HH'\E+_ +='_P N7_Q4#H__ -XFE]^Z]U9_[]U[KWOW7NO>_=>Z^<'\E_\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_ #+KX#_^-?\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_ #+KX#_^-?\
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M7V+[J??T=13Y#?..VJ,NV"JMAKAD-.LV32HPD$JYF4M,(7:-!*R0^Z]T,_\
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH#^9+_V5W_)9_\
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MML3(X[:<>UJ&BJ:F,XI8<?60)-.8ZMZJ*J-1#%']N@]U[H3?^$X7_9$':?\
MXM7OC_WT6QO?NO=6?_S"/^R$_F'_ .*U]S?^\!7^_=>Z)/\ R$_^W=&P_P#Q
M(G:G_O52>_=>Z(?TW0TW7W_"CSNO;>Q4_A>W]U;:SM5N>CQQ*4M9+NOH3!]G
M[C^\6ETH1+N/35NL@($X6_[@!]^Z]U[^0M0X[L#Y0_S!NX^P8(<AW9%NC!PK
M7Y%%ERF,INP-[;HR_8/V<TI9AYZ[&XV*8I;0L:)<K)8>Z]TI?YC7S\6EW%N3
M9WRB_E&;Y[1Z8Z5[DW#B^O>X>P-Y[_V3UYNG(TIK]IXG<F(S+;#-!)39FB:2
MI@QQRM732D0S+YI:6GGC]U[K80Z)WG0=C]']-]AXK;5)LS&;\ZJZ\WGCMGX^
M>&IH-J4&Z-HT><H]M45334])')#01SK2QO'20JRH"L48(1?=>Z8>YMBT7\%W
M'V_L7IWKGL/Y(]>;!WW5=&9/<^V]MR;@7>]3M.KH\%MJ@WIDVI*G&4F5J'CQ
M]?)'E:2,T\L@FGBBU.ONO=:YO\NG+9[%?S9NX,W\]\9N?K?YR]H[;K(NOMDX
M_"X*'J6HQ$NU8*JN7&;HP&5R2U4RX3$K28=0\M*8Z6J\U?4Y)XXU]U[K-\M>
MX.JOD#_.UZ6V-VIV5U_L+HOX:TN/R>>S?8^\-M;2VA7;_P % O8V3H8:_=53
M3TLU14Y=\#A*JC+:G6@J"$=$8GW7NHWP![9ZU^-O\X'Y#]"]8]C;"WST#\JI
M\CGNOL]U]O7;V[MF0;J6CG[-VOB*?+[=J)Z1):!:K/[=6E=A*933J"P:,R>Z
M]UM4>_=>Z][]U[JH#^<A_P RZ^ __C7_ /E@_P#P4V&]^Z]U[^?Q_P!N;?YA
M/_B ,O\ ^[V@]^Z]U&^9*T9_FZ?R774P_P 77"_S*%0*ZBN_N^_0.VCESXU.
MLTGWJXKSDC0)OM0Q#F._NO=)K^0G#+2_"GLR@$<SXW&_/7^8'0X/+T%9D:K8
M.XL5!\L-SZ,UU+'E::":';C3&>""-Y)V-7%62R2K+(\$'NO=&;_FS?\ ;NCY
M6_\ B.Z;_P!ZK'>_=>ZI)_E_=S_SGMK_ !!Z;P/Q=^)/Q\['Z'Q]#NQ=@;UW
MGN3!4.YLY33[_P M59R3*4M9V;@9$,.4>NIH]6)I[QQH0'!$K^Z]T9?^<YF>
MX]P_RH^J,U\@]IX#8W=.2[;ZRJ>Q]H[6J8*O;V W(V#W"*G'XFIILEF(WA50
MA#)E*D<G]P_0>Z]U<[\,O^R/OBC_ .*U]%_^^OQ?OW7NJ*_^$^7_ #-G^95_
MXD3J/_WI>Q_?NO=(W_A0-M7'[[^2'\O[9&6FJJ?%[RR6Z=JY*>A>..M@Q^X=
M^;8Q%9-1R3*Z+*L<S&,NC , 2I''OW7NB=8/N#?7PMZ0_F$_RK/D/DI E+LC
M=^X?C_N"KU4V'R%3-)'G:V@PDE99A0[EQVC-XV%6"Q5B5D# U545'NO=&%_[
MMH/_ ";O_GRO?NO=")\.>[_YWN ^+G1N%Z"^'?QRWOTQC>O\-2];[MW1N?;]
M)N'<&UHU;^'Y++TU3VGB)$F<7UJ^,IC_ ,VE]^Z]U;14]-_(SYS? 'L/I7YM
M;0VCT3W/V;#E<=4XSKRHH\UMS;DVV-V4VZ.M,_:AS^XDG3[O'T5174Z9?4Z!
MXP(&8:?=>ZI@V,?YT?\ +.V?4=65O2&WOE9\8]MTN7Q>/PV,PT7:&&I]JS5[
M/F_X%_<]Z7==%25"U;,T&X,7/2Q0F8I3+'%.4]U[JUCX"=N?#_Y[?$GNK9'2
MG2.U_C;CMWXC<76_?/4^P-M;0VS_  BK[%V9/MT[@Q^4VCC\?2Y2.KQYGAH<
MG44$,Y:F>.6GC6)-?NO=54; Z+_G+?RJ)]P;;Z"VK@/D[\=4SF4ST&W<-B:3
M>=#D:BMHA-+DX-D4%30;UQV1>GI@LU/BY)Z)JD!;U<CPF7W7NK-OY5?S'^-O
MR7RW;>"VA\7MC_%+Y.;<6*N[LVEMC9.VL!5[PBI<U-CJ[/SY[%8S%Y"IDI,K
M-*E?C\S3^>BGJE02U1>2;W[KW1B?YL&Y-P[4_EU_*S*[7:=,G/US%M^=J:5X
M95P.[MS8_:>ZCKC(.G^%UM9K%^5N#P3[]U[H$OY&&T]I[=_EO]-YC;D%$,KO
M?/=H[DWK6TT,4537[DI.R\KM6#^(%1K,E/C<;CZ5#(23'&C+9&4>_=>Z.MLG
MH_XC[>^179/:.QMI]5Q?)K- U/9.9QN2H,EV-01Y3!XF&62NP\E3--B(ZRB7
M%SS>"FIUG\XJ7UR5LLD_NO=:L'Q5WY\\]B?/G^8K4_!+I3K+NC<>0[J[+@[!
MH.R\KCL528/"0]SYZ3"UF*?([MVF'DFG,R2!9Z@A5%T3]1]U[J^GX>=M_P V
MS>?<4>%^9OQ?Z,ZEZ8.V,Y52;MZ^W!A<EN%=TP&'^!8T4U!V)N:3PS!I_*W\
M,(&D7EC_ +7NO=:TO<7Q3W?\JOGS_,YH>MZC*?Z3.FLCVIW=L;$8EV2LW-D=
MI]KXK'9/;](T2F;[N3'UU7-C1 5D>MBIXPP5V]^Z]TX?*WYP0?-GKG^5[EMQ
M5Z2]S]5]B=E[$[@I7=#4Y#*19GKG^[V^PBA?V<]2PO4.="JM9%6PH"D*NWNO
M=;GOR/\ ^R>.^?\ Q#':/_O#UWOW7NJ9?^$X7_9$':?_ (M7OC_WT6QO?NO=
M$]_FEYONS;G\YKXP9OXY;/V[O[N['=*[&GZ[V?NVIIZ/;F>S9W)O:-Z/+555
ME,+&D8IVGD!;*TXU*/7_ &6]U[H].R>_/Y^==O+:5%OCX2?&'#;*K-SX&EWA
ME\;NS;DN1Q6UJC*Q1;@R5!%'V[5,TT%(9I8E6EF)90!%(?0?=>Z)C_.[R/8>
M(_F)?R^<MU#@<5NGMC%R;#R/6&V,]-%3X/<?8=%WE%4[*P.9J)ZW'(E)69):
M:GJ'?(4JK&[$U$ 'E7W7N@#^6/S/_F0?([=*?RV?E/L[XT?$[)]Q939D>4S>
M9Q^[\%BJ[&1[@CS.W$CW]_>#=V-?'5F3Q\<:U>-B;RU%.:3[E"9HF]U[K:-^
M'7QRQOQ)^,_4GQXQ>:?<D?7& JZ7(;@:F-$F:W#G\[5[MW3DZ:A9Y6@@FR=?
M5R4\#2NT<11&=BI8^Z]U7Q_.-CIZO-?RC,;7O1_PNN_G/?$"2NARN8K,+@ZF
MHP6P>P-U;<3)ST5FGFCS%!CJC#4;D1U&6CQ\4ET8JWNO=/\ TQ_V_#^=_P#X
MH!\#?_?L]O\ OW7NO=S_ /;\/X(?^* ?/+_W[/4'OW7NK?\ W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_T]_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U7E_-MV3DNQ?Y7O\P79N'J:&CR68^'WR!-+49)ZB.A
M1\=UID<JZU$E+'+( RP,@*QM8D<6]^Z]U3%\H_YF/\VWXGTVQ_C7O7^6]\8]
MXU>]NLX=M_WQZ\^;&1J\+M?%S;+W&1F=QTV\MDX2L9EQ>T=R95H,92UA\=$8
M034U%)!4>Z]U<S_*-V7ENO?Y7/\ +XVAG):&;*XGX??']JN3&S33T=\CUKC\
MK$D4T\<3$K'.BOZ -08*66S'W7NK$??NO=>]^Z]U[W[KW7S@_DO_ -QM.W/_
M !8#XF__  $&S??NO=?1\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5$G\[GLK<7QZR
MW\MCY3XKJ/L#N[!?';YG[SWQN_K_ *K7 57866P9^&':8K6VQBMPUE#%634]
M-#55;4\<QED6$Q0I+/)%$_NO=$"^07\RGL_^:-\=NGL/U)_+?^9O5^P'^?/\
MNZ3-]N]UQ])[(VSMAS\F>M.R-M?Q?;%7NO\ O*8,[BMP;?K,-74^%DI:FGR5
M)5QS&DD,P]U[K;8]^Z]UK<_,;XR_S&=O?S0Q\V/B'\?=H]IT&W]AX3 ;=K=\
M[YZ\QNV:ZLK>NJG8^XX:_;V0W=MS,7ITJYC"XDB0R!&!DC!5O=>Z#KY)=/?S
MP_YA&UMN]"=Y=#= ="]72[LQFY-P[GVWN_:YHZB;&7AH?X_'0;UWEE9H:4RR
M5,5/CJ&,R2*/*Y"H![KW0^?S3?Y=?>'97Q!^'_QR^*FQZGM-OC]-0X#)2UFZ
MMB;.K),)A-@1;9I]P5DF]LICJ=YJRHB,LL-+*Y1G-E" 'W[KW4[_ &8;_A0W
M_P!X)?%3_P!"_;/_ -N7W[KW24_F??%CY\?*"D_EX]L=<=&;=W+W/U!M2HWK
MW5M.CWOU]M_:6S>VLC'L[<E9MBE_O5N>G>MQR97&Y*F1L?E:O]F$7K&+QS/[
MKW23[FVW_/F^:.QLI\>NS>C_ (\?';K7?JT^.WSO3;NZ]ML]7@!D()ZG$Y"3
M';TWIDUIWT!YDQN-CDFC5X7E\<AC?W7NK0=N_P MCIG&? !?@-E*JKR&U*O:
M\L.9WS3T=/2YZH[(JLS_ 'ND['HX&9PDT&9"3TE++*ZK2QQT,DDD(;5[KW57
M74W47\\KX$;9EZ'Z)VAT5\JNGL-5Y1=@9S=6X,+13;4Q%5,*Z*GH*7<^Z=H9
M&E$DDTC_ ,/FDR-/3RB9(93!XGE]U[H9/A3_ "\?F?/\TZ;^8'\Y.RMDCLJC
MQ&<Q^)ZZV7!09*=(<ULVIV11XK*UN$AIL504F*H:MDIHZ&6OEJ'0//4ZS))-
M[KW5^%924]?255#5Q^6EK::>DJ8M;Q^2GJ8C#-'KB*LNI6(NI!'X(/OW7NM8
M;:OQ$_G ? W<_>_6/PUIMA]V],=X[HRFY,9V+O;=.U8-X;%RN9C&/?>U7!N[
M.8>I7<0IFA2OJ!3Y>EJ&I8YU@$I\9]U[J%V3_*S^5_2W\M6C^*?0FSZ7N'N+
MOCMW%=B_)G-X3>^S=JX##8':U#'6[<V3B:OL+*88U]/#D*?'RK/'$S/-%5R/
M'&DE.%]U[JP7KC^1Q_+RP_7NQ<3V%T+_ 'LW[C-G;:H-[[H_TM]WXX;CW=28
M:&#<F<7'X3<E)1P"JK%FG$-+2Q1(&TQQHH"CW7N@2_EP_"7Y+_!?YP_)O;N,
MZXJ3\)>TDR4VQ-Z/OW960DQD^ RIS?6T=7MR7,39^1Z6@R&3P55/-C5>:81U
M+L(A=O=>ZOV]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=40?&#X9_)8_S<?DS\S^^NNWVQUU5T.^<)TEN"3>.P=P2[@IEJ\9U
M[LFN&(VYE*S(4*/M.AGE,5;1P,AF6-R)%9&]U[J]_P!^Z]U1'\#OAI\D]L?S
M(OF/\QOD7UT^S,-OU]Z8?IR>HW?L+<4N3P&YM]P38F9J#9N6R4U+)0X#$4%*
M17+%<3L%5G5O'[KW7?\ ,E^$_P B\M\L_C-\Y_A1L&#>';_7N5H\;VCMVFW5
ML?8K[DV]MZ77BJNORV],ACZ><5^,J,EMS(E#).:1Z9%'CA]'NO=&+_F?_ 3.
M?._J;KS*]>[@3K?O[IG+U.\.L*_/5)IJ19LW#22Y_:69S&W6JVH9S-0T%13Y
M&C:I2*II54:HIFFC]U[HB=>G_"AKM79+="YS9W1G4E)6T7]V\S\E:7=&RZ/>
M65QAJ!C:[*F?:.X<V]'+5T\CS&IQ6SJ.JC12T'VU5H!]U[HU6S?Y=^;^&O\
M+A^070WQKHJGM/Y%=O; S^,W!N=*O;VT:[>.[MVXK^Y[#$UFZ:ZEH\;CL-CZ
MNJDQ\51D RD33JS5504;W7NA,^"'PDJ^MOY;.'^)G>^VX\1N+?\ M/M+'=N8
M-*_!YIL?6]E9C)1^.GRF GJ:.6HHL=-0K%44U5)IEA5XY 573[KW5=O\FO\
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MW^R*_*G_ (8X_P!D]_T6_P#.1G]X_O\ _1W_ 'WZY_X"?[,O_I!\O][OXO\
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M[AO\QH5'D=%/NO=.73'_ &_#^=__ (H!\#?_ '[/;_OW7NO=S_\ ;\/X(?\
MB@'SR_\ ?L]0>_=>ZM_]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7%_."W7G-
MD_RKOYAFY]M5BT&;QOP^[\6AK&IJ6L$!K^NJ_&SN*:M22)CXIG UH0#8VX]^
MZ]U5%WU_)I^4?R:VKMCY%=S_ ,X'Y-[DWQL[J>'<>"BPO0?QAZ^P\<5/MC)9
MN+$Y/#=<8+$T60CT9G,8]I<A23NU'7UM(Q--53PR>Z]U:[_)]W7G-[?RKOY>
M>Y]RUBU^;R7P^Z#6NK%IJ6C$YH.NJ#&P.::B2.)3XH4!T( 3<VY]^Z]U8[[]
MU[KWOW7NO>_=>Z^<'\E_^XVG;G_BP'Q-_P#@(-F^_=>Z^CY[]U[KWOW7NO>_
M=>Z+;\J/E=T[\..L(^V.ZLCN*FV]6[FQ.S<%BMG[3SV^-W;GW3F:>IR%-A=O
M;9VY#-4U$J45%7Y"H;2L<5+2U$TCJL9]^Z]T-6R-Z;7[(V7M#L39&8I]P[+W
M[M? ;TVAGZ1*B*ESFU]TXF+.8#,4T=6D<JQU-)/%,BRQJX# ,JFX'NO=*CW[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T77Y1?*+JOXA=5S=N]NMNZ;;O]XMO[3QN'V%LS<'8&\MP[CW+5FGQN)V
M_M3;,,]54R^-)ZJ72H"0PRN3=0K>Z]T+FP-];6[1V'LGLS8V47-[*[$VCMO?
M6S\TE/54B9?:V[L-#G]OY1:2N2*>(5%)40RB.:-'759U5@0/=>Z5WOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ+?YX5'W/V!BO@+\=>@LWUWL_L[Y#
M_+_=VP\'OSM'"Y_<NTMGPR_##M:ER^3J-N[<J:.HJ:C[&KJ31,9S%'4K"TT%
M1#Y(F]U[JN;=G0_\U'^6Q\<^J<%VOW=\&N[>CLW\Z?Y9&-WC_=_ICNW;?=4L
M>Q.W^F.A^N*3;6XANJGV[3P4N-V#ML5S56 GFG_RV3R"6>,P^Z]UMU^_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_ #+KX#_^-?\ ^6#_
M /!38;W[KW7OY_'_ &YM_F$_^( R_P#[O:#W[KW4#YF?[B/YO?\ )7W#/'3R
MTN;P?\R[J>G\L/DF@S>Y^@-L=HT=52R*;QL*+8^2A9BFDK(5+JS(LGNO=</Y
M&ROA/B'V[U@DN-RN/Z3_ )@O\Q;JO#[SQL!A'8F-Q/S$W=GTWK5,))DD>HER
M4M/&T4TB"&")-;%23[KW5R/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MJ;_YP\#Y>7^59M+_ ''4L&Z?YR'PIGJ<[7TIJ9<$G6M%NSNZF_A;^2,0U.6J
M=KP;<$K/Q'D9%"R,RQO[KW3CTQ_V_#^=_P#XH!\#?_?L]O\ OW7NO=S_ /;\
M/X(?^* ?/+_W[/4'OW7NK?\ W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=?_U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M
M_P"W1_\ ,:_\5 [P_P#>)JO?NO=&_P#^Y6/_ "W_ /\ F=>_=>Z*!_)2_P"W
M1_\ +E_\5 Z/_P#>)I??NO=6?^_=>Z][]U[KWOW7NOG!_)?_ +C:=N?^+ ?$
MW_X"#9OOW7NOH^>_=>Z][]U[KWOW7N@[[2ZAZF[RV=7==]U]7]=]P]?Y.HHZ
MO);&[2V5MKL#9V0JL=.*K'U-=MG=E-5T4LD$H$D+R0$HP#*01?W[KW2ZH:&B
MQE%1XW&T=+C\=CZ6GH:"@H:>*DHJ&BI(A3TM'1TM.%CBBBC54CC10JJ   ![
M]U[J5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z#WM'J3JGO'9>3ZW[JZRZ][@Z[S4V/J,QL+M'9>V^P-EY:HQ%
M?'E<5/D]K;LIJNAG>EJH8JFG:6!C'*B2(0Z@CW7NEMCL=C\1CZ'$XFAH\7B\
M71TV.QN-QU-#18_'8^BA6FHZ&AHZ95CAAAC58XHHU"JH"J  ![]U[J9[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH#^9+_ -E=_P EG_Q?_?/_ ,!1
MVA[]U[KW\[?_ +)$ZK_\7_\ Y</_ ,&OLGW[KW5O_OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[JH#^<A_S+KX#_ /C7_P#E@_\ P4V&]^Z]U[^?
MQ_VYM_F$_P#B ,O_ .[V@]^Z]T!';WR1^.OR<_FL?R=-T_'#Y#]'_(3:NU)/
MYCN W'7=)=G[ [8Q.!W3D/C9@,AC!F,[L2OKTHJI*)*I4HYG1I8ZGRD6C2_N
MO="7_(1EJ9/@[OI*B&.B\'SG_F 118R-L51KB$/RWW7/)C?[IX]1/M_QRO(1
MALA+-41@B=9?MJBF1/=>ZNK]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5[;A
M_E];;W!_,0V3_,*F[@[&I=R;*ZY'7]-U5#2[8;:=93)MK<>UOM7W%)2'+Q82
M==RS9>NV]'4_;5&9H<7DV8248B?W7NK"??NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$B^?WPDVW\^NB:7
MH[='8&YNN:&AW]MGL"FS.W<7@=PP5>1VW35E%2T.?VUN6*6CKH(OOFR% ) #
M292EQ^10L]&L;^Z]T;?96V(=D[.VELRFRV>S]/M';.!VQ!G=TY'^,;GS4. Q
M46*BRVX\OHC^ZKZE8A-65/C7RRL[Z5U6'NO=*;W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U2C_.GK*"B@_E4RY3*XO!XR'^<M\+LKD<OG*J@APE!C]K83>6\
M:^?)TM8C23+X<=((9*>2(T,YBRE1(*&@JU;W7NDM\-.^NC?D7_.5^>?8'Q\[
MGZG[VV'#\&/@SMZ;>W3?8NT.S]HQ9_'=I=LU.0P<FY-DUE=1K601U%/)-3&;
MR(LL;,H#J3[KW0L=S_\ ;\/X(?\ B@'SR_\ ?L]0>_=>ZM_]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U6!_.M_P"W1_\ ,:_\5 [P_P#>)JO?NO=&_P#^Y6/_
M "W_ /\ F=>_=>Z*!_)2_P"W1_\ +E_\5 Z/_P#>)I??NO=6?^_=>Z][]U[K
MWOW7NOG!_)?_ +C:=N?^+ ?$W_X"#9OOW7NOH^>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[JH#^9+_V5W_)9_\ %_\ ?/\ \!1VA[]U[KW\[?\ [)$ZK_\ %_\ ^7#_
M /!K[)]^Z]U;_P"_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/
MYR'_ #+KX#_^-?\ ^6#_ /!38;W[KW5M.=P&"W3A\CM[<V%Q.XMOYBEDH<M@
M\[CJ/+X?*44PM-1Y'&9!)()XF'ZHY493^1[]U[K32E^)WSHE_GM_,[N_^73U
MC\-J;9?PY[1V.U;L+N[=^^>K-J9/<?R#_EQ=5X&KH]M;>ZAV]6BGGCH,?D_M
M:N204[5F3>6K@(A$I]U[JW7X'=&_S5?AAT;E^L<Y\?O@!W%OW>W>'R"[_P"T
M.U?^' ODIL;^_&_^_P#N/,]IY2O_ +HU/QFSOV7V5/DJ3$>C)R+4?:?=E8I*
MAXU]U[HY_P#I&_FF_P#>&_P _P#3EGR*_P#N3O?NO=>_TC?S3?\ O#?X ?\
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MU[_2-_--_P"\-_@!_P"G+/D5_P#<G>_=>Z]_I&_FF_\ >&_P _\ 3EGR*_\
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M?^Y?_?=9+W[KW0 ?RG?^W67\M/\ \4 ^&_\ \#KMSW[KW1?^Y_\ M^'\$/\
MQ0#YY?\ OV>H/?NO=6_^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[K__TM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M_P"W
M1_\ ,:_\5 [P_P#>)JO?NO=&_P#^Y6/_ "W_ /\ F=>_=>Z*!_)2_P"W1_\
M+E_\5 Z/_P#>)I??NO=6?^_=>Z][]U[KWOW7NOG!_)?_ +C:=N?^+ ?$W_X"
M#9OOW7NOH^>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH#^9+_V5W_)9_\ %_\ ?/\
M\!1VA[]U[KW\[?\ [)$ZK_\ %_\ ^7#_ /!K[)]^Z]U;_P"_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_ #+KX#_^-?\ ^6#_ /!38;W[
MKW5O_OW7NJ@/@G_V\Q_GC?\ B?\ X1?_  O?87OW7NK?_?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7_Y9?]DL?)?_ ,5_[E_]]UDO?NO= !_*
M=_[=9?RT_P#Q0#X;_P#P.NW/?NO=%_[G_P"WX?P0_P#% /GE_P"_9Z@]^Z]U
M;_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__3W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW58'\ZW_ +='_P QK_Q4#O#_ -XF
MJ]^Z]T;_ /[E8_\ +?\ _P"9U[]U[HH'\E+_ +='_P N7_Q4#H__ -XFE]^Z
M]U9_[]U[KWOW7NO>_=>Z^9'_ #%.^NI_B]_PL%S_ ,@>]-U_W&ZBZJ[@^*FZ
M=^[M_@6Y=S?P' T_PGV3335W\!V?1Y#)U5GE1?%144TAO<(0"1[KW6V]_P!!
M1W\BC_O.;_V6;YA__:^]^Z]U[_H*._D4?]YS?^RS?,/_ .U][]U[KW_04=_(
MH_[SF_\ 99OF'_\ :^]^Z]U[_H*._D4?]YS?^RS?,/\ ^U][]U[KW_04=_(H
M_P"\YO\ V6;YA_\ VOO?NO=>_P"@H[^11_WG-_[+-\P__M?>_=>Z]_T%'?R*
M/^\YO_99OF'_ /:^]^Z]U[_H*._D4?\ ><W_ ++-\P__ +7WOW7NO?\ 04=_
M(H_[SF_]EF^8?_VOO?NO=>_Z"COY%'_><W_LLWS#_P#M?>_=>Z]_T%'?R*/^
M\YO_ &6;YA__ &OO?NO=>_Z"COY%'_><W_LLWS#_ /M?>_=>Z]_T%'?R*/\
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M7O?NO=>]^Z]U[W[KW58'\ZW_ +='_P QK_Q4#O#_ -XFJ]^Z]T;_ /[E8_\
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M3[KW2R]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4!_,E_[*[_DL_\
MB_\ OG_X"CM#W[KW7OYV_P#V2)U7_P"+_P#\N'_X-?9/OW7NK?\ W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4!_.0_P"9=? ?_P :_P#\L'_X
M*;#>_=>ZM_\ ?NO=5 ?!/_MYC_/&_P#$_P#PB_\ A>^PO?NO=6_^_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKVW'A/YB$O\PW8V;V[N[KFF_E[4VP8
MDWKM68;:;=F0W(VT]T4]>B4L^#DSXS8W')LZJH:ZEW)#AUPT.4IJC&RY*6GJ
ME]U[JPGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW1(OY@&%^;.>Z"-%\!]U[=V?W@F\L'4U62SLFR:>IJ
M=F14%:*_'8&N['P.YL'!/)DCBFKI*[#3,<8E?'1M#D'I)H_=>Z-KLB'>%-LO
M:%/V%6X/);^@VO@(=\9';%-54>VZ_>$6)B3<M;MZDKR9XJ&6M$\E)',=:Q%%
M?U ^_=>Z5'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HO_P LO^R6/DO_ .*_
M]R_^^ZR7OW7N@ _E._\ ;K+^6G_XH!\-_P#X'7;GOW7NB_\ <_\ V_#^"'_B
M@'SR_P#?L]0>_=>ZM_\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M_P"W
M1_\ ,:_\5 [P_P#>)JO?NO=&_P#^Y6/_ "W_ /\ F=>_=>ZTN_Y>?SE_F^[&
M^#/Q/V=U!U[W7D>KML]$=<X;8-=A/Y0'9?<&(J]JT&W88,-/C>TL9W?@Z?/P
MM"%*96'#T:5 _<6GB!TCW7NCC_\ #B'\\/\ Y]AW_P#^F.>V?_NA/?NO=>_X
M<0_GA_\ /L.__P#TQSVS_P#=">_=>Z]_PXA_/#_Y]AW_ /\ ICGMG_[H3W[K
MW7O^'$/YX?\ S[#O_P#],<]L_P#W0GOW7NO?\.(?SP_^?8=__P#ICGMG_P"Z
M$]^Z]U[_ (<0_GA_\^P[_P#_ $QSVS_]T)[]U[KW_#B'\\/_ )]AW_\ ^F.>
MV?\ [H3W[KW7O^'$/YX?_/L._P#_ -,<]L__ '0GOW7NO?\ #B'\\/\ Y]AW
M_P#^F.>V?_NA/?NO=>_X<0_GA_\ /L.__P#TQSVS_P#=">_=>Z]_PXA_/#_Y
M]AW_ /\ ICGMG_[H3W[KW7O^'$/YX?\ S[#O_P#],<]L_P#W0GOW7NO?\.(?
MSP_^?8=__P#ICGMG_P"Z$]^Z]U[_ (<0_GA_\^P[_P#_ $QSVS_]T)[]U[KW
M_#B'\\/_ )]AW_\ ^F.>V?\ [H3W[KW7O^'$/YX?_/L._P#_ -,<]L__ '0G
MOW7NO?\ #B'\\/\ Y]AW_P#^F.>V?_NA/?NO=>_X<0_GA_\ /L.__P#TQSVS
M_P#=">_=>Z]_PXA_/#_Y]AW_ /\ ICGMG_[H3W[KW7O^'$/YX?\ S[#O_P#]
M,<]L_P#W0GOW7NO?\.(?SP_^?8=__P#ICGMG_P"Z$]^Z]U[_ (<0_GA_\^P[
M_P#_ $QSVS_]T)[]U[KW_#B'\\/_ )]AW_\ ^F.>V?\ [H3W[KW7O^'$/YX?
M_/L._P#_ -,<]L__ '0GOW7NO?\ #B'\\/\ Y]AW_P#^F.>V?_NA/?NO=>_X
M<0_GA_\ /L.__P#TQSVS_P#=">_=>Z]_PXA_/#_Y]AW_ /\ ICGMG_[H3W[K
MW7O^'$/YX?\ S[#O_P#],<]L_P#W0GOW7NO?\.(?SP_^?8=__P#ICGMG_P"Z
M$]^Z]U[_ (<0_GA_\^P[_P#_ $QSVS_]T)[]U[H-]N_*'^89WI_,9_E-[>^8
M.T.R]N[(Q'RWWYF=L56]OY>.]?A[CY]U#XG]@T*P4F^-S=G;XBR<WVDM2W\*
MCQ].Y4-4?<:83&_NO=7C?SM_^R1.J_\ Q?\ _EP__!K[)]^Z]U;_ ._=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_,NO@/_P"-?_Y8/_P4
MV&]^Z]U;_P"_=>ZJ ^"?_;S'^>-_XG_X1?\ PO?87OW7NK?_ '[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%_\ EE_V2Q\E_P#Q7_N7_P!]UDO?
MNO= !_*=_P"W67\M/_Q0#X;_ /P.NW/?NO=%_P"Y_P#M^'\$/_% /GE_[]GJ
M#W[KW5O_ +]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_]'?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5@?SK?\ MT?_ #&O_%0.
M\/\ WB:KW[KW1O\ _N5C_P M_P#_ )G7OW7NB@?R4O\ MT?_ "Y?_%0.C_\
MWB:7W[KW5G_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J
MH#^9+_V5W_)9_P#%_P#?/_P%':'OW7NO?SM_^R1.J_\ Q?\ _EP__!K[)]^Z
M]U;_ ._=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YR'_,NO@/
M_P"-?_Y8/_P4V&]^Z]U;_P"_=>ZJ ^"?_;S'^>-_XG_X1?\ PO?87OW7NK?_
M '[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%_\ EE_V2Q\E_P#Q
M7_N7_P!]UDO?NO= !_*=_P"W67\M/_Q0#X;_ /P.NW/?NO=%_P"Y_P#M^'\$
M/_% /GE_[]GJ#W[KW5O_ +]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO_]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5@?SK?\
MMT?_ #&O_%0.\/\ WB:KW[KW1O\ _N5C_P M_P#_ )G7OW7NB@?R4O\ MT?_
M "Y?_%0.C_\ WB:7W[KW5G_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[JH#^9+_V5W_)9_P#%_P#?/_P%':'OW7NO?SM_^R1.J_\ Q?\
M_EP__!K[)]^Z]U;_ ._=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MJ@/YR'_,NO@/_P"-?_Y8/_P4V&]^Z]U;_P"_=>ZJ ^"?_;S'^>-_XG_X1?\
MPO?87OW7NK?_ '[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%_\
MEE_V2Q\E_P#Q7_N7_P!]UDO?NO= !_*=_P"W67\M/_Q0#X;_ /P.NW/?NO=%
M_P"Y_P#M^'\$/_% /GE_[]GJ#W[KW5O_ +]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=5@?SK?\ MT?_ #&O_%0.\/\ WB:KW[KW1O\ _N5C_P M_P#_ )G7OW7N
MB@?R4O\ MT?_ "Y?_%0.C_\ WB:7W[KW5G_OW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[JH#^9+_V5W_)9_P#%_P#?/_P%':'OW7NA<_FD
M=']C?(;H+JCK?J["_P ;W*/FG\(M]UJ22&"BQ6SNK/DWMOLO?NXLE4A7\=/C
M\+B:ZKDLK,_C$<:O*Z(WNO=61^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NJ@/YR'_,NO@/_P"-?_Y8/_P4V&]^Z]U;_P"_=>ZJ ^"?_;S'^>-_
MXG_X1?\ PO?87OW7NK?_ '[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=%_\ EE_V2Q\E_P#Q7_N7_P!]UDO?NO= !_*=_P"W67\M/_Q0#X;_ /P.
MNW/?NO=%_P"Y_P#M^'\$/_% /GE_[]GJ#W[KW5O_ +]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=5@?SK?\ MT?_ #&O_%0.\/\ WB:KW[KW1O\ _N5C_P M_P#_
M )G7OW7NB@?R4O\ MT?_ "Y?_%0.C_\ WB:7W[KW5G_OW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH#^9+_V5W_)9_P#%_P#?/_P%':'O
MW7NE)_..WEN_8WQ6ZSS&R=U;DV?EZOYS_P OS;U5E=K9S)[?R53@-R_,/9V#
MW'@ZBNQ,L,KT>0HIYZ.MIF8QSP2/%*K1NRGW7NK6_?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW50'\Y#_F77P'_ /&O_P#+!_\ @IL-[]U[JW_W
M[KW50'P3_P"WF/\ /&_\3_\ "+_X7OL+W[KW5O\ []U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NB_P#RR_[)8^2__BO_ '+_ .^ZR7OW7N@ _E._
M]NLOY:?_ (H!\-__ ('7;GOW7NB_]S_]OP_@A_XH!\\O_?L]0>_=>ZM_]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_U=_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M_P"W1_\ ,:_\5 [P_P#>)JO?NO=&
M_P#^Y6/_ "W_ /\ F=>_=>Z*!_)2_P"W1_\ +E_\5 Z/_P#>)I??NO=6?^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/YDO_97?\EG_
M ,7_ -\__ 4=H>_=>Z]_.W_[)$ZK_P#%_P#^7#_\&OLGW[KW5O\ []U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ _G(?\RZ^ __ (U__E@__!38
M;W[KW5O_ +]U[JH#X)_]O,?YXW_B?_A%_P#"]]A>_=>ZM_\ ?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7_P"67_9+'R7_ /%?^Y?_ 'W62]^Z
M]T '\IW_ +=9?RT__% /AO\ _ Z[<]^Z]T7_ +G_ .WX?P0_\4 ^>7_OV>H/
M?NO=6_\ OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__UM_CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6!_.M_P"W1_\ ,:_\5 [P
M_P#>)JO?NO=&_P#^Y6/_ "W_ /\ F=>_=>Z*!_)2_P"W1_\ +E_\5 Z/_P#>
M)I??NO=6?^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@
M/YDO_97?\EG_ ,7_ -\__ 4=H>_=>Z]_.W_[)$ZK_P#%_P#^7#_\&OLGW[KW
M5O\ []U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ _G(?\RZ^ __
M (U__E@__!38;W[KW5O_ +]U[K7-Z>^>/PP^(G\TO^='MSY0?)_I/H3/;O[K
M^%N;VMB.T]_X#9V0S^(H?@%L&AK,EBJ;,31M-#%,1$\B @-P>??NO='S_P"'
MK?Y1_P#WL:^('_H\-D__ %5[]U[KW_#UO\H__O8U\0/_ $>&R?\ ZJ]^Z]U[
M_AZW^4?_ -[&OB!_Z/#9/_U5[]U[KW_#UO\ */\ ^]C7Q _]'ALG_P"JO?NO
M=>_X>M_E'_\ >QKX@?\ H\-D_P#U5[]U[KW_  ];_*/_ .]C7Q _]'ALG_ZJ
M]^Z]U[_AZW^4?_WL:^('_H\-D_\ U5[]U[KW_#UO\H__ +V-?$#_ -'ALG_Z
MJ]^Z]U[_ (>M_E'_ />QKX@?^CPV3_\ 57OW7NO?\/6_RC_^]C7Q _\ 1X;)
M_P#JKW[KW7O^'K?Y1_\ WL:^('_H\-D__57OW7NO?\/6_P H_P#[V-?$#_T>
M&R?_ *J]^Z]U[_AZW^4?_P![&OB!_P"CPV3_ /57OW7NO?\ #UO\H_\ [V-?
M$#_T>&R?_JKW[KW7O^'K?Y1__>QKX@?^CPV3_P#57OW7NO?\/6_RC_\ O8U\
M0/\ T>&R?_JKW[KW7O\ AZW^4?\ ][&OB!_Z/#9/_P!5>_=>Z]_P];_*/_[V
M-?$#_P!'ALG_ .JO?NO=>_X>M_E'_P#>QKX@?^CPV3_]5>_=>Z]_P];_ "C_
M /O8U\0/_1X;)_\ JKW[KW7O^'K?Y1__ 'L:^('_ */#9/\ ]5>_=>Z]_P /
M6_RC_P#O8U\0/_1X;)_^JO?NO=>_X>M_E'_][&OB!_Z/#9/_ -5>_=>Z]_P]
M;_*/_P"]C7Q _P#1X;)_^JO?NO=>_P"'K?Y1_P#WL:^('_H\-D__ %5[]U[K
MW_#UO\H__O8U\0/_ $>&R?\ ZJ]^Z]U[_AZW^4?_ -[&OB!_Z/#9/_U5[]U[
MKW_#UO\ */\ ^]C7Q _]'ALG_P"JO?NO=>_X>M_E'_\ >QKX@?\ H\-D_P#U
M5[]U[H$_DM_.2_E3;F^.7?\ MS;_ /,)^)F9SVX.D^U<)A,1C^Z=F560RN7R
MNQ:^@QN-H::*I+233S2)%$BB[,P Y/OW7NC6?RG?^W67\M/_ ,4 ^&__ ,#K
MMSW[KW1?^Y_^WX?P0_\ % /GE_[]GJ#W[KW5O_OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z_]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=5@?SK?\ MT?_ #&O_%0.\/\ WB:KW[KW1R\=CZW+?&>AQ6-IY*S(
M9/HNFQ]!20@&6JK:S8"TU+3Q V&IW956Y^I]^Z]U1-_+H^>^^_BG\$/B1\:^
MS_Y9'\UZH[$Z-Z$ZWZQWI/M3X>S9G;4VY-H[<AQ&5DP66J,_3/4TIEC8PS-!
M&76QTB]O?NO='/\ ^'=__!8/\W[_ -(K_P#SE]^Z]U[_ (=W_P#!8/\ -^_]
M(K__ #E]^Z]U[_AW?_P6#_-^_P#2*_\ \Y??NO=>_P"'=_\ P6#_ #?O_2*_
M_P Y??NO=>_X=W_\%@_S?O\ TBO_ /.7W[KW7O\ AW?_ ,%@_P W[_TBO_\
M.7W[KW7O^'=__!8/\W[_ -(K_P#SE]^Z]U[_ (=W_P#!8/\ -^_](K__ #E]
M^Z]U[_AW?_P6#_-^_P#2*_\ \Y??NO=>_P"'=_\ P6#_ #?O_2*__P Y??NO
M=>_X=W_\%@_S?O\ TBO_ /.7W[KW7O\ AW?_ ,%@_P W[_TBO_\ .7W[KW7O
M^'=__!8/\W[_ -(K_P#SE]^Z]U[_ (=W_P#!8/\ -^_](K__ #E]^Z]U[_AW
M?_P6#_-^_P#2*_\ \Y??NO=>_P"'=_\ P6#_ #?O_2*__P Y??NO=>_X=W_\
M%@_S?O\ TBO_ /.7W[KW7O\ AW?_ ,%@_P W[_TBO_\ .7W[KW7O^'=__!8/
M\W[_ -(K_P#SE]^Z]U[_ (=W_P#!8/\ -^_](K__ #E]^Z]U[_AW?_P6#_-^
M_P#2*_\ \Y??NO=>_P"'=_\ P6#_ #?O_2*__P Y??NO=>_X=W_\%@_S?O\
MTBO_ /.7W[KW7O\ AW?_ ,%@_P W[_TBO_\ .7W[KW7O^'=__!8/\W[_ -(K
M_P#SE]^Z]U[_ (=W_P#!8/\ -^_](K__ #E]^Z]U[_AW?_P6#_-^_P#2*_\
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M_P#_ $.?A1_]M#W[KW7O^')?EW_WI9^?_P#Z'/PH_P#MH>_=>Z]_PY+\N_\
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M-;7U];4LL<,,,:M)++(P5%!9B "??NO=$1_X=<_E;_\ >R?X"?\ I8OQW_\
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M'7/Y6_\ WLG^ G_I8OQW_P#LC]UUIZC]O6Z'KW_#KG\K?_O9/\!/_2Q?CO\
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MZ?)RT^W\#@Z262EQN\M[XZBD-/DMU5\),U;7S>44OE:CHF2E3]Q"\A<_+IT
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M?#_X59_'C:?Q*_E/_P KSXS;'TR;9Z,[!QW6M!7")8)<U/M?I"HQV4W)6QH
M/N<G5K/D:M@!JFFD:PO[43#2@'5%R:]:5?PZ^$?R?^?O;<_17Q)ZR_TL]J4V
MT<SON?:W]].O=B:-J;?K*2@R^5_C?9>6PV./AFKJ5/ *PS/KND;*KE6%4L:+
MU<D#CU:7_P! O?\ /0_[P=_]F7^'_P#]L#W?P9/3_!UK4O7O^@7O^>A_W@[_
M .S+_#__ .V![]X,GI_@Z]J7KZD^1VSF]E_ FNV=N:B_ANX]I_$.JVSN#'?<
MTE9_#\W@>F6Q>5HOO,?)+!+XIXI(_)!*\;6U(S*02K_#^7377PXO:#I_J^7$
M?\)D?YX.>Q.+SF)^$GW6+S..HLMC:K_9DOB+!]SC\C3+64=1X*G?R2)KC=6T
M2(K"]F -Q[<\*3T_P=5U+T03YI?RSOG5_+QKMM4?S%^.F[NF8-Y25-/M7<%5
ME-H;TV7GZVCI8ZZLQ>,W[UQDLQA):V&&5)):)<AYT6Y:,:6M5D9?B'6P0>'6
MS=_PDB_FL]R[7^3^(_EK]M[ZS>]NC^X-K[KK>A<?NO-562?J#L;8.VJG>E5M
MK9U5D6<TN#S6'H,D'PZ2+!'7Q4\M)'%+4U@JG87-=)X=588KU]('VJZ;Z][]
MU[K3*_X6N?\ 9!_Q0_\ %N$_]\WN7VQ/\(^WJZ<>M=?_ (2)?]OB-K_^*\]Y
M?^ZZ@]M0_'UM^'7U7?:SIOKWOW7NM*G_ (6R_P#9'7PV_P#%E]R?^^MKO:>X
M^$=73CUH3_#KX1_)_P"?O;<_17Q)ZR_TL]J4VT<SON?:W]].O=B:-J;?K*2@
MR^5_C?9>6PV./AFKJ5/ *PS/KND;*KE4ZJ6-%ZN2!QZM+_Z!>_YZ'_>#O_LR
M_P /_P#[8'N_@R>G^#K6I>O?] O?\]#_ +P=_P#9E_A__P#; ]^\&3T_P=>U
M+UL,?\*SO@OFQ\!_@'\K'P,E#OSXS[=V7\;>YZ6FEI*\TFVM[;,HYL'49*NH
M7F@>'#;EQ-3CX9:>8QO)F"0TBF-E=F7M#>G54.:=:^7_  F5^7C_ !-_FX=
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M)R6/:BSVW:W';MD2ER%/44LSQ5E)(DB/$Y61"C$&QIY]:ZTV^_O^$N_\JO\
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M'ZDP4U /KTR>/2D^1?\ V3YWM_XAOL__ -XFN]^/ ]>Z^$5[+^G^OO+=1?\
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M_I;]V^G^?\O]GK6OY=7S?R//Y%/_  S/EODGE/\ 9I?]F/\ ]F%QW5%!X/\
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M1@:)672%FQ-0IUW]"F!<%NFW/EUO4>U'5.OC<?\ "@[_ +?-?/[_ ,3)1_\
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M$/L?+#YO#YO)XO-'KMIUK?4-'(IU[K1$_P"@''_P:!_[)3_^EOVG^G^?\O\
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M?OI_G_+_ &>O:_EUN>_!;XP?[)9\0/CS\4O[\?Z2O] W6F"Z[_O[_=K^YO\
M>O\ @J,O\8_NM_$,K]CY=7_ ?^(U&FW^=;V^HTJ%].J')KU7;_-@_D(?#/\
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M:)/T^WW76NGAU0&AKU0S_+E_X2;?\-__ #6Z%^87^S]?Z6O]"&XL[GO]'?\
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A7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,8 F0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +1110 444F[G% "T4R29(MN]MNX[1[G&?Z4[KS0 M%,259"P4YVG!IV1R*
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M-J5V;6%\P2J 7!_A+"3'_3/MC([:W \O((;/\0[T </:?!/PCI5JT-EIKV4
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MR3C- &3\-_AQX7\6> ?#^LZYX>TG6=7U"RBN[N^O;")Y9I9%#.S';W)Z= ,
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M^SKO(!P<$C@'!Y/0UG+X8^)Y4-%XSTU4WL45M,5B%,BLN]@!OQ&&4[1'EF#
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M'D8^88[T 3445%;R/)&6DC:(Y(VL03UZ\$]>OXT 2T5#<221*ICB:;+JI52
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M!Z9..?0]L5(?SH \BU+X"I;Z?.+'Q)K$DWS.OVBSTNX<[I6E=1)-:,Q)9Y"
MS8!?L.G$:7X'M[Z:_M+?QEJEU=VNN)I<\9\/Z.LL8,$4C J;%>,2 [N>&[U]
M'Q3,ULDDJ&!V0,T;$$H<<@D'''L:^$/'OP2^+WC_ .-?C?7O!/Q?O/!/AF\\
M3VJ6UG;Z%#?1&8:=:C[4'>1<KGY>,X(..AP >S^(O NH_#WQ_P""UCUV74=-
MO]4CADBN](TL%P"G!:*SC*G+$@JV?E!SU%>Y>"8U7P9H: 846,( ';Y!7R/H
M_P )?BU\,/BAX%N_B/\ &UOB3IMWJ4=O:Z;)HD5CY,_FQ-YH9&);Y0RX/]_-
M?77@U@O@_12>GV*'_P! % %?P3X'T_P#I!T[3FE>#>'S*$!R(TC'W%4?=1><
M9)R223FCQ%X'T_Q-K&DZE=O*MQIK%H1&$P<O$_.Y21\T*<J0<9&<$BM^.195
M+(<C)7\0<']1227$<+1J[;6D;:O!Y."<?D#0!Y?^T1IS7O@+SH[RYL9[&62X
MBEMF4$G[+.I5MRD%2KD$8KT71-)70]-@LUN;B[$*[?.NY-\C<DY)P/7\*\U_
M:4\1:=X>^'<G]HW(MOMDKVL&59M\K6TY5> <<(W)XXKT?P_X@L?%&D6VIZ;/
M]IL;A2T4VQEW#)&<, 1R#UH TJ*** "BBB@"*:X6WP7.%ILEY'$Y1G56]"<5
M'J/W(3_TV0?^/59V\YR: *_VZ,#)EC_[ZJ6.=9%#*<@], U)BC:/2@""2\CA
M=59MI;IN! J&35H8Y K2#ZA21^?2KNT=N*-HH IRZI#"H9I%()P-N2?R%*=2
MA$7F&5 F-WOCZ5;VCI1M^M %.'5()]VV10!_>!7^=2?;H_\ GK'^=6,?A1CW
MQ0!7^W1_\]8_SH^VQ_\ /6/\ZL48]\4 0&\4 G*D*"W!!/'IS4XJK>*K>4I&
M[,@ZGIC)S^0(_&K0H 6BBB@ HHHH \[_ &@+,3?"7Q'>)#(][I]E/=VDT$Y@
ME@E$3IYB2 @JP1W'!Y!([UU_A>.2/PQI"3V/]F3+9PA[+S1+]G8(,Q[QPVT\
M;AUQFN0^/VL)I'PKUSS+:><7%M- )8K;[1';DPNPDF3#9BRN&!5@=P!4@FNQ
M\,N)/#>DND5Q"C6D)$=XI69!L'#@]&'<>N: +T-O';J%C4(H& H& *62WCF9
M&=%=DY4L 2,^E-@DDE4,T;1 C[K8R/K@D4Z1W62-51F#'EAC"_7G/Y9H \H_
M:<NM0L?AL;G3-/N-0O8;@R(MK>?9)(\0RY=9,C&!QU[UZCIEG#IUA;VEO&(;
M>"-8HXUZ*H& /P%>:?M(-$/AZ5F25HY)BA:.W,X3,,GS,FULJ/\ =.#@]0"/
M1]%OEU/3;>Z6&>V$T22>3=(4E3*@[74\JPS@@T 7J*** "BBB@!*SI(]FI)B
M21MW)7(P.&_'N/S%:-9DMQ')JT:K,-ZY4QX/H3_[** -+;N4<D?2G4W<% )[
MTZ@!H7!)R36=&S/J$L8D9%)+8&.<*@[BM(,"2!U%9/VM(M8822$9^0+@G'"$
M?KF@"Y)IL4K;G+EO4-C^5-TW2+?26NC;AA]IE\Y]QS\VU5X_!15VB@ HHHH
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MHHH **** "J$\8;5(#@$J"0<GCC&.OO5^LN0;=6MUD<,V&93L.?ID''<]NU
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MBB@ HHHH **** "BHYIX[6%Y9I%BB0%F=V 50.I)/05F_P#"7:%_T&M/_P#
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MIH+' !NX^>_K0!P7[2=H6^&-W>I<:E#):7%LPCTM4=Y=T\:;2CJP8#=D9'!
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ML>(LKH.I%7((M92,2",_=/.\\+]3P._%0>+M7O- T&>]T[39M:O5DBBBL8I
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M_OW;?_&: /-KSXT>(X;5S;_#_4KZZ7:PCA>98Y8_.>-G1W@7H C ,%+ M@8
M+=YX+UW5O$5K=SZKI"Z-Y<HCA1;AI6D&Q2S'=&F &)48SG:3WJ[_ &#=?]!W
M4/\ OW;?_&:/[!NO^@[J'_?NV_\ C- &KM_VC^=&W_:/YUE?V#=?]!W4/^_=
MM_\ &:/[!NO^@[J'_?NV_P#C- &KM_VC^=&W_:/YUE?V#=?]!W4/^_=M_P#&
M:/[!NO\ H.ZA_P!^[;_XS0!J[?\ :/YT;?\ :/YUE?V#=?\ 0=U#_OW;?_&:
M/[!NO^@[J'_?NV_^,T :NW_:/YUFZLI^W:/@,P^UDDA0<?N)><]OJ/IT)IG]
M@W7_ $'=0_[]VW_QFJ>H>&-1N'M7@\0WD;02^;^\M[9PPV,I _=C!^;K[>]
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MN?L*W[W$,UR$9VB065R[%0KH=WR8'S#K70^#_#M_X?T9HI&C6[FEDFF)FFN
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M9=LC8Z,6C8;=H\RK7A/QQXA\1:M!:7GP^&C1-=M!+-<W+';$JN3*H$.""50
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M%9\WP_\ '2YUF6\CLO#NJ>(((;^2R;4=,L7CM[>1)C%+%*)=LFZ)E;>R*P(
M*Y)V#UW:/2OGKX"_%#P7X7TWQSI^M>+M!TB_3QOX@9K6^U.&"50=0FVDJS C
M(Z>V* .ETOXUWEUX?$=S;[M?D:6"*6UTF_%J9?F\MBC1>9M' 9?O9!QD<UQG
MB/Q3K?@_X:^&=4U:.YT_3]*ETFQ^W+!/):RLT]K$)/L2A;F1GF8JJLN>$P!E
MG._K7B/X87-]<:C8_%?1])9I7N?L=EJ^G>292"6;#JQ&XY9L'DEC@$FN.^)O
MQ.^'WQ1^&&D>%(/B!X4M[I;G1+E+*/48IKFYGANK:Y6WBA64/\QC1/E+-EB
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MZ>2)/#&H?\)'!&!E)IH;>=%1\$' \TN#_>1<@C(/I7AO_D7=*P,#[+%_Z *
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M_P 3K54B^TS>%=6@BED'^K+V<HSG!(]\4 9OQO<Z3\/-0EU"\6VADE*PBZN
M0H\B3JQ/WCR< D87ZUZ['T.#G_\ 57E?[2C7T/PY:;3()9;Z&9GB>"_>R>(B
M"7YA*GS#TP.H)!XS7I>DV,6FZ?!:6ZLEO!&L4:.[.550 !N8DGIU)H N4444
M %%%% !6;+,C:O$@9"P4_P 7(('3_P >_2M*L^2,0ZA$L<*B,D$E0!@X;^=
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M++X=^(-5M?M:1?;XECBC:$H&9PDKK(&#?)AE5<\E@O-9G[1EA>:AX;\I[_\
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M#Q%KVD)\-=01],^SA9)=4M@)/-0MN8[L*!C&4,AX/ .!7K6U?0?E2X P ,4
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ME5&W+AC&' ^8=>HZT 8W[15U;6/P5\5W%W/#;VJVJ^9)-*(EVF11C>00I.<
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M%4444 %%%% !112'.#CK0 M%>,6_PU^)+*OG>,5BD^SQ*DD=W,_D3?*)WVE
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MEAI^S4(-3ECN;MO.+""<2111^4/,*9!+97'4@<9S?VO% ^ OC$],:%K)Z_\
M4(O: .D\+_%CP!8>"8]3_P"%@^'[K2(B3)JDFNQ30HSOPIG>0DX+A1N.>@]J
MZJQ\5Z+XDT>&ZT?7M.O+>^C/V2\M;E)HY,DJ&0JV'^8$<'JI%>%?LB_L[Z?^
MSA\%+;0+G6QK>GV]W<:B]S-;I& 7(SO*NX95V@CD8)R>5&.&\8?#GQ?X;\/>
M($T[QUXFM?"LM_->0V=CI+::\$<MZ]R\1G4"7:6F9 X9'')X&"0#O_ O@/XJ
M?#;2=5T*S\->$=>L&U_5=6M]2E\9ZCIT\BW=[-<J)(ET^7:RK,%($C [<YSF
MKVJ^"_B;XXUWPG'K/A_PKH&DZ7JO]ISWEGXMO=5NFVVUQ$J)%+80@@M,#_K1
M@ ]:\P^$G@JS\3>"_AK=W-Y\1O$%_J>CZ?/?SVWCK4K:-99H(9'EE9M10L3E
MW5(HR=H<;>!COOBS\ _&.K:WX U/P;XJET>+PG<37%PFK:E>7<6IP_NMD4P:
M4EFQ&P+-N^\6!#$%0#0U;X,>.9/BI>>)=,UK2+2REA1!YD;R-(ZJ@1FB9"%V
M_O0"';[P/!QMM^ ?!VO^&?B!+=>);ZVN]1N[J$HEA"5MDA$.H$%3L4*[.\C,
MHXR0W5S7/?!+X]^//C%IOCJTBM_"]CXA\-^++[PPD:_:)(9Q:^7ON2 VY4;>
MP'/7:,DGGH['0_';_'#POK?BMO#5W8VNFWEA''I8N(Y(IYRDJRA9 ZL0EI*F
M0RD"9NH)! /<**1?NBEH *S8F7^V)%#9;:6(YXX0?3I6E6;NVZN2SC9M*@$C
MKE.E &E14+WD,<;.9!M7J5YQ^5.CN(YF=4=7*':VTYP<9P?PQ^= $E%%% !1
M110 444AZ&@"EK$:S6>QUW(SHI![@N!_6D71+%9"XMU#$YR"?3KUZU3U+4+D
MW#VZZ?,84:)_M4DD8C;YP2J@,7+8Z94 GC-7M.U)=2A\U(9XDSC]_$T;>GW3
MS0 UM"L&_P"79?N[>"1Q2?V#I^Y6^S+N!)SD\Y.3GGGGUK0I.=W7B@"A_8-@
M<$VJ,0<AFR3QTY]..E!T&P96'V9<-P<$C\.OO6A2>M %'^P[$$G[.N2<GD_X
M^PH_L*P_Y]EQMV[<G&/ITJ\V>QQ10!1_L&PW!OLR$C///.>N?6D_L&PX_P!'
M7@Y^\?3'KZ5?.?6EH H'0; J1]G49&."0?SS2_V)8CD6Z@YSU/'T].@_*KJY
MYS0W((!Q[T 4!X?T\?\ +LO3&,G''X]?>E&A6 Q_HZGKU).<^O/-7A1W'- %
M#^P;#_GV4\[N23TZ=^GM2MH5@PP;=>F."1CG/'/'-7Z09R>2: *']@V'S?Z,
MOS<GD]?4<\'_  H70-/7&+90   ,G''3O5\T#/>@"C_8=CQ_HZ]SG)SS^-)_
M8%AQ_HRG!SU/Y=>GMTK0HH H/H5A)NW6ZG=P>2/Z_P"<TIT2Q92OV==ISP"1
MUZX].@Z>@J]10!0_L&P!R+5!QCC.,?YS^9I/[!L/^?92?<DY^O/-:%% &?\
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M9N4+]KE+*"#N !/RE:X?]@'36L/AW\5M,T_0K?0;.'XBZW!%I3SJHLE!C A
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M[W.U%="6/8!UIRZM:-(R+,&8=0N3V_\ U?G0!<HJG_:UH5+"8, -W )XIO\
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M5>%S&\MS;6Q8=566>.-B/?#G!]<5;&L6;8Q.IR<=_3/Y8[US_CC6K-='M<S
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MZ8]/PJ,_';P[?^'[:[=Y8KJ0Q$VL<CX63;YFPR(.@ .01S@JP!R*T_ OQO\
M#?CS4+33;-KJUU2XMVN?L=U RNB@GACR 2HW8ST(K%2PTFDK79Z=2AGU*G*I
M/VBC'=WEIY[[>>WF46_9B^$[%B?A[X?.Y=I_T%,8]ACC_P"L*$_9A^$\>P+\
M/M  084?8DQ_+D^_N?6J=]\=K328+C5;SP]JUM G]I1S^9-&1&+&.:4C8'(W
MN$;&T>FYN *[WP9XG_X3#01?FU:QF2ZN;.:W9P^R6">2"0!A]Y=T;8.!D$<#
MI3A["H^6*5_0SQ,<XPE)5JU2:C>U^>^NO9^3_IHXEOV6_A1Y81/ 6BP\_>@M
M_*?KD_,N#U]ZB_X95^%G_0GV?_?V;_XNO58(1;PI&I8JHP"[%C^)))/XTES;
MBZC5&9U"NK_NW9#E6# 9!'&1R.A&0<@D5O[*G_*CR_[2QW_/^?\ X$_\SYB^
M+_["OA;QI<:)-X7LM+T$V8F6YCN3>NLV]HBKCRKB/YE$;@!]Z?O#E3BO.=/_
M &;8/@-\:/A*;[5[2?2;S4K^!K@/+;W(QI]W)^\D1TC*Y(QB-6&,%V'%?<XZ
M"O&OC-_R6KX$?]AS4?\ TU758U:<%%675?FCT\MQV*J5Y1J59-.%3>3_ .?<
MCEM2\)^%-:^.6B>'(9+?6O#\FD7VL7.EW=X^H6S7GVNUC$QBE=UW[9Y0,C@.
M<#C(Z#QK^SXOB[P#JNE^&M?NO#DVJ6=SI[+<RW5WI\-O/%)#(D=E]HC1 JR?
M(!\J%5PI Q5OQ)M_X:<\,;EW'_A%;XKDXP?M]A6G\6+74FT_PQ*FHZA8V=O>
MW4VH)871MYI8ET^\9 &7KB58F"GY3@;@<8KK/FS2^($8\*_#^YO)_$>G:#<V
MJA(]>UJ;RH+8R.JY=MR@CD84D*S!,UX=\2OBM?>+M$N](M-<\+ZGI0M+6\9[
M&T:21PTZX2-HKJ1$X4G<Q.<'"D<GOO%?C3XJZ+?^%]"N?#OAN-_$.J-I5OJE
MGXEG$J%+:XNFDDB;3L#,5K(NU7^\X (^\N'XZTE= UBYT6XMKQ+C6M*D?;:Z
MI&5*131Y 9K4D/F0'/3:C'J!D XCX)?LVV6M_"GX<Z])X;TV\:7P]ITRK)KM
M[;;]]M"\FY8H^K,,X)8#+#!R,>\^+K;PMXQTW1='\5:,Q*LLZV<KN!;S!-H&
M]2-W#.H8?*Q! .>*Y#X)Z+K&D>#=)TK03=0Z9I=K;Z>!=ZC 6988@BL<69).
M%YP?THN)+_0]6T[PMOUBYF\41W-BE]<ZZUP/W4#L[CSK=@AY."B;22."HX -
M2Q_9)^%FFK=G3="OM)%W,UU-'INO:C;1O*V-TA2.X5=QP,G&3CFL#X<^#].\
M"_&S5],TF28V133I!%-JUU?[&V:RIYGED*/A%#*N!P/J>[\"^"_%'A>^U.6^
MUFYUJ.ZCB"/J%_%++&5:4L!LM(U"_O!Q@\YZ# KC?A[/J,GQ7\0'6H(?[<LI
MK>6\N-- ^Q&P<ZL;(X**XF"2*LK,6!?!7 XH ]]I,U475[23.V93SCC_ #SU
M'YTBZQ9L-RW"$8SD'M0!=I,U5;5+1<9G4$]B<=*%U2U;!$R<G'6@"RV#U&:P
M='LX+C7M>GEACEGBO$2.1U!9%^S0G )Z#))P.Y-:G]K6>TGSTP!DG-9WAV5)
MM3\1NC!E^WJ,C_KV@H W:*** "BBB@ HHHH ;)&DR[7177T89%1FUAR3Y2!C
MU8* ?;FIJ* (%LX%  AC^[M^Z.GI2?8+?>K>4@*],* *L44 0BT@"@"&, '.
M-@Z^M)]B@^;,*$-U!4$5/10!"UG"V[$2J6ZE0 3^-"VD"8(AC! V@[1G'I4U
M% $/V.$,I$:C;]T 8 _"C['!Q^XCX.1\@X/K4U% $'V*#:0T2N"<X89%*UK$
M<XC5?=1@_F*FHH A6S@4@^3'D#:#M&<>GZ4AL8#L_=* N< # YZ\5/10!#]C
M@P1Y,8YW?='7U^M)]CA(8-$C*W4,,CCVJ>B@" V<&&Q"BENI50#TQUH6RMU"
M@0Q_*-H^4=/2IZ* (/L</R_NE&W.T 8'/7BE^R0<'R8\@[@=@Z^M344 5_L-
MN=^848/C(901Q3FM(65AY2?,,'Y0.M344 0K:0KC]TF<8S@$XIOV&WRF(4 7
M( "@#FK%% $/V.W_ .>$?7/W!U]:Y3XI6]I_PA.H^=%$HW0N)6/EB)A/&5D+
MCE-C!7W#E=N>U=C7+?$JQ&J>$;FQ:9[=;V:VLVFB"[XUEN(XV9=P(W ,<9!&
M>H- %[P7LD\'Z(!ED^PP<.Q<_P"K7J3R?J>3UJ75-%6\>"6WD^QW=N_F12*,
MJQVE=KK_ !(=QR.#T((."*GA74((?#>DQ27*22K:QJQ9E#LP09.T #/7. ,>
M@Z5Q'Q^AT3Q1X+T;3]1BT_5M,N_$>D1S6MT(YH9HS>Q95E;*L, \$=J .FTO
M1#HGA'3-#O(Y+EU@&F_Z.1^\C163S"=HV;D&X^A.T$G&Y\&H:9XZ\+Z1JU]I
M=K<>'[RP34Q_:*K(T)=%9 8RI&=KOE@W&, '/&7HGP@^%_AVY-UI/@OPEI=P
MR>6TUEI%M"S(2"5)5 <9 ./4"J3? 'X..2?^%<^""6//_$BL_P#XW0 W]FCQ
M%8^+/A%8:OI=U]LTFZU#4WLI@K*#;_VA<"(*K %5"!0%(&  ,#&*D^-6KZAH
M&EG4M)MQ=:I:65Q/:PM!+.'E6:V* Q1*TD@R!\D8+MT4%B*PO@GK5EX/\&Z?
MH6DZ9;C2HKW7Y5AL2$%K!#JLBJL<:K@C;*#@$<)P"<"J/C'QIIVJ?$2R,,_A
MOQ!;Z'-+J5XJZT)+G3[:#8LS_9EA?#HS;L%@3MQG(5: $_9H^,'C_P"*&H^(
M(?&?A6?P[!90V[6KW&@W^EO([!O-4BY+*X!48,;'C!8*7"CWJN3E^)WARUF>
M%[R194WY7[+-_#MW<[.2-Z?]]57TWXP>%M8"&SU"28-;PW2D6LP_=RAS&?N<
M9$<G!Y&TYQQD Z^WF:>)7:%X&(R8Y,;A]<$C\C27$[0^7M@DGW.%/EE1M!/W
MCDC@>V3Z UQ5E\;?!VH-IRV^J/(VH+,]N!9S_.(B!(>8^,$XYZ]LU+)\9/"<
M=PT+:BX=;H69'V2;_6F,2A?N?W&#9Z<]<\4 =M42S,;EXC#(J*BL)CMV,26!
M4<YR, G(Q\PP3SCC[WXQ^$]-LWNKG4GB@3;N?[),?O2F(<!,_P"L5E_#/3FI
MIOBOX9@^U%[^11;1M+*?LDW"JH8_P<X#*?QH ZXG )IEO*TT"2/"\#,,F*0J
M67V.TD?D37'V/QB\)ZE;VTUOJ3O'<PQSQ-]DF^9'5G0_<[JI..O'2BR^,'A6
M^DBC@U"1VE,^P"SGY\F01RGF/C:Y"\]SQF@#L)IC"FX1O*=R@JF,@$@$\D<
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M<9<JT6WNK7F<OEZGLD,C2PH[1M"S#)C<@LOL<$C\C27$S0HK+#).2RJ5CVY
M) +<D< <GO@< GBO(HOVO/A%-!%,OC2SV2%@N89@>&VG(*<<XZ^N>G-,C_;
M^$,FX#QG:@K.;;F";EP,\?)TQ_%TKI]O2_G7WG@_V1F7_0-/_P  E_D>R;N
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M(#;AN&<$=#^%3T4 5VL('C=#&H5NNT8S3X;6&W:5HHDC:5M\A48WM@#)]3@
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M!8U*663Q(NEZ\?+\J%6TP((U))<?.[_>^7IC[HZ]N<G\,S>"=-T31;:33?\
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MP =U17->"_B)H/Q _M'^Q+U;S[!*L,^T@@,R!P002".2N1QE&':NEH ****
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M89F*X(RN=J9''*C/2@#TL=*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI-'X?D$/ER1S2&V90PRH"\Y!4 <X& PP>N.LL!_H-O\ ]<U_D*GX% ')6;^
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M6-X(\57'AWP9H.DS^'=9>:PL(+5VCLWVLR1JI(R <9'<5M?\+"?_ *%S7/\
MP#;_  H ?_PC?BG_ *'%O_!;#2?\(UXH/_,X-_X+8:;_ ,+"?_H7-<_\ V_P
MH_X6$_\ T+FN?^ ;?X4 );^$_$EI;Q00^+O+BC4(B+IL. H& *R?$6CZW8W?
MA^2_UQ]7B_M6 "$621[3\QWY7DX /'O[5K_\+"?_ *%S7/\ P#;_  K)U[7I
M?$TVC0+HNK6HAU.WG9YK*3& VWJ <?>R2<  ')H ]%!R :6D7[HI: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M/^)7_(/L/^NES_Z0W-=A7)_$*+S+/3B\=R\"W$JRM:VLEP\:O:SQAO+C!8C<
MZC@=Z .DL/\ CQM_^N:_R%.6U1;J2XS)YCHL9!D8IA2Q&%SM!^8Y(&3P#G Q
MY]!\0]2AMXH_[*G)10I(TS4\''_;G3_^%CZE_P! FX_\%FI__(= 'HE1SPK<
M0R1/N"NI4[&*M@^A!!!]QS7G_P#PL?4O^@3<?^"S4_\ Y#H_X6/J7_0)N/\
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MTGQE\;YO"WB/PSH&A_"/3M.OI-+U6Q:YDU]KBV^T,'F$J&$$8BC\M3N<\GH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_2.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      !(     0   $@    !  .@ 0 #     0 !  "@ @ $     0  !/N@
M P $     0  !G(     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ %#_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /_T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /_T?W\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_TOW\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_T_W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /_U/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /_U?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /_UOW\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_U_W\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_T/W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /_T?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /_TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /_T_W\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_U/W\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_U?W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /_UOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /_U_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /_T/W\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_T?W\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_TOW\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /_T_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /_U/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /_U?W\HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_UOW\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_U_W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKPCQ5\0/']QXOUKPK\.+#3)#X7M+:ZOY=5FDB6>6\WM%;0F/_5DI&2TS[E4L
MHV'DCW>O.?$GPE^'GB[7HO$OB+1DO+^-849C)*L<RV[F2);B%6$<XC<ED$JL
M%/3% 'B3_M&:M/XFN/"MAHS&ZG\5P>'[&5[6Y-H\$:HU](UT (6EBVSA45@?
MD!(/-85O^UC%?)\2=5TZWL;G2?#.EO?Z*\4WFS7IBFEM&\]5/[L27"+Y2X#&
M-@W\0KZ&N/A!\/+G3K?2I=*_T>UGO[F(+/.K+/J:RK=2;U<-OD$T@R3E=QVX
MXJO=?!3X5W?V</X<MHEMK>&T18=T*F"":*XCC98V4.%EAC8;@>F.A((!X+X9
M_:$\=:L4M6LM/U+[7K&D:1;WMO;7EG!]INGD;4+=H;H^:9+2",R%AA<L 1P1
M7:_$GXM^--&^)*> ?!=I%(EOID5[=W+Z5J&J[);F9XX8BM@1Y0*QNY:0X(''
M>O1=?^#'PY\37L^I:KID@NKB]347DM[NYM6^UI!]E$P,$L>U_)^0D8R.N3S5
M5?@=\.H]6CUV*VOHK]([:(S)JNH(TB68Q")=MP/-V9/^LW9R<YR: .,T'XK^
M.+WXMGP+J^GV%GI\DL\=OO\ /CGNX+>%7-Y:SD-;3J9"4>W5A+$/F8G!KB_%
MW[0OBZP^*NI^ O"EI8WW]GWUA86]G);7;76H33QI-=B*Z0_9HOL\3[V\S) 4
MDC&*]]T+X2_#WPUXBD\5:)I"VVHN]Q(K>;*\4+W;;IV@@9S%"TIY<QHI;OG-
M67^&/@>17#:8 TFK?VZ7$LH<:E@#SPX;<#M&W .W;\N,<4 ?/EK^TMJEN;G4
MM7TRW?3=0L=5NM#2WWBXOIK/5/[/MK?YB07N \3#:.-Q/05'X?\ CI\1[W6-
M:_MRULK32?#,]S#>RPZ5J4L,O]G6XDO&CO\ =]ECQ,LD:"0D_*,C) KWN+X0
M?#>(^%&30XL^"-_]CY:1OLGF*%8C+'>2 .7W$'YASS6+'\ _A=#%J5LFG77V
M;5Q=K=6YU*_-M*+XL;C,!G\L&0LQ)"@Y.1@T >;? 7XV^-_BEK(L]8L[*2S7
M2X[N\DL[6\M3IU[-Y;1V4WVL_O7>-RX:,  +GD,IKZLKG+#PEX>TO7;GQ+IU
MFMOJ-Y;06<TB,P$D%J6,*LF=F4WL V-V#C.,"NCH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#_]#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#_]']_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXXYKI].U'3]7L+?5-*N8KVRNT66&>%Q)')&XRK(ZDAE(Y!!P: +M%%(3@9/
M% "T5QV@?$+P'XKO6T[PSXBT_5;M8S*8K6ZBF?RU(4OM1B=H+ $].1ZBNQH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1@\55&E@C,D@+'J1'&!G\5)_4T :?FQ?WQ^='FQ?WQ^=9W]E1_W_ /R''_\
M$T?V5'_?_P#(<?\ \30!EZZZ-J/A_:P/^GMT/_3K<5U%<9J]DEOJOA^0-D_;
MV_A1?^72X_N@&NSH **** "BBB@ HHHH __5_?RBBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /@[XX>#9/$GQRGMT-BCWGAIW6[N+::6]LQ:M*Q6TECN85C$N?GW(W(4D
M$#%?>-?!GQQL/%EU\=)%\/O<I=OX:<VDT=]#;VT"(TIN1/!):SM,7&W;M9<
M$94G-?>= !1110 4444 %%%% 'R3^T+<>+O#TFM>(?"FH6=O_:.FZ;H]S%>6
MCW(,5Y=7,9DC:.>':Z"1B 0P)QG !S].^';=;3P]I=HI++#:PH">I"H!FOC?
M]J^R\33&[N+0W4NE?9-+C$5I?0V3)?M>3?9Y9/-M9S)&C8+*'7@$8;(Q]E:
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M'P__ -?[?^DMQ72T %%%% !1110 4444 ?_6_?RBBB@ HHHH **** "BBB@
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MD=Z2/X(?")+A[MO">GS3NBQF2:$3/L4DA=TFXA06)P#C))H S/\ AH;X-_\
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M^(?_ $(4O_@RL_\ XJN;_P"&7?V<O^B:^'__  70?_$T?\,N_LY?]$U\/_\
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M65C9Z996^G:= EM:6D:10Q1J$2.-!M5%4<!5   ' % %JBBB@ HHHH ****
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MXT ;E%1Q2Q7$23P.LD<@#*RD%64\@@C@@CO4E !1110 4444 %%%% !1110
M4444 ?G#XL\5>-[KQM%K>K-/;>,O[#NHAHR^&[HVQB8D/F]^VE!MR0).A'S;
M"!BOT>KX1^-_C2/PS\;[B]?[ RV'AMHVM[C48;6]N/MC2J#:6\@W3A-OS[2.
M2%')K[NH CF,HA<VZJTH4[ Q*J6QP"0"0,]3@U5TQ]2DTVUDUF**"_:)#<1P
M.98DE*C>J.RHS*&R Q521R0.E7J* "BBB@#.TR35I+>1M9@A@F$TP18)&E4P
MB1A"Q+(A#M'M+K@A6) 9@,G1HHH ^+?VF]1O$U*32]0O)])T&6WTB5[NWT>;
M5W-TE]-Y41$,\7EAC@$E6SDG*[37T)\*-8\4ZSX<FE\46WD&WN##9R&T>Q:X
MM%BC*2M!)-.R$N77E^0N<#-?./[57B]-,:]\.[M/MW-GIFI&74M2AT]'6TO)
MV,,(E!,LKXPJC^(J">:^Q?#\PN-!TVX52@EMH6"MPPW(#@^] &O1110 4444
M %%%% !1110 4444 %-=UC1G<X5023["G4A 8%6&0>"* ,6:YC>9YA'(4,)&
M?*?KG/I6I:_\>L/^XO\ *L:ZM].@N&61(XU,+8!P!D'MFMFU_P"/6'_<7^5
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MHH 0*!T&,\TM%% !2$!N&&:6B@ KEO'/_(D^(/\ L'W?_HEJZFN>\76MQ?\
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M4 %%%% 'QC\:O^2K2_\ 7IX-_P#4ICK[.KXQ^-7_ "5:7_KT\&_^I3'7V=0
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MU9FC4DGZF@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 ?&/QJ_Y*M+_UZ>#?_4ICK[.KXQ^-7_)5I?\
MKT\&_P#J4QU]G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5\=?'G_D8_'_\ V3#6?_1CU]BU\=?'G_D8_'__ &3#6?\
MT8] 'UCH?_($T_\ Z]XO_0!6I67H?_($T_\ Z]XO_0!6I0 4444 %%%% !11
M10 4444 %%%% 'P=\<-*\2ZA\<IH]$:5+R7PT[6ETNIM:16JQM*;A9+46LRW
M'F K@EEQC;E<YK[QKXA\8P>,O&=SJ_Q]T*0Z!HFF>'GBL;:_M8KA]1CE6226
M4F"ZW0KM*A-P!R267@"OMZ@ HJ*>400R3%6<1J6VH-S' S@ =2>PJKI=^NJZ
M;::FD$ULMW$DHBN(S%-&'4-MD1N5<9PRGD'B@"_1110 45F:3J:ZM;27*6UQ
M:B.>:#;<Q&)R8)&C+JK=4?;N1NC*01P:TZ /B#]JW3-?N#>7L ENM,%II<"P
M0ZFVFF.^DO)A!<-MM9_-6-MK%2R@@$8;=Q]D: LR:%IJ7#B25;:$.P& S;!D
MX]S7SE\9O!_B_P")/B#5_!OAK5K?2A:Z5INHJ)+3[0\]Q#=W+11[C-&J(3'A
MC@G#9!&*]H^'GB:3Q)HDD-YIUQI.H:-(EA>6UR8BR7"0QR':T,DJ,I612"&^
MH!H [RBBB@ HHHH **** "BBB@ HHHH ***:S!%+'H!F@#!U61X[V!U"GRD=
MSN)Y[<8!K:MVW6\;=,J#^8K&EO5:1[A8VV&$CJO4\_WJV+7_ (]8?]Q?Y4 3
MT44Q)$DW;&#;25..Q':@!]%%% !1110!C:N[;5MTV[ID=06S@=/0$U<TY_,L
M8'Z905%=S""[MW92V5D'&/\ 9]2*BT^Z4)#:2(RR$'K@CCZ$T :]%%% !111
M0 4444 %%%% !1110!__TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M X#0[*SG\8>*)YH(Y)$GM-K,H+#%LA&">>*[+^S=.S(?LL69LASL7Y\G)W<<
M\^M<MX>_Y&OQ7_UWM?\ TF2NVH ^&OVL_#GAB7PA=W5O9^1?Q:C9J\T1\APC
MVLZ[$DA*2;&0E74G# X((K[9TZ*."PMH84"1QQ(JJHP  H  'H*^2OVLQ>#P
M%<F>-4@.I6?DL  7_<3;\D<G!X&>G:OKFS_X](/]Q?Y4 6**** ,;1]-O].>
M_:^U.;4A=W3SPB5(T%M$P4"!/+5<HI!(+Y8Y.3TK9HHH *\@^*_@WX@^+UTI
M? OBN;PO_9[33R^04'VJ4!?(BEWQ2_N<[M^W#=,&O7Z^>OCHMDPM_M=_)9?\
M2?6_]7&9,KL@W/PR\IQ@=\]10!]"T444 %8]AIU]::CJ5Y<ZE+>07LD;P6[K
M&J6JI&J,D950S!V!<[RQ!.!@<5L44 %%%% 'FOQ3\*>+_&7AZ#1?!OB2X\*W
M+7*R37MH4%P(41_D0R1RK\TFS=E?N@X.<5VNA6^IVFB:?:ZU.+G4(;>)+F5?
MNR3*@$C#@<,V3T'TKSWXKBV-OX=^T7+VV-2?;L0OO/V"[^4X9<#&6SSR ,<Y
M'4_#\1#P'X;$$IGC&FV>V1AM9U\E,,1DX)'.,G'K0!UU%%% &/9:=?6VJZC?
MW&I2W5O>&(PVKK&([7RTVL(V50[>8?F;>3@],#BMBBB@ K'US3K_ %33_LFG
M:E+I,WFPOY\*1N^V.17=,2JZXD4%"<9 )((.#6Q10 54U"WN+NPN;6TN6LIY
MHG2.=%5FB=E(5U5P5)4\@,"#CD$5;HH K6<,UO:06]Q.UU+$BJ\K!5:1E&"Y
M"@*"QY(  ]!5FBB@ K+:QOCK2ZB-0D%FMNT1L]D?EF4N&$V_;YFX %<;MN#G
M&<&M2B@ HHHH 0Y((!Q[UFZ-97VG:5:V.I7\FJ74$862ZE1(WF8=798E5 3Z
M*H'M6G10 4444 9=[97US?:?<VVH26D-K([S0(D;+<JT;*J.S*64*Q#@H020
M 3C(K4HHH **** ,O2[&^LOM?V[4)-0\^XDEC\Q(T\F)\;85\M5RJ=BV6/<F
MM2BB@ K+U2ROKY+9;'4)-/,-Q%+(8TC<RQ1MEX6\Q6PL@X)7# ?=(-:E% !7
M+>.?^1)\0?\ 8/N__1+5U-<MXY_Y$GQ!_P!@^[_]$M0!Y=:?\A+X1?\ 7E<?
M^D"U[U7RYX8M_&D.O?"A_$E_I]W:FPN/*2TLY;>16^PI@L\EQ,&&,C 4<X.>
MU?4= !1110 4444 %9>N,B:)J#RD*BV\I8GH $.<^U:E96NQI+HFH12J&1[>
M56!Z$%""* /A;P3IWPC\1_'O24TS0K">RO/#5NL1?2_+MYIH_,=PCR0K&SA"
M&(!)V\]*^^+>W@M(([6UC6&&%0B(@"JBJ,!5 X  X '2OB[P)IWA^R_:$T72
M-*U6YN[?3O#%M/;V<VJW-Y%!)*)(GDCAFFD5&* )N ^[P*^UZ "BBB@ HHHH
M **** "BBB@ HHHH ^,?C5_R5:7_ *]/!O\ ZE,=?9U?&/QJ_P"2K2_]>G@W
M_P!2F.OLZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OCKX\_\C'X_P#^R8:S_P"C'K[%KXZ^//\ R,?C_P#[)AK/_HQZ
M /K'0_\ D":?_P!>\7_H K4K+T/_ ) FG_\ 7O%_Z *U* "BBB@ HHHH ***
M* "BBB@ HHHH ^%/'7@K1=*^*5OX!L]3U6W\//X<O)AI0UF^^RLT>[:/),^"
MBX "?<QQC'%?==?"7QN\$Q>*/CA/92RVT<&H>&GDE>73[6ZN8S9M*R?9[B96
M>#=N.[9WPP((K[MH **** "BBB@ HHHH ^0?VE;)+6.Y\2V6J7^C:G&-$M5G
ML=0N+%FAEOI@T;"&1%<')'S D9.",U]'>"/#.D^&=%$>EB8MJ#+=W$EQ<374
MTL[QHA=Y)W=R=J* ,X   %?*G[57@Y-4-[XCCDM3,+/2]-9+S3K6_017=Y.K
MO'YZ,T<@!.UE(YP2#@5]B:!"MMH.FVZ$LL5M"@+<DA4 Y]Z ->BBB@ HHHH
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MZR(-/,Y>1H(O)<7(_P!4(B&)&.=V3C%=XMOX7,NIXT20,RO]H;[$_P"_&_)
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M(D4'!!P0#]%Z*^3#^S'KA.?^%G>(/_ A_P#XY1_PS'KG_13O$'_@0_\ \<H
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M444 ?&/QJ_Y*M+_UZ>#?_4ICK[.KXQ^-7_)5I?\ KT\&_P#J4QU]G4 %%%%
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M,C..F:^./CKXC\(>*-5\53:/J5CK*V7PS\6._P!FFBN?*):U*D[&;:3@X^E
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M>E+30B*S.% 9NI Y./6G4 9=Z;87=O\ :@I7;)C<,C/RTW3;JV^S0P"15<#
M4\'\C4US$LMY;JQ8 +(?E8J?X>X(J&RM89K:&6?=*P^;YV9AD'@X)Q0!K444
M4 %%%% !1110 4444 %%%% '_];]_**** "BBB@ HHHH **** "BBB@ HHHH
M **** .)\/?\C7XK_P"N]K_Z3)7;5Q/A[_D:_%?_ %WM?_29*[:@#XZ_:X>1
M/AMJ_F7'G(]]IZI$I+&'KG<,84-UST-?7EG_ ,><'_7-?Y5\?_M8O;'X=Z\L
M2,LJWNF^:Q;(;.=N!VP.OK7V!9_\><'_ %S7^5 %FBBB@"K;7UE>M,MG<1SF
MVD,4HC<,8Y%Y*-@G##(R#S5JL72/#FA:!+?3Z-916<FISM=7+1C!EF?[SM[G
M_/4UM4 %5;J]L[(1&\GC@\^18H_,8+OD?[J+G&6/8#DU:K&UGP_HGB!;1=:L
MX[P6%Q'=P"09\N>+.QQ[C)H V:*** "BBN;T23Q6^HZNOB"*TCL5G T\V[.9
M&@V\F8-P&SZ>_H"0#I**** "BN;\52>*XM(9_!D5K-J?FQ +>,ZP^67'F'*<
MY"YQ[^O0])0 4444 58[ZRENI;&*>-[F *TD08%T5\[2RYR V#C/6K58MMX=
MT.SUN\\1VME''JFH)''<7 '[R1(AA 3[#^0ST%;5 !52^O['3+22_P!3N([2
MUA&7EF<1QH.F69B /QJW65K6B:3XCTN?1=<M4O;&Z $D4@RK;2&'Y$ @]B*
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MFK#J)!E^SWWB"QB4C_GE:V=]!:QK_LK#M/<5YS\4/V*OVC=&^#/BKPE:^(_
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MP,VQ@, ,"O?@<XH UJ*** "BBB@ HHHH **** "BBB@#_]']_**** "BBB@
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M>'-3UZ#1Y(X;F:-K*&-998Q*$'GW,;-A&!) QSC.<UZ9_P *W^'?_0K:5_X
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M4NB+JWB?5-9L] D26VM;M; 0EXX7@0N8;2)VVJY/WQDX)S7HW]C:1_SXP?\
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M?CG&,\8K[UH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>:^RM B>'0M-ADD,K);0J7/5B$ )/UH UZ*** "BBB@ HHHH **** "BBB@
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MEEQ_X"6O_P ;I?\ A'?%G_0V7'_@):__ !N@#MZ*XC_A'?%G_0V7'_@):_\
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M/^ALN/\ P$M?_C='_".^+/\ H;+C_P !+7_XW0!V]%<1_P ([XL_Z&RX_P#
M2U_^-T?\([XL_P"ALN/_  $M?_C= ';T5Q'_  COBS_H;+C_ ,!+7_XW1_PC
MOBS_ *&RX_\  2U_^-T =O17$?\ ".^+/^ALN/\ P$M?_C='_".^+/\ H;+C
M_P !+7_XW0!V]%<1_P ([XL_Z&RX_P# 2U_^-UGW^A^.8I+-;/Q//(LLX68F
MUM?DBV,2P^0<[@H[]>E 'H]8WB&.WFT'4;>ZP8I;:9&!.,J4((_*L'_A'?%G
M_0V7'_@):_\ QNO$OB5X)M?$&O:0?$'BNWO)-,MM2*17EEI]Q&K,L).8I8R
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MQ_\ %4;?B3_?TG_OFX_^*H [BBN'V_$G^_I/_?-Q_P#%4;?B3_?TG_OFX_\
MBJ .XHKA]OQ)_OZ3_P!\W'_Q5&WXD_W])_[YN/\ XJ@#N**X?;\2?[^D_P#?
M-Q_\51M^)/\ ?TG_ +YN/_BJ .XHKA]OQ)_OZ3_WS<?_ !5&WXD_W])_[YN/
M_BJ .XHKA]OQ)_OZ3_WS<?\ Q5&WXD_W])_[YN/_ (J@#N**X?;\2?[^D_\
M?-Q_\51M^)/]_2?^^;C_ .*H [BBN'V_$G^_I/\ WS<?_%4;?B3_ '])_P"^
M;C_XJ@#N**X?;\2?[^D_]\W'_P 51M^)/]_2?^^;C_XJ@#N**X?;\2?[^D_]
M\W'_ ,51M^)/]_2?^^;C_P"*H [BBN'V_$G^_I/_ 'S<?_%4;?B3_?TG_OFX
M_P#BJ .XHKA]OQ)_OZ3_ -\W'_Q55!?_ !!BU>WTJX&EM]I@FF#()QM\EHEP
M03SGS/PQ[\ 'H=%<KCQO_>T[\IO\:,>-_P"]IWY3?XT =517*X\;_P![3ORF
M_P :,>-_[VG?E-_C0!U5%<KCQO\ WM._*;_&C'C?^]IWY3?XT =517*X\;_W
MM._*;_&C'C?^]IWY3?XT =517GM_KGB73;F*SN7M&GF1I%2&VNYVV(0&)$0;
M RP'.*E.J^*Q=O9$6WF("Q(M+PQX SQ)MV$X[ Y)XZT ?)OQP7Q2?C?/_P (
M^-0_M ^&V^P-;/IZV*INE^U?;%N4:<DC;L\H_=W=&Q7W?7YN>/O'/C:?QO?>
M)A%!%XFMM&U>VM/#\FC:R);N"*1XXYOM8B\F-) 58L5*J'&3\IKT[_A8W[=G
M;X,^%O\ PJW_ /D&@#[5K\7_ (5_M$:?\ /VBOVG+S6O GBWQ58ZEXKMR;OP
MYI7]HV]LT,#96X?S8_+8A@5R,$9YK[+_ .%C?MV?]$9\+?\ A5O_ /(-?F7X
M]_9#_P""E?B+X@^.?&?@/5[7P%8^/-3.IWFG:7XBDC7S-@0!IHXXG<!1CD '
MTH _0:U_X*)_#B]T^75;?P#XM-K;X\UV31X_*)Z!U?5%9"?1@#7R5^VI^V/X
M=^.G[*7Q!\%^$_AKXYM1/%9N^J7NC1II-NMO>P2LTMY%<2( 0NU2N[+$#W'S
MI'^P;_P4=2TN+.1_"5RMV0T[W,&E7,\K+T:2>:Q>5F'9F<D>M<]XW_8Q_P""
MF.D?#/Q39>(O%PO?"(T^>>_TF/6GGMY;>V7SF2&TV>6&/EC:J!<G % '] _[
M/W_)!OAM_P!BUH__ *115Z[7B_[.8UA/@+\/8==LEL+N'0=-C,2R&0A$MHU0
ML61"KLH!9,'8Q*[FQD^T4 ?$7[5<?B)FO&A_M%M(^QZ6%73)K"%AJ'VR;[.T
M_P!MAD+1;MNX1D';NX)VU]C: )QH.FBZ(,WV:'>5Z;M@SCVS7R'^T]J]Y%?R
M:)=7<>C:1-!I$[W\FF7^I*;A+Z;RX-MDK;"YP,N1UR.AKZ'^%/B#Q#XA\-RS
M>(;'[(UI<&WMY!;W%J+FW2*,K,(;I5E0%F9>1SMR.#0!Z91110 45Y^?BI\/
M%\7KX#.O6W]NL_E"VW$GSMGF>5OQL$NP;O++;\<[<51TWXS?"W6+K4K+3/$E
MI<2Z3!-=7&UCM$%L<32(^-LJ1GAS&6"G@\T >G45YI=_&/X86&F0ZS>>(K6*
MQN+*UU%)B6V&TO91!;RYQPLDC!1GG.>.#3_$'Q<^'7A>2>'6]92&6WO!I[QI
M'++)]K, N?*"1(S%A"P<X! !YQ0!Z117E5]\;OA5I<>F2:IXB@LAJT8F@$ZR
M1-Y3/Y:R2JZAH8RXVAY0JD\ TX?&OX8?\)1<^#6UM8]7LC)Y\+P3HL2Q!BSO
M(T8C6,;&^<ML.#@T >IT5Y/:?'+X37VB:KXBM?$EO)I^B+$]W)B0&-)VV0N$
M*AV21N$9058_=)KJO"'COPEX]M+F]\)Z@M]'9R^1.NQXI(I-H?:\<BJZDJP(
MRHR#D4 ==114%Q]I\H_9=OF<8WYQ[]/TH RM0BDENCY9QB!L_,R]_P#9(K7M
M_P#41_[H_E7.W#W:3*K^;YTR,@P(]OKZUT4 Q!&#_='\J ):**8GF?-YF.IQ
MCT[9]Z 'T444 %%,'F;FW8V\;<=??-/H R=1@:ZFAM^"KK)N!+*"/E_ND&K&
MFY^P0!N2% _*H+[SOM5OY&[=MD^[MZ?+_>XJM8_;O*A^SY\GC/F[?NYYQLYS
M]: -ZBBB@ HHHH **** "BBB@ HHHH __]/]_**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIB21RH'C8.K<@@Y!H R?#W
MVK^P[$7L"VUQY*>9$BA%1L<@*. !Z5LUSWA?[+%X?TR"WN?M*?9TV.05:10!
M\VT\CJ/I70T 8'BI[:/PWJ3W<)N(%@D+QJVPLN.0&YQGUK?K'\0&\&B7QT^5
M8+D0OY;LP55;'!);@#ZUL4 >9_%[XBP_"KP!J'C66".Z>U>WABBFF^SQO+<S
M)"@>7:VQ07W,VTX )Q7SW<?M77D,6GV_]DZ8+B^O[ZV2\_M"X?2I;>QAAD:X
M@N([)Y9%,DPAXA"[U;#$5]3^*?!^C>,5TJ/6UD=-'U"WU*%4?:IN+;)BWC^)
M0QW;?4 ]JY3QA\)='\8>);7Q<VKZMHVIV=F]@DFFW?V;]Q)()74C:W5E4D^P
MH \LU7]H'Q+I+ZE>'PY9WND^&;72;C6;B"_D#HVJ_,$M$DME\[RXBDA\PQ$A
M@  :?H7[0VH^)/&.N:!H^DV5Q;:+=ZC;");JX;4KM=.5M[00"T\@EW4J@:X'
MY\5VY^ ?@N;Q+=>)=0N]3OOM]Y;ZA<64]X[64UW:)&D$LD( #E!$A"L2NX E
M2:AT;X >%=%TN]\/KK&M7>C7\5S%)8SZ@Y@7[6YED= @5EDWL65@V03D4 <)
MIO[0WB;5/ACXE^(=MX=TX?\ ".0+=RQ_VJQ0((VDFMI1]F$\-Y#M"M%)"%8L
M"KD9(P_%7[3?BCP=?IH6N:#HMOK2Z0FK/9/K$PEF\]V6"SM%^QEY[IPC90*
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M6R3Z[\(/A[J'P]TK5[36KD:GJ5_J,\[ZE)+)/=7L'"VS7+2 8ECA"Q%4^3"
MKC)%>M@8&/2EH **** .>U:9HKVV9<957(!#'<<=!M!_6MV'F&,_[(_E6'JL
MXAO;=\ A%=CEE7CIQN(S6W"<PQG_ &1_*@"6BBB@ HHHH **** ,G49VM9X;
MC VJLFXD,0!\O]T&K&FY^P0$\$J#^=5-7EV1B%0"TR.HRP49X[L15W3W$EC
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M=QYCXR"Y+]^HR30!K4444 %%%% !1110 4444 %%%% '_]7]_**** "BBB@
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M]%L/#GA[Q5KUCI>E01VUK;I=1%(8(5"QQKNA8D*H &23CJ: .A7XO?"U]/\
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MZ/\ LQ:'8:A%-J*Z-J5A817L.GV<FD$1VD=_>O?2JI^U'/[QMHP%^51G)YH
M]7/QH^%(U(:0?%-A]K) \OS1]XH9 N>F[8"VW.=HSC'-<CXH^/GAW1M;L+'1
MI++5=/*Q2ZC=?;?+^R0SWMM8HP01N'.^XW$,R#:IP2<"N7;]F/13K?VE?['7
M1&OTU1M+_L@^2UXED]@)"WVK_GF^?NYR!SCBH?$7[,VD:EJ5O-I=OHUA8W*V
M]OJ-M%I)\NY@MKR&_C#YN1G$EN$Q@_*[8P>: /6]2^-?PFTA$DU'Q580*^\C
M,P/$:EG; S\JJ"6/0#DXJQ=_&'X7V,/VBZ\3V*(61!B8,6>1@J*H&2S,Q
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MR(C8)4.G (PV>/LG0%F70=-6X8/*+:$.PX!;8,D?4T :]%%% !1110 4444
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M9-:,&NZGH7CJU\):MJ4=W8W>FW-ZDTZ)%.KV\T,84LA5&!$I)^0'(%<?\/\
MPAXY^'OA^:RCU74_$,E[=M/_ ,35_MTML@BC3RTDGU!FV,RLX'F-@L1M7OW^
MIZ;>:QJ[1ZMI4%Y90(_DM-:02X8H#P[W!;EAT\M0<8)Q\U '37%_H5W"]O<W
M-M-%(,,CNC*1[@G%?SC?\%1-4NO#?[9_@.7PC?-IL=[H6G6\IL9C$)(9+^=9
M(G\HC*L -RG@C&17[N:QX5N1X5O)+7P[9C4]V(@VG60XV\$K]H*XW8R=^?\
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MY'7/:@#2HHHH **R]+.MG[7_ &TMNN+B3[-]G+G-MQY9DW@8DZ[@N5Z8-:E
M!1169?G6?M5A_9@MS;^<?MGG%]_D>6^/)V\;_,V9W<;=W?% &G1110 445F:
M/_;/]FP_\)!]G_M#GS?LN_R?O'&W?\WW<9SWS0!IUR_C?0[CQ/X+U_PW9LD<
M^K:?=6D;29V*\\31J6P"< MS@'BNHHH _(KX(_ #XB_L^^'_ !WX9\?IHZ2O
MX!A@\W2+NZN_ML]I/<"2\N?M,$.R9UD2/";@4C09&T"OUUKYA^,__(1\7_\
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MH   P !V%.HH AGMX+I!%<Q+*@*MM=0PW*<J<'N",@]C4U%% !1110 4444
M>(^/=0URV\61PZ?K26-N8=))A,I0Y?5X4D.W!_UL1,0YY)V\9S7MU>(^/M#^
M&6H^---U7Q7+<IK.F)8M;B*298PLFH1+!N5/D?=<[%(<' YX^\/;J "BBB@
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MCY0< 9'[2Z)H]EH&DVNC:<K+;VB!$WR/*^!U+22%G8D\EF))/)H U:S=9_Y
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M:MI::5_9.G:3HBJER+GSGTUKH/-D(FU7,@V@Y/'.* /JFBBB@ HHHH ****
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MH ^3/V#O^31?AI_V#Y/_ $HEKZYKY&_8._Y-%^&G_8/D_P#2B6OKF@ HHHH
M**** "BBB@ HHHH *Y;QQC_A"O$&?^@?=_\ HIJZFORT^.?[5'QUL?''QB^'
MG@^P\,V^D>"K2&*S&IQ7\E_K$EY:0,\%H;>01F9);N%-K 8$J,?EW$ 'J/PJ
M\.>+9_&_PK^(WC.5EN]4L[FWMX)(1'(ML-.W*=K%FMX\C]W &W')DG+2L$A^
M^J^1?#'C)/$_BOX1:?#ID]G]BM+J1I)9[*5& TX)A1;7,KCEARR ?0\5]=4
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MJ'PMT?23I7BL)>0MJ0U766M;:(6L#P7<3-PSF6<@*3C=$W)YP ?=U%?&NH?
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M\,_''C:^B\6_#[6)/!^A(VHVL47VW4)IKZ-+D1P7$J7/RQC;"SIM&2LG4CJ
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M@DC/:@#[!\4:SK\'B_P[X=T6XAMH]2AOYI6FA,V3;"+8  Z8!\PYYSTZ4_\
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M50"S+Y;#.,T ?>E%?#=]^S3\4+OQ#'K9\1:2TZ364L=TUC&)X([5+I9((T6
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MX6-QXSM3;.)0+(O#';RR67E1F-Y8HKBY5'+%QCS,X )53Q0!ZA1110 4444
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MM;Q#,)G8[H=S$-&&9BFU@/3?A_XM3QYX'T'QK':FR77+*"\$#.)#$)D#["P
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MBEU?:]IDUNDM]<QVZ!X[2229LE\#8IYQG R1^B$YG$$AM0K3;3L#DA2V.-Q
M) SUP*^)OVWB=2TOX.>#$.?^$D^)7AJ"1>N8+622\ER/0""OMZ@"CI;:DVFV
MC:RD,>H&)#<+;LSPK-M&\1LZJQ0-G:2H)'4#I5;Q 9ET'4FMU#RBVF**3@%M
MAP"?K6O61X@E\G0=2F"&3R[:9MJ]6PA.![F@#X6T_P 7_$:_^(?A9I8KF'Q'
MHV@,18)X?1X'AO0GSF8ZR 2K0D  @GJ5Y%?<GAFYUN]\-Z5>>);5++5Y[2"2
M\@C.4BN&0&5%.YN%?('S'IU/6OB+X<>-O^$J_: \*ZBT^D;[SP]'$;*SU":Y
MOK<0PRR>;/"]K %B;?L#;C\X(P>H^^: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /SX^)WB'X2^)?C;;^*;Z
M.SU2TM?#]W;+?RV330QSAGV*+AHB@(?!!W<'D5^@]?,'BWX=>$-,T+Q9HL$^
MH06-EI<;6UG_ &QJ MUW";*K";C84.T#9M*X&,8XKZ?H *16# ,IR#R".A%(
MZ)(C1R ,K@@@]"#U%5--TW3]&TZUTG2;>.SLK*)(8(8E"1Q11@*B*HX"J
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MH5'\JYW4H-/AOK5'2.-7WY!PH/%='",1(!QA1_*@"2D#!LX.<'%+10 4444
M(&!)4'D=:6BB@#.N95BO+=F#'*R#Y5+?W>PJ&RNX8+:&*X#1,<+\ZE1DG@9(
MQ4]S#%->6ZS(' 60X(SS\M1:;:VRVL4HB7?C[V!GKZT :M%%% !1110 4444
M %%%% !1110!_]3]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+&WU/39TNK2[C2:&:-@R21R ,KJPX*L""".HH MT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117@WQ
MOU"YL/[#=+BZ2VA75+J6&UO)[$SFTT^::-'EMG23;O4'&<9P<'% 'O-%?(5S
M\#?CBVH7UQI7Q5GL+&YF,L%HRW=U]F0HH\L3371D<;@6RQXW8Z 5$/@9^T"%
MP?C!*3SS]EF_^2: /L*BOC&_^ G[0UWI\]G#\9Y[>69&19EM9MR$]Q_I745K
MZE\#_C3-K5[?:#\3Y](TZY\HQ6+&]O1 43:Y$]Q=&0^8?FP>%[4 ?6]%?'B?
M S]H%0=_QAE<Y)_X]9AQZ<7-(?@?^T0MC<6L'QC=)9E<+,;&1V1F7 8!KG^'
M@@=./>@#[$HKY)F^"/QNBO8Y]#^*$NG6PLK:"6"47E_YES"7\RY$ES=,R&4,
MH,:_*-H(Y)H7X-?M# L6^+NX$\#[!(,#T_X^.: /K:BODA/@U^T.N=_Q=W9.
M1_H#C ]/^/CFH(_@9\<K6/2O[/\ BK-!-:6/V:^DE6[NA?W6Y3]JV373+;MP
MP\N+Y?F_V10!]?45\D#X-?M#!B3\7<@]!]@DX_\ )BE7X-?M# DM\7-P)X'V
M"08'_@10!];45\D3_ [XT-X233++XERP>)TN?/.MNVH2HR^>93&=.-ZMMM\H
M^5@8P!N^]6 ?@?\ M8'&WX[6PP.?^) YR?7_ (_Z /M:BOBEO@?^U>3E?CK;
M*../[!<]N>?M_>G#X(?M6^;N/QTMBF[.S^P7^[GIG[?Z=Z /M2BOBI?@?^U>
M&R_QUMF&#Q_8+CG'!S]O['GWI!\#_P!J_:P/QUMBQQ@_V"_'KQ]OYS0!E_&W
MP>WB;XTW>DM/:QVFJ^'&EG,VG6]U<(UB9F3[//*"T.=YW;03G# @CG[JKXDT
M[]F/XF7-_J>O^/OB OB7Q#<VPL['48H[[3#86Y!\Q!;P7K13[V.X^9U^Z1BO
MMN@ HHHH **** /D']N33O$VJ_ "YL/"#RQZG-K?AY$,,ODOL?5;99!ORN 4
M)##/()'/2OJ_3]+TW2HF@TRUBM8W8NRQ($!8]2<=3[UX-^U%?V.F?"N.\U*X
MCM8$UWP^#)*P1 6U6V !+$#DG KZ(H ^)/VJO!ZZF;WQ'#-;K.+32]-9+K3[
M2_7R;N\F1VC^T1LT<@#'#(1S@D' K[$T"%;;0M-MD)*Q6T* GDD*@ R?6OCC
M]JW0M5O3>:G%''?V/V32[46TNHW]@(;J6\F$5TOV)U65HB0P60$?* " QK['
MT".2+0=-CE?S72VA#.?XB$ )_&@">_U;2M+"'4[V&S$F=OG2+'NQUQN(SBL[
M_A+O"G_0:LO_  )C_P#BJ^8_VC[Q=(U&Y\0);6\]UIGAV=X&N+>*Y$9DU&RC
M<JLR.FXH2 2I'0D'&*\M\&^"OB5XAGM]#\0:WH/A_P 130"Y6RD\/6,L5Q"0
M#YMG/Y*"= "-XVK)&>)$7*E@#[N_X2[PI_T&K+_P)C_^*H_X2[PI_P!!JR_\
M"8__ (JOEW_A0/Q3_P"AHT#_ ,)NQ_\ C=<QXJ^&/C7P;8QWVM^+="W7$@AM
MK>'PQ9375U,WW8H(5CW2.>N!P "S$*"0 ?76JZSX#US3+O1M7U+3[NQOHG@G
MADGB9)(I%*NC#=R""017F]O\./V=K32+W08-,T-+'4F@>XB\R+]Z;9MT.XEM
MV(VY09P#R*^6OAU:>--9\<R_#?Q[!IFFZA%>1I*]GIFF221QM9W-RJ M:F+<
M0L7F##@,K!)"IR?<KKX!Z/X;A73=-U">\?6[RY8HUAHJXDG62>4[WL#M7@A0
M!QP.E '77'PR_9RN8K*VO-+T.>/35=($DDC<(DDGFNF&<Y5G^8J<@GM6[KOA
M;X%^)]6MM?\ $-EH6H7]JJ)'-,8';;$<HIR<,$/*ALA3TQ7F6F? JZTG3;32
MK-7^SV4,<$>^VT-WV1*%7<QTW).!R3UJI%\$;?2];.I7DDUN^MR6]M(XM-$F
M53&K^61'_9P ')#$<GCTH ]I\2Z;\'_&%YI]_P"*UT?5;G27\RUDN7AD:)B0
MWRECT)53CID XR!7ID<B2HLL3!T< JP.00>A!':OE*_^#FC_  W@T>:QNUU.
MWN]<MXIK>]TS2V21=2N\S#=%9QR#!E)3:XVX Z#%>S?!I53X2>"T0!571K
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MVW!!"(C?+7KWA/P&FCZA)XI\27AUWQ1=(8Y+^1-B0Q$@F"TARP@@R!E02SD
MR.[ $:/A_P *>$/#6B2^']-AB:UNB[71G?SY+N248DDN9)"S3/(.&9R21QT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO+7Q!H_@;QAX?N?#T6LPW5X\K7ENR36]D8EDAWQ.64N\\>>F4W@'->E+\'O
MRJ%5-1 48'_$XU'H/^WBK-A\*/!.F7_]JVMO=_:_*: 2R:C>RL(G979 9)FP
M"RJ2!U('I0!X3;?%&"3XUZ9I'@OPX^JM<>&[G9':36T4,*6EW"&!9V10?WR[
M5&>_0"OSN_X*0_&/3/ /Q4^'&O\ Q2^'IN+>XT/6[.S$UQ%/)9W4EU82+?P"
MWE5O-MQ&=BB6(L6QO"[L_L7JGPN\&:S/;76HP73SV8D$,BZA>1N@FV^8 R3*
M<-L7(S@X'I7FGC;]DG]GGXE26<WQ#\(1^)GT]76V;4KN[NS"LA!<1F69MH8@
M9QUP* /P8^$GQ\^%OQB_:=^$?AW2M'N=9U-?%-I=R>(];L[*QOWM8[6>,V#6
MMDSVBQ"1ED5H1%N(_>([CS#_ $-WNNQ>"M2M-.TR?^TK36F:"TMWG#>1=(AD
MQYK%BL#1*['.=A3"@[@M?G_XZ_9<_9_\$_M6_ 7P=\*?!-EX=O)KC6M>U2>S
M,JR_8=-M/*CC8ES\DMQ<(#Z[<>M?HG??#;P?#9W$UGI"S7"1NT:&:4!G .T$
M[^,GB@#R6[^(.N^,-;C\/:+97$FNZ)=Z@TCZ3<V8006SK;X?[:#CS?,SA5R-
MI(84:KI7Q$O=%U'3H/"^H^?>6TL'FO>:6TK;@2 \K%I-N[D\_2OG[XA?L]:A
M>>"O$/C_ , G2O _B3Q8E@]WKVBW&IQ7[+'-$2K;9T5SM!CPW3)XS6W\;M#U
MO2/'VE>!OA]K=[HPUI-,V&>^O+F)+BXGN82[*\^X@H " < @-M+** /7+?X4
MZMX%\5>$/B/91:SXGUB"T_L_5HQ?QS 1"V?88XKF6&+"SG[RD-ANXZ>Q?\)Y
MK_\ T(6N_P#?6F?_ "=7@'@SX46GBR*ZM;GQAXCTK7-*98M1TZ6\5I+:1AE6
M5@H$D,@!:*51M=?1@RKY=\2O">K:/9ZI=>!/%NLZA9>&YX8]6O+FZ?[.9))D
MA:RMS$8V:<;\R2*VV' 7YI"50 ^VM!\>?VQXA;PQ?Z#J.B7OV0WB"]^S%9(E
MD$;;3;SS8(9AD-C@\9KOJ\(\'SSW?C;PK=74C333>#P[NY+,S--;DL2>22>2
M:]WH **** "BBB@ HHHH **** "BBB@ KS3QK\7? GP^U&+2O%%Y-!<2VSWK
M"&TN+E8;6)@CSS-!&XBC5B 7<@>_!KTNOFCQ[\)_B-XH\<^(]7T;5M-L=)\3
M:+;Z$\LT4TM[:6JM,]P8$!$1>0S'!8X4JI(.,4 >EO\ %OP8?$TGA*S:^U"_
MA>V25K+3KNZMHFNT62'S+F&)X4#(ROEG "G)P.:I6GQQ^%U_H]OKUEK:3V%T
MFIR)*D4I&S2 3>,PV9418[@;LC;G(SXAH?[/?B_P]XJUK6['^R'^USSRV-XU
MQ?K=6T:6HMK%&B0B!_)5$#%E.1NQSBJ=O^RIJ>E?VC8Z-K<$6F7VB6>F+;M&
MV(IW:U35)UQ_S]06B #^^6)X)H ^A%^,OPXDCTV:'5Q*FKV^G75J4BE821:M
M-]GLR,+P9) 1M."N"6  )JIIWQU^%>IQZE/#KJPV^E6TE[+-<0S6\+VL4GE/
M/!)*BI/$)/DWQ%AN('4C/C^C_LU:OH_B66^MM;A32H]=74K*'RF+VEG;0736
MEJH/RD0WEV\H!XV*J]:J:;^SKXV31M8L[K6=-L7FDTZZM+*SAN&TMKZPNQ=M
M<RVTLA$(N64++#;E4'WOF8"@#V4_'KX61Z->Z]>:P]A;:=<VEK<K>6MS:S0R
M7S!;;?#-&DH24G*OMVD G. <=K'XX\*O:Z]?MJ$<5IX8FD@U&:7,<5O)%$DT
M@9V 4A4=22"0.F<@BO!-3^ 6N>.=8;7/B3J%E>/JUQ&=2M;2.1+=;.TL[J"T
MMX"Y+,RS73SO(^,G 55 %:&D_ G6HO@/J/PMUS74N]?U626ZN=3,1:.:Z-P)
MHVDC)4LI5$1QD9&<'I0!W5K\=OA?=:5J&L_VL]O!IIMEECN+2YM[AOMA(MC%
M;RQ++*)R"(C&C;R#MS@UJZ/\6O >NKIHT[4',VJ7\NF1026\\-PM[!"T\D,L
M,B+)$R1*6/F*HQ@_Q#/GNM_#SXL^)(-,\0ZQJ^CMXBT+5HM2L;5+64:<L:6\
MENT4CEO.=F\UI%DQ\C8 4C)."_P5^(>GZS8>/M)UO3;KQ:;[4;Z]^UV\RV'F
MW]M#:(8$1S(/LT,*H@8GS S%BI(P =_J'[0/PNTY5=]0NKE3%=SL;73[RZ$<
M%C.UM/-)Y,+[(DE1EWMA3@D$CFM*V^-/@*\\6V_@FREOKC5+J..:(1Z;>/ ]
MO+@).)Q"8O))('F[]F>-V:\!G_9.N_[,N[:'7C)<6NF:7IM@3+<0P7$=M+)<
M7Z:A#$X6:*]EE?<AW;0>.>OT/X=\!3Z1\1]?\;SR0_9KW3].TS3[>)2OV6VL
M_-=U/0?/)+D!>@44 >G4444 %%%% !7R%^V5-)_PKW2;*VM+B_N)=3AE$5M$
MTSB*V5III& Z)'&I9B>@'&3@5]>U\F?M=WNLZ/X*TG6M!GAANEO'L7%Q"TR-
M;ZE"]K-@*\9#A)"4;) 8#*D<4 ?6=%%% !1110 4444 %%%% !1110 4444
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MK0L?E&Y2 23P,\T :]%%% !1110 4444 %%%% !1110!_]?]_**** "BBB@
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MUPMI$D0EN)&EF<(H7=)(W+.<99CR3S0!>HHHH _(SQS\5OVF/VO_ ($VNI>
M/@K:6WAV[U6SU.UOYO%%L'D30=465U:W:V1E,C6K("6^7.[!Z5]^M\3/B%+X
M$7QQ8^#(Y4FTU=0AMWU&)"Y>$2I$7VX!)(7=M]\=J\1_X)^6SW/[%_@VVC;Y
MYQK2C<> 6U.[ ^@KZ.\*>%/$8\,>'?#OB?R+:TT6TLXI8+=VF-S+:HH&]V5
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M06)IK=X]K01N%=TVG+D$D9/Y4 ?*/PR\6V?@_P =7U_/#)>W=QX=T6WL[*W
M-Q>7+V-ELBB4D#/!+,2%1 SN0BDCVB+X9^,-!U>;XSVC0ZA\0+R,1ZE9(0EG
M<Z>IW+I]NS ;'AQF.X;!EDR)<1E5B\=?]G;Q5KGB'P[KVK:;-I-WIUBEE>7-
MAK$0D9([.*W*VY^R"1%D>")G!?!"=,FMS7_V=/$']DRGPUJ>O#40T1C%QKR^
M6R"13*I(MR06CW!3@X8@T 36'B72O%WQG\6:[H[LT$W@R96213'+#*DJK)#-
M&WS1RQL"KHV"I%?4/P\_Y$#PS_V#++_T0E?,/PQ^&WAKPI>?$;5$@O;7Q/!9
MR6U^MU?0WWGI/:Q3),9$ABD9MJ)&"^<!2!7T]\//^1 \,_\ 8,LO_1"4 =A1
M110 4444 %%%% &7>_9?M=O]KV;=LF-^,9^7UHTNWMEM(94C0,1]X 9_.F:L
MG[HRJ[1O'&Y5E.".E7+!0ME"HZ!1UH MT444 %%%% !1110 4444 %%%% '_
MT/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K.NB1([ 9V(C?@K9-:-5Q_Q]M_N#^9H G!! (.0:6JBK+;?+&OF1
M=AG#+[#/!'\J=]H)^["Y/TQ^I.* "[/[@IWDPH^IX_\ KU#%"KF5BS#YST8@
M?H:FCC=G$T^-P^ZHZ+G^9]Z2'[LW^^U $ :U8 AY2#_OTN;;^_+_ ./T^WN;
M<6\8,J A5_B'I4WVJV_YZI_WT* *V;;^_+_X_1FV_OR_^/U:^TV__/5/^^A2
M?:K;_GJG_?0H JR*GV=IH9'XZ?,W4'T-:-9V0UE*RG(+/@CO\QK1H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\ %8NCX6UD
M6.1<FRN/*P0#O\MMO7CK705P_CSQCX8\)Z#?S^(-0BLP+:1MK'+[2-H.T9."
MQ"YZ9.,T ?&'[,DWPJ?XMP1^!=.U:PUD>$I#J1U:2ZD>3;J6QC&;F64!?M27
M.=F 3R/E*U^@]?G5^S+X;\7Z?\<SK_B'0+K1+2^\(7"6QNF@+3;]<GO 5$,L
MN!Y5S$3NP021C(-?HK0 57N[JWL;6:^NW$4%NC22.>BH@RQ/T JQ2$ \&@#+
MT/6]+\2:1::]HEPMW87\:RP2J" Z-T(!P?S%>5?M'^/O^%6_ /X@_$!7V3:'
MH=_/ <XS<"%E@&3ZRE1^->T(BQJJ1J%50  !@ #H!7Q1^W-GQ'X#\#_!V/YS
M\3/&>A:/.@ZFQAN/M]VQQ_"(K8AOKCO0![1^S/X _P"%6_L^?#OP Z".?1M#
ML8K@ 8_TEHE><X]Y68U[C2 8I: ,+_A(]"E\1/X/^U(VK):B]:VP=PMV?RPY
M.,8W#'7/M6M]FMMV_P I-P[[1FI-B;_,VC?C&<<X],T^@ K"\4027/AG5[:$
M9>6SN$7ZM&P%;M9>MRQV^BZA/,=J1V\K,?0!"30!\R_ _P 4WGC3Q%I=\="O
M-'@T'0'T>5KQ[8^;=6\MOYGEBWFE)08R&;;G/3K7U=7YT^#OC3+\(]$M_$FM
M^!_$-QIVLZG-"EQ]FAM(8H]0D@^S3/)>30+LD(P I+Y(RHS7J%M^V'I6I>)K
MKPMX?\ >(-;O%@N[BS6PDTR=KR.T9%+(@O0T8;S%(,H0#.&P>* /L:BO&=$^
M+]WJ>DVM_J7@/Q-I%U.FZ2TGL4DEA;)&UF@EDB)[Y1V&#ZY U?\ A:*?]"IX
MA_\ !<W_ ,50!ZC17/\ A?Q+I_BW1H];TQ)HX7DFA:.>,Q2QRV\K0RHZ-R"K
MHP/TR.*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OF3]I'2-$UZW\/:1KT%G<QW']JBV2_,0A^V#3I_L[ SD(KJ^"C
M$@J>01C-?3=4K_3=.U2$6^IVL5Y$IW!)D610P[X8$9]Z /F*X_:]^&UIJ%_I
M4VF:LUQILQMYO*BMIXQ($5R%DBN'1QAQRK'G(Z@U"G[8GPS=-XTK6P!GK:1Y
MX]O.KZ>M]&T>TB%O:6,$,2YPB1*JC/7@#%3_ -GV'_/M%_WPO^% 'R???MI?
M"O3=-GU6[TO6U@MHVD?_ $2,D*O7CSJU]2_:V^'.DZW?>'[O3=4:\T_RO-\A
M+6YB'G)YB8E@N7C)V]0&R.^*^EWTW3I%9'M8F5@008U((/4'BN3\4C3/!G@O
M7=<T?2[1'TNQNKQ(A$J1O)#$S@-M X)4 GKB@#PB+]L3X9R@LNE:V,$K\UI&
M.GUFZ5!-^V;\+K>QGU"72M<$5NCR/_H:%ML8);"^;D\#@#K7'Z!^T)XKGTZY
MEUK1--^T_9] NX,V-YIQ:/5[^.TF58;OYYEB#Y6>,^66(4]:]A^)/BSQII7C
M>R\'> ]/T9V?1;[5YFU*.4A_L<L,8B0PLNS?YO+$-C'0T <W=_M>_#6ROHM.
MFT[5'FFLK;4%\A+6X3R+HN(]SPW+JKGRVRC$,!@D8(J)/VQ/AFY=1I6M#8<'
M-I&/R_?<BN'B^/LUSH5WXP\'^'M%T;0-)LM)O-0%_%<&6674[876Q6LX7$*1
M1'!GD1U+=E S7L_QD\;>(? ^BZ9KG@W2=+U&*Z./*NB_VB\GD*"WL[.*)=S3
M3[F.\_+&%)92,E0#CX_VQ/AG+NVZ5K8VL5YM(QR/3]]S31^V-\,/)T>?^SM5
M==<L/[2MO+CM96^SEE7]ZL=RS0OEQ\D@5NO'!QO^!_C3H?COXR:[\.]*M; Z
M7I%CYD5RLL;SW%W#<-!<JJ*>(XF&T$C+$%A\A4GWRVT#0K-Y)+33;:!Y3ERD
M**6/7D@#/XT ?,$7[9/PTENIK;^QM=7R0IWM:1!'W _=/G<XQSZ5.G[8GPS=
MF4:5K8*G'-I&!^'[[FOJ3^S[#_GVB_[X7_"C^S[#_GVB_P"^%_PH ^*[CQS\
M/?B]K_AOXCZ=8PQ7,6JZ18Z;)?BT&HH\6H3I=B*-9))XE( #[@F]<'!7FOM^
ML>/P]X?BO1J,6F6J78.[SA"@DW'C.X#.?QK8H **** "BBB@#X0^-\7BJ3XX
MSCP^;X7[>&G^PO;S6,=DB!I?M7VM+F&69R1MV>41QN&0V#7W?7P?\<-?US2?
MCA/-I(62ZM_#;K;61TZ^NGOEF:43LMS;@PP>2 ,B7KNW<*#7WA0 445\'_$'
MXM_M1ZU^TCK_ ,$O@1#X/@L_#NA:=J\\_B-+\R.U]++&50VCXP/+[J/J>P!]
MX45\.>1_P4C_ .?KX5?]^]<_QH\G_@I&.3=?"G_OWKG^- %W_@G;_P F>^ _
M]_5__3K=U]K5\&_L8W/C'X5?LW>$OA_XN\&ZM+K.DF_%R]BEM/:LT]]/.#%)
M]H&5*R#&0".A&0:^NI/'FGQ^%+3Q:+"]>.]:-([5(0UUOD;8%*!L9!Z_-C'>
M@#Y8^,?C+XZZS^TYX=^!?PF\8V/@RRO?"EYK]Q<W6D)JK/+;7L5L(PC30[01
M+G.[C'0YXV?^%5?MG_\ 1>M&_P#"-B_^3ZR[.S\0^)_VWM"^(2:%?:9HECX#
MU#3));Y$A8W4VI03(JIO9B"B,=V,#&"<XK[:H _-[X@^$/VC?#C>(-6\9_&5
MK^]\.>%-7US39=&T.TTLK/9J/W<_G->>;&X8<+Y9&.IXQ^7_ .QY_P %#OVJ
M/'_QI\"?!G6M=L+C2M>U)X;B9["(7!$YDF8[U  ^8\87&.*_;7]H?_CR\;_]
MDZ\2?RCK\HOV%?\ @G[H]OJOPG_:.L_',XU"2WAUE-/?3T,2RM#N,1?SPQ0;
MQAPO/(^4XR ?KQ\1=*^/US96&@^ /&^G:+KFH3EEN+K3%O8DMX49I2808LY8
MHH.X8+#UKQ/X3^.OVCO#7[6+_ 3XR^,-+\7Z=<>#9?$<,VGZ4--:.9;]+14/
M[V4L,;CU'4<<5]NZ1H":=<3:E>7+W^I7"JDEQ* N$7D1QHH"H@/.!R3RQ8\U
M\>?M%_LLZI\1/B=9_'7PU\6]5^%VI:7H?]B32Z=#&_FVOVEKG#,SJ?F=A\H!
MR5&.>* /?KSQQ=Z7H@U76?$-A8S?V1/K30M92L4M+9%:9^)\E8]Z@X&3G@5\
M\:=_P4F_8RN+&VEO/B3;)<R1(\B+8:B0K$#<!_HQX!XKQ:?]F'QY-X,N?#'B
M+]H#X@W$\^GW$$UH9K&&V=#"3Y+QO&[H#$P#+D_Q!22./-/V6]=MM \4_#&X
MDNVL9Y?@CH*Q2"*65<_VK/N#+%'+U7IE>O((- 'U\W_!23]B:,[9/B?;(?1K
M'4 ?R-M7>_#S]M/]F7XKZO-H/P\\:QZU?V\!N7BCL[R,B%6"%]TL"*1E@.#G
MFN#\4_%K]G?2?$:WWQ#U30+_ %66 1SV^J6FRY%NKN;=XWGMER0&96!"*W!!
M!4[OH_3;O3_%'A'PSXZ\"68^R+;QW5G:&-8/-LKB,9B5>%1MFUDZ#*@$A230
M!Y-\6/VR?@5\'+K2+/QGXAAT^76EG>#[1'<HK"W*!L&."4YRXQD#H>:^BO"W
MB"+Q1HD&MP($CG+;=K^8K*K$*RMA<JPPPX!P>E?F7^W9\#OB?^TGKG@IO@9:
MV?\ ;?A1+BXG&KB2UCCBNE>!D(=.7).0#Z;@2.N3XK^-_P"V7^R=\!G\1^)/
MACX4?PSX(MK.UGDCUVZN+J3<\5LK[6B&2SNI// )QP * /UKHKY-_9[^-OQ-
M^./P9\*_%IO#]EIZ>([9KAH4DWK%ME>,@,\JDCY,\@5P,7Q'_;\U&-=0T;X8
M>#)=/N?WEL\NNW"2/"_,;,HA(!*X)&3B@#MOC7XVTGP5\:?!7ARTT&;5/$7Q
M)T7Q#I%E]D6WC9I+1+:Z_P!(FFDBQ&L:/MY8Y. .:^F?".FW6C>%-%TB] %Q
M8V5M!(%.0'BB56P>XR.M?F3X@;]J_7OVF?@_X_\ C!\/=*LM)^']OXDU"4>'
M=36]G:"YLTM79DNS;CY7>/ 0DG)..*_4?2=3M=:TNSUBRR;>^ACGCW##;)5#
MKD=C@]* -"BBB@ HHHH **** ,768?,B\P;28D<@.H=3TZ@U>T]/+L8$ZX05
M5U&%KF:&W'*NLFX;RF1\O=035C3<_88=W4*!Z]/>@"]1110 4444 %%%% !1
M110 4444 ?_1_?RBBB@ HHHH *R/$%_-I6A:EJ=N%,MG;33('SMW1H6&<8XR
M.>:UZYSQC_R*.N?]>-S_ .BFH :=9N/L?G^4V_9N^ZN,XZ_>SBI8M4F)=2#*
M$<J&0+M8#N/FKH,"C H Y.PO?)!$*LVZ.-FQ@X<@[@<L.?6K":O<&;:1N!,@
MVA1N7:0 3\V.<UTF!1@4 <RVL7 N-@7 W*-A5=Y#!B2/FQ@8%0WU[YI!D1E*
M(S)G:,N&3 &&Y/6NLP*,"@#GY=4F#(H_<AVP7<#:!@GLWJ,5$=8N/LBS>65<
MJI)(7:,XR3\V<"NEP*,"@#GX]5G9&^4OM9P&4+A@I(!'S=ZJ:?>^2C+"K.I6
M,DC!&XH-W5ASGK75X%&!0!S4.KW#2D,-P.\[5 W)M;: WS=QS1_:]QY^S'&X
M+LVC>05+;OO8QGBNEP*,"@#D[N]WSK(ZL'0(4!P"29%S@;N3CK[59N-6G0+M
M'E9W?,X7'"D@<-W(Q71X%&!0!SSZM.(5?84+;,E@N%W$ D_-VS49U6=[61BC
M,0' 90N#C(!'S=\5TN!1@4 <Q9WH@$D<"EX\K@KM(Y1<XRP[]?>G6^L7$CD,
MN[*YPJC*G<1@Y;K@9KI<"C H YI=7N#/LVY&YEV;1O "@AC\V,$G%07%X'N1
M,R$2)Y6P':&.7.['S>G6NLP*,"@#F[G5[B-1L'E\.<N!@E5R%&&ZDU))JLP5
M/E,>]E4LX7"@G!)PU=!@48% '+OJMQ+I[NT;;FC;E0H&<=1\V:GAU$J\PC5I
M$\PX9=I!X'0EA70X%&!0!S-MJT\GWU\S**QV*ORDDY4Y;J,4)JTYG*%<C+C8
M%7<H7;@GYNAR:Z; HP* .2EO UWYK(1*C1!1QN(.[=@;NGKS4]SJT\?W5V85
MF^=5^8@C"C#=3FNFP*,"@#G+G49'58<&)9&"EV"X4>OWO:H9M4FFTXM)&RF1
M!G 4 9Z_Q9Q74X%&!0!SEM?F)'CA1FC61PI4*1C<<8.[I3;75[B0'</,^5&R
M@& 6&2IRW45TN!1@4 <U'J]PTN&&X'?E54;DVM@;OF[CFH&OLWOG%&\T.JA?
MEW;/+;.!NQC/OUKK,"C H YJXU>X1@%7;\N<,HRQW*,+ANN#3[C59EVA1Y0.
M[+.!M&%) X;N1BNBP*,"@#F9]1DFM )8V4/LW9"@ $C.?FZ40:B\-LRQ1LRH
M9-N I! 8XP=W2NFP*,"@#G+?5IW#!OWN-OS(JXY4$CENQ.*;!K%P[D,-P()P
MH7*88KAOF[@9KI<"C H Y07O^F>?M;S?,V[>-VSR\YQNQC/OUJ:75YUEV@;0
M-AVLHW/N;!"_-V'-=+@48% '-W.KW$:C:/+X<Y=1C*J2!PW4FDN-0:6*-)HV
M5'>/=D* !N&<G=TKI<"C H Y>#4YH;$;(W;8K;>%(.,X_BS5B'5)FWJ?WH5L
M!T5=I& >[>^*Z# HP* .9M]8N)"=R[\J&PJKE268;6RW7 %01WN+TS!6,C-(
M&'RY"@)C(W=/2NMP*,"@#FI-7N%F"@;0"@VD#<VXD$K\V.,47.KW$?W!Y>%9
MOG4?,5QA1ANIS72X%&!0!@2ZI*NS@Q*SA2[A=J@]S\U>8>*_! \3?#76=&U"
MXA2[U_9-?3[]G[L3+(V'8' BA7:@(P,#/4FO7=6 _LVX_P!VN:\8?\B#KG_8
M+N?_ $0WO0!RME:6EC\4?#UC8R>;;6_AF[CB?(;<B7%H%;(X.0.HXKV"O"/"
M7_(Y^#/^Q/D_]&V5>[T %%%% !7Q-\0,>-_VZ/A9X27Y[?X>>&M:\4W"]5\_
M47CTNUW?[07SROXFOMFOB;]GW_BL_P!IK]H/XHL?,MM/O]*\'V+?W%T>T$]V
MH/O<71S_ +M 'VS1110!\M_MJ?$WQC\'/V8/'?Q+\ 7BV'B#0[:WDM)WB2=4
M:2[AB8F.0,C?([#D'UK\R_ ?BG_@KE\1+5I-!\9>&H;V***:?3[NWL(+VWCG
M7?$\D1M3\DBG*2*61A]UB00/O?\ X*2?\F2?%+_KSL__ $OMZ]DL/A_X>\6_
M##P;K-Y<R:)K&CZ/9R6>M6CK#=V0^SH7Q(P*M$P'[R*4-$X'SJ< @ ^9?A%=
M_P#!1'PYHE[:_&?1M-\8ZI+<;[>YT[5M/TR.*WV >6T9TZ3<VX%MV>A QQ7S
M)^V;\>?VY_!.E7=]X*2Q\-Z;H^FRRZ]8BZT_7+F.WF.U+F5A8P+;QD'8@8[I
M#]Q6PV/MBP^-/C[Q3+8>#=0OK?P[H^H3M:0^.H8&6RU;& L>FQSAD@N)<D"2
M<O Q!^S&XS\F#^VUX)\-^ _V'?BIH_AJU\B.73C-/+([2W%U.\T>^:XFD+22
MRM_$[L2>!T % '<77@ZT^(GB7X<^%M;U"_M],LO"O]II!:W#0QM=P2V:12R)
MRCE [;=RG:3D5J>,/@-H6F/I>M:3XBURPU.TFE$%W!>*DL0\EYF4?N]K*[0H
M'1U9& P5-,TS66T3QYX N%2)R_@B5<2R-&/]=8G@I'(<^V!]:]$U[7]3\3"T
MTK2TLTO&><PYFED5G^RS!58&&/"DGD[N.N#TH \P\/>!-4\=>)[S2=9^(/B6
M_P!-\.F/[5 MW%9"2YNK:*2(>;8P6\K+&KNS#>4+% 060UT?B3X9Z;X%N?#F
MO:%KNOFX&MZ; RW.LWMQ#)%/.L<B/%+*R,K*QX(->F>%[?7_  M8:5X4738[
MEH[-Y)KMKD_O+A"N\M^Z^]*[[O;GC@ \A\:/$<OAWPOIOB/Q/##I^D:7K6DW
M-W<"5Y1# DZ-)(RK%G:AX/M\QQC% '9?"O\ Y%N^_P"PWKW_ *=+FO2*\%_9
MX\8P>-?"6O7]G97%K:6OB778;>2>-H_M<+7TD\=Q&KJK>6ZRC:2.<&O>J "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JAJFF6.M:9=Z/J<0GL[^&2WGC)(#Q2J4=<@@C()'!S5^B@#Q>#]G
MOX30Z==Z7_9$TT-[#;6SM-?WLTR06DJS01Q323-)$B2*KA8V49 /:I+_ . 7
MPPU2*UBU*QO;K[)'<0H\FJZ@TIANF5IHGD-QODC<HN4<E>.!UKV2B@#RG7O@
MA\+/$L\<^JZ#&?+M8K%HX)9K:*:U@_U4$\4+HDT2=%2164#@#'%:GB[X6^"O
M'%YI6H>(;2=KG0UE6RDMKRYLV@$P"R;#;2Q_>50#[<=":]"HH Y"Q\ ^#=+\
M2OXQT[2(+;69+;[&US&NUVAWF3:0."2QR6QN/<XKKZ** "BBB@ HHHH ****
M "BBB@#X8\6:[XRUSQ#'\;+/P==#PFOAVZC,SWEF)]DRL5E$(E)V[6W$;@PZ
M;2:^YZ^!OB%X.\#:)\8+;P8+J>RTF;P[>7":8=6NTMGD4MM(MC<!" 0 %V[1
MTQ@XK[YH *^'?!'_ "D%^*'_ &)'A[_TJNJ^XJ^'?!'_ "D%^*'_ &)'A[_T
MJNJ /N*FL0%)/0"G5%/_ *B3_=/\J /F?X#>+-9^)OPHT_4=!M'T'3[J:[A>
MXN)(VNU$-Q)$_E1Q%T#$J=K,_P O!VD\#VSQ'::/IOA-M,>WD-M$L,%M# VV
M7S0RK (F)X</M*L3\I&XG )KR;]E+GX%>'\_W[W_ -*Y:]PU_P /:5XFT\Z7
MK$<DD&])!Y4TEO(KQG<I62%D=2#Z,/0\4 >5:'!XIM_B99IXKN[:ZN3I<FPV
M\;)M3S3@2,3B1_5E2-?1!7MK,$4NW102?H*^&[:WD\)_MW^'_!^BWMZNBWGP
M^U*^EM9[VYNHVN8M3MXTEQ<228949@,8X)K[D=1(C(W1@0?QH ^5_$=GK_QI
MT;7=5T?1+K1=-\0>"M3TZSN=2>V599=45&@;9;S3R*NT;FW*".F">*X_]B*X
MU(_LY?"&WEM%2!?#MFGFB)@2(X/E/G9VL&);Y.HQFO5_#UIXD\ ZK%\.KO73
MJ^C6GAN:6V\VVCAFA^Q-% @+QXWY1^<CJ,CTK\XOV-/VF/V-OAK\)/!<_C/Q
MOI&E^)K'2+.*19!<M<P7!AV7*L50J-S$\#/.3G!  !^O&M:Y%!<)H]E]HGU
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MC[%9_P#/"/\ [X% $'VNY_YX+_W\'^%'VNY_YX+_ -_!_A4_V*S_ .>$?_?
MH^Q6?_/"/_O@4 46-U/<1R96 1JP)W!\[L<8X]*KK=3:?Y-I(%E!5L,@8GY2
M.H'3.:UOL5G_ ,\(_P#O@4JVEJARL* ^RB@#(;6)!)M$7R@H#E6#?/GHO?&*
MKWFH._(,D7EQNXP&3)4KCZ]>E= ;6V+!S$F1WVC-#6ML^-\2-CIE10!AW&NM
M!>Z=:"%B+ZX,!+*R[0(9)<\CG_5XQ[UT=<OKL<:ZEX?*J ?M[=!_TZW%=10
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M^ARO._$>K:CKFG:WI'AZU26**"XMYKN>0QQ+*4(9(PJLTC)GYONJ#\NXL&
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M&2.<\4Z@ HHHH **:J[<\DY.>:=0 444UAG')&#GB@#F]?\ ^0CX>_Z_V_\
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M,4UO#'%C^^9I%;GML5O?%=/10!Y+<ZQXE6XL]8\4Z<;"ST^4S".-K8#>T;Q
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M:O+)UMV^ZC?*"PPZ[NN.HK5%K;*NU8E4>@ %5K73X[=2KD2DX&2!P% 4#]*
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M:[=-RL.ZD$<'@XK[M^#4<</P@\#0PJ$C30M,5548  M8P  .@% 'I-8'BO\
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M?/E1%#R;0N]@.6VC@9/.!TJ>B@ HHHH R_LFI?VU]N^W_P#$O^S^7]C\I?\
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MM#?WT2QL]M%&2NV),CH2H)YK]'O&S%?#]LP'E$:MI_?'_+_%SD@]>O2OSO\
MVDO@3;_#CQQ\&_&MAXV\4:M!J/Q4T(_V+?Z@D^DP274EQ-))!;B)"C[]Q!+G
M[[>O'Z(>-?.'AVU,P;>=4TXXR=P!OXB!E,GIZ4 ?F_K2>%9OCE\54\=:1J6M
M65S+;VVGKIYG94U5@[0EQ!)%AO[CN,+@\CO^G'@A;E/!>@)>DFX73[42;CEM
MXB7=D]SFOS9U/5+BV^-GQ"M['2=0U66TUS3=1N%LH&F,-I;))YDLA8J<#<
M,L<< BOTO\*7$5WX6T>Z@.Z.:RMW4],JT:D'!]J -^BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /_7_?RBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**$2H\@4 ?*S8).3[1=V'[)30RZ9JEOX6D1T,<L,R6S*ZL,%71A@@CJ",$4
M>F_!#_DB_@#_ +%_2O\ TDCKU"OF**/]D>"-(8$\+1QQJ%1$6V5551@!0.
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MB=(9%4[H)D9AAB-I)4YY!KC?"&E?LB-X.T./5+#PE]I.GVJS+)#:;M_DJ&#
MCKG((/.>M ,^%OV:OCQI7[/NDPOJ,5]J>G:R%6Y@6=Y!%,T<9CG"L'R3M=&
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MC5E3< =F00,CIBD\*_"+0M(M;Q_$*6^KZEJ%[<7LT\<!MH]\[9VI%YDA55
M&7)/6CZOC?\ G['_ ,!_^V#^V>%_^A?5_P#!Z_\ E1\FZ7_P4.\#W(;^U/"]
M]9%DCEBVOY^Z.4'!.V,;2,<C]:6#_@H;X'DOWBG\+W\5DQE6*</O9VB* @Q"
M/<H.[@DGI[BOK_2/@Q\+= 69=%\-6EF+@J9!$I7=MR%SST&3@=!GBBV^#/PM
MM-4GUNV\-VD5_<AA),JD.V[;NR<_Q;%SZX&>E'U?&_\ /V/_ (#_ /;"_MGA
MC_H7U?\ P>O_ )4?'TG_  4/\#+J*P1^&+Y[$-&CSE]KJ\BNPQ%Y>Y@-H!.>
M_L:-2_X*'^![9E_LWPO?W:*C23%G\DQQJR+E0T9WGYLX&.G7D5]+7WP(T2Y\
M:P^(H988=)$MM<3:?]F+-)/:07,"$3^:-JD7.67RR24&&&375ZI\&/A;K<EO
M+J_ANTNWM23$9%+;,E6..>A**<>H'I1]7QO_ #]C_P" _P#VP_[9X8_Z%]7_
M ,'K_P"5'R/J'_!0CP)$B)I/AJ_O;F60(L;L8%Q@DDNT9 P!TQS7 _%+]N'P
M%X]^$_B'PQ8:+?6U[KNF26\?F*VQ)+A-H#-LQ@$\GIWK[\U;X0_#37;7[#K'
MAZVNX-XDV2!B-ZYPW7J,GFLKQ-\%O!6M>$KWPOI5C!I1GM_(@E6,R+!M V$1
MEE#*N!\N1D<9%14PF-E%Q=6.O]W_ .V.C"\1<,T:L*T,OJWBTU^_6Z=_^?1\
MF_LV?'/3?"?P7TO1[S2[B:2PFU'S&BANI5/^ES.=K16SJW7LQ_/BO7= _:FM
M=50C4/#5Q93&WL;Q4C^TW2F#4;9+J$EXK0JKA7PZ'E2.X()]D\(?#'2?#FB_
MV=?LM[<RW-Y=32PK):Q-)>7$EPP2%9'"*OF;0-QX')J]H?PL\ >&;>2U\/Z/
M'I\,K*SI \B!BJ!%R W\**%'H  .!7HX.A[*C"DW>R2^X^+XDS98_,<1CHQY
M54G*5KWMS-NU^MKGANF_M36UY=P1W/AJX@M;^.]FLY5-S,\B6%XUC+YL26F^
M$F1<J'^\ISU!%#?M36PU$QCPS<'3EU"/2VN,W(E^URV3WR@6WV7S3'Y:$&3&
M-QQZFO<=/^%?P_TK4;O5M-T>.VO;XL9YHWD5Y-SF1MQ#?Q.2Q]6))YKE)/@W
M"_CL>)QJ>-)\^.[:P,3F0W$=G)9*1<^=D)LDR4V$[A]['%=)XIYMJO[55EI]
MVT-OX:N;B"UA@N+J1OM,+1Q7-Y#8H8XWM-TS>9,"53D*">I -K5_VGH+1[>U
MTKPW/>W5PMW($E-S:(([*UENY3YDMH%W%(B%4<EB.@R1[7J7PL\ :Q>VFI:I
MH\=U=6!#6\LCR,\9#K(-I+<8=%8?[2@]0#2ZW\+O 7B2V2RU_24OX(V+JDTD
MC@,R-&2,MW1F4^JD@\$T >*M^U#IT^GZ;=:9X>NKB?5YK"WMHI8[NW4R:A-'
M#%YDDEIMC4&0%F/0 ]\"JJ_M6Z1'X<O-?OO#]W$VGI>&>&.*[FP]DTB2*DB6
MFQP6C.U@<$8->T>)_AIIFL:&-,T67^R[J":TN+>9A)<1QO93QW$8:$R(&4F,
M*1N'!X(IGA?X7:)HGA>W\/:L?[5=5F%Q*?,B28SN[R?NA(P527(VY/'&30!Y
M58?M+1-=WVEZQX;GL[[3WMUD2'[3=Q$7-K#=QE98K0J?W<ZAAU# CT)S=&_:
MJL]3G5+KPU<VT=S:B]M67[3.9+<W5Q:9D6.T)B??;L=C\X([Y ]YT7X8^!?#
MMJUEH6E+8P._F,D4DJ@OM5,G#<D*JJ/0 #H!4>E_"SP!HEQ=WFD:/'9S7S;I
MWB>16D.YG^8AN?G=V^K,>I- 'A47[55I)J:P-X:N%L);VZTZ.<?:3*;FTMH;
MJ3=;BT\Q8RDP"N>"0?4$NO\ ]J:VM+R=+?PS<3V=C_9WVN9C<Q21_P!J73VD
M'EPO:;YL.A+[/NKS7H]I\&K:W\=2^)WU'?I;37%U'8B.19$N+FVMK5R;GSB6
M3;;@A?+!!8_,0 *ZN^^%?@#4M3M=:U#1X[B_LMODSN\ADCV,73!+9^5B67T/
M(YH \/US]J2WTT,NF^&;B^EBL=0U&59#<VH6VTV'SIBK2VH#.5("(.6/H 36
MC=_M+6:OI]IIOA^XN;S5;VTL;=)4N[:,RW<JQ(9)9+3:BC=DD^F!DD"O7]<^
M%7P_\2Q10>(-'CU".$L46=Y'"[UVOC+=&7AAT(X-5O%?PWL=<TR*#1Y_[-O[
M6[L[V">42W,:R6=PDZAXC*FY6V;2-P/.0<T >'C]K715\'2^+9O#UXH@M);E
MX5BNV.858L@D%KL/*D!\[>^<<UMV/[2<#W6HZ9JWAVXL[_2KV6QN$B%U=Q"2
M(*<I-%:%74AATZ'(/(KU#PW\*?#>C>#;'PAJ:'58[>S%I.[F1$N 5VR9BWLH
M5\G*Y(P<<UKZ/\./!7A^T%CHFFBRMP[2;(I)5&]SEF.&Y8GJ>IH \#T+]J>V
MU186O_#-Q9B\L+/5+;8;FYWVE\91$7\JT/E2?N6W1MR,BBU_:HM9]0ABE\-7
M$=C=SZC;6\P-R\KRZ88!-OMUM/,C4F<;&;[V#TRN?<M%^%7P^\.>?_8.C1V'
MVHJ9?)>1-^S.W.&Z+N; Z#)QU-<IH_P:@T[QG=>(KK4A<Z:[WTMO9")XY(I-
M0^S>:7N!,3(H^S#:-BXW').!0!YQ<_M46D&I- GAJX>QAN;*TFG/VE95FOX[
MB2+;;FT\QT MR&<# W#T;":Y^U3::7YS6?AJXNTLK&?4KHN;FW,=K;S00N8Q
M): RR;KA2(TY(!]L^Z3_  K\ 76LP^(KC1XY-3MPHCN6>0RJ$#JN&W9^42.!
MZ!FQU.36/A7\/_$#VTFN:/'?-9L6A,SR.4)96.,MW9%)'JH/84 >17?[2,9O
M],T;1O#L]YJ.K78LX$F^U6D6_P J24L\TMH$4!8FZ\DX K!?]K?0_P#A#8?&
M$/AZ]=+BU@N8X6BNT)-P%V(9#:;%Y< L3M YZ5[3XQ^&<.O6MBWA^]&D:CIU
MXEY%/,DEY&65'C*O$98\@K(>0PP<'GI5G3/A3X2M?"-EX/U.V_M.TM[*&QE\
MUY-LZ11B,EDWD8;&<=* /)8?VF[%!JD.I^'[B"ZT:[O+*Y2%+NXC\VRD:-S'
M*EIM=3MR"/H0""*IZ)^U';ZCOBU+PU<65P+>QNU6(W-TIAU"V2YB)>*T*APK
MX=>H([@@GWK3OAUX-T>R_L[2].%M;;G?RTEE"EI6+NQ^?DLQ)8GDDDFJNA_"
MSP!X:MWM= T>/3X92K,L+R("44(N<-_"BA1Z  #B@#PS3_VIK:[N[9+GPU<0
M6FHKJ+V<JFYE>1=,O/L4_FPI:;X29#E _P!Y>>.E$G[4]JFIF >&K@Z>M]#I
MK7'^DB474]G+>J!;?9/-,?EQ$&0# 8@>I'I'AOX.0:+XFN]9OM2^W6)%\MI:
MK$\+PC4+O[9+YDPF8RX?A?E7"]<GFNK?X5^ )-;7Q(^CQG5$4*+DO)YH 5D'
MS;L\(S*#UVDCH2* /"=9_:KM--GF6V\-7%S#8VT=Y=NWVF%DAENX;-?+1[0-
M,^^8,53G:#W(!Y/XO?'CQ%XF\'7W@KX::5'!XKUJ"Z_L^?4X[N*RADLH'O&:
M8M:KD;82 H.22.@R1]0ZG\*_A_K5U:WVK:/'>7%D089)7D9H\.L@P2W9T5L?
MWE!Z@5@^.OA1#XFM;/\ X1^_&CWUF]P5FFCDO$9+JTFM)%,9FCYVS%E;=P0,
M@C(H ^5D^+^JWWA#1HY-9UF].IKI<"6[:?';(\U[)#%&#,^FXC4/("7)^4#.
M<TEG\=?&&G^#K_%VEL-/748I8O[$O;@B6TDFCE/FQ_+)N=&;>O#9SCG%?8R?
M"_P?)X=M_#6J6?\ :%I#!# RRR2$2" +M8KNP""H8>A (JY8_#GP9INFIHUA
MIJP6**R+ DD@C"N26&W=C#%B3ZY.: /ESX3_ !\U30?!FG>%/'6A!/$.CV]I
M'>MIRWEQ9O)=6L-X&A<6S$+MG VL=RD$'/!-B\_:.MO&>F_V3-HUYH\>H0K?
MV5U;K+=2F.UOY(,R0FS<1,9+8_)(O*MZ@@?2NB?##P)X:M#8:!I*:?;LV\I#
M)(BE@JH"0&Y(554>@ '0"N/\'?!FU\-:SJ.HZCJ/]I6\Z/%:0I');M;PO>7-
MX5DD$S^:VZY*[L)PHXR2: / M"M/BG\;==N-7T+Q>VFZ#X8N#:3_ -IZ9'--
M>7:+!<A5A2*Q>*)5D&7+,6;H !D_$O[.7_!4GQ7\3OC#X'^!DWA2RMDU2\BT
MR:Y42 JD4;!G3]\W)V<9!%?JQI_AW1_#WQJ_XDT!MAJVAW$UV%=R)Y8;BWCC
MD<,2"ZH=H;KMXSBOGB__ &+?V8OA+XG\*?$;X=^!;?1O$=GXATXQ7D=S=R,O
MVB<))\LLSH=RL1RO&>,<4 ?>=%%>-7FA1>*OB?KECJE_J,5KI^E:4\$-IJ-W
M91J\\UZ)&*V\L89F$: ELG"@"@#RGXD?$KXQ:A^T78?L_P#PTETK2;&X\*R>
M(;W4[N.6:]B"WGV18[5,F'<6*G,J, ,G!("FXWP'U6:YCNKZRTV_EV.+B:ZN
M+J6ZN9R4,=S)<Y$JS0;6$+1L@B$CA H.*](/P"^&Y\4CQN8]4_X2%;(Z<-0_
MMK4OM(LC)YQ@W_:<^7YGS[?[W-;_ /PJOPY_T$-;_P#![J?_ ,DT ?(7BGQS
M^TSX ^,?@#X!:3K.BWUEX^M=7G@U34(II]1T^/2HT=T#*4BG;$B^6\J$DY\P
MMC+>J2_ C6[R>"[UBWT[6+G+M=W%_-//<7S,N$,LG!40M\\*Q!$B?F-5->CW
M_P"S_P##75/$6E>+]2BU.YUS0DN(K"]DUG4FGM4NPJSK$YN<J) H#>N!71?\
M*K\.?]!#6_\ P>ZG_P#)- 'PQ\:=)^+7A7XG?L_:#XDU>SU?PK<^/()(?.,T
MNIVUQ%87?EQBX; F@*,^6E!F!"C>PR1^E]>+:W\ /AMXDN](O_$$6IZC<Z!=
M"^T^2?6=2=K6Z"-&)HB;GY7".RY]":YCXP> M+T'X6^*M7TO7=>TR[M=/G>.
M[37=1#V[!3^]4R3L@*?>!92O'((H ^:_^"GGCZ?X5?"'X>?$VVMUNY?"GC[1
M-36%\[9#:Q74FTX*GG'J/K7YX:S_ ,%F_$&MVL=I<^";9$CN+>X^57R6MI5F
M4?\ 'QT)0 ^U?>GQ8_9&^$6MZ3H-I\0OBYXM\?V(U_1UBT77O$<-U9W<T]W'
M R&*.**1G\F23'EN& R0>M>M_P##MK]B+_HEUG_X&W__ ,DT ?(G["?[1%O^
MTCXZ^-GC<::=*NWT6)IH>L>9#.04Y8@<8P6)SSP" /UO^'G_ "('AG_L&67_
M *(2O$_ _P"S#\"/V?=!\6ZA\'?"</ANXUG3I(KMXI[B;S4A21D!$\L@&"QZ
M8]Z]L^'G_(@>&?\ L&67_HA* .PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#_T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7QU_R)'B'
M_L'7?_HEJZJN?\66WVSPKK-F&V>?97$>>N-T;#./QH \K^%?_(R7_P#V+OAO
M_P!!NZ]TKY7_ &==6\2ZMXA\91^)XK.&?1(M)TB/[&TC))':12L)6\P JS&4
M_*,@ #YCGCZHH **** "BBB@ HHHH **** "BBB@#Y>^#G_(4\&_]BG-_P"E
MD5?4-?'?[.>I:]KFM(VIV%O96OAFPO=$A>*Y>>2Y,%W&3,R&&,1 C&%#.<D\
M\<_8E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Y_Q9<_8O"VLWFW?Y%E<2;<XSMC8XS^%=!7*^.O^1(\0_\ 8.N__1+4
M > _LZZ9XFTOQ#XTE\3FS,^MQZ3J\0LC(4CBNXI5$;F4 EE,1RP !!' KZHK
MPOX5_P#(R7__ &+OAO\ ]!NZ]TH *R[[49K.]T^TCL9[I;Z5HWFB">7;!8V<
M/-N96"L5V#:&.YAD 9(U** "BBB@ HHHH R]9U&72=/>^@L9]2=&C406P0RL
M'=4) =D7" [F^;[H.,G .I110 4444 ?&W[-:>(]-UF>VUVSM8;?7H-0UJQD
MM[EYG^SSW<:A)D:&,)(."=K.O.,\<_9-?+_P<_Y"G@W_ +%.;_TLBKZ@H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /FKXS_P#(2\1_]B+KO_H<-5O@6"GQ ^)2
M<X-Z7R>.3J6IC'Y 59^,_P#R$O$?_8BZ[_Z'#4/P,/\ Q7_Q'!;<1>-CV7^T
M]4./SSQ^/>@#Z;HHHH R]'U6'6]/34;>&>W1VD0)<PO!*#&[(28Y & )7*DC
ME2"."#6I110 4444 %9<.JPSZO=:,L,ZRVD44K2-"ZP,)BX 24C8[#8=RJ25
MRN0,C.I10 4444 ?"/Q5TWQ+KGQ+U"#PP;-+G2=6.J/]M,GEO#I^DV3F-3$"
M0[F4#)R !T.:^R?!ET;_ ,'Z%?%=GVBPM9-N<XWQ*<9_&OFK6<_\+>\5<\&W
MU3CT/]DZ;G\",<_7TKZ*^'G_ "('AG_L&67_ *(2@#L**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH __]+]_**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N?\6VQO?"NLV8;:9[*XCSC.-T;#/ZUT%8'BNY%GX7UB\*[Q!9W$F,
MXSMC8XS0!\[_ +.VL>(]8\0^,8_$MK:6L^APZ1I"?8Y9)4E2SBE;S6,B(5+&
M4C8-P 'WCGCZGKY6_9UT[Q-IOB+QK-XH6S6;6TTK5X5LGDD2.&[BE58W:1$)
M=3$<D  @C@<U]4T %%%95]J@L;W3[(VEQ<?VA*T7F0QEXX=L;2;IF_@4[=H/
M=B!WH U:*** "BBB@ HK+UK5!HNGOJ!M+B]"/&GE6L9EE/F.J9"#&0N[<Q[*
M">U:E !1110!\=?LYZGKNNZU&=2T^"QM?#-A>Z)$\=RT[W+07<9,Q0Q1B-2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!GO4] ^''A+PQ!?^9JVDZIH]]?M-?7=Q:%-.NO/D%K%*62(L"0 D: G&<
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M %%%% !1110!_]3]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KE?'7_(D>(?^P==_^B6KJJY7QU_R
M)'B'_L'7?_HEJ /-?A7_ ,C)?_\ 8N^&_P#T&[KW2O"_A7_R,E__ -B[X;_]
M!NZ]TH ***R[[5[33[W3["X65I=2D:*(QPR2(&2-I#YCHI6,;5.&<@$X4')
M(!J4444 %%%% !167K&KVFA:>^I7JRO#&T:$00R3R9E=8UPD2LQ&6&2!@#).
M ":U* "BBB@#Y8^"<KSWG@B>6)H'D\(2,T;$%D+7<)*DCC(Z'%?4]?+_ ,'/
M^0IX-_[%.;_TLBKZ@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+KG_DM6G?\
M8OWO_I7;4?!3_DEGAS_KV_\ 9VHN?^2U:=_V+][_ .E=M1\%/^26>'/^O;_V
M=J /4:*** "BL[2M7TK7;"/5-%O(;^SF+!)H'62-BC%&PRD@X8$'T((K1H *
M*** "BBL^+5M+GU.XT6&[BDU"TCCFFMU=3+'',6$;LF<A7*,%)&#M..E &A1
M110!XMK?_(Y^._\ L5M/_P#1NIUW/P\_Y$#PS_V#++_T0E<-K?\ R.?CO_L5
MM/\ _1NIUW/P\_Y$#PS_ -@RR_\ 1"4 =A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '__UOW\HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_X3(_\ DVC_ (5-KW_/?PO_ .$R/_DV@#U3_A,O"'_0<L?_  )B_P#BJ/\
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M%B#M=2IQ^ZZX->CZ+I4&AZ/8:+:LSPZ?;Q6Z,^"Q6) @+8 &<#GB@#3HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_T/W\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_T?W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /_TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /_T_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __5
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&\0^(] \):+=
M^)/%.I6VCZ3IZ>;<W=W*D%O"@XW22.0JCGJ3BO&Q^U7^S$Q"K\6O"A). /[;
MLN2?^VM>=?\ !0#_ ),T^+'_ &!V_P#1J5^-G[)L/P#UOP+\._"_B[]D_P 0
M>+=2U*:&TN?%<5E</I\QGNBGVHRIA?+B! <]!L-)L:1_1!!\2/A[<^,Y/AS;
M^)M-E\5PP"Y?25NX3?K 55A(;<-Y@0JRG=MQ@@]Z\YD_:I_9EAD>&7XL>%4D
MC8JRG6K(%64X((\W@@\&OSH\+1I%_P %F/%4<8VJOA*( >@%E:"ORB^!GC[]
MGOX>^%/'VJ_'+X'7OQ)276YHK;5XR\%I:%T.VU>Y4@1R.07 &6QR!Q1<+']9
M=AXR\(ZKX</C'2]<L;S0!&\QU"&YBDLQ%'G>_GJQCVK@Y.[ P<UY+X1_:I_9
MN\>^)8O!W@WXEZ!J^M7#F.&TM[^%I9G'\,0W?O#[)FOQQ_9X_95^.WB__@F[
M\1O"FCW$>F2?$#4+;6O#^G->H8Y;&%H7=&E#;(_M(CV@.PY0>9M#''RE<S?"
M[P9#X%^'/[5GP+UOX.ZGX;N(5B\7^&!]CNKIXL#SKA+N&9+G# 2M)#,6!!,8
M .TEPL?TL>)OVA?@-X+URZ\,^,/B+X>T35[(J)[.]U6UM[B(NH==\<DBLN58
M,,CD$&M3P5\:O@]\2=2FT;X>>-]$\37]M$9Y;?3=0M[N5(0P4R,D+LP7<P&2
M,9(%?F%_P5'^!/P3_P"&;O%OQ^TOPW9R^-=0GT=O[;7<9YDDF@@#<-L^:'"\
M+TKZO_8F_9^^#7P\^$7@/XF^"O"EII'BCQ'X5TS^T+^'?YMQ]H@AGEW[F*_/
M(H8X Y% 'T_XY^*?PS^&,=G+\1_%>E>%DU%G6V;5+V&S$[1@%Q&9G7<5##..
MF1FN?\*?'WX&>.];B\->"OB%X?U_5IU=X[2PU.UN;AUC7<[+''(S$*HR2!P.
M37Y/?\%DS9K=_ 9]0TU]8M5UG4#+8Q@M)=1@V>Z! .2T@R@ ZDUZ[^QW:? S
M7?BK>7O@_P#9AUSX/ZSHVF7-Q!K&K6=Q;QMYA6!X(S)\OF.DA..NT-1<+'Z6
M^"_B-\/_ (D6=SJ'P^\2Z;XFM;*8V\\NFW<5VD4P 8QNT3,%;!!VGG!K6\2>
M)_#?@W1+KQ+XNU6UT72;)=\]W>S);P1+TR\DA"CG@9/6OR)_X(P@#X/_ !*Q
M_P!#7)_Z2PUB?\%)(KKXK_M3?L^?LT:_?36G@OQ%=1W5_%$YC%Q)-<^1@D?Q
MK&C+&?X3(2.30%C]/OA]^TM^S_\ %766\.?#GX@Z+X@U4!F%I:WL3SLJ\LR1
MY#. .25! [UW7CWXE?#[X6Z(?$GQ'\1V'AK2]VP7&H7$=O&SD9"(7(W,1_"N
M3[5^+G_!3+]F7X._L_\ PD\)?&_X%Z)!X!\5^&-<LK6WGTPM 9D=))%+#)W2
MQO$&$A^8C<&)'3GM<TZT_;%_X*.^$/ ?QJ!O?"OA[PCI^K1:27:.WFGN=.@O
MI4V@@X::X!?&"R1!2=HHN!^TGPU^.?P<^,0N1\+?&>E>*'L@&GCL+J.:6)2<
M!GC4[U4G@$C!]:S-=_:0_9\\,:Q>>'?$GQ+\-Z5JFGR&&YM+K5K2&>&1>J21
MO(&5AZ$ U^/O[8OPM\#_ +(O[5_[/_Q2_9^T^'PE=^)M5-AJ.FV&8K>XA2>V
MB?$*G:JS17#1N% 4D*V-V2?F'QIXG^$7@W]MG]H;Q%\9OA/>_%30K2^F<I:(
MQ332)DS<SN"!&C [-S$#)Q0%C^EWPAX[\$?$+3#K7@/Q!I_B.P5MAN-.NHKN
M(/C.TO$S '!Z$YK>U/4M.T73KK6-8NHK&QL8GGN+B=UCBBBC4L[N[$*JJH))
M)P!R:_%#_@DYX&U>]\>?%/X\^$-$'A'X5>*W-IH^D_;!=%98;@N >2_^CH2N
M9 "?,PN0":]Z_P""L7CK7M$_9ZT;X;>')FM[GXE:_9Z+-(IP?LOS2R+QV=UC
M5AW4D=#3$?<6J?M"? ;0],TG6M:^(OAZPT_7X7N-.N)]4M8HKR%&VM) [2!9
M%#<%E) -:7@WXV?!OXB:@VD> ?'6A^([Y%+M;Z=J5M=3!1U;9%(S8'<XQ7XA
M_P#!2'PEX/\ AQ\7_P!F'P2OA67Q5X:\.67V+^PK2,M/J%K;36\?V:-$Y9Y5
M&..23ZUY'\%=+\'_ +0/[;GP[U;]E3X82_"FR^'=S'>>)EN+P++Y,,^)0UNS
M[E8KN@*H"27Q(% S2N,_H5NOCA\&;*3Q#%>>.]#@?PD4765?4;=3IIDD\I!=
M@O\ N=TAV#?C+<=:Z[3_ !CX2U;PLGCG2]:LKOPX]NUVNI17$;V9MD!9IA.K
M&/RU )+9P #FOQ#^ ?PTTWXQ_M0_MN_"[5 OD>)1=689AQ'+)=3^5)]8Y KC
MW%?+OA7]J#5_ W_!.#QY^SGJ<K0^-=.\0MX5M[4L3.MEJ+O/<*%^\0IBN83V
M&]1WHN%C^A6;]I7]G>VTJRUVX^)WAJ+3=2>:.UN6U>T6&=[?:)5C<R;7,9==
MX!.W(SC-7?#/[0GP'\::Y;>&?!_Q%\/:WJ]Z6$%G9:K:W%Q*44NVR..1F;"@
MDX' !-?S^_M=?!NU^!6D_L??"N\\+MXMGTV"ZDU'18LK)JE[=W5I/=VH*@MF
M61VB4X)QCCC%?<O[)_A_P9/\<-'N+?\ 8YU'X0W-G#=3P^([J:=X[:01,FS#
MPHN959D&6[\ T7"Q^A-_^T_^S=I5]<Z9J?Q3\+VEY9RO#/#+K-FDD4L;%71U
M:4%65@00>01@UZGX8\6^%?&VD1Z_X-UFSU[3)B52ZL+B.Z@8KU DB9E)'<9X
MK^5SP5XW^!/@#XI?'O7_ (Y_!F]^*.G)XHNEAO8 RV^EEKRZ4I/*"JQF<E=F
M3D[#BOT^_P""0OPX\8>'? WC_P")5S9#1/!/CW48;KP[IHNENO*@@:=7<L"2
M,!DARX#MY9+ 87(F#1^J/C#XD?#WX>G3AX\\2Z;X=.KS?9[/^T;N*U^TS<?N
MXO-9=[<CY5R>17:$XK\:?^"NO_'S\ ?^QI?^=O7[*O\ <;Z&F(\%?]JK]F2)
MVBD^+/A170E6!UJR!!!P01YO4&MZR_: ^!6I2Z-#I_Q#\/W,GB.5H-,6/5+5
MC?2I((F2W D_>L)"$(3)W$#K7\SG[)ECX?NM'\9/JW[+]_\ ':0:U*%U*TEF
MC6R&T?Z,1'%("3]_J/O5]E_MD_!^W7]B7X>?'/X>?#:?X0ZQ\.-;DU!M"D+O
M<:?#>W7E.[,ZH^6GBMYAE0 K'ZE7'8_<+QM\2/A[\-;&WU/XB>)M-\,6=W+Y
M$,VIW<-G'++M+;$:9E#-M!.!S@9KC-?_ &C/V?\ PIK%UX>\3_$GPYI.J63!
M9[2[U:T@GB9E# /&\@925(/(Z$&OQW^*/CVP_;Y_:S_9V^'&C,MUX5TC1K7Q
M9KD2'=''+<(ES<6\GNHCB@YZ-*17A?CVUTFZ_P""B'QP75_@C=?'6,;"NDVC
MR1O:-LM?]*)CCD. /W?(ZOUH;"Q_0=HGQT^"OB31=8\2>'O'NA:GI/AY%EU*
M[MM2MIK>RC8$JUQ(CE8E(4X+D#@^E=OX9\4>&O&FAVOB?P?JMKK>CWP9K>\L
MIDN+>558HQ26,LK ,I!P>H(K\?FT;PY9?L0?M#:GHOP#NO@-<3Z4\,MI=R2R
M/J"11%DF!ECCPJ&1EX!Y)Y[5]<_\$U@/^&(_A?\ ]>M[_P"E]S0F(^O=#\<>
M#/$VK:QH/AS7;'5-3\/2K!J5K:W,<T]E*X)5+B-&+1,0"0& )P:ZFOR0\<7<
MOP2_X*L^#-0T+]SIGQI\/M::M"G"R75HLJQ2D#@L#!#\W7!?U-?K?3 ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__6_?RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH __1_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH __2_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __3_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __4
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH __5_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH __6_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH __7_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __0_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __1
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH __2_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH __3_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH __4_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __5_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __6
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH __7_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH __0_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH __1_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __2_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __3
M_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH __4_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH __5_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH __6_?RBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813502561456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viridian Therapeutics, Inc./DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1187261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent Street, Suite 103A,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">272-4600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRDN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,212,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503337696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 200,317<span></span>
</td>
<td class="nump">$ 102,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">552,923<span></span>
</td>
<td class="nump">374,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,103<span></span>
</td>
<td class="nump">9,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Unbilled revenue - related party</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">767,357<span></span>
</td>
<td class="nump">486,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">771,900<span></span>
</td>
<td class="nump">490,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,338<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other (including related party of $3,725 and $374 as of September&#160;30, 2024 and December&#160;31, 2023, respectively)</a></td>
<td class="nump">34,738<span></span>
</td>
<td class="nump">24,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue - related party</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,364<span></span>
</td>
<td class="nump">26,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">20,523<span></span>
</td>
<td class="nump">20,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue - related party</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">64,404<span></span>
</td>
<td class="nump">48,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 200,000,000 shares authorized; 79,181,445 and 53,986,112 shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,433,019<span></span>
</td>
<td class="nump">960,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(916,132)<span></span>
</td>
<td class="num">(725,908)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">707,496<span></span>
</td>
<td class="nump">442,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">771,900<span></span>
</td>
<td class="nump">490,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">61,188<span></span>
</td>
<td class="nump">78,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 127,697<span></span>
</td>
<td class="nump">$ 128,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813502466880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other</a></td>
<td class="nump">$ 34,738<span></span>
</td>
<td class="nump">$ 24,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">79,181,445<span></span>
</td>
<td class="nump">53,986,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">79,181,445<span></span>
</td>
<td class="nump">53,986,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">435,000<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">145,160<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">145,160<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities and other</a></td>
<td class="nump">$ 3,725<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504712832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development (including related party expenses of $7,725 and $10,937 during the three and nine months ended September 30, 2024, respectively, and $1,099 and $6,521 during the three and nine months ended September 30, 2023, respectively.)</a></td>
<td class="nump">69,158<span></span>
</td>
<td class="nump">30,385<span></span>
</td>
<td class="nump">166,294<span></span>
</td>
<td class="nump">121,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,408<span></span>
</td>
<td class="nump">20,911<span></span>
</td>
<td class="nump">45,499<span></span>
</td>
<td class="nump">62,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">83,566<span></span>
</td>
<td class="nump">51,296<span></span>
</td>
<td class="nump">211,793<span></span>
</td>
<td class="nump">183,214<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(83,480)<span></span>
</td>
<td class="num">(51,224)<span></span>
</td>
<td class="num">(211,563)<span></span>
</td>
<td class="num">(182,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">7,795<span></span>
</td>
<td class="nump">4,164<span></span>
</td>
<td class="nump">23,527<span></span>
</td>
<td class="nump">13,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest and other expense</a></td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="num">(2,188)<span></span>
</td>
<td class="num">(931)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">6,791<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
<td class="nump">21,339<span></span>
</td>
<td class="nump">12,098<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,689)<span></span>
</td>
<td class="num">$ (47,660)<span></span>
</td>
<td class="num">$ (190,224)<span></span>
</td>
<td class="num">$ (170,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (2.98)<span></span>
</td>
<td class="num">$ (3.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (2.98)<span></span>
</td>
<td class="num">$ (3.97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute basic net loss per share (in shares)</a></td>
<td class="nump">66,420,063<span></span>
</td>
<td class="nump">43,654,577<span></span>
</td>
<td class="nump">63,800,798<span></span>
</td>
<td class="nump">43,057,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">66,420,063<span></span>
</td>
<td class="nump">43,654,577<span></span>
</td>
<td class="nump">63,800,798<span></span>
</td>
<td class="nump">43,057,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,689)<span></span>
</td>
<td class="num">$ (47,660)<span></span>
</td>
<td class="num">$ (190,224)<span></span>
</td>
<td class="num">$ (170,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized gain on investments</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive gain</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (75,214)<span></span>
</td>
<td class="num">$ (47,551)<span></span>
</td>
<td class="num">$ (189,630)<span></span>
</td>
<td class="num">$ (170,548)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813498671056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party expense</a></td>
<td class="nump">$ 69,158<span></span>
</td>
<td class="nump">$ 30,385<span></span>
</td>
<td class="nump">$ 166,294<span></span>
</td>
<td class="nump">$ 121,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development - related party expense</a></td>
<td class="nump">$ 7,725<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
<td class="nump">$ 10,937<span></span>
</td>
<td class="nump">$ 6,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813492888352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>2024 Public Offering</div></th>
<th class="th"><div>2022 At The Market Offering</div></th>
<th class="th"><div>Series A Preferred Stock</div></th>
<th class="th"><div>Series B Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>2024 Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>2022 At The Market Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>2024 Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>2022 At The Market Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,381<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 395,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,470<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 741,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (390)<span></span>
</td>
<td class="num">$ (488,174)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,305,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares', window );">Issuance of common stock upon exercises of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue', window );">Issuance of common stock upon exercises of warrants</a></td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for exercises of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for exercises of stock options</a></td>
<td class="nump">6,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">15,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,151)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">350,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,235<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(556,325)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,055,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,381<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">395,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,470<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="num">(488,174)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,305,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(170,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">283,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,235<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(659,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">350,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,235<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(556,325)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,055,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock under license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock under license agreement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares', window );">Issuance of common stock upon exercises of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue', window );">Issuance of common stock upon exercises of warrants</a></td>
<td class="nump">935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for exercises of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for exercises of stock options</a></td>
<td class="nump">2,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">12,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">315,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,235<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">792,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(611,388)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,562,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock under license agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock under license agreement</a></td>
<td class="nump">693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for exercises of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for exercises of stock options</a></td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">13,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,660)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">283,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,235<span></span>
</td>
<td class="nump">$ 56,677<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(659,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 442,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,235<span></span>
</td>
<td class="nump">$ 128,281<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(725,908)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">53,986,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,986,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,142,858<span></span>
</td>
<td class="nump">1,561,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,696<span></span>
</td>
<td class="nump">$ 35,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,625<span></span>
</td>
<td class="nump">$ 35,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for exercises of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for exercises of stock options</a></td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">12,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="num">(705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(48,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,542)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,435<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">582,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,429<span></span>
</td>
<td class="nump">$ 128,281<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,156,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(774,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,798,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 442,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,235<span></span>
</td>
<td class="nump">$ 128,281<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="num">(725,908)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">53,986,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,986,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">$ 594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(190,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 707,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,188<span></span>
</td>
<td class="nump">$ 127,697<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932<span></span>
</td>
<td class="num">(916,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">79,181,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,181,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,435<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">$ 582,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,429<span></span>
</td>
<td class="nump">$ 128,281<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,156,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(774,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,798,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for exercises of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for exercises of stock options</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">11,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="num">(176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(64,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,993)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,435<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">529,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,429<span></span>
</td>
<td class="nump">$ 128,281<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="num">(839,443)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,879,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,571)<span></span>
</td>
<td class="num">(18,362)<span></span>
</td>
<td class="nump">2,729,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon the conversion of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,241)<span></span>
</td>
<td class="num">$ (24,085)<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">12,466,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">243,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,501<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for exercises of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for exercises of stock options</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">8,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (loss) gain on investments</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(76,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,689)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 707,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,188<span></span>
</td>
<td class="nump">$ 127,697<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,433,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
<td class="num">$ (916,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">79,181,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,181,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813493019648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember', window );">2024 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance cost</a></td>
<td class="nump">$ 15,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2024 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2022 At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_September2022AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_September2022AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813507001552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (190,224)<span></span>
</td>
<td class="num">$ (170,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">33,175<span></span>
</td>
<td class="nump">41,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock under license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest expense and amortization of debt issuance costs</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and amortization of premiums and discounts on available-for-sale securities</a></td>
<td class="num">(12,448)<span></span>
</td>
<td class="num">(8,423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Net loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtExtinguishmentExpense', window );">Fees paid directly to creditor related to extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of equipment</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(5,344)<span></span>
</td>
<td class="num">(4,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Unbilled revenue - related party</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue - related party</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,850<span></span>
</td>
<td class="num">(10,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">10,760<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(158,987)<span></span>
</td>
<td class="num">(146,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(513,289)<span></span>
</td>
<td class="num">(135,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">347,950<span></span>
</td>
<td class="nump">211,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(397)<span></span>
</td>
<td class="num">(850)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(165,736)<span></span>
</td>
<td class="nump">75,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, pursuant to January 2024 Public Offering, September 2024 Public Offering and September 2022 ATM Agreement</a></td>
<td class="nump">420,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of Series B preferred stock, pursuant to September 2024 Public Offering</a></td>
<td class="nump">25,001<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment of debt extinguishment costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the issuance of common stock upon the exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the issuance of common stock upon the exercise of stock options</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="nump">9,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the issuance of common stock for cash under employee stock purchase plan</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">422,213<span></span>
</td>
<td class="nump">26,729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">97,490<span></span>
</td>
<td class="num">(43,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">102,827<span></span>
</td>
<td class="nump">155,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">200,317<span></span>
</td>
<td class="nump">111,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">41,132<span></span>
</td>
<td class="nump">7,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Unpaid common stock issuance costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Extinguishment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issuance of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of issuance costs</a></td>
<td class="num">(24,132)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of issuance costs</a></td>
<td class="num">$ (1,500)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtExtinguishmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Extinguishment Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtExtinguishmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503706832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Viridian Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Viridian&#8221;), is a biopharmaceutical company advancing new treatments for patients suffering from serious diseases that are underserved by today&#8217;s therapies. The Company&#8217;s most advanced program, veligrotug (formerly known as VRDN-001), is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (&#8220;IGF-1R&#8221;), a clinically and commercially validated target for the treatment of thyroid eye disease (&#8220;TED&#8221;). The Company&#8217;s second product candidate, VRDN-003, is an extended half-life monoclonal antibody with the same binding domains as veligrotug designed for administration as convenient, low-volume, subcutaneous pen injections. TED is a serious and debilitating rare autoimmune disease that causes inflammation within the orbit of the eye that can cause bulging of the eyes, redness and swelling, double vision, pain, and potential blindness.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to developing therapies for TED, the Company is also developing a portfolio of engineered anti-neonatal Fc receptor (&#8220;FcRn&#8221;) inhibitors, including VRDN-006 and VRDN-008. FcRn inhibitors have the potential to treat a broad array of autoimmune diseases, representing a significant commercial market opportunity. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on a basis that assumes the Company is a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to its ability to continue as a going concern. The Company has funded its operations to date principally through proceeds received from the sale of the Company&#8217;s common stock, its Series A Preferred Stock, Series B Preferred Stock, and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. Since its inception and through September&#160;30, 2024, the Company has generated an accumulated deficit of $916.1 million. The Company expects to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no products approved for commercial sale, has not generated any revenue from product sales, and cannot guarantee when or if it will generate any revenue from product sales. Substantially all of the Company&#8217;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to incur significant expenses and operating losses for at least the next several years as it continues the development of, and seeks regulatory approval for, its product candidates. It is expected that operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of development programs and efforts to achieve regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company had approximately $753.2 million in cash, cash equivalents, and short-term investments. In addition, the Company also has access to additional undrawn funds under the Hercules Loan and Security Agreement Amended Term Loan, as further described in Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of the issuance date of these condensed consolidated financial statements, the Company expects that its current resources will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require additional capital in order to continue to finance its operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of the Company&#8217;s clinical development efforts, timing of market research and other professional and consulting </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities to prepare for commercial activities, equity financings, entering into license and collaboration agreements, and issuing debt or other financing vehicles. The Company&#8217;s ability to secure additional capital is dependent upon a number of factors, some of which are outside of the Company&#8217;s control, including success in developing its product candidates, operational performance, and market conditions, including those resulting from the current inflationary and broader macroeconomic environment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503237392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Updates (&#8220;ASU&#8221;), or the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company&#8217;s subsidiaries have no employees or operations. All intercompany balances and transactions have been eliminated in consolidation. Management has determined that the Company operates in one segment, which is the business of developing and commercializing novel therapeutics. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#8217;s consolidated financial statements and the accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 27, 2024. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these unaudited condensed consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties &#8211; Global Economic Considerations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan, the conflict in Israel and surrounding area and other political tensions. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, high interest rates, foreign exchange volatility and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s evaluation entails, among other things, analyzing the results of the Company&#8217;s clinical development efforts, license and collaboration agreements as well as the entity&#8217;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#8217;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents, and short-term investments balance.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs, including manufacturing activities, and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#8217;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s agreements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges including severance costs, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to have clinical trial materials manufactured on the Company&#8217;s behalf, purchases of laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or when other significant risk factors are abated. Such up-front and milestone payments are reflected as cash used in operating activities within the condensed consolidated statement of cash flows. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards to employees and non-employees in the form of stock options and restricted stock units (&#8220;RSUs&#8221;). The Company measures and recognizes share-based compensation expense for its stock-based awards granted to employees and non-employees based on the estimated grant date fair value in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Compensation - Stock Compensation&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and determines the fair value of RSUs based on the fair value of its common stock. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are reported as a component of stockholders&#8217; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-485">three</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Right-of-Use Assets and Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in ASU No. 2016-02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Leases (Topic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">842), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#8220;ASC 842&#8221;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#8217;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#8217;s operating lease assets in the Company&#8217;s condensed consolidated balance sheets. The Company&#8217;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#8217;s condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies - Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information related to the Company&#8217;s operating leases.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Debt Issuance Costs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#8217;s Term Loan (as defined in Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the nine months ended September 30, 2024 and 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the condensed consolidated statements of changes in stockholders&#8217; equity. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations and comprehensive loss as general and administrative expenses. No such expenses have been recognized during the nine months ended September 30, 2024 and 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements &#8211; To Be Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Report Segment Disclosures (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires enhanced disclosures about significant segment expenses, enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. ASU 2023-07 is effective for the Company&#8217;s annual reporting period beginning after December 15, 2023, and subsequent interim periods, with early adoption permitted. ASU 2023-07 requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 requires a company's annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#8217;s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its consolidated financial statements.</span></div>In November 2024, the FASB issued ASU-2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). ASU 2024-03 requires additional disclosures of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. ASU 2024-03 is effective for the Company's annual reporting periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503106736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">INVESTMENTS AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text">INVESTMENTS AND FAIR VALUE MEASUREMENTS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following as of September 30, 2024 and December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The money market funds above are included in cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company considers the unrealized losses in its investment portfolio to be temporary in nature and not due to credit losses. The Company has the intent and ability to hold such investments until their recovery at fair value. The Company did not have any realized gains or losses in its available for sale securities during the three and nine months ended September 30, 2024 and 2023. The Company did not have any sales of short-term investments during the three and nine months ended September 30, 2024 and 2023. The contractual maturity dates of all of the Company&#8217;s investments are less than 24 months.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503602240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHER<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED LIABILITIES AND OTHER</a></td>
<td class="text">ACCRUED LIABILITIES AND OTHER<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued outsourced clinical trials and preclinical studies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee compensation and related taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-605"><span style="-sec-ix-hidden:f-606">Operating lease liability, short-term</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal fees and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other professional service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of liability-classified stock purchase warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813506474016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan and Security Agreement with Hercules Capital, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into a loan and security agreement (the &#8220;Hercules Loan and Security Agreement&#8221;) among the Company, certain of its subsidiaries from time to time party thereto (together with the Company, collectively, the &#8220;Borrower&#8221;), Hercules Capital, Inc. (&#8220;Hercules&#8221;) and certain other lenders named therein (the &#8220;Lenders&#8221;). Under the Hercules Loan and Security Agreement, the Lenders provided the Company with access to a term loan with an aggregate principal amount of up to $75.0&#160;million, in four tranches (collectively the &#8220;Term Loan&#8221;), including an initial tranche of $25.0&#160;million, available to the Company through June 15, 2023. Upon signing the Hercules Loan and Security Agreement, the Company drew an initial principal amount of $5.0&#160;million (the &#8220;initial draw&#8221;). The Company incurred debt issuance costs of $0.2&#160;million in connection with the Term Loan and paid to the Lenders a facility fee of $0.1&#160;million, as well as $0.1&#160;million of other expenses incurred by the Lenders and reimbursed by the Company (&#8220;Lender Expenses&#8221;) in connection with the initial draw. The debt issuance costs and the Lender Expenses were being amortized as additional interest expense over the term of the loan. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was originally obligated to make interest-only payments through April 1, 2024, which was extended to October 1, 2024 upon achievement of a development milestone in August 2022. In addition, the Borrower was required to pay an end-of-term fee equal to 6% of the principal amount of funded Term Loan advances at maturity, which were being accreted as additional interest expense over the term of the loan. The obligations of the Borrower under the Hercules Loan and Security Agreement were secured by substantially all of the assets of the Borrower, excluding the Borrower&#8217;s intellectual property. The Term Loan had a maturity date of October 1, 2026. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company executed an amendment to the Hercules Loan and Security Agreement (the &#8220;Hercules Amendment&#8221;) to modify certain terms of the agreement and increase the aggregate principal amount to up to $150.0&#160;million. Upon execution of the Hercules Amendment in August 2023, the Company drew a principal amount of $15.0&#160;million. The Hercules Amendment was determined to substantially alter the Hercules Loan and Security Agreement and therefore was accounted for as a debt extinguishment. The Company </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized a loss on debt extinguishment of $0.2&#160;million in August 2023 related to unamortized debt discount and debt issuance costs.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hercules Amendment, the Lenders provided the Company access to an increased term loan with an aggregate principal amount of up to $150.0&#160;million, in four tranches (collectively the &#8220;Amended Term Loan&#8221;), consisting of (1) an initial tranche of $50.0&#160;million, $5.0&#160;million of which was drawn at closing of the Hercules Loan and Security Agreement in April 2022, $15.0&#160;million of which was drawn at closing of the Hercules Amendment in August 2023, $5.0&#160;million of which was available through December 15, 2023, and $25.0&#160;million of which is available from July 1, 2024 through December 15, 2024; (2) a second tranche of $20.0&#160;million, subject to achievement of certain regulatory milestones, available through February 15, 2025; (3) a third tranche of $20.0&#160;million, subject to achievement of certain regulatory milestones, available through March 31, 2025; and (4) a fourth tranche of $60.0&#160;million subject to approval by the Lenders&#8217; investment committee(s), available through June 15, 2025. The milestones for the second and third tranches have not yet been achieved. The obligations of the Borrower under the Hercules Amendment agreement are secured by substantially all of the assets of the Borrower, excluding the Borrower&#8217;s intellectual property. The Amended Term Loan has a maturity date of October 1, 2026.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Term Loan bears interest at a floating per annum rate equal to the greater of (i) 7.45% and (ii) 4.2% above the Prime Rate (as defined therein), provided that the Term Loan interest rate shall not exceed a per annum rate of 8.95%. Interest is payable monthly in arrears on the first day of each month. The interest rate as of September&#160;30, 2024 was 8.95%. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the terms of the Hercules Amendment, the Company was originally obligated to make interest-only payments through April 1, 2025. Upon achievement of certain development milestones related to topline results for the Company&#8217;s phase 3 THRIVE trial in September 2024, the interest-only period was extended to October 1, 2025. If additional development milestones are met, the interest-only period will be further extended to April 1, 2026. The Borrower is required to repay the Amended Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, the Borrower is required to pay an end-of-term fee equal to 6% of the principal amount of funded Amended Term Loan advances at maturity, which are being accreted as additional interest expense over the term of the loan.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total cost of all items (cash interest, the amortization/accretion of the debt issuance costs and the end-of-term fee) is being recognized as interest expense using an effective interest rate of approximately 9.3%. The Company recorded interest expense of $0.5 million and $1.7 million during the three and nine months ended September 30, 2024, and $0.4&#160;million and $0.8&#160;million during the three and nine months ended September 30, 2023, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of the Term Loan, on the Company&#8217;s condensed consolidated balance sheet at September&#160;30, 2024:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"><tr><td style="width:1.0%"></td><td style="width:74.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross term loan proceeds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued end-of-term fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Term Loan approximates its fair value. Future principal payments, which exclude the end of term fee, in connection with the Hercules Loan and Security Agreement as of September&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"><tr><td style="width:1.0%"></td><td style="width:74.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504186320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Zenas BioPharma</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company became party to a license agreement with Zenas BioPharma (Cayman) Limited (&#8220;Zenas BioPharma&#8221;) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma. Since February 2021, the Company has entered into several letter agreements with Zenas BioPharma pursuant to which the Company agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing. In May 2022, the Company entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma to manufacture and supply, or to have manufactured and supplied, clinical drug product for developmental purposes. The license agreement and subsequent letter agreements and supply agreement (collectively, the &#8220;Zenas Agreements&#8221;) were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. Under the terms of the Zenas Agreements, the Company granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the Zenas Agreements, the transaction price included upfront non-cash consideration and variable consideration in the form of payment for the Company&#8217;s goods and services and milestone payments due upon the achievement of specified events. Under the Zenas Agreements, the Company can receive non-refundable milestone payments upon achieving specific milestone events during the contract term. Additionally, the Company may receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to the Company for the royalty term in the Zenas Agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zenas Agreements would qualify as a collaborative arrangement under the scope of Accounting Standards Codification, Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 808&#8221;). While this arrangement is in the scope of ASC 808, the Company applied ASC 606 to account for certain aspects of this arrangement. The Company applied ASC 606 for certain activities within the arrangement associated with the Company&#8217;s transfer of a good or service (i.e., a unit of account) that is part of the Company&#8217;s ongoing major or central operations. The Company allocated the transaction price based on the relative estimated standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. Research and development activities are priced generally at cost. The Company&#8217;s license of goods and services to Zenas BioPharma during the contract term was determined to be a single performance obligation satisfied over time. The Company will recognize the transaction price from the license agreement over the Company&#8217;s estimated period to complete its activities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the arrangement, the Company evaluated whether the milestones were considered probable of being reached and estimated the amount to be included in the transaction price using the most likely amount </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method. As it was not probable that a significant revenue reversal would not occur, none of the associated milestone payments were included in the transaction price at contract inception. For the sales-based royalties included in the arrangement, the license was deemed to be the predominant item to which the royalties relate. The Company will recognize royalty revenues at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.2 million, respectively, of collaboration revenue related to the Zenas Agreements. During the three and nine months ended September 30, 2023, the Company recognized $0.1 million and $0.2 million, respectively, of collaboration revenue related to the Zenas Agreements. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company entered into a letter agreement with Zenas BioPharma (the &#8220;Zenas Letter Agreement&#8221;) pursuant to which Zenas BioPharma agreed to support the Company&#8217;s THRIVE-2 and STRIVE trials by initiating and managing the studies in China. Under the Zenas Letter Agreement, the Company agreed to reimburse costs incurred by Zenas BioPharma, including a full-time equivalent rate for services rendered. In connection with the execution of the Zenas Letter Agreement, the Company made an initial payment of $1.5&#160;million, which was recorded as research and development expense during the nine months ended September 30, 2024 as services were performed. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zenas Agreements are considered related party transactions because Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) beneficially owns more than 5% of the Company&#8217;s common stock and is also a 5% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharma&#8217;s board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody and Discovery Option Agreement with Paragon Therapeutics, Inc.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company and Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) entered into an antibody and discovery option agreement (the &#8220;Paragon Research Agreement&#8221;) under which the Company and Paragon will cooperate to develop one or more proteins or antibodies. Under the terms of the Paragon Research Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and the Company will pay Paragon agreed upon development fees in exchange for Paragon&#8217;s commitment of the necessary personnel and resources to perform these activities. The Paragon Research Agreement stipulates a final deliverable to the Company comprising of a report summarizing the experiments and processes performed under the research plan (the &#8220;Final Deliverable&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Paragon agreed to grant the Company an option for an exclusive license to all of Paragon&#8217;s right, title and interest in and to certain antibody technology and the Final Deliverable, and a non-exclusive license to certain background intellectual property owned by Paragon solely to research, develop, make, use, sell, offer for sale and import of the licensed intellectual property and resulting products worldwide (each, an &#8220;Option&#8221; and together, the &#8220;Options&#8221;). Paragon also granted to the Company a limited, exclusive, royalty-free license, without the right to sublicense, to certain antibody technology and the Final Deliverable, and a non-exclusive, royalty-free license without the right to sublicense, under certain background intellectual property owned by Paragon, solely to evaluate the antibody technology and Option and for the purpose of allowing the Company to determine whether to exercise the Option with respect to certain programs. The Company may, at its sole discretion, exercise the Option with respect to specified programs (&#8220;Programs&#8221;) at any time until the date that is 90 days after the Company&#8217;s receipt of the Final Deliverable the applicable program, or such longer period as agreed upon by the parties (&#8220;Option Period&#8221;) by delivering written notice of such exercise to Paragon. If the Company fails to exercise an Option prior to expiration of the applicable Option Period, such Option for such Programs will terminate. In consideration for Paragon&#8217;s grant of the Options to the Company, the Company paid to Paragon a non-refundable, non-creditable one-time fee of $2.5&#160;million, which was recorded as research and development expense during the three months ended March 31, 2022. In December 2022, the Company and Paragon entered into a first amendment to the Paragon Research Agreement, under which the Company obtained an additional limited license for the purpose of conducting certain activities. In consideration for the rights and licenses obtained under the first amendment, Viridian paid Paragon a non-refundable fee of </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3&#160;million (the &#8220;First Amendment Payment&#8221;), which was recorded as research and development expense during the three months ended December 31, 2022. The non-refundable upfront fee and the First Amendment Payment are separate from any development costs or cost advance paid or owing with respect to the specified program.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company entered into a License Agreement with Paragon (the &#8220;Paragon License Agreement&#8221;) as a result of exercising its Option under the Paragon Research Agreement to obtain exclusive licenses to develop, manufacture and commercialize certain antibodies, proteins and associated products. In connection with the execution of the Paragon License Agreement, the Company made an initial payment of $5.3&#160;million, which was recorded as research and development expense during the three months ended December 31, 2023. As further described below, the Paragon License Agreement was amended and restated by the Amended and Restated License Agreement with Paragon in September 2024. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company entered into a letter agreement with Paragon pursuant to which Paragon agreed to continue to perform development activities under the existing Paragon Research Agreement and Paragon License Agreement, which the Company renewed in July 2024. In consideration for the development activities to be conducted by Paragon, the Company will reimburse Paragon for actual development costs incurred and agreed upon development fees in exchange for Paragon&#8217;s commitment of the necessary personnel and resources to perform these activities. In September 2024, the Company entered into a second amendment to the Paragon Research Agreement to include additional development activities to be performed by Paragon. Under the amended Paragon Research Agreement, the Company will be obligated to make a one-time non-refundable payment of $3.5&#160;million to Paragon following the achievement of certain research and development objectives.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into the Amended and Restated License Agreement with Paragon (the &#8220;Amended Paragon License Agreement&#8221;) which amended and restated the Paragon License Agreement. In connection with the execution of the Amended Paragon License Agreement, the Company paid Paragon a non-refundable fee of $4.0&#160;million in September 2024, which was recorded as research and development expense during the three months ended September 30, 2024. In consideration for rights granted by Paragon, the Company is obligated to make certain future milestone payments of up to $16.0&#160;million on a program-by-program bases upon the achievement of specified clinical or regulatory milestones, with total milestone payments under all programs not to exceed $40.0&#160;million. Additionally, if the Company develops a product utilizing certain intellectual property rights granted to it under the Amended Paragon License Agreement, the Company is obligated to pay Paragon potential additional future development milestone payments of up to $3.1&#160;million and commercial milestone payments of up to $17.0&#160;million with respect to such product. If the Company successfully commercializes any product candidate subject to the Amended Paragon License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of such product&#8217;s net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2024, the Company recorded $7.7 million and $10.9 million, respectively, in research and development costs related to the Paragon Research Agreement and Amended Paragon License Agreement (collectively, the &#8220;Paragon Agreements&#8221;). During the three and nine months ended September 30, 2023, the Company recorded $1.1 million and $6.5 million, respectively, in research and development costs related to the Paragon Agreements. </span></div>The Paragon Agreements are considered related party transactions because Fairmount beneficially owns more than 5% of the Company&#8217;s capital stock and has two seats on the Company&#8217;s board of directors, and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503543232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with ImmunoGen, Inc. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company became party to a license agreement (the &#8220;ImmunoGen License Agreement&#8221;) with Immunogen, Inc. (&#8220;ImmunoGen&#8221;), under which the Company obtained an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to develop, manufacture, and commercialize certain products for non-oncology and non-radiopharmaceutical indications. In consideration for rights granted by ImmunoGen, the Company is obligated to make certain future development milestone payments of up to $48.0&#160;million upon the achievement of specified clinical and regulatory milestones. In December 2021, the Company paid a $2.5&#160;million milestone payment to ImmunoGen upon the submission of an investigational new drug (&#8220;IND&#8221;) application for veligrotug with the FDA. In May 2022, the Company paid a $3.0&#160;million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug. In December 2022, the Company recorded $10.0&#160;million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, amount which was paid in January 2023. Additionally, if the Company successfully commercializes any product candidate subject to the ImmunoGen License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $95.0&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of a specified product in each country until the later of (i) the expiration of the last patent claim subject to the ImmunoGen License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained for each product in such country, or (iii) the 12th anniversary of the date of the first commercial sale of such product in such country. On February 12, 2024, AbbVie Inc. acquired ImmunoGen.&#160;The terms of the ImmunoGen License Agreement did not change as a result of this acquisition. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and License Agreement with Enable Injections</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company entered into a Development and License Agreement (the &#8220;Enable License Agreement&#8221;) with Enable Injections, Inc. (&#8220;Enable&#8221;), under which Enable granted the Company an exclusive, royalty-bearing, sublicensable, non-transferrable license to (i) develop, commercialize, seek marketing approval for and otherwise use and exploit certain products, and (ii) make and have made such product solely for such permitted uses. Pursuant to the terms of the Enable License Agreement, the Company granted Enable a non-exclusive, royalty-free, non-sublicensable, non-transferable license. In consideration for the rights granted by Enable, the Company paid Enable an initial, non-creditable, non-refundable license fee of $15.0&#160;million in January 2023. This amount is included in research and development expense during the nine months ended September 30, 2023 in the accompanying condensed consolidated statement of operations and comprehensive loss. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make certain future milestone payments of up to $45.0&#160;million upon the achievement of specified development, clinical and regulatory milestones. Additionally, if the Company is successful in commercializing any product candidate subject to the Enable License Agreement, the Company is obligated to make certain commercial milestone payments of up to $150.0&#160;million and royalty payments equal to a percentage in the mid-single digits. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights Agreement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the merger agreement with miRagen Therapeutics, Inc. (&#8220;miRagen&#8221;), on November 4, 2020, the Company entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;), pursuant to which each holder of the Company&#8217;s common stock as of November 6, 2020, other than former stockholders of the private entity Viridian Therapeutics, Inc. (which merged with miRagen), received one contingent value right (a &#8220;CVR&#8221;) for each share of Company common stock held by such holder on that date. Under the CVR Agreement, holders </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of CVRs would have been entitled to receive a portion of the net proceeds for any dispositions of certain legacy miRagen assets consummated through December 31, 2021. As of December 31, 2021, the disposition period had expired. There were no dispositions of any such legacy assets prior to that time and, accordingly, there will be no payments made under the CVR Agreement. The CVR Agreement expires on November 4, 2025. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company and a third-party collaborator entered into an Exclusive License and Collaboration Agreement to collaborate and conduct certain IND-enabling activities with respect to the licensed compound and licensed product. Under the terms of the agreement, the Company was granted an exclusive, royalty-bearing, worldwide license to develop, manufacture, and commercialize certain licensed compounds and licensed products in the field (the &#8220;License&#8221;). In consideration for the rights granted by the License, the Company initially issued 204,843 shares of its common stock to certain stockholders of the third-party. The shares were valued at $5.0&#160;million and recorded as research and development expense during the three months ended June 30, 2023. On July 24, 2023, the Company issued 39,059 additional shares of its common stock to certain stockholders of the third-party and recorded the related $0.7&#160;million expense as research and development expenses during three months ended September 30, 2023. Additionally, upon the date when the Company decides to pursue certain studies for the licensed compound under the agreement, the Company shall issue the third-party collaborator the equivalent of $10.0&#160;million in shares of its common stock. The Company is also obligated to make certain future milestones of up to $45.0 million upon the achievement of certain development milestones. Remaining development milestone payments shall be payable in cash. If the Company is successful in commercializing products related to the licensed compound, the Company is also obligated to pay up to $60.0&#160;million upon the achievement of certain sales milestones as well as royalty payments equal to a percentage in the mid-single to double digits.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Colorado-based Office and Lab Space</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Colorado-based office and lab space (the &#8220;Colorado Lease&#8221;). The Colorado Lease includes rent escalation clauses through the lease term and a Company option to extend the lease term for up to three terms of three years each. Minimum base lease payments under the Colorado Lease, including the impact of tenant improvement allowances, are recognized on a straight-line basis over the full term of the lease. The lease term was amended in March 2021 to extend the lease maturity date to December 31, 2024. Upon adoption of ASC 842 and upon subsequent modification of the lease in 2020 and in March 2021, the Company recognized a right-of-use asset and corresponding lease liability for the Colorado Lease of approximately $1.6&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#8217;s estimated incremental borrowing rate, over the 12 months expected remaining term.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into a new, multi-year lease agreement for its Colorado-based office and lab space (the &#8220;New Colorado Lease&#8221;). Under ASC 842, the New Colorado Lease was treated as a lease modification representing an extension of the lease term for a reduced portion of the space currently in use under the existing Colorado Lease. As of the effective date, the Company recorded a $0.3&#160;million increase in the right-of-use asset and corresponding lease liability for the extension of the lease term. The remaining space under the Colorado Lease will terminate at the original maturity date of December 31, 2024. The New Colorado Lease provides for annual base rent of approximately $0.1&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes, and operating expenses. The New Colorado Lease is set to expire in December 2026. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Massachusetts-based Office Space</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a multi-year, non-cancelable lease agreement for its Massachusetts-based office space (as subsequently amended in July 2021, April 2022, July 2022 and April 2024, the &#8220;Massachusetts Lease&#8221;). The Massachusetts Lease includes rent escalation clauses throughout the lease term. Minimum base lease payments under the Massachusetts Lease are recognized on a straight-line basis over the full term of the Massachusetts Lease. Upon initial assumption of the Massachusetts Lease in October 2020, the Company recognized a right-of-use asset and corresponding lease liability of $0.1&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#8217;s estimated incremental borrowing rate, over the expected remaining term. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a Fourth Amendment of the Massachusetts Lease (the &#8220;Fourth Amendment&#8221;). The Fourth Amendment makes certain modifications to the Massachusetts Lease, including (i) securing 10,427 square feet of office space in a new building suite (the &#8220;New Premises&#8221;), (ii) the termination of the 10,956 square feet of leased space under the existing Massachusetts Lease (the &#8220;Original Premises&#8221;), and (iii) the extension of the expiration date of the leased space to five years from the delivery of the New Premises. The Massachusetts Lease provides for annual base rent of approximately $0.5&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses. Under the Fourth Amendment, the Massachusetts Lease will expire in July 2029. The Company has the option to extend the lease term for an additional period of three years upon notice to the landlord.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a new right-of-use asset of $1.6&#160;million and corresponding lease liability of $1.9&#160;million for the New Premises and simultaneously derecognized the right-of-use asset of  $1.1 million and corresponding lease liability of  $1.2 million for the Original Premises on the lease commencement date in April 2024.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into a Fifth Amendment of the Massachusetts Lease (the &#8220;Fifth Amendment&#8221;) to lease an additional 2,788 square feet of office space in the same building. The Fifth Amendment provides for additional annual base rent of approximately $0.1&#160;million for the additional office space and includes annual base rent escalation clauses during the lease term. The Fifth Amendment was treated as a lease modification accounted for as a separate contract and the Company recorded a new right-of-use asset and corresponding lease liability of approximately $0.5&#160;million related to the Fifth Amendment on the lease commencement date. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under noncancellable leases as of September&#160;30, 2024 are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.666%"><tr><td style="width:1.0%"></td><td style="width:69.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company&#8217;s operating lease obligations were reflected as short-term operating lease liabilities of $0.6&#160;million within <span style="-sec-ix-hidden:f-739">accrued liabilities</span> and $2.2 million of long-term lease obligations as <span style="-sec-ix-hidden:f-741">other liabilities</span> in the Company&#8217;s condensed consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $0.2 million and $0.8 million for the three and nine months ended September 30, </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024, respectively, which was included in operating expense in the condensed consolidated statements of operations and comprehensive loss. Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $0.2&#160;million and $0.6&#160;million for the three and nine months ended September 30, 2023. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to pay for certain costs, taxes, and operating expenses related to both the Colorado Lease and Massachusetts Lease, which were $0.1&#160;million and $0.3 million for the three and nine months ended September 30, 2024 and 2023, respectively. The operating expenses are incurred separately and were not included in the present value of lease payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503535520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">CAPITAL STOCK</a></td>
<td class="text">CAPITAL STOCK<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company is authorized to issue 205,000,000 shares of its stock, of which 200,000,000 shares have been designated as common stock and 5,000,000 shares have been designated as preferred stock, both with a par value of $0.01 per&#160;share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of common stock is entitled to one vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Sales Agreements - Jefferies LLC</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $175.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. No shares were sold under the September 2022 ATM Agreement during the three months ended September 30, 2024 and 2023. During the nine months ended September 30, 2024, the Company sold 1,561,570 shares under the September 2022 ATM Agreement with Jefferies at a weighted average price of $23.22 per share, for aggregate net proceeds of approximately $35.2&#160;million, including commissions to Jefferies as a sales agent. No shares were sold under the September 2022 ATM Agreement during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company issued and sold in private placement transactions an aggregate of 8,869,797 shares of the Company&#8217;s common stock at a price per share of $12.38 and 92,312 shares of the Company&#8217;s Series B Preferred Stock at a price per share of $825.3746, pursuant to securities purchase agreements with certain institutional and accredited investors. The Company received aggregate gross proceeds of approximately $186.0&#160;million, before deducting offering expenses payable by the Company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company entered into an underwriting agreement with Jefferies and Leerink Partners LLC  relating to the offer and sale (the &#8220;January 2024 Public Offering&#8221;) of 7,142,858 shares of the Company&#8217;s common stock at a public offering price of $21.00 per share. The aggregate gross proceeds to the Company from the January 2024 Public Offering were approximately $150.0&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into an underwriting agreement with Jefferies, Goldman Sachs &amp; Co. LLC and Stifel, Nicolaus &amp; Company, Incorporated related to the offer and sale (the &#8220;September 2024 Public Offering&#8221;) of 12,466,600 shares of the Company&#8217;s common stock, which included 1,800,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $18.75 per share, and 20,000 shares of the Company&#8217;s Series B Preferred Stock at a price per share of $1,250.0625 per share. The aggregate gross proceeds to the Company from the September 2024 Public Offering, including the exercise of the option, were approximately $258.8&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company&#8217;s board of directors has the authority to designate and issue up to 5,000,000 shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#8217;s stockholders. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into 66.67 shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December 31, 2023, there were 134,864 and 172,435 shares of Series A Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, 37,571 shares of Series A Preferred Stock were converted into 2,504,855 shares of common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in September 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December 31, 2023, there were 145,160 and 143,522 shares of Series B Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, 18,362 of Series B Preferred Stock were converted into 1,224,193 shares of common stock.</span></div>WARRANTS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at September&#160;30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at September&#160;30, 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(No. Years)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the nine months ended September 30, 2024 is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503522368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">WARRANTS</a></td>
<td class="text">CAPITAL STOCK<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company is authorized to issue 205,000,000 shares of its stock, of which 200,000,000 shares have been designated as common stock and 5,000,000 shares have been designated as preferred stock, both with a par value of $0.01 per&#160;share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of common stock is entitled to one vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Sales Agreements - Jefferies LLC</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;September 2022 ATM Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $175.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. No shares were sold under the September 2022 ATM Agreement during the three months ended September 30, 2024 and 2023. During the nine months ended September 30, 2024, the Company sold 1,561,570 shares under the September 2022 ATM Agreement with Jefferies at a weighted average price of $23.22 per share, for aggregate net proceeds of approximately $35.2&#160;million, including commissions to Jefferies as a sales agent. No shares were sold under the September 2022 ATM Agreement during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company issued and sold in private placement transactions an aggregate of 8,869,797 shares of the Company&#8217;s common stock at a price per share of $12.38 and 92,312 shares of the Company&#8217;s Series B Preferred Stock at a price per share of $825.3746, pursuant to securities purchase agreements with certain institutional and accredited investors. The Company received aggregate gross proceeds of approximately $186.0&#160;million, before deducting offering expenses payable by the Company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offerings</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the Company entered into an underwriting agreement with Jefferies and Leerink Partners LLC  relating to the offer and sale (the &#8220;January 2024 Public Offering&#8221;) of 7,142,858 shares of the Company&#8217;s common stock at a public offering price of $21.00 per share. The aggregate gross proceeds to the Company from the January 2024 Public Offering were approximately $150.0&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, the Company entered into an underwriting agreement with Jefferies, Goldman Sachs &amp; Co. LLC and Stifel, Nicolaus &amp; Company, Incorporated related to the offer and sale (the &#8220;September 2024 Public Offering&#8221;) of 12,466,600 shares of the Company&#8217;s common stock, which included 1,800,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $18.75 per share, and 20,000 shares of the Company&#8217;s Series B Preferred Stock at a price per share of $1,250.0625 per share. The aggregate gross proceeds to the Company from the September 2024 Public Offering, including the exercise of the option, were approximately $258.8&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s second restated certificate of incorporation, the Company&#8217;s board of directors has the authority to designate and issue up to 5,000,000 shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#8217;s stockholders. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into 66.67 shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December 31, 2023, there were 134,864 and 172,435 shares of Series A Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, 37,571 shares of Series A Preferred Stock were converted into 2,504,855 shares of common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series B Preferred Stock is convertible into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in September 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December 31, 2023, there were 145,160 and 143,522 shares of Series B Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, 18,362 of Series B Preferred Stock were converted into 1,224,193 shares of common stock.</span></div>WARRANTS<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at September&#160;30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at September&#160;30, 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(No. Years)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the nine months ended September 30, 2024 is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503237888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under its 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;), its amended and restated 2016 Equity Incentive Plan ( the &#8220;2016 Plan&#8221;), and the Viridian 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221; and collectively with the 2008 Plan and the 2016 Plan, the &#8220;Equity Incentive Plans&#8221;). Additionally, beginning in July 2021, the Company granted stock options and RSUs outside of its Equity Incentive Plans to certain employees to induce them to accept employment with the Company (the &#8220;Inducement Awards&#8221;). The terms and conditions of the Inducement Awards are substantially similar to those awards granted under the Company&#8217;s Equity Incentive Plans.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company&#8217;s stockholders approved the amendment and restatement of the 2016 Plan to, among other things, transfer the then remaining number of shares available for issuance under the 2020 Plan into the 2016 Plan so that the Company operates from a single equity plan going forward. In June 2023, the Company&#8217;s stockholders approved a further amendment and restatement of the 2016 Plan to, among other things, increase the number of shares reserved for issuance thereunder by 2,000,000 shares. In June 2024, the Company&#8217;s stockholders approved a further amendment and restatement of the 2016 Plan to, among other things, increase the number of shares reserved for issuance thereunder by 2,000,000 shares. The 2016 Plan will terminate on April 19, 2034.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company had the following balances by plan: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Available for Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,663,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,639,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,639,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted under the Equity Incentive Plans and the Inducement Awards generally vest annually over a 4-year period and are settled in shares of the Company&#8217;s common stock. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity is as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.666%"><tr><td style="width:1.0%"></td><td style="width:65.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.85</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.33</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.85</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the Equity Incentive Plans and the Inducement Awards have an exercise price equal to the market value of the common stock at the date of grant and expire 10 years from the date of grant. Options generally vest 25% on the first anniversary of the vesting commencement date and 75% ratably in equal monthly installments over the remaining 36 months or in equal monthly or quarterly amounts over periods of up to 48 months.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,533,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,945,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,434&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324,526&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,890&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Assumptions</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under its equity compensation plans. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected terms of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on a blend of historical data from public companies that are similar to the Company in size and nature of operations, as well as the Company&#8217;s own volatility. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company accounts for forfeitures as they occur. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted, and actual and expected option-exercise behaviors. The fair value of the underlying common stock is based on the closing price of the common stock on The Nasdaq Capital Market at the date of grant.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2024 and 2023 was $10.83 and $23.19, respectively. The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;padding-right:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.57</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$31.07</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) allows qualified employees to purchase shares of common stock at a price equal to&#160;85%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. As of&#160;September&#160;30, 2024, the Company had&#160;1,187,109&#160;shares available for issuance, and 102,426 cumulative shares had been issued under the ESPP.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans, the Inducement Awards, and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the condensed consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.236%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total share-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2024, the Company recorded an additional $4.6&#160;million in share-based compensation related to the acceleration of vesting for former executive officers, an amount which includes $0.3&#160;million related to the modification of the terms of options outstanding at the time of termination for one executive which would have otherwise forfeited. The Company also recorded $2.0&#160;million in share-based compensation related to the accounting for a modification of the equity awards to extend the post-termination exercise period of certain vested stock options for a former executive.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recorded an additional $9.1&#160;million in share-based compensation related to the acceleration of vesting for former executive officers, an amount which includes $1.6&#160;million related to the modification of the terms of options outstanding at the time of termination for one executive which would have otherwise forfeited.  </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company had $87.1 million of total unrecognized share-based compensation costs related to stock options, which the Company expects to recognize over a weighted-average remaining period of 2.95 years. As of September&#160;30, 2024, the Company had $5.9 million of total unrecognized share-</span></div>based compensation costs related to unvested RSUs, which the Company expects to recognize over a weighted-average remaining period of 3.03 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813599232528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of common stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Diluted net loss per share is the same as basic net loss per share of common stock, as the effects of potentially dilutive securities are antidilutive.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities include the following:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.000%"><tr><td style="width:1.0%"></td><td style="width:68.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock (as converted to shares of common stock)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,991,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,496,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock (as converted to shares of common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,677,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,261,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,785,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,760,431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813502461216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,689)<span></span>
</td>
<td class="num">$ (64,993)<span></span>
</td>
<td class="num">$ (48,542)<span></span>
</td>
<td class="num">$ (47,660)<span></span>
</td>
<td class="num">$ (55,063)<span></span>
</td>
<td class="num">$ (68,151)<span></span>
</td>
<td class="num">$ (190,224)<span></span>
</td>
<td class="num">$ (170,874)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503595296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504523728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Updates (&#8220;ASU&#8221;), or the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company&#8217;s subsidiaries have no employees or operations. All intercompany balances and transactions have been eliminated in consolidation. Management has determined that the Company operates in one segment, which is the business of developing and commercializing novel therapeutics. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#8217;s consolidated financial statements and the accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 27, 2024. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these unaudited condensed consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_GoingConcernPolicyPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s evaluation entails, among other things, analyzing the results of the Company&#8217;s clinical development efforts, license and collaboration agreements as well as the entity&#8217;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#8217;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents, and short-term investments balance.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs, including manufacturing activities, and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#8217;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised goods or services in the Company&#8217;s agreements typically consist of a license, or option to license, rights to the Company&#8217;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration or strategic alliance agreements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges including severance costs, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to have clinical trial materials manufactured on the Company&#8217;s behalf, purchases of laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></div>The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or when other significant risk factors are abated. Such up-front and milestone payments are reflected as cash used in operating activities within the condensed consolidated statement of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock', window );">Clinical Trial and Preclinical Study Accruals</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial and Preclinical Study Accruals</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards to employees and non-employees in the form of stock options and restricted stock units (&#8220;RSUs&#8221;). The Company measures and recognizes share-based compensation expense for its stock-based awards granted to employees and non-employees based on the estimated grant date fair value in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Compensation - Stock Compensation&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and determines the fair value of RSUs based on the fair value of its common stock. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses are reported as a component of stockholders&#8217; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:f-485">three</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Lease Right-of-Use Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Right-of-Use Assets and Liabilities</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in ASU No. 2016-02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Leases (Topic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">842), </span>and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#8220;ASC 842&#8221;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#8217;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#8217;s operating lease assets in the Company&#8217;s condensed consolidated balance sheets. The Company&#8217;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#8217;s condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt and Debt Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt and Debt Issuance Costs</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#8217;s Term Loan (as defined in Note 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div>The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div>Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the condensed consolidated statements of changes in stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</span></div>The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations and comprehensive loss as general and administrative expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FASB ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - To Be Adopted</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements &#8211; To Be Adopted</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#8217;s consolidated financial statements or disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Report Segment Disclosures (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires enhanced disclosures about significant segment expenses, enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. ASU 2023-07 is effective for the Company&#8217;s annual reporting period beginning after December 15, 2023, and subsequent interim periods, with early adoption permitted. ASU 2023-07 requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 requires a company's annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#8217;s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its consolidated financial statements.</span></div>In November 2024, the FASB issued ASU-2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). ASU 2024-03 requires additional disclosures of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. ASU 2024-03 is effective for the Company's annual reporting periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813506415296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Debt Securities, Short-term Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following as of September 30, 2024 and December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"><tr><td style="width:1.0%"></td><td style="width:39.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.736%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs <br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,613&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. corporate paper and bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International corporate bond holdings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813506467072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHER (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Components of Accrued Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued outsourced clinical trials and preclinical studies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued employee compensation and related taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-605"><span style="-sec-ix-hidden:f-606">Operating lease liability, short-term</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal fees and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other professional service fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of liability-classified stock purchase warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503125136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of the Term Loan, on the Company&#8217;s condensed consolidated balance sheet at September&#160;30, 2024:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"><tr><td style="width:1.0%"></td><td style="width:74.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross term loan proceeds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued end-of-term fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Payments of Debt</a></td>
<td class="text">Future principal payments, which exclude the end of term fee, in connection with the Hercules Loan and Security Agreement as of September&#160;30, 2024 are as follows (in thousands):<div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"><tr><td style="width:1.0%"></td><td style="width:74.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503225280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments under Noncancelable Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under noncancellable leases as of September&#160;30, 2024 are as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.666%"><tr><td style="width:1.0%"></td><td style="width:69.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503235168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s outstanding warrants:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Underlying Shares (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price at September&#160;30, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Contractual Life at September&#160;30, 2024</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(No. Years)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability-classified warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued April 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$127.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity-classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued February 2020 (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued November 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s warrant activity during the nine months ended September 30, 2024 is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813502539584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Summary of Balances by Plan</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, the Company had the following balances by plan: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares Available for Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement Awards</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,663,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,639,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2008 Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,639,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule Of Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity is as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.666%"><tr><td style="width:1.0%"></td><td style="width:65.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.85</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.33</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.85</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,533,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$19.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,945,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.93</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.05</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,434&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324,526&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,890&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested as of September&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions for Stock Options</a></td>
<td class="text">The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:<div style="margin-bottom:12pt;padding-right:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.57</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$31.07</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocation of Share-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans, the Inducement Awards, and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the condensed consolidated statements of operations and comprehensive loss as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.236%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total share-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503122416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities include the following:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.000%"><tr><td style="width:1.0%"></td><td style="width:68.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred Stock (as converted to shares of common stock)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,991,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,496,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred Stock (as converted to shares of common stock)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,677,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,414,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,352,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,261,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,785,710&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,760,431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504800576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 916,132<span></span>
</td>
<td class="nump">$ 725,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 753,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813505511616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503919584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Debt Securities, Available-for-sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 735,681<span></span>
</td>
<td class="nump">$ 462,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">736,613<span></span>
</td>
<td class="nump">463,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">183,690<span></span>
</td>
<td class="nump">77,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">183,690<span></span>
</td>
<td class="nump">77,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">231,010<span></span>
</td>
<td class="nump">148,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">231,210<span></span>
</td>
<td class="nump">148,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">311,036<span></span>
</td>
<td class="nump">227,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">311,765<span></span>
</td>
<td class="nump">227,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember', window );">International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,945<span></span>
</td>
<td class="nump">9,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 9,948<span></span>
</td>
<td class="nump">$ 9,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504712736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains (losses) in available for sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Available-for-sale securities, term (less than)</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813505170576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 736,613<span></span>
</td>
<td class="nump">$ 463,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">183,690<span></span>
</td>
<td class="nump">77,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">231,210<span></span>
</td>
<td class="nump">148,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">311,765<span></span>
</td>
<td class="nump">227,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember', window );">International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">9,948<span></span>
</td>
<td class="nump">9,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">736,613<span></span>
</td>
<td class="nump">463,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">183,690<span></span>
</td>
<td class="nump">77,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">231,210<span></span>
</td>
<td class="nump">148,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">311,765<span></span>
</td>
<td class="nump">216,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">9,948<span></span>
</td>
<td class="nump">9,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">183,690<span></span>
</td>
<td class="nump">77,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">183,690<span></span>
</td>
<td class="nump">77,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">552,923<span></span>
</td>
<td class="nump">385,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">231,210<span></span>
</td>
<td class="nump">148,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">311,765<span></span>
</td>
<td class="nump">216,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">9,948<span></span>
</td>
<td class="nump">9,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | U.S. corporate paper and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | International corporate bond holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504427952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED LIABILITIES AND OTHER - Components of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies', window );">Accrued outsourced clinical trials and preclinical studies</a></td>
<td class="nump">$ 21,676<span></span>
</td>
<td class="nump">$ 10,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and related taxes</a></td>
<td class="nump">10,011<span></span>
</td>
<td class="nump">10,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short-term</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AccruedLegalFeesCurrent', window );">Accrued legal fees and expenses</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued other professional service fees</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity', window );">Value of liability-classified stock purchase warrants</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 34,738<span></span>
</td>
<td class="nump">$ 24,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position [Extensible List]</a></td>
<td class="text">Total accrued liabilities<span></span>
</td>
<td class="text">Total accrued liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AccruedLiabilityofWarrantsonTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liability of Warrants on Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AccruedLiabilityofWarrantsonTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_AccruedOutsourcingClinicalandPreclinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Outsourcing Clinical and Pre-clinical Studies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_AccruedOutsourcingClinicalandPreclinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813490565616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,004,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 2,188,000<span></span>
</td>
<td class="nump">931,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember', window );">Hercules Loan and Security Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentNumberOfTranches', window );">Debt instrument, number of tranches | tranche</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountFirstTranche', window );">Debt instrument, face amount, first tranche</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from term loan</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFacilityFee', window );">Lenders facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentOtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentPrincipalAmountTermFee', window );">Term fee</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountSecondTranche', window );">Debt instrument, face amount, second tranche</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountThirdTranche', window );">Debt instrument, face amount, third tranche</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountFourthTranche', window );">Debt instrument, face amount, fourth tranche</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentInterestRateMaximum', window );">Maximum interest rate</a></td>
<td class="nump">8.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember', window );">Hercules Loan and Security Agreement | Secured Debt | Through December 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountFirstTranche', window );">Debt instrument, face amount, first tranche</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember', window );">Hercules Loan and Security Agreement | Secured Debt | July 1, 2024 through December 15, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_DebtInstrumentFaceAmountFirstTranche', window );">Debt instrument, face amount, first tranche</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountFirstTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, First Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountFirstTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountFourthTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Fourth Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountFourthTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountSecondTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Second Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountSecondTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFaceAmountThirdTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Third Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFaceAmountThirdTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Facility Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Other Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtInstrumentPrincipalAmountTermFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal Amount, Term Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtInstrumentPrincipalAmountTermFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtCovenantPeriodAxis=vrdn_DebtCovenantPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtCovenantPeriodAxis=vrdn_DebtCovenantPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_DebtCovenantPeriodAxis=vrdn_DebtCovenantPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_DebtCovenantPeriodAxis=vrdn_DebtCovenantPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504692656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Long-Term Debt Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 20,523<span></span>
</td>
<td class="nump">$ 20,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember', window );">Hercules Loan and Security Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross term loan proceeds</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Accrued end-of-term fee</a></td>
<td class="nump">523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">20,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 20,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503006080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Future Principal Payments (Details) - Hercules Loan and Security Agreement - Secured Debt<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2024 (remainder)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">4,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">15,559<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrdn_HerculesTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813505539680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,158<span></span>
</td>
<td class="nump">30,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,294<span></span>
</td>
<td class="nump">121,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember', window );">Zenas BioPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementInitialPayment', window );">Collaboration arrangement, initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember', window );">Zenas BioPharma | Fairmount Funds Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember', window );">Paragon Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementInitialPayment', window );">Collaboration arrangement, initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementUpfrontFeePayment', window );">Collaborative arrangement, upfront fee payment</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementRightsAndLicensesFee', window );">Collaborative arrangement, rights and licenses fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementMilestonePayment', window );">Collaborative arrangement, milestone payment</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments', window );">Future developments milestone payments</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementMaximumMilestonePayments', window );">Collaboration arrangement, maximum milestone payments</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum', window );">Future developments milestone payments</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum', window );">Commercial milestone payments</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember', window );">Paragon Therapeutics | Fairmount Funds Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vrdn_CollaborationRevenueMember', window );">Collaboration Revenue | Zenas BioPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commercial Milestone Payment, Intellectual Property Rights Development, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Future Developments Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Initial Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementMaximumMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Maximum Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementMaximumMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Milestone Payment, Intellectual Property Rights Development, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementRightsAndLicensesFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Licenses Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementRightsAndLicensesFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementUpfrontFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Upfront Fee Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementUpfrontFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrdn_ZenasBioPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=vrdn_FairmountFundsManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=vrdn_FairmountFundsManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrdn_ParagonTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vrdn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vrdn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813490173568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_term</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short-term</a></td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position [Extensible List]</a></td>
<td class="text">Accrued liabilities and other (including related party of $3,725 and $374 as of September&#160;30, 2024 and December&#160;31, 2023, respectively)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued liabilities and other (including related party of $3,725 and $374 as of September&#160;30, 2024 and December&#160;31, 2023, respectively)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued liabilities and other (including related party of $3,725 and $374 as of September&#160;30, 2024 and December&#160;31, 2023, respectively)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued liabilities and other (including related party of $3,725 and $374 as of September&#160;30, 2024 and December&#160;31, 2023, respectively)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term lease obligation</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, noncurrent, statement of financial position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization expense relating to operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_OperatingLeasesOperatingExpense', window );">Operating lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=vrdn_ColoradoLeaseMember', window );">Colorado Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Number of renewal terms (up to) | renewal_term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_OperatingLeaseAnnualBaseRent', window );">Operating lease, annual base rent</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short-term</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=vrdn_MassachusettsLeaseMember', window );">Massachusetts Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_OperatingLeaseAnnualBaseRent', window );">Operating lease, annual base rent</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property | ft&#178;</a></td>
<td class="nump">2,788<span></span>
</td>
<td class="nump">10,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, short-term</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_OperatingLeaseRightOfUseAssetDerecognized', window );">Operating lease right-of-use asset derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_OperatingLeaseLiabilityCurrentDerecognized', window );">Operating lease liability derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vrdn_ImmunoGenIncMember', window );">ImmunoGen, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementMilestonePayment', window );">Collaborative arrangement, milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum', window );">Potential royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vrdn_EnableInjectionsMember', window );">Enable Injections</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum', window );">Potential royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementRightsAndLicensesFee', window );">Collaborative arrangement, rights and licenses fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vrdn_ThirdPartyCollaboratorMember', window );">Third Party Collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum', window );">Potential royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted', window );">Shares issued in exchange for rights granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted', window );">Value of shares issued in exchange for rights granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted', window );">Shares issued exchange for rights for granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted', window );">Collaborative arrangement, value of shares to be issued for rights granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Potential Milestone Payment, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Additional Shares Issued For Rights Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Royalty Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementRightsAndLicensesFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Licenses Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementRightsAndLicensesFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementSharesIssuedForRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Shares Issued For Rights Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementSharesIssuedForRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Value Of Shares Issued For Rights Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Value Of Shares To Be Issued For Rights Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_OperatingLeaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_OperatingLeaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_OperatingLeaseLiabilityCurrentDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Current Derecognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_OperatingLeaseLiabilityCurrentDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_OperatingLeaseRightOfUseAssetDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset Derecognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_OperatingLeaseRightOfUseAssetDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_OperatingLeasesOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_OperatingLeasesOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=vrdn_ColoradoLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=vrdn_ColoradoLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=vrdn_MassachusettsLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=vrdn_MassachusettsLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vrdn_ImmunoGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vrdn_ImmunoGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vrdn_EnableInjectionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vrdn_EnableInjectionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vrdn_ThirdPartyCollaboratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vrdn_ThirdPartyCollaboratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813498758224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (remainder)</a></td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 2,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813490641344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CapitalStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_CommonStockVotePerShare', window );">Common stock, vote per share | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,014,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">134,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">145,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in shares)</a></td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Viridian Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant or right (in shares)</a></td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Viridian Merger | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Viridian Merger | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Preferred Stock | Series A Preferred Stock Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,504,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership', window );">Beneficial ownership</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Preferred Stock | Series B Preferred Stock Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">134,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">157,435<span></span>
</td>
<td class="nump">157,435<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">172,435<span></span>
</td>
<td class="nump">188,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Preferred Stock | Series A Preferred Stock Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">145,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">145,160<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="nump">143,522<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
<td class="nump">51,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B Preferred Stock | Series B Preferred Stock Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember', window );">ATM Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds', window );">Commission fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,561,570<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_SaleOfStockWeightedAverageSharePrice', window );">Weighted-average share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825.3746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,869,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember', window );">2024 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering | $</a></td>
<td class="nump">$ 258,800,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember', window );">2024 Public Offering | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,250.0625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember', window );">2024 Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">12,466,600<span></span>
</td>
<td class="nump">7,142,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Stock, Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Conversion, Percentage Of Ownership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_CommonStockVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Vote Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_CommonStockVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleOfStockWeightedAverageSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Weighted Average Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleOfStockWeightedAverageSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=vrdn_ViridianMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=vrdn_ViridianMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=vrdn_SeriesAPreferredStockConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=vrdn_SeriesAPreferredStockConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=vrdn_SeriesBPreferredStockConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=vrdn_SeriesBPreferredStockConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrdn_A2024PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503516960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">249,883<span></span>
</td>
<td class="nump">249,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.51<span></span>
</td>
<td class="nump">$ 15.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member', window );">Issued April 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 127.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsMember', window );">Subtotal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">249,102<span></span>
</td>
<td class="nump">249,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member', window );">Acquired October 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">29,446<span></span>
</td>
<td class="nump">29,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member', window );">Issued February 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">218,050<span></span>
</td>
<td class="nump">218,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 14.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedNovember2017Member', window );">Issued November 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet', window );">Number of underlying shares (in shares)</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightRemainingTerm', window );">Remaining contractual life</a></td>
<td class="text">1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassofWarrantorRightRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Remaining Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassofWarrantorRightRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedNovember2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=vrdn_EquityclassifiedWarrantsIssuedNovember2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813503050960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Stock Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightActivityRollForward', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">249,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightExercisedInPeriod', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">249,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassofWarrantorRightActivityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Activity [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassofWarrantorRightActivityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrdn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813506866944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">105 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,639,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,639,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized option employee stock-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vrdn_FormerExecutiveOfficersMember', window );">Former Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment arrangement, acceleration of vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Plan modification costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period for stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized employee stock-based compensation costs related to unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per option (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="nump">$ 23.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period for stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock | Former Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Plan modification costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock | Initial Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock | Subsequent Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for cash under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized for plan (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,639,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,639,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vrdn_FormerExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vrdn_FormerExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813504646672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Balance by Plan (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">11,352,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">4,639,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">514,540<span></span>
</td>
<td class="nump">804,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_InducementGrantsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">5,663,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_InducementGrantsMember', window );">Inducement Awards | Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_A2020PlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">125,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_A2020PlanMember', window );">2020 Plan | Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">5,563,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">4,639,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember', window );">2016 Plan | Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">514,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_A2008PlanMember', window );">2008 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrdn_A2008PlanMember', window );">2008 Plan | Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_InducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_InducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_A2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_A2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_Amended2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrdn_A2008PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrdn_A2008PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813506957056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of RSU Activity (Details) - Restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested beginning balance (in shares)</a></td>
<td class="nump">804,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(19,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(276,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested ending balance (in shares)</a></td>
<td class="nump">514,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding beginning balance (in dollars per share)</a></td>
<td class="nump">$ 14.85<span></span>
</td>
<td class="nump">$ 15.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">35.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">16.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding ending balance (in dollars per share)</a></td>
<td class="nump">$ 14.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813506785296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">11,352,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">11,533,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,996,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(232,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(2,945,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">11,352,087<span></span>
</td>
<td class="nump">11,533,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest (in shares)</a></td>
<td class="nump">11,352,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">3,324,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested (in shares)</a></td>
<td class="nump">3,324,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 19.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">9.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">22.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">17.93<span></span>
</td>
<td class="nump">$ 19.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">17.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">21.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested (in dollars per share)</a></td>
<td class="nump">$ 21.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term and Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">8 years 18 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">8 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">5 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested (Weighted Average Remaining Contractual Term)</a></td>
<td class="text">5 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding (Aggregate Intrinsic Value)</a></td>
<td class="nump">$ 68,434<span></span>
</td>
<td class="nump">$ 54,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest (Aggregate Intrinsic Value)</a></td>
<td class="nump">68,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable (Aggregate Intrinsic Value)</a></td>
<td class="nump">9,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested (Aggregate Intrinsic Value)</a></td>
<td class="nump">$ 9,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813601771216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term, in years</a></td>
<td class="text">5 years 1 month 9 days<span></span>
</td>
<td class="text">5 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.80%<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.08<span></span>
</td>
<td class="nump">$ 31.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813506979024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="nump">$ 13,606<span></span>
</td>
<td class="nump">$ 33,175<span></span>
</td>
<td class="nump">$ 41,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">4,673<span></span>
</td>
<td class="nump">4,003<span></span>
</td>
<td class="nump">17,142<span></span>
</td>
<td class="nump">11,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,047<span></span>
</td>
<td class="nump">$ 9,603<span></span>
</td>
<td class="nump">$ 16,033<span></span>
</td>
<td class="nump">$ 29,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46813491449824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Potential Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">30,785,710<span></span>
</td>
<td class="nump">23,760,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock (as converted to shares of common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">8,991,383<span></span>
</td>
<td class="nump">11,496,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock (as converted to shares of common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">9,677,817<span></span>
</td>
<td class="nump">3,414,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">11,352,087<span></span>
</td>
<td class="nump">8,261,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vrdn_CommonStockWarrantsMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">249,883<span></span>
</td>
<td class="nump">249,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">514,540<span></span>
</td>
<td class="nump">338,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vrdn_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vrdn_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#/H]".UN[/T2>_]R[%*NN9!MBZ3K4P3ZYQ)H&^H)#$H" RV! #/59">@*O1
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MQVMR\+L#]Z;B=2:H]"N*JL,.%@A<%:REANOZK2(Z!U 6=MK9"*"(:1.WE8P
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MB'(%D-\_,R9>;]0 ]=GX[%]02P,$%     @ [SEL6:KMH[3T @  $0D  !@
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M%N *@-^7C,F7B3)0W8+ZOP%02P,$%     @ [SEL67- KUP((   S1$" !@
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MBSF&:4R'2Z7DEF4DEI-806(EB54D5I-8 V&#F+*>8\H:&5/G1-.CZ;XXY*W
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MW:1*:'EA"ENKUC>KE6E]418DHE<CD;<EY2]TM/CWO^#4^X_)YS,IZT3 WT?
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MBT;3IAICH&/K.( 8S?H@;!*$.! I9=D_!<7(#<6/G$64QMO=RTBU)<$G.F)
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MDSR7FR&9I, 4%AM],(S=/31#6K(8Y((@"&V;H?@&=O,-IQ-4MKU.\W5P%QP
M:T-[@QR$,#B@R-T'BXH)^)Z3-"[KHD@;CD+29C2?LK+F;:KO^*0X6.UK#I:G
M#KZ3;)S*'\^EK1L0Q11\-U-H]K.9L\GJMGN(9'3; /-XVM\Y@Y2/+<#J*RK@
MH[^Z;6J:JQH7<0R/+6Z^DX.<O)EGTM8-D^(?OIM_W#(1 UZJQU"'=+9YRG
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MH3^3(0 X)H.*Q&7Z]IS.>W3$:_.QI#\8<7]*VV#7%0BQ&.=N?.--P2%5#S5
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M"!3%R]Z"%OD@8U:4A&<C?H@R62J0GCD6>5A'2C[LS#ZH\#17=<)GKMM![RD
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MO$+DT-_O%#_JMR.4&<0Q&G?@]KTD?,DG09"THUZ(U]&7?>0C0AQXK_9)Z$6
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MQG!3H29/N0:!=,>[9)][8 JE[:E%74)_-(91$K^4!->D*<?=<<*M"TC&*!E
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MTH3&35)+\WX(,ZGK"Q.OOW46>.I=P0,7'9 GO1GMX=D\1E^:\+)*;#9^7GQ
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M/L)3^C;/%[ICWTCI<+56^!HNUBX)\#G#I>ZUTXC'O</ Y!7*W<9_GAA_8\2
MS:M3W$;K##<QH^#IU+I;&!HJO[W",V!'TJC!M(1EK(=..U0H:32!'&%T4.2B
M7_7?\1+X,I9]OSIY"<T=O9<R/W#O@>1R(:WTJ60A:88WT;[J.3/!QI/GX^?=
MP]JCR?C[;:>UN_*!K11ZQ[8/E$D/:GK'*[Q^S>9+O%_U4-MJZ:A_I/TL'41\
M)26EI]M#OT\X3'YU DZ]H-_6&/N&I/T!2K@:?KYS9G^U$A^WO_WYP/4"FZ%"
MS&'I9/S\Z9X%%O^E437]AF6FFD:5]'$IH*/1^ #<GRL !_<%-P@_:CK]#U!+
M P04    " #O.6Q9W*  S-L/  !E-@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6S-6UMS&[G1_2LHQ4EYJRB*-UV\:[M*ZTNBK5AVV<[FX:L\@#.@
MB'AFP 5F)#&_/J<;F"'F0DI:YTOEQ::& /J"[M.G@>'+.V._N;52I;C/L\*]
M.EJ7Y>;'DQ.7K%4NW=AL5(%O5L;FLL2?]N;$;:R2*4_*LY/99')VDDM='+U^
MR<\^V=<O355FNE"?K'!5GDN[_5EEYN[5T?2H?O!9WZQ+>G#R^N5&WJ@OJOS;
MYI/%7R?-*JG.5>&T*815JU='E],??U[0>![PJU9W+OHLR)*E,=_HCZOTU=&$
M%%*92DI:0>*_6_5&91DM!#5^"VL>-2)I8ORY7OT]VPY;EM*I-R;[NT[+]:NC
MBR.1JI6LLO*SN?N+"O:<TGJ)R1S_*^[\V-/9D4@J5YH\3(8&N2[\__(^^"&:
M<#'9,V$6)LQ8;R^(M7PK2_GZI35WPM)HK$8?V%2>#>5T09ORI;3X5F->^?K-
MQP\?KKY^>'?]]8NXO'XKWGR\_GIU_>=WUV^NWGUY>5)"! T\2<)R/_OE9GN6
M>R$^F*)<._&N2%7:GG\"U1K]9K5^/\\.+OA%;<9B/AF)V62V.+#>O+%WSNO-
M]]EK\ER7B*K2"5FDX@W4U<6-*A*MG'BK79(95UDE_N]RZ4J+H/G'D!>\D,6P
M$$JD']U&)NK5$3+%*7NKCE[_Z0_3L\E/!TQ8-"8L#JW^]"W[CN7$7W6"#%3B
M\L8J16Y#?)9K<97G56'^K(J1N"J2,?X1'Y/2+)6EC<)VE6L%W^8;66S%4B4R
M5V(C;;D5I1%29&%5V:SZG";\Z0\7L]GDIV;QOG0>,?WIAUB+FT:+Y]T%ZN$C
M42$>K;A;ZV3=TLTL2R"72A$,0MTG6>4 $B-@U-+K*)<9_@2R9"D24S6:PXQ$
M69H+N\HFG S6MD(7)6 &N%/)3&PL$)0LMP00CF:FZA9HN!DAD8MJA1A#P(UX
M?H+P5#;1,M/_4CL)UJ15@KD 85&8XM@4R'MSL^4Y],#*5)O-6@*G$E65.H%@
M7:3XG[#/\08E^  3+#_BI8)&-U9"X50LM_&^QE[2#H[*](VD83 @E]]VVJTJ
MTK\VBG<SUYD"=!6TZ5N?;&8EJ@W-?;:X&$]H1$9J5!O\0Z)DLM98@:=CK-NH
M1*\TQ"4(6+:';+7JILID:>QV)\-;]U8E*@_Q-VUKOY$:^RN>S<:GC=R>AJ3:
M+O :M1 (N79<@J 5@D07MYA(KL S:%6@\*2VNMD%W_7;)DKE9I.%/6"'PT/Z
MQIH2PSF 2<+[MY=LP >Y)=UGP[K/(Y\]H+M56;U/M-)*6U=2D&H:F1J'K[0W
MKG%M:1%Q'0U[7NUH9E5B+$!>/)M.(N6D$P1YTB+1:,?BL%#W&TZ>2$,966/N
M_+.GFB+%1M^:$A8<- @9EIN*$(Q1X Z:LG>QPB_(0U 2LG(^%I=IJOWN9MN1
MT*N6V:Y*$N7<JL*7[70E!-C6N2H2&*]3:$\A]$]@06W$ 72#L))R#0[<4+("
M>WR>FJW,RNTNF=1OA"SL/F +5BE!H.I=S75Z[%#3,#G5-]KG7@%^YV2F7 =F
M#J?JB]/=SH[%UX<0(?AGW5?8\"YYUQPOM\>UE[PRV!2[I<?A(_$L"%A9DT?[
M'BE-EG ^1CA1+PDO*(!)O2R0O]09+T.Q9&G:<_T#/T \Z@"'9A6&^ "C^$HR
MJ?,G[!Y)9NN#Y!'D# HB-P5DH!V.,*VN0+J,*A-% %L46=B6@P$0%61-9R5E
M7H$Z9AT%=3"-8S%\WNM07G>/G+'X6(CW:FDY5:8SS\E&XG*Y!%GV%5@FOU7:
M0NG&3SYLX/C<U=(/^1 Y@X(&W=82K(S01%(Z@&/[V0@+EN$X0\< J!V\4##M
MX2OO"G;U5?%/WPTX K<XZ]O8AGG*,KAPCCTL)*8O0=8#W*6G48?#^.^'"4R8
M6]?M6/,VC0EY>+P$'@,1>KR&J -(;N%6REI>,^(WE"4-4VDA'=91ZAMRWGY3
MQ)XIFJVY#8C;\* [C84JHGEX@A3(#."MRVD\[^%,"1B2BK6\!8S)5+7CT9E,
M 71)AG^.H-(E>0!"P (^5=95LFARM15T^W:EO?&U2\-HR1X:<.@*L[W[#G@T
M=N@>!D:R^RS,2Q\@ K5:1$.0 #+S A/$JBYW"J"Q1;BT]G.E.+^?32-$[U>^
MKYQ?ODKBDRY@>.J+[(-%/:THQ%CG K@E<M\(*FH$!=JXTA.)T,O-ZVHED\1;
M2)/AH)062]E5)N,"F@I7XK^:&1*;]JRV+F7HL=9T3("@0?/F'E&H.M3U,%T]
M?1)=C5PS>A1W/<@VH/V.<)#+XCSDS'L,Y7A<[!_TU&,9P_2T10;)[.\C+^-=
MBUZ*7V56*?'9)\P.?:\*#B.;RB)1.V8-A6\0<;)="G+]&?(*"A(K-]PL=;$W
M#-F!+TRY-K<^@!>C@1:W4S"2G<JWK'+(\>%^]\VOG_M58B0V$9QYW&<6L#99
MZFE,I #-FI[_Y'B?H"WV)_E&U1/#&LW/:LU]EUJBQ!((P4U^O%^Y0<R-U;<4
M3%"*^,BOVNI4RV''>?W8X6G+S; #C8)";J(H(&2&/2.>R\@93:%LF(]#9\OX
M5?N[9>9:90R;7!1J]U XR9)9SUC\C8LG^ROV]4A$)N,;AT:_RD+]62H$"=N>
M^7P(=E#8&AN31N+6R,%$J=2%"KA%](+#>Y;"R]>)E*D;F6R;*)3.J=(QW-&Q
MJ"_GUE0WZUWO-9_RQDV!%;Q4[PL?BY%$2BQMR)#4<T^5,BK"B7?T3V%Z^C7<
M/2@8%$,04)DRWINESKE"CT*^4:)N63JMC*2'UVCQ)M>YB%?#W@\X'3\*RKJ!
MA#L=BW=U'6Z0S)_@99E<FE!46Z 06NH.N:-)DJBD38_]F532+$$!UTKEXHE2
MZ5RH^4J%"E5X> X1<'7]]E@1(C-^TZDT=@$V<]I0ZQ<A=RC?OLRA+*>\8O,T
M('\<X"W2(X>1GEK?FFX\0!@'3[Z>>G[5L\(-FN'J(H!"BBR,(3*XOD:&)[$I
M>AKF=PJ>YU 9E3Y78?!LLAA=+.8>;MB)NNQ :G3N-X29453Y\ Y+<=8QX,'C
MI7AVVBV2]6'*8XY/(J8%K% =JO5+!9BM61;W;+]4,''FTVC>K?EL^/S%:'+Z
M0LB&BOQG7- VC7<G'.@\FXS/&P?4=CW"=K<SOF=XGV-VR57#WI@DW8$TMIR1
M@L.EBD]HN?:JR,XJI12M@ZR?ECN,VY-S<"C@D?W=<U,+?_B\ !TNHB60R_8!
M&ZFS=W-ZW%=FSCR! #^9^-8+#9[^@KQ]5G0S2#OVP/FP]\^2GS!;)=(IW1JI
M_D1*W*!)Y_2PMVD]^MMW%I2IW7$V>8([_%%;Y%9)&  #*<9_+R$FY#75,J+&
M?U42>?/1:\R5''4)<92:8[JJ3,7'U0I6^T,+N11?Z%*J&R+1O4Q>9:4^WB(%
M0V-)A#KSC22+VA%82@6*OHY LQ.(>8)OP=ID-XSWNN\ W2L5?U>WG[21A  .
MC93'^B23U/$W3(EWEZ=0]0L%OKGAV? <V*?N2R!%=S09XK?88TI40.E/<H9C
M%CH6'Q#)>97S-7!8HMG$B.2TK!@%,VK$UM J\8=9( '49^=T=N*=BA0P=^1S
M.A:QBK'SID I3?T)*MU(4GT[IDN\<$J*N5XN'4E[D^K#3)+O/1O92\5?YAXR
M-7$D@EMBD8,N B4%X"(^&#(QHDL^%R ?E PP>%.3XLLO;\3%8L8;P9F"?M0A
MRCGU38I&.6F?NH;MYO:$9[44Z]\[!)](7^V/S>J8CYF(L@8:8OT9.KO=+Y]I
MN=09F5*C>"?<B 33.=:])AZ.DOEL.CYK,AY$ O&74 =?;R7?[3:-#*:W0V)$
M')O/3GW1/_MCRY"F9:/K),_\$2F6 P%P@')@S1V)(B(YVFWS=-:4O7NBBHI*
M; VRM,-,CG;%T!_2'FA6"W4WBC+_/Y;IU^I.[,MVSU=#G'CM^L,Y5$NKV#=\
M$AQB,@XAJ\(V^-,0'\&N%UQ-JM-Q,LH#L<YV%^<-2"I+:$.<L."SRUU>JWOM
M6$I;R[HKXR&KE>+73#A=]MR726(_\ZB>8]-#_#<$]O>&] 'K/1#L0L7;NP^V
M?#='\W3!C4S)@PRTT\0/V[@PT)0NO+R!726X8Y[E6^6"BA\CJ@U%M).%D_&T
M<59$?;N6/5C'_?U.D4*9-#K7<I2II;Q7X2@ZG"]"2LTY]UI"5$25'C>I;Z4M
MC&],SU RL(.H'=C+LG3MHOS_4(R'I(4\#?DI703&\&Y4"7R;P'A[B;8_"W>^
M]6,/Y\TW 5-"KK<$#Y7V@0&/KN^F*GL[_KA2/"3U^^OJP*JA"(:.DM*VRC<Q
MN@S;?^"EF>\O<]0YQ+GS/U/!#M6M;GSMJ5GO367+M;BDZ*VY]SXWQS6I.Z\=
MI+U5J5=R#5;$=<?57<6 Q)CRT26:4XF'K>EDM)B="P>^;_E*QE]HQ G*KS/0
M.R7+2F>\@JMTV2^LG^ [C1S9'1<WE\TU:$?1!\$O3L^Z@GFSTUXA:.K<0\[\
M6!>#OC+A3J^Y_NY4I>@^/+Z6;BD$_ZZHDGH"WKP+D*J,;K:;:^W8&?NAYNDU
MY_2_4W/VEIS=B5XW*D=[(YUK]JX4U<C]HJWLFE@5U?)'-$:RB ^%PJERIS=B
MAE^84OM-BTUN"XX8$$7X *CQ84=$NA\'<M/QBV9&383BL.!EG*9Z*@ME*I?1
M64\$L'MHEU][^F1M9CUM>IDBPO&!7X!/,%#<_1L0E! Z1L*G$OKW>O6[L+$]
MK;F%P9J!;[2"838ZO[AX",N86-/+GS6<!:#M:-A.SYV,)[+#VMW1"BV%?&<9
M2$=O[0$"<B#UNR8\IE>A2Q-?3-E.&N44&!_M.%V,T>O&K.2>OF%/UCPJ+@\
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MB&D OE\94]9_D(#FEV6O_PU02P,$%     @ [SEL6; GZBSS#   #2T  !D
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&ULW5H);]LX%OXK1"93)("B6/*9
M'@'2M-WI;(]@G-EBL5@L:(FV.95$EZ+B9'[]?H^49,E7DID,9G:+QK8D\O'=
M[WL47RZ5_IK/A3#L-DVR_-7!W)C%\]/3/)J+E.>^6H@,3Z9*I]S@4L].\X46
M/+:3TN0T['0&IRF7V<'Y2WOO2I^_5(5)9":N-,N+-.7Z[K5(U/+507!0W?A)
MSN:&;IR>OUSPF1@+\_/B2N/JM*82RU1DN509TV+ZZN B>/ZZ1^/M@'](L<P;
MOQE),E'J*UV\CU\==(@AD8C($ 6.KQMQ*9*$"(&-;R7-@WI)FMC\75%_9V6'
M+!.>BTN5?)&QF;\Z&!VP6$QYD9B?U/('4<K3)WJ12G+[R99N;(#!49$;E9:3
MP4$J,_?-;TL]-":,.CLFA.6$T/+M%K)<ON&&G[_4:LDTC08U^F%%M;/!G,S(
M*&.C\51BGCF_O+AZ?WWQ@8VO/U_^_>6I 4EZ<!J5TU^[Z>&.Z6?LH\K,/&=O
MLUC$[?FG8*7F)ZSX>1WN)3@6"Y]U.QX+.V%O#[UN+5_7TNONH/?V6R'-'?O7
MQ20W&B[P[VTR.A*][20H+)[G"QZ)5P?P^USH&W%P_NR[8-!YL8?!7LU@;Q_U
M^PVP=_IVYEHTV:5*4_C_V*CH*_L9=M+,S 7=7O#L[MEWHS 8OLA9+B*5Q0BT
MW' C8A8);>141KA@:LID%BF]4)I3,'E-"DSFC!=FKK3\%?.,PHV\$+!@W^MT
M.O3'\CD'84O'8"EBQ:.KY5Q&<XSLK(^<\QO!)D)D"+%<SC++$L]9Y(2Q%!@'
MOQMK[)H)]4R%UK@HEY\H,T>TX8.S!=?LAB>%%?6PXW<"MH">+$F?74/8K$@G
MN(/'#5E78K7X2OD=.""5(4_F&*<TF*DN)G=6>WPZE916D)38C7)*IOMSE<!$
MEB@'I5^P%!RX?+AA-+O><JX8&&$B,](DS@9$TF=O.=1KN=Q@$E9KCE>9*.=<
MMYEH:WQM%2TB00+$\D;&(HMS\ +-DV&@<LB<<.WD7W!I12?[3Q37,=&.)0@8
MI7._[:5CGD"M%S,M! H 9IRP'\44YI.X_>'#)7N/D6)AA+4)4D78]DC,$;2N
MS, CS]AGU##VD>NOJ')$>T6:C3^R(YI**@T[+]I4V<7UQ]58.R1X<>R<ILW0
M43F_OEL-]MBBT'G!L11X<?[>9)5\1=$<JS24JV0M6%KZAW/+;$8B\1G8FKG@
MI!5Q=Z%E9.U<+&BMPV#8]SLH&DE"]6^J5<H,"BH]L]_<N"FY71I#H+0TI\=P
MWEC0%;*-M5KJ=$<90E("R&DRB6$)8<F*"6]=.51VB>/<1;XU+*I]9OS&H"5X
MK'V)6Y&10XAKD.[ZG>\K_Y]IE5,HJTB(V,4(=+@C#',X,2OJA+?/M#[[I"HR
M2[C.8^:RN+#JM^J8XR9+74T45!,;4ZNR9M6-'UV?O5E-S:#K^V:VO=SR&'C]
M ?Z&=?Y[(-/K9C+0^])B&$J7-T+#2"N/.@2S(%'G1(\!#S9\,!.F;94%KFXE
MTIM([MAAM^^'E2-ZE!>3(B:Y5X:V;M=@!__;SO(T]GF DF&5*RUO2*JK!(75
M)2 DG$_JIEZBNUX!4?!B%\'$F,Q(=9;&HJ+!@#^RG$=E^+0CF(V\T>#,&YX-
M&\Z\+>&WLS$9S=FHMHRU5A#ZW9%EYRSTND%X#]&Q4_IK"%[5R/'^!49AW^\.
M>X-V=@.$@*H-T<+M:(YR!RGK)&Y=CF %>@6H*$<9*4@;/'$%(T*%1'JQ>?L&
M,,36A>N&FLL,$3=4MR4AM%TO& U621!%7\!Q*;O%A4M,=?84MR@2.;'.[_@$
M-:*LT^7B\(IBDLB(?2XG6)_XD6<%>IDMP;E>@JRO+DD[E UWAB'T\$$0_:_L
MBFN341&F^J)%PNU42MYST2P95,^:):S)TSK3=0F#HH9>T N]47_T>)=S1#<+
MSV$8^$!B:]!II[5*62J5N0J%&_LD<.&_;N1^9Z^16\J/91ZI@AR2U-=,0;8,
M@@']"*]81R)/X08>^QNR2(KA8^"WG#WCZ>(%2/K6%8C+,:"Y2#SV2:(!Y,5J
MB%W5 U<56A>Q\QV'U^YQG;8D^YPG"+W>8. -6MC^/N_Q2OSC"H"@XC7::!#6
M0*I-K,@7@!Y9V<E;9=%:XE;H2.:$M-FT (0HC5,KN82PN"=ATX6=#2VLDE/L
MX RO0=<]_AV,_&&_609=*5\3X6ER;."%Y-:#L/^[ VJ_79L5N:764A2G.&]K
MY(7]D3_Z<R)O79%_0&M;4]CL6 #%<]?'N780/1JT7[><5B+7!SLTOJT7WFA)
MX0N$DDE/6I@2+-G6#&@K)<VBH<I)*;C.5R4#]*?RUK*S4# 3,HBC+;(*WFN"
M=KES6!KWK>")TP$9P&.)3*6I+D"=E 6G=&B%+"/4M.DH5<=7$X:*@1K=9EUY
M"_TD#:TN77L!N2&Q2$NG(GX2^:V0L5V\R;?K)51A$-S:.H?KDS5S*&K-(]I-
M<=G!^E7@76SXRP^K'G?GF/O[74I5M4%WTA&D;H\&$_#+3^3TQ.D+[GABU(GK
M?D_<X G/96DI6)\DS#FZ+-J!M5UUO3;4 +((0]M<MSBA6<U,ZK.WMQ&R !&P
M@;:D -?@2VK7XB5\Z97)8H<0L<+M3!FWQ=(RK@]M+@7D\6B!1+F.K]V;[54R
MK(S@S&*;CIHYS+:&6'3E#+]Y\\30UD1CH35U[>+/8T?RF/'$4';2#)4CFU'I
M(&^G'+@KZBB(K'+8#&QF57+>MTQS'9B\#-7+=KIZ4^88&SZ80Y/L6+M;L">U
M$5679"&#IF5B%14.F\N,N=T(5%E*HE25:@FA;20]9\]2I$U][Y/KYKC>#'-M
MV/[-M#VD0(E8 R-VYP%X(K$;&0EH&[1P]4X!B,YD9J.C!!$[_4\+>GN1-[NX
MECLB4NT["\KJ[!TJ&JG; #-<KSHZ=F3WNZ9VPZ2,VMUV.R93'-W <A8?5NCP
M;AT10A\+:)Z53TO1J,3.%%AS:."!\<H;SHF:I)S!&ZG7H[J#]K5P%^!P*:T&
M3E#!VJAF?6-Q)PLR+^N"D53"K9R#@3\8[@)\3>.66TPE;FMYW*HBY<7DEU)%
M56O9*F5-:&.A5DG@'JX!<N9R8IM1BZ(J*5I98S<!DG,7I)UZ;GL##XO$T/.\
M@#)7]=-S-QRCR(9J)FS46I>@(*?LETBX%95(523(WR*#[T72^KM:9@XL0.*,
M]E'@0_!#< <<&9'KS@CVVVT^@D0 @_E\M3%=*F@BS))VT7O^V=GW-BB",_IY
M7*=313&P"N7]$'XMJIA,4S3[#D7R*04!LJ3%?3;9V.V$MEI\=E%J?>N&VAN4
M9G<W\%9;--""A:U!M^>-!FYD,$3STNT_Q)"M/%!&(Y)Y<O<;MNZZ0Z\_#!ZR
MJN6XQ@?.FT*OWX$(_?X./?N[.XRML;HY[+&Q^A2QMY6+Q\3>%@+_7[&W"KT_
M,_*NMV,<K\;V>]L)7C9?=3^!)A(-J.WJVJAH2WM,F[W"4-$C"]Q76=$'):X"
MMWK>P-\"][<O]GBXOTGG?Q#N;PKQ-'!_NY+_.G!_@[\_!NYO7>;Q<)]@XU\-
M\6^(UH*E]_G5T\+2WX,0>GTO&'1<NNUUO7X8/L2;GQ(A!".O.PCW+K<-&@1>
MB-G!67<G-+BV74.2J*5ER"9>>US$.8([VV4/24VJD%O?5&D&TI)K=#XF?\X^
MU37([KXE=_1X[+@X"H[9E_*-XLE%^4;Q;;6W>&5W/.%T6XSUDVW(B-0E5*9=
MWF,?Y'37A*-/RF?_%%SGQVN/6S;_(/D$Q=O<G=AM-%>7*V'8>U<N+Q9:)B ;
M#-EP%-B_PR <^F=]UO'[(^9.%&VE<!&5^?5S9%19>3HL//-ZO4'U18=+0M;W
MST;5@N_$1%>O.SKL*#QF(1RAT^_4WX=!S^_UL'QW6$UJO(P$HX$WZ S*3RPP
M.,/8(&3C8N*@0M@[\P(L6WT?!GT_Z+-K^[!FGYZ.1MWZFT;U _:?+?^L<=^W
M@H_0H*M5,#T*C+WEWL.CV".ANXNJG%&P1'P!D)#(7U?9K2Y6QS:Y;4_?&\<B
M7/_,\A3E$3I91T:NQ)1RKK:WW::[ YS(F/9%@$5%FK:O2^34WJYHO6/?%A+;
MR-7G@)"?ZA<.R1WP<5N!$&F"/.'4YRY*Q6AA$W-;GP_5UA^IJ=41IR?257U,
MRK>1,%YU&"LDO3J%TL8.=)3F!H4"(!LA7)EQGT1E^6@P5+UN:@4E[%:=6MWU
M>J=:P)XR)1#RN$,'/7N(+B^3-!)KZSC4EXJ_,MU6697MR*J?&\I&PMRH>ZL(
M9R[$J_FQ?1$8A"_PI/JU1FP+Z^O4MIV*/&T<44V%GMF#N!3%L)8[K5K?K<_Z
M7K@CKJOA[J#P1ZYGM%V7B"FF=OQA_\!AE.K"J(4]\#I1QJC4_IP+#B^D 7@^
M58"0Y04M4)^ /O\O4$L#!!0    ( .\Y;%E4W4)I!0T  !DM   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;-U:"V_;1A+^*PO7+6R ID7JZ;P QTFO
MZ>5A1.X%A\/AL")7TC845UV25MQ??]_,DA2IEYW617L7Q))([L[.>[Y9[K.5
ML9^SN5*Y^+)(TNSYT3S/ET_.S[-HKA8R\\U2I7@R-78A<US:V7FVM$K&/&F1
MG(>=SN!\(75Z].(9W[NV+YZ9(D]TJJZMR(K%0MJ[ERHQJ^='P5%UXZ.>S7.Z
M<?[BV5+.U%CE/RVO+:[.:RJQ7J@TTR855DV?'UT&3U[V:#P/^(=6JZSQ6Y D
M$V,^T\6;^/E1AQA2B8IRHB#Q=:NN5)(0(;#Q2TGSJ%Z2)C9_5]2_9]DART1F
MZLHDGW2<SY\?C8Y$K*:R2/*/9O6#*N7I$[W()!E_BI4;V^L<B:C(<K,H)X.#
MA4[=M_Q2ZJ$Q8;1O0EA.")EOMQ!S^4KF\L4S:U;"TFA0HQ\L*L\&<SHEHXQS
MBZ<:\_(7GRX_?KQ\?S-^=IZ#&MT[C\J9+]W,<,_,"_'.I/D\$Z_36,7M^>?@
MHF8EK%AY&1XD.%9+7W0[G@@[8>\ O6XM6I?I=??0^Y#/E15OM9SH1.=:9>*5
MSJ+$9(55XE^7DRRW\(E_[Y+<$>[M)DQQ\B1;RD@]/T(@9,K>JJ,7WWT3##I/
M#[#=J]GN':)^T"('9^[FZ^KR^LW-Y5LQOOEP]7=Q918+Q,(X-]%G\1,,9P6T
M1+>7,KW[[IM1& R?9B)3D4EC!%V6RUS%(E(VUU,=X4*8J=!I9.S26$F!Y34I
M")T)6>1S8_6OF)<;W,@*!9/VO4ZG0W\BFTL09CHYEB)6/+I:S74TQ\C.YLBY
MO%5BHE2*<,OT+&669"8B)PQ3$!+\;JVQ;R;4,U76XJ)<?F+R.2(/'U(LI16W
M,BE8U...WPG$$GIBDKZX@;!IL9C@#AXW9%V+U>)K(>_  :D,.3/#.&/!3'4Q
MN6/MR>E44XI!@A*WQBF9[L]- A,Q40E*/V.I_*YZN&4T7F\U-P*,")7F.D^<
M#8BD+UY+J)>YW&(25FN.-ZDJY]RTF6AK?&,5JR)% L3Z5L<JC3/P LV38:!R
MR)Q(Z^1?2LVBD_TG1MJ8:,<:!')C,[_MI6.90*V7,ZL4B@%FG(D?U13FHXA^
M^_9*O,%(M<P5VP2Y(VQ[).8H6E>GX%&FX@/JF7@G[6=4/**])BW&[\0)3265
MAIVG;:KB\N;=>BP/"9Z>.J=I,W12SJ_O5H,]L2QL5D@L!5Z<OS=9)5\Q-(>5
MAM*5; 1+2_]P;IW.2"0Y ULS%YRT(NXNK8[8SL62UCH.AGV_@P*2)%0+I]8L
M1([B2L_X6^9N2L9+8PB4MLCH,9PW5G2%;,-66SC=48;0E  RFDQB,"$L63'A
M;2J'2C!QG+G(9\.B\J>YWQBT H^U+TD6&3F$N ;IKM_YMO+_F349A;*)E(I=
MC$"'>\(P@Q.+HDYXATSKB_>F(K."ZWS-7!$7K'Y6QQPWQ<(5245%LC&UJG.L
M;OSH^N+5>FH*7=\WL^WES&/@]0?X&];Y[X%,;YHIA]Y7C&<H7=XJ"R.M/>H8
MS()$G1,] 6S8\,%4Y6VK+''U12.]J>1.''?[?E@YHD=Y,2EBDGMM:':[!COX
MWW:6Q['/ Y0,JUQ;?4M272<HK"X!(>&\-[?U$MW-"HB"%[L()L9T2JIC&LN*
MA@#T2#,9E>'3CF Q\D:#"V]X,6PX\ZZ$W\[&9#1GH]HR;*T@]+LC9N<B]+I!
M> _1L5/Z2PA>U<CQX05&8=_O#GN#=G8#A("J&7;A=C1'N8.4=1)GER-8@;X!
M*LI01@K2ADQ<P8A0(9%>.&_? H9P7;AIJ+G,$'%#=3L20MOU@M%@G011]!4<
ME[);7+C$5&=/]05%(B/6Y9V<H$:4=;I<'%Y13!(=B0_E!/:)'V5:H*_9$9R;
M)8A]=47:H6RX-PRAA[>*Z'\6U]+F*15AJB]6)9*G4O*>JV;)H'K6+&%-GC:9
MKDL8%#7T@E[HC?JCKW<Y1W2[\!R'@0\DM@&=]EJKE*52F:M0N'%( A?^FT;N
M=PX:N:7\&!V!*<@A27W-%,1ED#N(AWO%)A)Y##?PQ-^01188/@9^R\1W<K%\
M"I(^NP)Q.08T5XDGWFLT@[)8#^%5/7!5H745.]]Q>.T>UVE+<LAY@M#K#0;>
MH(7M[_,>K\0_K@ H*EZCK09A Z1R8D6^ /1(RZZ>E45KJ2_*1CHCI"VF!2!$
M:9Q:R26$Q3T-FRYY-K2P3DZQ@S.R!EWW^'<P\H?]9AETI7Q#A,?)L8$7DEL/
MPO[O#JC#=FU6Y)9:2U&<XKR=D1?V1_[HSXF\347^ :UM36&[8P$4SUP?Y]I!
M]&C0?MURLD2N#W9H?%<OO-62PA<()9.>K,I+L,2M&=#6@C2+ABHCI> Z6Y<,
MT)_J+\S.TL!,R"".MDHK>&\)VF7.86G<+X5,G [( )Y(]$+GU06HD[+@E ZM
MD&64F38=I>KX:L)0,5"CV[@K;Z&?I*'5I6LO(#<D5HO2J8B?1/]2Z)@7;_+M
M>@E3Y ANR\[A^F0K'(K:\(AV4UQVL'X5>)=;_O+#NL?=.^;^?I=256W0O704
MJ=NCP03\LC,]/7/Z@CN>Y>;,=;]G;O!$9KJT%*Q/$F8271;MQG)77:\--8 L
MPI";ZQ8G-*N927WQ^DN$+$ $.-!6%. 6?&GK6KQ$KKPR6>P1(C:XG9K<;;&T
MC.M#FRL%>3Q:(#&NXVOW9@>5#"LC.-.8TU$SAW%KB$77SO";-T]RVIIH++2A
MKGW\>>)$GPJ9Y)2=K$#E2&=4.LC;*0?NBSH*(E:.F('-M$K.AY9IK@.3EZ%Z
MU4Y7K\H<P^&#.32)Q_)NP8'41E1=DH4,EI:)350X;*Y3X78C4&4IB5)5JB6$
MMI'TG#U+D;;U?4BNV]-Z,\RU88<WTPZ0 B5B#8SPS@/P1,(;&0EHYVCAZIT"
M$)WIE*.C!!%[_<\J>I.1-;NXECLB4OG]!65U\3TJ&JD[!V:X67=TXH3WNZ:\
M85)&[7Z[G9(I3FYA.<:'%3J\VT2$T,<2FA?ETU(T*K$S ]8<&GA@O,J&<Z(F
M&6?P1NKUJ.Z@?2W<!3A<:=; &2I8&]5L;BSN94%G95W(-95PEG,P\ ?#?8"O
M:=QRBZG$;2V/6U>DK)C\7*JH:BU;I:P);1AJE03NX1H@9ZXGW(PRBJJD:&6-
M_01(SGV0=NJY[0T\+)*<GF<%E+FNGYZ[X1A%-C0SQ5'++D%!3MDOT7 K*I&F
M2)"_50K?BS3[NUFE#BQ XI3V4>!#\$-P!QP9D>O."/;S-A]!(H#!;+[>F"X5
M-%'YBG;1>_[%Q;<<%,$%_3RMTZFA&%B'\F$(OQ%50B\6:/8=BI13"@)D2<9]
MG&QX.Z&M%E]<EEK?N:'V"J79W0V\]18-M,"P->CVO-' C0R&:%ZZ_8<8LI4'
MRFA$,D_N?L/677?H]8?!0U9ECFM\X+PI]/H=B-#O[]&SO[_#V!FKV\.^-E8?
M(_9V<O$UL;>#P/]7[*U#[\^,O)O=&,>KL?W!=D*6S5?=3Z")1 /*75T;%>UH
MCVFS5^54],@"]U56]$&)J\"MGC?P=\#]W8M]/=S?IO,_"/>WA7@<N+];R7\=
MN+_%WQ\#]W<N\_5PGV#C7PWQ;XG6@J7W^=7CPM+?@Q!Z?2\8=%RZ[76]?A@^
MQ)L?$R$$(Z\[" \NMPL:!%Z(V<%%=R\TN.&N(4G,BAGBQ,O'19PCN'->?&!J
M4H7<YJ9*,Y!6TJ+SR;,GXGU=@WCW+;FCQV/'Q4EP*CZ5;Q3/+LLWBJ^KO<5K
MWO&$T^TPUD=NR(C4%51F7=X3;_5TWX23]\87_U329J<;CULVK\X%W9WQ-IJK
MRY4PXHTKEY=+JQ.0#89B. KX[S@(A_Y%7W3\_DB\AF?NH7 9E?GU0Y2;LO)T
M1'CA]7J#ZHL.EX2B[U^,J@6_5Q-;O>[HB)/P5(1PA$Z_4W\?!SV_U\/RW6$U
MJ?$R$HP&WJ S*#^QP. "8X-0C(N)@PIA[\(+L&SU?1ST_: O;OAAS3X]'8VZ
M]3>-Z@?B/SO^L7'?M(*/T*"K53 ]"@S?<N_A4>R1T-U%5<XH6"*Y!$A(]*_K
M[%87JU-.;KO3]]:Q"-<_BVR!\@B=;"(C5V)*.=?;VV[3W0%.9$Q^$<"HR-+V
M=8F<VML5K7?LNT)B%[GZ'!#R4_W"(;D#/FXK$")-D"><^MQ%J1BK.#&W]?E0
M;?V1FEH?<7HD7=7'I'R.A/&ZPU@CZ?4IE#9VH*,TMR@4 -D(X<J,AR0JRT>#
MH>IU4RLH8;?J!.N^USO5 GSBE$#(UQTZZ/$ANJQ,TDBLK>-0GRK^RG1;956Q
M)ZM^:"@;"7.K[JTC7+@0K^;'_"(P")_B2?5K@]@.UC>I[3H0>=XXKKI0=L:'
M<BF*82UW<K6^6Y_[O73'7=?#W:'A=]+.:+LN45-,[?C#_I'#*-5%;I9\^'5B
M\MPL^.=<27@A#<#SJ0&$+"]H@?HT](O_ E!+ P04    " #O.6Q9USW=_!,,
M   S(P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6S=6EEOVT@2_BL-
MCS-( )KFJ2,78">>F2PPB6$GF8?%/K3(EM0(#X6'%>^OWZ^JFQ0IR482S,-@
M'VSQZ*JNXZNKI9?;LOI2KY5JQ+<\*^I7)^NFV3P_/Z^3M<IE[98;5>#-LJQR
MV>"V6IW7FTK)E(GR[#SPO,EY+G5Q\OHE/[NN7K\LVR;3A;JN1-WFN:SN+U56
M;E^=^"?=@QN]6C?TX/SURXU<J5O5?-I<5[@[[[FD.E=%K<M"5&KYZN3"?WX9
MT7I>\%FK;3VX%J3)HBR_T,V[]-6)1P*I3"4-<9#XN%-O5)81(XCQU?(\Z;<D
MPN%UQ_TWUAVZ+&2MWI397SIMUJ].9B<B54O99LU-N?U#67UBXI>46<W_Q=:L
MC<(3D;1U4^:6&!+DNC"?\INUPX!@YCU $%B"@.4V&[&4;V4C7[^LRJVH:#6X
MT06KRM003A?DE-NFPEL-NN;U[1\7-U=GEQ>W5V_%FP]_7E^]O[WX^.[#^Y?G
M#;C3FO/$<KHTG(('.,W%GV71K&MQ5:0J'=.?0ZI>M* 3[3)XE.&MVK@B]!P1
M>$'T"+^P5S5D?N%#_-:R4F>7<&$JKN4]D-6(BZJ2Q4KQ];\O%G53 2;_.::\
MX1T=YTVA\[S>R$2].D%LU*JZ4R>O?_W%GW@O'I$\ZB6/'N/^0T[Z.4[BZFNK
MFWOQKDA@"L2)N,YD48N/:R7>E/E&%O=B+6NQ@KF:6B"ZZT86J2Y6HH6[*Z'Q
M%(E@=IR1>-J T:^_S(+ >\'+Z"G?^R^>.4PMX00 1X MHAWL&]P$GC]YB*48
M\<2Z,4_B0RL^ZTJG&@2 D?==XF'9@!4S0IAQ'KE3V3TBM%DSZUZ3?K->#F<H
MW7'C=J*ZXB)-->4HF67WCEBHE2X*,JTNQ+]:; B1?,.P\P7[ ?9!?DB^B')#
MU#5+<7/[R?A'ITJ42S;M \YM2I&HJD'F%BK?9.6]4OQ0%VF;*-HOIUN9)&K3
MV"4<*;T!.G&&]GO'U":ZMK)*!WH2FAI5Y;6U:6'4KDE.XG! *A"QJ!<+ ENC
MR3RBUKG.9$6"->NR5D*:E9U%#!P'PM'V_O3%0U9P\0!6+LAW0> <I60KK\L,
MG"'29E.5=\KXFT'+ @]@R_=6I1X0$!B8S$NXM<0+$A$NKK$A!*^75F;\4:VC
M:DH *-I\@3?@55/RPN9W$MHO,B50CX6NZU9"G8'2/7KA13;14(2:'LAFY#J4
M]PHRUV)9E;F0L&^Q GMEC+4ALE5)LF!#LO3(7N&/V$N*95NQZG^#U721H >I
MV6*'9K(I.!U;B1@H8ZH%@LKQ/(_^+-%(L>C_2K&/HYVW.LLX#'4!Z01:HXM-
MI3/ASZG4AA'R$4<DZB^$I_V[(CS.06MI8F")W%AN"2(+F9$\-4E!R'DN;F""
M2B<4F+><JCX5E) ^#.J'>?[!IK#1&Z/SQ0CS[SJE#Y,%NREX(6)G,@F=21#W
M3W91T3WQ@]@)YY/!BLX\L1\Y<>2!2PPN7A2(R)F$<R>*HD'"[^FB_O)CV<BL
M)_=])XSABMET0/^ .3AG'R:P!])V5VL.#;!2!8*9LN0=-L+"HN4[H!38%-'9
MO4+F1,#KTM193J^J:3+LBRI@06:QN@_^I,R!5Q,#P$C7Q]-R*&#Z:Y)70\3:
MHJ)^;I3[B[MCE9Y=0!0T^^)WTE:\)0#^)G4E/LNL5>)]69#D*G7$6Y58\/D,
MOE#,O,B91U-QZL?N+# <('?L1,$,#V?N+!:?F5H\!99]/WXF3L/8A3/0P"^5
MYC?!=.), P^O_(D;AL,M#P'?>_/4CXC]'E;MY]_@N;7$(L!*?5-5HA']B,B$
MLS @9?,XC/T%4]H=6\KZ:.@383-[RE&]-&+QGNK;1L/3OB<( #;5'RQU=PJ-
M<13$3RA+<*SKR@ +2E6U]3Z]H(44LR20*JQRS)X$F((#J@R"^)YP9M3*:5S@
M!XCX+".*VD"5&.Z*8#@Q2_&R.J3&,]Q7R&>X04)M>RX&YPSG=D-&C&:6T1YZ
M1T8TO=2#:'[?9^3.6 ?0ONI\>,T^/'A_TVOV!M+0P$'Z?$1"%A>K5:569+5W
M> /#Z,1&QC O2M;I,$"0<N(P=*)9!+S.W<E,S-P8V!5QY$RGNX@)G/E\XOCQ
MA$.)>G8K,85'2.5C@O"8NZ$_"!S8V<"(%B$.D1ZC*98%@1O/CHAW))@&*?'4
MG[ISA+3KQ9!O,G.B,.J"UR)6<9J$VTPN^UFF5C>N'P\R"9T0U2T.8)' =R<3
M$;OA'#SFSFSN]7+]'/4@O5V@=N46-L/)JJVI\<:#RTPF7\YN$[08E(<-%"D5
MD%WS,E6<#"C4<@()1R2Q[W/">!X8)R:J-+:M ^(WJJBEX6_:X(\'^YL-*Z*A
MLJ"+#;S,1;C2]9>S9:44=9F*^AP*;^6(%$&3H@<2]UIE2*EW989-,NSI[/F5
MQP";/*R\KKA4B6QM[S,<.Z7(T/83W5I#11.V1M=-6R5KZI>(?2W)RS9TG=UN
M.S$HGA=\!$!!+H *D(&9X:L31"*REC0I<M,N,D1@PI)H]A%R+!?-X12RDY5J
MJ/ZOD07-55NQ4TR+31HZ!**M0O\EZZ,UMMP6 V'=$4JX;\/0A#P+9V-GLE0G
M"-49:#=4M#!'=N1B)$4T> 2 @9YCHU0J4W=4,, X1P-*LA^S'[G? M,<!HR%
MQ+!H4C"M6YKLT?+DP@K#<4G25H9FAR("#U-T.9LF3%W8$K=+DIE>LD653-:=
M%$.'TOI/[BW85ZS"O<&AP)9WBFO'<@F-NDJ),.HKJ:F6)(/L.B13R\"&I.MG
MWA&$1]1&J_'[IT2'<5Q07J\XGPVL\FQ@SEVX5HK/D,B*Q-M*0SN1O(S!?1(Y
M]!;V6*C1&0WA$79"%M \/'3U?VC;8Q'9\3?!:Q>.XM@L/.O[EH5"*Z/+RL)B
MG)V(,^>B[+[K%?JZN^_&)"MI%+6-T+%V!Q>TQ7M9I_*K>",WFOKO/TV7=*P7
M,B)MNWHL;3WF=V>\<BSNOI'3MB*)>##3F!-M5V*.K8[4!3(4%^8MP'_J>^XL
MY&>G0>C2L 4G;[I#I0-S$4VJS)@&]IBHOK- M'4GY&XP.]!9[BH1>AI29GAX
M>TP95N1JB&V:56U#&;N^CW_Q=+=BD#)F:,V?B+E'_V^.5PX1N>$3$=**GL.X
MEG1CUI/=1==9B4ZKO>[9=C>GH>]ZD,P><=DF_KJK&SS.]1/RHZN>=N=YM]?7
MW:F6D-P94A.*[*0AS>@LK2]/N]EJOV>7^\W^C/IM WBPYF[SN7BJGQV)"POS
MW9%A%[_(<PS6+GE48/ 8!UL&C]#^R'& [_BSJ>-[\\?/JTPZ\;T H]L$R3EO
M"2MWO9&(U4*I@@G&@Q4L[XKA2?Z;82M#V"E@;+/ Y)-1KX,J)VV*A-^Z=L@>
M(=K=X#(2L^F*^_%ASCD^R1G52-FN2TL[K4Q:/JH2$W"N[^#2%4+SK567>KCN
M[=)&YUU-S5F2M:D9XVUF3\D4?,Q:EYE.C2C=@50];DSL@6R.PK.F;]SN"'KU
M>/3YN*:P?21/?&\>L<ED=_64A2[;&E*@)N[=WJ 62IB%94P5LF6Y88N?TLG*
M-.1/SZ-/'^"+ KKP\<87OYM!UE2O%)E4TS<\;#J01%.TZ!,0^A/'"R'0W(GB
MT)[CU ]!2%F,G8H9'2309B&XH/D7&+[\*<T>$0(!RKW]L8(QCJ=*)65EOA"!
M[-T7!.(T<C$/HQ7DWJ=X6,X!U/FD.DG0X1EWD^^[@=WV:;FB^4XE+1L'*0"Y
MH6(TVZ%:;-<:/K X0SWSW+"78V\O%"*DPJ3?J^G/_0=5==2?[/5C]G"2R+E!
M*M1 ."/(MFQ1%/C<A ]0MY3WE]VXNM>49G6YL^=IX'H_:4$R1&<T>53-<4:A
M8>U;H^RQSZ:LF[.A;KMZU;=XW1<RYDQJ;YXSV^Y[R_U!G(7?A[.YZ_\C<.8/
M\/X/Q-GW%\?3V71@4MJ>$TU;D =6!>;&]&$K)\!./=1_A S'"CO<TK3HC,%^
M@^XD^* ?W)VV[: 8N//8]'<_I&7LSK]+R6/?BY\/?L@ I*SXYQIT\@Q@F-\T
M]$_[7X1<F!]"[):;GY-@#D!/5(M,+4'JN=/X! ,G_T3#W#3EAG\6L2B;ILSY
M<JTDJC(MP/ME63;=#6W0_T[F]?\ 4$L#!!0    ( .\Y;%GD517*L0,  -<(
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)U6VV[C-A#]E8$*%"V@
M1E??4MN O9MB%^AVC7C;?2CZ0$MCBPA%JB05)W_?(64K3M=VBC[8(JDY9\X,
MR1E-]TH_F K1PE,MI)D%E;7-;129HL*:F1O5H*0W6Z5K9FFJ=Y%I-++2@VH1
MI7$\C&K&93"?^K65GD]5:P67N-)@VKIF^GF)0NUG01(<%^[YKK)N(9I/&[;#
M-=K?FY6F6=2SE+Q&:;B2H'$["Q;)[3)W]M[@#XY[<S(&%\E&J0<W^5C.@M@)
M0H&%=0R,'H_X#H5P1"3C[P-GT+MTP-/QD?T7'SO%LF$&WRGQE9>VF@7C $K<
MLE;8>[7_@(=X!HZO4,+X?]AWMED<0-$:J^H#F!347'9/]G3(PPE@? F0'@"I
MU]TY\BK?,\OF4ZWVH)TUL;F!#]6C21R7;E/65M-;3C@[_^WN"_SZ>;V&U=T]
MK#\L[N^FD25>]S8J#AS+CB.]P#&!3TK:RL"=++%\C8](3R\J/8I:IE<)U]C<
M0!:'D,9I?H4OZX/,/%]V@>^.:<GESL *-:PKIA'^7&R,U70F_CH7;T>7GZ=S
M]^36-*S 64 7P:!^Q&#^_7?),/[YBMB\%YM?8_^/.W*5X[S";XEAR0PO0-+=
M%\H8:"@]QJ>'&RA4W;062]@\0\D?>4D9!%OABSE[9%RPC4"PRIG7=,OHP!8/
ME1(E:N.0#K#W5P/+G]@C:KKI(-MZ0Z[4]A4*J&88RZ1S= /ON?#>WQ!G>$T:
MM'AV&C:7PL&G AM+8ICUBDJ4BBX3LTH[-BX+*FB&Z(B$)J(ML0NU%\K*DKLR
MPD1':;Y1[\GWJA4E5!0H;!#E:4C MYZS41:EY9>)*E9V8&Y,2YH(?L2^K6*/
M%&[I<D?%[JTL.DK#:N(UEW/W+P^A,W9 W&ZILGH%?4CBN?<-!HM6DUH2Z6@8
M&;SH6KV!.-V$K1+4.BB#MT"%P:+?DF-U<'\9K6N'6L"*:CIJ31&O?3I^8.ZL
M2#IWMMO=\VG[$<;A9)*$V3B#) GSR3!,\^1(N_S_M)-P.!J%XV0$69@G>9B,
M$OC<N"TT#M:TNJCHX+W>0U*0#=(P'H](5CI,W ^^,JTIAU=@:3X)QQ3 \7F/
M5.%XX6^)-V@E)_R 9 SR&+)L'(Y' _BB+!TGRN=H/ A'20QI%HZ&<9AG"9PK
M9]%)LZE1[WQ+=>EHI>WZ3K_:=^U%UZQ>S+N6_XGI':=,"-P2-+X9#0+071OM
M)E8UOG5ME*5&Z(<5?7F@=@;T?JOH'!TFSD'_+3/_!U!+ P04    " #O.6Q9
M;Y2)[N0"  !,"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RMEFMO
MVR 4AO\*\JIID];Z[ER66&J:ZZ1.4;-NGZE-8JLV>("3]M\/L.,F%8FL+E\2
MP._S'C#'< 8[0I]9@A '+WF&V=!(."_ZILFB!.60W9 "8?%D36@.N>C2C<D*
MBF"LH#PS'<L*S!RFV @':FQ)PP$I>99BM*2 E7D.Z>L(960W-&QC/_"0;A(N
M!\QP4, -6B'^6"RIZ)F-2YSF"+.48$#1>FC<VOV%)_5*\#M%.W;0!G(E3X0\
MR\XB'AJ6G!#*4,2E Q1_6W2'LDP:B6G\K3V-)J0$#]M[]ZE:NUC+$V3HCF1_
MTI@G0Z-K@!BM89GQ![*;HWH]OO2+2,;4+]A56M\W0%0R3O(:%C/(4US]PY?Z
M/1P ]BG J0'G/>"= -P:<-L"7@UX;0&_!ORV0% #05N@4P.=MF^I6P/=MA%Z
M-=!3Z5#MG]K\,>0P'%"R U2JA9MLJ Q2M-CS%,M<7W$JGJ:"X^$2OH(M TM$
MU7>#(P3&*8LRPDJ*P#5X7(W!EZNOX JD&/Q*2,D@CMG Y"*V=#"C.LZHBN.<
MB..">X)YPL $QRC6\//S?.\,;XHU-PMW]@L?.6<-5ZBX :[U#3B6XVGF<W<>
M_U'BL_CX/'X/J<#MD_BD_>1=#3YM/WD=/FL_>1T^_[\WO_CPVH\2P6V^ %?Y
MN1_Y G2)7MEY>CMY-_59 2,T-,3EPQ#=(B/\_,D.K.^Z++NDV?B29I-+FDTO
M:3:[I-G\DF:+"YD=Y;'7Y+%WSCW\*0HCD;3:L[DB T7*ZF<;7G>"H-L;F-O#
M9-3( J_7<X]E8XW,Z_J><RR;Z&0BJG4LFVIDOF\%[X+.='/KVKY]+)MK9';/
M<N1!<ZA;Z'0=J]MYTU6;8!Y<K3FB&U67,1"1$O/JC&E&F]+O5E4\[\9'=G]F
M:\;GHE2L*KLW^ZK.%,?L)L4,9&@M0EDW'5%"T*IVJSJ<%.IB?R)<E FJF8AR
M%U$I$,_7A/!]1P9H"NCP'U!+ P04    " #O.6Q9 'J/JT,"  "*!@  &0
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M#0OSLP!I \SS3 A]FM@-^M]/\@=02P,$%     @ [SEL69$4R,9F(   >VP
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M4AKQW380 _*@8M%D%\#YK*C1*^M:S*2A<.-36-,"/8#PW>(@,^I#A[5D[UB
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M:8 MJ=5T5,U'6X\_N*2,?[QJ[D%V V"KG%3.V#?$2-$-G)I?8#8-1,:HZ%T
M[+0Y S7I%GL_Q<\8::$6V[UO:Q48!3!FJA(6-!J:._594UH1M-C6=-[$I-WS
MW@@&(4]>3M6!N!&[*(V%F U]N)(;_VST&)*3#\I44D*0SMO ]20[A]$*4D%Q
MBXT)0C"G0)X%!?)L5NPO/1M\)#9  K^'"?W3JWZH]MB#3TWP4UKE3P2?^_2T
M1S&52A$]?*>3)AKE@C<E_54%GUFC?ATCE==OZ(D)%LW7Y]>4-*)40;:S2K)=
MZ ),IYP.D#ULH9&B?D(/!_0PX[:5C 8YHQ#0P(Z86#$5:X8 ,LA.:S<*'$-?
MILR[=48O,]?MFHH$)\5[;ZQCUFNF.$4.,R8&+38&^NI' "=I=DYS- -U4&-#
M,E<B8OK)&=I)TWL5TL'_5'8J82I4OXM"-^#6UMS;7ND:I-SN69UVW!T9E\.=
M/;ZD;P=2PFWP!9*>I50"?<T^;70G?P@#DW9P15H"RK/_(<'!K9H^HTPV8<JM
MIQ3F19(4.E*GN[5[RB=WXX$49.<T54KRD^:M7,$5S3F]<G8:3Q">SHK^%=G@
ME\3%EXD-GCPE^'V@1KW(;L!^XKXM/V?M843><$(#Z87]*?&);^?"+G_,1"$
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MN9UZ@==L//#5VMB-WFQ2L!4NT'PO[A6M>BU*RC/,-9<Y*%Q.O7EP=A'9\^[
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MM*.6=O01^FQ!!9B6 D$NX8DIQ7*C#W'\$.4PQ\<UPE(*JDB>K\#8R(.3TA7
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M#EQM'-JXH=SN8JJE^4H-3B>3JW1\-YW=3V]OX/8:+A_2Z<U5FL+^!#6A3!W
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M-T"9AT,92?/OM2TKS^-COG^2W3!.!.7(CH;) R[R#C.WK&J\MP. !V-= ,<
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M752'+$?/\D:+K)C>%D+C+%A<KG%<!VD,\'TLA-[?F(&P_@,P^A=02P,$%
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M]3&L(N_'\HGBJ6EI%EQA@V2&*^QA06@#?!]RKIXGNDLJNV+O#U!+ P04
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MP@6GG\BNZN9"MS&R<;VXDH8ZVRU+&J6H; #=KZ4T3QO;WOUPSOX"4$L#!!0
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MI3E0F@NE>5":#Z4%4%J(HJE*J<UDZ\U?M+:@;UI#:3:4YD!I+I3F06D^E!9
M:2&*IBJJ]J4MO2^MV99(']E9"2TOX3:7G(XHY$#;Y4)I7DL'K.9ZTQ&% FB[
M0A1MFV7]O3T=$\8?RSU$<[(H5HZV&\OMSN[V*;TH=^<\.']EGKIFRWG///6W
MNY#6^.VFJ->4/T9I3F+V(*LR3B9RZL:W^XQN#T2V+G>4_)P)D27EQQ6C2\:+
M O+O#UDF7@Z*"G:[O<[_!U!+ P04    " #O.6Q9.!_5XYP0  "&!0$ &0
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M*5?B*;=WW/Y%:^)0;3+>=H^FS2/"Z'W74,U -1/5+%2S4<U!-1?5/%3S42U
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M:#@U1J<FJ):BFD0UA6H9JFE*,Z.BZC1WFW>:Z\^_QK\>._^RTVV/;5#-1[4
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MQ5EF%*GYJ!:@6HAJ$:H)5(M1+4&U%-4DJBE4RU!-4YJ9455WNV?M70*]2/N
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M$:H)5(M1+4&U%-4DJBE4RU!-4YH93EX53J>>!?W^<M.I]^7;R=8IA!:L42U
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M!JH6NC90[Y>,R?V-'B _79S\#U!+ P04    " #O.6Q9*FB:UK8"   Z"
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RU5EUOVC 4_2M6-DVMM)$0
M"!]=B 3MINVA%8)M/)OD0JPZ=F8;:*7]^/DCI$Q+LQ9I+\1V?,X]]^3:E_C
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M=>P#K@>H]RO&Y,N-=E ?).-_ 5!+ P04    " #O.6Q9/3J>%*4%   _'P
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M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MM@LX1 ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O'VQV$^CMJ+<3
MZ.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H7:/>-8'>->I=_Z?>*9_W,=U[;FM\_G]2
MG2_WQOOCK\O;R<%+N.(<X(?TRS=02P,$%     @ [SEL62BT:!/# 0  B1X
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=G);L(P% 707T'95L1X@ X"-FVW
M+8O^@)L\("*)+=M0^/LZ89!:T:B(2KV;1(GM=U]LZ6PR?MM9\KUM5=9^DBQ#
ML ^,^6Q)E?:IL53'D;EQE0[QT2V8U=E*+XB)P6#$,E,'JD,_-#62Z?B)YGI=
MAM[S-K[VA:DGB:/2)[W'_<0F:Y)H:\LBTR&.LTV=?TOI'Q+2N+*=XY>%]3=Q
M0L+.)C0C/P<<UKUNR+DBI]Y,N_"BJSB+;4OFPZXDGW:7.-.CF<^+C'*3K:NX
M)/76D<[]DBA49;HO>M.='.(.T_[*K\YORW0%QIDS9ZR/)^;H\KCCD32K^S86
M(A>*[D\\)<;25W\?-:>=4_[+[+B]'\:MVO/PK+U=O\=?S_A4_\(^!$@?$J0/
M!=+'$*2/$4@?MR!]W('T<0_2!Q^@-((B*D<AE:.8RE%0Y2BJ<A16.8JK' 56
MCB*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM D56@R"I19)4HLDH4626*K!)%
M5HDBJT215:+(*E%DE2BR*A19%8JL"D56A2*K0I%5H<BJ4&15*+(J%%D5BJQ#
M%%F'_RGKNS&KO_XYVMS32A?U,9^U?Z"GGU!+ 0(4 Q0    ( .\Y;%D'04UB
M@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ [SEL65+CZ%?N    *P(  !$              ( !KP   &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ [SEL69E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #O.6Q9K/R]^.H%  #M'@  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ [SEL66[DU!YY!@  \1P  !@
M             ("!+0X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( .\Y;%ES0A/>_@,  (<2   8              " @=P4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #O.6Q9,:R6I9P&   G
M'P  &               @($0&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ [SEL6:KMH[3T @  $0D  !@              ("!XA\
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .\Y;%ES0*]<
M""   ,T1 @ 8              " @0PC  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #O.6Q9=D#Q"[X"  #N"   &
M@(%*0P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ [SEL
M63T]0Y%+"0  8RT  !@              ("!/D8  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( .\Y;%G(1)YT0@H  /88   8
M      " @;]/  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .\Y;%D/<C5IRP\  . T   9              "
M@8>1  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ [SEL
M6=R@ ,S;#P  938  !D              ("!B:$  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #O.6Q9L"?J+/,,   -+0  &0
M        @(&;L0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( .\Y;%E4W4)I!0T  !DM   9              " @<6^  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ [SEL6=<]W?P3#   ,R,
M !D              ("! <P  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #O.6Q9Y%45RK$#  #7"   &0              @(%+V
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .\Y;%EOE(GN
MY (  $P+   9              " @3/<  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ [SEL60!ZCZM# @  B@8  !D
M ("!3M\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #O
M.6Q9D13(QF8@  ![;   &0              @('(X0  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .\Y;%D+M..9M00  /@,   9
M          " @64" 0!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#
M%     @ [SEL63\Q-8I. P  [@8  !D              ("!40<! 'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #O.6Q9DOL1G6@#  "Z
M!P  &0              @('6"@$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+ 0(4 Q0    ( .\Y;%D> <_%SP(  /D%   9              " @74.
M 0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ [SEL60"&
MAD.,!   '0L  !D              ("!>Q$! 'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"% ,4    " #O.6Q9N4BQOG@&   B$   &0
M    @($^%@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M .\Y;%F2[/.,^0(  &T&   9              " @>T< 0!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ [SEL6:XD71N2 @  'P8  !D
M             ("!'2 ! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #O.6Q9&=G^[X$#  #!#0  &0              @('F(@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .\Y;%EUV!@6[00
M &T9   9              " @9XF 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ [SEL6=I=;QD? P  90H  !D              ("!
MPBL! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #O.6Q9
MV.C\*YP(  #S3@  &0              @($8+P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( .\Y;%GTYN.<Y0,   P,   9
M      " @>LW 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ [SEL6?)/YZP)!P  ;C\  !D              ("!!SP! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #O.6Q9TSD95Q0#   A"P
M&0              @(%'0P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( .\Y;%D-!#47;@(  *@%   9              " @9)& 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ [SEL6:_T/M7(
M!P  ^54  !D              ("!-TD! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #O.6Q9.!_5XYP0  "&!0$ &0
M@($V40$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( .\Y
M;%F8QKFM]P(  !<(   9              " @0EB 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ [SEL61@+*FH^%@  OH\! !D
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M=#0V+GAM;%!+ 0(4 Q0    ( .\Y;%F]XD+*F@,  %0.   9
M  " @6^1 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M[SEL63TZGA2E!0  /Q\  !D              ("!0)4! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " #O.6Q95)'=35<#   /"0  &0
M            @($<FP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( .\Y;%D3UB)]Q ,   41   9              " @:J> 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ [SEL6?8<F\(7!
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M2P$"% ,4    " #O.6Q9H9?JE,D!  "@'@  &@              @ 'GKP$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #O.6Q9*+1H
M$\,!  ")'@  $P              @ 'HL0$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     .P [ !00  #<LP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>300</ContextCount>
  <ElementCount>328</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - ACCRUED LIABILITIES AND OTHER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHER</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHER</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - CAPITAL STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CAPITALSTOCK</Role>
      <ShortName>CAPITAL STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTS</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - ACCRUED LIABILITIES AND OTHER (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERTables</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHER (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHER</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/DEBT</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTSTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/WARRANTS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Debt Securities, Available-for-sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Debt Securities, Available-for-sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - ACCRUED LIABILITIES AND OTHER - Components of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails</Role>
      <ShortName>ACCRUED LIABILITIES AND OTHER - Components of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails</Role>
      <ShortName>DEBT - Schedule of Long-Term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails</Role>
      <ShortName>DEBT - Schedule of Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - COLLABORATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails</Role>
      <ShortName>COLLABORATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - CAPITAL STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails</Role>
      <ShortName>CAPITAL STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viridiantherapeutics.com/role/CAPITALSTOCK</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - WARRANTS - Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails</Role>
      <ShortName>WARRANTS - Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - WARRANTS - Stock Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails</Role>
      <ShortName>WARRANTS - Stock Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - SHARE-BASED COMPENSATION - Balance by Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Balance by Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - SHARE-BASED COMPENSATION - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vrdn-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - NET LOSS PER SHARE - Schedule of Potential Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Potential Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="vrdn-20240930.htm">vrdn-20240930.htm</File>
    <File>vrdn-20240930.xsd</File>
    <File>vrdn-20240930_cal.xml</File>
    <File>vrdn-20240930_def.xml</File>
    <File>vrdn-20240930_lab.xml</File>
    <File>vrdn-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="812">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vrdn-20240930.htm": {
   "nsprefix": "vrdn",
   "nsuri": "http://www.viridiantherapeutics.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "vrdn-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "vrdn-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vrdn-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vrdn-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vrdn-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrdn-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 281,
   "keyCustom": 47,
   "axisStandard": 24,
   "axisCustom": 1,
   "memberStandard": 28,
   "memberCustom": 29,
   "hidden": {
    "total": 11,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://fasb.org/us-gaap/2024": 5
   },
   "contextCount": 300,
   "entityCount": 1,
   "segmentCount": 61,
   "elementCount": 601,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 812,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.viridiantherapeutics.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-61",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-61",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS",
     "longName": "9952158 - Disclosure - DESCRIPTION OF BUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952159 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS",
     "longName": "9952160 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHER",
     "longName": "9952161 - Disclosure - ACCRUED LIABILITIES AND OTHER",
     "shortName": "ACCRUED LIABILITIES AND OTHER",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.viridiantherapeutics.com/role/DEBT",
     "longName": "9952162 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS",
     "longName": "9952163 - Disclosure - COLLABORATION AGREEMENTS",
     "shortName": "COLLABORATION AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.viridiantherapeutics.com/role/CAPITALSTOCK",
     "longName": "9952165 - Disclosure - CAPITAL STOCK",
     "shortName": "CAPITAL STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://www.viridiantherapeutics.com/role/WARRANTS",
     "longName": "9952166 - Disclosure - WARRANTS",
     "shortName": "WARRANTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION",
     "longName": "9952167 - Disclosure - SHARE-BASED COMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE",
     "longName": "9952168 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables",
     "longName": "9954472 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERTables",
     "longName": "9954473 - Disclosure - ACCRUED LIABILITIES AND OTHER (Tables)",
     "shortName": "ACCRUED LIABILITIES AND OTHER (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.viridiantherapeutics.com/role/DEBTTables",
     "longName": "9954474 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "longName": "9954475 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.viridiantherapeutics.com/role/WARRANTSTables",
     "longName": "9954476 - Disclosure - WARRANTS (Tables)",
     "shortName": "WARRANTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables",
     "longName": "9954477 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables",
     "longName": "9954478 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails",
     "longName": "9954479 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
     "longName": "9954481 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Debt Securities, Available-for-sale (Details)",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS - Debt Securities, Available-for-sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails",
     "longName": "9954482 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9954483 - Disclosure - INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "INVESTMENTS AND FAIR VALUE MEASUREMENTS - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails",
     "longName": "9954484 - Disclosure - ACCRUED LIABILITIES AND OTHER - Components of Accrued Liabilities (Details)",
     "shortName": "ACCRUED LIABILITIES AND OTHER - Components of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vrdn:AccruedOutsourcingClinicalandPreclinicalStudies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vrdn:AccruedOutsourcingClinicalandPreclinicalStudies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
     "longName": "9954485 - Disclosure - DEBT - Narrative (Details)",
     "shortName": "DEBT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-169",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails",
     "longName": "9954486 - Disclosure - DEBT - Schedule of Long-Term Debt Instruments (Details)",
     "shortName": "DEBT - Schedule of Long-Term Debt Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-173",
      "name": "us-gaap:DebtInstrumentFeeAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
     "longName": "9954487 - Disclosure - DEBT - Schedule of Future Principal Payments (Details)",
     "shortName": "DEBT - Schedule of Future Principal Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-173",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-173",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
     "longName": "9954488 - Disclosure - COLLABORATION AGREEMENTS (Details)",
     "shortName": "COLLABORATION AGREEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-182",
      "name": "vrdn:CollaborationArrangementInitialPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "longName": "9954489 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails",
     "longName": "9954490 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Future Lease Payments under Noncancelable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
     "longName": "9954491 - Disclosure - CAPITAL STOCK (Details)",
     "shortName": "CAPITAL STOCK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vrdn:CapitalStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-237",
      "name": "us-gaap:ConversionOfStockSharesIssued1",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails",
     "longName": "9954492 - Disclosure - WARRANTS - Stock Warrants Outstanding (Details)",
     "shortName": "WARRANTS - Stock Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails",
     "longName": "9954493 - Disclosure - WARRANTS - Stock Warrant Activity (Details)",
     "shortName": "WARRANTS - Stock Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9954494 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-288",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
     "longName": "9954495 - Disclosure - SHARE-BASED COMPENSATION - Balance by Plan (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Balance by Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-259",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails",
     "longName": "9954496 - Disclosure - SHARE-BASED COMPENSATION - Summary of RSU Activity (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Summary of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-268",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-267",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails",
     "longName": "9954497 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-269",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
     "longName": "9954498 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Fair Value Assumption for Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-269",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-269",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails",
     "longName": "9954499 - Disclosure - SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Allocation of Share-based Compensation Expense on Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails",
     "longName": "9954500 - Disclosure - NET LOSS PER SHARE - Schedule of Potential Dilutive Securities (Details)",
     "shortName": "NET LOSS PER SHARE - Schedule of Potential Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vrdn-20240930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "vrdn_A2008PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "A2008PlanMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2008 Plan",
        "label": "2008 Plan [Member]",
        "documentation": "2008 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_A2020PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "A2020PlanMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan",
        "label": "2020 Plan [Member]",
        "documentation": "2020 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_A2024PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "A2024PublicOfferingMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Public Offering",
        "label": "2024 Public Offering [Member]",
        "documentation": "2024 Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED LIABILITIES AND OTHER",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r693"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accretion and amortization of premiums and discounts on available-for-sale securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "vrdn_AccruedLegalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "AccruedLegalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal fees and expenses",
        "label": "Accrued Legal Fees, Current",
        "documentation": "Accrued Legal Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other (including related party of $3,725 and $374 as of September\u00a030, 2024 and December\u00a031, 2023, respectively)",
        "verboseLabel": "Accrued liabilities and other",
        "totalLabel": "Total accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "vrdn_AccruedLiabilityofWarrantsonTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "AccruedLiabilityofWarrantsonTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of liability-classified stock purchase warrants",
        "label": "Accrued Liability of Warrants on Temporary Equity",
        "documentation": "Accrued Liability of Warrants on Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_AccruedOutsourcingClinicalandPreclinicalStudies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "AccruedOutsourcingClinicalandPreclinicalStudies",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued outsourced clinical trials and preclinical studies",
        "label": "Accrued Outsourcing Clinical and Pre-clinical Studies",
        "documentation": "Accrued Outsourcing Clinical and Pre-clinical Studies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other professional service fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive gain",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r74",
      "r131",
      "r523",
      "r551",
      "r552"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r20",
      "r430",
      "r433",
      "r472",
      "r547",
      "r548",
      "r809",
      "r810",
      "r811",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r693",
      "r955"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r819",
      "r820",
      "r821",
      "r822",
      "r896",
      "r956"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r361"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r729",
      "r739",
      "r771"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r732",
      "r742",
      "r774"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r767",
      "r775",
      "r779",
      "r787"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r403"
     ]
    },
    "vrdn_Amended2016PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "Amended2016PlanMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan",
        "label": "Amended 2016 Plan [Member]",
        "documentation": "Amended 2016 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense and amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r668",
      "r669",
      "r814",
      "r908"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of property",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r895"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r895"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r107",
      "r125",
      "r154",
      "r188",
      "r192",
      "r205",
      "r206",
      "r245",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r425",
      "r427",
      "r453",
      "r518",
      "r598",
      "r660",
      "r661",
      "r693",
      "r710",
      "r859",
      "r860",
      "r914"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "verboseLabel": "Assets:",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r132",
      "r154",
      "r245",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r425",
      "r427",
      "r453",
      "r693",
      "r859",
      "r860",
      "r914"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash equivalents and short-term investments",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r679"
     ]
    },
    "vrdn_AtthemarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "AtthemarketOfferingMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement",
        "label": "At-the-market Offering [Member]",
        "documentation": "At-the-market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r253",
      "r517"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "verboseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r441",
      "r512",
      "r679",
      "r683",
      "r831",
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r253"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DESCRIPTION OF BUSINESS",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r82",
      "r83"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of property and equipment in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "vrdn_CapitalStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CapitalStockSharesAuthorized",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Capital Stock, Shares Authorized",
        "documentation": "Capital Stock, Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r79",
      "r150"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r79"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r128",
      "r129",
      "r130",
      "r154",
      "r177",
      "r178",
      "r180",
      "r182",
      "r190",
      "r191",
      "r245",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r319",
      "r320",
      "r323",
      "r326",
      "r333",
      "r453",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r586",
      "r607",
      "r625",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r797",
      "r815",
      "r823"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r190",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r331",
      "r333",
      "r559",
      "r560",
      "r561",
      "r562",
      "r670",
      "r797",
      "r815"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "vrdn_ClassOfWarrantOrRightConversionPercentageOfOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClassOfWarrantOrRightConversionPercentageOfOwnership",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beneficial ownership",
        "label": "Class of Warrant or Right, Conversion, Percentage Of Ownership",
        "documentation": "Class of Warrant or Right, Conversion, Percentage Of Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails",
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average exercise price (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "vrdn_ClassOfWarrantOrRightExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClassOfWarrantOrRightExercisedInPeriod",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Class of Warrant or Right, Exercised in Period",
        "documentation": "Class of Warrant or Right, Exercised in Period"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value",
        "documentation": "Class of Warrant or Right, Exercised In Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by each warrant or right (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of underlying shares (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net",
        "documentation": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "vrdn_ClassofWarrantorRightActivityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClassofWarrantorRightActivityRollForward",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number",
        "label": "Class of Warrant or Right, Activity [Roll Forward]",
        "documentation": "Class of Warrant or Right, Activity [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_ClassofWarrantorRightRemainingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClassofWarrantorRightRemainingTerm",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining contractual life",
        "label": "Class of Warrant or Right, Remaining Term",
        "documentation": "Class of Warrant or Right, Remaining Term"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_ClassofWarrantorRightWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClassofWarrantorRightWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Trial and Preclinical Study Accruals",
        "label": "Clinical Trials And Pre-clinical Study Accruals [Policy Text Block]",
        "documentation": "Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "vrdn_CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments",
        "label": "Collaboration Arrangement, Commercial Milestone Payment, Intellectual Property Rights Development, Maximum",
        "documentation": "Collaboration Arrangement, Commercial Milestone Payment, Intellectual Property Rights Development, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborationArrangementFutureDevelopmentsMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborationArrangementFutureDevelopmentsMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future developments milestone payments",
        "label": "Collaboration Arrangement, Future Developments Milestone Payments",
        "documentation": "Collaboration Arrangement, Future Developments Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborationArrangementInitialPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborationArrangementInitialPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration arrangement, initial payment",
        "label": "Collaboration Arrangement, Initial Payment",
        "documentation": "Collaboration Arrangement, Initial Payment"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborationArrangementMaximumMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborationArrangementMaximumMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration arrangement, maximum milestone payments",
        "label": "Collaboration Arrangement, Maximum Milestone Payments",
        "documentation": "Collaboration Arrangement, Maximum Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future developments milestone payments",
        "label": "Collaboration Arrangement, Milestone Payment, Intellectual Property Rights Development, Maximum",
        "documentation": "Collaboration Arrangement, Milestone Payment, Intellectual Property Rights Development, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborationArrangementPotentialMilestonePaymentMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborationArrangementPotentialMilestonePaymentMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Collaboration Arrangement, Potential Milestone Payment, Maximum",
        "documentation": "Collaboration Arrangement, Potential Milestone Payment, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Revenue",
        "label": "Collaboration Revenue [Member]",
        "documentation": "Collaboration Revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborativeArrangementAdditionalSharesIssuedForRightsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementAdditionalSharesIssuedForRightsGranted",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued exchange for rights for granted (in shares)",
        "label": "Collaborative Arrangement, Additional Shares Issued For Rights Granted",
        "documentation": "Collaborative Arrangement, Additional Shares Issued For Rights Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COLLABORATION AGREEMENTS",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r110",
      "r118"
     ]
    },
    "vrdn_CollaborativeArrangementMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, milestone payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "documentation": "Collaborative Arrangement, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborativeArrangementPotentialRoyaltyPaymentsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementPotentialRoyaltyPaymentsMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential royalty payments",
        "label": "Collaborative Arrangement, Potential Royalty Payments, Maximum",
        "documentation": "Collaborative Arrangement, Potential Royalty Payments, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborativeArrangementRightsAndLicensesFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementRightsAndLicensesFee",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, rights and licenses fee",
        "label": "Collaborative Arrangement, Rights And Licenses Fee",
        "documentation": "Collaborative Arrangement, Rights And Licenses Fee"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborativeArrangementSharesIssuedForRightsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementSharesIssuedForRightsGranted",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in exchange for rights granted (in shares)",
        "label": "Collaborative Arrangement, Shares Issued For Rights Granted",
        "documentation": "Collaborative Arrangement, Shares Issued For Rights Granted"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborativeArrangementUpfrontFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementUpfrontFeePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, upfront fee payment",
        "label": "Collaborative Arrangement, Upfront Fee Payment",
        "documentation": "Collaborative Arrangement, Upfront Fee Payment"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborativeArrangementValueOfSharesIssuedForRightsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementValueOfSharesIssuedForRightsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of shares issued in exchange for rights granted",
        "label": "Collaborative Arrangement, Value Of Shares Issued For Rights Granted",
        "documentation": "Collaborative Arrangement, Value Of Shares Issued For Rights Granted"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, value of shares to be issued for rights granted",
        "label": "Collaborative Arrangement, Value Of Shares To Be Issued For Rights Granted",
        "documentation": "Collaborative Arrangement, Value Of Shares To Be Issued For Rights Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "vrdn_ColoradoLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ColoradoLeaseMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colorado Lease",
        "label": "Colorado Lease [Member]",
        "documentation": "Colorado Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r101",
      "r520",
      "r585"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r271",
      "r272",
      "r645",
      "r851",
      "r856"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r701",
      "r702",
      "r704",
      "r705",
      "r706",
      "r707",
      "r819",
      "r820",
      "r822",
      "r896",
      "r954",
      "r956"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r586"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r68",
      "r586",
      "r604",
      "r956",
      "r957"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.01 par value; 200,000,000 shares authorized; 79,181,445 and 53,986,112 shares issued and outstanding as of September\u00a030, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r522",
      "r693"
     ]
    },
    "vrdn_CommonStockVotePerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CommonStockVotePerShare",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, vote per share",
        "label": "Common Stock, Vote Per Share",
        "documentation": "Common Stock, Vote Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock",
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r135",
      "r137",
      "r142",
      "r513",
      "r532",
      "r533"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r112"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled revenue - related party",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r338",
      "r349"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of deferred revenue - related party",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r349"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue - related party",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r349"
     ]
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description [Axis]",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name [Domain]",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares converted (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares issued (in shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r292",
      "r321",
      "r476",
      "r493",
      "r516",
      "r651",
      "r653"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtCovenantPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtCovenantPeriodAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Covenant Period [Axis]",
        "label": "Debt Covenant Period [Axis]",
        "documentation": "Debt Covenant Period"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtCovenantPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtCovenantPeriodDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Covenant Period [Domain]",
        "label": "Debt Covenant Period [Domain]",
        "documentation": "Debt Covenant Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtCovenantPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtCovenantPeriodOneMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Through December 15, 2023",
        "label": "Debt Covenant Period One [Member]",
        "documentation": "Debt Covenant Period One"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtCovenantPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtCovenantPeriodTwoMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 1, 2024 through December 15, 2024",
        "label": "Debt Covenant Period Two [Member]",
        "documentation": "Debt Covenant Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r152",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r277",
      "r278",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r304",
      "r311",
      "r312",
      "r314",
      "r460"
     ]
    },
    "vrdn_DebtExtinguishmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtExtinguishmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees paid directly to creditor related to extinguishment of debt",
        "label": "Debt Extinguishment Expense",
        "documentation": "Debt Extinguishment Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r58",
      "r59",
      "r99",
      "r100",
      "r159",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r690",
      "r816",
      "r852",
      "r853",
      "r854",
      "r907",
      "r909"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross term loan proceeds",
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r100",
      "r315"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r460",
      "r461",
      "r666",
      "r667",
      "r690"
     ]
    },
    "vrdn_DebtInstrumentFaceAmountFirstTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentFaceAmountFirstTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount, first tranche",
        "label": "Debt Instrument, Face Amount, First Tranche",
        "documentation": "Debt Instrument, Face Amount, First Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtInstrumentFaceAmountFourthTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentFaceAmountFourthTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount, fourth tranche",
        "label": "Debt Instrument, Face Amount, Fourth Tranche",
        "documentation": "Debt Instrument, Face Amount, Fourth Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtInstrumentFaceAmountSecondTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentFaceAmountSecondTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount, second tranche",
        "label": "Debt Instrument, Face Amount, Second Tranche",
        "documentation": "Debt Instrument, Face Amount, Second Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtInstrumentFaceAmountThirdTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentFaceAmountThirdTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount, third tranche",
        "label": "Debt Instrument, Face Amount, Third Tranche",
        "documentation": "Debt Instrument, Face Amount, Third Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtInstrumentFacilityFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentFacilityFee",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lenders facility fee",
        "label": "Debt Instrument, Facility Fee",
        "documentation": "Debt Instrument, Facility Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued end-of-term fee",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r317",
      "r460",
      "r461",
      "r690"
     ]
    },
    "vrdn_DebtInstrumentInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentInterestRateMaximum",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum interest rate",
        "label": "Debt Instrument, Interest Rate, Maximum",
        "documentation": "Debt Instrument, Interest Rate, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r290"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r690",
      "r816",
      "r907",
      "r909"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r159",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r690",
      "r816",
      "r852",
      "r853",
      "r854",
      "r907",
      "r909"
     ]
    },
    "vrdn_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt instrument, number of tranches",
        "label": "Debt Instrument, Number Of Tranches",
        "documentation": "Debt Instrument, Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtInstrumentOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Debt Instrument, Other Expenses",
        "documentation": "Debt Instrument, Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_DebtInstrumentPrincipalAmountTermFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "DebtInstrumentPrincipalAmountTermFee",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term fee",
        "label": "Debt Instrument, Principal Amount, Term Fee",
        "documentation": "Debt Instrument, Principal Amount, Term Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r42",
      "r45",
      "r54",
      "r91",
      "r92",
      "r159",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r690",
      "r816",
      "r907",
      "r909"
     ]
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid common stock issuance costs included in accounts payable and accrued liabilities",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt and Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gains (losses) in available for sale securities",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt Securities, Short-term Investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r846"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, term (less than)",
        "label": "Debt Securities, Available-for-Sale, Term",
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance cost",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r909"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance cost",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r906",
      "r907",
      "r909"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r188",
      "r196",
      "r206",
      "r660",
      "r661"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r363",
      "r394",
      "r395",
      "r398",
      "r676"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summary of Balances by Plan",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r47"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. corporate paper and bonds",
        "verboseLabel": "U.S. corporate paper and bonds",
        "label": "Debt Security, Corporate, US [Member]",
        "documentation": "Debt security issued by corporation domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r833",
      "r845",
      "r865"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r175",
      "r177",
      "r180",
      "r181",
      "r182",
      "r187",
      "r420",
      "r423",
      "r438",
      "r439",
      "r514",
      "r534",
      "r655"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r177",
      "r180",
      "r181",
      "r182",
      "r187",
      "r420",
      "r423",
      "r438",
      "r439",
      "r514",
      "r534",
      "r655"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r184"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r183",
      "r185",
      "r186"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee compensation and related taxes",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining weighted-average period for stock options and RSUs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized employee stock-based compensation costs related to unvested RSUs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized option employee stock-based compensation costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to Purchase Common Stock",
        "terseLabel": "Options to purchase common stock",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_EnableInjectionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "EnableInjectionsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enable Injections",
        "label": "Enable Injections [Member]",
        "documentation": "Enable Injections"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in share)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_EquityClassifiedWarrantsAcquiredOctober2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "EquityClassifiedWarrantsAcquiredOctober2020Member",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired October 2020",
        "label": "Equity-classified Warrants, Acquired October 2020 [Member]",
        "documentation": "Equity-classified Warrants, Acquired October 2020"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r120",
      "r139",
      "r140",
      "r141",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r171",
      "r173",
      "r189",
      "r246",
      "r247",
      "r262",
      "r335",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r472",
      "r530",
      "r547",
      "r548",
      "r549",
      "r564",
      "r625"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "vrdn_EquityclassifiedWarrantsIssuedFebruary2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "EquityclassifiedWarrantsIssuedFebruary2020Member",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued February 2020",
        "label": "Equity-classified Warrants, Issued February 2020 [Member]",
        "documentation": "Equity-classified Warrants, Issued February 2020 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_EquityclassifiedWarrantsIssuedNovember2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "EquityclassifiedWarrantsIssuedNovember2017Member",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued November 2017",
        "label": "Equity-classified Warrants, Issued November 2017 [Member]",
        "documentation": "Equity-classified Warrants, Issued November 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_EquityclassifiedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "EquityclassifiedWarrantsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subtotal",
        "label": "Equity-classified Warrants [Member]",
        "documentation": "Equity-classified Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r729",
      "r739",
      "r771"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r726",
      "r736",
      "r768"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r451",
      "r480",
      "r481",
      "r482",
      "r666",
      "r667",
      "r672",
      "r673",
      "r674",
      "r679",
      "r683"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r445",
      "r679",
      "r901",
      "r904"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r351",
      "r356",
      "r442",
      "r449",
      "r480",
      "r672",
      "r673",
      "r674",
      "r679"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r351",
      "r356",
      "r442",
      "r443",
      "r449",
      "r481",
      "r666",
      "r667",
      "r672",
      "r673",
      "r674",
      "r679"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r442",
      "r443",
      "r444",
      "r445",
      "r449",
      "r482",
      "r666",
      "r667",
      "r672",
      "r673",
      "r674",
      "r679",
      "r683"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r445",
      "r679",
      "r901",
      "r904"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r449",
      "r451",
      "r480",
      "r481",
      "r482",
      "r666",
      "r667",
      "r672",
      "r673",
      "r674",
      "r679",
      "r683"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r904"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "vrdn_FairmountFundsManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "FairmountFundsManagementMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount Funds Management",
        "label": "Fairmount Funds Management [Member]",
        "documentation": "Fairmount Funds Management"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r313",
      "r331",
      "r435",
      "r452",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r531",
      "r664",
      "r679",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r694",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r846",
      "r847",
      "r848",
      "r849",
      "r897",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENTS AND FAIR VALUE MEASUREMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "International corporate bond holdings",
        "terseLabel": "International corporate bond holdings",
        "label": "Debt Security, Corporate, Non-US [Member]",
        "documentation": "Debt security issued by corporation not domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r845",
      "r865"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "vrdn_FormerExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "FormerExecutiveOfficersMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Executive Officers",
        "label": "Former Executive Officers [Member]",
        "documentation": "Former Executive Officers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss on disposal of equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on debt extinguishment",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r39"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r609"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "vrdn_GoingConcernPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "GoingConcernPolicyPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern",
        "label": "Going Concern Policy [Policy Text Block]",
        "documentation": "Going Concern [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_HerculesTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "HerculesTermLoanMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hercules Loan and Security Agreement",
        "label": "Hercules Term Loan [Member]",
        "documentation": "Hercules Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_ImmunoGenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ImmunoGenIncMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ImmunoGen, Inc",
        "label": "ImmunoGen, Inc [Member]",
        "documentation": "ImmunoGen, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r85",
      "r680"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r86"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r269",
      "r270",
      "r446",
      "r447",
      "r450",
      "r544",
      "r546",
      "r610",
      "r648",
      "r682",
      "r925"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r446",
      "r447",
      "r450",
      "r544",
      "r546",
      "r610",
      "r648",
      "r682",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax penalties and interest expense",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r558"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unbilled revenue - related party",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue - related party",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r813"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r767",
      "r775",
      "r779",
      "r787"
     ]
    },
    "vrdn_InducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "InducementGrantsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Awards",
        "label": "Inducement Grants [Member]",
        "documentation": "Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r791"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r791"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r791"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest and other expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r812"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r149"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest payable",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r554",
      "r555",
      "r556",
      "r557",
      "r633",
      "r634"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under license agreement",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r798"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r798"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Right-of-Use Assets and Liabilities",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Lease Payments under Noncancelable Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remainder)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "vrdn_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of renewal terms (up to)",
        "label": "Lessee, Operating Lease, Number Of Renewal Terms",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r58",
      "r59",
      "r60",
      "r63",
      "r64",
      "r65",
      "r66",
      "r154",
      "r245",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r426",
      "r427",
      "r428",
      "r453",
      "r584",
      "r656",
      "r710",
      "r859",
      "r914",
      "r915"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r102",
      "r525",
      "r693",
      "r817",
      "r850",
      "r905"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r123",
      "r154",
      "r245",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r426",
      "r427",
      "r428",
      "r453",
      "r693",
      "r859",
      "r914",
      "r915"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_LiabilityClassifiedWarrantsIssuedApril2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "LiabilityClassifiedWarrantsIssuedApril2017Member",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSStockWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued April 2017",
        "label": "Liability-Classified Warrants, Issued April 2017 [Member]",
        "documentation": "Liability-Classified Warrants, Issued April 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r100",
      "r301",
      "r316",
      "r666",
      "r667",
      "r690",
      "r923"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current portion of long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r159",
      "r306"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r159",
      "r306"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remainder)",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "verboseLabel": "Long-term debt, net",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r37",
      "r852",
      "r853",
      "r854"
     ]
    },
    "vrdn_MassachusettsLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "MassachusettsLeaseMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts Lease",
        "label": "Massachusetts Lease [Member]",
        "documentation": "Massachusetts Lease"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r358",
      "r404",
      "r445",
      "r509",
      "r543",
      "r545",
      "r553",
      "r576",
      "r577",
      "r632",
      "r635",
      "r636",
      "r637",
      "r638",
      "r646",
      "r647",
      "r663",
      "r670",
      "r675",
      "r683",
      "r684",
      "r688",
      "r689",
      "r696",
      "r861",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r358",
      "r404",
      "r445",
      "r509",
      "r543",
      "r545",
      "r553",
      "r576",
      "r577",
      "r632",
      "r635",
      "r636",
      "r637",
      "r638",
      "r646",
      "r647",
      "r663",
      "r670",
      "r675",
      "r683",
      "r684",
      "r688",
      "r696",
      "r861",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r81",
      "r103",
      "r121",
      "r133",
      "r136",
      "r141",
      "r154",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r172",
      "r173",
      "r179",
      "r245",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r420",
      "r423",
      "r439",
      "r453",
      "r529",
      "r606",
      "r623",
      "r624",
      "r708",
      "r859"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements - To Be Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Non-Cash Lease Expense",
        "documentation": "Non-Cash Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r767",
      "r775"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of long-term debt",
        "label": "Notes Issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_NotesReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesReduction",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of long-term debt",
        "label": "Notes Reduction",
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r825"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r657",
      "r824",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "vrdn_OperatingLeaseAnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "OperatingLeaseAnnualBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, annual base rent",
        "label": "Operating Lease, Annual Base Rent",
        "documentation": "Operating Lease, Annual Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESFutureLeasePaymentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease, liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, short-term",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "vrdn_OperatingLeaseLiabilityCurrentDerecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "OperatingLeaseLiabilityCurrentDerecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability derecognized",
        "label": "Operating Lease, Liability, Current Derecognized",
        "documentation": "Operating Lease, Liability, Current Derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, liability, current, statement of financial position [Extensible List]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term lease obligation",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, liability, noncurrent, statement of financial position [Extensible List]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense relating to operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "vrdn_OperatingLeaseRightOfUseAssetDerecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "OperatingLeaseRightOfUseAssetDerecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset derecognized",
        "label": "Operating Lease, Right-Of-Use Asset Derecognized",
        "documentation": "Operating Lease, Right-Of-Use Asset Derecognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease remaining term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r692"
     ]
    },
    "vrdn_OperatingLeasesOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "OperatingLeasesOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expenses",
        "label": "Operating Leases, Operating Expense",
        "documentation": "Operating Leases, Operating Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERComponentsofAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in unrealized gain on investments",
        "terseLabel": "Change in unrealized (loss) gain on investments",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r97"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive gain",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r97",
      "r134",
      "r137",
      "r169"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities Disclosure [Abstract]",
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash items",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r734",
      "r744",
      "r776"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r734",
      "r744",
      "r776"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_ParagonTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ParagonTherapeuticsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon Therapeutics",
        "label": "Paragon Therapeutics [Member]",
        "documentation": "Paragon Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt extinguishment costs",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of short-term investments",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r144",
      "r212"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock",
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r701",
      "r704",
      "r705",
      "r706",
      "r707",
      "r954",
      "r956"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r319"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r586"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r319"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r586",
      "r604",
      "r956",
      "r957"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r521",
      "r693"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from the issuance of common stock, pursuant to January 2024 Public Offering, September 2024 Public Offering and September 2022 ATM Agreement",
        "terseLabel": "Proceeds from the issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of Series B preferred stock, pursuant to September 2024 Public Offering",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of long-term debt, net of costs",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r559"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from term loan",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock upon the exercise of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of short-term investments",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r832"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of short-term investments",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r144",
      "r212",
      "r244"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock upon the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock for cash under employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r511",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r650",
      "r671",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r857",
      "r858",
      "r864",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r511",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r650",
      "r671",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r857",
      "r858",
      "r864",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r470",
      "r515",
      "r528",
      "r693"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r113",
      "r116",
      "r527"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r350",
      "r358",
      "r389",
      "r390",
      "r391",
      "r404",
      "r445",
      "r483",
      "r492",
      "r509",
      "r543",
      "r545",
      "r553",
      "r576",
      "r577",
      "r632",
      "r635",
      "r636",
      "r637",
      "r638",
      "r646",
      "r647",
      "r663",
      "r670",
      "r675",
      "r683",
      "r684",
      "r688",
      "r689",
      "r696",
      "r702",
      "r855",
      "r861",
      "r901",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r275",
      "r276",
      "r350",
      "r358",
      "r389",
      "r390",
      "r391",
      "r404",
      "r445",
      "r483",
      "r492",
      "r509",
      "r543",
      "r545",
      "r553",
      "r576",
      "r577",
      "r632",
      "r635",
      "r636",
      "r637",
      "r638",
      "r646",
      "r647",
      "r663",
      "r670",
      "r675",
      "r683",
      "r684",
      "r688",
      "r689",
      "r696",
      "r702",
      "r855",
      "r861",
      "r901",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r726",
      "r736",
      "r768"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r357",
      "r473",
      "r474",
      "r519",
      "r526",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r603",
      "r605",
      "r631"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r473",
      "r474",
      "r475",
      "r476",
      "r519",
      "r526",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r603",
      "r605",
      "r631"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r357",
      "r473",
      "r474",
      "r519",
      "r526",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r603",
      "r605",
      "r631",
      "r913"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r292",
      "r321",
      "r476",
      "r493",
      "r516",
      "r652",
      "r653"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development (including related party expenses of $7,725 and $10,937 during the three and nine months ended September 30, 2024, respectively, and $1,099 and $6,521 during the three and nine months ended September 30, 2023, respectively.)",
        "verboseLabel": "Research and development - related party expense",
        "netLabel": "Research and development costs",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r727",
      "r737",
      "r769"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r728",
      "r738",
      "r770"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r735",
      "r745",
      "r777"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units Outstanding",
        "verboseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r93",
      "r524",
      "r550",
      "r552",
      "r563",
      "r587",
      "r693"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r171",
      "r173",
      "r246",
      "r247",
      "r262",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r429",
      "r431",
      "r432",
      "r434",
      "r437",
      "r462",
      "r463",
      "r547",
      "r549",
      "r564",
      "r956"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue - related party",
        "netLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r188",
      "r193",
      "r194",
      "r204",
      "r206",
      "r208",
      "r209",
      "r210",
      "r347",
      "r348",
      "r511"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r649"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_SaleOfStockWeightedAverageSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "SaleOfStockWeightedAverageSharePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average share price (in dollars per share)",
        "label": "Sale Of Stock, Weighted Average Share Price",
        "documentation": "Sale Of Stock, Weighted Average Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_SaleofStockCommissionFeePercentageofGrossSaleProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "SaleofStockCommissionFeePercentageofGrossSaleProceeds",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commission fee percent",
        "label": "Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds",
        "documentation": "Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/ACCRUEDLIABILITIESANDOTHERTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Accrued Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails",
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r42",
      "r45",
      "r54",
      "r91",
      "r92",
      "r666",
      "r668",
      "r818",
      "r907"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONAllocationofSharebasedCompensationExpenseonStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Principal Payments of Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r470"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r362",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Restricted Stock Units",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r94"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Assumptions for Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r89",
      "r91",
      "r92",
      "r93",
      "r128",
      "r129",
      "r130",
      "r190",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r331",
      "r333",
      "r559",
      "r560",
      "r561",
      "r562",
      "r670",
      "r797",
      "r815"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/WARRANTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofFuturePrincipalPaymentsDetails",
      "http://www.viridiantherapeutics.com/role/DEBTScheduleofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r207",
      "r209",
      "r658",
      "r659",
      "r662"
     ]
    },
    "vrdn_September2022AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "September2022AtTheMarketOfferingMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 At The Market Offering",
        "label": "September 2022 At The Market Offering [Member]",
        "documentation": "September 2022 At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_SeriesAPreferredStockConversionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "SeriesAPreferredStockConversionMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock Conversion",
        "label": "Series A Preferred Stock Conversion [Member]",
        "documentation": "Series A Preferred Stock Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A Preferred Stock",
        "terseLabel": "Series A Preferred Stock (as converted to shares of common stock)",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r863"
     ]
    },
    "vrdn_SeriesBPreferredStockConversionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "SeriesBPreferredStockConversionMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock Conversion",
        "label": "Series B Preferred Stock Conversion [Member]",
        "documentation": "Series B Preferred Stock Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/NETLOSSPERSHAREScheduleofPotentialDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series B Preferred Stock",
        "terseLabel": "Series B Preferred Stock (as converted to shares of common stock)",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r863"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, acceleration of vesting",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units outstanding (in shares)",
        "periodStartLabel": "Nonvested beginning balance (in shares)",
        "periodEndLabel": "Nonvested ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r362",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized for plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term and Aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value per option (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (Aggregate Intrinsic Value)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (Aggregate Intrinsic Value)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest (Aggregate Intrinsic Value)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested or expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan modification costs",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONBalancebyPlanDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONSummaryofRSUActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Vesting Period",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Vesting Period",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r367",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r399",
      "r400",
      "r401",
      "r402"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONFairValueAssumptionforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term, in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (Aggregate Intrinsic Value)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (Weighted Average Remaining Contractual Term)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (Weighted Average Remaining Contractual Term)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (Weighted Average Remaining Contractual Term)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested or expected to vest (Weighted Average Remaining Contractual Term)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock, percentage of fair market value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments:",
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r151"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r128",
      "r129",
      "r130",
      "r154",
      "r177",
      "r178",
      "r180",
      "r182",
      "r190",
      "r191",
      "r245",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r319",
      "r320",
      "r323",
      "r326",
      "r333",
      "r453",
      "r559",
      "r560",
      "r561",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r586",
      "r607",
      "r625",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r797",
      "r815",
      "r823"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r68",
      "r71",
      "r72",
      "r120",
      "r139",
      "r140",
      "r141",
      "r160",
      "r161",
      "r162",
      "r164",
      "r169",
      "r171",
      "r173",
      "r189",
      "r246",
      "r247",
      "r262",
      "r335",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r463",
      "r472",
      "r530",
      "r547",
      "r548",
      "r549",
      "r564",
      "r625"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r189",
      "r463",
      "r511",
      "r554",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r625",
      "r703"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r189",
      "r211",
      "r463",
      "r511",
      "r554",
      "r575",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r608",
      "r609",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r625",
      "r703"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon the conversion of convertible preferred stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r68",
      "r71",
      "r93",
      "r305"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under license agreement (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r93",
      "r559",
      "r625",
      "r640"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for exercises of stock options (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r93",
      "r373"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon the conversion of convertible preferred stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r68",
      "r71",
      "r72",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under license agreement",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r93",
      "r564",
      "r625",
      "r640",
      "r709"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for exercises of stock options",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r67",
      "r68",
      "r93"
     ]
    },
    "vrdn_StockIssuedDuringPeriodValueWarrantsExercisedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedShares",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercises of warrants (in shares)",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Shares",
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "vrdn_StockIssuedDuringPeriodValueWarrantsExercisedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedValue",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercises of warrants",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Value",
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r84",
      "r588",
      "r604",
      "r626",
      "r627",
      "r693",
      "r710",
      "r817",
      "r850",
      "r905",
      "r956"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCK",
      "http://www.viridiantherapeutics.com/role/WARRANTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CAPITAL STOCK",
        "verboseLabel": "WARRANTS",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r153",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r335",
      "r436",
      "r628",
      "r630",
      "r644"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r629"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "vrdn_ThirdPartyCollaboratorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ThirdPartyCollaboratorMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Party Collaborator",
        "label": "Third Party Collaborator [Member]",
        "documentation": "Third Party Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r912"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r313",
      "r331",
      "r435",
      "r452",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r531",
      "r679",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r694",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r846",
      "r847",
      "r848",
      "r849",
      "r897",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSDebtSecuritiesAvailableforsaleDetails",
      "http://www.viridiantherapeutics.com/role/INVESTMENTSANDFAIRVALUEMEASUREMENTSFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. treasury securities",
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r672",
      "r674",
      "r679",
      "r922"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r410",
      "r678"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r109",
      "r111",
      "r114",
      "r115"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "vrdn_ViridianMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ViridianMergerMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CAPITALSTOCKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Viridian Merger",
        "label": "Viridian Merger [Member]",
        "documentation": "Viridian Merger"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "vrdn_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants Policy [Policy Text Block]",
        "documentation": "Warrants Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used to compute diluted net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r182"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used to compute basic net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r182"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "vrdn_ZenasBioPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.viridiantherapeutics.com/20240930",
     "localname": "ZenasBioPharmaMember",
     "presentation": [
      "http://www.viridiantherapeutics.com/role/COLLABORATIONAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zenas BioPharma",
        "label": "Zenas BioPharma [Member]",
        "documentation": "Zenas BioPharma"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001590750-24-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001590750-24-000023-xbrl.zip
M4$L#!!0    ( .\Y;%FE:[O3WP<  /\K   1    97@S,3%?,C R-"TP.2YH
M=&WM6EUSVS86?=]?@;5G4WM&DD59MFS9R4R:N#-^V+1-/>WC#D1>FEB3! N
MDM5?O^<"U(<M.94WWJC:<68BB\3%Q05P<.X!A,O,%?F[RXQD\NYOEW]OM\5'
M'=<%E4[$AJ2C1-16E;?BMX3LG6BW&ZL/NIH:=9LYT>OV^N(W;>[46(9RIUQ.
M[V9^+H_"\^61;^1RI)/IN\M$C85*WNZIP8#.!_'I\:!_=M*/9"Q'YVDT.$]2
M&IUUHY/3?T5[J KS4,>Z:4YO]PI5MC/B]H?]7F=P4KF+B4I<-HRZW7_L>=-W
MEZDN'=HSJ!^^!C<KSAS=N[;,U6TY]%W:"U5GQ;'.M1GN=_V_"RYII[)0^73X
MW8TJR(I/-!&?=2'+[UI6EK9MR:@T&%KU!R$FA.<?)R'D ?SDJJ19%Z(>!WUU
MGZF1<N(XZD0/(]YFK/VUL;[9CTZ[%YM$&0,"9+8TI!^N/M]<_W#]X?W-]8^?
M-HGVW[5U*IW^Y4=UNW%>M\0OCJJ,2O%/F>F2IBT1D^&(A,ND>[-_<K8#W7CV
M<%_X5ZI,@.EAK]<![6PI]*@3@E_^%-<BDV,2AL:*)B!NERDK?JZEP0+,I^(S
M5=HXH4OQ@S:%B+KMGUM"FV!F?"&>4_&K,BI1LA0W&1E94>U4;%OBNHP[+2'%
M1\KE1!H2L3:H(YW2)2;\?#<'<H<QT%N'@>^EQ<QCCHNIN"OU)*?DEEK+<RP2
MC1A*C02/)J0JA2RGHBZ=J0E=0,KWV1] D*+ DU$R%ZF,'6-%%TA03@>[%8.2
M8K)6FBF;%/*.T.Z23XMW"8)!D[F7#FB##6)E(!5@5J(Z(DG(B$FFXDS8FC\6
M]2<$W 4GW(%"V1R:@N7)1+D,';05Q3Y ]ELA-)V@FV-42\1HNCP,KY#=0NC'
MSX(LB525  7C:P$"<% )<Q2;I7)5IB U3T;X'N=U I\ V@-R2Z5B(JR $X8X
M0S_/%QANX&,?-8UEDBAVW&*+.H<!@*N!+M^<]?'$TF8BS?7$SE!MZ%999R0:
MDOPRQ(TH6TO@M+-@5J)]Q>>W#3WJ(?3^.GS>/)C,-_MGO6AP81L$-K*'*4BG
MJ<*CG^9KP1F2 06 J%%.//&"@.)1KFS&YFQ6@'Z9@ODY43;.M:U]9@4;ZSP@
MJS(ZI@2OK3@ D!(",@-:KN[C3):W)-Z#\S[7.2RB8^D#C"ZBDP,Z] ZBDV3Y
M77BI6)67 =W<EF"27 )] "''M5&C;;A.Y\V%IT/?Y\=+ 1:L4IXK$1]@Y/AT
M1\%]TM]:X ?R$-+-(C+,H\^K?PXX+P]C6=O-JW#N'1$ T[04LKFN#1R \L;*
M>B*%%97>#^\7%A2\3.,&0M,CL$GG"Q2U&HKG0@4Z1BQ6YRKQQQ6V'EG6KT9Q
M!U00'3ZQE.RIMBP$_.*U7C5XVM66$) #S7.E"I)9Q74N.5N@6SZ(A:! C2!/
MEE45OHV(#4'HJ$_)5Q'X%H&RNP@?/4;XQB2W O3-Z7%CO&.-C%7",)96EY)S
M@K18 JQZ&=O2)#.< ?E*CE2NW)35Q+IF>=5Y2'JTA07SP'1)-?O4<]]TJ*JQ
M:[,8=58_,?9PB0_ Z^=;*B%J<H >)53Q:F(3[ T"L+'J5 7&?X7V-]8E!_&A
MN!K+O/8,Q_-.:0JIJL:8,;M&<LY5R@:,'1[7JU"/9%0$V]J@=4>Z=D]'L$E.
MD7-K8B&?_OE>38QF6P2_."F,Q.S<@1O8K3G=<3 FX-DPSZMXX;.$1B#ZDK6@
M? :[LCK0<5P;1L52*E[CM=#6X3T?.,.7C>'H]W#X)0Z>J)("WN"]1]9-X-C2
MD3\&X1.2LI['=1BBRJ2=ZQ9F3+\<*/&IQ(]'0_-3D:L[RILSD4?VK:\>HO]F
M">PDXK>Z,3QYN8VA/Z--9NNGM> VIMIE#"]HCE'X#"VSHI?GH4EH9J>-G<L'
M_P(NBT(Y1_2%1#+2$"A<GBC$YYT< .G@;<MY 7]9N<^6)_U>*X3OEV)=QOZ<
MY/"K]GS1V2M3/YNIL>=[GT,+(C8%#/(&G+?RL2* IDG]\[W7A.0=Y_*@#7TV
M]ZK6G_O.3KN>!<5FFQ2.0M;0H4Q0T=*<#9^$;:.%4078@V1M!4%AH29L7138
MZ_U!OC--%EI[+O@J%K8!06S*WD,3I 94TP(@R+,C(.4/\!OLM4)*5>58YV/B
MO%K*V^9W"-,0*A55KJ>$TDFF XO*!\@&$E]$='16AODO.>= _:TJVTY70[[^
ML.XG=^=WF8W]".N&3!O1Y[*R-)Q]N4 NJG(Y':K2Q^ K733>1]HY7?@&QIS0
M().:1GQ[H;BY>G%^TNF?#OCVA3/XG\P:;BYF=/S%C".7K);U!IW>\=/%W4[T
M9-F7W$:GG5ZW_^)NCSMGW9</MG_6.3X]W<CMD1_?,,:815O)\NW>\=ZL0B43
M/DD8]JI[$3U$1D[IRD06*DER^O;TX,?P(PC RP+Q"<NQ&&%%1KV6OU,T!WXS
M'%_H:9?[N;>1Z8:#$H"]I4'Y?OI0*?U_].K-?A\T[#\?WQYYT-,-T?V,.7]9
MTX9'F7=A*_S!LY@-WRY-R"Y/PBZ-\T\&,IIU6$M\R!2EXNJ>XII/SL2/2SO#
MC\V^ZG4>_D?S</!3.,"&UEN9@</543_R0FA%!:ZY4+HDRA[=2:VT]3<'AN&W
MK#&MW%)=L(H76MU%%3D"M=3NZ2I/7;)\\LIK\QDNX![YB[__ 5!+ P04
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M[M7/PU)(*]OS*CQ!;*K<XU4>NVC]Z"7]^G?\DX&#\*<*_P502P,$%     @
M[SEL6>)_*6%/!@  (R0  !$   !E>#,R,5\R,#(T+3 Y+FAT;>U:66_C-A!^
M[Z^8)NAN MB.9#N7[0VPR('FH7LE[3X6E#BRV)5(+4G%<7]]AY1D.W;2)MO-
MM4@0!)$XQS?#X?EIE-H\.QBER/C!3Z.?VVTX4G&9H[00:V06.91&R#%\YFB^
M0+M=2QVJ8JK%.+70#;I]^*ST%W'!JG8K;(8'C9W15O4\VO).1I'BTX,1%Q<@
M^)LUP7>PG^Q&P3[NQ'T6=/<Y[B88=7G Z3G:^3-<(U42KW2,G6;X9BT7LIVB
M\S_H=SN[VX4=3@2WZ2 ,@E_6O.C!*%'2DC]-^M6_E9D58Q8O;9ME8BP'/J2U
M2K5ICE6F]& ]\#]#U]).6"ZRZ>#UN<C1P#N<P">5,_FZ99@T;8-:))6@$7\C
M82)X_G%20=XE.YF0V(00=AWHX\M41,)"K]L)KR)^3*S]:[&^6@]W@N%M4,94
M J@?*:5GQX?GI^_?0=C;#N#P^-/YZ<GIX5OWZ@E!_[\9_JLT5B331\)YS.(4
M5 (V12@E1VT($_(6G%DL4I3P&TN5Q&D+#E.!"1Q?8EQ:<8'P/DE$C-HI_R&T
MX()).$]1LP))(#8M.)5QIP4,CC!C$Z818J4+I9D52L*&\_AJ?:_;#8:'*B^8
MG/JG<+A).I+#&=H4?F4Z5Y+0H!1*DZ,8X8-&([B;XLCUB9!,TDNG\3:.52FM
MF^[JB&K#+> *"!I&4R#(+MTM*$IM2D96K()P#W[OG'4..^0H]O!\R3$#C*O"
MS:*+THW,?K#3.#IC.F(23?O]98930N+!=8.@VZ)V9EM.SPE&:'Q3*@Q\D6J2
M(1\C;(2;OO5CR335;#:%3TB9(DD))TKG$ ;MCTM!04()<<]?9TH%U8#B@-2/
M+G\$/(]05Z78"UI^KF^YJ!)!?F$B*,,>/?6I%E906;D\'E_&*9-C[RD7QKA8
MZ==)<EI2?"8)RV(/5G#G'9B4&>&)"6GFK,X\:?Q:"HUN83$NGGFZ-]@F4$#A
M]@;?G&5UCFN&J4YMN-^K0F&Y#[>JF8UNE4<A*3EY56@QC0%&=<_IK6^L4YLP
MX7-&U>30M%PSRS(@-4HCRPBK*0B>:7FMQ!>:>T\&N?"FG4N2*K,J&$7Y]S[-
M4E=UJB[XUCGAFD7P/V8\RZ(,&X%(:1K7;9I1,E88'#3_#+DP1<:F R']O."5
MACG38UJ=(V6MR@=N9;YP(R9F6>W$^ZN:YXMV)Z@6;DM +6\\U\T=W[1E^6I;
MM]?9#VYN#CKAC6WW9/;?VFAE[^U_=[#]G<[VSNT ;?G\5CFF;C147&_6>FN-
M0L$XI]EO$$!8V 5[#R[:+2Z=\'"A-C-,5DJIJJ*'7_F":H7N[PZ-_[N\V,W&
MVG/(>3V\K2H&) M&98)#D[[GU"'/N1.>4YYG^Z>;]W1N83NB=3JV2K_TPSWU
MP\8'+6A'4="68J4'-G_DK.>"\PP?*>M'M+U[M;Z]-X1WZL+OCR'L5EOCZW+>
MP&ML]'TNGG@_7!&]9?$\AQ&SM('^,::!.P=UC]/@[-[M 9,0=I<W8_.#_]+-
MWTLY_X!!/=86]]%J_:6^7X)Z">H!SI-WNS/^D7?<3^6<<S*[1*W/.;03WQ_"
M7&#A"O_E)/243D);_G9XX?KYCE?3]\YR>8L#8<E=? O>Z]P1,!471/U1W>;'
ML;^N;V@0$HC056+-<22EEL*DR&N:HV$U2*ZB%%I@4L<@2&5)$SABCGRF[2B7
M1C.:KC Y1:D+9? J*[+W34P(65.DI"?"()@R^HO,.?XI$RP2F;#3BNGSQ-3,
MEXOX.OBD%SE"I>'NZ!6AUYB@1C>)"DD2/@@RO<*\S3Q="6&.O+>"_,[13E)T
MP4+.N*/7*)?H[+#$UHX]9^5A+?24T#6]XRY=J-%A':-$39/0/%B7F(S<EVR,
M5XDD4\9I'7('WD+%FI)?,:8I+INYFU 8%DG<$@C_64;-@/DL+A")\UX#WGS!
MP4IZEM;7IQQ3U''#&/K'*]WL>4J7?Q>Q0\-L28GP7<R* IDVGO^:%N3:D6.^
M>FM&##,"HI44,5PX!MCQ?7</(&5NP)!LH=6%X%7M+-:"*[&)H J+'!%8YW)I
M*#B9V4!K#-R&G]0@K'$PDP3*@MXXG&ALYWOS;4O?K="@]63@0&/&7#6M?,DR
M/\5X2BV8J["(CC*EO5GEIJ\9;OPLIOY;?:2SY3\.^@=02P,$%     @ [SEL
M60\ A*(C)@  CVT! !X   !E>&AI8FET,3 Q7V)I+7=A=&-H9F%C=&]R>2YH
M=&WM7>ESVSBR__[^"KQD=\:NDC6Z+-OQ[%0Y/EZ\E:MLSV3GTQ9$018W%,GA
M85O[U[_N!L!+I$3Y$"F'6[-)))$@V&C\^F[\.@UFUF^_3@4?__8_O_[OWAX[
M<XQP)NR &9[@@1BST#?M6_9M+/SO;&]/777JN'//O)T&K-?I#=@WQ_MNWG'Y
M>V &EOA-C_/K+_+SK[_00WX=.>/Y;[^.S3MFCO_QQNP81X>&<33LC\>#P6AX
M<#0X$L+8[PDACHS!X=&_NV_@5KA<WN,'<TO\X\W,M/>F I__[J#G!L?WYCB8
MONMV.G]_D[HN$ _!'K?,6_L=S19^G3CP;NIGP[$<[]W;#OWO&'_9F_"9:<W?
M_7QCSH3//HM[=N7,N/USR^>VO^<+SYS("WWSO^)=%Q].'^_5;& <R[2%GEVW
MAU,Z?YB:(S-@W4Z[^^LO>+U^IX4W2\S8 .H)[]FGW"TQY6.:QE@8CL<#T['?
MA?98>'C5F]\N+B]N/K"33^>?S^#_-^SF"_MX?G)]GGZQ$J\$O.#]MG#7LM]R
M1OQ/Z ?F9/[B5!KD+NQ/;[O#SO'BGS=3TV=Z^IM?OM6+5 6QV$Z 9/GI;7]P
M7"5M3@"6QA*:JB,&46&7 3UF?"P8]YDS8<%4L.[1BTSKH-W=+S&Q8]?Q3=KQ
MGK!@Z]^)X\!QW^WUVX=X^YWP M/@EMI\(^X+"0K!M%+. MI="S<0LY'P6E(D
M[2 Q?WI[V.MU*N6V\\E$&$A(=@;BM%J6 V)T@>E&<\;M,1N)X%X(NU*<^G9R
M<_J!G5[>_,G^ )SZ_>K\FGVZ81\_5DFHTQ;C[!/W?6Y,0U\$@<\L<V:B,F29
M?&1:9C!GAC-SN3UOL2F_0P6)VXR/QY[P?<9!>?KI[>#@V&'OA?==6&+.+NT[
MX0>(.GX+/ACM%NOV]MD'>"R[#CPA@A:[#N$9;+_?;;'WCA\X=BLSBTZOV^VP
MG1IP]4=@('C2N [\W")NKI(:?UQ>79Y=GGQF-Q_.KTZ^GO]^<WEZ#<O\^;1=
M)8&0C<\ QN^Y)X!?/5=I<P4\"\1DI_ !E;0,3PXZP)/?N!5,^:S%%KARL-^O
M!5?>")M7+=8CGO29'QH&T-;QF&G#?Z#Y @2PP&%_F)XY-CDLQ,>/ZX!-+8BL
M)X]SKP.IV^N;"5MN752Y^E?G%^=7YY]/J[4DM-H,>XDS Y12#COLHP!UM,7&
MY+7X)[=#[LU9MT_Z8">K]&@!1E\F61HWKL019+#NP;'/7$^ *;RPDUO,#3T_
MA"MQ'@"-0325$]\']B$W"HY_ZM@^_OOD%D"5OB4[&*8)8SG1G%!CU?-JJ4FD
MYJ?P0KYAI/"RWH%\1P(=CM8-_ SOFYK2A>D!^$2V#TZ9"*;I%5IS-J1QNC3.
M)/1@/E[A>-?"<&!JA0.>N)YI:?+W2@T)5K.W9$2:8N\H&A">7F+0"P<O6#7/
MPYI9#=E9*UZL<M/MLIV8O5JL)H2BI:R#&&(30 ?-=( 8,].'A\ >\4V0(:!L
M@8W*7==S'LP9,!ZP<K?3&O0.F ?+RT>68/Y?(2IJ$]"[F"/18$*;=J?K!S"^
MY< 38)3WH6F-842?O>T>TC9XVSV2"L?4N;?Q'U)KZW;Z)WHDUT)E+PA RP"F
M)[P2:A_ ]=I!>;+7;==G$R3>XJLB: U6FL$JU(1 7SSSUK2Y52?R[+;9RRMD
MTC]M A+9P;O^T'U^QWY)]P78>^<GU]4:>4I1& O?!+4$][9X$)X!_,!,L"9D
MF 9P0X*))R:A#RP#EUER^Y,12$X_^#H-4;W6P>%A*83:1J>E7ZFIF(/H[*U2
MXA:!_'TND+_,_+-!K0(E'+0N@0KX2T4ZRL36E@6JDD)MOU)*O;Q +1>'Q&%>
M5E24(\@F)6DYRB3V68T(M%NM/-\_.FY\*S^:-I%RC&@?A/'==NXM,;X5TKBV
MG6"*\@K,&[1WR)'!*+H;V]G^E%L6&X&=C3X/LCEFSAA6G*$G4T4[ ^'-?'H4
M>A-(B$>1T 7+_=Z$CZ#BN,(@,[[*M=KAE6[.K(M*JW)CYAA&Z'+;B$B<8T6U
MJB7=:'=#S\^G'1(E*0G9%3+7J3,#)C.D>PY#M>3N(&Y')D67XUA,8EY?Y,_=
M!0:M)_F-:CF7E%@^)SICW'Z1/NP],C.N2L64&E=+*0W%L2,Z)EN&M1107\[
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MMDI7ZL!B[#K.71?,?#H)PB[5S@6/D5#]D<;"$KHQM"=<BQOP(6H.%HFRRAK
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M9F*)7:*##A"&'KXN@5;39UGF)DXR#09?//.6YA;1ZSKT/*R]]%0G@D3VB<Q
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MEA?7(H/'@=,!)T=!IELJ[F@=\.^/%5EFL^"-A(]%(4.P%&_1/4DJLMRR*%F
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M#RH2S/-, JSV7;D*@?R<<"C1OLKI#]^?_/CZLOTF:);; $'N:X#@_/--,DU
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MD8_U/T'>95;RWV4-XZ6-C;PXX)-4*NX:R:(B!AQ-UX,*.4T^21TE9:*L^R9
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M8Z9?O5B A8H&@], R>''"XPQE!2 HA_KC<"V38&#+,TWSL-'7^Q;^6+'N@N
M4EO!7W'V.:>J@LJC<_8H^G#$+[8GA7.+'JE"Y@ !73//X9"O4\G9%W11L*CZ
M1L[1^E? W22+U#YA9:=_HXD_P'"F&FV"!DX3<JHT$#&F@M22.GY?9S#@6%6'
M$M@WN!4I^%!T;_U#4(9D_NJG[,Z^&,&!G7WA2;!B#(T.D)=1QS'*P'CP/HJ"
M&0&"/0J&2T9\T#)\]M[E11K?)?$.'6PC"J\C=];/]$?R"( GBY(]5&6@.33_
M#ENV<4>Q "RSQ-D8K%3=PGNNWL[T]8\CS&V-^'*@VP<A'HVT)S?2MK=SXK'O
M9^8(V6M/RN\??= R?M#V-(HF?9@66]C2K.<$>^!T#K>.!,6"L,O&(B]+2:%O
M5>ZI;/!$\:(I0.Z'6A95'EPF4;X[NWI$PK4GQ<F6>R/'7<2'</$>*O$>8J$S
M9?E="@:,G"++ >7P0^;SFVLL!6Z'N:"J$_KEOF)J(*B(ZI'7HI4.]M#$WHBA
M61-D*J@\VD/8A9*"MD4A*]AAMV*:+H-4+# M"S>>2CEVK7)>WL>ZTWZE-I .
M$U,0TCQ#RD5,88J,R1D+>9M_P@]C&9,LFDK&!65$==\U%'J\#$DII_LL?C<R
M15)8(B</4?X1ZQ!)0F/!=2C"O!7HD^F2^060%+W!;*"I$#2%@B4?0,H0WDM<
MM>VD99'B9%&0YTH !;-Q<--*^LT?=9&4\%)<#L-UES=YRLBPF4I*X.O)B$C=
M,4$"'XM4;6=XAA2I?AO];Y@@U#$*?T:UF@(Q85C%F=/ X**'GWL^''*O1O!E
MYY#3X9(+6)\Y&DA^6&VCRSR RWQL7.:M@A7X;EN_&N&#*]7.V']NU#V44SUA
MGE>WPFVZ77JHI88BD&M9?'.ET[^_3B^O+LY^/0\N+KY0B0XZ^E\OSL[??3S_
MR!#WJ_.S_WSW_M?W?_V?X.KR]-W'M^>7NW$R'$^>Z&#HF^56F_-#G(75^,)M
MV'^;K/;+D\%6>T6W^R',@.,C;&J_3B$K21ATV8./]?0/IZ[)H09RRY[=&)?7
MAW-P/'D6[&$Q07%KJG0N\0[E_J '7&@RXABE@U-7@<9=<#?U#;$(D# HN&KO
M8"I%00$'(JPHDUL9[,E;F2$K%-Q WUF'V&TCZWW&DM,W"IG>IK#A"PA6:<#K
MU4V1U]<WS%.Y0/AG0F1W7*RA'F?(\!(\Q;"\+>$AM*ES3/W'E8QN,ICO:U57
MQ6U+UKYPEF<']J4]>)E?1/3I&FX(7UU\<,K#DM:[."-8.<A975 <ZC$'V^0<
MNO@0=MN[F'XQ:MC[5-*@.994Y'HN/L'_WHA;+$V+%2]OB"$T&,=,%:>I"\H\
MQ1XL<R2&01G%_]+M*<QVEY14-I?F2=7'LQ*VV](DB@A44W/H,LVW"8<*=0MV
MAF[Q&GSCK4UW_"FIX-"+-MCL1-L:8Z3S)K]#JI%P2-7#8<TLKS#D6%8B,Y)H
M.BTRD&=I._!PA\I X;;5)F 62TQ]8%)!JRTCC<V]JB5:DS&[3XM2@26.)(8E
M>J6>K1_,U: +QOI"-K6%*@I=((\HAK'[5=*WV,HZ8-[8R3V;%A9?+HPI01U&
M*T;KKQCKG2C=5EBQXXVB;LM7]+12-8/$,]ZL&B0><)ZJ-S+%4F",O%-B68O@
M'/_F.#X-S;TNN,-><GKW-JN^X%=XMG;GELXIF#P4;#N_]"E-,7[>F&4*=SCS
MK$YV]6?O;./GW0F'7Z$1D*"UEK=>65=CTLZ&E\(:[1C+T?N7PM9JP)),976'
MJ1F'6(\+TYR#RA@M!;7Q@ >NW^@)E8X8]:"&WDZTZL7?8_J\P4-H'ICH*F"V
MO]I#:[@=Z'SYDR\$@?+('SL\7N^0O8,#[(PS?\,Z968;@,:1Z8QM*9?FKFWE
M\R'J'%L=(?%')([\$8EC$HGO_F*5^ALFO@^#WRP? ZI0RQL!SW*]X5+*3T%/
M[Q!4@OOAUT55AEJAX]X5FIKSXD"-9$;_]WK0I=.EU;)Y;HJR3,JJ4]2=9.8
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M97E>H4A/'D&(_]P3^S2*8ISC;9CC45VWU?6_4Q!\ [*>R:OG!N_2$Z1_[)*
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MO5/2@N&@"U5LH%])\CI&Z-#0J/A7<%DB9[T5Q<UZ=+6XQ.O">&O52AQ?4XF
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MCZJ G-45J2'>V[KK&8I%2KJ"L4),-X&]5G""EYTV*Y.65=-A]VJ0--$84#^
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MK^"(LAI_9SC17SY1?J6_KJ$)0#+FN7)@M[?6N=HH8-+L'67@F;T!VBYUF()
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M0;V MUXH4XU>K^<*I(IB-AAFQ:"(1Z0X5-5[]I>%V>[;-2@JF)B(O)D<FW"
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ME].(A%U@Q'<;6I\D-\B<I ]DDA;Z0Y]5F@"MZ+.A(/AU$,T=96L#D5TU!1O
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MYQ29K'CU[SCKOPO,5HO?RSL^/-[M;-Z;XQ^[U)S#Y@%C1<OU5)U-!55;%('
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MA-/&=&IP@X&?9HO[5*;;M$W3C:QK?^YKKK4RWQF-,++R;#FL?FF'O XRR4/
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M=>M66ZDW?T$3]8]),KN#_[O.%]&__C]02P,$%     @ [SEL6>6Z@#ZW4@(
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M#(J37IPHH>LG$#3*L#YP3CZ70- XZ?6"$CH[ D&C#'GZ\^'&2:>D2VC>BW-
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M$2)W@GP5+@^W@<[WQ"?/GOLTH#X9T2BTS3V4R<ZOQF?5;&RH7M0R75.XO)B
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MJK'\IU6W.M"DM+6W^LC)%9.,<07X_7-%KZ2#1\0"W^92D53F$WW<-$P;O<'
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MO.U#N+*Z\^^9,6:*:9)E5RKM[YVBWN3>8Q;?^7_V*'8'DD>H+%33C%KV,$T
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M;<1KA8P1O.Y4EO[*K*\JC8@OO1 GHK 2+ 6#=0GCC0*TEC]KF)!-M);>?5L
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M1,**F&(RH0. Q08'4[K)CS?&K&[K@!S>&X?'NDV*0LYK><P[.?X1/L2<E2<
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M'GT]N3$;F?/>*YR^S'L441 /+X@^E :NVVP:LXHN\ZJ@2,5^F10J+LCBS.;
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MS%((IEZP9!I;2N:6\U@CFK5*6[]H+>YK.[YHGL/QK__B?U"K2MBLR#.-8^A
MB@)J2:''WGLX8IQ;C*FA,'8N\B[BW-AR5][$Q%L? RKSLI*RH!-SX#:"(PKO
M^EQN@KLH#$)&=D:;1):SY$RGQ*M^H.DF$KXPZ]P3AMTU==G0%%E9T@)HR1>[
M@V[79-Y)@E8[(FC7)5N*G&YAH&U5VH8NUVN&7&MD,&5[ ^V9;:5>@87C(;>^
M+A=1X&R+ FY=9=I6EYN*(C>RA$?8;. T)$0_HHBL2PH4.=W"9$3GREVI-9B"
M%U9&"EEU%K49&%XO1#,UH2/9*Q:I^G1 W<!^H3PRW:XA8,&Q 5Y?T/7G5,V
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M5?V3^MXR!5T;HTH0%7WH;5[C%I*"Y(-EZ?\2-R+^.VSY,J3[J.?8IG37[U.
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M3U-47IC07./_+T_PG>0* *[/('>P!!)YB!)6<N[LYH0(QY><^41=/T8^D7E
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M&RAA*&&EEK!< I:EY_IN<@6'2&HM6=>;POM_9[!]9.6Q7]&(?0P'% #"YAL
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M7()[YA'D+@=4:[P/2;-65&<@!!JJ@3/FSJ%2<BLUP++HKEYIZUI11SX@A%#
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M#ZJCMAC>G@4?M9_UR6#5&A:\ UIMP)F;E4&[VNDW2X)9[TGQO?/<"[)K;'3
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MBU%"A4DWYB.2F5'HV=-IY"8P(P0<F1$BH^V.'7/*:UKI2#8?F^/Y0UL G1'
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M,Q:(4F<2;R9;3$A#@GHV\JI=N:U\NR2;X\E;</#XU(J"3NQ/8X]X3'6Q$C1
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MO$9,6DZJL)+:*Y**MGAQZF+5=]C86W)F^MS5):4M+^C"?<6EZC&X5'V!]^#
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MK3F7KY\"EG->$U\,[I+)+^"6Y"UO<HOQC7,#62PRQ$R]&29-2FMZ]3*I_B$
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M.)=&4DBU4U*V[5L7Z)68)Z5L2O=<I?TV']S#C[PJ'U/I@((D'(WB>D=X%7>
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M\VHE/\P?K++,5>_PPE33%08 GSB]Z//C%0F438:>'I+Y8V8)IQE\0ZPCS6&
M+\<%W$DZ>O8I&O>P\$;938&:D=DXXIVW4Q"N)%B1\P1!X LCHNC8(N>*OYB
MEH 1GH]/0F896$3SV-@$6SDP)LP1,VK16LH]6?JMEL?XGH?,P?8MAM((2?$_
M16X48%A:O6?ADJ3R8#[!7/T6Q),WLN/Y0&I'[*'I_L%+8/@ 1RPYV" Q6 >Z
M4X'NK@YTEV OAPYTYPT9J5]TMPUT/XC6BIA8&5ZY%@9\9RN#?5L.5BR-I)<G
MY0.ZY3%/4E-.%;F0(XU+BYEZ1":/F 29>3![))I;8=J44H/&M<LI=C7X2W1*
M_*)^38ZO*0Y8MC9.=$I2&Z. @7%K.+S0;)P8+J  ).&K%#0!.J,+^^?%Q+;
M'OV(N->N#$C,BUM#@;0:W>N]C1'^!^WPFST&6N;YV_]9L>'"81<?K<A_Q0(K
MYB9TT*D,J"\]1N&"1>7PTOB& ZLITFA/J?@GL5<$D)D"*-)Z>&X[>1J51#@'
M%S(^*-.C*7W-9:_85%*D:,<^B53K*PS@>CCHF+?D\=$IYBV]F>25(EY(8\JI
M)I3NWTU:8(@1DS'ZQ*WF9HXYXDY:D=F&$34,2 5);2ASDRK2Y46R\:0OBR>_
MD;D[-?^%'KQ%@(KYW0C2(LVA;]AKD-%%+D_]R2G9[IU5R?9]7/9%D ##",G=
M&U_@U+ZKQ+O_+7%,%6XW+3-ANGF-PN'31@D8LY)63!X<M:.!@8T$T6?H<<.D
MBK$F@B[Q:M$K*NE02R$07H(S]:PX9ASP/MR<%6#QR$_JZ_S,UP("3NY.K,ZO
MRT>Z#7BWTQ5M$B*:-*HV=^:N)NEXXFN2J4:E,PLO4\,]J]^8[AA$"<E\":4R
MT0[BKG/QN[-&5]+%,?_DBV&H6>0'./]=>G2>(YNGV0,'NWK\8=QYET:C5N]<
MU!KE2K*O<FH,C ]4!W#,'/K_Y]_JG=J^7;5;@J?7:OR2U$5D#<92.6*(7]%0
MV6@8@-I&.AO@O94J[>+5;4Z,HA]5! 5&V*RJ'_0NZC6>493^L&Y\$)-.0'?!
M3"QE'AL +54I$[!-R4AZ4V63LS#.OD??1QR?3JLT/"N&^L;P4#IG$'$>R@(+
MB'6EA.UP^E_XG8QVIXLI,BPG_V!J[T'^A2U+S]"1&XI&7=1\;.03!59%.=_(
MY$X,#%U'LM7: F"6] 9>LIGEG83S*E53I:U!?K7IPHL6*[Y31=Y\*[Z4]I'<
MUTI>/X]G0 LW=5)3J>++;B?C>HA:G4%Y"=%T$172K?<H%I"V5W@\(!>S'A,_
MI"/N6<DR$>!+O)*F*@T!>>L-X8I<3"+.$$55Z, BLTQ(..H'R,PP[IB\@$GK
M#Z.&$;FTS'&L?<<V3D@M=QZ09^>R9*5D@"!36R:(8DZZ)R8,CQ"++@0FW"<M
MI(XI!WE"D15/25?+@&4<=TF9[B)=+E@Q6UDM7]APN?/FC/H<X#E%&RGXRVV
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MPZ5?NZ';C)U5OP=M[FU&=YTC:Y_4[Z%9*ZK:17L3S@F]WJY[]H"M:YS2.'6
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MZP%61@Q_-?*998=BR4OC27G_Q.1OMH%UP^+XH#FT'3N<XX,8\32":#11-A#
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MO6ZA-\-CP4=!Y(2)J!6;C<73C#K'-(VGOW^__<<-GV&!V)O,(N(A^W"2V3^
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ML( >K!I8V>[Q3C'*3ZSD-S:SJL8(\!)EAV'YT3."QXI&(97%*^?&6$/DS[R
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M5:*GVU]@C:<]MC$A_P5_K&+L:B0=F=C]:\1L:B?E7O@,6PGPEBW9/2B3)Y!
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M%'_.):B>ITN^IV%\\:)1)ZVV3&9=CL=_.#:;TY8(A$=T:C 3W21A%-81$H0
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M.1*UFD]#HCZ1:-1+7^,DB4@:35-^M0K-;&+0+]*W3I--="LK8(6$DZ\A+>B
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MTP@:D<:$6CPLFTT<_5Q1[OKX'0:UPJ%]:Z;$@KH5DSJL6UC6+1N/^$::JHC
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M_\[GXTQM69F7_7XL-\+1]A:\QIXO7/_1MNF'CB<KBN;X5PL4/2A#_@A*CX@
M<CDZ_:[HV_2YRP<KF&K[1&Y:VL$\%#25!4ZRSB#U50/D%E8Q(K,M'22/$3K
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MCEM=1=5->'EO.2X*GH]^0.5 )7M@1TU$?C=;PX'9:J9+A'CS@ITM^2XJ[G5
MC%K>Q.82VM+TV6D"F+RXS)B29;'FO_3V$5J\V3:[&0W QF0U7W%AK+S1P _
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M!/"5-VFH;]*/Y/=P 5\F2Q]#%)B6.$X=?D,I)H[:DY:(6U*<*-&.F')8JXE
M=).TEIXIV$>^;L$*+QMU OSHN\1^XT,6ZH5/FL#?Y-=DI 0]*:G,R*@"%FS
M2Q_0I4\:?:%N4,>6G/48D?CAV!D:HP:%;$%&P=?AOHO@9F#? K51T],.\4>@
MMY?P@=L5[ P=2"N4>-TR@*F^*Y@)+T_D7[$ZIX F;2<9,N5 )IH[<S@59X'"
M)VG(2[,Z'LZ*^2"<BA(&/^IDC2(BS0LG#A;8*H@;XF+UH4!( TO(QP0*H=?Q
M#69YRG8/QX1E%.PX[X (P6D6^O+!SW17X /.+9+QUGC%0/<@V+Y[_H.';/#'
MM_>?SYO-UFOA*ROI1Y02O^UP%'\UGJR6%CCG^-L$79&=T#;6N/;.%]8<7U)B
M'/15YSY8WB*4,65;SIKKZS39RDO$->^ "QA2.5,0J^LI[N8:09YGS#= <J);
M>^_PET3H";XA6:0>F7V<DN& U-KWLM8N H@3A5S QS?1G0[OR+:F>ZSQ'1OM
M^2'KV<JEH[1N?3RD2,*:G)\*Q'R!+'$01=6C)\RC)W"P&B? 1$J K BC]7,[
M2W'HRT[*8.%*H&@4!HGD&IXP0;]%08VB3T\;Y+W0Y/"(DNMT43!2OP1KCP0Z
M.C9WOLC^ZU?9^Y\V7%I!<#UTSTFVA3/5LV*X%Y!C7+& GQ9.XN-\ ;(M%!?
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MR601+1!@ T25V;]^SS7S))!@%6591=I\(]YIF47BDGGR7)_S',H.M5(%Y$O
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MW4,&B_P2R3"$. /.1PG;,+G*2\WCD]_?@JO(DC4OVMD2)(/3$&7!V:O"W>P
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M_R>/S5&;[]O"S-PS>N[# :%C\*2GU:G#6,@]Z)RW2S"93%87*)59D/_R(%A
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M!?2:I'OY;1\D\W_\_<RSO^/13?<1F%@!'<]A3OYV?'%CHPCO /@<GV6;P$I
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M:AI&57B^^T 01F-/HK*_R34(ZUGT_@J>=:V.#1@!R*=1YQ6I:T* II3CAF*
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M46:/4G)AP5*.H%=9:[7A_"3)4D 6E!S-9T^>/2O8^Z"7U*\ZX2QLD[#IZ_5
M51$@#O;;EI)Z\:@U;*L> '(ZX)U6X1G_4;$ 3QBZ1O0':RB-%-)@?5$'/[6#
M08X"#Y1_;SDA!F15O0-.@J0S/.N($'5NZL/9KH0:)"V#J]J42+)>T-@!P@/S
M ,"8KZDID2H:X=P*]G?+!0W"/5/QK#*2'VK#$O_R!7WP/X,D)LD'8BA!BF>(
MDAO^1( WNP>9&LJ"R"W$$;85!3%L^FY?;;<"3.:P0^!'G#,F3I'%T.>O)"#1
MUA;I\Q7I>X4O:T+5TZ-:EY'C+R1 T!32.1?FI9)<AH0P/,O#01[<7B^X%-!.
M>(P?&J[8":B("Q(&)GOSPDJ@JU+345(L:A;_-00;_)2BP6>2B H_B)@-@+UC
M@S:*8+3&+JN844\\+RZ#7;61H$%Y11WTF)PK$53MI0&*?1/_2A;!L?FJI,]Z
M[)/U5?7!WQ'!F5TG.F<E^407G*=3S+WH'M ;AP7$ 5;9&-QO1Z9YG_P$R[LJ
M5Y?ZQ"F<P[BEDI>)N$37Z_-\_-#!AQO]HH^UG'&K&JUL\AD;BNH,[P^>F$Q%
M[X83(-\8$SN08Q#KH?]5<N-I *JFXGSQ7? 5Z&P0;5VBU&K9MF0KIS*RM@[%
M;93H%%'B1%O1:>"XQ[6BJ#@Y:ZT1<WUC;M1CM?A'[5Q84?V*#M4]VD%=Q3\\
MY4;Z,62PQ_,^.X'6*AOCU-XF=RD8B8T%ON#<V=;F(R;2V\I,OJL.!<'?*HPW
M/(/LJLKW $FJ)O:9X=U(,@P."8N*T<^7';="1VRBWPAN"GVKSSB(SX_7_/.Q
MZL156U.7*"^@&^\?^^B$K\'8&KK,M+KGOJ\GQ!VQ:3FBBGPSR(C%^A0",EWO
MOZAOP[(GX0%:BF=OY++X]ZMJ?/Y8U?AX3\FQY!EH"N!V'U#PBE5P\@R[R!W(
M1?QVHN3.&0&28?-JYDGR2=?.#@76DZ?/K4@9M4.=I*$UQ)O%[+R\;#SY"HE"
MJFVDE<ON:>@!T0&+L_L/;<K2&F_-[R!8P=Q;$MP!!Y558'S"V8T [I;,P?GB
M[WIN^1GHT7J^'+V@C#2.%[B )T@YIHZ)LB1*T%W04U2)3M>)>;;NVBH<B>VQ
MJGKCEF1FO1Y(:RK-DX=2<_^MYL<H FL[1L8C$Q&?OB(.O<C ?=$I#\SX8606
MT4J'#$\R7,@(1C'U_>6Q1Y8*U(V)?&*UJWME#=%OH1I!Z[!KF_ "XQ^YV?7C
MRF4@>JM+<FJ4+5(?'# K282Z:)_6QT792!NI#))<2I2HG=I"%Q]F5Y4],H\2
MX9'=6UUJR'@]ZK_2]G?BA*C6FMWE?24_':4[X,XF@PJ?C/;2-=%5LBBKY&V)
M++\:=6/K=A(6?HEV:=[OJU]Q.K&OC49DI*#-I#7;9!_H8M6M@/)A3S@5:0-W
M:0(1"H7[F[G4:$NE^VB:[[Z^;&6N&2V=82>ZG85J4T;9.2-0W+9O9;N5A187
M,IX3J?SU0 RV/S.FIK"38+KZ?#[)E=#\Z_F-R2*^['O12MRVO;^^6X[QJW%Q
M7Z!.F8QC^C2@K4A6NT1H!K=A:MX0GH182U($]G P6#3B-5&\A.BP[M$I$]ZD
MU,QV\%6'L.*ZL$37^@9#9_B!T?$P9HW()I<T9OSG @M<3Z%0/'++8K4/8PE
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MQ-&;^,=>=FVYCD+8E8V\##J\>/NV,\W;EOB1-^:C,Z&[^2=]]. ),TD" !O
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M5)XRR7C?SZ*BCX(HVBM5CBEZ0;-N6/$7G*YR^ATI':ZK;<E.9[!1FLQ<3L7
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MS\-0G_UWO?H F"_YJ(,F&_4KWV"UO.#5\IS6)=WOS>6Q#X8HC-N;\LBF\-U
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MT:-FK?0[F'#H)%>W4/YZ:3"0;JA$KO8!9X<)>&)I*%*I0 ]1N=@0Q1E2P2=
M?)R+UQBYR*<Q?9ZKJW94@UD0AK1C[?4?,^W.^^ 3,)00Z3-%^+Q_^77";C-/
M03+75>2D7\\7+UVO)*07JWSN?RX5+8EL=6!&[ZJ56*:)3NJ=X"2Q-H18F"V%
M/;NAI-&XP^O5*!.LE2[EDO:M>ENJ48F0QR^KB,RDZ8VF)6WNR5%*."H)T:^
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M(*WT8"W9D[3(D\*GL,GVF!5=+TE")0K?Q)&A&*H78670V>Q1D)&/;0OS=<R
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M\BKG'5!WIEZQ'A3HT_DOF8 !'74<QJ%-#-<MKYD%(#Q];\5&Y'/I8R1I%]*
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MG1K9W(G-+_W[+?Q_OQ+$YX\EB%^E!!$66$.QZG8"9:*<BSL?0<T"[:D$!\9
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M-V)O]:TT$LSAUN&.2 N"F3,W5VNK7;+*]=QDZBSI))A3&1D%7L[]%MU=U#"
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M/Z!WX& "+X+WK2A!].P1>BFB(]<EM#'Z+01&+#N&Q&Z&$]FLO'O8E;<?MD6
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M?\5KR1)3DT_LP9Z>>[<@GJ+$Z] O6Q^PHSR&[H3^QXO[O<__!U!+ P04
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M$#RO;2.XQE4-I"5?H!B#=<XE@D\$[_"AW>IVC)M.MS,6L2O\TA]_;@_SH);
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MP\*F1""'4 8/Z#@4=ATESH8AGLZXG&/N8E.-99,&A-F8O#I?W&-'=(."3]Z
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M09#!@2I,@U..4F.O'=>1ZV!;1\1WP-BD6D%C,JPJ]'8NXPL+Y[56<F0G4_R
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M;B'JS$%:-"DX'3&V[JVZ'\V&NL"5B-%(]NV<WV3\_@BGQ[4MXAJ69!.YVL+
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M@5LGC+!9A*>E&F'<I(;LS:/:8Y6X8(GFXO7Z)=+E?_OI_P!02P,$%     @
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M$.\VT[:HS2YQ]X7HYQVE[@>O8[:JF PZ1D['KJVMZ9("[X)Q-J'4N<LA]U#
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M1")"DX YJXH/2@G7>L=Z(-3=9]P65-CA\N#6BW(MLD2+^!Y<8@$]>1&LSC%
M($$QB+4MO G..UU#F[IU4M3JZ':?7WT4]:B6UX 9';0H$B1J0AH*UD&2M.TZ
MB\R;8&7SY,[5T>T\I3HIJL/%PA*DEZG-"P1CN5(VUH0NI^O [R3!)U<@%0P^
M))W4S8YFO:AU!\I=->9;*:;'@7?EG/Y>G'&EFGZ@./FM23H(*3I0= )#S*A
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M6XKF&1.GD8IZU+",3VJB:GHQGGP>3\(,KQNRYR"-$XIKK2 G<HA49.0+1:7
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M)[/:/SR?IMGAY @G7X;I["['Q6!CG<B:,%0+E03KM=!T>C OD.E(2UJ%S?2
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MO<J8(?H2Z3#,*7$59 K-,SVWS9-[S,]'I\DZ.F@=GUYH*'T'>WY8!IZT%D)
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M+IU\(:FO#ZH3B'2,*:(OC@6EA*=UC.[=O_QYOB3M*BP)5OL;UL::*F$"'Z.
M8AU/0N; 7.N+PF/P\?HPO&LP-!QUNC5/JQK=>9Z565K]R9NSM%C]03A]A$=B
M4?AZY4+(6L1;FS=&"3I+:0+W"7WS+BP3\'50@%V#980YL#=G$2Z^DB_P.,N_
MUT$^R^HB5^Z6G^:/,/+[_/R_\?P#IOGGLYK3NE7#LCPIW'B&04(*GA&G$<'5
M'F.NWG\-(BJ56M< 3,+8JU.)_N RQ@#<T;B\M +)[[CZJOX>/V%!<)8-Z;RN
M9R)W"KQ)$H02+I/5YQD?K9)J$@X/:M(/@%K."QY_5[AYTN4?O:L]#S_]&<ZN
M=PK+BPZL6 @\&^)<>8BI:- F*FE1RLA:S^W;&;,'+>H25NMG*T_<L_2G<%IG
MR<=OU?QLWK?TT:=/TKOT>;[ZZ5_*C#0,R;WEVCM0TF=P/M5(#M,1C62H>"^N
MW]O^^I>R5$CM% =ER/I3-M4"%,. LR2Y]#*B;'Y%\A7V+QV"TO'ZEPX1=I?]
M2R5Y)@YC!,:DJY?=-)UM&,$&5,R%9!)OW?_GQ^I?.@@!3_4O'2*)\5M:;D+-
M:^E?.D@R3_>V?,FR3M"_E#$M(T]@DZ]##:P EW*@#R^YH5W5&KV'0A[2O[2A
MC(>L9NN:GS=G^2*MMJW?;H_UP<*+<HP#DQJ))&4@%"/ 2.Z854P0@1L5^SS^
M_-UW,!VRY/.VZ]5ZPN%1':%UJYVJ4'3"H%)@?(Z@6# 0"TH@!RZ25Q<Y_<)&
MLKOWX/T5VC8K-$W#X.PS\UHJ*%SDFB'DM6%&!L%Y$<HH-&Q#F3WV^#V6W-:K
MU7I0'&&)N5NT>/0A1A9 YUIOKF.=;6H5".&E<MFQ:#:;ZW7OP7LLLRU6:(2K
MUW>;;G)CHU6*#FM;.V\JZVN6A7X**C-C4+G-BIP'6"X_6'OG;?R7E\MB7]H[
M;\+3H;WSH/;.@V R19_<E\AX7]H[:Y:5D$)#YBZ0BD?BS=+^CYHEY@N=!7;R
M653=X'90>^?N8#M$M).W=XZH8[")_&>KZAC.FLWE3("6J#G]2SJW4=.C ;A[
M#>V=!\E\4'OG(0+KJ7K_<N[PFS/B[6*UJO?SH#>YU<L+]"?&AE*<#F0')S)?
M#1<0HJR5@]D9I3SWL;7%.!ES':)\Y$1.E[#I23^NV'EW<;X\#V=Y=O;YBJ'H
MF''UZG+"4I>=/J+U#$+.N4BME5*R%SU8Q\0![Y/"8!=&[TO+H9APUB%'X*DV
M\8A%@(^N]F!R1A>':'/KE,:A1F[7*&\)BEZF.'^\^/(E++[-"]EJ1^E\]K6V
M+VM],>JIETQR/VIC+ONY)F4E2RA+!*WJK4!9$D23!<1"&R=7,N70S0'ZMK]K
M4CFH:E(5X(J1+DK&(":5P4KCI8\)F6U=3O$:KTD-0>EXUZ2&"+N7:U)WPS]$
MK0Z2SC/CD1,'#B&2C012N!@S+Y(UGU?U@R4:!F'@R43#$%GL2Z!V$YX.B89!
MB89!,)DB8OL2&>\+?EG)5M3R@BQK&M%S27ZD=5"4EB*B,TXV/\[W!K>#$@W=
MP7:(:"=/-#"&3 NM0!B6*W$<G.$UD<U]\1*]X*UOV[^&1,,@F0]*- P16$^!
MU,TCQA_FIZ>_SA?UCTY,1)29(UA?R.@1UH!SI,PEZV(Q9)EB-V&H%W'8(=Y'
M=HKZ!=!^JLM5(-K:$(QVKH[L"<0H5Q!2\5"*1U6$YX&WSA@?\G([0>G.<GA#
M(-93KN-91N_V CV)BCG:TV(-N]/VEIFG(]:9ZGB[DJ72O'DOAJEX.VC23C1I
M"X#MXJ;GB_G\YTH>-WP:E5B0DNP$Y/523)U8C6@A.RM\E0=K7A<U%6\'1=J)
M(FT!L)[:F#_+)TFAX.PVJUX5,K$+N7Q8+] X=.!$DL!EU-S%+&+NIJ'<</8.
MZK03==H.9F.U.9_$F%4EAF@P@,QU$C,=NN MLW0&B\B$-$:8_3'RGO27NI3"
MLPWW;RN/DCI%C@64RH*4!SWX:*K1I'C!0);4_?+;?9#5D"78H_UQ;\)$HT%P
MKWS?S9?C1-CBT#M/UE:@,RS8# ZC!A2^2*,U.3/=W-AIR/<>Z5X/X.]0D0<A
M=Z^T=^@4&V)?)%\TA&SJ;#X?(/*$X!3'Q(-#U4];ZM;,'_2X3ST>$\-['#U[
M?B$"YTZII&A7T^2PF60A1D9;FPE%"HU"VFZ&";=F_J#,?2KSF!C>QPC>Q0*7
MSZ\"LYB*4@&0URJB$ UM;DD""P:]#XK[YBV,^^#\H,9]JO%HZ-W/F.$&XR%C
ML";Y5"=#UO9 DM: 7 QP&I-UU6*1^Y/J&NH;3UW2]7U.Q'@57>O?,4U!UX8\
M]E//E:1TC'$/.96ZD=%^$ 6C34$81QZV#:6?,^QM?_5<)651!'((3#,Z#,@&
M\CD7,+GPHIF.&9MO(*^PGFL(2L>KYQHB[#[KN9B*0DK,D)75M=]KIO/.!M".
M1QVC\A$/]5SM,/!D/=<06>Q-/<P&/!WJN0;5<PV"R22%,2^0\;[@M]9D:!$U
M.%\O4RBFP*.NW4.50A4"-V'R&=/=X'90/5=WL!TBVA'@>F=R\*6'<%4:5(KT
MY(@[2$'RVIY#0U1.0I:).YF]B;EU"<!:8CH,[(PNZW6CJ[825$]%*0^[(-V.
M9*5BT$JIP23M0/F4(9: (#0G[J+.*G53@?(D)QUB=V3'9O> Z!OF5W<&BW3*
M*TV[@74*5!VT2#\9D$8(74S)B)-W@_V!>[XU1-?H?>"&0*.G&R:/YN!_6\R7
MRY,28_",*RB8B241%+'$"[CD.%INBNRGT^=Z-@YX[P >8US#J%;5F^7R O,O
M%PM:JTO:5FPL;T^2/OX;%VE&?)VD6+@W(@/+M5]_)K)#S@Z$<"$75J0,S0$]
MF,H#7L<7;D\7"1XF7&]J,9A"C<HC9!]C98F#E[F ,DBN,+=>]5.BL)Z- Z [
M@$=/:?>U-I3WR;%L"K"D:X]H)2&02P-2E.@*"T'I/3.OIU_5R_M71V?Y^.^_
ML/:0^32O7SU<;&TQ\Q(9H*OMY)1*X'E,]?J&4RSQ1'CN;+$WY6V/=IP^_/=1
M0-.AEW-E+=3TVQ5#H?C K' @O:.=$P.O-W8<L**U\^AYPMYB5@^8.,!]4ACT
M=*7\:?U]R*?/7B=!UHO7KK8,4Q:<$0*"\/0SM\7RWD[837D[:$$/H.G0L[IU
MBMV[SGCM/+Y?S-+J3FZYMO31,F1<@JDCC!6*5'OL!2BNZ.*,USS;SM1D.)<'
MA>D+2'V[:$]Q?,)SR1B$H>.3]@7%HH"HR7NSV5IM!4_*L_W4ESU2DHE0NANE
M&@2QKNX(;5+D>)=5$<B=8L: "=: XDC&J"P,K$G9.:O1)SZU-K5C[Z!1VVK4
MCJ#6U<CA>^'_S;B5P@@,UD(=V0PJ<E-'D"K(@JGB8N DFMX4:Q"'!]T:6[?&
M ]PN/*?GN'TDZ_ DO\5F*1BFVA86B5_E(91L(5N68@BN#C3K3<$&\GA0L;%5
M;$S0[;&/)9Q5B,X#9];346T+T-'M01CO9?!**]M-@>DV/E8WT=.-!>-#$<XK
M8+G.E Y)@D_UGK#)*J/1,L7>@D7;<;Q'6V ?@:,) ?9P@].[5J]; >6GV93"
M"TMN2!0US.R+A^B*K*U] Q="6L3>@D@;LG90F X@\U SS*XUX_D,S)/<AYA\
M"%J "$@60= (WDD+9!]8QG5A.>Y?,N^@1_L)L(?J97>M7D<YK^ 13G^9+6NE
M?'4ICN+R?!'2^4DD+X9Y3[YY'6&BG$-PS)!1+3&G$&0D?'6F/4\R=%".G<'C
M(?9=$^S'YYF+@UVO#UB%2]__/#];L7H13C_AXHLX\4$8F[#VI/?$,DL.?-&*
MF)=<15)V74;).TS+YA[I27N@/J9"':-LK$3>%BP/]N76K00_L8+KF P9KLQR
M4,EF\-[H>NFL&)V1O+Y1;N!VP?U!#?<>DV,E!+=8B?66[7J677%&HE#@>+5R
MBXH04U"0-$K-.!;I1G&CIF7SH&_[@[*Q4H'MMYB7K(1-QE@3$Y1"\E)"9@C9
MTL)X$R46VF'X*)UQNN#^H(9[C\F^<XAOB+/9V7*6+MO2:E4[\:($R60]U#U>
M]LH72G/->='$7V=1CK7,''2G-\1TF&UZWA8^^OQY@9_#.=YC/%@G(F8!4M0"
M<JTE>)4\!!*3-<@*'R?\L0MF#ZJT;X@;*WW5Q@R^RQ@_459Z5MN:REQ+TR/C
MX(N2D)S/QF61A>G8I[K'S4%9NL-,A]FFYZW1==N 5LX$+C0PJ3*H[$6]RA;
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M1WS4Y4UX8I5J]5X*4UOTNJ!)63W/X -9VTE$)V30S(EN0L//<M,AAD=V</H
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M O/#%[0V,=>^9W+-?EYJ#VR\YQ9I;4AIC99>?5T_:L'9?_S;_P-02P,$%
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M$ZL/26K='B.J')'^<?KF\J3!!8&^J..6MZV49IKBM(!C\IG=!3@BC-T%@/Y
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MZ4Z\,C]\_NWJZVVS<8/+S^_ ^\L/7\!OEQ]_O0*?KBZ__OK%9E/7A51O(4\
ME-GJWC+0BQI5TV_DAG([T@2Z5&=5#X90/-<9IJ];YB'PJN)\O__<%[[BO^.E
M.M->"!%ZGH<HI'$L%0A#<C]'20A%F@6()"$A*#-*21BF-W5V0D/] A3[O2$O
M0-FR ,Q[0HX!J*<N',)BIB8VB!QTA^RH@]LA1,SS&/3D=)72,$)MWNP&/=$/
M$ATT7[-;_A]6\HOGU:;<UN=BM5T:"X]D29"0$&9IRN72%QXD-$70SWR.I3W/
M,L+,RFD/4-/ZPL^IF[VAW=2%*_H':6;K?0@Q[$D+2X0$AI0V!<ACZ?SX%&81
MCH,T\A.2<1-E>2Y>Y_0CZ-!RCI&>/G0DN9DNW K=4;T ?;KNE*"&<(X4X!"E
M696?ALC/%9_.*W9*KSGA4ZF<);^30^>/_,.*%O?\8U%5GWE]+6[QCYNB;,H\
M];)!;HLV%V1! Q;&29;!.(I]B(1<YE@J2LB".&#,#XE<[R9986?R,TL*6:LQ
M:9])\!WGAM4:SD5>3WG,B*>9@FG/[/<X RUKX"?%W)^EQN&U.NR4'*K*#V5;
M8&_BE"1'>+GJYGTF-_.V^W8#W4$_<$?#6F0M?+B_7Z^*7_A*4NQ"EV$<9\@G
M G+!4HC\3!J"@J20\30(69P%6:155NK$^%.;,AN"%VJM&1Q7'T%B6/\XD,_0
M8-D3S::"PQ$9#4[9SY/5[N!<<SK-#K]/"S)XGGWDM?F.J$_SO'?J//"89>@9
MYV5S9/U)NJ+KLCE0JKYPNBY51Y7N(^()95$8,>C3B$*$TQ22C"$8I2GQ&?']
M.,5&<6<-HA/K$<5"FYNA@B,=9<,0LPYTFO%EQX 8!I>/83'!$9*)E*Y"R3HD
MYXTC&X!P$$0V>?=EJJO_TM9C6;6]F'XII8FS$'X:D-#CD"=(A9Y2 0F+8YBF
MB0JQ,!]EP9SETX_P.+&VZ9)^SFCR-L&TZ*FF%P;;3).YK&K>,K[K$:=^(YE_
M/57+!Y!])67)CW'XAZH[/@"QZ\+B0Z1L<P2?-<=^\_3K*O_GFK_C%2WSAFQS
M#S<2<<)%2"&-0ND1>L2'.$M#*-5S*!B*".5&%Y5U"4^L=!O2O9) H$?>ZA*S
M-J!ZFG4*F S5Y1D(G=_:?D3<J9K<GR+[LNWN1\ 8;7P_]KZ="KE<U7E3_R=_
MY%^5G9G7.:^N?M#EFG'V7HKUMJD2U.BZ:W&%2W7?MI(ZK-%U'[>M'QF./!02
M#'G,(HAXFD"2H!A*TS!#7N#%+#&J9>Z*L8E54)]-L.,3;!@%ZLL /595M'C#
MK+([6DOEC%Z<SF903Z>]Q+R8Z;Q9I\182;K&SY$2=<;6K$K6-9C/E;#S\2U=
M=KSDW2Z@.C)>BUMI2E:8*JKOBGN<KQ9AY!,FF >S&"72PDLHS,*,PP#'*/8#
MCDF0&'G@HR2GMNTD TTYM<:"^=;2-%2-&KAINLA.T3 TX<R ,'=2M65SY7..
M$YS7A=0&X, CU'_3ONK4;5<U9^%%A 6Q3V$J6  14D&VA 0P2UF0QB&+XRPS
M26/H#SY+3@*3A,R+2FWEUUNJME*9+<K](E)NZT8]Y]YAO:CMT+/7B7HNU+'Z
M4 ?/F-=2O%E5JTOV]^JF++\^TK=5W1W2:-91//'ZQ%O=C4H94"%,]O=U5;>)
M_S=E7DA#E)>/JJ7BVZ+27#E#( PO($?RFZTC/=$=GE1I2&E5+?'4F+-52AP1
MJE\E<>Q1LV7'>+YXUZ4&O,\KBI=M@/.]_%VU\%-&2<82&#85EI.(0!QC#T9I
MF*(H%2&)M6X5#E*9>'UNZ(*6<'=: !K2>JMR&*/A=>E,<K.5:26T]C+4$FI@
M(<KWVX4H?]@MQ.%19UF*6H)M%J/>P^:[X.5R>?5#NJO*;7V+:_Z]**7;:K85
M#HTQ=4QMN01;VF!'7'\'' 1@?!MT);MAW.J$V(YW/QWAK+; P8%GVP=UQ.MO
MAEK/FR_!MW?J5)#=<%[^4A;KA_>KW8U4S14X,,3$"["C#!1IT-"^D(J_J%=%
M;5#$>PB"\37H2'JS)3@DN.,+N)HR6JW$H7%G6X@:PO77H<[C9R0\D?%S>V+<
M$/P+5S$>^?NWQ:KI>+]N+_D%BT3X+ I#JBI6$HBXQV'&20)9&J=>% 0D-KN&
M^P(R3*QC>AR!GP[::6RY CVVFKNM-FE5,T^^9DSY=4^I89#:85K67N<4@R_#
M<=[6RTR-R[RNF268/^_K9:;H:%[8"[%BF?115;RN+DG5#+J(HB04@JMTW4QE
M[_I,;E;8AYD(<1HE)(X3H^S=_>&G=A8;8H8I$_OR)YE@H4"J?%Y*(2)"RI_$
M'HP"GA"1A#$G;"%GA!33(] G8XC!7\\"06_3LA?,T!=NZ(!O&THN$S".BN J
MC6)_\'F3(8X*=I#2</RI,^\6O7EZTW8:^'K'>=T8\%)MW:I+CHL,^ZH$10BC
M% <0^8S"+& >1)B2D*411D%J=;=H@.C$2J=_GT9:-1T;H.$#;!B1#J-BQ3!G
M00M2O<7J&BBS)>P&(_LK2!I"N[Z"-$3R9:X@:8!P\@J2SKLS7T':\B:UV/J^
M-9]4O0DJ;:9W^6/.^(I]P35?1'&$28H\B 7-((HH@22D*60^P2'QN1^8Z9S)
M.9Y886U( M;1!$\Y7VH6 Y]OV@P\Y]<R&;/[R3N]"GIB7(#M%&\D 4J45W"9
MR13UE[[:I,WO'^.BDRG\SJX]&1.VSSM0'>46(<))H+IN^%XH=;XG.,Q2/X$T
MY8C&T@AE5.L.^_.!Y\HN4+3,TPD:T8?UYCD"F:DW/5FLL@3ZC)^5&- ,-'LN
M0)_]8\?_>W^WLZKVV^)LRG&I%78EA%QU^2/?]5Q?Q,)CF*A6B2(@TD+*I*T4
MJGN!C+(PHBB(/:-RWT;4I[9V-A1!OBD15P[MA0[@U+-<)@/)<)D^;TZUK:2G
M6)&FQ!:_'3?N# DK$!P9!6:T9]W@K6!YOEG;#6*79_MF)>KJDOW=(K7AQ.L3
MJX5-LND;ON(BKZM^UJE-@L,I$(9U@2/YS5:\GN@3I#B,2&J=:WMLS%ES;0>$
M>IYK._2H^=)K[E(T%G?;BO-+O?JMVJ9-&"]%S>$F7IKM!9$>&^ +K]?E"OQ6
M]9)Q])>F+DCC2W4"?,R6KAXT$RQ=0\FMEK(NC=F6MJ'0_:5N^NK+9#-=_9#[
M?UZI**[F:;._2-/(#[ ?04]5QT8QC513@01Z28RY($D:FW4E>0$9)H^O;CEZ
MS=E,-I-O$)-]O5,Z>Y3V>A>6W0KV!\UF.F-J7DDVDXT$?ZALIC.FR'4VTSFL
MS'R:V/:P[[7K:<HXW][A52?+;])WYFQ3L6M!@S03)$IAG#&Y#:HV703S&(HL
MCIC\_WTLHDV#C=L9SA8-^=?2E_LM.V[-=\*6Y@O4032=S8G/&J>8G)?:S%I9
M]AJ3M:7Q:RG.;JOKIGY;3_$5G#U:SL)+'T&:LOW'.(FTG QG!Y*V]"V3;!]Q
MOE3;X/NB5(5"5&AV5T/H\EZU _B7DJ&J):=YM:!9Y@D4)M#/8BRWEYA#U;T9
M"B32-%/EU3 WJ>]ARH"1BV1> V1+T*":@366>LI]2H0L3F1VI"_ EC4HBA(J
MYN3O]! TSXBUA,%5SJPI^7FS:BW!.<B[M1W'HB?(L^YSR@J_%K]6O,G]?<=+
M3HOO*T5MP2D*O=C/(,H2#A'W YB2V(,I(\1#?IQE5.N>FAG9B8,QN]Z(3;=(
M4"I.8"'@6OX#*V8 ZW%CT'Y#']AA!30=7&9JY["+9 /5M8"2#] P MY-#95!
M Y-)(+/K:^(,.K/.)\8(##9$T1]MOCXIQA+NM4\Q?_M5I# W,1-^4^:4+_P@
MQ!3[/O1\I.J\D12FW)=F843"V.>"H,#\[O DK$ZLQS?Q(XB[:"GOB(,'1;V)
M,;!BN<1E!>2TM_&&N<(-X_,X<8#!Z>S,'E(XG<7<37$CPBN((&C#_-(Q@W%&
M_QA1 FW )TY4/D;Q%>P57_+J'^]+SONY70O?%VG (P&3D$@S/E,W6%F"812J
MHJ%^YJG6SR^U91SC>.*=0Y&$0M(\)P%T^FE[@1WBW,EX-1N%$@0H2?:35U_I
MCC$$^VO<.([R^\?=/X;@GW0;&21LMIM49;WXA'_D]^O[39_7Q$]]+-T#Z2^H
M"R]4.@H9%U (@;Q(1 P%5$?K'XP\L7;N:.EIXT.QA[7F6<*8:;>.C,/Z?">9
M'](1\J6>?I#_VNF&P_%F6<,GQ=BLM=,/F.?#MJ<Z:N&U"W6[^-[E0LA%)SFU
MR% W&W7J[++V_'7+36\G!#M^;%+8#<$;7GK3XF:V-DTAFR!_U@X*JS1:0U*S
M9=/:0=!/JK4<X46:8;UY.CY TS$N%2%%5""84!')S=K#4'IF,0R],/8(\N7V
M/6=_K"%>)]9FI_HSV33LFW+&-,^07\<\F&E'RRF8N]F5#CBOH__5(*=_I)98
M.I [[I*E1=)2H5-:K%=U)=TT=?3^=EW*':->D! ',>$)Y'XH(,)(P#1.A?QG
M0N*0BCC$9KKX*)FIU6A'%#RT5 T5YW%D-'7>V?(:JJN-J!W!"]"1=*BI!D5R
MI62.$YE7/PP*>K"TAY\^:U5*'7!3+'.JEOJF"J&7BBP*8P(YCS-5(8[!- H$
M] 7"G(C4BSUNL3*/D)IG=:K\@ UEG6J&IG@9K=<S4;!:LZ8 V"[< =G<+MYC
MA%YB 0\(?&(1#[UAMY"_\$>^6O<^QPQ[G'N(PB3!%"*?J[)K7@:S..8)Q8SB
MT&AC?4Y@ZF.CEIQA(=4#%/06Y3FRF2W%#:5)UM\I,1RMNH/A9UUKIX1[OL).
M/F=Y8$SO.%LWO26/GC0T'2<W.>N'H9&JJ=&XB]IY&8MYR$*8^AA!I+I'XC1"
MJAXK36/BQ5FL51AK&O8F7M,;9E4+U>-GB4"H=G--=]6.:<-S8K>SI7DH_&)S
M8'@"W(-_X)1W#_Z+HV';JJL5"YP&:J?%T]71KEOFYCW'G038@T/;::A8Y-Z_
M50F)I"B?GQJ_7]?KDK^3&\6R>&AN'WW*E[RJBQ7O&*T6A/$,<1_#*,8"HBA&
M, O#&(:!%R8B8AYEH78V_AF,3*R26PX Z[$ [C<\J'!&\RN#7/-S,!]6MW,B
M::98]YCJY]-<@ [?/F-@R]E&\\Z%KT%V_TPXV^7[3X>WV04 !R -7@DX9_SY
M+@DX0&'OVH"+\<S+UW;AM+;UYW]S7%ZMV#N5&(@$%QZA'*9)BJ4?'0<P\SP!
M61@S)-UH$1$M/WJ(R,1*OB.[:1^K" -)&;S3SL,<1&A8;;N2VU EVXAL5 QW
M3":KPK@G!YVM2.Z86/V"N://VKG<'WE5<;Y_>^ACCDF^S.NG7U=,DE,Q-,ZN
M?E#YZ.6]^M="9"D-HP@K?UJU&0A#2%B00NEO$^+Y+$T]9%$1Q(H9K>_Z[/(>
MBK6_@EP=YS6E'MJT1C.'V0YK/;]X.NBL5$++CBH']>RVX):G"]#G"K1L@98O
M=^[M6; X\F+M>)C563T+IN<^Z7F#F2<'?U%&2Y.Y@C%A<2 2F IUJ]M+$4Q1
ME, L"#T?Q23Q RWS86_4J>-TRAZOZESMG)\D5-+L:@)$)EE!^R@,*PQKV0SC
M7W9B&64,'XAQ1K;P;JS9,H4/V.]G"1_^T:)8-2\^XWNM<^/>XQ-_[S=7UT"1
M,2@WW8DQ_%U;2F#V58\R;U8C>I]=NYK0W1CSU8#>9WJOYO.S/]E9I&^7N*JN
MQ=^P\D;KZ[*]R[[K%;I(2!JAP..0"1I!A(,0ICSR8>(S%J,T\R,_7#PTI8RD
M%BIK/=MSC*S)1_6<N/;W]89_SU=-64S2M8VSKB<W"B.AB:"!SV#HQT1=M_=@
M%OH9]*0Y3Q@C"/F\@U&Z&B\%XH:T-H17;6OMZ?'3L\M=(F+HE2O*ZOBIHRT7
M85NK8Z_3M#M36U=21U;U*+E9#6A=X9_;RMKOF>_^GXO5E_62^QZ)_,NRO"WO
M5S5[O\3?=>V!DP-,;"%(NE 1!HHR]/?NS*JZJ?E*^?#Z]L-I(,8M"B<8F*U;
M/?'!-\6%HQL[HU):F2:G1YW-6!D5K&^^C#]LM0B55<2+R\?O39U\E1%^>5\;
MK,&C[\^P!!M;5_[?IF1WVX]A_S;[<+1&'PVMA7@V$.;K\'P,3-?AH)"VR_#X
MH'.NPD&QGBW"X6?MG I5X51NITU\1+#8CSTO@8$?!A 1U?PMCJ4[D2;(B["/
M ZYU??S(V!,ORXZ2U8VQ/@)ZIJNE7&:K3%,D8VOT"/..#,_^R+/:F$=$>FY.
M'GMDHMH]U:ER$,U_5%O'RQ6[D7.M0@+O"E4"?^$3@N7_\R!)B5QYJ: PXYX/
MO=0+I.LIPC@PZKTX!9,3+^&&<-,F%'QK"1JNXTDF1D\AO#3<9IK%!&GW17+.
M@&*NNC@V++ZN4CAG@&Q<_>8<6N9^0R\$\(730IJ?3Q]6S"2:?WJ$J7T'H^#^
M@*#C3H$;&<W42H\FV!!5C629ZNRMFABY.Q\8%\_*(1@8=C:78%RTOE.@\;1%
MQO)O>9FS'*\^\?([+[LB2Q&E?D)Y!#'S"$19D$!,_1#&C,5!'/",8:T[(R<I
M3.TB="1!2],@V?4H',-KT(F0AO["OGSC-:@T!35(USU78+L\7-V)-<NJ'9)E
M,%WVZ(OSY<$.\;V7X#KXH)UK=%,6E'-6J0(/'ZIJK<Z9KD53OX$SU=Y@$:*,
M>2),(8]9 A'G,<S"2$ 688082V(OC4S\G%&*4Y_9=_2!F@4@![@'RP*OS!R7
M<=CTO!"G8)@IGWT<-L2;*UXM>:#HN_,RM$5UY#*,TYO5_M<6_[DQK_^B97!$
MW:I2 \O1UJ6Z7]X>^#?GS,<]B85'0B^B?@R#))2&18 "F.*40,8)880CS Q[
MR9KS,+&6Z*\'6MS?%RM0-=<;U3W330G[YD2Z_77176^T;YEG,0V:D8YIP373
M.BU5T+)ST=XFK2Z.WRKM7\_!XO_G[DV;([>5->&_PHB9F/&)$,[+!5QPYY.L
M[O953+NE5RW;<<(?*D L4MU3*NJP2K)U?OT 7*I8&XE$@91\[^)6MXK(S(>5
M"60B%_42O2]%*<5<5W,XC'[8P^,JN&'!P;2Q"WN(#D(39RQU;AW^F2VN.K7X
MJ?*L:$Y1DG"ICD2A0"0-0B0C'*892WA.8.;/.8LC6\=N0?AML58:.J>+Q9OW
MZ; =G6T9OK.796@DW_45 &UH!_U330!;?NO378=C_5#+LQ[Q69O>B<KR76/K
MO#3?&8/O5)[O&N#3)?K.*<'CRM5M>C6!>O%V2^?\U]55\5TL!%L+WJ3I@UM&
M0]8<V<CN9F8T/'F:*>]U]?=*I^GRS6NY:RL3S,/5(/R& ]AC00<SCI:HC= Z
MV@8/JQ@XB-!D47$;\;MQ<JOGSTAJ:V*GT%RV20+AG?0MBP0UH_#WF4+!E+2;
MCN9N\$*/".<EFTT9$>X1XFAJV5E18%V<=3]?Z_U\>^E7957E.!,DQ0%B:<)T
MNS&.LBC+4:0[%T0YC_T@-ZT^/$IA9(VI:.JS;N<R$UJ%>!R9?C5R(B],F6I1
MZ9(K5VPUK_8]EX6)O=*<4:1X?-W)"A9[Q>H6+_9_T+)Y+N?5BZ(+O;-=+Z_H
M\WQ-%XVA]@6CN1_KZJ6<()S@!)&0)<CW4YYB$898@#++>JF-G2*VH5V=P=!\
MZ37D@>US>Q$S\_&=X0#3S],0.-S[0#*Z:J;;2VO:?KHF8A^TU#5ZR++PLUB^
M*FVI?-\JYEFGUM>1SV 6A8Q*K%-&8XZ5BF<IRBG.$<>Q3T,<1)09-8DS(S>Z
MH]H2UQONL_IRB5+?']8W(^MBYP(%6+C8#Z.9WKL#!^J*=G&I*%\T)1;-!8C#
M@D4C&5V5*_83F[98T4CP@U)%LZ?@[F2=0/GT<*L48%T^+4%%BD<?'GN#KC.+
MYT]5DW=%6*RKNCQ(4>)QH8?]S;/E!6[$)T5U6H#8*Y65(WI\Q<G<T5Z!NDYI
M_P?M-M+K)2MUTYU/HOY3;=/%LNK/_=M\_7CUHC:5)U%>KE9B/1-QGJ5AEJ#8
M)Q'"-,T1Q9E$.8YY3'C, R8L.GD!6##Z\I[=O^N793Y?+-37MJQ;EGM(_;2H
M*FF?:;E^@^VQ$(3--ES7@%EI>\N$]T/+QM\\??1N./'^4*QX+2\77L6-N_W8
M @)'FS.$\J0[M04D^]NVS1+GM7]^%9TTE,U5]UWQ1A?KM[9[:#,%=89SF:4B
MI8CJ5B28X0!EC!!$@BB.112%/I4VK9\A3(Q\7-A0]\J:_)FMGD'X]EN?J5"#
M.@$=AG9SFK98-DQMV@Q?>*#QRF>!:M?;>2QPS^[K[!)DZZ;.-NB8-G0&K?TN
MS9QMI#_5R-EJK;-Z=57NX%?E%5ROQ=-J%L<)I0'U$9&I;M!%$T1TU:^,_%2&
M/$^QA$5JCE$9.T#3=D^J)W3\KNEZ%6%@O>YQB RC,.<*#K2[%C+;MHDZ+I/;
MWE![--ZC(=1Q,4]T@3KQ83O5_";^Z,P_*XNE^I'5E:S5-+2W^K_;;!6!,<GB
M2**$88%P$J2(<,Z5ZH;"EXPD.0'-,(,R,+)"WPE694AWQO/M\*0<POO"^U%M
MA;QX-NXO98VVF0$8$T.8;5"<G,;NHAYU^.;]WOPY2DZD+1B.C J8_*3VQA:<
M?5-DO8Z=E=K/<:RRH06?29%G"8DPB@*NW4(9J<-$%",>^VD8X#Q-!&@>Z@DZ
M8^<@B;6W*-2>^BS*NL3EPN,UY:KJA>M#6]GY-;  YA1Z9L;% 28P&W*80WWA
M-43=68D!J1P9@U-4)M7Y 5'W57OHXY:U(J+4@U5OVRO,ZA#3Y!BHPSZ6E!(D
M1<H03G5G=A\3E"K=#E@HPU@$LU=1YH5QV<=I:I#O;9>F\=>WINU=>AOJ]4$9
M6*[1@U>4D8S0*$)ABA.%EP@1E4F"$I+Q5- @SRBL/Y(;M&RJ74Y@Y?U 5QZK
M;A*U$5P73>7??LT@M!*P!U0S8^@(*IA!/(F2^R07 _E<58;T4)JVQ&-8Y(-:
M#8-';$N&Z;HZ1G5]O2HYDI T\!.?HM0/ X0IB97?%1$4<4DP86$6^T81\$%*
M$T=,+'H4G@;)4(E=B'Y>S,1Q&\-!B9S5TYZB,W'5[("XA[6Q0P\XR.[6%V5W
M^K)8EZL_SI_OB\_*/5J_-<WS6,!]'J<$,=\/$1:8H8PI?6:)S/R0)3@*C5H&
M6= >6:6/9H2#NA;:X-FOZR.C!-/^8WGDSGH-GB&IRQSS 8KOEWUN!D5O7KKA
M$A8SJ<2S^LH\TI6X?"A%;:&JH5=EE6W2:;V92Y]D,@L1%Z'4(R]31#"5*",Q
M57M_[!/?-YY994IU[*- AVC5#\_":I@C.&PO1L$%>$Z 0P*;A045\9Q96<:T
MIINE!15_9]86^&$['^"N3CVK"[T/<W#VKPCB.(HB&N8H#F.L'(.<H5PJQ\#/
M9,0SZD>8@QP#&/G1KV/J-#S=S_%A66V=,%\!"*:9 S$>1#!KT:+3=*(XEGXW
M[EV+'1".G!$@\4D]%#M@]MT6RU7LS,[N),YZPI#\11D[G?-W^524Z_F_JQ/0
MYS]U&P QRV*:QW$0H%R$RJ'A688R/^"(QEAR(7 <YBG$\$ 9&-GT="EZHB99
M)P/KF\UUX16;H;6+*ANVU!RC0J(7]1>JF0:VZ &_ 3-K-2:N,'MU,.;WKH5,
ML5/G"5]X==NJ.5,VG[^P7HL/ME>V4#BR6&#RD]HL6W#VK9;U.O":H*9;!:3A
M>>>1L:]U01W.NZ+TZ_494L#4M6W@XJY5^1&VK<IVNNM,5JQSA/ENB<ZQ7\.^
MT5S,9W5@X5I[%6JWG[^*3W1-KU[*4GD;LSA,>,;\%-$PHDAML#[*?2)1&#.<
M4IS[>6(TDFB(T,B*49/V.K0]3=QKJ)OIS"!8_4KD$@*85ME*;ZQHIJ+U:)Y:
MHM8\]<-6\P87GD053<5K==/X\V-6T6T&V\]8$G$6Z.X3D1XKED0IRC!6.HQI
M'/D)SK,4=&H&TA]9M3^U%]03UL]ML34[#X^(&,P2 .OH-AQ-74MW ,6D]71;
MZA^PINX &KNZNL-EX&?A.[%J;SD_%6+UK5C?B7^]S$O1SD(!=VPT7W'T*."&
M$8\K3KQEL59VI>)E,UW'_*@-0&KX)#X.2- XX!8?S82GN/#N]O 9H0\C7':K
MTSZ S&3. %STKJ]@\?3Y0TB^TZJ[["N=+W1'XB]%J?]EVV&V&JZ1L5@RED4H
M$'FN78P$$9+XB(68IT$8^$%D/9/$A(&1+<GN:(Z5(E]/&G@LRC6J)I;,EZ_J
MY0#J;JVA-CNMC D@S,KL8J<I:^@TS4Y[[ MOPQZ218GTQ\:9= (!8X3!)T;D
MWVT."@2<OK$HH'7.&"&;]XQ4;"8JYOL3%6_JP2!ZF*W@ETNNPXFZA>U]H?_I
M<SU)1'/]F] Q2/69>CSWG="7M//E0WL2>Z&+>Z7ZP2R)TS0),X*2/(T0S@E'
M.<UBE/!<^#*/8I\9I6A]/-%&-JLUH]X/+3N;2>@;AKP.1YYF"9JZ_6&@A$S!
M_1 ,C[<C=&?+['8'WXKIY6_'9]!H62^\1MH+K_D*Z22Y5F)]R:;_^<+K2'WA
M ;YDCB?Y?JC7Z7+^[\<0;/JIP1]#[A/[\ ?D$)[A>//'4FTGC_/G*C\_PY0D
MF 0HD7F"<,9S1'Q,$<W"* W\G,>A<1;CSLHC[V\;6N!.U[OR]V\=9TD%L]S&
M H&R"X\R?T8&X>YZDV4)'A6CFPEX_ .6O5'HZE'__V?E_[^JL[7R.Y7*?M<.
MJ=:]ZZT[.E.G4LP225%.M/:D1%\$LAQ%<4@EUY.(.>CJP)STR.JEF;CPF/JO
M)[:\5&<!%YXY &*SL]TXP,$TN,9,_]?KL'%1@59Q@C0KWK4!:/#F+&#Y775L
M,2<\;1L7," 'O5W@*YP[M*\J@GHL%NK9E2:[?OM6K,5O5!\PUJN;LLK<6742
MC4F2ASG'*$D$1UAPB6@B]?3BF/N9Q#PPV[S/YF1D:]0= M?R8#MK#XJQH6\Y
M!7) 5[ #6I>I_^W5;.DK">V[-9RIKVR=_+>::#Z>)5#.Q^!!^7BG:7>6<)T>
M:F>[X,0QQ>H_VDM27E#-TJWREG37Q <QRVGHISD1".<B0#B) Y3%>:3L(8E9
M)(3(*.AN9!0N)XCTZ4C+<TUPHB!>[VL9.1[G"NS)0VMU4_;VA=6L5^G5#?,?
M(#AF@NU[Q[EZ>?QKA*Q,8'86?3(B9MFL\$6WV+B1FPSS[^*A]MNB$"NG.$^1
MB&.&<)@JTRSB#/DY9A1G011A6%?"4Y1&-J\U77V(VE:7K!K2P%:#)[$RLY=.
M$(#9O*WPVT*1[T/"P_L##@GFJA'@23K3=OP;$O>@M=_@ Q9]W_4]\?5RM2ZK
M%M1?*!/U6)C[QWG)[Y5-40?%&<<YDY+Z*"1)A'#,(T2TJTDS*0*1T#@B1N<K
M8XJC)\/F:V^^X>'"DXH+CU9L7'AKS8BWKCD!=",W@K)?QT<!"*;K%3;7'6PT
M \T(IPNOXL&['P<;0%MVUQC9]6!W@16LX3I$[M[NZD8+3==*'2+73M]TT(.V
MJ7K=;F+5V6I53\V:2<'B3#=)#V*1*^]3QH@025 89S01:9Z'&3 I[Q2IT=/O
M=B;87;1M_>85\:K9:?TOP.R0'NS,3CMN$(&9P+UN?A>U+[=R/L!N6#9GZ7$G
M"4V<"#<D\&'*V^ 3YT;;O]!Y^2M=O-1EL#JXWR;]S\6JJ1WD-\L[G5I7JE.7
M<NGGJRHTNHT.$Q8E21@GB(LH09C$!)%4)DAFA.@V@#R/8(T_77(W851><^M5
M[#;3I>J[P@[+7LNS5RR]#==>Q;9M+-_%&X3&]R=^+_8Q__->R427  [1='XQ
MX(*W=[HL< CKZ0L$ET3.[,VJF)DOU9%O3A=M/[_+?%5E3,VP+V2&$XFPR/0=
M@;+36>;[**(T3+-$.;(^:*B-"=&Q+>^FMDCK><M$IY5ARX=M&]<^/ T-IF.4
M@';P?(#L.[X:2.RZ^6L?R??I VL PLF6L";/GG$+^>-^"'TFL.0XECZB649U
M&A=&-. A(B%/$B:3-(Y@>11'R8QM%*I[IRKXKSNR;^^GFDY)%A>#AT@!;O;.
MDM_^:FYSY=8=C/=-?7NKO*P!*.SNV4Y*ZO*B[)#(]#==)P4]>E5U^M,NE;>>
MPUS'>^[_*)K9 7F24QF%*<J#)$18!@P1+@(4A4E&\C3G3(;G:_11VF.K^4N^
M$O]ZT5_Q]B*Y[L_E0K^/@WF.TI\-D6-+T+#B*5[&&-8 QV!4&W&<\@<P'+V0
MF%F3_B4L;L0NU^M'\43+?PIU I%"NRSM>!>?1S&F*?*IK_P(XFN[D@D4AYA*
M&7%*0J.[['XR(QN.R_N?O4V;7, -SFE8#*ZTG @+,P&7:Z1HHIJHUU(=5G:(
MY( +*R<(V-U2V2(!NYD:%+#W.NKTT]/=00U*L'/Q-/QIRU2:8KG),+E>JA.\
M:$ZK&\\[C5.299RH4TP0(,QH@'(>,2123 -)0^[#W)1!BB-;I!L%9.G-*\K>
M#XV;\K?_ &;5#,)F=GQQ"@;,8G5)>]<-' WUOXT2JS 6UE7FS2"]:3-P3,4_
MR,0Q?M#.!NQ>:E?=\=09_XZN114<X9T<6RPEXR1AR(]3@7!$",JC,$(T3WU?
MF0),20XQ!N:D1[8*+6E/P0P,6@#@,S,*XX "LPX'N28;@#0?%U[-R2A9Q'#Q
M'=D+ .%)#0<<D'T+8K&"G2GI[Q"S_5O;G#6/(AQ*GR+N4WV3S3.4I<J\1"2,
M>)Y'''.0/0'2'STX>G[1*A11,Q,S(DX6=J:_;=2%NY:X9XKOR,Y J4]J;"RA
MV;<XMLM81%#J*9P_[N;N7%5#8U?*<6V<9^)+'!,A4!PQAG"FA^4R]9\\PFDF
M BPB:C0>QYSDV,:EG@;[X\$TV"T?@*B#&8@&L1?GT !#L<.HV 1ES. !!&B<
MPV07K#GG2P0+V( $[@W>F*TT72 ')-E.4 ?VI.W]U6'K@$V00OELJ1\D%-'0
MSQ!6/IP>*9"A@&5^2F1 <F"62@^Q=SEK <,ZO6"97DBY@0!Z W6LT\<X&2<&
M CJ[7NHA-?%]TK#0AQ=(!L]8*O7+\_.BNE*A"]TMY,NB^.-ZJ0[,3W0G:XK'
M<2!8FB*2I1'",LT0C7W=SS?)HQ2+@,>P%!,SNJ-?1F^Y\/A\Q19%-9^FD'7O
M(*FX4D9@PQ;0!AAB:V@.W",&M Q=L*HV09H%K\/#.%8")K<K@V%(=5K; 8/B
MP(P '[>S*)^?GA?%FU!^6ODZ9^+XY?>WHK)DHJ[M7MT7FJ7.[Z^*U?I;L?Z'
M6#=S.O]=A9;F!5=>8&=T9S"CS*=YG&*4IERH@T>8HRS((L1SQD,<B=A/0(9I
M6O9'MF_;/J9_-(T9$6U:G#Y7['CJ[=>54UY1]WBLDNSOOO\"#"Y-_-;-3.;'
M?9?0,]EP?F M0]NI0S-=S6QX$VMORW<["[%Z[283<,'6^GT@=V3T)V9^TKWC
M?5[,_A;T3EPXSFB882S]/*0Y\@569V!!),HX92BFF(J411')U*:C^3;;=$Y2
M NT/&WI6&0P7WE( NR^=!LC,/CL1&V9*>W,5)DA0F"HQX8,D)( 3$<X)WU\5
M"_5SH5=]%9W]\>?Y0IF38BF:O7,6D"C-,BD19WF,<.9SE+&8(.Y+%OHI27-L
M'L$WI3KR46^'#8]V3P=/+2?><\T*(%QMC*E!0'\,I&#:OPO2SA%JPT1[PAH#
M)$!8?PRP["+[3D"#A?BAPO=&^8T7FR[0#Y5O)]8/?MCN]*/.4LIG5(>M\EG3
M$KNWK>T]E50G'N)CA,,H0!C3#"G;RE&<DRQ0SKAD"9TICS,O3/UO$[*0[WR7
M."R':UFI"5UXK.7%RPOE'.N>HVK; CK(1G!FDOJ1H!*))%4;$XLPRG0!4!CZ
ML8BY.E@&H"06UV#:IL.] Y1F)U#7 ,&VHV[*RIMVVALN*H=>?6*$"A^(P([.
MJ$8D)SVN0D#8/[F"GK7T.\5:AV=OR^)US@7_\>T7Y2!?+^O+'Z4NEWK@=$5N
MEJ8^3_7$YSA.*,)12O5)-E O 2=,4.S[DH(<46/2(WNFBI'Z"N:'%QWUFB__
MYCTW3.DFM?.6(8]N. +ZKN8@&SJSHT ']&X5:M7-S&T'JQ]^:1'<\.)=#J,&
M]WG! +AR@LT)3^L5@P$Y<)/A*]B9G)M=9_QKL5K-<L%TP4ZD'&1]Y<NDLBVQ
M<IIE2L(@HC@-N(38EB,T1C8BFD0]6[0)-A1+H)4XAHN9.3A36IC>WQR$M#0]
MA_&L'FD<*?$Q"I-J:X^(^VK9]U&GO0$.>F/_N-\;N^VM>\GYO#YCU[WF+E_6
MCT6I(^.SB$9!*BA!@?+'$$YCB92?05&>L#A)4I^JPX*#7@(N>!W9%]D2;MM$
MT@WIZDKL67W<OF?DF"_1S.A\D%<#,UX.!A-L^WQW7G'3_'(KPNA]$ESB/&Y?
M!2><?H0^#"XA-^S;X)2DW79Q)U9"/?1XN>2?Q*M8%,^:=G.%\OE/MGCAU>GP
M7R_S4A\8JP'<JY6^.)V1F,@L\B/DASQ&.-95V($O$2%I( 5C@N$,LAV<P<OH
MV2\U9U5*"]_RIBU\PY97BD55?OA,R_5;VVIJI2W)_TPOTC"NGOV?@7]!HM3C
M+U4#@O6C4/]?"E']<CE?"N^I6*X?5YY8:I_KN_HZ5W$ +_(O/*V2%XK.2H],
MG2LFWBZ:12]\0NH?DXLX#*R7CW:7_SMPVSKGR\1#&6029XA%?HAPQ#)$?>&C
M(*0XQ(E,$\Y@\=^)ODY68>&37RAT_'LTW7O )$RR*$R0# E!.-#]O+. JS,>
MYY*SE";JC+<4ZX_Q#DC]#EI^SL>?*<I S^X<M,T.8Q-]DV&'K1T(.VRUK>5T
M,D1K&UO6/'4@;IBK$LL<^I4.,')T4#J'DTD/0@X@VS_HN%C2[B#3Z;BKAY,>
MC/2;T2A+6!A%2#".E?.:AH@&D8^$2)F/XSPC.2C /41PY(A4E<OF+3H]K*N1
MQ!TV_M?_R,(@_3_5V.+U&\RF#:)I9KA<8@2S3E_W@/G<#P+8W)A*YLBF#)*;
MU'"8"K]O'8R?@YD I="SNY>%"/P\#I13=5\^+=?\RX(^F'@?IY\>VZG0[>DU
M513L!"AT>=9\J<^ 9CK;(WZ_EKJ1''AJ&!3:^UUSX."B>EB\(\JY$NSO#\7K
M_Z<>;O22\:TZ]BPYB0(.B]2JG,$GX4IVN5A<\O^Z+W00HTF.,%2PPR?'#M N
M%IZB^-)6G:Z+G8B@N68=D7E8J\X3%Z91 Y(ZS/SHE\Q*F8XL-YDBG1:EJT0]
MGSJOJNVN]O,[>V+;+H=3%K$\D2BF/M<#0PFB,@]12.-$YHPD"0%5P ]2'%L7
M&2OU""W1\+';E%V?SMJ8QYK^"<V^&(;3[*CJ%"28!K>D40M#A_@(C8:,)75<
M"W6:WKN4+PV*?ZKB:/A!RS39=HK,CV^;'_]S+DKM3[]]U=[TY9_SU2P069;*
M+$1$5!D5(48T9@F2/,R"((@H558+DMEI1'9D$[$=T>1M:%>6X=OEK][OF@'@
M !=#,,UL@WN(8 ;B''3@>9T@85UE=IH1G3:W$P3$078G[&D[DW&]9*6@*_%)
MU'_J@)IXIG/^J>G>TS9E7?*J0*^>3Z7.-9D?)B1$*:^F004"T9P0E EUX/"Q
M% G-9DOQH,W<O;DEL>,&%N??X\E8A1I.MO=R6GV*JFB15FS S(LE\&;F9D0<
MK<Q/RX_W0\O1W^I ?@UI&^_7B-9EH)?]B()-TGF .#)1EDQ,:K+. VK?A)VY
MFF6WUDVFPZVB=+V\HL_S-5W,@H +H=N""4RJ >P9RG+E&4DN<,99DH?$J-)R
M@,YT>6,:2*34B-6$@1U83Z!D9F <R Z,46S%UA2U];@:$!O>/[5?*%=]4D]0
MF;8?:K^H!WU/!SY^[OC@4V6$.LBOYXV=^+6>6+/211?%LAZ&.9,RX8GR;A"/
MPAQA1@*4L40@WT]Q* 41Q ?-$G?/XLCFX62!;+6Y=O]>;[3K1ZHT:>>A>EHM
M=-RE^W=I9HG>]PW!C-@$+^>,^<&N\7,^1-@9@^\T2=@UP*?'"3NG9&?@KXJG
MI_FZ)7Q5+'6=@E@RW2][T^!PTWHP#D2(@P C1D6J?,I8MW7,,Z3KD&44XR#C
MH/GO(.JCF^4-+Y6N[W#C;=FQ'C<,@]K,M(X&(-1JNL,.;!ZM,'!D^6"T)S5J
M5K#LVRN[1<YKQK.3,W^M>W/I,VW=$86)- H%]U&5Y(4CG"+"9(J2(,&I8$P2
M;'1K!J YW6E0WY-UVZ7,:S[.:\/3AV:_C1D)(^OSV&Z)CQX,5,-S5@.>/GCL
MVN\X@NGLYCNV<%FWWC$0W+3Q3M]2[])VQT"V4TUW3!X]USG_F:Z;CA(W\FNQ
M?-")5KK31'5"O!=_KG]40OUS%HB 95% 4*0[X&*92402DJ$\RX)4IF$6)JF=
MZVW&P,BFM&5'E^-\>5GK\\9M.5>;U?/V:U_5ZFC.;'UG0ZBAGK%[ &%VMHO=
MEA?]-\U-W>"_ZC]3>[>>9LFK>!K%T87!X=R--23_3DXJ#)S3+BAP'7@JX2]+
M7B[>'MJ613__<ZWTD8FKQ^7#K7)Q#-,*^U<9V:8HXD)1U_4M+0-*/ZH)PQ47
MWM6CMNWFJ88#F/3;#;=PP"R$(1(7[6A&-ZF(9M):I24.+#U9BJ*9B-UT1<,G
M+-RP-M_I[6I!5ZNYG O^6^63K%?7J]6+X)?/Y7P1^D':I,DR/U(<I:ERR+(4
MX0#GZC211RA+<X9EGK)(&$7SK:B/K/LU3:\BZFFJ !<##*2!+S8F/#!;L.$$
M;5GQ6EZ4J[$/G,WD,S"" '=M3"3M'#?WB,+\.%M$>CTZ\*+3^7:V\NYX>=:+
MP(]2UTL^?YWS%UJG-!H>G7:?&MM<;H@9#C\[(M?P\<=>))B)V])QEGQYFGVK
M\\O>4I.=5XZ+T#V?G/B$991#5Q#6ZO2IZGA1SVZH<BWOQ&JM3C[K9H)AW4U%
MK&_DEZ*48JY# *L935B>8\S5P206"&,9(^JS$ 5)X),TI#'/05URSV5H9#7\
MM>G9J%SW<L--,[3G93F')D&>#;]A)&1"4(&1D0JY9@.N>6O&XES4Z=H7WI;!
M9HAIVV=*^48Z%K5ETV&LQ!%@KF(GY[(S;2S%$7@'L157ZUJF53)U]'RI"E>J
M[!1=SE:*1[%<S5]%W7RP.2O3),WS%&.44AZAZDJ?I"E#. ^)2),@B<Q&6H I
MCYUZN>6C2=#9X<3[B<Z70]TNSX36S-Z- AC,L%W>7%U[EVOUI<Q?UE50=UUX
MMU07.8W021PLL*M<3F.ZTV9W0N$XR/<$+S!2J]'5J;9V-_6$P(YYNU[6]O"W
M9KK@93U<\/.?HF3SE:B"6+,TRVB<Q 11X>L)C2)!6>H'"-.$TQ#+-.2@AG-3
M"S"RA6NX4?:M*'6A2]5Q2?<@Y?K*L5SI28UU/U+7[4A=OVC#@^$'?GW @Z1!
MX]+50.?21J:+[IFR*M-I#J2M9%XCFM?*5L?H)VQI.M)KF:K/J6OV/U;STY%>
M#K@CZEA\G+'5Y<,-7/-];C>UGY?JZ/]4LZ[+IEA=QO@4S+A4Q^N,A"@)4ZJV
M,DD13:0Z?B>8A;D?I42"SMOCL3KR]M72\M2S3SK%S7L3:M>RV*K&>5& 3>G=
MX7>__0SL/IT2]0[_%][FI6H1'.\QHZ+L<C<9A]'I]XU1 3^Z0XQ+T28965_G
MW,CF+N>FO--;3KO3\'8GFN$LQT&(&1*TFI20,D2R,$>I3[G/N9 QCP$5]@#2
M1E;B['+Z#5GXC ,(C 8WWPY1L<M"UO1U*+?A0/M>%0\7WA:DS3'</4203&3G
M4%EF(KN!#)B-#!*^/QO9;*D)LY%!LNUF(\,>A5G,5;F>W98%?V%JY690>W67
MFS(BA (6)1'-$29YJ@?)1"@E0:A.O&G&0J-:C5,$1CZI-B2K>J:&*JA)T4E<
M^NV="VEAQLU"4&.M')*F[P"FGNT<OM3?M@>OD\M.HHY#0K6Z-_@YRR;8Q?)A
MW:;JJB4^%4]TOIQQ+'&* XS\1$=+8U^YF+%2-Q93/TZDG\<A:&[3<3(C*UV5
M;+YND\TO/$W8^[TF#2RW/ &3F8-WOO P'=Q-LC>5&][0NE<L5VVLCQ.9MGEU
MKZ '+:O[/PU34R[FL\_+]7S]=LFY>N6K[^KD)&[*:BJC8GX6$1&0+ B03Q.,
ME <1HMPG*2(QIU% L!0I,U'4(4)C1W(JTEY#^\*KJ.M37DO?3%T'X>I76)<@
MP%367GYCM345KB=]3"U1ZZSZ8:NJ@PM/HJRFXK7J:OQYNWU5+?,LRO7;K7K-
MZ\LEU^WJJ\D67^=+<;T63ZM9%-&4Y4&*HCC1\^NQC[(,JSTVYTF:RS2@F8#L
ML<,DQS_D5@Q<>!4+FRD*]9"7WS4;7L4'</,UP-)L(W:+$/A@?"XXX!W:7%Y'
MN[4!P4EW;G, ]G=QP).VF:C*W.Q^B7-"LRSE')$\43YNENE['18C[HM0QB26
MF22PW-)]$B,;@ W!,Y3]""Z&URAG20N\_H ):I&/>4H69QF6!P0FSID\)>!A
M%N3)3\(+'SZ756K3Y9(NWE;SU;;"VK $XM3S8Y^.R[)8BN)EM7?7UK!A7B!Q
M4OY^%7,E.O!,W"^U][O3LG$3&:TJ*TXN.EF-Q9!8W6J+P<_:[7:;J>5- ]C5
MIC55$(61VMP8DC@E""?41WFNCL*$,.JG,J1!XD,VO9.41M;1#=U-PVC#PJ5A
MB,SV/R>"PS1T*W-+<Y2>7(.2.=H43].9=&\<%'=_BQQ^ +Y35D: K5_H8O&F
M>\#^NJK&!U;WY_4$MKOU$KQ_PE8=66-W=Y6&J[K;\.OJ[UX]+K'#FG<GUB\E
M8! 4$,/A/7@\^&!Z;XG<"#NV'2)6^SB0U&2[NQT$W3W?<@7;7)BBO3LNZKOC
MOB3,NV*Q^%*4.DEGEE.>)R&-4.YSJDX*)$24)AQ%- Z3T ]([AO%R\[F9&2[
M9)MV[1CN?G,T*8A ZW0J660HH=W[7?/G-0Q"VDN<!30T'V<"P!UGZ;@"WB)_
MYTRPAK-Z; E,G.MS)@Z'&4#G+FCG1U8=JZ6RJ7H:<)4$H8Z]-_++?$F7;$X7
MUTMU\JV^NBM]][HZ_JLVR2&.?4&S"$7"9PC[@B&:)3["/*$TC /..*B6WR5S
M(^\Q&\)>A[)E;H33=V+FZ[X7TK"-R!)DL'\\!AJ.7&JGK$WJA8\!ZK[C/@H-
M.\/:-/IHM##@*4[S/$8^CJ2RC,I&*HN8(TEEYN-4I#@'W43MK#ZR:6M;EM@9
MLUT<S*R1M70P<V(L&-B '!7 D07877M2%3XJUKX.'O_02.7MIRH4]>WR^JVC
MTU45_OTC73:UB]^*Y:MB5.Q7+/ZD3V"?Z%IL2EAF/ S#.(R5AUR-/>.91%F8
M811%@9_$3-!4)$Y+WB<0:NS8_<MZM:9+KK4K%P_SY;+ZB:H/*>=DDGKX*;X9
M+!*I3P*,8AQBA#-.4993BI(TC4B21R0-_-ESE;[_><G_>WX[=L6S^H:(YHOR
MW^WK8;;9?0161TSL.+^NM99SY\C?F>ZUZ;FPD?9(GX5*8D^+W*F2G;#=PH2O
M<*H6#%.(]+':,DSX$L&M&J;DS;(NING&.A>5<Z:;K-57(:N:Q\WE/,MEEN5^
MBM0FJC;5T,]0+C%'0120E"0<<P8*(ID2'OE(U&&CKN7J,/*__D<6!NG_:2P=
ML)#&%%>SW6@,M& [QCY0C?D?(P\"*JRK$AQ3LM,6Y0#!."C3@3X/+V3]>;Z<
M/[T\-:W\_#3Q,RDPDBS)=$Q%(AJ&'$5!GF=Q'.>16=>6@Y5'M@0-+?,ZU5VQ
M^_7X+&%@BMJ0<=B-\"3S9Q2B[JXW607J43&ZI:?'/P#/*]*-2YN$WD]"E\G-
ME]7A0._=IEE$?6N,K P=TMX.[>JT;IX:U M#O\JX1 "F09;"@Q)Z3"2S2M_I
M77BR9!T3\;JI.4:?GSA8V1S%?ZW.X;HTINV44^A_ZD1*OKW4[8$CGF991/5
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M-T/M3W8!JO<<3.-84A*A.-7SJB,<(9J&.4I(EON8XTA*D -J2GCLK;F_5=7
M-G8>I(:!Q1&  F[U9V$$C^ !!785@3,E.VT$#0C&000,^OS[7+!T(FJ]HZ\$
M"\*8)3[B"98(J[,+(KDR17DN?9($A,D,-VF]W]?J###-+8LA]Q -W9?!6%E_
M_%@YW<#WF_  AVDLD.]3IMYO1E#&N*^CGEDN,LQS$D^6MCWVVP5G9G_^0-G8
MP!<[S27:"*_J_>[0=J[)/LY\.K>OX(-<GYER_9>Z/0.^"M>79U#R9W9;^RH4
M'U5Y_HW\9:7'&XGU+,VXVDF$1)(&B?):DAAEG! 4Q3XF+,8RCNPZKAVC-K*K
MLNU MM#$O5)31X5$+^HO5#-@V83M*')F!ML9'C SNX6BHGM1M][06"C:WF4O
M%O8MV?ID=-V6[2BM]VG-UB?VR?9LO0]9-S.]$ZQ0)N0-%.0_]NS(JKIIY[EX
MJ[?U_>- RPRXG>DN L,7 ><*#]-+8[G=7A#T"7E.']/=!:?N87I4G"/]2X]_
M[MW]^"9[CDOEKLM8HEP0??60*F<]BF*4^H3*E+& Y/%,L9\74^5$GI52U^74
MW"O0%1=>?<.Y\HI.?>V[93\>OJB01D+]GU":D!"$LRA$1#G="%.19*D._N+@
M74,K\)?E.(CR05Y4'H4QPWF&>$35BPI\BD@@)<I()+*<2YX']!UC)+:OR44T
MY(.\H<F#'7^EU. /G?W[T=-\_^+YO),E[KK*T*U:QCXN'ZZ77W2I]>7J1OZZ
M6B\?/JWUA4KYC_+SO]9OEW^4?*7^F5\OKUY+_H^R*0<T;11MN?[(/LS5H\9:
M3YKM3"^G5<_+MCM3U;5!_?U6V>_2^X>@95L27+V+55L&H-:XTD=4]:/^$*"K
MM"WTPX[1%*C#C.QX@#NL W4!G5U+:ENBTS6G/A.6G3;5YZYE68BPR>"[D8,F
M>'7*!F_;O)-4!+'D 2*8)PAC'JF?&*M:1^"$JU^3%%2UX):_D2UH>_>N-?;[
MR],3+=_TCS_6!]:5/C#IRWA@:8/C5V1V5GU'X&%&M).#JE$W.+>N>@^N3:#*
M<]K-?V147=5F..9NVD*.<: ]J/H8B8S%O(%+!5.F[4ES!,JB#,>!B!&+8XPP
MB1C*28Y1A'T1\DC]/>3&(P3V%A_9<&IB --X5/Q^NW:N4#"CM)%G^" V+!B@
MA?X9 MIUQ1]^<;"V]B<$Z.U4O__,=,WG3W"[TT_^U&?L"T>W'<2N:%F^*3?A
M\JEX6:YG)":!)-Q'B:!ZQ*84B! 1H) 1$6,FDS2)H26CIXB-;!!^*@M="*IK
M0A>%4J/GLF!"<,-I@$9HB3B7E"8IBEB>JJ.JLI19% B4)9012:.<,#%;ZUDQ
M$Z.U(6F,5C71QB$TAD=$1P+#3*N>0(]T=:6GZ5]XU3?%;4'LD% .2V%/DIJ\
M"'9(Z&/EKX//P&-O=:?$/TM69Q$:1M1VGQK[KM]B8M$1T88C5O92P52J]GM<
MYQ>>EL J'+2WU&1!GN,B=$,W)SYA<:+7.J7#>$NZ7-]6=V0W2]&< K&/$U^(
M#,6$2H2#F.H.>PSQ3&W[H9!9'F?&I_L>0B,KS_UC6;P\/"KCS2IR7A!?>.I%
M1X #<A],!EZ (^&!80K=VZ&EZM5D/477QD'HDQ_@+#C"P<YQ.(6'(S_"0+9>
MGZ+O^>G\"P,I=GP-D\];=@S6V7UM@>(+7>@#V.6?\]4LR.(T2H1 ,0TIPB*B
M*/-9@OPH4N=G$L12&.WB0X1&-DL56:]#M^JSXOVN20.K 4]"97:J=@$ \$1M
M)3N\P>^ 8*X:^IXB,VT#WP%A#QKV#GW>3FT_TU(G-:V4,:@"D=M;@(3&A# 6
MH)!SY?VF881(%A+$91CZ"4YSGH"J>T]2&EEQOWV^][[>?/_NW7Z^\[[_Y^7=
M9YBVGD;(3%V=R W3UY:DWC7K>PS'LX>-97.DLJ?I3*JS@^+N*^WP [:-GSZ]
ME/4!#M3TJ7UJ9)7KIH"U)*%]GS8"#GO!]K+!U.I8OZ=!\2Q:/>U+<D:;I\U2
M$[=XVA?AL+W3P2<LL]-U'O7U:O4BN%I1O9WZ5%MERGQ^>EX4;T)4G[E5+_51
M;:$ZT#XCZBB:Y&F.<!YQA#,:(DHRCG+U/V$<^")@1A=A9W$QLA)J=JHLV$)Z
MK'AZ*I;>JDHZET7I,;IZ]%Z6>CB]:/AK?OO<<.@]@_,0[-Z%V2XZ.L(P4U"G
M[]?\>#5#C8MZ46=I77@M5_7L$*_ER]%=F!-<7&6P6O$P;9;J.3 =9**>M9A%
MU.]+43Z)\O.?@KVLYZ_B1LHY4P:A">CD(9-Y$,4HDZDR9DRJ@WH41(CY,M<-
MQGF4&F54#9,:V6+5M+T-<:^E#HA\]4-E$/MS!@#,H)R4W2;\UP\"( #H# R[
M$"#\"P&+ 1J)UQL%[%]ANCB@D20[D4"S)\XXE!V?:Q4F/$H2PE 0YAG"-(T1
M3;E ?IZDB2!A%*6@#(1WFQ!V;"*8J!CX#XM3TSE#P-YC[%=-Y\*[7*_+>?ZR
MKA(BUX5W2\NJ =@(X[\F&_CU449\P8=Z.1_C=7;MS>!$PVIRX>IZ61^AAJ>T
MQ@3'E,09(E3ZZK 3Y8@0*9",U7])E%!.8/;CHT@VLKFJ""I?Y6./ZX5^&PP-
MY$?A=T1_=++!O;7(NIRH]7?_^\SOM7R=[UT(ZERNOT8!Z5BO<[IQOK8,6B8.
M;3GY0EG5,_B+$+-4R"AG/-$G\A!AGF)$68A1DN:18,P73(:@M*&C9$:_G=>Q
MS)4G&XJ>%(9Y=P/H&$0,G,@,,_=5;LR6YH774O6^.)(;F"5TMOQGY B!<8 G
M"O6*-Y@F=/SI:9.$>B4X2!'J_[2%^?FN>*PB"PJA\')]_RA^IN4_Q?I&2J$C
MJ$UHBJ4D3GG*D22!.MT+S%'FZV1&3L(0Z\D$W&@H 8#FR(9)TU9>LJ>H>S5Y
MKZ4/T%-#^ R,E7M0@ ?5EK[7@XQ-S-,0(H!=<P^5G9$S@LR1L8/)W&OY#)>:
MS@S"9-NQB<!'[8(LUTM6/(E[^N=ML9BSMVV>41KX"4F(0$E. H0S%B/">( "
M*H0(B1\KTPB)>9PB-/:%=$764W0%L$KK)#)F_K\+>6%6;BOJA5<3]7YO_APE
M#VM(0D<>ZDDRDSJ,0\+N^V^#G[<8*B9$^5-9O#Q7M\#EZLMR^YTTG3-V>HF1
M]5!3]BK27D-;G9N+8KTL(-/Y^B#H5TN'TL.TLD]PQPF2AC+:C2WK67>Z26;#
MPNT,-S/XN(5;\3-=K2A[?%F)]7I594BWQ[PD%"+C.<I)%NJA( '*@CQ&&24^
M"V1, YX;.Q*GJ(RLISMDZZ[6@//P26@,G 07 L-4\XBL-D[ Z>^#^;'?A?!V
M!WW("X<=ZX=DZCW(GWQXNJ/[$/\[A_7!#]L>SY4.BY6>DU3%<>MCQ2R-DB3)
M>8AXQC#"218C2K,$<1[D01+FG,'&"1PG,_K1O"9:S?$JJEN?>447>DX_"I'I
M*?U<P:%G]([,]4W7=;_,%L?R/I&<'<J/$IGX2-XGZ.&!O/?3MO6'JY40N\,&
M="LFW6W@3L^.#OV,<9E%B$5<(*Q'%M(TY2@.,.$D3W@4@.J9A@B.?N.A]TC>
M$/1*X]':QH"9J:U+&& *7%/6;83W)G^TY+T[)S.XH9(Z*U,<(#=QN:*9\(=E
MBX;/P9WPG]=E506YNI%U20G8!S^]PNA'>_70O*FCK=JY'JDM,O?%>Y 8=L7=
M@  ][AO(/X)+/BRKE4?>L^QD#OFP:%U_W.#3%N[X555F5&4A_EJL15OU. NB
M%(M,8A0*/7)+AC[*0N62^S2.,TQC%@7F%0HGB(RLL5>="JH+[U5'C#;I<P '
M]11"!DZY [EA2MJ(_+T66=/<UA,[$!G@DCL0W<XCMX( YIH/R-;KF9]Z=CK'
M?(#[';]\Z+,6K< 6B^LEG[_.^0M=M.4MI@W!CCP[L@U1)+T.34!?L&-R#N_L
MYXH(,Q=[TCEN,-\GBUVWL&,+3M<SK$><G<YA?9^SV*%_HV65<UA?A>U?I\8B
M)XF?Q,@G%",<J1T[DX0@PJ7P29!*QHU:]0R3&EG36MJ ;:H?&8/]V9F\,+5K
MR=K<,T-1 &S9SM"PV[CW4'&T5QL)U;MC]Z\PW;YM),G.[FWVA,U5>@';N#</
MC'U-_OD&<AM>&&_+5@+ C(+BW?'^>\"TY=5U,?5.>\#X[K7T_B\MFVX73WH<
M#[LJRN="AV)U$NUWP5[*^7HNVA.;Y*F?1I2C.,0!PE@$B-(H04D8IJ'@4B81
M* )M1'5D+?GE[]__[K&6 >^9:J]8WZCDQ1+<C-L(19]2003&B/JZ@MC/ I1Q
MEB"2<!)AR:,XE;#IH<YQM)H(.CV29@%^Y^C 3%F5XM^0>[OP-EQ<>+]\=VCC
MK*1UU>;;B.:T_;XA,!PT_@8];-L!3?E%W^B3<0/PG8=&-HJ:!+3?62O.\/G!
M6A*8XAV)R%]T''RO5TB+KF=[ IW1]*Q=:>*>9WL"'+8\V_^ ;7,-I5'Z;=S(
MGM81U.<DCW-UUF#:E0\2C$@6$Q1@XDL_BGT>&#4#!U$=6:TV/%1SO#I<_.^V
M>-F@[\09F)KME\Z1@JFM$Y LFG, A';6I\.$YL0M.P P'';O@#QL$?P[=A=?
MC\*]D7=B*?ZHNPJO9FD2"T%2J9/8=.O?+%&';2R0X)S(P.>42*."$Q#5L??D
MBJ16BK(F6LT.6GD_O#Q[Z\*P P8,1H.@X1C@P.S%R2R:!K ;Z36,U)?U8P %
MB"N. 9A=B-$9<+ 8)!2 WG"D\6+312:A\NT$*<$/VQW!+E_I?*%;7GTIRN]T
ML>??7#+U=7I9*&/.J]%3ORQ+01?S?ZN_TOGR1R&+4E<CS>(D$(QE/@H$X0B+
ME* \2#@B<1Y$(I513$"#$9QP-;(5KJ>V;6E[FC@PN.$&?;/#W.28V@='%#\7
MWH9?I&@CS;'ZMRV7WE'\+[R\8E77*[H[$CJ%SM&1T0U/DQXIG<*X?^1TN[CE
M!(JV8ZXH7^=,'.^V\ZU8OE9S[.NA]M4XP^[OKXK5^ENQ_H=8WPE6/"PUD]N5
MZH?VN^_, B:""(L8!=H]QI3[R@ SAH)42C^._#"3(!_YW209.\:OWGO+REZ[
M<)17K<18M^484Q*LU"F[MCCKPGMI)/;NOO\"M/7O]^4PVQ_^$J\<&$ XUB*N
M&P/<B+/I'/<G6[Q4L<*:.1VE7ZW5Y];>FUA[6Z'47E1-?W0X@.2]\7<UX.3=
MY)AV@,I[OZZ# 2WOSM#$#5D;\K_6\BSYYS^?!5,_WA?ZGYH)G_I$4+M-LX!G
MA+(D0&D4A B'/$59EF*D&S4SCI,XB:?IMPID?.0ML6:CZJ9:I8"OIFJA"GU_
MAC'K#_A6['<MRP:HFQ:GS<O5=^^M//H8H__YPNO(U(9Z/D!K4\OW\-Z=2Z%L
M_S4:DUJ^#&=]1VWI6Q;>%LL''533ON//=-WXCG?BN>9H=2-OR_F2S9_IXDX\
M*<>1ZVC<E_F*T<4_!"UGOL BB8E$) WU5:4>-$A2'Y$X%00G><XQJ(+^7(9&
MWCJT]G@_E"UEX,9Q-MIF&\*4& +O*Q1GJ!H_JGF[\!KNWBZ\#2/ZDJ=FQ=.\
M.*P =H2*JPKA<]F9MH+8$7@'%<:NUK4S?^K@+U;U,*A@EH8T2%,2(Q[&%.$X
M]U&6Y!E*]4 Y]?Y\'"004]9=?&2SU!T7M] ZIJ]'/:Y A1FH'3S,C(VME###
M45%I1K:Y,PG'>'>DWCM+3ZJJQX3:5[NCG[$HX:N\XZM%L1+WQ<_+Y[EN#G"O
M#R?@:GZ#I4;6H9H#KV)!3TBXGS]54W%^_G9[776E4+]X*?4]3<46H #0 *5^
M71L!()CZF6+C_5YQY+9/)E!ZNX)"@_6GJR\T%W:GW!#PF$4"TN[%_.5R^4(7
MVGNY4_OT3"1I0*(D15DN&,(XH"B+0XX"(7,J2<H%,6\2T$=I9".PS0=9U/D@
MM*+NZ9L2G7MDN)\. ]:O\$YA@*GZ049,3=C3E'5.C#,$ 'E#KI"PRQ6R1P26
M'&0B96]"4.\"TR4!F<BQD_AC](!EJ)T]"OZR$#?2Z++@<E&](_633CEJKP/J
M"2_ZHF!5F=,9"7.?Z@HP&1*!,$\"I*Q<CF3L!WGHLX1D($]A%"['SN>N8K'Y
MZ9M&';A:KII0[!5]GJ_K](/V'K$Y*T"3O4=YH8:!]O=^38[O@L]^0_ 0^9@(
MNHJ'C\+CM,'O,6$^B'2/2@SNE'[1\[8NJ\A1^8_R\Y(KQOZU?KO\0QV.?RJ7
M:WZ]K'ZS^K+@OZ[6RX<K7:+YJ50_J-WH'R6LH-T-M9%M]:T"MZS"J9[BL#/7
M3\>+FL*2QL5K1TTJ)^]R^>9UGEP_TK5^=%$Y?D(H8_+\O)BSRN'3=Q/ZA*2E
MFU<7&%X]75W]RZLHU8*]P=RQ7N*P6SW]^X,9\8_RZAQW)' +NY7+[XB%R:("
M;B'K!@X<KVQW4K^K4PYO:;E^^U3H4/],9A+'"8L1]P.),,$!HCC*44C"P/=C
MSD@$2E\Y)#&RW6T(>A5%[_>:)O# >P07L]/J>=+"K%0KJ#Y(?BN694?NN8X*
M#DD./DB>%L[1*? (@4F/<*<%W#]_]7S2J@OH0OVL"__GKZ+C+5SR>G.@B^I8
MUUP>?"G*.SWW=-7L/3/IRR21#".6QP'"(N.(<BQ0XF>4QCX7)#1*!W# RQ3^
M[\J;5[0]\2=[U.QY4NVY9<5&]>-#9W(W*-?,Q<LPB#%.!S',H.SPM>NU;EGS
MFG=0,^<I[KR:O?8H-!W4H'ZH4T%NVS9U5.BA#59=@#70A_4L$E.V:W6!Q5Y7
M5R=+VIWXKNCJ\7+)]1_:D7FE"YWQL1F8O;U6G)$L3&A.,W7R$Y$Z"#*!<NQC
MY(<BPX'T4YK$L*Y1QK0A^F;5.4JSX(DM#[#3H3F&9H?&47 !FGX-2!V15#]T
MN+CH>K];3MP=*L'".SIKFM.=] @*AF/_9 I?X(PLKCO!7UBU^Z91HKM<Y"C"
M 4<8^[&R%@E!RM4588PQHQFH4]_N\B,?*S__J8,Q+_/58]L&YNQ\KBTR9C;
M7EZ8HM<Y71M"CM.Z#@1PF=BU77SZU*X#P8XF=QU^RB*]Z^%A_;DL=?3^\FEM
MG,FU\]3825L/#Z5XT"T7%<EB*8J7U5X%27_-XI#,PP%D>W%AVG*NI+!TJZ-"
MV656[2XU71+541%V\J6.?P*F)US,9U\5EHO;1_52FKHM(D1 ?4P1E51'0>(
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M)L-&'7*R7*8$Y2GW$<[3')$T8TCD48R)GT82@^:Q&5$=61T;'JK"/KK#!>S
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MOK>B^":*R]>':D12-=EY\79+YQR0US*PS 2*JT=F?5/_WS;YW>TOW+#C:7[
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M;@07X[6L+:NC=3U.;]8UKBW^X7K7?]':.4HY9]5'R7*]_RN72[7P&6-^$A"
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M8Y+L!7+OI\U>,I#+(/'F6ESN*Y_JX'3)C7)N5TVVP"+,((L%\@&*PQC ,(8
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MAZB!J]ZIPRU:9HMZ'ZA^V;U]SXK#RI[:TKJJZ#E.<-Y*GMH '%7PU'_SDF"
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M#!,8QHF/]8ND#E":V%ALVS[C+3W;WN1#8 TK;J<0F*G9EFH32;[M@;VC[ H
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MC@%"JBU8$$& PC0!) A$A%+JDX"99<P/4#/YZ*SRYQO:WCMO2[VY\C(,?AG
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M7F=+<([\T+;CV(=%-U7W;E;L@SP>+@1FF$<A!\(/4P CP@&*4]6L/( P$%D
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MY;RZ?L'Y4AEZ'XOR&U[RKQPO\W]Q]A><KU3(^ +Y.$Q]PE3&()'J!_N <(H
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M[N3O'W';HZ%Z+,HU6*N0X7SUPMO*5(8])0TAUM,74\!F5[FK942Y3UI6/(U
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M\W053J_FP&8F+!9&AC9B[55LP0L*@DU.V3&GF=?-IT4]1M"X20CMX=-.^CU
M*:7SL_/U6>Q#63R7C"DD!B(K8+!V3U>10<#(P;#"F& R6]ZZ2'QCXL9MB3(
MQ ;12@=P>X\KD@WFJ]+#JZ-_IF2Q%&ADIQ/)*G%P7G((HM@<HDG6MI\/?A\E
MXY:2MP=2 WEW@)J'AQL;E6N"8@".HI9J80"'T9&HI'&"96-S:Z/T/$:%-XG?
M]Q)W![BY;R!MT,GGP("'6%.IO8 8B0/I@A<AN9)8ZT2 YS,J?"OU;C J? M9
M=X"6QV96.\85ANQ )_042:8 'I,$Y[S3%$TZU?R\YUF-"M]&TUN,"M]&[%T$
M\(_-K-:,G#4?-&1;R"1'B1 E[;S&.Q7KY&.EFE]6/*=1X7MC:'^Q]X&A\[BL
M-Y*+;R?A%*_;YY"T1^$-^7]<@TI*@+?U4*MP'FAU&-9\@,>#Q'0R7+6!M]-$
MW#WL7S_(?QO.Z,MK67Z7:\PR+9U1#D(J%"T&VN6]%@JB4LF;(%S4K;V?GU,U
MLC?41OVW0=56%R.BJR9H3 ZJ6M^=Q]-I.B[T>@HE+ZTKRS*(H#VP&$E(EED(
MNE@0UF,D <IL?YKQ\?@K1H9'8T7.FTMU;&R<X.?5FFKB1ARL/GS"W\+B[[4.
MZP9+*EBG S)P;'T70_Z<4R0O)PSWY,IQ]&PCH&SVOI&#\0%1,X"\>]B\[J;P
M:<FS*61ZM?6UF;A7Y/=+ ]+26@A"%QE;EX'LF$T[_ #PAH<ZNPFX XC<+ET^
MFMU->GH_/SU]/5_\(RSR1 ;)G546BO3KJGD+D?$$ KGSGDNG_ #C[K8AL9-S
MH!T1<:=7\G#JZ0!]-V/+NTW#B@J,2-80A9*T-D.JDWH"6!N=,D5EWMQ:_82D
MT2L@AX/#EO/HM]'-SE#[O.ZO0(MJL6JT(]X6UT0HY3/])@A=TQ0LHST]>0[,
M>XDZH<V^^2GD'2I&GQ/W9+#:4P/=(.G1H<0YE9KTXJ!X7_N96X00,H,:W]9%
MXPOK;AKTD'-RG@Q=S;32#<[6O%P,3']U7D.1BY8S%]R]G,^^D Q)D<?EXNO5
M-%YOB30ILK;6]!9XP7B1K1=C,>!Y$+GH9+-HW?1G/XI''\3SM);P:33;@:OW
M +?_$4[/\>?,ZIBM*B:#CI&3LV$SD,.AP+M@G$TH=1YDD]Z5X-&G)XR-X@'T
MVB^(+Y;LQ><DTQ-<?)DFXDXZQTO1!9@E%E6I>XWCY.>4VHR;"=J&6J>E;T?A
MZ',;QH9I"\WUB\OU(KS+G,W.QF@36&YHYZBG$B%+I&^E3)PI(?E3&M/=4#GD
M4(BQ4=E ;_V"\F+)O<5_K'^TG&1MF>+*@122Y,=D .]=!*F=3]&X;%/S^_>-
M*!M]:,38,-Q'4_WB;[VX?C EG5#",P1T1H)2)+P@&(F1UI@/R#3)]0F-X7;H
M&W)BQ-CHVT-/H]_>/L+1W\)B$6:KY>%77*3I\FI4QH3)E((6#A(OB3P.@1"Y
MT% <.AF]9AANU:0]=)6[_<O''QDQ.-B>1"_/"G?K3R?%1F082YW;FNOMIZ"O
MBH2(Q"EB,*A*>]BM/]T,=<_Z+N4IM-+O3GNQ@J[&YV&N-3@X6ZY5/!'!.Q*G
M 6>-!A5RAFB9K@V%:FJ.I#BK?:.(K<G<#*-_G(N9 978+T[7:^X!#F,@-]<G
M#SD;#TK7L7T<-828HN6:^.3M6^YN2^5F*/U#7/ ,K,)^07JQ#@_//I_.OR&N
M?^G=^2)](G;?G8;9<F*MB2[F -$%DFJ)M&=HKZ'6'1:GC"OYB9#Z,U(W@^L?
M_XZGD3+[Q>QZ53[(Y8398I):W_:33%6ZZ.#-H* 7AB<OHFI]2[X3H9OA]0]_
MF]-&D?VB]6)1OL?E:C%-J\N\IX,JTO4 #!)OP>GJO :%1B6T/ED(I:;TU3%R
MSM&W/*3$631,E=8-9/8F>C,4__$O>YHKN%]$KY?M1OQ*X3.7AL0K$TG;<P17
MN"3VR;%GA;:<V+[GXWXT;X;G/_PU47/U=@#G'X/<EA_F#W0&6B_F>-O9?X\D
M^.5TA9>79A>">H]I_G&V?LK%^8K+&2D0*$!2<:"L<>!9RH#!<,N%=@Y;MYX?
MFJ?-EL,?XKJJ*WATL%R&GI18)%/990>9(;EW+E/LG)R$VNE/E*@TEZV/ZKH8
MK/F'N%WK"1P=K)6;DZ"5(JF6&K-X@S6CPD-01@#*C#X:+B2V/C/9?NJV>-87
M;_L+OHO^$3^KAE%1Q\*1.,BU\M2X0%L&C[4XABNM+&?-6R"UJ%02S_IZ;0CE
M[)GX?SC+0Q4J<6&,<!2)IE+3;WQ@X%(I8,FW-X'$%VSKX26[%BK]<2[$=E=!
M)T!ZM")&Y.R2T1)<O;I3Y-^"MPG!)^&1#+1CK'7RT]YU2N(/<8_53"U-8=;I
MQ)OA!^UN_/*N9N$,/V)WLV$HB2=6HF84+RM->!4"?*WB2+HDG8+W@K<>N#O&
M8!S+K4G$*]0V>:!*;6B.T@!G"6LO66:&FT3W; ;C;(.%GPS&V4;>'826CP_N
MB 6YCRQ JMW+55**?%!)80]J]#DEU&:PV<W=#\;92M-;#<;91NP=8.C^9M5<
M6)5%UL $5Z!"#!"DN!@,&HNE3['U=>.S&XRSE:(W&HRSC=0[@,[= 1PB9%NS
MYB$('H@!5B#X+"!)]-ID5,:TON78;<S)$X_$V4JQ/QUSLHV4.X#)PZT9N8Q>
MF5! !K[N7U_S.!6)12O/7#;<ZN;I.'LU0GVJMN][[4Y-Q-T#;G[>?<]1W)I#
M\9"53'7"N26)$5LZ%.XDF>7,FH<!S[81ZE;JW[X1ZC:Z&+MLY>&6G9B*,8ZV
M<A'7)RS$#YG6FLG+>2P^E5#^Z(U0MU+D9HU0MY'JV-C8L#'G^K(1@X;$&:_]
MR!4XIA70%TESY5C0:B.@_$$:H>Z,F@'DW</F=;<KHPE!2<,U9.D-*&$M^#J6
MPY&(6"[&Y]NM<\=JA/I4_=Z;!.&[";@#B+RZ?.WKZ2S,$M:Y\\NWN)HH&V0Q
M+M8,( =*,@.^,L0X*A]5+!0Y-,;) Z1T$GWOJ.%Y>W$W0\VHUQX')W]]_>;X
M;R?#W&M\?_H(%Q?W<];^9N)E6'YZ?3K_Q_+[(;00KE[%9K)=CE"D:I_NX )@
MC*)4":KA#EOOH:?Q/03*8#!$"2CK41>KPU=8SJ"-]S9Z+IEO7S?3Y3W$?IK_
MR?7#-F+N8 -[_'C4U0$'+B;0N::T:N9H<W>E)H3+5+@5OOV0DF=S_;"5IK>Z
M?MA&[!U@Z/[STJQUYL58*+K(.BM3@HLE@';<RL"]IH_^IU\_;*7HC:X?MI%Z
M!]"Y>S".SHCL-8-"?B H6P1X)R.M+VZM*5GFYB;G65P_;*78GUX_;"/E#F!R
M[S0Y8:/1)13(5A#E.<<Z5@5!<J<\UTH4UMI=ZV]Z7WNP["WK#O!R3]CI<PA&
ML  AD""4-1*B, 4"6FY9RBKS/)0KL]W)S5-=4#7Q7W83< <0>8NK&@>\6\R_
M3"FN?/'M]R7FH]GQ9XI:5]/9QX.TFGZYJ&SY'B48FTN( DJIQY>NME<0Q@$&
M*;*V!6-SCV9[*CMQ=W;$Q=WRCR&5U <,KQ6X8+0Z*Z')6M>ISY$IB([,K$7M
MLC&T5[OQ*XL& \_0VGZTMF@;T7> FQO5K+44=9:FIWB#I0_S;:7)O))"2@^<
M29*FJBDN' L8;GT6UBC6?"SR$'R,N\L^,8I'!T('B^&!%EZ.1&HM%R"0O!S%
MI0%O:LR##J,OZ\NIUB[?'IW6A@+D^ BY[3SNKZX.0%<[:]1+J*OTG%F^:LMY
MK?OZ\>+E:9A6+R@9G3TW$ .O-U1>07". X5I&442+/K6U?!;$3BNS>P.HL,I
MMP/D'IS5ROS_7FOWN%S<I9((U[>IQ.FKZ3+-SXG52;3!!2X3:.'7';H*>&*T
MIIR)+,DK\J4U:#>E;=P<B.[P.HA*.X#J*Z0WI^F:+_KZ%-<:GN7K_$X<LU[9
MR*$(3!1A:@N!14819M(.C8W!MG9;-Z%KW)EDW4&TN2J[Z/!PD-+B@I,;*_#[
M@B,&WRWP;'I^MCR:?<%+C4PLD];YJ"#Y;.M000T^:0.&F13J=N&:=T[;C=)Q
M1Y)U!^(G4/?VL/87L)[AQ[#"_*%-"NW;^:P*]DTM:3_\6KUTG!C'G$,K03I?
M2V ,0E3& N-.<E0L"[R5_?A ONP]#Q]WJ%@W0&LB^PXV[K^$Z6Q9Q49N\NSP
M:Y70^73YZ2(!YQ7&U<0+;7T*&KA*O#K-NH9[!@I3ACR1:(MM?2'S4Z+&G2'6
M#0B'4>*^AFU_FU9)OLG&]]45"2RI6-!81V=X5IMRD)?LK1!:VX 9_4:6[<%7
MC#L7K!MH-=1#)U:NRNYX=E%=0=(C>:V^U?[6ZXR?SY6YB1:.2)<90K*U:BLC
M>&?K<$B5!/,, VM=B;T99>.."^L&E .J<WQO[HJY=4M'\BP2"?1"P%>+SEOK
MHG0.C$\(RB55>YPI0,\Q%M3!J]8[\8/$C#Q4K#M(MM%:/RB\VRWKN^0N>_!^
M%QL7*1>R^6 CJ\M,67!!%\#,K2XQ*9M;MQG;G+J1QY!UA].!]-K!'G^7,XKP
M/X=IOBI&NER0%/JO%^L!N<L4\NL@"TO<@S*"_BE!4<@O&:3@Z&,1BPNMRRUV
MHW3<R\FA</-3>#978L\V]N5\MI;AWZ:K3R_)<)")N&!Q8@LS)>8$-GD'*GH2
MJB\1ZAAS25)%8UIW7]B"O'%O)4?#9AMU/3= OIF&.#VM#5-+Y-FY8D"J.G@B
MU)'1D;YRUL? 63+1-+\LWX[$<:\?NP+F;FKK<F,_2!>G^._"MW6&M%=!>&\B
M8-1D_A47$$M)X(WE2:!"J?3@.+Q%U+BWBJ,A;Q_5](JUQ3G1<;EZR ^?>"$T
M5UJ "77]\" A2*; >NY$\5FF)W 9[](U[A7@F(C;1T$=@&[S3-2)+%E)^B\$
M+S.H=7Y^9A($<6LT9]PWA][FU(V[V3Y]5OH02ML=CG-:8D/"\>*>_'Y!&FF4
MCR*!#+KV"HD97!$.F+9)!Y:SS:TWX.VI[*2HZ\V0%3>ME-2!520/XFH(6/JO
M\^GBQTRCFMIY8Z;1^HI3%!*>51%X,,2>80QJBQI(R7!?!$,?6Q]#;DEBEU4[
MS1!SNSQU0/6->D/]G<'%/"'FY6N2=.7G8)9_"ZO*TK?C\C"SDR"C\0XUQ'H?
MKV(BH:))P)Q5Q0>EA&MM*W<DM<OZG,'P^@3J[-&JWK@[):9_7)^R@)YB-%8'
MH""08!G$.J?$!.>=KA?_NG7NX^;4=>EK/IDM;:.T?@X>-Y?GA!D=M"@2)&IB
M,!0$K^L^X2PR;X*5S9/(-Z=NW$.?)T;E0$KK-P+Z7JYQCR M5\K&FN?I=*ZW
M_!)\<@52P>!#TDG=;E$[%"P?H;*3AJ2#1D"ME-3#7GW-)?E1Z':M2=!$<25S
MD@Y"BK4?GA(0,RI0209AHF)2M$;=3XGJ,LIIAHI'O,;]5=1%I<R5LW%94GG%
MU;I$;5*T+4Y7\ET=[UK3FJ+ #%SXRAJWOK1NK?(8/5U&*(-AK95B^O'['EH^
MY$(L5E.*MVXVN9HH<E.DI_TBFUIZ[G5M?,YITXC,A(0^Q.:-+[8DL<NXY*FM
M7POU=;O_OIG//M(*.%N?6CG!63%:@>.B@#(*Z[+3H'1=<<E)M*U;5_R<JBZC
MD*?%X,Y*Z@%VW^W\W?J+"V/O5-3.:@^)Q0@*BZXIQ0&B<TS[:$J2K?-N?DK4
MN+?/HVW%+534^WY\U5)C$DMA+J<"K"ABBLQY;;_-P-HB-4LENMS<^WN4HG&+
M4;NP=#LIIP<K=_V\O7H'QY^KWI:'7W&1IB3(B</B$Q(;R*NWD)D +XN"Z$4)
MDD1G5>L.PS\E:MS"TQ$!M[^*>L1</3]?3J1!QY3/4!19:,48N:4E1PA,4E1E
ML>:(# VT-27CUIZ.C:[ME=$!I#87VL1&XDOS ,0&.9\I"'",%= N*JFU8*:Y
M/=N<NG$K3)\8>@,IK8.;B\I6_5^]$/P23JN/^AY)8M-$?F+]P<$LW_S@VF^^
MP\5TGN]F6*;3\TQ2.?R:/H791WQ//N=A*4A*4-)F@\)"JF-V5:E)&RP;0!.=
M%IB8TJT#D:?E<-Q0NO&-2<?@>.Y+A[:M[#)# 5C/MU1VM?&^=, ,ET$G[TD&
M/:V$<</UGH"]E>IVQNGG]?(AOA>K#M"J<PX>91U/'"K+BD&000%GO C),:K<
MVN,='JV#Q?E=H74;U>V)UL-9FTS)D_//GT_7 @RG5S/=CF9EOCB[4.&52Z>1
M:RZU!ROKE"4G:U-!88#D&27]PX)H/OIC,]+&#?L;XV\(=700B1W-Z%FT;-Z%
M::ZS1A/Y&H:I!$R6VD%51?#<(23AL CR1"2FYE5:-T@8>SC] &J^4XVUN\P[
M@,R56+[W;;G*7)OE>V+!VCSR=+X\7^"/]#F7M>9HP&H3ZUPX"\ZY.IO"Q618
MR,JU'C.]+\WCGC$-L)4^F0)[ .SZ:GVY[F5ZT?#\K%;;UML S'P2.0^,JP "
M>9T+7R)$YSTX'Y@S:$L6S=VZ1RD:UP(^+3KNS/)KIJH.@%>O.6\D'%'@?U[I
M>'6^("E>2OAX\8[BFVDXO?S^PR+,EB3(VC%:)%="</4,K68:>RL@8C(0/..U
M/XOFNG6 O#?1XZ:7C0K?IU5X!PB_+%)?]Q?*TQ7)\3O++\Y7;^>K_\2UFS-A
MWC(AL@(G7085R'.*7C!()5OK9(F&M[X$WY2V<9//QC6W0ZBO U@2Y;A\C_G\
M8E%)K6A9^0@E%=HV2DJT8RCRF))$C,YPU7Q4TDT*QCT0'Q5B>ZBB%R!=>1_)
MD?MAE0>I=/4^0DW$M!Z*E%D(]"*PUK'Q]?>/>_@\/HAV44,S"/W+KW>D3L'8
MW]<_6O^D_M5[++_4___]_=&-YW^9+J9Y&F:U]U[XC.>K:5K^.<W/+E[UZO#D
MY?NC=Q^.CM\>OW[Q^\G1V\.3DYL,+*=GGT_Q)K;NMNB^_T&__J#Q-O67S[N#
MD[WIQ:\KVE P_VG/IKZ+CV%V.8:"(H/E_'2:P^5@E7?7>/D^$RB<?@^5?]QY
M>S2!U[&7,@;:N[B0X*-F$)G'R(.2(K8N'6]"^+ZVZ\7Y<CK#Y?(5+M-B^OGR
M]2_"<KJLS9]_4/&!U/7BM*::<UVXRG64MO4UT]<C!$YK-*7"283,YM0Z%-Z>
MRG'#XZ?'Y&UC.+!>GX/)//G]M]\.WO_G\>N3H[^\/7I]]/+@[8>#ER^/?W_[
MX>CM7]X=OSEZ>72XDPW=\,G-C>HN'#6RLI?-YVC_?D=@3M?3A21:8;GSM&>[
MVB'6%0A"(6 TNI"[EK5KW1WF86KVOE";?IQ-RS35XO\[+_FQ5EAQ7M:,I91M
M[;U'P;>GAP'S*EJ>B&73^G1Z,\I&GK/:!B5WKM7:*^4Y&+"CM_]Q>/+AM\.W
M'TX.WKYZ?7#T_C\.WOQ^^-OAP<GO[P_7G^]BO39Y;'/3M34OC>S6ZS!=_$<X
M/<<?P<:U;N\4(/#B.%B+O'9+Y!0D^'IT$43$X&VQK2W78_3L:[N^^Q)',WK@
M^=J9^/&:'^M$8V(R> <<$S&K:^*E]QS0LI*E\,DVG[RW(6GC6J]F6+EMOX90
MS',P8.2;O/_]\-6;HX,71V^./I!O0FO_^,-?#]_O8K<>>5IS<[4IY8VLU&5+
MWSH[<=US-9S>B )RS!0%*'+Y0>50V_QZ UF)9)F+R0ELO%H?(:?!L-#K38SO
M=IB]&C]P[:,?2^5E/76>K7ZL& PQ\)0<N1&\]ML6H?9D<I"L844K$[QN'8NV
MY6!<B]<*=_?,"!U+R\_!+KXZ?/%AM[,[^KL!CNIN4]/(JM6+SOO.>+-5)0H-
MPA.F5#'V8I<S,13!)*<-L'5GG?LI:7%S?]\V3F&-TR8'R%B'"%F-$%+]JBA=
M<M*BO5OY "GC6I<&^K_O[GQ?D3=L!32@C7AY_.;-P8OC]P?U"/W@+^\/=P_X
M'GI4<TNR$<U='?MC$=Q)IB%SF4#);,"9HB%%EBT6R\3MH:=_C&/_E_-3^G1>
M^ZE_P8-:YOYQ_8+[UE8*OACD#$PF02E96RTD)0!5%*4HSI-L7G^S.7E_A(/^
M;5!X-QEN&$T^!S_JY?%OOQU]/U1Z>;P^!C]\N^NQ_F./&\!6;DA[(WM9&^=-
M+\8E$C;K%*,I(666[K^'3S:ZZ"."E(F!PNS!8>WP(Z/BA%(O=.OKT*T(W-_^
M;?"R'PM'1A%*R:[.L""G(I&CX1-%(3IJBC\8:I+2&.+HQ H.AZV[UFXPO3T+
M@W?P[NC#P9N3#\<O_WTG"W?][]N;M >I:V3#:K'>ZMNU0"(@QYHLE#UMFXDP
MY+)PD&J=C(]!HFM=(G^3@KTO&VOR^J?Y*:W.Y<63:P[3?4 VM"JDX0Y$E/+J
M!*0(T%;(G'U1%IO?-VY*W+BV9P],W+EF'$0=S\&N_.W@_?N#':/+[W_;W)[<
M3U6K^/'!X\<?)Z")&2>BAL"9J/UR$)S5!*UBK"P1M>7-@\.?4O5T-L<+[KFM
MT,YIW6?/0K". ]=!INB<3*'U.=TSL3F-L;.['=I&1<_CV.ODKP?O#U\<G!Q2
M2/3;N\.W)^NSI)V2M.Y_4ONDK TH;G6@_AT"ZT;H=5SWFOCW>%J;5:Z+B4X^
M$81C6&*^ZJ3Y'9.*!Z$%6BB,ZSJ<UH#G3()A/LC,=1:E=9>L_2C>^X!^T[>_
MN/[V'\LKI*A## (XTAI3AI:72RX!Y\:B*DDJUWHR^)XDCWS@_W3XO',Q\(2J
M?@X>W=O##V^.3T[>';Y?VZ==#.CM1S2WG(_2V"ID#(O9=/:Q]MA:J__'@%)G
MDBZJ'K=J AO3K X7XY"4<(Y)D85IG3GP$"W[FKG;S[V&:F32&D4.B$!6YQ=P
MB,8@!*^T42PPGUNW?7F0F)'#Q!8XN&UTV@C^.9B3S3+/KU)RA\NI__Z&D7+K
M[^=P^!Q[AM9:%30D&1&4IDBB8@A$T-E&],$V;P\^7([]917*K1=\N_CW^IV^
ML\YXBF;(+2">:_,XS1.X+)&'J(C@UL9K,\JZS;'?!B5W"H;:*V7$TMQJ7R9_
MF1,;+^>SA(O9_=R@4=F&%""E7.\'8@$RU20U)5D2UFIIY<\,UV:O&K??16/,
M#"#=#LJX?U]2['"X7$W/*&)83JRVR"QC8)2U]6R%@?>)0W91B&B5,:9UM'R3
M@G%;3@QD9O80<@<0>8]?<':.M:]ZO7NLTOC;=/7IY?ER-3_#Q>T%P!@*Q;T%
MU+7_%G<&HHH*$O.<P)]2XJU[ 6Q'X;@M)P:"V(!*Z@*"2R0":B?35\3HZ7P]
MG'C=G&6)%[Q-LB^^9O, DZ8.SK;U,"-'R)G65DG"R^85VAN0-6YKBL' UE8=
M8_M,+^G3:0JG'Q;36@RPSF)+EY^=K,[SMZLZ@=O+R+/('>;J";),3-):"C:4
M>GAGG9.J:"P;N5*[4C!N(^,A/*PGT44')NW'N>SUD]OCJZ8%1^1BSFIVXWJ*
MR>6:X@I#X"9 YO7F2PI61QTB&.ZSH!]@*,T;&F]/YKC-C0<R>4.KJP-$7K8*
MOSVGX;;GD!C9+FN@\%S'@@4'H18R<.]X5LFXV+P)P$:$C=N'=B#4M5=)!SB[
M:)!5/88[L3-%15:1+TH+AX$*M?N941XX%][PPF61LC&V'B1FW %& ^&IC>@[
MP-#WJO5K-0;7ZLPO#;#-0L:L*="V(M:RJ  >;0:K@[:%>Q%D\YK_30C;["R5
M/3-PM==)!T!;G_75>'I]KSY=_OTET3!=U:\FM"Z8B)9!LJZ.GRZULB1(R(C:
M"AZ$T*V;9SY"SF:@>FXG]*WDWP&4WBWFGW&Q^E9=Q!7MZG5'_WR?+=8I&E^*
M!*NB)[Z$@HA,0@G1&IU#$&F J?0;T;89R)[+D?Z@FND <6]PN41\4P>KW7$:
MG7)*.!\@J10H7.:FYOX80$D,&IVDT*WKM1\A9S-</;=S_U;R[P!*M0;]#@O!
M.2]XA*AKV8$U')Q)$H32,6FBOY36I2CWD+$9=)[;>?Z^\NX ,G<SNN\PE+71
MC",P4P7$@B !)8ICT7E#LHLYM2ZX_"E1F\'IN9W8M]5%!^ Z.OM,X4;=HX\7
MKZ;+S_-E.#TN;^:SCV^F7S ?D.&]>U!B3<@N.@&268IT.84=OD0#V2D3@T^H
M6>N$HEWHW R"S^54_\DTU@$J;^=&WF9'9BE]<@I28KXFAY#_R%+M-J5E*%AL
MM$.GINZ$M>=V6M]2#QW JEXY+/ 3SI:T4HYF:7Z&#R0?\9),%AETJ,M%:O(5
M4HR B1?#D=9/;%V]MBEMFP'MV1W0#Z&9#A!WP<J'\/7.RO'6.*\0'*]\H&$0
M@K4@ZXP]U$4RV=J"/43+9HAZ?D?T#20_=D+%WT+MR7.UG=^YK_*L[MP"M"J2
M0M]4-W5>:]9]9DJ@)I=SHZR)1U^S6?+I<SED;RS6#DS,"7ZLSN![_#Q?/)QZ
M;=&10#*#HD*=^E9[W+'B(6E$#$X4PYJ'B)L0MAFZGMMI>WN== "TM_B/:^):
MS&?T9<)K=U)W^-/*!<<,<%\SB:HL8T$%'BE&9BI:U?P:>EL:-X/?<SN''U13
MSZ'B;(.! 1_6O8MO,M5L!,+EP\<8A' ?7T\Q#B$*[YEV&BPK@HP9*Q =>5G2
MT9X9R,HY_YS&(=1SXQ-,YXN+CM-?PO2T"O;U?'$23G$MY&L%FPHM:AZ *[Z^
M@Z@%FRY#'7V4/%I1Q! '^)O2U_%@A&U0<]_1_B JZF"O/4F?,)^?UA20*_%=
M'.P=S*YW0O\-0Y5G/IZ]KX*H$X#7I7BWF->L9NWF",+6I"0>?$U*(O/NLQ"^
M*!]YZVJDI@R,6_\V&(#'4_)SV,,?GJ*Q^];]TV<^X2R0 3?JQR8S:":-TUF0
M(?04W1;FP2LC(0M/,:]FR976964#3@3YL81N3XVX?->-P1&W5@Q&SZUBEKQK
M&>LX] #.\@32%N&"1AY]\[Z(>]#;[[2/;3#UL!$<6(//P>;5:1J[6[=K?SW(
MG(\!+=8#TQY<%-%&BD9+LHKB4EN'F(H(,F<L0GFOS;##,-K;J?K\:]F\UV)P
M+G-1-D"0#FL_XPQ19$.\RLB9%\:7UKS^G*HN9X!L@XJ'S4T31705*OP65I?!
MT$4^P =<G%4N;QG-A)E80 DENEK@%TE\,F5P1M5B4_)H5>N1#-O2.*[#/RCL
M!E#2<]C9'IE8L/N&]_.'/N7DA0&WQ^UZY.<LF"OUAC/7K S/%03MR#42&+Q!
M3":WSGM_TOD+%^G QY^Q5C/,/J[S@J]\Q&^7Z^O;K?7DLLG(A0-:K+RVAW0U
M,.8@HY'6E(3%M Y[=B#S.4UBV 9E]R=T#Z?!YV 1KQJ4[V[^;CUAL!;J QJV
M#9IARY@D]TR!$2& LD)#-+E 9C$RYG@RV-I=>8)&ZM_]@?O[=5]E*!POWD\_
M?KKNG<:<<A&!@2-7M!;#<P@I&F#>J1"#83D-Y[UM26SWC=:WP=;#+MV0*GP.
MENS^)N:[V[5'G_=$+=B'/.O8K]%UYIZ;9#T@J_/>DC1UR_5@E9%&U+0!UWJD
M<S^-V.]O'W)M<MWRQ;<[G;H/_A$6^5IH58+3*G%@*5I0N="B5[HN>F=X2IB<
M:%V]T)B%9]VH?1O\/M:H_:FAT-51S_W,OT>2\321$M9;TN^S*<F]<GR05M,O
M=UWJPJ046A5@M@[3Y:04IZ2&E&TH=:IC%LW[(+5E8>2#HO%6PIA0> 8K8<WT
M15>IY0,<QZ)L$8K<KJ0T^7Y1@.="0"('3)/S%ZP9T)'>D>IQV[IVC/?&"N\4
MXM=WL>L<U]R1"Q0LE^=G%Y_=XEYRG9G4%KBW#E1Q#B)S"3!(:P-CGK/F [F:
M<C!NN]G.H/]$0.AJ&1Q2[#C_AGB"BR_3A _X?Z?K1ZZG9K_'-/\XF_XWB0L7
MT_F%DJYM>39(M"Y 4(CD_%F$8)(';DW1W#"GXG#I'XV9&;<];A>+8TQX/(=3
MFEL#DW8_GKG_04,/>!KP0.;!\3Y.&)6T(A>!6?(8DJN58+5/%D:E@G4DD=:-
MR88:\W0MS6JV(JF?GM<NJS_2IP^_IM-S$N5%X_.SS^>KRU7RR)@B$67RRH(,
MF4*&8@)XFVGMVN*\8HZ)/%Q6<2LN.ATLM0WR'LFH&T/5S\$6OCH\>?G^Z%T]
MZ#U^_>+WDZ.WAR<GKW 5IJ<[9MX]\KP!<O$VI;[5+=WB8Z"-<DWV2_(HYZ?3
M'"X[-K^[QM*UAI4G] G>W.9],<F9$ %-[=25Z:OH4@0O:SE&0!EXZQ+4)H3O
M/W2!-#/#?+6\#E(Z/SM?>T:OL$S3=#4IFF7/1 #&N 2E.(+7-@"6F$OA0:7F
MF<@_IVKDV[LGQ]S=Z0Q-];:]7?07RWV&'^L[F_4FO]4%F^1Y\FF^6-5$M!]]
MC9>35&1Q12NPV2E0SG'P.2'PP@Q3 9,PS;NR;DS=N.>^XV-S(#T^A[U[LUF+
M;^OM>_5[]MC5=WS32-,E'^=X^"F3)B7MD?";E">7U:& 2+$\2%6212M8:7Z<
M,MR4R1\^](,];=<!Z83GE!G7" 9C!.6#!<<=0O;&.)^EEZYU7N&FM'4[:7(;
MI#P<W#14S(C'G,O%:O*^WE@??)V2K<[:D&0X<(E$-(H(]426HD#.A%32&;71
M(3T]]1J2Z+L?*+KQPG$A,HPNY_L*M@<T_(9G$1<39FLCF%";&W-'*X5;B#86
M$"%IC98Q4UPK/%R\<AQ$[*&LV^K>07(C*_RWZ6QZ=GYV2;@-@6F"->BR;DZL
MR%VK P9-82R%K$O@&R7O_T3E-UXZLM)W4=F\A?S&5GSX>HUPIY&+: )(47OB
MZVC H_) 4D$3=,S&MECK-UXZ3AC53/$[RZ^#>\T'MSR*$_"(8L7E1 LA3(D*
M),\6*%3#VK374OB6-5,B,V5:7]G_G*IQ(^]!78:!5-,!V-Z>UR5R7+Y7W%PV
MJ%M.T'"?M. D'2R@1)000T%0R>9<R)AZUSH+ZD%B1FYPT%CKMWNR-5%!!UAZ
M4$Z_+[&<G[Z9%IRH%%/![ $-TB:<G8> 1M5>=H'Q4&1FK1-+-R!K7-,U,+Y:
MJZ4#I%WK='^[O_U?\32_GB^(MXGV,BF5D<(#R4%Q,O>Q'G>B9TC"E#J[UM=*
M&Q$V;JKFP&AKKYH.\/;[;/$])>A#^/H"9UBF9* EEUZ;R*&X*BA+/J;+FAR*
M*(RSQ(EW&WGF6R#L 5+&S8$<&%,MQ-\!BKXW'C_\&LZFL[5VWN$LG*Z[%-81
MQ_0N7%Z->9^X'*7(+@!W3-"F+Q0$IDB"@4>9@\@FM_;RMR1QW.3"H2W9@.IZ
M#M=I&[24?:#19IDOEN%TGPNV9N\>H]'N#E)YBCZ\LD)>%]IDE:J!KP\0R'J"
M*UPS)^A3;-UT>^0^O!.KM'8\9M#%^#H3Q-7Y\!E\4,P:(Z-P0W0)^PE9'7?=
MW08C.W3=W4HA'>S8]TQ97M]#6"91%F_JY <*S W6]DM>DOLJ-+?:"Q2M_;X'
M2!F_#5M3E=\>>-U _AW Z,,BS);TYG4FSKH(83K[>/\,[P_TR.7]/WHU/PO3
MV40QF55!3QS7V1#5N0DIU9.AF$C$S!?;NH=32_I'-GXM #7O1+L=(/NW^0R_
M_186?\?5Z_-97E[>N CEA:\]4XQ9CZ#GMBYW!*TTCSHGE6SK??=^2L9%VWC(
MF#=74P=@^_WDPV+=\?S;CSWGDA-=TP!D2J!EHCC/!0DAZ !%YFR<%%+;UA4G
M#U,S[FER-Z!KI*Z=@?<%%W'>:CCW_(PB_6EZ.5]\GB_""F]Z/I=L&2<4UUI!
M3K5]4V3D.$>EP(;,11;>Z=!\VL<FA(U[X-P-(-LKL0.C2+XV3C_.'N=)UL/0
MP!T@JS-.M$M +$EPCJN VCLK6V?L;T+7N(?6W>"RN0J[,)G7B@UOQ84_>/MQ
M4!M+,(+3@D.3R %'2:LN9/JJE.2+SU['X1H.;4#@^'VGAXRSA]-5!Q;R-DNW
MA'E6!S'^]T4O@O7TG(E)7!:6D7P2I*66R$6)Q6D*"VF1!RFEUZWO7;:EL9?T
M[.9PF3^A[G;'YGP53I\"FS_J"O^RF"^7]1XTG%:&_T)[SHMZHU#OIR91)^64
MS8 Q^-J_B-A7*H!4PJ/0UI?FZ8!-".\E8W!D% ^@Y?[-[H-,OZ'O?C#-2Q;D
M]A"KUM;99::VYK(1."LN9_*P)&M]VMF$\'%#KOZAO;N6]ZV6_C 8PG_P?5,*
M$Z^]]T8@1)T="5@)H-U)0G!>QDC<2C$TB!^B;=P0;#R<-M'5'R2+HT5%]"ZO
M&2,WXTEJH1^]8K?9)AZ]!9Z,J_-[>$U:TY BCRZ&5#"T;C(]7AK&^VN>3#7Y
M$TMKRV=:69@E.3$Y>@I0A:2@-1NK1,1H6L?YVU'8<7+&-LC9+CEC+S5UX&N^
M6\P38E[6QE65G\?VDRJ)B4@B*D=NAJW7#BH+ TZY3/+,UD3#LFG>5F=;&CL>
M;;P/$ =550=0_,E1'2[.)DR4[#*MIL@SJ[WE WC-%5@=#28O,Z;XM%EI1-6X
M <M(=F]K=?Q!/+Y;4\7#O5/%Y[>FB@_K'>Y%TAB>9#L9/H77R;4.J+0%89PA
MD&L&(7D-,F9EE%+&N=8;WI!>Y_=GO_CV(IR&6>WJB[CZRV)^_IED?7$C@CY8
ME252O"@UJ$"K.SA![@R+R;FB0HBMZ[\VH:MC#W,;E-RYQ6RMD@XV\VL\7:[H
M>N?[>H'_=8ZS]&V=.BB=Q:!1@39%@9*\U*.#",*J5$J*UMC!XKF'R>H$9,VP
M\##8FBBF)ZS=Q]!EEH%Q DV=45&<%K0^T8%/ND 2+&N1%;(TF!5_F*QNL-8&
M"@]!K9%>.H7:\KNC<IEP4K1UP8;:7KIV34EUSG2Q!ICR3"G)5&[>_V$3NCH!
M6RLP; "VO333$]I>?/O^Y5^GY'4OTJ=O;_ +GJ[7* J#@FL'0B4$A2AK^:0#
MR9G6@G/7?GKA9I1U<A#S!%MI*_7T!+KK"^DN?Y=+EC8$59*K+:&<!.5BK,>=
M!8QW13H7@U&M3Z6W(K 3H]<0(9O8O2;JZ@F+1[//YZOE6F+\TI:KH!GC04$6
MA5:ND@&\PWKS[5 R06SYUF>!CY#3"<[:@^ AN.VID4[!)2Y9B4X2L8E$Q%0"
MI8, Q[@&QHW$DC$RW[H>X1%R.ME'1P'7+AKI%%SRDA6.3C 5%7C4%I11')RF
M;Q/32K"DN0FM2ZX>(:>3ZXM1P+6+1GH UP.UN,HZ;3674&K$K@Q+X"P/()"+
M8G(=@M#<&=NCN'YX4 WF^3=00 <X:EO'HTL)1"58'6IFF5,0O4XUY4S4'D*9
M\=9;YA^_NGXK0 U:7;^%=CM ]@-EVSF@\K9PT*J.*TX!(4:3P#/MN%#6>-UZ
MY_WC5]=O@XS-JNNW45,7%7N/%&S7/-ODDB37PE!L'SSYK=K7!6V=C5$765H/
M,_F?45^_!^P:J:L#.[=987;2NI!L?.W:[RAVDL1>\G$]>5)A0.9XZP/B_W'5
M]7O L;T2NS"*&Q5GE^"2MUQ 298B.H$)0CTX0I]3":5$[IN'+/_#ZNOW0&9S
M%79@,G\$A_>$AG=G"[X,GZO:KQ73!,,S1V>AQ'52)2=^ \O BF08<TY>#99*
ML"/-X\+Y"2_BGD"E'4#X(F_RQV!K%766%!6:Y,EGB86HMQ0NYIP=3Y&V!MTZ
M6^\F!9U<?CR)]F]7Q^VNBBXVZ3KPE':9VW-/OX\51-0AFPC&, 7*NMK55!9@
M7@>I+8])M:Z_?)RBD0<P[J'M>Z;--A)\!Q;I?F[NR9B=\")LS6\')[2JW@)]
MQ>OXC"01:;D995HG1VU,W+C@:HF(C<"VKWJZ,&#WS6?^+K/H56(V:,BL%J@P
M2TZ%B!DD9A<\S]KZYI-D'Z%GW..7AL:KF= [,%T;U[='+^IX<0:"PITJ, L>
MN01K':,8*KH46I^B-.U%,%Q3HV9HV+7UP#:JZ<)J7:S%^PRP5DEZYNH8#%>7
M)2_@A8Z L=""19YL:ET4\2 QG>2=C.?7[ZN@9GVR!BQZ/'CY\OWOAZ_>'!V\
M.'IS].'HL-;M'7_XZ^'[E_.SS_-97<WS<I#2XARO%^KM4=2X[RN;%RTVE4&C
MHL1WX5LU??4,</WB<'IMV(1.62@K(444M9]+ ,_K/T)SE7410;2^QWR$G%V-
M807&Y%*HQ^<DX?-%/>A\2;\W377-YW<+3)??G:S.\[K+#+DFWF<)M+)KEQGB
M/P2LVPO3TG$AG?8_P]\N+QYYD&8C,%R9N<%%WX%C=TBF:/X-R2RNVVA=6[8O
MSQ=5Z!,6K(M:U X=W%?)%8B6&W)0?#;6FXBF]4GN3XD:>:!F8YP-HXL.P/5]
MY.P;#/3(2WZ^77&3BV9,&"3R69T_JXB1G#DDXU2(.OGH6X]Q>)RBD2=G#@2K
MAEH8$5/7C?$;_!A.7^./=5'0F9Q#!"=<!F6UALA]!$U"2V2-N;%IF_WN]@M&
M'G\YX+ZVER@[,#&7;+Q;S LNEZ20F]P8)FL6M"=(2PJL'>$Z2@JQ!5I-H#?<
MF^;'$8]2-/)(RX%,3$,M]&)BKLSDO/RM]O2KL<WL Y[5*_[%MWH^O/HVX=HP
M1L$L2)]HK?CDP<6LP!K.N"B".:ZW,CL;O'0C )GG J!!1=Z!>;H:XGHIMZL%
M@:)886BG)>^-@@26:C:(IE618^:**:]U:[-T/R4;H<D^%S0UE'H'V#FNQS!W
MCU.NN)%:9^3>0@E(*X%KB@JDYU#3W;U7@3G=^MKF<8HVPI)[;EAJJ(4.,/4P
M(R+'&$TLH)%'(.(E!(D14I V6FL<RZV#L?V0Y)\;DMK(OH.I$H\'E-_O&JXE
M7+Z;+Z=5?8?UU'<Y)>F^F2Y7$XN%1VEJLVU3RU5I!47.:H?V*),,QO'F;5);
MT;[922=[;A@=1;7/H>OEJ\,7'UHT,K_W.<VO:GY.;:/[EWK%_./:[SL$BS":
MD4,.QM<60C'685'%@JMG3!'K")W6&7'W4]*BW>Z/;/&+)%S%8I02'802+"B5
M)?@Z*$5[JY)2T0G9^E[I'C+&G\R]I][O:Z6[CZ@[\*YNLK"N3<VR)'I5 I,2
M;>W:,HB.%9"5+5WG/P\,EO&[->ZMV$>!LK64N\/)VW"&EV4HS!FD7]>7Z6;<
MK9N1![!1.=I$+(;0>M+60[3TA)GM=?PH9'84^-@GDW_%13HGGZ\FD;V9A]EE
M91$F%YCW#%*I:5WU5,-G9."*+3I&A9QM=@AY__-[PL&NBINWE6('%N3-?/:1
MGG96Y5.KVR[:D,9H?6V.QG,1%Q/<HJ<0P%O++!=,:='Z5/$^.L:?9=IRM]E;
MTAVBY7(-^> 8ETY =C7KU&0'3H0,B:&I86(VS4^A[Z=D7!NSOX9_ ID=Q-T!
M:-:9PY@K$U<SHD,*6G@'5M6:PR 4>!T<R*0#B\J8(IL/4;Y-1%]0V46SMZL$
M]A+SV#Y))?OE_ O.PFSU#A?3>5ZO'I9HNPS" K,^TVXJ2TTJMH#<B&!,('\M
M;.23W/_\<?-T6NTPK038'P8NEP5ZF93E^?]O[\V6W+J1=M'[\RXX!_-PLR/*
M&OPKMJQ22-7NZ'/#P%CB;A:I)EFRU4^_$R1KYK!(8A%@V8ZP0B,6,O/+1 (Y
MH10C>.S2$/#1%$$J61(D%IY0<B *:IX;Q>2V'0<',+$])%R.XUWW0 F:D9Q'
MPDF@PV0ZF,D#0)2E(7')\:%@N/](4W@X1'[;$7$8,]L#Q=4?D[L>5@JVG5)
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M^XL\1D2!.VAMKCJ5B45B6 Z(%O=V-FRF;DU+/^Y.";ZW</-^8FH7N7SO8QS
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MXJ+BN3^;SO.4@G#KYY?3KW'Z8^B7SZO:6>7R%&L?;?:D%4-&4 &G#38T8N&
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MCI: 8#GIM JY>[WZ,OEI1_.?=TFZ=VIE6=*),7"":"Z0)?G!2!F32V6=%'!
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M-6.PX=H*1*/PA@CIK"D=QMRZH==427D,",M)K0$(KM.H7 65^U5_L?,X\.!
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MNLUGV?B)RC.M^C0O1;C:@'FYA-OZQ6@T6>0!7G[/O+D;IVPQ%C@29%/.L%=
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MA2QLO_H70%O6[=-M?DZ%7RPN'Q]FL]L8/CQ1'QYP(M8%@ M<9^$(3\AA2I'
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M\UQ1'A3<).'7R##M7*0!;I6EDTCZ"T!OUI4[;G^9C$;O)],_[#0,,,&&YD(
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MGP \!P4MY.I3K7B,VB""E0&70B4$+H9!5!K#K.&"JV;:3O1PLVSOZ:91=:P
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MP*NT<&!I;X6UMC!V7^5$L[U L'6BV3X2:0!.AS-NRQ0CPKC4EBH$UQ@,/)#
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M+3 Y+FAT;5!+ 0(4 Q0    ( .\Y;%GM[:"W$@@  +$P   1
M  "  0X(  !E>#,Q,E\R,#(T+3 Y+FAT;5!+ 0(4 Q0    ( .\Y;%GB?REA
M3P8  ",D   1              "  4\0  !E>#,R,5\R,#(T+3 Y+FAT;5!+
M 0(4 Q0    ( .\Y;%D/ (2B(R8  (]M 0 >              "  <T6  !E
M>&AI8FET,3 Q7V)I+7=A=&-H9F%C=&]R>2YH=&U02P$"% ,4    " #O.6Q9
MJV49'"2V  !:&08 '@              @ $L/0  =FER:61I86XM<&%R86=O
M;F%M96YD961A;F0N:'1M4$L! A0#%     @ [SEL6>6Z@#ZW4@( J4P8 !$
M             ( !C/,  '9R9&XM,C R-# Y,S N:'1M4$L! A0#%     @
M[SEL60F"\#5\$   ++(  !$              ( !<D8# '9R9&XM,C R-# Y
M,S N>'-D4$L! A0#%     @ [SEL60UX ="J&0  ?_(  !4
M ( !'5<# '9R9&XM,C R-# Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( .\Y;%D
M!3S,&VD  -3=!  5              "  ?IP P!V<F1N+3(P,C0P.3,P7V1E
M9BYX;6Q02P$"% ,4    " #O.6Q9M8W+R'H+ 0"@D@H %0
M@ %(V@, =G)D;BTR,#(T,#DS,%]L86(N>&UL4$L! A0#%     @ [SEL6<5D
M2P[/F0  _&$' !4              ( !]>4$ '9R9&XM,C R-# Y,S!?<')E
:+GAM;%!+!08     "P + -\"  #W?P4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>vrdn-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vrdn="http://www.viridiantherapeutics.com/20240930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vrdn-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:September2022AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrdn:DebtCovenantPeriodAxis">vrdn:DebtCovenantPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrdn:DebtCovenantPeriodAxis">vrdn:DebtCovenantPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrdn:HerculesTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vrdn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ZenasBioPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrdn:ParagonTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vrdn:FairmountFundsManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:EnableInjectionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:EnableInjectionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vrdn:ThirdPartyCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:ColoradoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vrdn:MassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrdn:A2024PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vrdn:ViridianMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesAPreferredStockConversionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesAPreferredStockConversionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesBPreferredStockConversionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">vrdn:SeriesBPreferredStockConversionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:LiabilityClassifiedWarrantsIssuedApril2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityClassifiedWarrantsAcquiredOctober2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedFebruary2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsIssuedNovember2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vrdn:EquityclassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:InducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:InducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:Amended2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2008PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrdn:A2008PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vrdn:FormerExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vrdn:FormerExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vrdn:FormerExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vrdn:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590750</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>vrdn:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>vrdn:tranche</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="renewal_term">
        <measure>vrdn:renewal_term</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>vrdn:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0001590750</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-29">Viridian Therapeutics, Inc./DE</dei:EntityRegistrantName>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-117" id="f-485">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-605">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-606">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-739">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-741">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36483</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-7">47-1187261</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">221 Crescent Street, Suite 103A,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">272-4600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-14">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-15">VRDN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-17">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-18">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-19">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-20">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-22">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-23" unitRef="shares">79212747</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">200317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">102827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">552923000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">374543000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">14103000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">9006000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">14000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">102000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">767357000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">486478000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">1290000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">1672000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">2400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">1670000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">853000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">604000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">771900000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">490424000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">6338000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">2239000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">3725000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-51" unitRef="usd">374000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">34738000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">24108000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">288000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">288000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">41364000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">26635000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">20523000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">20205000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">356000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">573000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">2161000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">989000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">64404000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">48402000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-68"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-70" unitRef="shares">435000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-71" unitRef="shares">435000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-72" unitRef="shares">134864</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-73" unitRef="shares">134864</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-74" unitRef="shares">172435</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-75" unitRef="shares">172435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-8" decimals="-3" id="f-76" unitRef="usd">61188000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-77" unitRef="usd">78235000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-78"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-10" decimals="INF" id="f-80" unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-81" unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-10" decimals="INF" id="f-82" unitRef="shares">145160</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-10" decimals="INF" id="f-83" unitRef="shares">145160</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-9" decimals="INF" id="f-84" unitRef="shares">143522</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-85" unitRef="shares">143522</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-10" decimals="-3" id="f-86" unitRef="usd">127697000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-9" decimals="-3" id="f-87" unitRef="usd">128281000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-88"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-89"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-90" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-91" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-92" unitRef="shares">79181445</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-93" unitRef="shares">79181445</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-94" unitRef="shares">53986112</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-95" unitRef="shares">53986112</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">792000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">540000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-98" unitRef="usd">1433019000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">960536000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-100" unitRef="usd">932000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-101" unitRef="usd">338000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-102" unitRef="usd">-916132000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">-725908000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-104" unitRef="usd">707496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">442022000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-106" unitRef="usd">771900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">490424000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-11" decimals="-3" id="f-108" unitRef="usd">86000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-109" unitRef="usd">72000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">230000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-111" unitRef="usd">242000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-14" decimals="-3" id="f-112" unitRef="usd">7725000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-15" decimals="-3" id="f-113" unitRef="usd">10937000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-16" decimals="-3" id="f-114" unitRef="usd">1099000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-17" decimals="-3" id="f-115" unitRef="usd">6521000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-11" decimals="-3" id="f-116" unitRef="usd">69158000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-12" decimals="-3" id="f-117" unitRef="usd">30385000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">166294000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-13" decimals="-3" id="f-119" unitRef="usd">121208000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-11" decimals="-3" id="f-120" unitRef="usd">14408000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-121" unitRef="usd">20911000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">45499000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-123" unitRef="usd">62006000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-11" decimals="-3" id="f-124" unitRef="usd">83566000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-12" decimals="-3" id="f-125" unitRef="usd">51296000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">211793000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="-3" id="f-127" unitRef="usd">183214000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="-3" id="f-128" unitRef="usd">-83480000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-129" unitRef="usd">-51224000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">-211563000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-131" unitRef="usd">-182972000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c-11" decimals="-3" id="f-132" unitRef="usd">7795000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-12" decimals="-3" id="f-133" unitRef="usd">4164000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">23527000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-13" decimals="-3" id="f-135" unitRef="usd">13029000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpenseNonoperating contextRef="c-11" decimals="-3" id="f-136" unitRef="usd">1004000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-12" decimals="-3" id="f-137" unitRef="usd">600000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">2188000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-3" id="f-139" unitRef="usd">931000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-11" decimals="-3" id="f-140" unitRef="usd">6791000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-141" unitRef="usd">3564000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">21339000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-143" unitRef="usd">12098000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-144" unitRef="usd">-76689000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">-47660000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">-190224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-147" unitRef="usd">-170874000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">-2.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-2.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">-3.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-3.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-156" unitRef="shares">66420063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-157" unitRef="shares">66420063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-158" unitRef="shares">43654577</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-159" unitRef="shares">43654577</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-160" unitRef="shares">63800798</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-161" unitRef="shares">63800798</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-162" unitRef="shares">43057658</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-163" unitRef="shares">43057658</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-164" unitRef="usd">-76689000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-165" unitRef="usd">-47660000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-190224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-167" unitRef="usd">-170874000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-11" decimals="-3" id="f-168" unitRef="usd">1475000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-169" unitRef="usd">109000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">594000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-171" unitRef="usd">326000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-11" decimals="-3" id="f-172" unitRef="usd">1475000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-173" unitRef="usd">109000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">594000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-175" unitRef="usd">326000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-11" decimals="-3" id="f-176" unitRef="usd">-75214000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-177" unitRef="usd">-47551000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">-189630000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-179" unitRef="usd">-170548000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-180"
      unitRef="shares">172435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-181" unitRef="usd">78235000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-182"
      unitRef="shares">143522</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-183" unitRef="usd">128281000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-184"
      unitRef="shares">53986112</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-185" unitRef="usd">540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-186" unitRef="usd">960536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-187" unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-188" unitRef="usd">-725908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-189" unitRef="usd">442022000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-24"
      decimals="INF"
      id="f-190"
      unitRef="shares">-15000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-24" decimals="-3" id="f-191" unitRef="usd">-6806000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-25"
      decimals="INF"
      id="f-192"
      unitRef="shares">1000048</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-25" decimals="-3" id="f-193" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-26" decimals="-3" id="f-194" unitRef="usd">6796000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-27" decimals="-3" id="f-195" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-28" decimals="-3" id="f-196" unitRef="usd">9304000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-29"
      decimals="INF"
      id="f-197"
      unitRef="shares">7142858</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-198" unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-199" unitRef="usd">140625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-200" unitRef="usd">140696000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-32" decimals="-3" id="f-201" unitRef="usd">1088000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-33"
      decimals="INF"
      id="f-202"
      unitRef="shares">1561570</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="-3" id="f-203" unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="-3" id="f-204" unitRef="usd">35162000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-35" decimals="-3" id="f-205" unitRef="usd">35177000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-25"
      decimals="INF"
      id="f-206"
      unitRef="shares">66191</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-25" decimals="-3" id="f-207" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-26" decimals="-3" id="f-208" unitRef="usd">837000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-27" decimals="-3" id="f-209" unitRef="usd">838000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-25"
      decimals="INF"
      id="f-210"
      unitRef="shares">22642</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-26" decimals="-3" id="f-211" unitRef="usd">356000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-27" decimals="-3" id="f-212" unitRef="usd">356000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-25"
      decimals="INF"
      id="f-213"
      unitRef="shares">19115</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-25" decimals="-3" id="f-214" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-26" decimals="-3" id="f-215" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-27" decimals="-3" id="f-216" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-217" unitRef="usd">12688000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-218" unitRef="usd">12688000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-36" decimals="-3" id="f-219" unitRef="usd">-705000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-3" id="f-220" unitRef="usd">-705000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-221" unitRef="usd">-48542000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-222" unitRef="usd">-48542000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-223"
      unitRef="shares">157435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-224" unitRef="usd">71429000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-225"
      unitRef="shares">143522</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-226" unitRef="usd">128281000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-227"
      unitRef="shares">63798536</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-228" unitRef="usd">638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-229" unitRef="usd">1156999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-230" unitRef="usd">-367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-231" unitRef="usd">-774450000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-232" unitRef="usd">582530000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-45"
      decimals="INF"
      id="f-233"
      unitRef="shares">81139</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-45" decimals="-3" id="f-234" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-46" decimals="-3" id="f-235" unitRef="usd">209000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-47" decimals="-3" id="f-236" unitRef="usd">210000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-46" decimals="-3" id="f-237" unitRef="usd">11767000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-47" decimals="-3" id="f-238" unitRef="usd">11767000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-48" decimals="-3" id="f-239" unitRef="usd">-176000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-47" decimals="-3" id="f-240" unitRef="usd">-176000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-49" decimals="-3" id="f-241" unitRef="usd">-64993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-47" decimals="-3" id="f-242" unitRef="usd">-64993000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-50"
      decimals="INF"
      id="f-243"
      unitRef="shares">157435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-244" unitRef="usd">71429000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-51"
      decimals="INF"
      id="f-245"
      unitRef="shares">143522</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-246" unitRef="usd">128281000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-52"
      decimals="INF"
      id="f-247"
      unitRef="shares">63879675</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-248" unitRef="usd">639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-249" unitRef="usd">1168975000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-250" unitRef="usd">-543000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-251" unitRef="usd">-839443000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-252" unitRef="usd">529338000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-57"
      decimals="INF"
      id="f-253"
      unitRef="shares">-22571</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-57" decimals="-3" id="f-254" unitRef="usd">-10241000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-58"
      decimals="INF"
      id="f-255"
      unitRef="shares">-18362</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-58" decimals="-3" id="f-256" unitRef="usd">-24085000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-59"
      decimals="INF"
      id="f-257"
      unitRef="shares">2729000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-59" decimals="-3" id="f-258" unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-60" decimals="-3" id="f-259" unitRef="usd">34299000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-11" decimals="-3" id="f-260" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-61" decimals="-3" id="f-261" unitRef="usd">15524000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-58"
      decimals="INF"
      id="f-262"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-58" decimals="-3" id="f-263" unitRef="usd">23501000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-59"
      decimals="INF"
      id="f-264"
      unitRef="shares">12466600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-59" decimals="-3" id="f-265" unitRef="usd">125000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-60" decimals="-3" id="f-266" unitRef="usd">219600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-11" decimals="-3" id="f-267" unitRef="usd">243226000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-59"
      decimals="INF"
      id="f-268"
      unitRef="shares">84676</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-59" decimals="-3" id="f-269" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-60" decimals="-3" id="f-270" unitRef="usd">1108000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-11" decimals="-3" id="f-271" unitRef="usd">1109000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-59"
      decimals="INF"
      id="f-272"
      unitRef="shares">21494</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-60" decimals="-3" id="f-273" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-11" decimals="-3" id="f-274" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-60" decimals="-3" id="f-275" unitRef="usd">8720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-276" unitRef="usd">8720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-62" decimals="-3" id="f-277" unitRef="usd">1475000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-11" decimals="-3" id="f-278" unitRef="usd">1475000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-63" decimals="-3" id="f-279" unitRef="usd">-76689000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-280" unitRef="usd">-76689000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-64"
      decimals="INF"
      id="f-281"
      unitRef="shares">134864</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-282" unitRef="usd">61188000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-65"
      decimals="INF"
      id="f-283"
      unitRef="shares">145160</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-65" decimals="-3" id="f-284" unitRef="usd">127697000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-66"
      decimals="INF"
      id="f-285"
      unitRef="shares">79181445</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-66" decimals="-3" id="f-286" unitRef="usd">792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-67" decimals="-3" id="f-287" unitRef="usd">1433019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-3" id="f-288" unitRef="usd">932000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-3" id="f-289" unitRef="usd">-916132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-290" unitRef="usd">707496000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-70"
      decimals="INF"
      id="f-291"
      unitRef="shares">188381</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-70" decimals="-3" id="f-292" unitRef="usd">85470000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-71"
      decimals="INF"
      id="f-293"
      unitRef="shares">51210</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-71" decimals="-3" id="f-294" unitRef="usd">56677000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-72"
      decimals="INF"
      id="f-295"
      unitRef="shares">41305947</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-3" id="f-296" unitRef="usd">414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-3" id="f-297" unitRef="usd">741067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-74" decimals="-3" id="f-298" unitRef="usd">-390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-75" decimals="-3" id="f-299" unitRef="usd">-488174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-76" decimals="-3" id="f-300" unitRef="usd">395064000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-77"
      decimals="INF"
      id="f-301"
      unitRef="shares">-15946</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-77" decimals="-3" id="f-302" unitRef="usd">-7235000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-78"
      decimals="INF"
      id="f-303"
      unitRef="shares">1063118</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-78" decimals="-3" id="f-304" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-79" decimals="-3" id="f-305" unitRef="usd">7225000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-80" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares
      contextRef="c-78"
      decimals="INF"
      id="f-307"
      unitRef="shares">57553</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue contextRef="c-78" decimals="-3" id="f-308" unitRef="usd">1000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue contextRef="c-79" decimals="-3" id="f-309" unitRef="usd">945000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue contextRef="c-80" decimals="-3" id="f-310" unitRef="usd">946000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-78"
      decimals="INF"
      id="f-311"
      unitRef="shares">612846</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-78" decimals="-3" id="f-312" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-79" decimals="-3" id="f-313" unitRef="usd">6932000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-80" decimals="-3" id="f-314" unitRef="usd">6938000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-78"
      decimals="INF"
      id="f-315"
      unitRef="shares">15854</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-79" decimals="-3" id="f-316" unitRef="usd">320000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-80" decimals="-3" id="f-317" unitRef="usd">320000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-79" decimals="-3" id="f-318" unitRef="usd">15216000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-80" decimals="-3" id="f-319" unitRef="usd">15216000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-81" decimals="-3" id="f-320" unitRef="usd">216000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-80" decimals="-3" id="f-321" unitRef="usd">216000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-82" decimals="-3" id="f-322" unitRef="usd">-68151000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-80" decimals="-3" id="f-323" unitRef="usd">-68151000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-83"
      decimals="INF"
      id="f-324"
      unitRef="shares">172435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-83" decimals="-3" id="f-325" unitRef="usd">78235000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-84"
      decimals="INF"
      id="f-326"
      unitRef="shares">51210</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-84" decimals="-3" id="f-327" unitRef="usd">56677000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-85"
      decimals="INF"
      id="f-328"
      unitRef="shares">43055318</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-85" decimals="-3" id="f-329" unitRef="usd">431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-86" decimals="-3" id="f-330" unitRef="usd">771705000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-87" decimals="-3" id="f-331" unitRef="usd">-174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-88" decimals="-3" id="f-332" unitRef="usd">-556325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-89" decimals="-3" id="f-333" unitRef="usd">350549000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-90"
      decimals="INF"
      id="f-334"
      unitRef="shares">204843</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-90" decimals="-3" id="f-335" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-91" decimals="-3" id="f-336" unitRef="usd">4998000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-92" decimals="-3" id="f-337" unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares
      contextRef="c-90"
      decimals="INF"
      id="f-338"
      unitRef="shares">56666</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedShares>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue contextRef="c-90" decimals="-3" id="f-339" unitRef="usd">1000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue contextRef="c-91" decimals="-3" id="f-340" unitRef="usd">934000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue contextRef="c-92" decimals="-3" id="f-341" unitRef="usd">935000</vrdn:StockIssuedDuringPeriodValueWarrantsExercisedValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-90"
      decimals="INF"
      id="f-342"
      unitRef="shares">245381</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-90" decimals="-3" id="f-343" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-91" decimals="-3" id="f-344" unitRef="usd">2131000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-92" decimals="-3" id="f-345" unitRef="usd">2133000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-91" decimals="-3" id="f-346" unitRef="usd">12302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-92" decimals="-3" id="f-347" unitRef="usd">12302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-93" decimals="-3" id="f-348" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-92" decimals="-3" id="f-349" unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-94" decimals="-3" id="f-350" unitRef="usd">-55063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-92" decimals="-3" id="f-351" unitRef="usd">-55063000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-95"
      decimals="INF"
      id="f-352"
      unitRef="shares">172435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-95" decimals="-3" id="f-353" unitRef="usd">78235000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-96"
      decimals="INF"
      id="f-354"
      unitRef="shares">51210</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-96" decimals="-3" id="f-355" unitRef="usd">56677000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-97"
      decimals="INF"
      id="f-356"
      unitRef="shares">43562208</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-97" decimals="-3" id="f-357" unitRef="usd">436000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-98" decimals="-3" id="f-358" unitRef="usd">792070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-99" decimals="-3" id="f-359" unitRef="usd">-173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-100" decimals="-3" id="f-360" unitRef="usd">-611388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-101" decimals="-3" id="f-361" unitRef="usd">315857000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-102"
      decimals="INF"
      id="f-362"
      unitRef="shares">39059</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-103" decimals="-3" id="f-363" unitRef="usd">693000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-12" decimals="-3" id="f-364" unitRef="usd">693000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-102"
      decimals="INF"
      id="f-365"
      unitRef="shares">84360</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-102" decimals="-3" id="f-366" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-103" decimals="-3" id="f-367" unitRef="usd">710000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-12" decimals="-3" id="f-368" unitRef="usd">711000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-102"
      decimals="INF"
      id="f-369"
      unitRef="shares">15362</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-103" decimals="-3" id="f-370" unitRef="usd">260000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-12" decimals="-3" id="f-371" unitRef="usd">260000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-103" decimals="-3" id="f-372" unitRef="usd">13606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-373" unitRef="usd">13606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-104" decimals="-3" id="f-374" unitRef="usd">109000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-375" unitRef="usd">109000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-105" decimals="-3" id="f-376" unitRef="usd">-47660000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-377" unitRef="usd">-47660000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-106"
      decimals="INF"
      id="f-378"
      unitRef="shares">172435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-106" decimals="-3" id="f-379" unitRef="usd">78235000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-107"
      decimals="INF"
      id="f-380"
      unitRef="shares">51210</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-107" decimals="-3" id="f-381" unitRef="usd">56677000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-108"
      decimals="INF"
      id="f-382"
      unitRef="shares">43700989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-108" decimals="-3" id="f-383" unitRef="usd">437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-109" decimals="-3" id="f-384" unitRef="usd">807339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-110" decimals="-3" id="f-385" unitRef="usd">-64000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-111" decimals="-3" id="f-386" unitRef="usd">-659048000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-112" decimals="-3" id="f-387" unitRef="usd">283576000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">-190224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-389" unitRef="usd">-170874000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">33175000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-391" unitRef="usd">41124000</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c-13" decimals="-3" id="f-393" unitRef="usd">5693000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">318000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-13" decimals="-3" id="f-395" unitRef="usd">194000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">417000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-397" unitRef="usd">372000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">12448000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-13" decimals="-3" id="f-399" unitRef="usd">8423000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <vrdn:NonCashLeaseExpense contextRef="c-1" decimals="-3" id="f-400" unitRef="usd">188000</vrdn:NonCashLeaseExpense>
    <vrdn:NonCashLeaseExpense contextRef="c-13" decimals="-3" id="f-401" unitRef="usd">59000</vrdn:NonCashLeaseExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-13" decimals="-3" id="f-403" unitRef="usd">-181000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <vrdn:DebtExtinguishmentExpense contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">0</vrdn:DebtExtinguishmentExpense>
    <vrdn:DebtExtinguishmentExpense contextRef="c-13" decimals="-3" id="f-405" unitRef="usd">514000</vrdn:DebtExtinguishmentExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-406" unitRef="usd">-449000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-13" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-13" decimals="-3" id="f-409" unitRef="usd">-31000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">5344000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-411" unitRef="usd">4489000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-1" decimals="-3" id="f-412" unitRef="usd">-88000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-13" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">-216000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-13" decimals="-3" id="f-415" unitRef="usd">-216000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">3850000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-3" id="f-417" unitRef="usd">-10524000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-418" unitRef="usd">10760000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-13" decimals="-3" id="f-419" unitRef="usd">188000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-420" unitRef="usd">-158987000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-421" unitRef="usd">-146170000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">513289000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="-3" id="f-423" unitRef="usd">135385000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-424" unitRef="usd">347950000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-13" decimals="-3" id="f-425" unitRef="usd">211694000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-426" unitRef="usd">397000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-427" unitRef="usd">850000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-428" unitRef="usd">-165736000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-429" unitRef="usd">75459000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-430" unitRef="usd">420014000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-113" decimals="-3" id="f-432" unitRef="usd">24132000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-114" decimals="-3" id="f-433" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-1" decimals="-3" id="f-434" unitRef="usd">25001000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-13" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-115" decimals="-3" id="f-436" unitRef="usd">1500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-116" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-13" decimals="-3" id="f-439" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-1" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-13" decimals="-3" id="f-441" unitRef="usd">514000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-13" decimals="-3" id="f-443" unitRef="usd">1881000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-444" unitRef="usd">2157000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-3" id="f-445" unitRef="usd">9782000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">673000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-13" decimals="-3" id="f-447" unitRef="usd">580000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-448" unitRef="usd">422213000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-449" unitRef="usd">26729000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-450" unitRef="usd">97490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-451" unitRef="usd">-43982000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-452" unitRef="usd">102827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-76" decimals="-3" id="f-453" unitRef="usd">155579000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-454" unitRef="usd">200317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-112" decimals="-3" id="f-455" unitRef="usd">111597000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-456" unitRef="usd">1367000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-3" id="f-457" unitRef="usd">434000</us-gaap:InterestPaidNet>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">41132000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c-13" decimals="-3" id="f-459" unitRef="usd">7235000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-1" decimals="-3" id="f-460" unitRef="usd">370000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-13" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">88000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-13" decimals="-3" id="f-463" unitRef="usd">25000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NotesReduction contextRef="c-1" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:NotesReduction>
    <us-gaap:NotesReduction contextRef="c-13" decimals="-3" id="f-465" unitRef="usd">4707000</us-gaap:NotesReduction>
    <us-gaap:NotesIssued1 contextRef="c-1" decimals="-3" id="f-466" unitRef="usd">0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1 contextRef="c-13" decimals="-3" id="f-467" unitRef="usd">5000000</us-gaap:NotesIssued1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-468">DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Viridian Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d; or &#x201c;Viridian&#x201d;), is a biopharmaceutical company advancing new treatments for patients suffering from serious diseases that are underserved by today&#x2019;s therapies. The Company&#x2019;s most advanced program, veligrotug (formerly known as VRDN-001), is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (&#x201c;IGF-1R&#x201d;), a clinically and commercially validated target for the treatment of thyroid eye disease (&#x201c;TED&#x201d;). The Company&#x2019;s second product candidate, VRDN-003, is an extended half-life monoclonal antibody with the same binding domains as veligrotug designed for administration as convenient, low-volume, subcutaneous pen injections. TED is a serious and debilitating rare autoimmune disease that causes inflammation within the orbit of the eye that can cause bulging of the eyes, redness and swelling, double vision, pain, and potential blindness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to developing therapies for TED, the Company is also developing a portfolio of engineered anti-neonatal Fc receptor (&#x201c;FcRn&#x201d;) inhibitors, including VRDN-006 and VRDN-008. FcRn inhibitors have the potential to treat a broad array of autoimmune diseases, representing a significant commercial market opportunity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared on a basis that assumes the Company is a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to its ability to continue as a going concern. The Company has funded its operations to date principally through proceeds received from the sale of the Company&#x2019;s common stock, its Series A Preferred Stock, Series B Preferred Stock, and other equity securities, debt financings, license fees, and reimbursements received under collaboration agreements. Since its inception and through September&#160;30, 2024, the Company has generated an accumulated deficit of $916.1 million. The Company expects to continue to generate operating losses for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no products approved for commercial sale, has not generated any revenue from product sales, and cannot guarantee when or if it will generate any revenue from product sales. Substantially all of the Company&#x2019;s operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to incur significant expenses and operating losses for at least the next several years as it continues the development of, and seeks regulatory approval for, its product candidates. It is expected that operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of development programs and efforts to achieve regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, the Company had approximately $753.2 million in cash, cash equivalents, and short-term investments. In addition, the Company also has access to additional undrawn funds under the Hercules Loan and Security Agreement Amended Term Loan, as further described in Note 5. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of the issuance date of these condensed consolidated financial statements, the Company expects that its current resources will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will require additional capital in order to continue to finance its operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of the Company&#x2019;s clinical development efforts, timing of market research and other professional and consulting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;activities to prepare for commercial activities, equity financings, entering into license and collaboration agreements, and issuing debt or other financing vehicles. The Company&#x2019;s ability to secure additional capital is dependent upon a number of factors, some of which are outside of the Company&#x2019;s control, including success in developing its product candidates, operational performance, and market conditions, including those resulting from the current inflationary and broader macroeconomic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#x2019;s financial condition and its ability to develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-469" unitRef="usd">-916100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-5" id="f-470" unitRef="usd">753200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-471">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Updates (&#x201c;ASU&#x201d;), or the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company&#x2019;s subsidiaries have no employees or operations. All intercompany balances and transactions have been eliminated in consolidation. Management has determined that the Company operates in one segment, which is the business of developing and commercializing novel therapeutics. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#x2019;s consolidated financial statements and the accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 27, 2024. The Company&#x2019;s management performed an evaluation of its activities through the date of filing of these unaudited condensed consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risk and Uncertainties &#x2013; Global Economic Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, and instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine, the rising tensions between China and Taiwan, the conflict in Israel and surrounding area and other political tensions. Such challenges have caused, and may continue to cause, recession fears, concerns regarding potential sanctions, high interest rates, foreign exchange volatility and inflationary pressures. At this time, the Company is unable to quantify the potential effects of this economic instability on its future operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s evaluation entails, among other things, analyzing the results of the Company&#x2019;s clinical development efforts, license and collaboration agreements as well as the entity&#x2019;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#x2019;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents, and short-term investments balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs, including manufacturing activities, and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#x2019;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised goods or services in the Company&#x2019;s agreements typically consist of a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration or strategic alliance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges including severance costs, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#x2019;s behalf, costs to have clinical trial materials manufactured on the Company&#x2019;s behalf, purchases of laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or when other significant risk factors are abated. Such up-front and milestone payments are reflected as cash used in operating activities within the condensed consolidated statement of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Trial and Preclinical Study Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#x2019;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#x2019;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#x2019;s research and development expenses may be necessary in future periods as its estimates change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues stock-based awards to employees and non-employees in the form of stock options and restricted stock units (&#x201c;RSUs&#x201d;). The Company measures and recognizes share-based compensation expense for its stock-based awards granted to employees and non-employees based on the estimated grant date fair value in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Compensation - Stock Compensation&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and determines the fair value of RSUs based on the fair value of its common stock. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are reported as a component of stockholders&#x2019; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:f-485"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease Right-of-Use Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in ASU No. 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Leases (Topic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;842), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#x201c;ASC 842&#x201d;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#x2019;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#x2019;s operating lease assets in the Company&#x2019;s condensed consolidated balance sheets. The Company&#x2019;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#x2019;s condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Refer to Note 6. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies - Lease Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information related to the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt and Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#x2019;s Term Loan (as defined in Note 5. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the nine months ended September 30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the condensed consolidated statements of changes in stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations and comprehensive loss as general and administrative expenses. No such expenses have been recognized during the nine months ended September 30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC Topic 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#x2019;s partners are denominated in U.S. dollars, except where noted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &#x2013; To Be Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Report Segment Disclosures (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires enhanced disclosures about significant segment expenses, enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. ASU 2023-07 is effective for the Company&#x2019;s annual reporting period beginning after December 15, 2023, and subsequent interim periods, with early adoption permitted. ASU 2023-07 requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 requires a company's annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#x2019;s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2024, the FASB issued ASU-2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). ASU 2024-03 requires additional disclosures of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. ASU 2024-03 is effective for the Company's annual reporting periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-472">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Updates (&#x201c;ASU&#x201d;), or the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company&#x2019;s subsidiaries have no employees or operations. All intercompany balances and transactions have been eliminated in consolidation. Management has determined that the Company operates in one segment, which is the business of developing and commercializing novel therapeutics. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#x2019;s consolidated financial statements and the accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 27, 2024. The Company&#x2019;s management performed an evaluation of its activities through the date of filing of these unaudited condensed consolidated financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-473"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <vrdn:GoingConcernPolicyPolicyTextBlock contextRef="c-1" id="f-474">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s evaluation entails, among other things, analyzing the results of the Company&#x2019;s clinical development efforts, license and collaboration agreements as well as the entity&#x2019;s current financial condition including conditional and unconditional obligations anticipated within a year, and related liquidity sources at the date the financial statements are issued. This is reflected in the Company&#x2019;s prospective operating budgets and forecasts and compared to the current cash, cash equivalents, and short-term investments balance.&lt;/span&gt;&lt;/div&gt;</vrdn:GoingConcernPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-475">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs, including manufacturing activities, and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-476">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements and certain other agreements that are within the scope of ASC 606, under which the Company licenses, may license, or grants an option to license rights to certain of the Company&#x2019;s product candidates and performs research and development services in connection with such agreements. The terms of these agreements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; developmental, clinical, regulatory, and commercial sales milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized, for agreements within the scope of ASC 606, the Company performs the following five steps: (i) identification of the goods or services within the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct within the terms of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the identified performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised goods or services in the Company&#x2019;s agreements typically consist of a license, or option to license, rights to the Company&#x2019;s intellectual property or research and development services. Performance obligations are promises in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available, and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each agreement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration and other research and development revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration or strategic alliance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction, and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-477">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, restructuring charges including severance costs, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#x2019;s behalf, costs to have clinical trial materials manufactured on the Company&#x2019;s behalf, purchases of laboratory supplies, depreciation, and facilities and overhead costs. The Company records research and development expense in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/div&gt;The Company records up-front and milestone payments to acquire and retain contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved for sale by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or when other significant risk factors are abated. Such up-front and milestone payments are reflected as cash used in operating activities within the condensed consolidated statement of cash flows.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <vrdn:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock contextRef="c-1" id="f-478">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical Trial and Preclinical Study Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#x2019;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#x2019;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#x2019;s research and development expenses may be necessary in future periods as its estimates change.&lt;/span&gt;&lt;/div&gt;</vrdn:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-479">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues stock-based awards to employees and non-employees in the form of stock options and restricted stock units (&#x201c;RSUs&#x201d;). The Company measures and recognizes share-based compensation expense for its stock-based awards granted to employees and non-employees based on the estimated grant date fair value in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Compensation - Stock Compensation&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and determines the fair value of RSUs based on the fair value of its common stock. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The use of the Black-Scholes option-pricing model requires the Company to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The Company recognizes share-based compensation expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-480">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-481">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of highly-rated corporate and U.S. Treasury securities and have been classified as available-for-sale securities. Accordingly, these investments are recorded at their respective fair values, as determined based on quoted market prices. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations, and thus investments with maturities beyond one year are generally classified as current assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses are reported as a component of stockholders&#x2019; equity until their disposition. Realized gains and losses are included as a component of other income (expense), net based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-482">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-483">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-484">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:f-485"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-118" id="f-486">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-487">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease Right-of-Use Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is, or contains, a lease at contract inception and during modifications or renewal of existing leases. Operating lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The Company has recorded operating lease assets and liabilities pursuant to the guidance in ASU No. 2016-02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, Leases (Topic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;842), &lt;/span&gt;and subsequent amendments to the initial guidance: ASU No. 2017-13, ASU No. 2018-10, and ASU No. 2018-11 (collectively, &#x201c;ASC 842&#x201d;). These operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. The lease payments used to determine the Company&#x2019;s operating lease assets may include lease incentives, stated rent increases, and escalation clauses and are recognized in the Company&#x2019;s operating lease assets in the Company&#x2019;s condensed consolidated balance sheets. The Company&#x2019;s operating leases are reflected in operating lease right-of-use asset and operating lease liability within accrued and other liabilities in the Company&#x2019;s condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-488">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt and Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs and expenses paid by the Company to its lenders are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Debt issuance costs represent legal and other direct costs incurred in connection with the Company&#x2019;s Term Loan (as defined in Note 5. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). These costs are amortized as a non-cash component of interest expense using the effective interest method over the term of the loan.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-489">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;The Company records shares of non-voting convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-490">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-13" decimals="INF" id="f-491" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-492" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period without consideration of common stock equivalents. Since the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-494">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;Comprehensive loss is comprised of net loss and adjustments for the change in unrealized gains and losses on investments. Unrealized accumulated comprehensive gains or losses are reflected as a separate component in the condensed consolidated statements of changes in stockholders&#x2019; equity.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant deferred tax assets are for net operating loss carryforwards, tax credits, accruals and reserves, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations and comprehensive loss as general and administrative expenses.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-3" decimals="INF" id="f-496" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c-1" decimals="INF" id="f-497" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c-13" decimals="INF" id="f-498" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <vrdn:WarrantsPolicyPolicyTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC Topic 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, FASB ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and classifies warrants for common stock as liabilities or equity. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.&lt;/span&gt;&lt;/div&gt;</vrdn:WarrantsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-500">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in&#160;one&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#x2019;s partners are denominated in U.S. dollars, except where noted.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-501"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &#x2013; To Be Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards have or may have a material impact on the Company&#x2019;s consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Report Segment Disclosures (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires enhanced disclosures about significant segment expenses, enhanced interim disclosure requirements, clarifies circumstances in which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with a single reportable segment, and contains other disclosure requirements. ASU 2023-07 is effective for the Company&#x2019;s annual reporting period beginning after December 15, 2023, and subsequent interim periods, with early adoption permitted. ASU 2023-07 requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the effect that adoption of ASU 2023-07 will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 requires a company's annual financial statements to include consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company&#x2019;s annual reporting periods beginning after December 15, 2024. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2023-09 will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;In November 2024, the FASB issued ASU-2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"). ASU 2024-03 requires additional disclosures of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. ASU 2024-03 is effective for the Company's annual reporting periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-503">INVESTMENTS AND FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following as of September 30, 2024 and December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The money market funds above are included in cash and cash equivalents on the Company&#x2019;s condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, the Company considers the unrealized losses in its investment portfolio to be temporary in nature and not due to credit losses. The Company has the intent and ability to hold such investments until their recovery at fair value. The Company did not have any realized gains or losses in its available for sale securities during the three and nine months ended September 30, 2024 and 2023. The Company did not have any sales of short-term investments during the three and nine months ended September 30, 2024 and 2023. The contractual maturity dates of all of the Company&#x2019;s investments are less than 24 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-504">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following as of September 30, 2024 and December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-119" decimals="-3" id="f-505" unitRef="usd">183690000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-119" decimals="-3" id="f-506" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-119" decimals="-3" id="f-507" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-119" decimals="-3" id="f-508" unitRef="usd">183690000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-120" decimals="-3" id="f-509" unitRef="usd">231010000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-120" decimals="-3" id="f-510" unitRef="usd">252000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-120" decimals="-3" id="f-511" unitRef="usd">52000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-120" decimals="-3" id="f-512" unitRef="usd">231210000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-121" decimals="-3" id="f-513" unitRef="usd">311036000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-121" decimals="-3" id="f-514" unitRef="usd">779000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-121" decimals="-3" id="f-515" unitRef="usd">50000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="-3" id="f-516" unitRef="usd">311765000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-122" decimals="-3" id="f-517" unitRef="usd">9945000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-122" decimals="-3" id="f-518" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-122" decimals="-3" id="f-519" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="-3" id="f-520" unitRef="usd">9948000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="-3" id="f-521" unitRef="usd">735681000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-522" unitRef="usd">1034000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-523" unitRef="usd">102000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="-3" id="f-524" unitRef="usd">736613000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-123" decimals="-3" id="f-525" unitRef="usd">77724000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-123" decimals="-3" id="f-526" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-123" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-123" decimals="-3" id="f-528" unitRef="usd">77731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-124" decimals="-3" id="f-529" unitRef="usd">148423000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-124" decimals="-3" id="f-530" unitRef="usd">255000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-124" decimals="-3" id="f-531" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-124" decimals="-3" id="f-532" unitRef="usd">148673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-125" decimals="-3" id="f-533" unitRef="usd">227463000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-125" decimals="-3" id="f-534" unitRef="usd">142000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-125" decimals="-3" id="f-535" unitRef="usd">85000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="-3" id="f-536" unitRef="usd">227520000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-126" decimals="-3" id="f-537" unitRef="usd">9304000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-126" decimals="-3" id="f-538" unitRef="usd">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-126" decimals="-3" id="f-539" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="-3" id="f-540" unitRef="usd">9328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-541" unitRef="usd">462914000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-542" unitRef="usd">428000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">90000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-544" unitRef="usd">463252000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-11" decimals="INF" id="f-545" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-13" decimals="INF" id="f-546" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-1" decimals="INF" id="f-547" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-12" decimals="INF" id="f-548" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-12" decimals="INF" id="f-549" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="INF" id="f-550" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="INF" id="f-551" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-11" decimals="INF" id="f-552" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="c-3" id="f-553">P24M</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-554">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.009%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.133%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.736%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. corporate paper and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International corporate bond holdings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-127" decimals="-3" id="f-555" unitRef="usd">183690000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-128" decimals="-3" id="f-556" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-129" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-130" decimals="-3" id="f-558" unitRef="usd">183690000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-131" decimals="-3" id="f-559" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-132" decimals="-3" id="f-560" unitRef="usd">231210000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-133" decimals="-3" id="f-561" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-134" decimals="-3" id="f-562" unitRef="usd">231210000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-135" decimals="-3" id="f-563" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-136" decimals="-3" id="f-564" unitRef="usd">311765000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-137" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-138" decimals="-3" id="f-566" unitRef="usd">311765000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-139" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-140" decimals="-3" id="f-568" unitRef="usd">9948000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-3" id="f-570" unitRef="usd">9948000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-143" decimals="-3" id="f-571" unitRef="usd">183690000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-144" decimals="-3" id="f-572" unitRef="usd">552923000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-145" decimals="-3" id="f-573" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-146" decimals="-3" id="f-574" unitRef="usd">736613000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-147" decimals="-3" id="f-575" unitRef="usd">77731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-148" decimals="-3" id="f-576" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-149" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-150" decimals="-3" id="f-578" unitRef="usd">77731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-151" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-152" decimals="-3" id="f-580" unitRef="usd">10978000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-153" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-154" decimals="-3" id="f-582" unitRef="usd">10978000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-155" decimals="-3" id="f-583" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-156" decimals="-3" id="f-584" unitRef="usd">148673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-157" decimals="-3" id="f-585" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-158" decimals="-3" id="f-586" unitRef="usd">148673000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-151" decimals="-3" id="f-587" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-152" decimals="-3" id="f-588" unitRef="usd">216542000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-153" decimals="-3" id="f-589" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-154" decimals="-3" id="f-590" unitRef="usd">216542000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-159" decimals="-3" id="f-591" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-160" decimals="-3" id="f-592" unitRef="usd">9328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-161" decimals="-3" id="f-593" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-162" decimals="-3" id="f-594" unitRef="usd">9328000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-163" decimals="-3" id="f-595" unitRef="usd">77731000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-164" decimals="-3" id="f-596" unitRef="usd">385521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-165" decimals="-3" id="f-597" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-166" decimals="-3" id="f-598" unitRef="usd">463252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-599">ACCRUED LIABILITIES AND OTHER&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued outsourced clinical trials and preclinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-605"&gt;&lt;span style="-sec-ix-hidden:f-606"&gt;Operating lease liability, short-term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued legal fees and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other professional service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of liability-classified stock purchase warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-600">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued outsourced clinical trials and preclinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued employee compensation and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-605"&gt;&lt;span style="-sec-ix-hidden:f-606"&gt;Operating lease liability, short-term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued legal fees and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other professional service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of liability-classified stock purchase warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vrdn:AccruedOutsourcingClinicalandPreclinicalStudies contextRef="c-3" decimals="-3" id="f-601" unitRef="usd">21676000</vrdn:AccruedOutsourcingClinicalandPreclinicalStudies>
    <vrdn:AccruedOutsourcingClinicalandPreclinicalStudies contextRef="c-4" decimals="-3" id="f-602" unitRef="usd">10724000</vrdn:AccruedOutsourcingClinicalandPreclinicalStudies>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-603" unitRef="usd">10011000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-604" unitRef="usd">10513000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-607" unitRef="usd">589000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-608" unitRef="usd">843000</us-gaap:OperatingLeaseLiabilityCurrent>
    <vrdn:AccruedLegalFeesCurrent contextRef="c-3" decimals="-3" id="f-609" unitRef="usd">846000</vrdn:AccruedLegalFeesCurrent>
    <vrdn:AccruedLegalFeesCurrent contextRef="c-4" decimals="-3" id="f-610" unitRef="usd">399000</vrdn:AccruedLegalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-3" id="f-611" unitRef="usd">762000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-612" unitRef="usd">473000</us-gaap:AccruedProfessionalFeesCurrent>
    <vrdn:AccruedLiabilityofWarrantsonTemporaryEquity contextRef="c-3" decimals="-3" id="f-613" unitRef="usd">100000</vrdn:AccruedLiabilityofWarrantsonTemporaryEquity>
    <vrdn:AccruedLiabilityofWarrantsonTemporaryEquity contextRef="c-4" decimals="-3" id="f-614" unitRef="usd">100000</vrdn:AccruedLiabilityofWarrantsonTemporaryEquity>
    <us-gaap:InterestPayableCurrent contextRef="c-3" decimals="-3" id="f-615" unitRef="usd">149000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-616" unitRef="usd">154000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-617" unitRef="usd">605000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-618" unitRef="usd">902000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-619" unitRef="usd">34738000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-620" unitRef="usd">24108000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-621">DEBT&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loan and Security Agreement with Hercules Capital, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the Company entered into a loan and security agreement (the &#x201c;Hercules Loan and Security Agreement&#x201d;) among the Company, certain of its subsidiaries from time to time party thereto (together with the Company, collectively, the &#x201c;Borrower&#x201d;), Hercules Capital, Inc. (&#x201c;Hercules&#x201d;) and certain other lenders named therein (the &#x201c;Lenders&#x201d;). Under the Hercules Loan and Security Agreement, the Lenders provided the Company with access to a term loan with an aggregate principal amount of up to $75.0&#160;million, in four tranches (collectively the &#x201c;Term Loan&#x201d;), including an initial tranche of $25.0&#160;million, available to the Company through June 15, 2023. Upon signing the Hercules Loan and Security Agreement, the Company drew an initial principal amount of $5.0&#160;million (the &#x201c;initial draw&#x201d;). The Company incurred debt issuance costs of $0.2&#160;million in connection with the Term Loan and paid to the Lenders a facility fee of $0.1&#160;million, as well as $0.1&#160;million of other expenses incurred by the Lenders and reimbursed by the Company (&#x201c;Lender Expenses&#x201d;) in connection with the initial draw. The debt issuance costs and the Lender Expenses were being amortized as additional interest expense over the term of the loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was originally obligated to make interest-only payments through April 1, 2024, which was extended to October 1, 2024 upon achievement of a development milestone in August 2022. In addition, the Borrower was required to pay an end-of-term fee equal to 6% of the principal amount of funded Term Loan advances at maturity, which were being accreted as additional interest expense over the term of the loan. The obligations of the Borrower under the Hercules Loan and Security Agreement were secured by substantially all of the assets of the Borrower, excluding the Borrower&#x2019;s intellectual property. The Term Loan had a maturity date of October 1, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company executed an amendment to the Hercules Loan and Security Agreement (the &#x201c;Hercules Amendment&#x201d;) to modify certain terms of the agreement and increase the aggregate principal amount to up to $150.0&#160;million. Upon execution of the Hercules Amendment in August 2023, the Company drew a principal amount of $15.0&#160;million. The Hercules Amendment was determined to substantially alter the Hercules Loan and Security Agreement and therefore was accounted for as a debt extinguishment. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized a loss on debt extinguishment of $0.2&#160;million in August 2023 related to unamortized debt discount and debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Hercules Amendment, the Lenders provided the Company access to an increased term loan with an aggregate principal amount of up to $150.0&#160;million, in four tranches (collectively the &#x201c;Amended Term Loan&#x201d;), consisting of (1) an initial tranche of $50.0&#160;million, $5.0&#160;million of which was drawn at closing of the Hercules Loan and Security Agreement in April 2022, $15.0&#160;million of which was drawn at closing of the Hercules Amendment in August 2023, $5.0&#160;million of which was available through December 15, 2023, and $25.0&#160;million of which is available from July 1, 2024 through December 15, 2024; (2) a second tranche of $20.0&#160;million, subject to achievement of certain regulatory milestones, available through February 15, 2025; (3) a third tranche of $20.0&#160;million, subject to achievement of certain regulatory milestones, available through March 31, 2025; and (4) a fourth tranche of $60.0&#160;million subject to approval by the Lenders&#x2019; investment committee(s), available through June 15, 2025. The milestones for the second and third tranches have not yet been achieved. The obligations of the Borrower under the Hercules Amendment agreement are secured by substantially all of the assets of the Borrower, excluding the Borrower&#x2019;s intellectual property. The Amended Term Loan has a maturity date of October 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Term Loan bears interest at a floating per annum rate equal to the greater of (i) 7.45% and (ii) 4.2% above the Prime Rate (as defined therein), provided that the Term Loan interest rate shall not exceed a per annum rate of 8.95%. Interest is payable monthly in arrears on the first day of each month. The interest rate as of September&#160;30, 2024 was 8.95%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Per the terms of the Hercules Amendment, the Company was originally obligated to make interest-only payments through April 1, 2025. Upon achievement of certain development milestones related to topline results for the Company&#x2019;s phase 3 THRIVE trial in September 2024, the interest-only period was extended to October 1, 2025. If additional development milestones are met, the interest-only period will be further extended to April 1, 2026. The Borrower is required to repay the Amended Term Loan amount in equal monthly installments of the principal amount and interest between the end of the interest-only period and the maturity date of October 1, 2026. In addition, the Borrower is required to pay an end-of-term fee equal to 6% of the principal amount of funded Amended Term Loan advances at maturity, which are being accreted as additional interest expense over the term of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total cost of all items (cash interest, the amortization/accretion of the debt issuance costs and the end-of-term fee) is being recognized as interest expense using an effective interest rate of approximately 9.3%. The Company recorded interest expense of $0.5 million and $1.7 million during the three and nine months ended September 30, 2024, and $0.4&#160;million and $0.8&#160;million during the three and nine months ended September 30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of the Term Loan, on the Company&#x2019;s condensed consolidated balance sheet at September&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross term loan proceeds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued end-of-term fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Term Loan approximates its fair value. Future principal payments, which exclude the end of term fee, in connection with the Hercules Loan and Security Agreement as of September&#160;30, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-167" decimals="INF" id="f-622" unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <vrdn:DebtInstrumentNumberOfTranches
      contextRef="c-167"
      decimals="INF"
      id="f-623"
      unitRef="tranche">4</vrdn:DebtInstrumentNumberOfTranches>
    <vrdn:DebtInstrumentFaceAmountFirstTranche contextRef="c-167" decimals="INF" id="f-624" unitRef="usd">25000000</vrdn:DebtInstrumentFaceAmountFirstTranche>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-168" decimals="-5" id="f-625" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-167" decimals="-5" id="f-626" unitRef="usd">200000</us-gaap:DeferredFinanceCostsGross>
    <vrdn:DebtInstrumentFacilityFee contextRef="c-168" decimals="-5" id="f-627" unitRef="usd">100000</vrdn:DebtInstrumentFacilityFee>
    <vrdn:DebtInstrumentOtherExpenses contextRef="c-168" decimals="-5" id="f-628" unitRef="usd">100000</vrdn:DebtInstrumentOtherExpenses>
    <vrdn:DebtInstrumentPrincipalAmountTermFee contextRef="c-167" decimals="2" id="f-629" unitRef="number">0.06</vrdn:DebtInstrumentPrincipalAmountTermFee>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-169" decimals="INF" id="f-630" unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-170" decimals="-5" id="f-631" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-170" decimals="-5" id="f-632" unitRef="usd">-200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-169" decimals="INF" id="f-633" unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <vrdn:DebtInstrumentNumberOfTranches
      contextRef="c-169"
      decimals="INF"
      id="f-634"
      unitRef="tranche">4</vrdn:DebtInstrumentNumberOfTranches>
    <vrdn:DebtInstrumentFaceAmountFirstTranche contextRef="c-169" decimals="INF" id="f-635" unitRef="usd">50000000</vrdn:DebtInstrumentFaceAmountFirstTranche>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-168" decimals="-5" id="f-636" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-170" decimals="-5" id="f-637" unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <vrdn:DebtInstrumentFaceAmountFirstTranche contextRef="c-171" decimals="INF" id="f-638" unitRef="usd">5000000</vrdn:DebtInstrumentFaceAmountFirstTranche>
    <vrdn:DebtInstrumentFaceAmountFirstTranche contextRef="c-172" decimals="INF" id="f-639" unitRef="usd">25000000</vrdn:DebtInstrumentFaceAmountFirstTranche>
    <vrdn:DebtInstrumentFaceAmountSecondTranche contextRef="c-169" decimals="INF" id="f-640" unitRef="usd">20000000</vrdn:DebtInstrumentFaceAmountSecondTranche>
    <vrdn:DebtInstrumentFaceAmountThirdTranche contextRef="c-169" decimals="INF" id="f-641" unitRef="usd">20000000</vrdn:DebtInstrumentFaceAmountThirdTranche>
    <vrdn:DebtInstrumentFaceAmountFourthTranche contextRef="c-169" decimals="INF" id="f-642" unitRef="usd">60000000</vrdn:DebtInstrumentFaceAmountFourthTranche>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-169"
      decimals="INF"
      id="f-643"
      unitRef="number">0.0745</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-170"
      decimals="INF"
      id="f-644"
      unitRef="number">0.042</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <vrdn:DebtInstrumentInterestRateMaximum
      contextRef="c-169"
      decimals="INF"
      id="f-645"
      unitRef="number">0.0895</vrdn:DebtInstrumentInterestRateMaximum>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-173"
      decimals="INF"
      id="f-646"
      unitRef="number">0.0895</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <vrdn:DebtInstrumentPrincipalAmountTermFee
      contextRef="c-169"
      decimals="INF"
      id="f-647"
      unitRef="number">0.06</vrdn:DebtInstrumentPrincipalAmountTermFee>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-169" decimals="3" id="f-648" unitRef="number">0.093</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseNonoperating contextRef="c-174" decimals="-5" id="f-649" unitRef="usd">500000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-175" decimals="-5" id="f-650" unitRef="usd">1700000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-176" decimals="-5" id="f-651" unitRef="usd">400000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-177" decimals="-5" id="f-652" unitRef="usd">800000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-653">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of the Term Loan, on the Company&#x2019;s condensed consolidated balance sheet at September&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross term loan proceeds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued end-of-term fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-173" decimals="-3" id="f-654" unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-173" decimals="-3" id="f-655" unitRef="usd">523000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebt contextRef="c-173" decimals="-3" id="f-656" unitRef="usd">20523000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-173" decimals="-3" id="f-657" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-173" decimals="-3" id="f-658" unitRef="usd">20523000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-659">Future principal payments, which exclude the end of term fee, in connection with the Hercules Loan and Security Agreement as of September&#160;30, 2024 are as follows (in thousands):&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.166%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.259%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-173" decimals="-3" id="f-660" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-173" decimals="-3" id="f-661" unitRef="usd">4441000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-173" decimals="-3" id="f-662" unitRef="usd">15559000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-173" decimals="-3" id="f-663" unitRef="usd">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-664">COLLABORATION AGREEMENTS&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Zenas BioPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company became party to a license agreement with Zenas BioPharma (Cayman) Limited (&#x201c;Zenas BioPharma&#x201d;) to license technology comprising certain materials, patent rights, and know-how to Zenas BioPharma. Since February 2021, the Company has entered into several letter agreements with Zenas BioPharma pursuant to which the Company agreed to provide assistance to Zenas BioPharma with certain development activities, including manufacturing. In May 2022, the Company entered into a Manufacturing Development and Supply Agreement with Zenas BioPharma to manufacture and supply, or to have manufactured and supplied, clinical drug product for developmental purposes. The license agreement and subsequent letter agreements and supply agreement (collectively, the &#x201c;Zenas Agreements&#x201d;) were negotiated with a single commercial objective and are treated as a combined contract for accounting purposes. Under the terms of the Zenas Agreements, the Company granted Zenas BioPharma an exclusive license to develop, manufacture, and commercialize certain IGF-1R directed antibody products for non-oncology indications in the greater area of China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the Zenas Agreements, the transaction price included upfront non-cash consideration and variable consideration in the form of payment for the Company&#x2019;s goods and services and milestone payments due upon the achievement of specified events. Under the Zenas Agreements, the Company can receive non-refundable milestone payments upon achieving specific milestone events during the contract term. Additionally, the Company may receive royalty payments based on a percentage of the annual net sales of any licensed products sold on a country-by-country basis in the greater area of China. The royalty percentage may vary based on different tiers of annual net sales of the licensed products made. Zenas BioPharma is obligated to make royalty payments to the Company for the royalty term in the Zenas Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Zenas Agreements would qualify as a collaborative arrangement under the scope of Accounting Standards Codification, Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 808&#x201d;). While this arrangement is in the scope of ASC 808, the Company applied ASC 606 to account for certain aspects of this arrangement. The Company applied ASC 606 for certain activities within the arrangement associated with the Company&#x2019;s transfer of a good or service (i.e., a unit of account) that is part of the Company&#x2019;s ongoing major or central operations. The Company allocated the transaction price based on the relative estimated standalone selling prices of each performance obligation or, in the case of certain variable consideration, to one or more performance obligations. Research and development activities are priced generally at cost. The Company&#x2019;s license of goods and services to Zenas BioPharma during the contract term was determined to be a single performance obligation satisfied over time. The Company will recognize the transaction price from the license agreement over the Company&#x2019;s estimated period to complete its activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the arrangement, the Company evaluated whether the milestones were considered probable of being reached and estimated the amount to be included in the transaction price using the most likely amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;method. As it was not probable that a significant revenue reversal would not occur, none of the associated milestone payments were included in the transaction price at contract inception. For the sales-based royalties included in the arrangement, the license was deemed to be the predominant item to which the royalties relate. The Company will recognize royalty revenues at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.2 million, respectively, of collaboration revenue related to the Zenas Agreements. During the three and nine months ended September 30, 2023, the Company recognized $0.1 million and $0.2 million, respectively, of collaboration revenue related to the Zenas Agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2024, the Company entered into a letter agreement with Zenas BioPharma (the &#x201c;Zenas Letter Agreement&#x201d;) pursuant to which Zenas BioPharma agreed to support the Company&#x2019;s THRIVE-2 and STRIVE trials by initiating and managing the studies in China. Under the Zenas Letter Agreement, the Company agreed to reimburse costs incurred by Zenas BioPharma, including a full-time equivalent rate for services rendered. In connection with the execution of the Zenas Letter Agreement, the Company made an initial payment of $1.5&#160;million, which was recorded as research and development expense during the nine months ended September 30, 2024 as services were performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Zenas Agreements are considered related party transactions because Fairmount Funds Management LLC (&#x201c;Fairmount&#x201d;) beneficially owns more than 5% of the Company&#x2019;s common stock and is also a 5% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharma&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Antibody and Discovery Option Agreement with Paragon Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company and Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) entered into an antibody and discovery option agreement (the &#x201c;Paragon Research Agreement&#x201d;) under which the Company and Paragon will cooperate to develop one or more proteins or antibodies. Under the terms of the Paragon Research Agreement, Paragon will perform certain development activities in accordance with an agreed upon research plan, and the Company will pay Paragon agreed upon development fees in exchange for Paragon&#x2019;s commitment of the necessary personnel and resources to perform these activities. The Paragon Research Agreement stipulates a final deliverable to the Company comprising of a report summarizing the experiments and processes performed under the research plan (the &#x201c;Final Deliverable&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Paragon agreed to grant the Company an option for an exclusive license to all of Paragon&#x2019;s right, title and interest in and to certain antibody technology and the Final Deliverable, and a non-exclusive license to certain background intellectual property owned by Paragon solely to research, develop, make, use, sell, offer for sale and import of the licensed intellectual property and resulting products worldwide (each, an &#x201c;Option&#x201d; and together, the &#x201c;Options&#x201d;). Paragon also granted to the Company a limited, exclusive, royalty-free license, without the right to sublicense, to certain antibody technology and the Final Deliverable, and a non-exclusive, royalty-free license without the right to sublicense, under certain background intellectual property owned by Paragon, solely to evaluate the antibody technology and Option and for the purpose of allowing the Company to determine whether to exercise the Option with respect to certain programs. The Company may, at its sole discretion, exercise the Option with respect to specified programs (&#x201c;Programs&#x201d;) at any time until the date that is 90 days after the Company&#x2019;s receipt of the Final Deliverable the applicable program, or such longer period as agreed upon by the parties (&#x201c;Option Period&#x201d;) by delivering written notice of such exercise to Paragon. If the Company fails to exercise an Option prior to expiration of the applicable Option Period, such Option for such Programs will terminate. In consideration for Paragon&#x2019;s grant of the Options to the Company, the Company paid to Paragon a non-refundable, non-creditable one-time fee of $2.5&#160;million, which was recorded as research and development expense during the three months ended March 31, 2022. In December 2022, the Company and Paragon entered into a first amendment to the Paragon Research Agreement, under which the Company obtained an additional limited license for the purpose of conducting certain activities. In consideration for the rights and licenses obtained under the first amendment, Viridian paid Paragon a non-refundable fee of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3&#160;million (the &#x201c;First Amendment Payment&#x201d;), which was recorded as research and development expense during the three months ended December 31, 2022. The non-refundable upfront fee and the First Amendment Payment are separate from any development costs or cost advance paid or owing with respect to the specified program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Company entered into a License Agreement with Paragon (the &#x201c;Paragon License Agreement&#x201d;) as a result of exercising its Option under the Paragon Research Agreement to obtain exclusive licenses to develop, manufacture and commercialize certain antibodies, proteins and associated products. In connection with the execution of the Paragon License Agreement, the Company made an initial payment of $5.3&#160;million, which was recorded as research and development expense during the three months ended December 31, 2023. As further described below, the Paragon License Agreement was amended and restated by the Amended and Restated License Agreement with Paragon in September 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2024, the Company entered into a letter agreement with Paragon pursuant to which Paragon agreed to continue to perform development activities under the existing Paragon Research Agreement and Paragon License Agreement, which the Company renewed in July 2024. In consideration for the development activities to be conducted by Paragon, the Company will reimburse Paragon for actual development costs incurred and agreed upon development fees in exchange for Paragon&#x2019;s commitment of the necessary personnel and resources to perform these activities. In September 2024, the Company entered into a second amendment to the Paragon Research Agreement to include additional development activities to be performed by Paragon. Under the amended Paragon Research Agreement, the Company will be obligated to make a one-time non-refundable payment of $3.5&#160;million to Paragon following the achievement of certain research and development objectives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2024, the Company entered into the Amended and Restated License Agreement with Paragon (the &#x201c;Amended Paragon License Agreement&#x201d;) which amended and restated the Paragon License Agreement. In connection with the execution of the Amended Paragon License Agreement, the Company paid Paragon a non-refundable fee of $4.0&#160;million in September 2024, which was recorded as research and development expense during the three months ended September 30, 2024. In consideration for rights granted by Paragon, the Company is obligated to make certain future milestone payments of up to $16.0&#160;million on a program-by-program bases upon the achievement of specified clinical or regulatory milestones, with total milestone payments under all programs not to exceed $40.0&#160;million. Additionally, if the Company develops a product utilizing certain intellectual property rights granted to it under the Amended Paragon License Agreement, the Company is obligated to pay Paragon potential additional future development milestone payments of up to $3.1&#160;million and commercial milestone payments of up to $17.0&#160;million with respect to such product. If the Company successfully commercializes any product candidate subject to the Amended Paragon License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of such product&#x2019;s net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2024, the Company recorded $7.7 million and $10.9 million, respectively, in research and development costs related to the Paragon Research Agreement and Amended Paragon License Agreement (collectively, the &#x201c;Paragon Agreements&#x201d;). During the three and nine months ended September 30, 2023, the Company recorded $1.1 million and $6.5 million, respectively, in research and development costs related to the Paragon Agreements. &lt;/span&gt;&lt;/div&gt;The Paragon Agreements are considered related party transactions because Fairmount beneficially owns more than 5% of the Company&#x2019;s capital stock and has two seats on the Company&#x2019;s board of directors, and beneficially owns more than 5% of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragon&#x2019;s board of directors and has the contractual right to approve the appointment of any executive officers.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-178" decimals="-5" id="f-665" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-179" decimals="-5" id="f-666" unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-180" decimals="-5" id="f-667" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-181" decimals="-5" id="f-668" unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <vrdn:CollaborationArrangementInitialPayment contextRef="c-182" decimals="-5" id="f-669" unitRef="usd">1500000</vrdn:CollaborationArrangementInitialPayment>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-183" decimals="2" id="f-670" unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-183" decimals="2" id="f-671" unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <vrdn:CollaborativeArrangementUpfrontFeePayment contextRef="c-184" decimals="-5" id="f-672" unitRef="usd">2500000</vrdn:CollaborativeArrangementUpfrontFeePayment>
    <vrdn:CollaborativeArrangementRightsAndLicensesFee contextRef="c-185" decimals="-5" id="f-673" unitRef="usd">2300000</vrdn:CollaborativeArrangementRightsAndLicensesFee>
    <vrdn:CollaborationArrangementInitialPayment contextRef="c-186" decimals="-5" id="f-674" unitRef="usd">5300000</vrdn:CollaborationArrangementInitialPayment>
    <vrdn:CollaborativeArrangementMilestonePayment contextRef="c-187" decimals="-5" id="f-675" unitRef="usd">3500000</vrdn:CollaborativeArrangementMilestonePayment>
    <vrdn:CollaborativeArrangementUpfrontFeePayment contextRef="c-187" decimals="-5" id="f-676" unitRef="usd">4000000</vrdn:CollaborativeArrangementUpfrontFeePayment>
    <vrdn:CollaborationArrangementFutureDevelopmentsMilestonePayments contextRef="c-187" decimals="-5" id="f-677" unitRef="usd">16000000</vrdn:CollaborationArrangementFutureDevelopmentsMilestonePayments>
    <vrdn:CollaborationArrangementMaximumMilestonePayments contextRef="c-187" decimals="-5" id="f-678" unitRef="usd">40000000</vrdn:CollaborationArrangementMaximumMilestonePayments>
    <vrdn:CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum contextRef="c-187" decimals="-5" id="f-679" unitRef="usd">3100000</vrdn:CollaborationArrangementMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum>
    <vrdn:CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum contextRef="c-187" decimals="-5" id="f-680" unitRef="usd">17000000</vrdn:CollaborationArrangementCommercialMilestonePaymentIntellectualPropertyRightsDevelopmentMaximum>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-188" decimals="-5" id="f-681" unitRef="usd">7700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-189" decimals="-5" id="f-682" unitRef="usd">10900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-190" decimals="-5" id="f-683" unitRef="usd">1100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-191" decimals="-5" id="f-684" unitRef="usd">6500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-192" decimals="2" id="f-685" unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-192" decimals="2" id="f-686" unitRef="number">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-687">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with ImmunoGen, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Company became party to a license agreement (the &#x201c;ImmunoGen License Agreement&#x201d;) with Immunogen, Inc. (&#x201c;ImmunoGen&#x201d;), under which the Company obtained an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to develop, manufacture, and commercialize certain products for non-oncology and non-radiopharmaceutical indications. In consideration for rights granted by ImmunoGen, the Company is obligated to make certain future development milestone payments of up to $48.0&#160;million upon the achievement of specified clinical and regulatory milestones. In December 2021, the Company paid a $2.5&#160;million milestone payment to ImmunoGen upon the submission of an investigational new drug (&#x201c;IND&#x201d;) application for veligrotug with the FDA. In May 2022, the Company paid a $3.0&#160;million milestone payment to ImmunoGen related to the first patient dosed in the clinical trial for veligrotug. In December 2022, the Company recorded $10.0&#160;million as research and development expense related to a milestone owed to ImmunoGen related to the first patient dosed in a pivotal clinical trial for veligrotug, amount which was paid in January 2023. Additionally, if the Company successfully commercializes any product candidate subject to the ImmunoGen License Agreement, it is responsible for royalty payments equal to a percentage in the mid-single digits of net sales and commercial milestone payments of up to $95.0&#160;million. The Company is obligated to make any such royalty payments on a product-by-product and country-by-country basis from the first commercial sale of a specified product in each country until the later of (i) the expiration of the last patent claim subject to the ImmunoGen License Agreement in such country, (ii) the expiration of any applicable regulatory exclusivity obtained for each product in such country, or (iii) the 12th anniversary of the date of the first commercial sale of such product in such country. On February 12, 2024, AbbVie Inc. acquired ImmunoGen.&#160;The terms of the ImmunoGen License Agreement did not change as a result of this acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Development and License Agreement with Enable Injections&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company entered into a Development and License Agreement (the &#x201c;Enable License Agreement&#x201d;) with Enable Injections, Inc. (&#x201c;Enable&#x201d;), under which Enable granted the Company an exclusive, royalty-bearing, sublicensable, non-transferrable license to (i) develop, commercialize, seek marketing approval for and otherwise use and exploit certain products, and (ii) make and have made such product solely for such permitted uses. Pursuant to the terms of the Enable License Agreement, the Company granted Enable a non-exclusive, royalty-free, non-sublicensable, non-transferable license. In consideration for the rights granted by Enable, the Company paid Enable an initial, non-creditable, non-refundable license fee of $15.0&#160;million in January 2023. This amount is included in research and development expense during the nine months ended September 30, 2023 in the accompanying condensed consolidated statement of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to make certain future milestone payments of up to $45.0&#160;million upon the achievement of specified development, clinical and regulatory milestones. Additionally, if the Company is successful in commercializing any product candidate subject to the Enable License Agreement, the Company is obligated to make certain commercial milestone payments of up to $150.0&#160;million and royalty payments equal to a percentage in the mid-single digits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Value Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the merger agreement with miRagen Therapeutics, Inc. (&#x201c;miRagen&#x201d;), on November 4, 2020, the Company entered into a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;), pursuant to which each holder of the Company&#x2019;s common stock as of November 6, 2020, other than former stockholders of the private entity Viridian Therapeutics, Inc. (which merged with miRagen), received one contingent value right (a &#x201c;CVR&#x201d;) for each share of Company common stock held by such holder on that date. Under the CVR Agreement, holders &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of CVRs would have been entitled to receive a portion of the net proceeds for any dispositions of certain legacy miRagen assets consummated through December 31, 2021. As of December 31, 2021, the disposition period had expired. There were no dispositions of any such legacy assets prior to that time and, accordingly, there will be no payments made under the CVR Agreement. The CVR Agreement expires on November 4, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Exclusive License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company and a third-party collaborator entered into an Exclusive License and Collaboration Agreement to collaborate and conduct certain IND-enabling activities with respect to the licensed compound and licensed product. Under the terms of the agreement, the Company was granted an exclusive, royalty-bearing, worldwide license to develop, manufacture, and commercialize certain licensed compounds and licensed products in the field (the &#x201c;License&#x201d;). In consideration for the rights granted by the License, the Company initially issued 204,843 shares of its common stock to certain stockholders of the third-party. The shares were valued at $5.0&#160;million and recorded as research and development expense during the three months ended June 30, 2023. On July 24, 2023, the Company issued 39,059 additional shares of its common stock to certain stockholders of the third-party and recorded the related $0.7&#160;million expense as research and development expenses during three months ended September 30, 2023. Additionally, upon the date when the Company decides to pursue certain studies for the licensed compound under the agreement, the Company shall issue the third-party collaborator the equivalent of $10.0&#160;million in shares of its common stock. The Company is also obligated to make certain future milestones of up to $45.0 million upon the achievement of certain development milestones. Remaining development milestone payments shall be payable in cash. If the Company is successful in commercializing products related to the licensed compound, the Company is also obligated to pay up to $60.0&#160;million upon the achievement of certain sales milestones as well as royalty payments equal to a percentage in the mid-single to double digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Colorado-based Office and Lab Space&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a multi-year, non-cancelable lease agreement for its Colorado-based office and lab space (the &#x201c;Colorado Lease&#x201d;). The Colorado Lease includes rent escalation clauses through the lease term and a Company option to extend the lease term for up to three terms of three years each. Minimum base lease payments under the Colorado Lease, including the impact of tenant improvement allowances, are recognized on a straight-line basis over the full term of the lease. The lease term was amended in March 2021 to extend the lease maturity date to December 31, 2024. Upon adoption of ASC 842 and upon subsequent modification of the lease in 2020 and in March 2021, the Company recognized a right-of-use asset and corresponding lease liability for the Colorado Lease of approximately $1.6&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#x2019;s estimated incremental borrowing rate, over the 12 months expected remaining term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2024, the Company entered into a new, multi-year lease agreement for its Colorado-based office and lab space (the &#x201c;New Colorado Lease&#x201d;). Under ASC 842, the New Colorado Lease was treated as a lease modification representing an extension of the lease term for a reduced portion of the space currently in use under the existing Colorado Lease. As of the effective date, the Company recorded a $0.3&#160;million increase in the right-of-use asset and corresponding lease liability for the extension of the lease term. The remaining space under the Colorado Lease will terminate at the original maturity date of December 31, 2024. The New Colorado Lease provides for annual base rent of approximately $0.1&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes, and operating expenses. The New Colorado Lease is set to expire in December 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Massachusetts-based Office Space&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a multi-year, non-cancelable lease agreement for its Massachusetts-based office space (as subsequently amended in July 2021, April 2022, July 2022 and April 2024, the &#x201c;Massachusetts Lease&#x201d;). The Massachusetts Lease includes rent escalation clauses throughout the lease term. Minimum base lease payments under the Massachusetts Lease are recognized on a straight-line basis over the full term of the Massachusetts Lease. Upon initial assumption of the Massachusetts Lease in October 2020, the Company recognized a right-of-use asset and corresponding lease liability of $0.1&#160;million by calculating the present value of lease payments, discounted at 6%, the Company&#x2019;s estimated incremental borrowing rate, over the expected remaining term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the Company entered into a Fourth Amendment of the Massachusetts Lease (the &#x201c;Fourth Amendment&#x201d;). The Fourth Amendment makes certain modifications to the Massachusetts Lease, including (i) securing 10,427 square feet of office space in a new building suite (the &#x201c;New Premises&#x201d;), (ii) the termination of the 10,956 square feet of leased space under the existing Massachusetts Lease (the &#x201c;Original Premises&#x201d;), and (iii) the extension of the expiration date of the leased space to five years from the delivery of the New Premises. The Massachusetts Lease provides for annual base rent of approximately $0.5&#160;million during the lease term. The Company is also obligated to pay the landlord certain costs, taxes and operating expenses. Under the Fourth Amendment, the Massachusetts Lease will expire in July 2029. The Company has the option to extend the lease term for an additional period of three years upon notice to the landlord.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a new right-of-use asset of $1.6&#160;million and corresponding lease liability of $1.9&#160;million for the New Premises and simultaneously derecognized the right-of-use asset of  $1.1 million and corresponding lease liability of  $1.2 million for the Original Premises on the lease commencement date in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2024, the Company entered into a Fifth Amendment of the Massachusetts Lease (the &#x201c;Fifth Amendment&#x201d;) to lease an additional 2,788 square feet of office space in the same building. The Fifth Amendment provides for additional annual base rent of approximately $0.1&#160;million for the additional office space and includes annual base rent escalation clauses during the lease term. The Fifth Amendment was treated as a lease modification accounted for as a separate contract and the Company recorded a new right-of-use asset and corresponding lease liability of approximately $0.5&#160;million related to the Fifth Amendment on the lease commencement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under noncancellable leases as of September&#160;30, 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, the Company&#x2019;s operating lease obligations were reflected as short-term operating lease liabilities of $0.6&#160;million within &lt;span style="-sec-ix-hidden:f-739"&gt;accrued liabilities&lt;/span&gt; and $2.2 million of long-term lease obligations as &lt;span style="-sec-ix-hidden:f-741"&gt;other liabilities&lt;/span&gt; in the Company&#x2019;s condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $0.2 million and $0.8 million for the three and nine months ended September 30, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024, respectively, which was included in operating expense in the condensed consolidated statements of operations and comprehensive loss. Amortization of the operating lease right-of-use assets, and corresponding reduction of operating lease obligations, amounted to $0.2&#160;million and $0.6&#160;million for the three and nine months ended September 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also required to pay for certain costs, taxes, and operating expenses related to both the Colorado Lease and Massachusetts Lease, which were $0.1&#160;million and $0.3 million for the three and nine months ended September 30, 2024 and 2023, respectively. The operating expenses are incurred separately and were not included in the present value of lease payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum contextRef="c-193" decimals="INF" id="f-688" unitRef="usd">48000000</vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum>
    <vrdn:CollaborativeArrangementMilestonePayment contextRef="c-194" decimals="-5" id="f-689" unitRef="usd">2500000</vrdn:CollaborativeArrangementMilestonePayment>
    <vrdn:CollaborativeArrangementMilestonePayment contextRef="c-195" decimals="-5" id="f-690" unitRef="usd">3000000</vrdn:CollaborativeArrangementMilestonePayment>
    <vrdn:CollaborativeArrangementMilestonePayment contextRef="c-196" decimals="-5" id="f-691" unitRef="usd">10000000</vrdn:CollaborativeArrangementMilestonePayment>
    <vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum contextRef="c-193" decimals="INF" id="f-692" unitRef="usd">95000000</vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum>
    <vrdn:CollaborativeArrangementRightsAndLicensesFee contextRef="c-197" decimals="-5" id="f-693" unitRef="usd">15000000</vrdn:CollaborativeArrangementRightsAndLicensesFee>
    <vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum contextRef="c-198" decimals="INF" id="f-694" unitRef="usd">45000000</vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum>
    <vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum contextRef="c-198" decimals="INF" id="f-695" unitRef="usd">150000000</vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum>
    <vrdn:CollaborativeArrangementSharesIssuedForRightsGranted
      contextRef="c-199"
      decimals="INF"
      id="f-696"
      unitRef="shares">204843</vrdn:CollaborativeArrangementSharesIssuedForRightsGranted>
    <vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted contextRef="c-200" decimals="-5" id="f-697" unitRef="usd">5000000</vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted>
    <vrdn:CollaborativeArrangementAdditionalSharesIssuedForRightsGranted
      contextRef="c-201"
      decimals="INF"
      id="f-698"
      unitRef="shares">39059</vrdn:CollaborativeArrangementAdditionalSharesIssuedForRightsGranted>
    <vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted contextRef="c-202" decimals="-5" id="f-699" unitRef="usd">700000</vrdn:CollaborativeArrangementValueOfSharesIssuedForRightsGranted>
    <vrdn:CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted contextRef="c-203" decimals="-5" id="f-700" unitRef="usd">10000000</vrdn:CollaborativeArrangementValueOfSharesToBeIssuedForRightsGranted>
    <vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum contextRef="c-199" decimals="INF" id="f-701" unitRef="usd">45000000.0</vrdn:CollaborationArrangementPotentialMilestonePaymentMaximum>
    <vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum contextRef="c-199" decimals="INF" id="f-702" unitRef="usd">60000000</vrdn:CollaborativeArrangementPotentialRoyaltyPaymentsMaximum>
    <vrdn:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="c-204"
      decimals="INF"
      id="f-703"
      unitRef="renewal_term">3</vrdn:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-205" id="f-704">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-206" decimals="-5" id="f-705" unitRef="usd">1600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-206" decimals="-5" id="f-706" unitRef="usd">1600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-206" decimals="2" id="f-707" unitRef="number">0.06</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-206" id="f-708">P12M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-205" decimals="-5" id="f-709" unitRef="usd">300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-205" decimals="-5" id="f-710" unitRef="usd">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <vrdn:OperatingLeaseAnnualBaseRent contextRef="c-207" decimals="-5" id="f-711" unitRef="usd">100000</vrdn:OperatingLeaseAnnualBaseRent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-208" decimals="-5" id="f-712" unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-208" decimals="-5" id="f-713" unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-208" decimals="2" id="f-714" unitRef="number">0.06</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-209" decimals="0" id="f-715" unitRef="sqft">10427</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-210" decimals="0" id="f-716" unitRef="sqft">10956</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-209" id="f-717">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vrdn:OperatingLeaseAnnualBaseRent contextRef="c-211" decimals="-5" id="f-718" unitRef="usd">500000</vrdn:OperatingLeaseAnnualBaseRent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-209" id="f-719">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-209" decimals="-5" id="f-720" unitRef="usd">1600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-209" decimals="-5" id="f-721" unitRef="usd">1900000</us-gaap:OperatingLeaseLiabilityCurrent>
    <vrdn:OperatingLeaseRightOfUseAssetDerecognized contextRef="c-209" decimals="-5" id="f-722" unitRef="usd">1100000</vrdn:OperatingLeaseRightOfUseAssetDerecognized>
    <vrdn:OperatingLeaseLiabilityCurrentDerecognized contextRef="c-209" decimals="-5" id="f-723" unitRef="usd">1200000</vrdn:OperatingLeaseLiabilityCurrentDerecognized>
    <us-gaap:AreaOfRealEstateProperty contextRef="c-212" decimals="0" id="f-724" unitRef="sqft">2788</us-gaap:AreaOfRealEstateProperty>
    <vrdn:OperatingLeaseAnnualBaseRent contextRef="c-213" decimals="-5" id="f-725" unitRef="usd">100000</vrdn:OperatingLeaseAnnualBaseRent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-212" decimals="-5" id="f-726" unitRef="usd">500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-212" decimals="-5" id="f-727" unitRef="usd">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-728">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under noncancellable leases as of September&#160;30, 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.286%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.968%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-729" unitRef="usd">273000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-730" unitRef="usd">723000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-731" unitRef="usd">748000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-732" unitRef="usd">613000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-733" unitRef="usd">627000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-3" decimals="-3" id="f-734" unitRef="usd">370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-735" unitRef="usd">3354000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-736" unitRef="usd">603000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-737" unitRef="usd">2751000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-5" id="f-738" unitRef="usd">600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-5" id="f-740" unitRef="usd">2200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-11" decimals="-5" id="f-742" unitRef="usd">200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-5" id="f-743" unitRef="usd">800000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-12" decimals="-5" id="f-744" unitRef="usd">200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="-5" id="f-745" unitRef="usd">600000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <vrdn:OperatingLeasesOperatingExpense contextRef="c-12" decimals="-5" id="f-746" unitRef="usd">100000</vrdn:OperatingLeasesOperatingExpense>
    <vrdn:OperatingLeasesOperatingExpense contextRef="c-11" decimals="-5" id="f-747" unitRef="usd">100000</vrdn:OperatingLeasesOperatingExpense>
    <vrdn:OperatingLeasesOperatingExpense contextRef="c-13" decimals="-5" id="f-748" unitRef="usd">300000</vrdn:OperatingLeasesOperatingExpense>
    <vrdn:OperatingLeasesOperatingExpense contextRef="c-1" decimals="-5" id="f-749" unitRef="usd">300000</vrdn:OperatingLeasesOperatingExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-750">CAPITAL STOCK&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s second restated certificate of incorporation, the Company is authorized to issue 205,000,000 shares of its stock, of which 200,000,000 shares have been designated as common stock and 5,000,000 shares have been designated as preferred stock, both with a par value of $0.01 per&#160;share. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#x2019;s stock who are entitled to vote. Each share of common stock is entitled to one vote. The holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Sales Agreements - Jefferies LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;September 2022 ATM Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $175.0&#160;million from time to time at prices and on terms to be determined by market conditions at the time of offering, with Jefferies acting as its sales agent. Jefferies will receive a commission of 3.0% of the gross proceeds of any shares of common stock sold under the September 2022 ATM Agreement. No shares were sold under the September 2022 ATM Agreement during the three months ended September 30, 2024 and 2023. During the nine months ended September 30, 2024, the Company sold 1,561,570 shares under the September 2022 ATM Agreement with Jefferies at a weighted average price of $23.22 per share, for aggregate net proceeds of approximately $35.2&#160;million, including commissions to Jefferies as a sales agent. No shares were sold under the September 2022 ATM Agreement during the nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Private Placements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company issued and sold in private placement transactions an aggregate of 8,869,797 shares of the Company&#x2019;s common stock at a price per share of $12.38 and 92,312 shares of the Company&#x2019;s Series B Preferred Stock at a price per share of $825.3746, pursuant to securities purchase agreements with certain institutional and accredited investors. The Company received aggregate gross proceeds of approximately $186.0&#160;million, before deducting offering expenses payable by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2024, the Company entered into an underwriting agreement with Jefferies and Leerink Partners LLC  relating to the offer and sale (the &#x201c;January 2024 Public Offering&#x201d;) of 7,142,858 shares of the Company&#x2019;s common stock at a public offering price of $21.00 per share. The aggregate gross proceeds to the Company from the January 2024 Public Offering were approximately $150.0&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2024, the Company entered into an underwriting agreement with Jefferies, Goldman Sachs &amp;amp; Co. LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated related to the offer and sale (the &#x201c;September 2024 Public Offering&#x201d;) of 12,466,600 shares of the Company&#x2019;s common stock, which included 1,800,000 shares of common stock issued in connection with the exercise in full by the underwriters of their option to purchase additional shares at a public offering price of $18.75 per share, and 20,000 shares of the Company&#x2019;s Series B Preferred Stock at a price per share of $1,250.0625 per share. The aggregate gross proceeds to the Company from the September 2024 Public Offering, including the exercise of the option, were approximately $258.8&#160;million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s second restated certificate of incorporation, the Company&#x2019;s board of directors has the authority to designate and issue up to 5,000,000 shares of preferred stock, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company&#x2019;s stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Certificate of Designation, (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (iv) increase the number of authorized shares of Series A Preferred Stock, (v) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or (vi) enter into any agreement with respect to any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. Each share of Series A Preferred Stock is convertible into 66.67 shares of common stock at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024 and December 31, 2023, there were 134,864 and 172,435 shares of Series A Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, 37,571 shares of Series A Preferred Stock were converted into 2,504,855 shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series B Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series B Preferred Stock is convertible into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of common stock issued and outstanding immediately after &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;giving effect to such conversion. The powers, preferences, rights, qualifications, limitations, and restrictions applicable to the Series B Preferred Stock are set forth in the Certificate of Designation filed in September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Certificate of Designation, or (iii) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution, or winding-up of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024 and December 31, 2023, there were 145,160 and 143,522 shares of Series B Preferred Stock outstanding, respectively. During the nine months ended September 30, 2024, 18,362 of Series B Preferred Stock were converted into 1,224,193 shares of common stock.&lt;/span&gt;&lt;/div&gt;WARRANTS&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s outstanding warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Underlying Shares (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Life at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(No. Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued April 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$127.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued February 2020 (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued November 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the nine months ended September 30, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vrdn:CapitalStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-751" unitRef="shares">205000000</vrdn:CapitalStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-752" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-753" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-754"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-755"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <vrdn:CommonStockVotePerShare contextRef="c-3" decimals="INF" id="f-756" unitRef="vote">1</vrdn:CommonStockVotePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-214" decimals="INF" id="f-757" unitRef="usd">175000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds
      contextRef="c-214"
      decimals="INF"
      id="f-758"
      unitRef="number">0.030</vrdn:SaleofStockCommissionFeePercentageofGrossSaleProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-215"
      decimals="INF"
      id="f-759"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-216"
      decimals="INF"
      id="f-760"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-217"
      decimals="INF"
      id="f-761"
      unitRef="shares">1561570</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <vrdn:SaleOfStockWeightedAverageSharePrice
      contextRef="c-217"
      decimals="2"
      id="f-762"
      unitRef="usdPerShare">23.22</vrdn:SaleOfStockWeightedAverageSharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-217" decimals="-5" id="f-763" unitRef="usd">35200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-218"
      decimals="INF"
      id="f-764"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-219"
      decimals="INF"
      id="f-765"
      unitRef="shares">8869797</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-220"
      decimals="INF"
      id="f-766"
      unitRef="usdPerShare">12.38</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-221"
      decimals="INF"
      id="f-767"
      unitRef="shares">92312</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-222"
      decimals="INF"
      id="f-768"
      unitRef="usdPerShare">825.3746</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-223" decimals="-5" id="f-769" unitRef="usd">186000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-224"
      decimals="INF"
      id="f-770"
      unitRef="shares">7142858</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-225"
      decimals="INF"
      id="f-771"
      unitRef="usdPerShare">21.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-226" decimals="-5" id="f-772" unitRef="usd">150000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-227"
      decimals="INF"
      id="f-773"
      unitRef="shares">12466600</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-228"
      decimals="INF"
      id="f-774"
      unitRef="shares">1800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-229"
      decimals="INF"
      id="f-775"
      unitRef="usdPerShare">18.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-230"
      decimals="INF"
      id="f-776"
      unitRef="shares">20000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-231"
      decimals="4"
      id="f-777"
      unitRef="usdPerShare">1250.0625</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-232" decimals="-5" id="f-778" unitRef="usd">258800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-779" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="c-233"
      decimals="INF"
      id="f-780"
      unitRef="number">0.30</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-233"
      decimals="INF"
      id="f-781"
      unitRef="shares">66.67</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="c-234"
      decimals="INF"
      id="f-782"
      unitRef="number">0.0499</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="c-235"
      decimals="INF"
      id="f-783"
      unitRef="number">0.1999</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-784" unitRef="shares">134864</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-785" unitRef="shares">172435</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-236"
      decimals="INF"
      id="f-786"
      unitRef="shares">37571</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-237"
      decimals="INF"
      id="f-787"
      unitRef="shares">2504855</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-66"
      decimals="INF"
      id="f-788"
      unitRef="shares">66.67</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="c-238"
      decimals="INF"
      id="f-789"
      unitRef="number">0.049</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership
      contextRef="c-239"
      decimals="INF"
      id="f-790"
      unitRef="number">0.199</vrdn:ClassOfWarrantOrRightConversionPercentageOfOwnership>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-791"
      unitRef="shares">145160</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-792" unitRef="shares">143522</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-240"
      decimals="INF"
      id="f-793"
      unitRef="shares">18362</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-241"
      decimals="INF"
      id="f-794"
      unitRef="shares">1224193</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-795">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s outstanding warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Underlying Shares (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Life at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(No. Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued April 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$127.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equity-classified warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued February 2020 (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued November 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;If the Company subdivides (by any stock split, stock dividend, recapitalization, or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split, or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Subject to specified conditions, the Company may voluntarily reduce the warrant exercise price of the warrants issued in February 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s warrant activity during the nine months ended September 30, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.966%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-242"
      decimals="INF"
      id="f-796"
      unitRef="shares">781</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-243"
      decimals="INF"
      id="f-797"
      unitRef="shares">781</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-242"
      decimals="2"
      id="f-798"
      unitRef="usdPerShare">127.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm contextRef="c-244" id="f-799">P0Y6M29D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-245"
      decimals="INF"
      id="f-800"
      unitRef="shares">29446</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-246"
      decimals="INF"
      id="f-801"
      unitRef="shares">29446</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-245"
      decimals="2"
      id="f-802"
      unitRef="usdPerShare">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm contextRef="c-247" id="f-803">P5Y11M23D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-248"
      decimals="INF"
      id="f-804"
      unitRef="shares">218050</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-249"
      decimals="INF"
      id="f-805"
      unitRef="shares">218050</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-248"
      decimals="2"
      id="f-806"
      unitRef="usdPerShare">14.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm contextRef="c-250" id="f-807">P0Y4M13D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-251"
      decimals="INF"
      id="f-808"
      unitRef="shares">1606</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-252"
      decimals="INF"
      id="f-809"
      unitRef="shares">1606</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-251"
      decimals="2"
      id="f-810"
      unitRef="usdPerShare">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassofWarrantorRightRemainingTerm contextRef="c-253" id="f-811">P0Y1M13D</vrdn:ClassofWarrantorRightRemainingTerm>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-254"
      decimals="INF"
      id="f-812"
      unitRef="shares">249102</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
      contextRef="c-255"
      decimals="INF"
      id="f-813"
      unitRef="shares">249102</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-254"
      decimals="2"
      id="f-814"
      unitRef="usdPerShare">15.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet contextRef="c-3" decimals="INF" id="f-815" unitRef="shares">249883</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet contextRef="c-4" decimals="INF" id="f-816" unitRef="shares">249883</vrdn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-3"
      decimals="2"
      id="f-817"
      unitRef="usdPerShare">15.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-4" decimals="INF" id="f-818" unitRef="shares">249883</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-4"
      decimals="2"
      id="f-819"
      unitRef="usdPerShare">15.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vrdn:ClassOfWarrantOrRightExercisedInPeriod contextRef="c-1" decimals="INF" id="f-820" unitRef="shares">0</vrdn:ClassOfWarrantOrRightExercisedInPeriod>
    <vrdn:ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-821"
      unitRef="usdPerShare">0</vrdn:ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-3" decimals="INF" id="f-822" unitRef="shares">249883</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-3"
      decimals="2"
      id="f-823"
      unitRef="usdPerShare">15.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-824">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has grants outstanding under its 2008 Equity Incentive Plan (the &#x201c;2008 Plan&#x201d;), its amended and restated 2016 Equity Incentive Plan ( the &#x201c;2016 Plan&#x201d;), and the Viridian 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d; and collectively with the 2008 Plan and the 2016 Plan, the &#x201c;Equity Incentive Plans&#x201d;). Additionally, beginning in July 2021, the Company granted stock options and RSUs outside of its Equity Incentive Plans to certain employees to induce them to accept employment with the Company (the &#x201c;Inducement Awards&#x201d;). The terms and conditions of the Inducement Awards are substantially similar to those awards granted under the Company&#x2019;s Equity Incentive Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company&#x2019;s stockholders approved the amendment and restatement of the 2016 Plan to, among other things, transfer the then remaining number of shares available for issuance under the 2020 Plan into the 2016 Plan so that the Company operates from a single equity plan going forward. In June 2023, the Company&#x2019;s stockholders approved a further amendment and restatement of the 2016 Plan to, among other things, increase the number of shares reserved for issuance thereunder by 2,000,000 shares. In June 2024, the Company&#x2019;s stockholders approved a further amendment and restatement of the 2016 Plan to, among other things, increase the number of shares reserved for issuance thereunder by 2,000,000 shares. The 2016 Plan will terminate on April 19, 2034.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, the Company had the following balances by plan: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Available for Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,663,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,639,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2008 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,639,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted under the Equity Incentive Plans and the Inducement Awards generally vest annually over a 4-year period and are settled in shares of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$35.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the Equity Incentive Plans and the Inducement Awards have an exercise price equal to the market value of the common stock at the date of grant and expire 10 years from the date of grant. Options generally vest 25% on the first anniversary of the vesting commencement date and 75% ratably in equal monthly installments over the remaining 36 months or in equal monthly or quarterly amounts over periods of up to 48 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,533,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,945,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,324,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,324,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under its equity compensation plans. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected terms of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on a blend of historical data from public companies that are similar to the Company in size and nature of operations, as well as the Company&#x2019;s own volatility. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company accounts for forfeitures as they occur. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted, and actual and expected option-exercise behaviors. The fair value of the underlying common stock is based on the closing price of the common stock on The Nasdaq Capital Market at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2024 and 2023 was $10.83 and $23.19, respectively. The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-right:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$31.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) allows qualified employees to purchase shares of common stock at a price equal to&#160;85%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. As of&#160;September&#160;30, 2024, the Company had&#160;1,187,109&#160;shares available for issuance, and 102,426 cumulative shares had been issued under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans, the Inducement Awards, and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the condensed consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2024, the Company recorded an additional $4.6&#160;million in share-based compensation related to the acceleration of vesting for former executive officers, an amount which includes $0.3&#160;million related to the modification of the terms of options outstanding at the time of termination for one executive which would have otherwise forfeited. The Company also recorded $2.0&#160;million in share-based compensation related to the accounting for a modification of the equity awards to extend the post-termination exercise period of certain vested stock options for a former executive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2023, the Company recorded an additional $9.1&#160;million in share-based compensation related to the acceleration of vesting for former executive officers, an amount which includes $1.6&#160;million related to the modification of the terms of options outstanding at the time of termination for one executive which would have otherwise forfeited.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, the Company had $87.1 million of total unrecognized share-based compensation costs related to stock options, which the Company expects to recognize over a weighted-average remaining period of 2.95 years. As of September&#160;30, 2024, the Company had $5.9 million of total unrecognized share-&lt;/span&gt;&lt;/div&gt;based compensation costs related to unvested RSUs, which the Company expects to recognize over a weighted-average remaining period of 3.03 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-256"
      decimals="INF"
      id="f-825"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-257"
      decimals="INF"
      id="f-826"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-827">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024, the Company had the following balances by plan: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.735%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares Available for Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,663,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,563,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,639,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2008 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,639,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-258"
      decimals="INF"
      id="f-828"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-259"
      decimals="INF"
      id="f-829"
      unitRef="shares">5663625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-259"
      decimals="INF"
      id="f-830"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-260"
      decimals="INF"
      id="f-831"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-261"
      decimals="INF"
      id="f-832"
      unitRef="shares">125396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-261"
      decimals="INF"
      id="f-833"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-262"
      decimals="INF"
      id="f-834"
      unitRef="shares">514540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-263"
      decimals="INF"
      id="f-835"
      unitRef="shares">5563042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-263"
      decimals="INF"
      id="f-836"
      unitRef="shares">4639444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-264"
      decimals="INF"
      id="f-837"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-265"
      decimals="INF"
      id="f-838"
      unitRef="shares">24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-265"
      decimals="INF"
      id="f-839"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-266"
      decimals="INF"
      id="f-840"
      unitRef="shares">514540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-841" unitRef="shares">11352087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-3" decimals="INF" id="f-842" unitRef="shares">4639444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-267" id="f-843">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-844">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.949%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;804,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$35.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$14.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-268"
      decimals="INF"
      id="f-845"
      unitRef="shares">804947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-268"
      decimals="2"
      id="f-846"
      unitRef="usdPerShare">15.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-267"
      decimals="INF"
      id="f-847"
      unitRef="shares">5428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-267"
      decimals="2"
      id="f-848"
      unitRef="usdPerShare">18.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-267"
      decimals="INF"
      id="f-849"
      unitRef="shares">19115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-267"
      decimals="2"
      id="f-850"
      unitRef="usdPerShare">35.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-267"
      decimals="INF"
      id="f-851"
      unitRef="shares">276720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-267"
      decimals="2"
      id="f-852"
      unitRef="usdPerShare">16.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-266"
      decimals="INF"
      id="f-853"
      unitRef="shares">514540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-266"
      decimals="2"
      id="f-854"
      unitRef="usdPerShare">14.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-269" id="f-855">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-270"
      decimals="INF"
      id="f-856"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-271"
      decimals="INF"
      id="f-857"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-271" id="f-858">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-269" id="f-859">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-860">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,533,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$19.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,945,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$22.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,324,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested as of September&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,324,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$21.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-272"
      decimals="INF"
      id="f-861"
      unitRef="shares">11533484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-272"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">19.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-273" id="f-863">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-272" decimals="-3" id="f-864" unitRef="usd">54772000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-269"
      decimals="INF"
      id="f-865"
      unitRef="shares">2996156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-269"
      decimals="2"
      id="f-866"
      unitRef="usdPerShare">15.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-269"
      decimals="INF"
      id="f-867"
      unitRef="shares">232006</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-269"
      decimals="2"
      id="f-868"
      unitRef="usdPerShare">9.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-269"
      decimals="INF"
      id="f-869"
      unitRef="shares">2945547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-269"
      decimals="2"
      id="f-870"
      unitRef="usdPerShare">22.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-274"
      decimals="INF"
      id="f-871"
      unitRef="shares">11352087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-274"
      decimals="2"
      id="f-872"
      unitRef="usdPerShare">17.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-269" id="f-873">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-274" decimals="-3" id="f-874" unitRef="usd">68434000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-274"
      decimals="INF"
      id="f-875"
      unitRef="shares">11352087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-274"
      decimals="2"
      id="f-876"
      unitRef="usdPerShare">17.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-269" id="f-877">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-274" decimals="-3" id="f-878" unitRef="usd">68434000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-274"
      decimals="INF"
      id="f-879"
      unitRef="shares">3324526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-274"
      decimals="2"
      id="f-880"
      unitRef="usdPerShare">21.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-269" id="f-881">P5Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-274" decimals="-3" id="f-882" unitRef="usd">9890000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="c-274"
      decimals="INF"
      id="f-883"
      unitRef="shares">3324526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-274"
      decimals="2"
      id="f-884"
      unitRef="usdPerShare">21.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-269" id="f-885">P5Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-274" decimals="-3" id="f-886" unitRef="usd">9890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-269"
      decimals="2"
      id="f-887"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-275"
      decimals="2"
      id="f-888"
      unitRef="usdPerShare">23.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-889">The fair value was determined by the Black-Scholes option pricing model using the following weighted-average assumptions:&lt;div style="margin-bottom:12pt;padding-right:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$31.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-269" id="f-890">P5Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-275" id="f-891">P5Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-269" decimals="3" id="f-892" unitRef="number">0.888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-275" decimals="3" id="f-893" unitRef="number">0.908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-269" decimals="3" id="f-894" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-275" decimals="3" id="f-895" unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-269"
      decimals="INF"
      id="f-896"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-275"
      decimals="INF"
      id="f-897"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-274"
      decimals="2"
      id="f-898"
      unitRef="usdPerShare">15.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-276"
      decimals="2"
      id="f-899"
      unitRef="usdPerShare">31.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-277"
      decimals="INF"
      id="f-900"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-278"
      decimals="INF"
      id="f-901"
      unitRef="shares">1187109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-279"
      decimals="INF"
      id="f-902"
      unitRef="shares">102426</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-903">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation related to all equity awards issued pursuant to the Equity Incentive Plans, the Inducement Awards, and for estimated shares to be issued under the ESPP for the purchase periods active during each respective period is included in the condensed consolidated statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.633%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-280" decimals="-3" id="f-904" unitRef="usd">4673000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-281" decimals="-3" id="f-905" unitRef="usd">4003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-282" decimals="-3" id="f-906" unitRef="usd">17142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-283" decimals="-3" id="f-907" unitRef="usd">11671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-284" decimals="-3" id="f-908" unitRef="usd">4047000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-285" decimals="-3" id="f-909" unitRef="usd">9603000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-286" decimals="-3" id="f-910" unitRef="usd">16033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-287" decimals="-3" id="f-911" unitRef="usd">29453000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-912" unitRef="usd">8720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-913" unitRef="usd">13606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-914" unitRef="usd">33175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-915" unitRef="usd">41124000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-288" decimals="-5" id="f-916" unitRef="usd">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-289" decimals="-5" id="f-917" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-288" decimals="-5" id="f-918" unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-290" decimals="-5" id="f-919" unitRef="usd">9100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-290" decimals="-5" id="f-920" unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-921" unitRef="usd">87100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-269" id="f-922">P2Y11M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-266" decimals="-5" id="f-923" unitRef="usd">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-267" id="f-924">P3Y10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-925">NET LOSS PER SHARE&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of common stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Diluted net loss per share is the same as basic net loss per share of common stock, as the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock (as converted to shares of common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,991,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,496,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock (as converted to shares of common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,677,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,261,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,785,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,760,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-926">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Preferred Stock (as converted to shares of common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,991,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,496,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Preferred Stock (as converted to shares of common stock)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,677,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,414,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,352,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,261,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,785,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,760,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-291" decimals="0" id="f-927" unitRef="shares">8991383</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-292" decimals="0" id="f-928" unitRef="shares">11496241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-293" decimals="0" id="f-929" unitRef="shares">9677817</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-294" decimals="0" id="f-930" unitRef="shares">3414171</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-295" decimals="0" id="f-931" unitRef="shares">11352087</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-296" decimals="0" id="f-932" unitRef="shares">8261261</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-297" decimals="0" id="f-933" unitRef="shares">249883</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-298" decimals="0" id="f-934" unitRef="shares">249883</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-299" decimals="0" id="f-935" unitRef="shares">514540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-300" decimals="0" id="f-936" unitRef="shares">338875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-937" unitRef="shares">30785710</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="0" id="f-938" unitRef="shares">23760431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-11" id="f-939">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-11" id="f-940">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-11" id="f-941">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-11" id="f-942">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
